,Unnamed: 0,compound_id,standard_inchi_key,compound_name,synonym,target_id,target_pref_name,gene_names,wildtype_or_mutant,mutation_info,pubmed_id,standard_type,standard_relation,standard_value,standard_units,activity_comment,ep_action_mode,assay_format,assaytype,assay_subtype,inhibitor_type,detection_tech,assay_cell_line,compound_concentration_value,compound_concentration_value_unit,substrate_type,substrate_relation,substrate_value,substrate_units,assay_description,title,journal,doc_type,annotation_comments,pDTC_Value,SMILES,base_rdkit_smiles
0,0,CHEMBL336100,AAADQEFQWNJHOZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,12.3,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.910094888560603,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C=CC=C3F,OC1(c2ccc(Cl)cc2)c2cccc(F)c2C2=NCCN21
1,1,CHEMBL336100,AAADQEFQWNJHOZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,91.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.040958607678906,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C=CC=C3F,OC1(c2ccc(Cl)cc2)c2cccc(F)c2C2=NCCN21
2,2,CHEMBL336100,AAADQEFQWNJHOZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,23.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.636388020107857,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C=CC=C3F,OC1(c2ccc(Cl)cc2)c2cccc(F)c2C2=NCCN21
3,3,CHEMBL14144,AAEKULYONKUBOZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,5.25,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [3H]WIN-35428 as the radiotracer,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,8.279840696594043,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)OC4=CC=CC=C4,CN1C2CCC1C(C(=O)Oc1ccccc1)C(c1ccc(Cl)cc1)C2
4,4,CHEMBL3323101,AAHLCKVWZXFMPB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,4.5,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.346787486224656,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)NC=C4,CN1Cc2ccccc2C(c2ccc3[nH]ccc3c2)C1
5,5,CHEMBL3323101,AAHLCKVWZXFMPB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,3.8,NM,314444,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.42021640338319,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)NC=C4,CN1Cc2ccccc2C(c2ccc3[nH]ccc3c2)C1
6,6,CHEMBL12,AAOVKJBEBIDNHE-UHFFFAOYSA-N,DIAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
7,7,CHEMBL12,AAOVKJBEBIDNHE-UHFFFAOYSA-N,DIAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
8,8,CHEMBL26649,AASZEODWFQQIRF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,8.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.096910013008056,C1CN(CCN1CCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCc3ccccc3)CC2)c2ccc(F)cc2)cc1
9,9,CHEMBL3334773,AAXDLPLNFKHHPR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,291.4,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.535510452566029,C1CCN(C1)C(CCN2CCC(=CC2)CC3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(C(CCN2CC=C(Cc3ccccc3)CC2)N2CCCC2)cc1Cl
10,10,CHEMBL456654,ABAOWFCFAADMKA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,62.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.207608310501746,C1CNCC1(CC2=CC=CC=N2)C3=CC4=C(C=C3)NC=C4,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)nc1
11,11,CHEMBL2169900,ABCUTHOEKRCYIS-UHFFFAOYSA-N,AZETIDIN-3-YL(PHENYL)METHANOL HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,3.9,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,3.9,C1C(CN1)C(C2=CC=CC=C2)O.Cl,OC(c1ccccc1)C1CNC1
12,12,CHEMBL990,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,BUTENAFINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32,CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
13,13,CHEMBL990,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,BUTENAFINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32,CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
14,14,CHEMBL3577956,ABJWJGMTLYSISP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25893048.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to human DAT at 1 uM,,ACS Med. Chem. Lett.,PUBLICATION,,,C1CC(C1)N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4,O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CCC2)CC1
15,15,CHEMBL551556,ABLMTRUAAOJKSC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNCCC1C(C2=CN=CC=C2)OC3=CC=CC=C3C(F)(F)F,FC(F)(F)c1ccccc1OC(c1cccnc1)C1CCNCC1
16,16,CHEMBL2205816,ABONQAUMSMWLEK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=N7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1
17,17,CHEMBL2205816,ABONQAUMSMWLEK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=N7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1
18,18,CHEMBL565844,ABPSWEJOHYDZDP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.187086643357143,CC1=C(C=C(C=C1)C(=O)C(C)NC(C)(C)C)Cl,Cc1ccc(C(=O)C(C)NC(C)(C)C)cc1Cl
19,19,CHEMBL565844,ABPSWEJOHYDZDP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,1150.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.939302159646387,CC1=C(C=C(C=C1)C(=O)C(C)NC(C)(C)C)Cl,Cc1ccc(C(=O)C(C)NC(C)(C)C)cc1Cl
20,20,CHEMBL565844,ABPSWEJOHYDZDP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,410.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.3872161432802645,CC1=C(C=C(C=C1)C(=O)C(C)NC(C)(C)C)Cl,Cc1ccc(C(=O)C(C)NC(C)(C)C)cc1Cl
21,21,CHEMBL115710,ABQQJUQDHRDZGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,660.69,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.180002266489224,C1CC2CC(CC1N2CCOCCN3CCOCC3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,Fc1ccc(C(OC2CC3CCC(C2)N3CCOCCN2CCOCC2)c2ccc(F)cc2)cc1
22,22,CHEMBL512472,ABWNRPAQIBGXIY-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@H]1N(CC2=C(C=C(C=C2)Cl)Cl)C(=O)C3CC3,O=C(C1CC1)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
23,23,CHEMBL275212,ABXUYGWOEIXKBD-KTKRTIGZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,22.0,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,7.657577319177793,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)/C=C\I)C(=O)OC,COC(=O)C1C(c2ccc(/C=C\I)cc2)CC2CCC1N2C
24,24,CHEMBL553395,ABYFXYVIEFXQPH-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,2950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.530177984021837,CSC1=CC=CC=C1C(=O)N([C@H]2CCNC2)C3CCCCC3,CSc1ccccc1C(=O)N(C1CCCCC1)[C@H]1CCNC1
25,27,CHEMBL765,ACGDKVXYNVEAGU-UHFFFAOYSA-N,GUANETHIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCCN(CCC1)CCN=C(N)N,NC(N)=NCCN1CCCCCCC1
26,28,CHEMBL765,ACGDKVXYNVEAGU-UHFFFAOYSA-N,GUANETHIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCCN(CCC1)CCN=C(N)N,NC(N)=NCCN1CCCCCCC1
27,29,CHEMBL496,ACGUYXCXAPNIKK-UHFFFAOYSA-N,HEXACHLOROPHENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
28,30,CHEMBL496,ACGUYXCXAPNIKK-UHFFFAOYSA-N,HEXACHLOROPHENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
29,31,CHEMBL606809,ACGWDXHPVXMSNJ-KOQKOIQBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,5.5,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.259637310505756,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OCCCCCN4C=CN=N4,CN1C2CCC1[C@@H](C(=O)OCCCCCn1ccnn1)[C@@H](c1ccc(Cl)cc1)C2
30,32,CHEMBL1069,ACWBQPMHZXGDFX-QFIPXVFZSA-N,VALSARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
31,33,CHEMBL1069,ACWBQPMHZXGDFX-QFIPXVFZSA-N,VALSARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
32,34,CHEMBL404013,ACZMLOPMXAUHFP-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,C=CCN(CC=C)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
33,35,CHEMBL334577,ADCPRYKGPAHETD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,2.1,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.67778070526608,C1CN=C2C3=C(C=CC4=CC=CC=C43)C(N2C1)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=NCCCN21
34,36,CHEMBL334577,ADCPRYKGPAHETD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,KI,=,2.01,NM,,,,,,,,,,,,,,,Inhibition of [125I]- RTI -55 binding at the Dopamine transporter sites on HEK-hDAT cells,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.69680394257951,C1CN=C2C3=C(C=CC4=CC=CC=C43)C(N2C1)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=NCCCN21
35,37,CHEMBL334577,ADCPRYKGPAHETD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,20.3,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,20.3,C1CN=C2C3=C(C=CC4=CC=CC=C43)C(N2C1)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=NCCCN21
36,38,CHEMBL2030634,ADGIWWYGVBZYMC-UHFFFAOYSA-N,N-(CYCLOHEXYLMETHYL)PYRROLIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCC(CC1)CN2CCCC2,C1CCC(CN2CCCC2)CC1
37,39,CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N,COc1cc(N)nc2[nH]c(-c3ccc(F)cc3)c(-c3ccncc3)c12
38,40,CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N,COc1cc(N)nc2[nH]c(-c3ccc(F)cc3)c(-c3ccncc3)c12
39,41,CHEMBL1702607,ADVPTQAUNPRNPO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S(=O)O,NC(CS(=O)O)C(=O)O
40,42,CHEMBL220801,AEEJHYWVYVJIRH-OFVILXPXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,2240.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.649751981665838,CC(=O)C1=CC(=CC=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CCO)CC3=CC=C(C=C3)F,CC(=O)c1cccc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CCO)c1
41,43,CHEMBL466538,AEKDVQNDZQYMPK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,100.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.0,C=C(CC1=CC=CC=C1)CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,C=C(Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
42,44,CHEMBL313833,AELCINSCMGFISI-UHFFFAOYSA-N,TRANYLCYPROMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,5100.0,NM,,,,,,,,,,,,,,,,,,,,5.292429823902063,C1C(C1N)C2=CC=CC=C2,NC1CC1c1ccccc1
43,45,CHEMBL252557,AEMRFAOFKBGASW-UHFFFAOYSA-N,GLYCOLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)O,O=C(O)CO
44,46,CHEMBL252557,AEMRFAOFKBGASW-UHFFFAOYSA-N,GLYCOLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)O,O=C(O)CO
45,47,CHEMBL44884,AEUTYOVWOVBAKS-UWVGGRQHSA-N,ETHAMBUTOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NCCN[C@@H](CC)CO,CC[C@@H](CO)NCCN[C@@H](CC)CO
46,48,CHEMBL44884,AEUTYOVWOVBAKS-UWVGGRQHSA-N,ETHAMBUTOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NCCN[C@@H](CC)CO,CC[C@@H](CO)NCCN[C@@H](CC)CO
47,49,CHEMBL399147,AEWPIBYOYSOWAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,=,33000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,CN(C)CC1CC1C2=CC=CC3=CC=CC=C32,CN(C)CC1CC1c1cccc2ccccc12
48,50,CHEMBL399147,AEWPIBYOYSOWAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,12.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,CN(C)CC1CC1C2=CC=CC3=CC=CC=C32,CN(C)CC1CC1c1cccc2ccccc12
49,51,CHEMBL14257,AEYFRZGFXCIRPL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,5.6,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,8.2518119729938,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)C=C(Br)Br,COC(=O)C1C2CCC(CC1c1ccc(C=C(Br)Br)cc1)N2
50,52,CHEMBL405728,AFBGSNRISAOHKD-FUHWJXTLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(CCC3)C=C2,CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)CCC3)C[C@H]1CN
51,53,CHEMBL88563,AFEGPFDFZHEVOA-IOCOHYSWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,235.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.628932137728263,CN1C2C[C@H](C1C(C(C2)C3=CC=CC=C3)C(=O)OC)O,COC(=O)C1C(c2ccccc2)CC2C[C@@H](O)C1N2C
52,54,CHEMBL88563,AFEGPFDFZHEVOA-IOCOHYSWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,518.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.285670240254768,CN1C2C[C@H](C1C(C(C2)C3=CC=CC=C3)C(=O)OC)O,COC(=O)C1C(c2ccccc2)CC2C[C@@H](O)C1N2C
53,55,CHEMBL596001,AFKZQXYPUGXQNH-SESHTJHWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,1.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,9.0,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OCCCCCCN4C=C(N=N4)COC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)OCc1cn(CCCCCCOC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)nn1)[C@@H](c1ccc(Cl)cc1)C2
54,56,CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1726.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.762959208620808,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
55,57,CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1371.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.862962545210488,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
56,58,CHEMBL1818467,AFOUVNVDHQZVBK-RTBURBONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,19.95,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.700057099977232,CC1=CC=C(N1C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C,Cc1ccc(C)n1C[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
57,59,CHEMBL530334,AFPFOKAYUJMERG-CABCVRRESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,2000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,C1[C@H](C2=CC=CC=C2[C@H]1OC3=CC=CC=C3)N,N[C@@H]1C[C@H](Oc2ccccc2)c2ccccc21
58,60,CHEMBL1204414,AFRJOWOPSIECIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,50.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CNCCCC1CC2=C(C=CC(=C2)F)N(S1(=O)=O)C3=CC=CC=C3F.Cl,CNCCCC1Cc2cc(F)ccc2N(c2ccccc2F)S1(=O)=O
59,61,CHEMBL121611,AFTYGKFAHDIZJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,68.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.167491087293763,C1=CC=C(C=C1)CCNCCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,Fc1ccc(C(OCCNCCCNCCc2ccccc2)c2ccc(F)cc2)cc1
60,62,CHEMBL121611,AFTYGKFAHDIZJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,28.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.552841968657781,C1=CC=C(C=C1)CCNCCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,Fc1ccc(C(OCCNCCCNCCc2ccccc2)c2ccc(F)cc2)cc1
61,63,CHEMBL121611,AFTYGKFAHDIZJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,2.4,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,2.4,C1=CC=C(C=C1)CCNCCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,Fc1ccc(C(OCCNCCCNCCc2ccccc2)c2ccc(F)cc2)cc1
62,64,CHEMBL508112,AFZSMODLJJCVPP-UHFFFAOYSA-N,BENZOTHIAZYL DISULFIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,245.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.610833915635467,C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
63,65,CHEMBL508112,AFZSMODLJJCVPP-UHFFFAOYSA-N,BENZOTHIAZYL DISULFIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,194.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.7121982700697735,C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
64,66,CHEMBL134342,AGBQKNBQESQNJD-SSDOTTSWSA-N,LIPOIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSS[C@@H]1CCCCC(=O)O,O=C(O)CCCC[C@@H]1CCSS1
65,67,CHEMBL134342,AGBQKNBQESQNJD-SSDOTTSWSA-N,LIPOIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSS[C@@H]1CCCCC(=O)O,O=C(O)CCCC[C@@H]1CCSS1
66,68,CHEMBL379536,AGCDRDCNYZHHKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC(=CC=C2)C(=O)N)C3=CC=CC=C3,NC(=O)c1cccc(CC(c2ccccc2)N2CCNCC2)c1
67,69,CHEMBL267744,AGHANLSBXUWXTB-UHFFFAOYSA-N,TICRYNAFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
68,70,CHEMBL267744,AGHANLSBXUWXTB-UHFFFAOYSA-N,TICRYNAFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
69,71,CHEMBL2207386,AGKMPGSBLMAGAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23141912.0,INHIBITION,=,3.66,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM by radioligand displacement assay,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.66,CN1CCN(CC1)CC2=C3C=CN(C3=CC=C2)S(=O)(=O)C4=CC=CC=C4Br,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2Br)CC1
70,72,CHEMBL1741,AGOYDEPGAOXOCK-KCBOHYOISA-N,CLARITHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
71,73,CHEMBL1741,AGOYDEPGAOXOCK-KCBOHYOISA-N,CLARITHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
72,74,CHEMBL382768,AGRVUDWDZKZCAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,CCCC(C(=O)C1=CC(=C(C=C1)OC)OC)N2CCCC2,CCCC(C(=O)c1ccc(OC)c(OC)c1)N1CCCC1
73,75,CHEMBL216736,AHEMMEONOCHONP-DBUDALRPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17154506.0,KI,=,29.9,NM,,,,,,,,,,,,,,,Displacement of [3H]RTI-55 from human DAT,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,7.52432881167557,COC(=O)[C@H]1[C@H](CC2CCC1N2)C3=CC=CC(=C3)/C=C/I,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1cccc(/C=C/I)c1)N2
74,76,CHEMBL112528,AHIVDMYTJFPCST-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,14.13,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.849857838151442,C1CC2CC(CC1N2CCNC(=O)C3=CN=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=C(NCCN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2)c1cccnc1
75,77,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,490.0,NM,,,,,,,,,,,,,,,,,,,,6.309803919971486,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
76,78,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,490.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
77,79,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,268.0,NM,,,,,,,,,,,,,,,,,,,,6.571865205971212,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
78,80,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,963.0,NM,,,,,,,,,,,,,,,,,,,,6.016373712875465,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
79,81,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,KI,=,400.0,NM,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.3979400086720375,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
80,82,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,672.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.172630726946175,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
81,83,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,534.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.272458742971443,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
82,84,CHEMBL449047,AHRDEWSZTRJWJB-BTXUNPJVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,3.6,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,8.443697499232712,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C#C.Cl,C#C[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C
83,85,CHEMBL407803,AHXRAUZDJFQCSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,IC50,=,1667.0,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [3H]DA binding to dopamine (DAT) transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.778064400171995,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
84,86,CHEMBL407803,AHXRAUZDJFQCSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,KI,=,21.7,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [125I]RTI-55 binding to dopamine transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.663540266151471,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
85,87,CHEMBL407803,AHXRAUZDJFQCSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,76.8,,,,,,,,,,,,,,,,Ratio of uptake inhibition to binding affinity to human DAT (IC50/Ki),Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,76.8,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
86,88,CHEMBL273208,AIBJZSMLYKTKIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,1910.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.718966632752272,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2OC3=CC=CC=C3,CNCc1cnc(C)cc1Oc1ccccc1Oc1ccccc1
87,89,CHEMBL273208,AIBJZSMLYKTKIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,1910.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.718966632752272,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2OC3=CC=CC=C3,CNCc1cnc(C)cc1Oc1ccccc1Oc1ccccc1
88,90,CHEMBL512636,AIFFHNCKAUEKKT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,4.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.397940008672037,CC(CCN1CCN(CC1)CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)(C4=CC=CC=C4)O,CC(O)(CCN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
89,91,CHEMBL1224241,AIGSBZFJFSQVPD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.698970004336019,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C(S2)Cl)Cl,CC(C)(C)CCC1(C(=O)c2cc(Cl)c(Cl)s2)CCNC1
90,92,CHEMBL565332,AIHZABOGLZWKHW-PMACEKPBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCN(C)C[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CCN(C)C[C@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
91,93,CHEMBL583,AIJTTZAVMXIJGM-UHFFFAOYSA-N,GREPAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
92,94,CHEMBL583,AIJTTZAVMXIJGM-UHFFFAOYSA-N,GREPAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
93,95,CHEMBL446281,AILKVNMCCFEAQT-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)(C)C(=O)N(CC1=C(C(=CC=C1)Cl)Cl)[C@H]2CCNC2,CC(C)(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1
94,96,CHEMBL14,AIXAANGOTKPUOY-UHFFFAOYSA-N,CARBACHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)N.[Cl-],C[N+](C)(C)CCOC(N)=O
95,97,CHEMBL14,AIXAANGOTKPUOY-UHFFFAOYSA-N,CARBACHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)N.[Cl-],C[N+](C)(C)CCOC(N)=O
96,98,CHEMBL1818463,AJFRCYMRJNJFPE-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,15.85,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.799970733446231,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=CC=C4,Clc1ccc([C@]23CCNC[C@@]2(Cn2cccc2)C3)cc1Cl
97,99,CHEMBL3633757,AJIMVLSQIMXLNV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26475518.0,KI,<,300.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-WIN35428 from recombinant human DAT after 1.5 hrs by Microbeta scintillation counting analysis,Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT2A receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,CN1CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OCC6=CC=C(C=C6)Br)OC,COc1cc2c3c(c1OCc1ccc(Br)cc1)-c1cc4c(cc1CC3N(C)CC2)OCO4
98,100,CHEMBL54440,AJLFOPYRIVGYMJ-INTXDZFKSA-N,MEVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
99,101,CHEMBL54440,AJLFOPYRIVGYMJ-INTXDZFKSA-N,MEVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
100,102,CHEMBL559610,AJLUMLBNDXXSIW-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,29.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,29.0,CCN1C2=C(C(=CC=C2)F)N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CCn1c(=O)n([C@@H](c2ccccc2)[C@H](O)CNC)c2c(F)cccc21
101,103,CHEMBL1618305,AJPSBXJNFJCCBI-YOHUGVJRSA-N,NALOXONAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
102,104,CHEMBL1618305,AJPSBXJNFJCCBI-YOHUGVJRSA-N,NALOXONAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
103,105,CHEMBL1818546,AJRLLMMPWPRYOM-BPGUCPLFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,19.95,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.700057099977232,C1CNCC2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=CC5=CC=CC=C54,Clc1ccc([C@]23CCNCC2(Cn2ccc4ccccc42)C3)cc1Cl
104,106,CHEMBL3323187,AKCCORFIPGKYKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,1400.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,5.853871964321763,CN1CC(C2=C(C1)C=C(C=C2)NCCO)C3=CC4=C(C=C3)SC=C4,CN1Cc2cc(NCCO)ccc2C(c2ccc3sccc3c2)C1
105,107,CHEMBL324518,AKCFGSWTIGIRNF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,8.13,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.089909454405932,C1CC2CC(CC1N2CCNCC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,Fc1ccc(C(OC2CC3CCC(C2)N3CCNCc2ccccc2)c2ccc(F)cc2)cc1
106,108,CHEMBL67024,AKCNZFOHJFSRSN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,320.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.494850021680094,C1CN(CCC1NCCC2=CC=C(C=C2)F)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,Fc1ccc(CCNC2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
107,109,CHEMBL67024,AKCNZFOHJFSRSN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.9586073148417755,C1CN(CCC1NCCC2=CC=C(C=C2)F)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,Fc1ccc(CCNC2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
108,110,CHEMBL217928,AKEDNWBVXPATHJ-LVXARBLLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,,,,Not Determined,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CC(F)(F)F)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CC(F)(F)F)cc(C(C)=O)c1
109,111,CHEMBL364713,AKNNEGZIBPJZJG-MSOLQXFVSA-N,NOSCAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C
110,112,CHEMBL364713,AKNNEGZIBPJZJG-MSOLQXFVSA-N,NOSCAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C
111,113,CHEMBL497492,AKOJURNFNIUCOV-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,4000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CNC[C@@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3SC,CNC[C@H]1OCc2ccccc2[C@@H]1Oc1ccccc1SC
112,114,CHEMBL497493,AKOJURNFNIUCOV-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3SC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1SC
113,115,CHEMBL125954,AKRLDNUSUDYWEE-YPBBTIAZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.657577319177793,COC(=O)C1[C@H](CC2CCC1N2CCCC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2CCCc1ccccc1
114,116,CHEMBL575131,AKRRCLREANRVLZ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,11.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,11.0,CNC[C@H]([C@H](C1=CC=C(C=C1)F)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccc(F)cc1)n1ccc2ccccc21
115,117,CHEMBL203674,AKYOXKZSLULYCY-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,29.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.5376020021010435,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)CC(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(CC(N)=O)cc21
116,118,CHEMBL1224470,ALCQDLGGOYWNLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,18.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,18.0,CN(C)CCC(C1=CC2=C(C=C1)C=C(C=C2)Cl)N3N=CN=N3,CN(C)CCC(c1ccc2cc(Cl)ccc2c1)n1ncnn1
117,119,CHEMBL2110816,ALELTFCQZDXAMQ-UHFFFAOYSA-N,BUTRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,3940.0,NM,,,,,,,,,,,,,,,,,,,,5.404503778174425,CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)CN(C)C,CC(CC1c2ccccc2CCc2ccccc21)CN(C)C
118,120,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2684.6,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.571120414148381,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12
119,121,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2133.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.671009144550571,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12
120,122,CHEMBL567945,ALLVIFFNCLDETM-SECBINFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=C(C=CC(=C1Cl)Cl)C(=O)N(C)[C@@H]2CCNC2,Cc1c(C(=O)N(C)[C@@H]2CCNC2)ccc(Cl)c1Cl
121,123,CHEMBL476315,AMBALGQRTVWPRL-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CC[C@@H](C1)N(CC2=CC=CC=C2C3=CC=CC=C3)S(=O)(=O)C,CN1CC[C@H](N(Cc2ccccc2-c2ccccc2)S(C)(=O)=O)C1
122,124,CHEMBL271707,AMFULWSAWGAJBH-PZAXRMSQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,31.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.508638306165728,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC(=O)CCCCCCCCC(=O)OC[C@H]4[C@H](CC5CCC4N5C)C6=CC(=C(C=C6)Cl)Cl,CN1C2CCC1[C@@H](COC(=O)CCCCCCCCC(=O)OC[C@@H]1C3CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N3C)[C@@H](c1ccc(Cl)c(Cl)c1)C2
123,125,CHEMBL1909080,AMGRXJSJSONEEG-UHFFFAOYSA-L,STRONTIUM CHLORIDE HEXAHYDRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,O.O.O.O.O.O.[Cl-].[Cl-].[Sr+2],O
124,126,CHEMBL1909080,AMGRXJSJSONEEG-UHFFFAOYSA-L,STRONTIUM CHLORIDE HEXAHYDRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,O.O.O.O.O.O.[Cl-].[Cl-].[Sr+2],O
125,127,CHEMBL3331484,AMGZVHXDDMROJU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,265.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.576754126063192,C1CC1N(CC2=CC(=C(C=C2)Cl)Cl)C3CNC3,Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl
126,128,CHEMBL3331484,AMGZVHXDDMROJU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,12.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,12.0,C1CC1N(CC2=CC(=C(C=C2)Cl)Cl)C3CNC3,Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl
127,129,CHEMBL1945780,AMIHUYQKNJHXPT-DRABBMOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,6.31,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,8.199970640755867,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C
128,130,CHEMBL441465,AMIHUYQKNJHXPT-MVAQFVTJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,,,,,Not available,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the Dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen; Not available.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,,CN1C2CCC1[C@H](C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)[C@H]1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
129,131,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,1.09,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,8.962573502059378,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
130,132,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,0.4,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,9.397940008672037,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
131,133,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,1.09,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.962573502059378,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
132,134,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,0.4,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,9.397940008672037,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
133,135,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,1.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.958607314841776,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
134,136,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.698970004336019,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
135,137,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,0.38,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,9.42021640338319,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
136,138,CHEMBL87031,AMIHUYQKNJHXPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,1.09,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.962573502059378,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
137,139,CHEMBL42553,AMIHUYQKNJHXPT-XNSJETLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11425531.0,IC50,=,1.1,NM,,,cell_based,,,,,,,,,,,,Ability to inhibit human dopamine uptake by the human dopamine transporter in EM4 cells stably infected with Flag HA-hDAT,[3H]MFZ 2-12: a novel radioligand for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.958607314841776,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N2C
138,140,CHEMBL42553,AMIHUYQKNJHXPT-XNSJETLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,0.2,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]CFT from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,9.69897000433602,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N2C
139,141,CHEMBL42553,AMIHUYQKNJHXPT-XNSJETLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,2.3,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]dopamine from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.638272163982407,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N2C
140,142,CHEMBL42553,AMIHUYQKNJHXPT-XNSJETLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,1.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.958607314841776,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N2C
141,143,CHEMBL1818446,AMIXKESLNNOGEZ-HZPDHXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,2.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.698970004336019,CC1=CC(=NO1)[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1cc([C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)no1
142,144,CHEMBL1170585,AMKBEJSLPSMHMK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,398.11,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,CNC1=CC=C(C=C1)N2CCNCC2CC3=CC=CC=C3,CNc1ccc(N2CCNCC2Cc2ccccc2)cc1
143,145,CHEMBL541226,AMLGZPQHVSFYSD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,C1CNCCC1C(C2=CC=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2ccccc2)C2CCNCC2)c1Cl
144,146,CHEMBL598562,AMNKPXBJLVWEJK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,5500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,C1CNCCC1C2=C(N=CC=C2)OC3=C(C=C(C=C3)Cl)Cl,Clc1ccc(Oc2ncccc2C2CCNCC2)c(Cl)c1
145,147,CHEMBL596775,AMOKJMKEFDPTPN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,>,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.0,CC(C(=O)C1=CC(=CC=C1)[N+](=O)[O-])NC2CCCC2,CC(NC1CCCC1)C(=O)c1cccc([N+](=O)[O-])c1
146,148,CHEMBL2048522,AMQSLZSYEJWDRW-XPOMLNETSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,699.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.155522824254319,CN(C)C(=O)[C@@H]1[C@H]2CC[C@H](N2CC[18F])C[C@@H]1C3=CC=C(C=C3)Cl,CN(C)C(=O)[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2CCF
147,149,CHEMBL1085233,AMRZCARGTNPWTE-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,=,91.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,91.0,C[C@H](CNC)CN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNC[C@@H](C)CN1c2ccccc2N(c2ccccc2F)S1(=O)=O
148,150,CHEMBL1083741,AMRZCARGTNPWTE-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,=,88.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,88.0,C[C@@H](CNC)CN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNC[C@H](C)CN1c2ccccc2N(c2ccccc2F)S1(=O)=O
149,151,CHEMBL257738,ANDYBNKRXGVQGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,330.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.481486060122112,CNCC1=C(C=CC(=C1)C(=O)N2CCCN(CC2)C3CC3)OC4=CC(=C(C=C4)Cl)Cl,CNCc1cc(C(=O)N2CCCN(C3CC3)CC2)ccc1Oc1ccc(Cl)c(Cl)c1
150,152,CHEMBL496911,ANKBUMUPFQMGBF-SLWGAWGTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,8.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,8.096910013008056,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CN(N=N4)CCN5CCCCC5.Cl,CN1[C@H]2CC[C@@H]1[C@@H](c1cn(CCN3CCCCC3)nn1)[C@@H](c1ccc(Cl)cc1)C2
151,153,CHEMBL1813311,ANLYZSJGJNCZJB-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,9772.37,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.010000098195094,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC(=C(C=C3)OC)OC,COc1ccc([C@]23CCCC[C@H]2CN(C)C3)cc1OC
152,154,CHEMBL562476,ANOKEIWYHCYLAM-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
153,155,CHEMBL562476,ANOKEIWYHCYLAM-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,19.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,19.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
154,156,CHEMBL562476,ANOKEIWYHCYLAM-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,19.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,19.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
155,157,CHEMBL562476,ANOKEIWYHCYLAM-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,IC5,=,358.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,6.446116973356125,CNC[C@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
156,158,CHEMBL562476,ANOKEIWYHCYLAM-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,19.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,19.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
157,159,CHEMBL566816,ANOKEIWYHCYLAM-QZTJIDSGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,31.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,31.0,CNC[C@H]([C@@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@@H](c1ccccc1)n1ccc2ccccc21
158,160,CHEMBL570856,ANOKEIWYHCYLAM-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CNC[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
159,161,CHEMBL565309,ANOKEIWYHCYLAM-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNC[C@@H]([C@@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CNC[C@H](O)[C@@H](c1ccccc1)n1ccc2ccccc21
160,162,CHEMBL319523,ANQFEILAMAXVIW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,335.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.4749551929631535,COC(=O)C1C2CCC(C2)CC1C3=CC=C(C=C3)F,COC(=O)C1C2CCC(C2)CC1c1ccc(F)cc1
161,163,CHEMBL1242950,ANTKBACNWQHQJE-UHFFFAOYSA-N,AC-42,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20684563.0,KI,>=,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to human dopamine transporter by radioligand displacement assay,"Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.",J. Med. Chem.,PUBLICATION,,6.0,CCCCC1CCN(CC1)CCCC(=O)C2=CC=CC=C2C,CCCCC1CCN(CCCC(=O)c2ccccc2C)CC1
162,164,CHEMBL451,ANTSCNMPPGJYLG-UHFFFAOYSA-N,CHLORDIAZEPOXIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O,CN=C1CN(O)C(c2ccccc2)=c2cc(Cl)ccc2=N1
163,165,CHEMBL451,ANTSCNMPPGJYLG-UHFFFAOYSA-N,CHLORDIAZEPOXIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O,CN=C1CN(O)C(c2ccccc2)=c2cc(Cl)ccc2=N1
164,166,CHEMBL1945253,ANVGMCMHHXCVBX-RDKMSUMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,28.84,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.540004743952608,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C/C=C/I
165,167,CHEMBL469222,ANVIRSRIYYSFBV-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)CC(=O)N(CC1=C(C=C(C=C1)Cl)Cl)[C@H]2CCNC2,CC(C)CC(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
166,168,CHEMBL517424,ANZMQHLROXAIJU-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,14.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,14.0,CCN1C2=C(C(=CC=C2)F)N(C1=O)[C@H](CCNC)C3=CC(=CC=C3)F,CCn1c(=O)n([C@H](CCNC)c2cccc(F)c2)c2c(F)cccc21
167,169,CHEMBL521589,ANZXOIAKUNOVQU-UHFFFAOYSA-N,BAMBUTEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1
168,170,CHEMBL521589,ANZXOIAKUNOVQU-UHFFFAOYSA-N,BAMBUTEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1
169,171,CHEMBL460499,AOCCBINRVIKJHY-UHFFFAOYSA-N,CARMOFUR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O
170,172,CHEMBL460499,AOCCBINRVIKJHY-UHFFFAOYSA-N,CARMOFUR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O
171,173,CHEMBL573361,AOCFDQDGDIOFRW-CCRGXQTGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,74.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.130768280269023,CCCN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)SC)C(=O)OC,CCCN1C2CCC1[C@@H](C(=O)OC)[C@@H](c1ccc(SC)cc1)C2
172,174,CHEMBL53463,AOJJSUZBOXZQNB-TZSSRYMLSA-N,DOXORUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
173,175,CHEMBL53463,AOJJSUZBOXZQNB-TZSSRYMLSA-N,DOXORUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
174,176,CHEMBL417,AOJJSUZBOXZQNB-VTZDEGQISA-N,EPIRUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
175,177,CHEMBL417,AOJJSUZBOXZQNB-VTZDEGQISA-N,EPIRUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
176,178,CHEMBL1173087,AOUKQWFJPNRGAH-FGJGXXMFSA-N,"6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,1.26,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.899629454882437,COC(CC=C)[C@@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,C=CCC(OC)[C@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
177,179,CHEMBL1173087,AOUKQWFJPNRGAH-FGJGXXMFSA-N,"6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,1.58,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.801342913045579,COC(CC=C)[C@@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,C=CCC(OC)[C@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
178,180,CHEMBL1200623,AOXRBFRFYPMWLR-XGXHKTLJSA-N,ETHYLESTRENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
179,181,CHEMBL1200623,AOXRBFRFYPMWLR-XGXHKTLJSA-N,ETHYLESTRENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
180,182,CHEMBL3287723,AOYJKNKRKBOUAP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24735492.0,INHIBITION,=,-7.7,%,,,,,,,,,,,,,,,Binding affinity to human DAT at 10 uM by radioligand displacement assay,Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu2/3) Receptor Positive Allosteric Modulators (PAMs): Pharmacological Characterization and Assessment in a Rat Model of Cocaine Dependence.,J. Med. Chem.,PUBLICATION,,-7.7,CC1=C(C=CC(=C1O)C(=O)CC(C)(C)C)OCCCCOC2=C(C=CC(=C2)C(=O)O)OC,COc1ccc(C(=O)O)cc1OCCCCOc1ccc(C(=O)CC(C)(C)C)c(O)c1C
181,183,CHEMBL1784685,APARPRRWRUIPGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21570838.0,INHIBITION,<,50.0,%,Active,,,,,,,,,,,,,,Inhibition of human recombinant DAT at 10 uM by radioligand binding assay,Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC1=C(C=CC(=C1)C(=O)N)C2=C(C=CN2C3=CC(=C(C=C3)C(=O)O)O)C4=CC=C(C=C4)OC,COc1ccc(-c2ccn(-c3ccc(C(=O)O)c(O)c3)c2-c2ccc(C(N)=O)cc2C)cc1
182,184,CHEMBL1224317,APFRQKRCPYHTLD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.16,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381597,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C(C=C2)N)Cl,CC(C)(C)CCC1(C(=O)c2ccc(N)c(Cl)c2)CCNC1
183,185,CHEMBL1076586,APHXKHUFVKITGC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1C(=O)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)C4=CC5=C(C=C4)C=CN5,O=C(c1ccc(-c2ccccc2)cc1)N1CCN(C(=O)c2ccc3cc[nH]c3c2)CC1
184,186,CHEMBL379205,APJFYUJBFNMVNI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CN(CCN1)C(CC2=CC=CC=C2OCC(F)(F)F)C3=CC=CC=C3,FC(F)(F)COc1ccccc1CC(c1ccccc1)N1CCNCC1
185,187,CHEMBL267345,APKFDSVGJQXUKY-INPOYWNPSA-N,AMPHOTERICIN B,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2
186,188,CHEMBL267345,APKFDSVGJQXUKY-INPOYWNPSA-N,AMPHOTERICIN B,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2
187,189,CHEMBL241646,APMCQNBYSJNSHZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=C(C=CC(=C1)OCCO)SC2=C(C=C(C=C2)F)N,CN(C)Cc1cc(OCCO)ccc1Sc1ccc(F)cc1N
188,190,CHEMBL3673134,APOHGRUBKIYISF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,449.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.347173697438994,[C-]#[N+]C1=CC=C(C=C1)C2=CC3=C(C=C2)C4(CCN(C3)C4)C5=CC=C(C=C5)Cl,[C-]#[N+]c1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)C2)cc1
189,191,CHEMBL2322001,APQGMQHBIOJWDO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,10.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.0,C1C=CCNCC1C2=CC3=CC=CC=C3C=C2,C1=CCC(c2ccc3ccccc3c2)CNC1
190,192,CHEMBL2206509,APTVKHQLUJFYAC-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,36.2,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.441291429466834,CC1=CC2=C(C=C1)[C@@H](CN(C2)C)C3=CC=C(C=C3)F,Cc1ccc2c(c1)CN(C)C[C@H]2c1ccc(F)cc1
191,193,CHEMBL3323088,APTVKHQLUJFYAC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,KI,=,36.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.443697499232713,CC1=CC2=C(C=C1)C(CN(C2)C)C3=CC=C(C=C3)F,Cc1ccc2c(c1)CN(C)CC2c1ccc(F)cc1
192,194,CHEMBL404754,APWBVHFSBGGAAZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008057,CNCC1=C(C=CC(=C1)C(=O)NC)OC2=C(C=C(C=C2)Cl)Cl,CNCc1cc(C(=O)NC)ccc1Oc1ccc(Cl)cc1Cl
193,195,CHEMBL249161,AQBBMDYZYWMBQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,,,,Not Determined,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CC1CC1C2=CSC3=CC=CC=C32,CN(C)CC1CC1c1csc2ccccc12
194,196,CHEMBL249161,AQBBMDYZYWMBQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,24.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,24.0,CN(C)CC1CC1C2=CSC3=CC=CC=C32,CN(C)CC1CC1c1csc2ccccc12
195,197,CHEMBL878,AQCHWTWZEMGIFD-UHFFFAOYSA-N,METOLAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
196,198,CHEMBL878,AQCHWTWZEMGIFD-UHFFFAOYSA-N,METOLAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
197,199,CHEMBL3323107,AQEBNLPGUGBPPZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,78.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.107905397309519,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=NS4,CN1Cc2ccccc2C(c2ccc3cnsc3c2)C1
198,200,CHEMBL1083706,AQGRUVIDIWOMIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,1400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321763,C1CC1COC2=CC=CC=C2CC(C3=CC=CC=C3)N4CCNCC4,c1ccc(C(Cc2ccccc2OCC2CC2)N2CCNCC2)cc1
199,201,CHEMBL452861,AQHHHDLHHXJYJD-AWEZNQCLSA-N,(-)-PROPANOLOL ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@H](O)COc1cccc2ccccc12
200,202,CHEMBL452861,AQHHHDLHHXJYJD-AWEZNQCLSA-N,(-)-PROPANOLOL ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@H](O)COc1cccc2ccccc12
201,203,CHEMBL275742,AQHHHDLHHXJYJD-CQSZACIVSA-N,DEXPROPRANOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@@H](O)COc1cccc2ccccc12
202,204,CHEMBL275742,AQHHHDLHHXJYJD-CQSZACIVSA-N,DEXPROPRANOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@@H](O)COc1cccc2ccccc12
203,205,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
204,206,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
205,207,CHEMBL257593,AQIDZODGJIWGLO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,10200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.991399828238082,CN(C)CC1=C(C=CN=C1)OC2=C(C=C(C=C2)Cl)OC,COc1cc(Cl)ccc1Oc1ccncc1CN(C)C
206,208,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
207,209,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
208,210,CHEMBL438682,AQLXYFDUEYMEOO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,67900.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,4.168130225719498,COC(=O)C1=C(C2CCC1N2)C3=CC=C(C=C3)[N+](=O)[O-],COC(=O)C1=C(c2ccc([N+](=O)[O-])cc2)C2CCC1N2
209,211,CHEMBL2407328,AQLYDOOFZXWOAC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,1100.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,5.9586073148417755,COCC(C1CCNCC1)C2=CC3=CC=CC=C3C=C2.Cl,COCC(c1ccc2ccccc2c1)C1CCNCC1
210,212,CHEMBL768,AQNDDEOPVVGCPG-UHFFFAOYSA-N,ESMOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
211,213,CHEMBL768,AQNDDEOPVVGCPG-UHFFFAOYSA-N,ESMOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
212,214,CHEMBL202518,AQQRGNNYEPRIIF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,CCCC(C(=O)C1=CC=C(C=C1)C#N)N2CCCC2,CCCC(C(=O)c1ccc(C#N)cc1)N1CCCC1
213,215,CHEMBL202518,AQQRGNNYEPRIIF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,5900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.229147988357856,CCCC(C(=O)C1=CC=C(C=C1)C#N)N2CCCC2,CCCC(C(=O)c1ccc(C#N)cc1)N1CCCC1
214,216,CHEMBL428408,AQRRWNJTDQZWAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,140.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321763,C1CC(=C(C1)C(=O)NCC2=CC=CS2)C3=CC(=C(C=C3)Cl)Cl,O=C(NCc1cccs1)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
215,217,CHEMBL3673151,AQSSBDDIMZJNQJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,63.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.200659450546419,CS(=O)(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C4(CCN(C3)CC4)C5=CC=C(C=C5)Cl,CS(=O)(=O)c1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)cc1
216,218,CHEMBL253182,AQWGYBOWCFEBRM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18085744.0,KI,>,2000.0,NM,,,cell_based,,,,,MDCK,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in MDCK cells,"Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands.",J. Med. Chem.,PUBLICATION,,5.698970004336019,CN(C)CC1=C(C=CC(=C1)F)SC2=C(C=C(C=C2)CO)N,CN(C)Cc1cc(F)ccc1Sc1ccc(CO)cc1N
217,219,CHEMBL551443,AQWUGZUSQXSOTJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCC1=CC(=CC=C1)OC(C2CCNCC2)C3=CN=CC=C3,CCc1cccc(OC(c2cccnc2)C2CCNCC2)c1
218,220,CHEMBL361493,AQYGKZKOQFVRAD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,2730.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.563837352959244,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)F,COC(=O)C1=C(c2ccc(F)cc2)CC2CCC1O2
219,221,CHEMBL1204412,AQZJYBPKTZMMER-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,3.8,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.8,CNCCCC1CC2=CC=CC=C2N(S1(=O)=O)C3=C(C=CC=C3F)F.Cl,CNCCCC1Cc2ccccc2N(c2c(F)cccc2F)S1(=O)=O
220,222,CHEMBL1945781,ARDZHBGLAMKFGJ-IXKJSCDLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,18.2,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.739928612014924,CC(C)OC(=O)[C@@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl,CC(C)OC(=O)[C@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C
221,223,CHEMBL3334784,ARIJCTMJQZWJNV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,46.6,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,46.6,CN(C)CCC(C1=CC=C(C=C1)F)N2CCCC2,CN(C)CCC(c1ccc(F)cc1)N1CCCC1
222,224,CHEMBL498495,AROKURNCLIVVKP-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,4200.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602098,CC1=CC=CC=C1O[C@@H]2[C@H](COC3=CC=CC=C23)CNC,CNC[C@H]1COc2ccccc2[C@@H]1Oc1ccccc1C
223,225,CHEMBL498495,AROKURNCLIVVKP-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@H](COC3=CC=CC=C23)CNC,CNC[C@H]1COc2ccccc2[C@@H]1Oc1ccccc1C
224,226,CHEMBL497461,AROKURNCLIVVKP-KDOFPFPSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2[C@@H](COC3=CC=CC=C23)CNC,CNC[C@@H]1COc2ccccc2[C@H]1Oc1ccccc1C
225,227,CHEMBL498142,AROKURNCLIVVKP-KSSFIOAISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2[C@H](COC3=CC=CC=C23)CNC,CNC[C@H]1COc2ccccc2[C@H]1Oc1ccccc1C
226,228,CHEMBL445082,AROKURNCLIVVKP-RDTXWAMCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CNC,CNC[C@@H]1COc2ccccc2[C@@H]1Oc1ccccc1C
227,229,CHEMBL445082,AROKURNCLIVVKP-RDTXWAMCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,3400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,CC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CNC,CNC[C@@H]1COc2ccccc2[C@@H]1Oc1ccccc1C
228,230,CHEMBL1614641,ARPYQKTVRGFPIS-VIFPVBQESA-N,FLUNOXAPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1
229,231,CHEMBL1614641,ARPYQKTVRGFPIS-VIFPVBQESA-N,FLUNOXAPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1
230,232,CHEMBL378839,ARSOFBZWWWOBKV-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-11.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-11.0,CC(C)CN(CC1=C(C=CC(=C1)C(F)(F)F)Cl)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1cc(C(F)(F)F)ccc1Cl)C1CCNCC1
231,233,CHEMBL232070,ARUHQVGRDPJNBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,605000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.2182446253475314,CC(C)(C)C1=CC=C(C=C1)C2=C(CCCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)(C)C)cc2)CCCC1
232,234,CHEMBL232070,ARUHQVGRDPJNBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,CC(C)(C)C1=CC=C(C=C1)C2=C(CCCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)(C)C)cc2)CCCC1
233,235,CHEMBL471211,ASCGGWXVCATSKL-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,=,5539.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.256568634853316,C1[C@H]([C@@]1(C2=CC=CS2)C(=O)N3CC4=CC=CC=C4C3)CN,NC[C@@H]1C[C@@]1(C(=O)N1Cc2ccccc2C1)c1cccs1
234,236,CHEMBL589179,ASGNFMOFCHAUOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,=,3604.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.443215217692973,CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)OCCCCF)CN(C)C)N,Cc1ccc(Oc2ccc(OCCCCF)cc2CN(C)C)c(N)c1
235,237,CHEMBL250689,ASRDPULQBHFPGU-WFIHMLKPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17418570.0,KI,=,490.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,CC(=O)C1=CC(=CC=C1)NC(=O)N[C@@H]2CCCC[C@H]2CN3CCC[C@H](C3)CC4=CC=C(C=C4)F,CC(=O)c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1
236,238,CHEMBL659,ASUTZQLVASHGKV-JDFRZJQESA-N,GALANTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2
237,239,CHEMBL659,ASUTZQLVASHGKV-JDFRZJQESA-N,GALANTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2
238,240,CHEMBL446,ASWVTGNCAZCNNR-UHFFFAOYSA-N,SULFAMETHAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1
239,241,CHEMBL446,ASWVTGNCAZCNNR-UHFFFAOYSA-N,SULFAMETHAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1
240,242,CHEMBL444633,ATEBXHFBFRCZMA-VXTBVIBXSA-N,RIFABUTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(c4c3C2=O)=NC2(CCN(CC(C)C)CC2)N=5)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
241,243,CHEMBL444633,ATEBXHFBFRCZMA-VXTBVIBXSA-N,RIFABUTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(c4c3C2=O)=NC2(CCN(CC(C)C)CC2)N=5)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
242,244,CHEMBL461153,ATQOTXBBRYXYCL-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CCN1C2=CC=CC=C2N(C1=O)[C@H](CCNC)C3=CC=CC=C3,CCn1c(=O)n([C@H](CCNC)c2ccccc2)c2ccccc21
243,245,CHEMBL598561,ATVZOYVGUWYSKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,6410.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.193141970481181,COC1=C(C(=CC=C1)F)OC2=C(C=CC=N2)C3CCNCC3,COc1cccc(F)c1Oc1ncccc1C1CCNCC1
244,246,CHEMBL2047572,ATXUZVSWVVGJPF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,73.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,73.0,COC1=C(C2=C(C=C1)C=C(C=C2)C(CCN3CCC(CC3)(CC4=CC=CC=C4)O)O)Cl,COc1ccc2cc(C(O)CCN3CCC(O)(Cc4ccccc4)CC3)ccc2c1Cl
245,247,CHEMBL612232,AUIYTQCQFPAFCD-MLVZRXLZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,=,3600.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for binding affinity to dopamine transporter using [125I]RTI-55 as a radioligand in HEK cells expressing human transporters.,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,5.443697499232713,COC1=CC=C(C=C1)/C=C/2\CN3[C@@H]4CCC3[C@@H]([C@@H]2C4)C(=O)OC,COC(=O)[C@H]1C2CC[C@@H]3C[C@@H]1/C(=C/c1ccc(OC)cc1)CN23
246,248,CHEMBL612232,AUIYTQCQFPAFCD-MLVZRXLZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,=,3700.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for inhibition of [3H]DA uptake in HEK-hDAT cells expressing Human dopamine Transporter,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,5.431798275933005,COC1=CC=C(C=C1)/C=C/2\CN3[C@@H]4CCC3[C@@H]([C@@H]2C4)C(=O)OC,COC(=O)[C@H]1C2CC[C@@H]3C[C@@H]1/C(=C/c1ccc(OC)cc1)CN23
247,249,CHEMBL2113279,AUJWWBGAFLMMKB-SMTRIPRVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,885.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.053056729302175,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=C(C=C5)OC)OC)N3C,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(C)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1OC
248,250,CHEMBL2113279,AUJWWBGAFLMMKB-SMTRIPRVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,529.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.276544327964814,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=C(C=C5)OC)OC)N3C,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(C)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1OC
249,251,CHEMBL1950743,AUNMHWAGSWQKHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22290075.0,INHIBITION,=,8.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1(CC(=NNC1=O)C2=CC=C(C=C2)OC3CCN(CC3)C4CCC4)C,CC1(C)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NNC1=O
250,252,CHEMBL2206514,AUOGWJKRNSZLMZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,129.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.889410289700751,CN1CC(C2=C(C1)C(=CC=C2)O)C3=CC=CC=C3,CN1Cc2c(O)cccc2C(c2ccccc2)C1
251,253,CHEMBL1642902,AUOZLNRXVPELRP-ABAIWWIYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,11.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.9586073148417755,C1[C@@H](CC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)CN,NC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
252,254,CHEMBL1642905,AUOZLNRXVPELRP-IAQYHMDHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,92.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.036212172654443,C1[C@@H](CC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl)CN,NC[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
253,255,CHEMBL1642904,AUOZLNRXVPELRP-NHYWBVRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,45.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.346787486224656,C1[C@H](CC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)CN,NC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
254,256,CHEMBL1642903,AUOZLNRXVPELRP-XHDPSFHLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,111.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.954677021213343,C1[C@H](CC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl)CN,NC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
255,257,CHEMBL50588,AUVVAXYIELKVAI-CKBKHPSWSA-N,EMETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21
256,258,CHEMBL50588,AUVVAXYIELKVAI-CKBKHPSWSA-N,EMETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21
257,259,CHEMBL1079263,AUYQRPCINYAISL-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,945.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.024568191490737,C1CNC[C@H]1N(C2=CCOC=C2)C(=O)C3=C(C(=CC=C3)Cl)Cl,O=C(c1cccc(Cl)c1Cl)N(C1=CCOC=C1)[C@H]1CCNC1
258,260,CHEMBL1544,AUYYCJSJGJYCDS-LBPRGKRZSA-N,LIOTHYRONINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
259,261,CHEMBL1544,AUYYCJSJGJYCDS-LBPRGKRZSA-N,LIOTHYRONINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
260,262,CHEMBL964,AUZONCFQVSMFAP-UHFFFAOYSA-N,DISULFIRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,4637.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.333762904104195,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCN(CC)C(=S)SSC(=S)N(CC)CC
261,263,CHEMBL964,AUZONCFQVSMFAP-UHFFFAOYSA-N,DISULFIRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,3684.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.433680378475188,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCN(CC)C(=S)SSC(=S)N(CC)CC
262,264,CHEMBL611063,AVDNQARKBDHXAZ-UBNPUMAJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,3.98,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.400116927926312,C1CC(C1)OC[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl.Cl,Clc1ccc([C@]23CNC[C@H]2[C@@H]3COC2CCC2)cc1Cl
263,265,CHEMBL174,AVKUERGKIZMTKX-NJBDSQKTSA-N,AMPICILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O
264,266,CHEMBL174,AVKUERGKIZMTKX-NJBDSQKTSA-N,AMPICILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O
265,267,CHEMBL2205829,AVNYJOIRGGOFFW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC8=C(C=C7)OCO8)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2
266,268,CHEMBL2205829,AVNYJOIRGGOFFW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC8=C(C=C7)OCO8)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2
267,269,CHEMBL456,AVOLMBLBETYQHX-UHFFFAOYSA-N,ETHACRYNIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl
268,270,CHEMBL456,AVOLMBLBETYQHX-UHFFFAOYSA-N,ETHACRYNIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl
269,271,CHEMBL465515,AVSJNVNTDDYDEP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,24000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,C1CN(CCN1)CCC2=CC3=C(C=C2)C=C(C=C3)F,Fc1ccc2cc(CCN3CCNCC3)ccc2c1
270,272,CHEMBL1085339,AVTQGGVDIQOXSO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,=,95.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,95.0,CC(CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F)NC,CNC(C)CCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
271,273,CHEMBL3310488,AVYVBCVILBXGLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,162.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.790484985457369,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(F)c1
272,274,CHEMBL3310488,AVYVBCVILBXGLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,19.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,19.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(F)c1
273,275,CHEMBL3310488,AVYVBCVILBXGLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,97.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,97.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(F)c1
274,276,CHEMBL3310488,AVYVBCVILBXGLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(F)c1
275,277,CHEMBL1202031,AVZJOJWZRMWFIR-OZIFAFRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,290.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.5376020021010435,CN(C)[C@@H]1C[C@H](C2=C1C=C(C=C2)I)C3=CC(=C(C=C3)Cl)Cl.C(=O)(C(=O)O)O,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(I)cc21
276,278,CHEMBL1202031,AVZJOJWZRMWFIR-OZIFAFRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,310.0,NM,,,,,,,,,,,,,,,Binding affinity against human cloned dopamine transporter using 40-80 pM [125I]RTI,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.508638306165728,CN(C)[C@@H]1C[C@H](C2=C1C=C(C=C2)I)C3=CC(=C(C=C3)Cl)Cl.C(=O)(C(=O)O)O,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(I)cc21
277,279,CHEMBL1202031,AVZJOJWZRMWFIR-OZIFAFRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,0.94,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,0.94,CN(C)[C@@H]1C[C@H](C2=C1C=C(C=C2)I)C3=CC(=C(C=C3)Cl)Cl.C(=O)(C(=O)O)O,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(I)cc21
278,280,CHEMBL123830,AWHFBFFVXKIBQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,47.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.327902142064282,C1=CC(=CC=C1CC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)F,O=C(Cc1ccc(F)cc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
279,281,CHEMBL123830,AWHFBFFVXKIBQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,54.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.267606240177032,C1=CC(=CC=C1CC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)F,O=C(Cc1ccc(F)cc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
280,282,CHEMBL123830,AWHFBFFVXKIBQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,0.9,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,0.9,C1=CC(=CC=C1CC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)F,O=C(Cc1ccc(F)cc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
281,283,CHEMBL3321789,AWIYLVWAILOVMX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,=,620.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2076083105017466,C1CC2CC(CC1N2CCCOC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCOc1ccc(F)cc1
282,284,CHEMBL1233879,AWNMAACWZSNOOV-UHFFFAOYSA-N,KURASOIN B,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23880542.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin) at 10 uM by ligand displacement assay,Neuroactive diol and acyloin metabolites from cone snail-associated bacteria.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1=CC=C(C=C1)CC(=O)C(=O)CC2=CNC3=CC=CC=C32,O=C(Cc1ccccc1)C(=O)Cc1c[nH]c2ccccc12
283,285,CHEMBL3703730,AWYWUACFNBIOSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,80.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.096910013008057,C1C(C2=C(CN1)C=C(C=C2)C3=NN=C(C=C3)C(F)(F)F)C4=CC(=C(C=C4)Cl)Cl,FC(F)(F)c1ccc(-c2ccc3c(c2)CNCC3c2ccc(Cl)c(Cl)c2)nn1
284,286,CHEMBL344110,AXJNQTWCGWGLCZ-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,680.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.167491087293763,CC(C)N(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
285,287,CHEMBL344110,AXJNQTWCGWGLCZ-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,960.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.017728766960433,CC(C)N(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
286,288,CHEMBL344110,AXJNQTWCGWGLCZ-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,1.4,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,1.4,CC(C)N(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
287,289,CHEMBL356981,AXJNQTWCGWGLCZ-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,180.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.7447274948966935,CC(C)N(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
288,290,CHEMBL356981,AXJNQTWCGWGLCZ-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,190.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.721246399047171,CC(C)N(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
289,291,CHEMBL356981,AXJNQTWCGWGLCZ-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,1.1,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,1.1,CC(C)N(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
290,292,CHEMBL2430698,AXKWQHHRWNPPGK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,2143.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6689778289581705,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccccc1
291,293,CHEMBL2430698,AXKWQHHRWNPPGK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,70.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,70.0,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccccc1
292,294,CHEMBL2430698,AXKWQHHRWNPPGK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,91.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,91.8,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccccc1
293,295,CHEMBL18972,AXNGJCOYCMDPQG-UHFFFAOYSA-N,GLEMANSERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15999145.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=CC=C3,OC(c1ccccc1)C1CCN(CCc2ccccc2)CC1
294,296,CHEMBL3331502,AXOLLJKPTOLJBQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,118.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.928117992693875,C1C(CN1)CN(CC2=C(C(=CC=C2)Cl)Cl)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl
295,297,CHEMBL3331502,AXOLLJKPTOLJBQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,36.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,36.0,C1C(CN1)CN(CC2=C(C(=CC=C2)Cl)Cl)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl
296,298,CHEMBL2440659,AXVLPJHYYFHCHK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24074843.0,INHIBITION,>,35.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [125I]-RTI-55 from human recombinant DAT expressed in CHO-K1 cells at 10 uM relative to control,Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,PUBLICATION,,35.0,CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)F)OC3=CN=CN=C3,Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1
297,299,CHEMBL591514,AXVMBCUCHZMEOH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,=,4186.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.378200775997333,CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)OCCF)CN(C)C)N,Cc1ccc(Oc2ccc(OCCF)cc2CN(C)C)c(N)c1
298,300,CHEMBL133902,AYCFVKGYERYDRT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,730.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.136677139879544,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=CC=C4)O,OC1(c2ccccc2)c2ccccc2C2=NCCN21
299,301,CHEMBL133902,AYCFVKGYERYDRT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,1070.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.97061622231479,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=CC=C4)O,OC1(c2ccccc2)c2ccccc2C2=NCCN21
300,302,CHEMBL3310632,AYEJAYBDNXGSOD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,18.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,18.0,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)F)F,Cc1ccc(OC(CC2CNC2)c2ccc(F)c(F)c2)cc1
301,303,CHEMBL340281,AYESQVUVFADUMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,3.3,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.481486060122112,C1CN2C(=N1)C3=C(C2(C4=CC5=CC=CC=C5C=C4)O)C=CC6=CC=CC=C63,OC1(c2ccc3ccccc3c2)c2ccc3ccccc3c2C2=NCCN21
302,304,CHEMBL340281,AYESQVUVFADUMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,KI,=,2.83,NM,,,,,,,,,,,,,,,Inhibition of [125I]- RTI -55 binding at the Dopamine transporter sites on HEK-hDAT cells,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.548213564475711,C1CN2C(=N1)C3=C(C2(C4=CC5=CC=CC=C5C=C4)O)C=CC6=CC=CC=C63,OC1(c2ccc3ccccc3c2)c2ccc3ccccc3c2C2=NCCN21
303,305,CHEMBL340281,AYESQVUVFADUMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,13.0,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,13.0,C1CN2C(=N1)C3=C(C2(C4=CC5=CC=CC=C5C=C4)O)C=CC6=CC=CC=C63,OC1(c2ccc3ccccc3c2)c2ccc3ccccc3c2C2=NCCN21
304,306,CHEMBL316428,AYJLXYNWMUJZRS-ABHNRTSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,246.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.609064892896622,CN1C2C[C@@H](C1CC(=C2C(=O)OC)C3=CC4=CC=CC=C4C=C3)O,COC(=O)C1=C(c2ccc3ccccc3c2)CC2[C@@H](O)CC1N2C
305,307,CHEMBL442843,AZMKBJHIXZCVNL-BXKDBHETSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=C(C=C1)F)[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1[C@H]1CC[C@H](CN)O1
306,308,CHEMBL442843,AZMKBJHIXZCVNL-BXKDBHETSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=C(C=C1)F)[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1[C@H]1CC[C@H](CN)O1
307,309,CHEMBL457967,AZMKBJHIXZCVNL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=C(C=C1)F)C2CCC(O2)CN,COc1ccc(F)cc1C1CCC(CN)O1
308,310,CHEMBL457967,AZMKBJHIXZCVNL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,42760.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.36896230346326,COC1=C(C=C(C=C1)F)C2CCC(O2)CN,COc1ccc(F)cc1C1CCC(CN)O1
309,311,CHEMBL221903,AZOHUEDNMOIDOC-NVQXNPDNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,855.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.068033885271827,CC(=O)C1=CC(=CC=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CC=C)CC3=CC=C(C=C3)F,C=CCN1CC[C@@H](Cc2ccc(F)cc2)C[C@@H]1CCCNC(=O)Nc1cccc(C(C)=O)c1
310,312,CHEMBL578346,AZTPZTRJVCAAMX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,C1CC(C1)N(C2CCNCC2)C(=O)C3=CC4=CC=CC=C4C=C3,O=C(c1ccc2ccccc2c1)N(C1CCC1)C1CCNCC1
311,313,CHEMBL3353960,AZXLOZLZVXIRFJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,120.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,C1CC12CNCC(=O)N(C2)C3=CC(=C(C=C3)Cl)Cl.Cl,O=C1CNCC2(CC2)CN1c1ccc(Cl)c(Cl)c1
312,314,CHEMBL373508,BAWNTPWIVXZYLH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17367122.0,ACTIVITY,,,,Not Active,,cell_based,,,,,CHO,,,,,,,Displacement of radiolabeled BTCP from human recombinant DAT expressed in CHO cells at 10 uM,Designing active template molecules by combining computational de novo design and human chemist's expertise.,J. Med. Chem.,PUBLICATION,,,C1CC(CNC1)C2=CC=CC=C2C(=O)O,O=C(O)c1ccccc1C1CCCNC1
313,315,CHEMBL376952,BAYDYCDSOWCJTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=N2)C3=CC=CC=C3,c1ccc(C(Cc2ccccn2)N2CCNCC2)cc1
314,316,CHEMBL206152,BBGHTDMYOQEIGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-4.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-4.0,C1CNCCC1N(CCC#N)CC2=C(C=C(C=C2)F)C(F)(F)F.C(C(C(=O)O)O)(C(=O)O)O,N#CCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
315,317,CHEMBL43524,BBGVXIKGGVJPNA-MDWZMJQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,5.88,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.88,COC1=CC=C(C=C1)N(CCN2CCN(CC2)C/C=C/C3=CC=CC=C3)CC4=CC=CC=C4,COc1ccc(N(CCN2CCN(C/C=C/c3ccccc3)CC2)Cc2ccccc2)cc1
316,318,CHEMBL256058,BBLALPDUHCRAKZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CC1=CC=CC=C1OC2=CC=CC=C2,CN(C)Cc1ccccc1Oc1ccccc1
317,319,CHEMBL549509,BBNHSIZBHGYEBG-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3110.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.507239610973163,CCCN([C@H]1CCNC1)C(=O)C2=CC=CC=C2SC,CCCN(C(=O)c1ccccc1SC)[C@H]1CCNC1
318,320,CHEMBL573898,BBYFZRZFESDGLZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1450.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.838631997765025,CC1=CC(=C(C=C1)C2CCNCC2)OC3=CC(=CC=C3)F,Cc1ccc(C2CCNCC2)c(Oc2cccc(F)c2)c1
319,321,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,8500.0,NM,,,,,,,,,,,,,,,,,,,,5.070581074285707,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
320,322,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
321,323,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,=,25600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,4.591760034688152,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
322,324,CHEMBL372435,BCHCCPODJPHTTL-GKQVGWSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15121762.0,KI,=,43.0,NM,,,,,,,,,,,,,,,,,,,,7.366531544420414,CN1[C@@H](CCC[C@@H]1/C=C/C2=CC=CC=C2)/C=C/C3=CC=CC=C3,CN1[C@H](/C=C/c2ccccc2)CCC[C@@H]1/C=C/c1ccccc1
323,325,CHEMBL512044,BCZUZJIUZQQTDT-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,8000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008057,CC1=CC(=C(C=C1)O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O)C,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccc(C)cc1C
324,326,CHEMBL497666,BDCMARKCSKLIKU-SUMWQHHRSA-N,MDL-28618,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@H]1CC2=CC=CC=C2[C@@H]1OC3=CC=C(C=C3)C(F)(F)F,CNC[C@@H]1Cc2ccccc2[C@@H]1Oc1ccc(C(F)(F)F)cc1
325,327,CHEMBL3238485,BDCZAGDCRBJPLT-HKWRFOASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=CC=C1N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O)Br,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(Br)cc3)c(O)c12
326,328,CHEMBL497680,BDDVUVHPEHJEPJ-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)F)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccc(F)cc1C
327,329,CHEMBL258449,BDGQOYDELXXRKV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNCC1=C(C=CN=C1)OC2=C(C=C(C=C2)Cl)OC,CNCc1cnccc1Oc1ccc(Cl)cc1OC
328,330,CHEMBL3323179,BDLAKWIEWPJWSY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,5.3,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.275724130399214,CN1CC(C2=C(C1)C=C(C=C2)CN(C)C)C3=CC4=C(C=C3)SC=C4,CN(C)Cc1ccc2c(c1)CN(C)CC2c1ccc2sccc2c1
329,331,CHEMBL3323179,BDLAKWIEWPJWSY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,4.4,NM,314452,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.356547323513812,CN1CC(C2=C(C1)C=C(C=C2)CN(C)C)C3=CC4=C(C=C3)SC=C4,CN(C)Cc1ccc2c(c1)CN(C)CC2c1ccc2sccc2c1
330,332,CHEMBL401417,BDOAHAJYARXKHW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,,,,Not Determined,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CC1CC1C2=CC3=CC(=C(C=C3C=C2)C#N)C#N,CN(C)CC1CC1c1ccc2cc(C#N)c(C#N)cc2c1
331,333,CHEMBL401417,BDOAHAJYARXKHW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,80.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,80.0,CN(C)CC1CC1C2=CC3=CC(=C(C=C3C=C2)C#N)C#N,CN(C)CC1CC1c1ccc2cc(C#N)c(C#N)cc2c1
332,334,CHEMBL514200,BDOFPOSOPQRCSW-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CC1(C2=C(C(=CC=C2)F)N(C1=O)[C@H](CCNC)C3=CC=CC=C3)C,CNCC[C@H](c1ccccc1)N1C(=O)C(C)(C)c2cccc(F)c21
333,335,CHEMBL208178,BDXVEVIJMYWTJE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-8.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-8.0,COCCCN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(C(C(=O)O)O)(C(=O)O)O,COCCCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
334,336,CHEMBL467757,BEEXRDPWWKFYAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,30.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.522878745280337,C=C(CCN1CCN(CC1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,C=C(CCN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
335,337,CHEMBL388759,BEKJWERDBUYMAG-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,107.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.97061622231479,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)Br,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(Br)cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
336,338,CHEMBL388759,BEKJWERDBUYMAG-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,35.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.455931955649724,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)Br,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(Br)cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
337,339,CHEMBL194781,BEKVIGOVWYQMOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,5.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=C(C=C1)N2C3=C(CC(C2=O)CCCNC)C=C(C=C3)F,CNCCCC1Cc2cc(F)ccc2N(c2ccc(C)cc2)C1=O
338,340,CHEMBL194781,BEKVIGOVWYQMOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1=CC=C(C=C1)N2C3=C(CC(C2=O)CCCNC)C=C(C=C3)F,CNCCCC1Cc2cc(F)ccc2N(c2ccc(C)cc2)C1=O
339,341,CHEMBL3673142,BENAFAMTKPICCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,156.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.806041021980812,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=CN=CN=C4)C5=CC=C(C=C5)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(-c4cncnc4)ccc23)cc1
340,342,CHEMBL3703741,BEWPJYFILUTZHB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,24.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.610833915635467,C1C(C2=CC(=C(C=C2CN1)C3=CC=C(C=C3)C(=O)N)F)C4=CC=C(C=C4)Cl,NC(=O)c1ccc(-c2cc3c(cc2F)C(c2ccc(Cl)cc2)CNC3)cc1
341,343,CHEMBL42442,BEZZFPOZAYTVHN-UHFFFAOYSA-N,OXFENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc([S+]([O-])c3ccccc3)cc2[nH]1
342,344,CHEMBL42442,BEZZFPOZAYTVHN-UHFFFAOYSA-N,OXFENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc([S+]([O-])c3ccccc3)cc2[nH]1
343,345,CHEMBL588119,BFCDFTHTSVTWOG-YLJYHZDGSA-N,SULOCTIDIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2570.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.590066876668706,CCCCCCCCN[C@H](C)[C@H](C1=CC=C(C=C1)SC(C)C)O,CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1
344,346,CHEMBL588119,BFCDFTHTSVTWOG-YLJYHZDGSA-N,SULOCTIDIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2041.9,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.6899655308640105,CCCCCCCCN[C@H](C)[C@H](C1=CC=C(C=C1)SC(C)C)O,CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1
345,347,CHEMBL2012118,BFJBGRWXGVSGLZ-LCLYSXEGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)[C@@H]1[C@H](CC2CCC1O2)C3=CC=CS3,COC(=O)[C@H]1C2CCC(C[C@@H]1c1cccs1)O2
346,348,CHEMBL2012118,BFJBGRWXGVSGLZ-LCLYSXEGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@H](CC2CCC1O2)C3=CC=CS3,COC(=O)[C@H]1C2CCC(C[C@@H]1c1cccs1)O2
347,349,CHEMBL2012119,BFJBGRWXGVSGLZ-WPAICRMJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=CS3,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cccs1)O2
348,350,CHEMBL2012119,BFJBGRWXGVSGLZ-WPAICRMJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=CS3,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cccs1)O2
349,351,CHEMBL120633,BFNAZBHYEHFJJD-NIGMOEJFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,IC50,=,470.0,NM,,,,,,,,,,,,,,,Antagonism of cocaine''s inhibition of [3H]DA uptake at the dose of 50 nM,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,6.327902142064282,CC1=CC=C(C=C1)C(=O)C2CN(CCC2(C3=CC=C(C=C3)C)O)C.CN1C2CCC1[C@H]([C@H](C2)C(=O)OC3=CC=CC=C3)C(=O)OC,Cc1ccc(C(=O)C2CN(C)CCC2(O)c2ccc(C)cc2)cc1
350,352,CHEMBL120633,BFNAZBHYEHFJJD-NIGMOEJFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,IC50,=,717.0,NM,,,,,,,,,,,,,,,Antagonism of cocaine''s inhibition of [3H]DA uptake at the dose of 200 nM,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,6.1444808443322,CC1=CC=C(C=C1)C(=O)C2CN(CCC2(C3=CC=C(C=C3)C)O)C.CN1C2CCC1[C@H]([C@H](C2)C(=O)OC3=CC=CC=C3)C(=O)OC,Cc1ccc(C(=O)C2CN(C)CCC2(O)c2ccc(C)cc2)cc1
351,353,CHEMBL120633,BFNAZBHYEHFJJD-NIGMOEJFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,IC50,=,1161.0,NM,,,,,,,,,,,,,,,Antagonism of cocaine''s inhibition of [3H]DA uptake at the dose of 500 nM,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,5.935167780261426,CC1=CC=C(C=C1)C(=O)C2CN(CCC2(C3=CC=C(C=C3)C)O)C.CN1C2CCC1[C@H]([C@H](C2)C(=O)OC3=CC=CC=C3)C(=O)OC,Cc1ccc(C(=O)C2CN(C)CCC2(O)c2ccc(C)cc2)cc1
352,354,CHEMBL691,BFPYWIDHMRZLRN-SLHNCBLASA-N,ETHINYL ESTRADIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,559.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.252588192113577,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
353,355,CHEMBL691,BFPYWIDHMRZLRN-SLHNCBLASA-N,ETHINYL ESTRADIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,444.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.35261702988538,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
354,356,CHEMBL1200604,BGDKAVGWHJFAGW-UHFFFAOYSA-N,TROPICAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1
355,357,CHEMBL1200604,BGDKAVGWHJFAGW-UHFFFAOYSA-N,TROPICAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1
356,358,CHEMBL231858,BGHABJXKIQKRJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,22000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.657577319177793,COC(=O)C1=C(CCCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCCC1
357,359,CHEMBL231858,BGHABJXKIQKRJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,26000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.585026652029182,COC(=O)C1=C(CCCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCCC1
358,360,CHEMBL231858,BGHABJXKIQKRJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,8511380382023.76,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.93,COC(=O)C1=C(CCCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCCC1
359,361,CHEMBL1084577,BGJYOLBNUMRPNE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,3460.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.460923901207224,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC(=CC=C3)F,Fc1cccc(C(Cc2ccccc2OC(F)F)N2CCNCC2)c1
360,362,CHEMBL512665,BGQYUSCFJWWBHR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,19000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.721246399047171,CCCCN(C1CCNCC1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2,CCCCN(C1CCNCC1)S(=O)(=O)c1ccc2ccccc2c1
361,363,CHEMBL267044,BGRJTUBHPOOWDU-NSHDSACASA-N,LEVOSULPIRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
362,364,CHEMBL267044,BGRJTUBHPOOWDU-NSHDSACASA-N,LEVOSULPIRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
363,365,CHEMBL26,BGRJTUBHPOOWDU-UHFFFAOYSA-N,SULPIRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
364,366,CHEMBL26,BGRJTUBHPOOWDU-UHFFFAOYSA-N,SULPIRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
365,367,CHEMBL395408,BGSBHLAICAANSC-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CC1=C(C(=CC=C1)CN([C@@H]2CCNC2)C3CCOCC3)C,Cc1cccc(CN(C2CCOCC2)[C@@H]2CCNC2)c1C
366,368,CHEMBL247733,BGSBHLAICAANSC-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,727.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.138465589140963,CC1=C(C(=CC=C1)CN([C@H]2CCNC2)C3CCOCC3)C,Cc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1C
367,369,CHEMBL247733,BGSBHLAICAANSC-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,727.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.138465589140963,CC1=C(C(=CC=C1)CN([C@H]2CCNC2)C3CCOCC3)C,Cc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1C
368,370,CHEMBL247733,BGSBHLAICAANSC-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,727.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.138465589140963,CC1=C(C(=CC=C1)CN([C@H]2CCNC2)C3CCOCC3)C,Cc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1C
369,371,CHEMBL247733,BGSBHLAICAANSC-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,=,727.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.138465589140963,CC1=C(C(=CC=C1)CN([C@H]2CCNC2)C3CCOCC3)C,Cc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1C
370,372,CHEMBL89476,BGWLJJSQLYVDMU-BWULQTGUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,3.04,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.517126416391246,CN1C2C[C@@H](C1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2C[C@H](O)C1N2C
371,373,CHEMBL330228,BGWLJJSQLYVDMU-BZORQXCASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,1.19,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.924453038607469,CN1C2C[C@H](C1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)C1N2C
372,374,CHEMBL330228,BGWLJJSQLYVDMU-BZORQXCASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,1.42,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.847711655616944,CN1C2C[C@H](C1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)C1N2C
373,375,CHEMBL330228,BGWLJJSQLYVDMU-BZORQXCASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,48.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.3187587626244115,CN1C2C[C@H](C1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)C1N2C
374,376,CHEMBL606929,BGWLJJSQLYVDMU-SSUBCMSUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,0.76,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,9.119186407719207,CN1[C@@H]2C[C@H](C1[C@@H](C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)[C@@H]1C(c2ccc(Cl)c(Cl)c2)C[C@H]2C[C@@H](O)C1N2C
375,377,CHEMBL91184,BGWLJJSQLYVDMU-WYXSCQSXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,0.3,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,9.522878745280336,CN1[C@@H]2C[C@H](C1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)C[C@H]2C[C@@H](O)C1N2C
376,378,CHEMBL2310846,BGWLJJSQLYVDMU-XPZHSIPCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,482.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.31695296176115,CN1[C@@H]2[C@@H](CC1CC([C@@H]2C(=O)OC)C3=CC(=C(C=C3)Cl)Cl)O,COC(=O)[C@H]1C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)[C@H]1N2C
377,379,CHEMBL2310846,BGWLJJSQLYVDMU-XPZHSIPCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,2690.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,5.570247719997592,CN1[C@@H]2[C@@H](CC1CC([C@@H]2C(=O)OC)C3=CC(=C(C=C3)Cl)Cl)O,COC(=O)[C@H]1C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)[C@H]1N2C
378,380,CHEMBL407815,BGXIKTHXOUZBOU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNCC1=CC=CC=C1OC2=C(C=C(C=C2)Cl)F,CNCc1ccccc1Oc1ccc(Cl)cc1F
379,381,CHEMBL120269,BGZGKVAVORWNIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,8190.0,NM,,,,,,,,,,,,,,,Binding Affinity to cocaine site of dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol. ,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,5.086716098239582,CC1=CC=C(C=C1)C2C3CN(CCC3(OC(=O)O2)C4=CC=C(C=C4)C)C,Cc1ccc(C2OC(=O)OC3(c4ccc(C)cc4)CCN(C)CC23)cc1
380,382,CHEMBL272744,BHAREOZDRRGSHA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCNCC1CC1(C2=CC=CC=C2)C(=O)N(CC)CC,CCNCC1CC1(C(=O)N(CC)CC)c1ccccc1
381,383,CHEMBL1099212,BHCVJMVHWIDLDP-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,=,30.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,CN1CCN(CC1)C[C@@H](C2=CC(=CC=C2)Cl)C3(CCCCC3)N,CN1CCN(C[C@@H](c2cccc(Cl)c2)C2(N)CCCCC2)CC1
382,384,CHEMBL339401,BHKDMCGCJODKJK-ISRILLDMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,389.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,6.410050398674293,CN1C2CCC1C([C@H](C2)OC(C3=CC=C(C=C3)Br)C4=CC=C(C=C4)I)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(Br)cc1)c1ccc(I)cc1)N2C
383,385,CHEMBL205596,BHQCQFFYRZLCQQ-OELDTZBJSA-N,CHOLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O
384,386,CHEMBL205596,BHQCQFFYRZLCQQ-OELDTZBJSA-N,CHOLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O
385,387,CHEMBL525532,BHTUHPLMWNGSLY-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2[C@H](OCC3=CC=CC=C23)CN,Cc1ccccc1O[C@@H]1c2ccccc2CO[C@@H]1CN
386,388,CHEMBL524798,BHTUHPLMWNGSLY-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](OCC3=CC=CC=C23)CN,Cc1ccccc1O[C@H]1c2ccccc2CO[C@H]1CN
387,389,CHEMBL524798,BHTUHPLMWNGSLY-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](OCC3=CC=CC=C23)CN,Cc1ccccc1O[C@H]1c2ccccc2CO[C@H]1CN
388,390,CHEMBL3622346,BIALXFMHWCNRAQ-OQIWPSSASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25801931.0,INHIBITION,=,18.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 uM relative to control,Pseudosaccharin amines as potent and selective KV1.5 blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,18.0,COC1=C2C(=CC=C1)S(=O)(=O)NC2=NCC3(CCC(CC3)O)C4=CC=CC=C4,COc1cccc2c1C(=NCC1(c3ccccc3)CCC(O)CC1)NS2(=O)=O
389,391,CHEMBL1813470,BIDMNSYJUSJTRE-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,61.66,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.209996479609512,CN1C[C@H]2CCCC[C@]2(C1)C3=CC4=CC=CC=C4C=C3,CN1C[C@H]2CCCC[C@@]2(c2ccc3ccccc3c2)C1
390,392,CHEMBL1813313,BIDMNSYJUSJTRE-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,20.42,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.689944262249107,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC4=CC=CC=C4C=C3,CN1C[C@@H]2CCCC[C@]2(c2ccc3ccccc3c2)C1
391,393,CHEMBL1813313,BIDMNSYJUSJTRE-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,309.03,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.509999358109048,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC4=CC=CC=C4C=C3,CN1C[C@@H]2CCCC[C@]2(c2ccc3ccccc3c2)C1
392,394,CHEMBL3084803,BIDUPMYXGFNAEJ-APGVDKLISA-N,ASTROMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N,CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN
393,395,CHEMBL3084803,BIDUPMYXGFNAEJ-APGVDKLISA-N,ASTROMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N,CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN
394,396,CHEMBL439423,BIHDNMFWZMAKEI-WCQYABFASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C#CCN(C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
395,397,CHEMBL1629810,BIIFEDMBGOQTDO-USCPGHQQSA-N,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1687.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.772884917410876,CC(COC[C@H]1[C@H]2[C@H]([C@@H](CO1)O[C@H]3[C@@H](O[C@H]([C@H]([C@@H]3O)O)O[C@H]4[C@@H](O[C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H](O[C@H]([C@H]([C@@H]5O)O)O[C@H]6[C@@H](O[C@H]([C@H]([C@@H]6O)O)O[C@H]7[C@@H](O[C@H]([C@H]([C@@H]7O)O)O[C@H]8[C@@H](O[C@H]([C@H]([C@@H]8O)O)O[C@H]9[C@@H](O[C@@H](O2)[C@H]([C@@H]9O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O,CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)OC[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@H]9[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O
396,398,CHEMBL1629810,BIIFEDMBGOQTDO-USCPGHQQSA-N,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1341.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.872571222148402,CC(COC[C@H]1[C@H]2[C@H]([C@@H](CO1)O[C@H]3[C@@H](O[C@H]([C@H]([C@@H]3O)O)O[C@H]4[C@@H](O[C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H](O[C@H]([C@H]([C@@H]5O)O)O[C@H]6[C@@H](O[C@H]([C@H]([C@@H]6O)O)O[C@H]7[C@@H](O[C@H]([C@H]([C@@H]7O)O)O[C@H]8[C@@H](O[C@H]([C@H]([C@@H]8O)O)O[C@H]9[C@@H](O[C@@H](O2)[C@H]([C@@H]9O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O,CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)OC[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@H]9[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O
397,399,CHEMBL1224401,BINJCVHVYJSTMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C(C(=C2)Cl)Cl)F,CC(C)(C)CCC1(C(=O)c2cc(F)c(Cl)c(Cl)c2)CCNC1
398,400,CHEMBL1516187,BIPNUYXEYOEPHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24494745.0,KI,=,390.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to wild type human DAT expressed in African green monkey COS7 cells assessed as inhibition of [3H]-dopamine uptake after 5 mins by beta-scintillation counting analysis,Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues.,J. Med. Chem.,PUBLICATION,,6.4089353929735005,C1=CC=C(C=C1)C(C2=CC=CC=C2)SCCN,NCCSC(c1ccccc1)c1ccccc1
399,401,CHEMBL540333,BISDZXSPECCJOM-MOGJOVFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,4310.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3655227298392685,COC1=CC=C(C=C1)[C@H](CN)[C@H](C2CCCCC2)O.Cl,COc1ccc([C@H](CN)[C@@H](O)C2CCCCC2)cc1
400,402,CHEMBL38190,BIVQKVVWOOKOMH-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,5.3979400086720375,COC(=O)[C@@H]([C@@H]1CCCCO1)C2=CC3=CC=CC=C3C=C2,COC(=O)[C@H](c1ccc2ccccc2c1)[C@@H]1CCCCO1
401,403,CHEMBL288186,BIVQKVVWOOKOMH-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,6.366531544420414,COC(=O)[C@H]([C@@H]1CCCCO1)C2=CC3=CC=CC=C3C=C2,COC(=O)[C@@H](c1ccc2ccccc2c1)[C@@H]1CCCCO1
402,404,CHEMBL399228,BIXIBQFJRMFLKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,830.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.080921907623925,CONC(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl,CONC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
403,405,CHEMBL467123,BJBCUOODXPAOKN-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CNC[C@H]([C@H](C1=CC=C(C=C1)OC)N(C)C2=CC=CC=C2)O,CNC[C@@H](O)[C@H](c1ccc(OC)cc1)N(C)c1ccccc1
404,406,CHEMBL451838,BJICBLMMTYZFKB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23707254.0,KI,=,3900.0,NM,,,,,,,,,,,,,,,Antagonist activity at DAT (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,C1=CC=C2C(=C1)C=CC=C2OC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53,O=C(Oc1cccc2ccccc12)N1c2ccccc2Sc2ccccc21
405,407,CHEMBL445206,BJIOGJUNALELMI-ARJAWSKDSA-N,ISOEUGENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C\C1=CC(=C(C=C1)O)OC,C/C=C\c1ccc(O)c(OC)c1
406,408,CHEMBL445206,BJIOGJUNALELMI-ARJAWSKDSA-N,ISOEUGENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C\C1=CC(=C(C=C1)O)OC,C/C=C\c1ccc(O)c(OC)c1
407,409,CHEMBL202811,BJJMXMMHXNEXRL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2CN(C)C)N,Cc1ccc(C(=O)c2ccccc2CN(C)C)c(N)c1
408,410,CHEMBL578612,BJLKZFUZNNATGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,2060.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.6861327796308485,CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C(C)(C)C,CC(C(=O)c1cccc(Cl)c1)N(C)C(C)(C)C
409,411,CHEMBL578612,BJLKZFUZNNATGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,6400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.1938200260161125,CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C(C)(C)C,CC(C(=O)c1cccc(Cl)c1)N(C)C(C)(C)C
410,412,CHEMBL578612,BJLKZFUZNNATGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C(C)(C)C,CC(C(=O)c1cccc(Cl)c1)N(C)C(C)(C)C
411,413,CHEMBL401676,BJQGGALRPGCIFD-WCQYABFASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,CCN(CC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
412,414,CHEMBL402794,BJQHLKABXJIVAM-BGYRXZFFSA-N,BIS(2-ETHYLHEXYL)PHTHALATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC,CCCC[C@H](CC)COC(=O)c1ccccc1C(=O)OC[C@H](CC)CCCC
413,415,CHEMBL402794,BJQHLKABXJIVAM-BGYRXZFFSA-N,BIS(2-ETHYLHEXYL)PHTHALATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC,CCCC[C@H](CC)COC(=O)c1ccccc1C(=O)OC[C@H](CC)CCCC
414,416,CHEMBL208232,BJSTYDNATGHOTI-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,120.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CC(C)CN(CC1=C(C=C(C=C1)C(F)(F)F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccc(C(F)(F)F)cc1F)C1CCNCC1
415,417,CHEMBL408940,BJWRNMDFZRRXMB-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,C#CCN(CC=C)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
416,418,CHEMBL526825,BKCSCHQRSOSNPN-HKUYNNGSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=C(C(=CC=C1)F)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CCc1cccc(F)c1O[C@H]1c2ccccc2CO[C@H]1CNC
417,419,CHEMBL1944980,BKHDTODCSABTEV-JFOHDYCDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CC(C)C1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3)I,COC(=O)[C@H]1[C@@H](c2ccc(C(C)C)c(I)c2)C[C@@H]2CC[C@H]1N2
418,420,CHEMBL570593,BKMZXLKUUMOTKA-XMMPIXPASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821575.0,IC50,=,2.8,NM,,,,,,,,,,,,,,,Inhibition of DAT,Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,8.55284196865778,CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=C(C=C(C=C3)CCC(=O)O)C#N)O,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1ccc(CCC(=O)O)cc1C#N
419,421,CHEMBL198018,BKQSBMKFNNGLCD-NEPJUHHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter; nt is not tested,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,,CN(C)C[C@H]1C[C@@H]1C2=CNC3=CC=CC(=C32)C#N,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2cccc(C#N)c12
420,422,CHEMBL42150,BKQZGZZNBPJCTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.96,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.96,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCN(Cc3ccccc3)c3ccccc3)CC2)cc1
421,423,CHEMBL42150,BKQZGZZNBPJCTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.66,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.66,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCN(Cc3ccccc3)c3ccccc3)CC2)cc1
422,424,CHEMBL157138,BKRGVLQUQGGVSM-KBXCAEBGSA-N,LISURIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
423,425,CHEMBL157138,BKRGVLQUQGGVSM-KBXCAEBGSA-N,LISURIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
424,426,CHEMBL2430681,BKSQHIKAUPPMAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,179.3,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.746419710437817,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc(Cl)cc1
425,427,CHEMBL2430681,BKSQHIKAUPPMAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,91.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,91.8,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc(Cl)cc1
426,428,CHEMBL2430681,BKSQHIKAUPPMAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,99.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,99.0,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc(Cl)cc1
427,429,CHEMBL3704751,BKVALIDOPGIDPZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.698970004336019,CCOC1=CC=C(C=C1)C2(CCC2)C(CC(C)C)NCCNC(=O)OCC,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
428,430,CHEMBL3704751,BKVALIDOPGIDPZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,158.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.799970733446231,CCOC1=CC=C(C=C1)C2(CCC2)C(CC(C)C)NCCNC(=O)OCC,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
429,431,CHEMBL3704751,BKVALIDOPGIDPZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1924.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.7157949322982065,CCOC1=CC=C(C=C1)C2(CCC2)C(CC(C)C)NCCNC(=O)OCC,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
430,432,CHEMBL3704751,BKVALIDOPGIDPZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,158.5,NM,317681,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.799970733446231,CCOC1=CC=C(C=C1)C2(CCC2)C(CC(C)C)NCCNC(=O)OCC,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
431,433,CHEMBL463431,BKWWNLJWEVOUOL-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCBr)OC,COc1ccc(C2=NN(CCCCCBr)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
432,434,CHEMBL463431,BKWWNLJWEVOUOL-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCBr)OC,COc1ccc(C2=NN(CCCCCBr)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
433,435,CHEMBL463431,BKWWNLJWEVOUOL-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCBr)OC,COc1ccc(C2=NN(CCCCCBr)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
434,436,CHEMBL463431,BKWWNLJWEVOUOL-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCBr)OC,COc1ccc(C2=NN(CCCCCBr)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
435,437,CHEMBL480988,BKWWNLJWEVOUOL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NN(C(=O)C3C2CC=CC3)CCCCCBr)OC,COc1ccc(C2=NN(CCCCCBr)C(=O)C3CC=CCC23)cc1OC
436,438,CHEMBL480988,BKWWNLJWEVOUOL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NN(C(=O)C3C2CC=CC3)CCCCCBr)OC,COc1ccc(C2=NN(CCCCCBr)C(=O)C3CC=CCC23)cc1OC
437,439,CHEMBL600053,BKYSPAJPVPEZOE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19954972.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(O6)NCC7=CC(=CC=C7)F,Fc1cccc(CNC23OC4C5C6CC(C7C6C4C72)C53)c1
438,440,CHEMBL600053,BKYSPAJPVPEZOE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19954972.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(O6)NCC7=CC(=CC=C7)F,Fc1cccc(CNC23OC4C5C6CC(C7C6C4C72)C53)c1
439,441,CHEMBL479409,BKZBLBKUEHCXOL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,8000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008057,CN(C)CC1=C(C=CC(=C1)S(=O)(=O)N)OC2=CC=C(C=C2)OC(F)(F)F,CN(C)Cc1cc(S(N)(=O)=O)ccc1Oc1ccc(OC(F)(F)F)cc1
440,442,CHEMBL232068,BLAXQDSTBRMZPC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.823908740944319,COC(=O)C1=C(CCCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCCC1
441,443,CHEMBL232068,BLAXQDSTBRMZPC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,12000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.920818753952375,COC(=O)C1=C(CCCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCCC1
442,444,CHEMBL232068,BLAXQDSTBRMZPC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,85113803820237.6,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.93,COC(=O)C1=C(CCCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCCC1
443,445,CHEMBL1254439,BLBRFFAJTBEQKE-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,77.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.113509274827518,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=C(C=C2)[N+](=O)[O-],COC(=O)[C@H](c1ccc([N+](=O)[O-])cc1)[C@H]1CCCCN1
444,446,CHEMBL1171975,BLEJWKMRQPRJHY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,15.85,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4,c1ccc(CC2CNCCN2c2ccc3[nH]ncc3c2)cc1
445,447,CHEMBL278172,BLFLLBZGZJTVJG-UHFFFAOYSA-N,BENZOCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=CC=C(C=C1)N,CCOC(=O)c1ccc(N)cc1
446,448,CHEMBL278172,BLFLLBZGZJTVJG-UHFFFAOYSA-N,BENZOCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=CC=C(C=C1)N,CCOC(=O)c1ccc(N)cc1
447,449,CHEMBL15245,BLGXFZZNTVWLAY-SCYLSFHTSA-N,YOHIMBINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21
448,450,CHEMBL15245,BLGXFZZNTVWLAY-SCYLSFHTSA-N,YOHIMBINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21
449,451,CHEMBL1643651,BLHHCJYOCBBQLB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,332.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.478861916295964,C1CC2C(=C(CC1S2)C3=CC(=C(C=C3)Cl)Cl)C4=CC(=NO4)C5=CC=CC=C5,Clc1ccc(C2=C(c3cc(-c4ccccc4)no3)C3CCC(C2)S3)cc1Cl
450,452,CHEMBL499,BLJRIMJGRPQVNF-JTQLQIEISA-N,TIMOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1
451,453,CHEMBL499,BLJRIMJGRPQVNF-JTQLQIEISA-N,TIMOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1
452,454,CHEMBL596714,BLKKGRNFYMEBJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6170.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.209714835966757,CC1=CC=CC=C1OC2=C(C=CC=N2)C3CCNCC3,Cc1ccccc1Oc1ncccc1C1CCNCC1
453,455,CHEMBL1224490,BLKNUASSHDJVDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,5.01,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,CC(C)CC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CC(C)CC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
454,456,CHEMBL1224490,BLKNUASSHDJVDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,7.94,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,CC(C)CC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CC(C)CC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
455,457,CHEMBL506137,BLPFKCJJWVVUNI-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,5000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CC1=C(C=CC(=C1)F)O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccc(F)cc1C
456,458,CHEMBL1306,BLSQLHNBWJLIBQ-OZXSUGGESA-N,TERCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,5472.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.2618539112879406,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
457,459,CHEMBL1306,BLSQLHNBWJLIBQ-OZXSUGGESA-N,TERCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4347.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.361810359809163,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
458,460,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4
459,461,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4
460,462,CHEMBL2047579,BLVOPMLJPLEJNF-QVKFZJNVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,56.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,56.0,C[C@H]([C@H](C1=CC(=C(C=C1)Cl)Cl)O)N2CCC(=CC2)CC3=CC=CC=C3,C[C@H]([C@@H](O)c1ccc(Cl)c(Cl)c1)N1CC=C(Cc2ccccc2)CC1
461,463,CHEMBL2047580,BLVOPMLJPLEJNF-YCRPNKLZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,64.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,64.0,C[C@@H]([C@H](C1=CC(=C(C=C1)Cl)Cl)O)N2CCC(=CC2)CC3=CC=CC=C3,C[C@@H]([C@@H](O)c1ccc(Cl)c(Cl)c1)N1CC=C(Cc2ccccc2)CC1
462,464,CHEMBL461143,BLWMSZSENYHERE-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,3500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,CC1=C(C(=CC=C1)O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O)C,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1cccc(C)c1C
463,465,CHEMBL1070,BLXXJMDCKKHMKV-UHFFFAOYSA-N,NABUMETONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,COc1ccc2cc(CCC(C)=O)ccc2c1
464,466,CHEMBL1070,BLXXJMDCKKHMKV-UHFFFAOYSA-N,NABUMETONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,COc1ccc2cc(CCC(C)=O)ccc2c1
465,467,CHEMBL2203713,BLZNLOLTHDUEOL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22840695.0,INHIBITION,=,40.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]BTCP from human recombinant dopamine transporter expressed in CHO cells at 10 uM after 120 mins,"Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.",Eur. J. Med. Chem.,PUBLICATION,,40.0,C1CNCCC1N2CCC3=C2C=CC(=C3)N=C(C4=CC=CS4)N,NC(=Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1
466,468,CHEMBL2338038,BMBZYVSLEAFRRW-KSSFIOAISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,2511.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,COC1=C(C=CC(=C1)[N+](=O)[O-])O[C@H]([C@H]2CCNC2)C3=CC=CC=C3,COc1cc([N+](=O)[O-])ccc1O[C@@H](c1ccccc1)[C@H]1CCNC1
467,469,CHEMBL2432063,BMHWWKPJPARTBN-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CC1CCCCC1)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CC1CCCCC1)[C@H]1C2C3CC4C5C3CC2C5C41
468,470,CHEMBL101905,BMNNHOAPHMYHIH-NUWOQIAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,67.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.173925197299173,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC4C2C(=C)CN34,C=C1CN2C3CC[C@@H]2C[C@H](c2ccc(C)cc2)C13
469,471,CHEMBL377785,BMNNHOAPHMYHIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784855.0,KI,=,40.99,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT transfected in HEK293 cells,Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3873220816834975,CC1=CC=C(C=C1)C2CC3CCC4C2C(=C)CN34,C=C1CN2C3CCC2C1C(c1ccc(C)cc1)C3
470,472,CHEMBL219224,BMRJUXFHOOHDBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,22.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.657577319177793,CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(c1ccc(Cl)cc1)C1CCCCN1
471,473,CHEMBL219224,BMRJUXFHOOHDBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,1500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.823908740944319,CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(c1ccc(Cl)cc1)C1CCCCN1
472,474,CHEMBL219224,BMRJUXFHOOHDBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,180.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.7447274948966935,CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(c1ccc(Cl)cc1)C1CCCCN1
473,475,CHEMBL219224,BMRJUXFHOOHDBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,>,3900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.4089353929735005,CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(c1ccc(Cl)cc1)C1CCCCN1
474,476,CHEMBL566207,BMWDQBTXNBGORC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC1=CC=C(C=C1)C(=O)C(C)NC(C)(C)C,Cc1ccc(C(=O)C(C)NC(C)(C)C)cc1
475,477,CHEMBL566207,BMWDQBTXNBGORC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC1=CC=C(C=C1)C(=O)C(C)NC(C)(C)C,Cc1ccc(C(=O)C(C)NC(C)(C)C)cc1
476,478,CHEMBL566207,BMWDQBTXNBGORC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,1950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.709965388637482,CC1=CC=C(C=C1)C(=O)C(C)NC(C)(C)C,Cc1ccc(C(=O)C(C)NC(C)(C)C)cc1
477,479,CHEMBL132941,BNGGAXDPIFCFSB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,INHIBITION,=,5.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane at a concentration of 10e-6 M,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.0,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C5=CC=CC=C5C6=CC=CC=C63,OC1(c2ccc(Cl)cc2)c2c(c3ccccc3c3ccccc23)C2=NCCN21
478,480,CHEMBL1643647,BNMCKPDOHSHTAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,C1CC2C(=C(CC1S2)C3=CC=CC=C3)C4=CC(=NO4)C5=CC=CC=C5,c1ccc(C2=C(c3cc(-c4ccccc4)no3)C3CCC(C2)S3)cc1
479,481,CHEMBL192,BNRNXUUZRGQAQC-UHFFFAOYSA-N,SILDENAFIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
480,482,CHEMBL192,BNRNXUUZRGQAQC-UHFFFAOYSA-N,SILDENAFIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
481,483,CHEMBL211494,BNTIEMZWVNNNAF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.0506099933550885,CN1C2CCC1C3COC(=O)CCCCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCCCC(=O)Nc3ccc(cc3)C1C2
482,484,CHEMBL1200545,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,DIFLORASONE DIACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
483,485,CHEMBL1200545,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,DIFLORASONE DIACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
484,486,CHEMBL334923,BOHGZALGHLQJNA-QINSGFPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11229746.0,AFFINITY,=,5.28,%,,,,,,,,,,,,,,,Compound was tested for binding affinity against dopaminergic uptake,First tricyclic oximino derivatives as 5-HT3 ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.28,CC1=CSC\2=C1N3C=CC=C3/C2=N/OCCN(C)C,Cc1csc2c1-n1cccc1/C2=N/OCCN(C)C
485,487,CHEMBL2047578,BONBIWJAPUUALK-AVRWGWEMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,22.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,22.0,C[C@@H]([C@H](C1=CC2=C(C=C1)C(=C(C=C2)OC)Cl)O)N3CCC(CC3)(CC4=CC=CC=C4)O,COc1ccc2cc([C@H](O)[C@H](C)N3CCC(O)(Cc4ccccc4)CC3)ccc2c1Cl
486,488,CHEMBL2047577,BONBIWJAPUUALK-IQGLISFBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,51.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,51.0,C[C@H]([C@H](C1=CC2=C(C=C1)C(=C(C=C2)OC)Cl)O)N3CCC(CC3)(CC4=CC=CC=C4)O,COc1ccc2cc([C@H](O)[C@@H](C)N3CCC(O)(Cc4ccccc4)CC3)ccc2c1Cl
487,489,CHEMBL373233,BOPYYBXXVMRACX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,7.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC=C(C=C1)N2C3=C(CC(C2=O)CCCNC)C=C(C=C3)Cl,CNCCCC1Cc2cc(Cl)ccc2N(c2ccc(C)cc2)C1=O
488,490,CHEMBL373233,BOPYYBXXVMRACX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1=CC=C(C=C1)N2C3=C(CC(C2=O)CCCNC)C=C(C=C3)Cl,CNCCCC1Cc2cc(Cl)ccc2N(c2ccc(C)cc2)C1=O
489,491,CHEMBL427216,BOVGTQGAOIONJV-UHFFFAOYSA-N,GLICLAZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1
490,492,CHEMBL427216,BOVGTQGAOIONJV-UHFFFAOYSA-N,GLICLAZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1
491,493,CHEMBL2165524,BPDIPISJQZBBJL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,0.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CN(C)C1CCC2=C(C1)C3=C(N2S(=O)(=O)C4=CC=CC=C4)C=CC(=C3)Br,CN(C)C1CCc2c(c3cc(Br)ccc3n2S(=O)(=O)c2ccccc2)C1
492,494,CHEMBL2165524,BPDIPISJQZBBJL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,7.7,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.7,CN(C)C1CCC2=C(C1)C3=C(N2S(=O)(=O)C4=CC=CC=C4)C=CC(=C3)Br,CN(C)C1CCc2c(c3cc(Br)ccc3n2S(=O)(=O)c2ccccc2)C1
493,495,CHEMBL133043,BPGNWJZOLVBWNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,30.4,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.517126416391246,COC1=CC=C(C=C1)C2(C3=CC=CC=C3C4=NCCCN42)O,COc1ccc(C2(O)c3ccccc3C3=NCCCN32)cc1
494,496,CHEMBL133043,BPGNWJZOLVBWNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,36.2,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.441291429466834,COC1=CC=C(C=C1)C2(C3=CC=CC=C3C4=NCCCN42)O,COc1ccc(C2(O)c3ccccc3C3=NCCCN32)cc1
495,497,CHEMBL379699,BPGTUWPLEUDMHZ-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-18.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-18.0,CC(C)CN(CC1=C(C=CC=C1F)C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1c(F)cccc1C(F)(F)F)C1CCNCC1
496,498,CHEMBL482294,BPTUECTWLFZRON-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=C(C=CC(=C1)S(=O)(=O)N)S(=O)C2=CC=C(C=C2)C(F)(F)F,CN(C)Cc1cc(S(N)(=O)=O)ccc1[S+]([O-])c1ccc(C(F)(F)F)cc1
497,499,CHEMBL539054,BPTVMTODGGFNIG-KUGOCAJQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,340.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.468521082957745,CC1=CC(=C(C(=C1)C)[C@@H]([C@@H](CN)C2=CC=CC=C2)O)C.Cl,Cc1cc(C)c([C@H](O)[C@@H](CN)c2ccccc2)c(C)c1
498,500,CHEMBL395910,BQCMCDRDLYXGDO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,625.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.204119982655924,COC(=O)C1=C(CCCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCCC1
499,501,CHEMBL395910,BQCMCDRDLYXGDO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,2100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.6777807052660805,COC(=O)C1=C(CCCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCCC1
500,502,CHEMBL377498,BQKRARPXRCZXGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,CCC(CC(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CCC(CC(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
501,503,CHEMBL377498,BQKRARPXRCZXGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,8440.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0736575533743435,CCC(CC(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CCC(CC(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
502,504,CHEMBL203640,BQLSUBYYRRZHRK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,185.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.732828271596986,CCCC(C(=O)C1=CC=C(C=C1)F)N2CCCC2,CCCC(C(=O)c1ccc(F)cc1)N1CCCC1
503,505,CHEMBL203640,BQLSUBYYRRZHRK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,82.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.086186147616282,CCCC(C(=O)C1=CC=C(C=C1)F)N2CCCC2,CCCC(C(=O)c1ccc(F)cc1)N1CCCC1
504,506,CHEMBL497340,BQYHDNIHHQQZPU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.0,CCN(CCC1=CC(=CC=C1)OC(F)(F)F)CCN2CCCC2,CCN(CCc1cccc(OC(F)(F)F)c1)CCN1CCCC1
505,507,CHEMBL367461,BRCFAGPWPWYSAX-QOCRQHEPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15012999.0,INHIBITION,=,36.0,%,,,,,,,,,,,,,,,Inhibitory activity against human dopamine transporter at 10 uM,Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.,Bioorg. Med. Chem. Lett.,PUBLICATION,,36.0,CCN1C(=CC(=N1)CC2=CC=C(C=C2)S(=O)(=O)C)C3CCN(CC3)C[C@H]4CN(C[C@@H]4C5=CC(=CC=C5)F)[C@@H](C(=O)O)C(C)(C)C,CCn1nc(Cc2ccc(S(C)(=O)=O)cc2)cc1C1CCN(C[C@H]2CN([C@@H](C(=O)O)C(C)(C)C)C[C@@H]2c2cccc(F)c2)CC1
506,508,CHEMBL435990,BRDDKFGREBLJEO-VPMYNCEMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,6.619788758288393,CC1=CC=C(C=C1)C(C2=CC=C(C=C2)C)O[C@H]3CC4CCC(C3C(=O)OC)N4C,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(C)cc1)c1ccc(C)cc1)N2C
507,509,CHEMBL232104,BRIVIXLMMUIBJY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17606674.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.",Antimicrob. Agents Chemother.,PUBLICATION,,,CN1C=NC=C1CN2CC(CC3=C2C=CC(=C3)C#N)N(CC4CCN(CC4)C(=O)OC)S(=O)(=O)C5=CC=CC=N5,COC(=O)N1CCC(CN(C2Cc3cc(C#N)ccc3N(Cc3cncn3C)C2)S(=O)(=O)c2ccccn2)CC1
508,510,CHEMBL270165,BRKDRAMGEIRGGU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,8300.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.080921907623925,CNCC1=C(C=CC(=C1)C(=O)N2CCN(CC2)C3CC3)OC4=CC=C(C=C4)SC,CNCc1cc(C(=O)N2CCN(C3CC3)CC2)ccc1Oc1ccc(SC)cc1
509,511,CHEMBL256817,BRMWMWORGPTOCB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,2130.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.671620396561263,CN(C)CC1=CC=CC=C1OC2=C(C=C(C=C2)F)Cl,CN(C)Cc1ccccc1Oc1ccc(F)cc1Cl
510,512,CHEMBL219335,BRQZSYKMAXVFLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,2.8,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.55284196865778,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)Cl,CC(C)CC(c1cccc(Cl)c1)C1CCCCN1
511,513,CHEMBL219335,BRQZSYKMAXVFLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,88.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.055517327849832,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)Cl,CC(C)CC(c1cccc(Cl)c1)C1CCCCN1
512,514,CHEMBL219335,BRQZSYKMAXVFLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,3.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.431798275933005,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)Cl,CC(C)CC(c1cccc(Cl)c1)C1CCCCN1
513,515,CHEMBL219335,BRQZSYKMAXVFLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,140.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.853871964321763,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)Cl,CC(C)CC(c1cccc(Cl)c1)C1CCCCN1
514,516,CHEMBL385607,BRTWZDQCGNRNRK-LVXARBLLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,2659.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.575281662668433,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CC(=O)N)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CC(N)=O)cc(C(C)=O)c1
515,517,CHEMBL186056,BRZFVBLWHJLYPD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=CC=CC=C1CC2=C(C=C(C=C2)I)N,CN(C)Cc1ccccc1Cc1ccc(I)cc1N
516,518,CHEMBL3331501,BSFXNCULKKRGGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,327.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.485452247339714,CC1=CC(=CC=C1)CN(CC2CNC2)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Cc1cccc(CN(CC2CNC2)c2ccccc2)c1
517,519,CHEMBL3331501,BSFXNCULKKRGGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,22.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,22.0,CC1=CC(=CC=C1)CN(CC2CNC2)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Cc1cccc(CN(CC2CNC2)c2ccccc2)c1
518,520,CHEMBL466963,BSMJJWYXCCOYNP-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCCC(=O)N(CC1=C(C=C(C=C1)Cl)Cl)[C@H]2CCNC2,CCCC(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
519,521,CHEMBL488638,BSMNRYCSBFHEMQ-GZMMTYOYSA-N,DOV-102677,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18539031.0,IC50,=,129.0,NM,,,,,,,,,,,,,,,Inhibition of dopamine uptake at human cloned DAT,Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.889410289700751,C1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@@]23CNC[C@@H]2C3)cc1Cl
520,522,CHEMBL488638,BSMNRYCSBFHEMQ-GZMMTYOYSA-N,DOV-102677,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,199.53,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.699991797446188,C1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@@]23CNC[C@@H]2C3)cc1Cl
521,523,CHEMBL488638,BSMNRYCSBFHEMQ-GZMMTYOYSA-N,DOV-102677,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,38.02,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.419987887470577,C1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@@]23CNC[C@@H]2C3)cc1Cl
522,524,CHEMBL592374,BSMNRYCSBFHEMQ-KCJUWKMLSA-N,AMITIFADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18539031.0,IC50,=,96.0,NM,,,,,,,,,,,,,,,Inhibition of dopamine uptake at human cloned DAT,Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.017728766960433,C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
523,525,CHEMBL592374,BSMNRYCSBFHEMQ-KCJUWKMLSA-N,AMITIFADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.900008766455317,C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
524,526,CHEMBL592374,BSMNRYCSBFHEMQ-KCJUWKMLSA-N,AMITIFADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.100015437450608,C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
525,527,CHEMBL592374,BSMNRYCSBFHEMQ-KCJUWKMLSA-N,AMITIFADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,159.3,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.7977842241988675,C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
526,528,CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18539031.0,IC50,=,78.0,NM,,,,,,,,,,,,,,,Inhibition of dopamine uptake at human cloned DAT,Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.107905397309519,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CNCC2C3)cc1Cl
527,529,CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,251.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6003262785189625,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CNCC2C3)cc1Cl
528,530,CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,93.8,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.027797161620937,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CNCC2C3)cc1Cl
529,531,CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,78.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.107905397309519,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CNCC2C3)cc1Cl
530,532,CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,96.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.017728766960433,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CNCC2C3)cc1Cl
531,533,CHEMBL528995,BSMNRYCSBFHEMQ-UHFFFAOYSA-N,DOV-216303,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,394.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.404503778174425,C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C23CNCC2C3)cc1Cl
532,534,CHEMBL1944978,BSMPOYNWUIFFDN-XNISGKROSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,263.03,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.5799947150409475,CCC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3)I,CCc1ccc([C@H]2C[C@@H]3CC[C@@H](N3)[C@H]2C(=O)OC)cc1I
533,535,CHEMBL206608,BSUHUYQWXIGAFH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)C(C2=CC=CC=C2CN(C)C)OC)N,COC(c1ccc(C)cc1N)c1ccccc1CN(C)C
534,536,CHEMBL1808426,BSUNLXLBVQPAFJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21724392.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 0.5 uM,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN1CC(=C(C1)Cl)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=C(C=C4)F,CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)C1
535,537,CHEMBL257424,BSYKAWMTFFQDNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,194.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7121982700697735,CN(C)CC1=CC=CC=C1OC2=CC(=CC=C2)Cl,CN(C)Cc1ccccc1Oc1cccc(Cl)c1
536,538,CHEMBL257424,BSYKAWMTFFQDNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,910.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.040958607678906,CN(C)CC1=CC=CC=C1OC2=CC(=CC=C2)Cl,CN(C)Cc1ccccc1Oc1cccc(Cl)c1
537,539,CHEMBL25,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,ASPIRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)Oc1ccccc1C(=O)O
538,540,CHEMBL25,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,ASPIRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)Oc1ccccc1C(=O)O
539,541,CHEMBL3310496,BSZJUUFTQGBZQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,15.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,15.0,C1C(CN1)CC(C2=CC3=CC=CC=C3C=C2)OC4=CC=CC=C4Cl,Clc1ccccc1OC(CC1CNC1)c1ccc2ccccc2c1
540,542,CHEMBL458080,BTBAPWWSVZCOSR-DXWGQUKGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,7.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,8.154901959985743,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OCCC4=CC=C(C=C4)N.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OCCc2ccc(N)cc2)N3C)cc1
541,543,CHEMBL467432,BTDIKAPSRZPGSC-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19067522.0,KI,=,327.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT receptor expressed in canine kidney cells,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter.",J. Med. Chem.,PUBLICATION,,6.485452247339714,CC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,Cc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
542,544,CHEMBL475937,BTDNKAUJHUIUPT-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,10.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC1(C2=C(C(=CC=C2)F)N(C1=O)[C@H](CCNC)C3=CC(=CC=C3)Cl)C,CNCC[C@H](c1cccc(Cl)c1)N1C(=O)C(C)(C)c2cccc(F)c21
543,545,CHEMBL1170211,BTDSNKFEFWKZPW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,15.85,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC(=C4C(=C3)C=CN4)F,Fc1cc(N2CCNCC2Cc2ccccc2)cc2cc[nH]c12
544,546,CHEMBL2207493,BTJHDQFIFDTGOW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23043306.0,INHIBITION,=,15.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DAT at 1 uM by CEREP assay,Systematic in Vivo Screening of a Series of 1-Propyl-4-arylpiperidines against Dopaminergic and Serotonergic Properties in Rat Brain: A Scaffold-Jumping Approach.,J. Med. Chem.,PUBLICATION,,15.0,CCCN1CCC(CC1)N2C3=C(C=C(C=C3)Cl)NC2=O,CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
545,547,CHEMBL185792,BTJIDHHCKXJAMB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,238.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.623423042943487,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CC2CCC1O2
546,548,CHEMBL3310636,BTQKCUGOWJLBQO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,14.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,14.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC(=C(C=C3)F)F,Fc1ccc(OC(CC2CNC2)c2ccc(F)c(F)c2)cc1F
547,549,CHEMBL566090,BTTZJAYHAIJMSO-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=CC=C3F)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2c(F)cccc21
548,550,CHEMBL3238479,BUGXTLSSMXNMDP-QNGOZBTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1C(=O)O)F)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(C(=O)O)cc3F)c(O)c12
549,551,CHEMBL1762,BUJAGSGYPOAWEI-UHFFFAOYSA-N,TOCAINIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,Cc1cccc(C)c1NC(=O)C(C)N
550,552,CHEMBL1762,BUJAGSGYPOAWEI-UHFFFAOYSA-N,TOCAINIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,Cc1cccc(C)c1NC(=O)C(C)N
551,553,CHEMBL477572,BUJVJHVEEOZSIE-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.530177984021837,CSC1=CC=CC=C1CN([C@H]2CCNC2)S(=O)(=O)C,CSc1ccccc1CN([C@H]1CCNC1)S(C)(=O)=O
552,554,CHEMBL378070,BUKUIUSQEZHUTR-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,1.8,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.8,CC(C)CN(CC1=C(C=C(C=C1)OC)OC)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,COc1ccc(CN(CC(C)C)C2CCNCC2)c(OC)c1
553,555,CHEMBL89709,BUQAUHAWFXKDNS-IOCOHYSWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.9586073148417755,CN1C2C[C@H](C1C(C(C2)C3=CC=C(C=C3)F)C(=O)OC)O,COC(=O)C1C(c2ccc(F)cc2)CC2C[C@@H](O)C1N2C
554,556,CHEMBL89709,BUQAUHAWFXKDNS-IOCOHYSWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,123.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.910094888560603,CN1C2C[C@H](C1C(C(C2)C3=CC=C(C=C3)F)C(=O)OC)O,COC(=O)C1C(c2ccc(F)cc2)CC2C[C@@H](O)C1N2C
555,557,CHEMBL3581693,BURHGPHDEVGCEZ-KJGLQBJMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25879485.0,IC50,=,3400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) by cell-based assay,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",J. Med. Chem.,PUBLICATION,,5.468521082957745,CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\C2=CC3=C(C=C2)NN=C3)/C4=C(C=C(C=C4)F)Cl,CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl
556,558,CHEMBL481280,BUZBVOKDNAZIIM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18588282.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,PUBLICATION,,10.0,C1CN(CCC1C(=O)O)CC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3,O=C(O)C1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1
557,559,CHEMBL481280,BUZBVOKDNAZIIM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18588282.0,INHIBITION,=,20.0,%,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,PUBLICATION,,20.0,C1CN(CCC1C(=O)O)CC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3,O=C(O)C1CCN(Cc2ccc(Oc3nc4ccccc4s3)cc2)CC1
558,560,CHEMBL504028,BVTKYAZPIRQNNS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,28.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.552841968657781,C1CC(OC1CN)C2=CC3=CC=CC=C3C=C2,NCC1CCC(c2ccc3ccccc3c2)O1
559,561,CHEMBL504028,BVTKYAZPIRQNNS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,512.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.29073003902417,C1CC(OC1CN)C2=CC3=CC=CC=C3C=C2,NCC1CCC(c2ccc3ccccc3c2)O1
560,562,CHEMBL460407,BWBCTVUBHWYIEP-UONOGXRCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,7618.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.118159031675074,COC1=C(C=C(C=C1)F)CCC[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CCC[C@H]1CC[C@H](CN)O1
561,563,CHEMBL460407,BWBCTVUBHWYIEP-UONOGXRCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,7328.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.135014539340205,COC1=C(C=C(C=C1)F)CCC[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CCC[C@H]1CC[C@H](CN)O1
562,564,CHEMBL459367,BWBCTVUBHWYIEP-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,6288.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.201487466968649,COC1=C(C=C(C=C1)F)CCC[C@@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CCC[C@@H]1CC[C@H](CN)O1
563,565,CHEMBL459367,BWBCTVUBHWYIEP-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,4576.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.339513984215032,COC1=C(C=C(C=C1)F)CCC[C@@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CCC[C@@H]1CC[C@H](CN)O1
564,566,CHEMBL668,BWPIARFWQZKAIA-UHFFFAOYSA-N,PROTRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,2100.0,NM,,,,,,,,,,,,,,,,,,,,5.6777807052660805,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,CNCCCC1c2ccccc2C=Cc2ccccc21
565,567,CHEMBL597608,BWQFRVKQDHYVEW-HUBLWGQQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.100015437450608,CCOCC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOCC[C@H]1[C@@H]2CNC[C@]12c1ccc(Cl)c(Cl)c1
566,568,CHEMBL232675,BWUZPMKOTOLHJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,6540.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.1844222516757315,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)[N+](=O)[O-],COC(=O)C1=C(c2ccc([N+](=O)[O-])cc2)CCC1
567,569,CHEMBL232675,BWUZPMKOTOLHJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)[N+](=O)[O-],COC(=O)C1=C(c2ccc([N+](=O)[O-])cc2)CCC1
568,570,CHEMBL592697,BWXOLUJTEOFJOY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,=,960.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.017728766960433,CC1=CC(=C(C=C1)OC2=C(C=CC(=C2)F)CN(C)C)N,Cc1ccc(Oc2cc(F)ccc2CN(C)C)c(N)c1
569,571,CHEMBL3673147,BXKXPJPYACCXTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,58.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.23210238398191,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=CC5C(C=C4)NC(=O)O5)C6=CC=C(C=C6)Cl,O=C1NC2C=CC(c3ccc4c(c3)CN3CCC4(c4ccc(Cl)cc4)CC3)=CC2O1
570,572,CHEMBL100010,BXNXEXWOZMNHST-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,3816.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.418391633967943,COC(=O)C1=C(CC2CCC1C2)C3=CC=CC=C3,COC(=O)C1=C(c2ccccc2)CC2CCC1C2
571,573,CHEMBL3593399,BXQHWNKKHXHIDQ-HTKOBJQYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,=,70.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,7.154901959985742,CN(C)C(=O)[C@@H]1CNCCO[C@H]1C2=CC(=C(C=C2)Cl)Cl.Cl,CN(C)C(=O)[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1
572,574,CHEMBL1083392,BXRBQSOCONPANY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,1475.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.831207979685818,CNCC(=O)CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCC(=O)CCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
573,575,CHEMBL203821,BXVHYBOSHLZFER-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)S(=O)C2=CC=CC=C2CN(C)C)N,Cc1ccc([S+]([O-])c2ccccc2CN(C)C)c(N)c1
574,576,CHEMBL584173,BXXRQIARNFYYBC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,13.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693162,C1CNCCC1C2=CC=CC=C2OC3=CC=C(C=C3)F,Fc1ccc(Oc2ccccc2C2CCNCC2)cc1
575,577,CHEMBL192619,BXZSHOGOEKAIFQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,=,2121.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.673459331483438,CCNCC1=CC=CC=C1SC2=C(C=C(C=C2)C)N,CCNCc1ccccc1Sc1ccc(C)cc1N
576,578,CHEMBL1460,BXZVVICBKDXVGW-NKWVEPMBSA-N,DIDANOSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1
577,579,CHEMBL1460,BXZVVICBKDXVGW-NKWVEPMBSA-N,DIDANOSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1
578,580,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1701.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.769295686387432,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
579,581,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1352.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.869023308394383,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
580,582,CHEMBL3593404,BYHRMOSVXQWMGN-SLHAJLBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=C(C=CC(=C1)[C@H]2[C@@H](CNCCO2)CNC(=O)C)Cl.Cl,CC(=O)NC[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(C)c1
581,583,CHEMBL2012110,BYLVESCSSPPPGZ-RLWKDEEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,39.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,7.4089353929735005,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC4=CC=CC=C4O3,COC(=O)[C@H]1C2CCC(C[C@H]1c1cc3ccccc3o1)O2
582,584,CHEMBL2012110,BYLVESCSSPPPGZ-RLWKDEEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC4=CC=CC=C4O3,COC(=O)[C@H]1C2CCC(C[C@H]1c1cc3ccccc3o1)O2
583,585,CHEMBL628,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,PENTOXIFYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
584,586,CHEMBL628,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,PENTOXIFYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
585,587,CHEMBL575854,BYRGPNIGCQCEQB-INXRADFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,232.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.6345120151091015,CCSC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3C,CCSc1ccc([C@H]2CC3CCC([C@H]2C(=O)OC)N3C)cc1
586,588,CHEMBL496938,BYTXKMDEYAZNON-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18793858.0,KI,>,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]GBR-12935 from human cloned DAT expressed in HEK293 cells,"Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)NCC3=CC=C(C=C3)[N+](=O)[O-],Cc1ccc(Sc2ccccc2CN(C)C)c(NCc2ccc([N+](=O)[O-])cc2)c1
587,589,CHEMBL476313,BYZZRTNQROTLCL-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2070.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.684029654543082,CCCS(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CCCS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
588,590,CHEMBL462384,BZEJZLOEKMOQPW-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@]1(CC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3SC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccccc1SC
589,591,CHEMBL28376,BZEWSQBMUDXXBU-FKZOYECMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,377.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4236586497942065,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)C(F)(F)F,CN1C2CCC1[C@H](C(=O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
590,592,CHEMBL28376,BZEWSQBMUDXXBU-FKZOYECMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1190.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.924453038607469,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)C(F)(F)F,CN1C2CCC1[C@H](C(=O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
591,593,CHEMBL282332,BZEWSQBMUDXXBU-HHTDUIENSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,not isolated,,,,,,,,,,,,,,Ability to displace [3H]mazindol to dopamine receptor; not being isolated,,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)C(F)(F)F,CN1C2CCC1[C@@H](C(=O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
592,594,CHEMBL282332,BZEWSQBMUDXXBU-HHTDUIENSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,not isolated,,,,,,,,,,,,,,Inhibitory concentration required for [3H]dopamine uptake; not being isolated,,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)C(F)(F)F,CN1C2CCC1[C@@H](C(=O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
593,595,CHEMBL20,BZKPWHYZMXOIDC-UHFFFAOYSA-N,ACETAZOLAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CC(=O)Nc1nnc(S(N)(=O)=O)s1
594,596,CHEMBL20,BZKPWHYZMXOIDC-UHFFFAOYSA-N,ACETAZOLAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CC(=O)Nc1nnc(S(N)(=O)=O)s1
595,597,CHEMBL1808437,BZMIEAZWZMSACC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21724392.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 0.5 uM,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN1CC(=C(C1)Cl)C2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=C(C=C4)OC,COc1ccc(S(=O)(=O)n2cc(C3=C(Cl)CN(C)C3)c3cc(OC)ccc32)cc1
596,598,CHEMBL1630579,BZRYYBWNOUALTQ-UHFFFAOYSA-N,MYRTECAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOCCC1=CCC2CC1C2(C)C,CCN(CC)CCOCCC1=CCC2CC1C2(C)C
597,599,CHEMBL1630579,BZRYYBWNOUALTQ-UHFFFAOYSA-N,MYRTECAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOCCC1=CCC2CC1C2(C)C,CCN(CC)CCOCCC1=CCC2CC1C2(C)C
598,600,CHEMBL519819,BZXPKSLKLWOLEJ-BJUDXGSMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18487050.0,KI,=,1155.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.,Bioorg. Med. Chem.,PUBLICATION,,5.937418015771838,[11CH3]OC1=CC=CC2=C1CCN(C2)CCCC3=CNC4=C3C=C(C=C4)I,COc1cccc2c1CCN(CCCc1c[nH]c3ccc(I)cc13)C2
599,601,CHEMBL487869,CAAOEKZYPZJLCR-QAPCUYQASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=CC=C3OC,COc1ccccc1O[C@H]1C[C@@H](N(C)C)c2ccccc21
600,602,CHEMBL515988,CACJRDOFRVCXPK-WIOPOQQRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,14.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.853871964321763,CC(C)OC(=O)[C@@H]1[C@H]2CC[C@@H](N2C)C[C@@H]1C3=CC=C(C=C3)OC.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC(C)C)N3C)cc1
601,603,CHEMBL229381,CACJYDSRIOGEJW-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.3979400086720375,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)Cl)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(Cl)cc4)s2)N3C)cc1
602,604,CHEMBL229381,CACJYDSRIOGEJW-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,212.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.6736641390712474,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)Cl)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(Cl)cc4)s2)N3C)cc1
603,605,CHEMBL247933,CAISPEIKDAWTHS-LOSJGSFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17583504.0,KI,=,107.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,Pyrrolidino-tetrahydroisoquinolines bearing pendant heterocycles as potent dual H3 antagonist and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.97061622231479,C1CCN(CC1)CCCOC2=CC3=C(C=C2)[C@@H](CN4[C@@H]3CCC4)C5=CN=CC=C5,c1cncc([C@@H]2CN3CCC[C@@H]3c3cc(OCCCN4CCCCC4)ccc32)c1
604,606,CHEMBL1159650,CBGUOGMQLZIXBE-XGQKBEPLSA-N,CLOBETASOL PROPIONATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
605,607,CHEMBL1159650,CBGUOGMQLZIXBE-XGQKBEPLSA-N,CLOBETASOL PROPIONATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
606,608,CHEMBL395110,CBHCDHNUZWWAPP-UHFFFAOYSA-N,MEPAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1
607,609,CHEMBL395110,CBHCDHNUZWWAPP-UHFFFAOYSA-N,MEPAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1
608,610,CHEMBL497463,CBIWVBLPTDWHKB-APWZRJJASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,3800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.420216403383191,CC1=CC=CC=C1O[C@H]2[C@H](CCC3=CC=CC=C23)CNC,CNC[C@H]1CCc2ccccc2[C@H]1Oc1ccccc1C
609,611,CHEMBL525375,CBIWVBLPTDWHKB-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](CCC3=CC=CC=C23)CNC,CNC[C@@H]1CCc2ccccc2[C@@H]1Oc1ccccc1C
610,612,CHEMBL525375,CBIWVBLPTDWHKB-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](CCC3=CC=CC=C23)CNC,CNC[C@@H]1CCc2ccccc2[C@@H]1Oc1ccccc1C
611,613,CHEMBL498686,CBIWVBLPTDWHKB-VQIMIIECSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@H](CCC3=CC=CC=C23)CNC,CNC[C@H]1CCc2ccccc2[C@@H]1Oc1ccccc1C
612,614,CHEMBL561599,CBKZFNTYOMFOLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,1584.89,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC(C1=CC=CC=C1)N(C2CCNCC2)C3=CC4=C(C=C3)NC=C4,CC(c1ccccc1)N(c1ccc2[nH]ccc2c1)C1CCNCC1
613,615,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11454918.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
614,616,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
615,617,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15664840.0,DISPLACEMENT,>,200.0,%,,,,,,,,,,,,,,,Displacement of dopamine by the compound against dopamine transporter was determined at 1000 nM,Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,200.0,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
616,618,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
617,619,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19067522.0,KI,>,2000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT receptor expressed in canine kidney cells,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter.",J. Med. Chem.,PUBLICATION,,5.698970004336019,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
618,620,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,IC5,>,10000.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
619,621,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,19952.62,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7000000685570305,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
620,622,CHEMBL14370,CBQGYUDMJHNJBX-UHFFFAOYSA-N,REBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,60.0,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,7.221848749616356,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
621,623,CHEMBL14370,CBQGYUDMJHNJBX-UHFFFAOYSA-N,REBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [3H]WIN-35428 radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,5.0,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
622,624,CHEMBL14370,CBQGYUDMJHNJBX-UHFFFAOYSA-N,REBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,>,25000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
623,625,CHEMBL14370,CBQGYUDMJHNJBX-UHFFFAOYSA-N,REBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,>,25000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6020599913279625,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
624,626,CHEMBL14370,CBQGYUDMJHNJBX-UHFFFAOYSA-N,REBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
625,627,CHEMBL14370,CBQGYUDMJHNJBX-UHFFFAOYSA-N,REBOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1OC(c1ccccc1)C1CNCCO1
626,628,CHEMBL445977,CBSIZHJYORKATA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,13190.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,4.879755204453635,CCN(CCC1=CC=CC=C1OC(F)(F)F)CCN2CCCC2,CCN(CCc1ccccc1OC(F)(F)F)CCN1CCCC1
627,629,CHEMBL272790,CBSPAZYMJJLPIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C(C1(C2=CC=CC=C2)C(=O)NC3=CC=CC=C3)CN,NCC1CC1(C(=O)Nc1ccccc1)c1ccccc1
628,630,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
629,631,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
630,632,CHEMBL202939,CCCKABNBMAAFTD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,CCC(CC(=O)C1=CC=C(C=C1)C)N2CCCC2,CCC(CC(=O)c1ccc(C)cc1)N1CCCC1
631,633,CHEMBL374634,CCEQAXVCJWOVQY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,5.7,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.244125144327509,CCCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
632,634,CHEMBL374634,CCEQAXVCJWOVQY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,67.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.173925197299173,CCCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
633,635,CHEMBL374634,CCEQAXVCJWOVQY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,2.3,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.638272163982407,CCCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
634,636,CHEMBL374634,CCEQAXVCJWOVQY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,29.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.5376020021010435,CCCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
635,637,CHEMBL576063,CCGVLNAUEKVICK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,1460.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.835647144215562,CC(C(=O)C1=CC(=CC=C1)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(F)c1
636,638,CHEMBL576063,CCGVLNAUEKVICK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,4510.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.345823458122039,CC(C(=O)C1=CC(=CC=C1)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(F)c1
637,639,CHEMBL576063,CCGVLNAUEKVICK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,2320.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.6345120151091015,CC(C(=O)C1=CC(=CC=C1)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(F)c1
638,640,CHEMBL479783,CCLDYFDEDOTWJF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,3600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,CN(C)CC1=C(C=CC(=C1)N(C)S(=O)(=O)C)SC2=CC=C(C=C2)SC,CSc1ccc(Sc2ccc(N(C)S(C)(=O)=O)cc2CN(C)C)cc1
639,641,CHEMBL2012107,CCRLYNSHUUHLKL-OQGULXLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CS4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cccc(-c3cccs3)c1)O2
640,642,CHEMBL2012107,CCRLYNSHUUHLKL-OQGULXLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CS4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cccc(-c3cccs3)c1)O2
641,643,CHEMBL378319,CCVMCNVDASICFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,9200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0362121726544435,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CN=CC=C3,Clc1ccccc1CC(c1cccnc1)N1CCNCC1
642,644,CHEMBL1077638,CCXVQWDBHGEOJC-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,2070.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.684029654543082,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)C(F)(F)F)Cl,CC(C)CN(C(=O)c1cccc(C(F)(F)F)c1Cl)[C@H]1CCNC1
643,645,CHEMBL10,CDMGBJANTYXAIV-UHFFFAOYSA-N,SB-203580,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1
644,646,CHEMBL10,CDMGBJANTYXAIV-UHFFFAOYSA-N,SB-203580,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1
645,647,CHEMBL573897,CDVPUDLPRZVZHB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1810.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.742321425130816,C1CNCCC1C2=CC=CC=C2OCC3=CC=CC=C3F,Fc1ccccc1COc1ccccc1C1CCNCC1
646,648,CHEMBL1684044,CDXVXAPUCWBZKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,<,1.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CC(C)CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N,CC(C)CC(N)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
647,649,CHEMBL3310621,CEILENYWVBYUHW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,32.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,32.0,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
648,650,CHEMBL3310621,CEILENYWVBYUHW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,99.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,99.0,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
649,651,CHEMBL3310621,CEILENYWVBYUHW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
650,652,CHEMBL1644474,CEJARUPLPSANRD-PTEHBNRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,380.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.420216403383191,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC=C3)Cl,Clc1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
651,653,CHEMBL2107687,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,VALETHAMATE BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1
652,654,CHEMBL2107687,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,VALETHAMATE BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1
653,655,CHEMBL1684054,CELRKOSFIVSEBS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,530.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.275724130399211,CC(C1(CCCCC1)C2=CC=C(C=C2)C3=CC=CC=C3)N,CC(N)C1(c2ccc(-c3ccccc3)cc2)CCCCC1
654,656,CHEMBL2112595,CEQQBJFDYJRGJS-FOCLMDBBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,1380.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,5.860120913598763,C1=CC(=CC=C1CCC(=O)N/C=C/NCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)Br,O=C(CCc1ccc(Br)cc1)N/C=C/NCCOC(c1ccc(F)cc1)c1ccc(F)cc1
655,657,CHEMBL2112595,CEQQBJFDYJRGJS-FOCLMDBBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,510.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.292429823902062,C1=CC(=CC=C1CCC(=O)N/C=C/NCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)Br,O=C(CCc1ccc(Br)cc1)N/C=C/NCCOC(c1ccc(F)cc1)c1ccc(F)cc1
656,658,CHEMBL2112595,CEQQBJFDYJRGJS-FOCLMDBBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,2.7,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,2.7,C1=CC(=CC=C1CCC(=O)N/C=C/NCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)Br,O=C(CCc1ccc(Br)cc1)N/C=C/NCCOC(c1ccc(F)cc1)c1ccc(F)cc1
657,659,CHEMBL577283,CEUJKSVEPJAVKD-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,9500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.022276394711152,CC(C)CN([C@@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2,CC(C)CN(C(=O)c1ccc2ccccc2c1)[C@@H]1CCNC1
658,660,CHEMBL567932,CEUJKSVEPJAVKD-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,744000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.128427064454121,CC(C)CN([C@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2,CC(C)CN(C(=O)c1ccc2ccccc2c1)[C@H]1CCNC1
659,661,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12784105.0,KI,=,3220.0,NM,,,,,,,,,,,,,,,,,,,,5.492144128304169,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
660,662,CHEMBL396402,CFBLMCGUBGGURK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,=,351.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.454692883534176,CN(C)CC1=C(C=CC(=C1)OCCO)SC2=CC=CC=C2N,CN(C)Cc1cc(OCCO)ccc1Sc1ccccc1N
661,663,CHEMBL3639720,CFCQNYUGCHNQOU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,613.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.211902366619703,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC=C(C=C5)C(F)(F)F,FC(F)(F)c1ccc(C23CCN(CC2)Cc2cc(Oc4ccc(C(F)(F)F)nn4)ccc23)cc1
662,664,CHEMBL207023,CFFAIDBFDNPCHJ-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-31.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-31.0,CCCCN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CCCCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
663,665,CHEMBL133070,CFMJSXBSNWAVPU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(=O)C1=C(C=C(C=C1)C2CC3CCC(C2C(=O)OC)N3C)C(=O)C,COC(=O)C1C(c2ccc(C(C)=O)c(C(C)=O)c2)CC2CCC1N2C
664,666,CHEMBL508102,CFOYWRHIYXMDOT-UHFFFAOYSA-N,CARBIMAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1C=CN(C1=S)C,CCOC(=O)n1ccn(C)c1=S
665,667,CHEMBL508102,CFOYWRHIYXMDOT-UHFFFAOYSA-N,CARBIMAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1C=CN(C1=S)C,CCOC(=O)n1ccn(C)c1=S
666,668,CHEMBL27979,CFUHKRLMDNFZED-SFTDATJTSA-N,"A-349,821",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12657274.0,KI,=,4897.79,NM,,,,,,,,,,,,,,,Binding affinity towards human UPTK-DA transporter,Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309999839831226,C[C@H]1CC[C@@H](N1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCOCC4)C,C[C@H]1CC[C@H](C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1
667,669,CHEMBL3323100,CFUHORQJAJFNTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,110.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.9586073148417755,CN1CC(C2=CC=CC=C2C1)C3=CC=CC4=C3SC=C4,CN1Cc2ccccc2C(c2cccc3ccsc23)C1
668,670,CHEMBL605501,CFVHNYYHCCJXDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,693.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.159266765388192,CC(C(=O)C1=CC(=CC=C1)F)NC2CCCC2,CC(NC1CCCC1)C(=O)c1cccc(F)c1
669,671,CHEMBL520869,CGANQTTYLGBMNA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,115.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.939302159646387,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4,c1ccc(CC2(c3ccc4[nH]ncc4c3)CCNC2)cc1
670,672,CHEMBL6,CGIGDMFJXJATDK-UHFFFAOYSA-N,INDOMETHACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
671,673,CHEMBL6,CGIGDMFJXJATDK-UHFFFAOYSA-N,INDOMETHACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
672,674,CHEMBL3310479,CGKMHQPZZRFYHQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,14.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,14.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3OC(F)(F)F,FC(F)(F)Oc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
673,675,CHEMBL3310479,CGKMHQPZZRFYHQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,69.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,69.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3OC(F)(F)F,FC(F)(F)Oc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
674,676,CHEMBL3310479,CGKMHQPZZRFYHQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3OC(F)(F)F,FC(F)(F)Oc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
675,677,CHEMBL468376,CGOSWAKWGGDJPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,57.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.244125144327507,CC(CC1=CC=CC=C1)(CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O,CC(O)(Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
676,678,CHEMBL524313,CGROONDICFFSDT-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)O)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccc(O)cc1C
677,679,CHEMBL245482,CHDGVSNCSOCUHK-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,1600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344076,CC1=C(C(=CC=C1)CN(CC2=CC=CC=N2)[C@H]3CCNC3)C,Cc1cccc(CN(Cc2ccccn2)[C@H]2CCNC2)c1C
678,680,CHEMBL392016,CHDGVSNCSOCUHK-LJQANCHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,1470.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.832682665251824,CC1=C(C(=CC=C1)CN(CC2=CC=CC=N2)[C@@H]3CCNC3)C,Cc1cccc(CN(Cc2ccccn2)[C@@H]2CCNC2)c1C
679,681,CHEMBL2037531,CHGXPKZHRZIZSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22520153.0,KI,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human DAT by liquid scintillation assay,Benzothiazoles as probes for the 5HT(1A) receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants.,Eur. J. Med. Chem.,PUBLICATION,,,C1CN(CCC1C2=CC=CC=C2)CCCCC(=O)C3=NC4=CC=CC=C4S3,O=C(CCCCN1CCC(c2ccccc2)CC1)c1nc2ccccc2s1
680,682,CHEMBL278165,CHLYWPGOYPDIPF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9986702.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,In vitro binding affinity against Dopamine transporter in LLC-PK1 cell membranes.,"A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I]IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)Br)CO,CN(C)Cc1ccccc1Sc1ccc(Br)cc1CO
681,683,CHEMBL56337,CHNUOJQWGUIOLD-NFZZJPOKSA-N,EPALRESTAT,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1
682,684,CHEMBL56337,CHNUOJQWGUIOLD-NFZZJPOKSA-N,EPALRESTAT,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1
683,685,CHEMBL241694,CHNXZKVNWQUJIB-CEGNMAFCSA-N,ETHISTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
684,686,CHEMBL241694,CHNXZKVNWQUJIB-CEGNMAFCSA-N,ETHISTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
685,687,CHEMBL2172192,CHVVPMVMKPMDFR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22664127.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to DAT at 1 uM by radioligand displacement assay,"Antagonists of 5-HT(6) receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines-Synthesis and 'structure-activity' relationship.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNC1=NN2C=C3CN(CCC3=NC2=C1S(=O)(=O)C4=CC=CC=C4)C,CNc1nn2cc3c(nc2c1S(=O)(=O)c1ccccc1)CCN(C)C3
686,688,CHEMBL1813486,CHWUQEOFMAPDHN-BBRMVZONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,489.78,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.309998953116938,CN1C[C@@H]2CCCC[C@@]2(C1)CC3=CC(=C(C=C3)Cl)Cl,CN1C[C@@H]2CCCC[C@]2(Cc2ccc(Cl)c(Cl)c2)C1
687,689,CHEMBL1813487,CHWUQEOFMAPDHN-CZUORRHYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,478.63,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.320000083770781,CN1C[C@H]2CCCC[C@]2(C1)CC3=CC(=C(C=C3)Cl)Cl,CN1C[C@H]2CCCC[C@@]2(Cc2ccc(Cl)c(Cl)c2)C1
688,690,CHEMBL2432039,CHZUEGVOEFMIJH-ZKRSMWHSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,126.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,6.8996294548824375,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC67C8C9C6C1C9C8C71,C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42
689,691,CHEMBL1572,CIDUJQMULVCIBT-MQDUPKMGSA-N,NETILMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O
690,692,CHEMBL1572,CIDUJQMULVCIBT-MQDUPKMGSA-N,NETILMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O
691,693,CHEMBL207810,CIIUAPSLDQFRMB-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-2.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-2.0,CC(C)CN(CC1=C(C=CC(=C1)F)OC)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,COc1ccc(F)cc1CN(CC(C)C)C1CCNCC1
692,694,CHEMBL569048,CIJDFRPQIGEUOQ-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,2.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,2.0,CNC[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=C2C=CC(=C3)OC)O,CNC[C@H](O)[C@H](c1ccccc1)n1ccc2cc(OC)ccc21
693,695,CHEMBL1644481,CIJDXZHBTVURGN-PTEHBNRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,3861.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.413300198375951,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=C3)C(F)(F)F,FC(F)(F)c1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
694,696,CHEMBL2021581,CIVPMJLKYXGWQT-KFWWJZLASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.900008766455317,C[C@]12CNC[C@@]1([C@@H]2CCOC)C3=CC(=C(C=C3)Cl)Cl,COCC[C@H]1[C@@]2(c3ccc(Cl)c(Cl)c3)CNC[C@]12C
695,697,CHEMBL2021580,CIVPMJLKYXGWQT-KKUMJFAQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,IC50,=,15.85,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in LLCPK cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.799970733446231,C[C@@]12CNC[C@@]1([C@H]2CCOC)C3=CC(=C(C=C3)Cl)Cl,COCC[C@H]1[C@]2(C)CNC[C@]12c1ccc(Cl)c(Cl)c1
696,698,CHEMBL2021580,CIVPMJLKYXGWQT-KKUMJFAQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,50.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C[C@@]12CNC[C@@]1([C@H]2CCOC)C3=CC(=C(C=C3)Cl)Cl,COCC[C@H]1[C@]2(C)CNC[C@]12c1ccc(Cl)c(Cl)c1
697,699,CHEMBL2021580,CIVPMJLKYXGWQT-KKUMJFAQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.199970640755867,C[C@@]12CNC[C@@]1([C@H]2CCOC)C3=CC(=C(C=C3)Cl)Cl,COCC[C@H]1[C@]2(C)CNC[C@]12c1ccc(Cl)c(Cl)c1
698,700,CHEMBL196,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ASCORBATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O
699,701,CHEMBL196,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ASCORBATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O
700,702,CHEMBL3238489,CJAGPIDGMDDWHO-XKZIYDEJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=C2C=C(C(=C(C2=C(C=C1S(=O)(=O)O)N)O)N=NC3=C(C(=C(C(=C3F)F)Br)F)O)S(=O)(=O)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3c(O)c(F)c(Br)c(F)c3F)c(O)c12
701,703,CHEMBL507379,CJCQYKYOUMGRPX-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@]1(CC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3CO)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccccc1CO
702,704,CHEMBL459,CJCSPKMFHVPWAR-JTQLQIEISA-N,METHYLDOPA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
703,705,CHEMBL459,CJCSPKMFHVPWAR-JTQLQIEISA-N,METHYLDOPA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
704,706,CHEMBL2105617,CJDRUOGAGYHKKD-FUIWMBJSSA-N,AJMALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O
705,707,CHEMBL2105617,CJDRUOGAGYHKKD-FUIWMBJSSA-N,AJMALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O
706,708,CHEMBL481153,CJGNMVAAMQAWEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23707254.0,KI,=,970.0,NM,,,,,,,,,,,,,,,Antagonist activity at DAT (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.013228265733755,C1CCN(C1)CCOC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42,O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21
707,709,CHEMBL1172526,CJIGYBHHAXYYSY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,15.85,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,CC(C)CC1CNCCN1C2=CC3=C(C=C2)NN=C3,CC(C)CC1CNCCN1c1ccc2[nH]ncc2c1
708,710,CHEMBL3105243,CJJUYQAVCJRKRK-KOSPPIAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24262882.0,KI,=,1.33,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT after 2 hrs by liquid scintillation counting analysis,"Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [(11)C]IPCIT and [(18)F]FE@IPCIT.",Bioorg. Med. Chem.,PUBLICATION,,8.876148359032914,C1C[C@@H]2[C@H]([C@H](C[C@H]1N2C/C=C/I)C3=CC=C(C=C3)I)C(=O)OCCF,O=C(OCCF)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
709,711,CHEMBL814,CJOFXWAVKWHTFT-XSFVSMFZSA-N,FLUVOXAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,9200.0,NM,,,,,,,,,,,,,,,,,,,,5.0362121726544435,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
710,712,CHEMBL814,CJOFXWAVKWHTFT-XSFVSMFZSA-N,FLUVOXAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10691690.0,KI,=,3.08,NM,,,cell_based,,,,,,,,,,,,Inhibition constant against [3H]citalopram in murine kidney cells transfected with human dopamine transporter,"Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.",J. Med. Chem.,PUBLICATION,,8.511449283499555,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
711,713,CHEMBL814,CJOFXWAVKWHTFT-XSFVSMFZSA-N,FLUVOXAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
712,714,CHEMBL814,CJOFXWAVKWHTFT-XSFVSMFZSA-N,FLUVOXAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,1.46,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,8.835647144215566,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
713,715,CHEMBL1172381,CJOKQBSVKKHHCD-COPLHBTASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,1258.93,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.899998417198647,COC[C@H]1[C@H]2[C@@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@H]1[C@@H]2CNCC[C@@]21c1ccc(Cl)c(Cl)c1
714,716,CHEMBL1173342,CJOKQBSVKKHHCD-MISXGVKJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,398.11,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.399996913372259,COC[C@@H]1[C@H]2[C@@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@H]1[C@@H]2CNCC[C@@]21c1ccc(Cl)c(Cl)c1
715,717,CHEMBL234379,CJOTYXSOAIOWPI-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1140000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,2.9430951486635277,CC(C)(C)C1=CC=C(C=C1)[C@H]2CCCCC[C@H]2C(=O)OC,COC(=O)[C@@H]1CCCCC[C@@H]1c1ccc(C(C)(C)C)cc1
716,718,CHEMBL376852,CJUVIUZOUUBMJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,23.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(c1ccc(Cl)cc1)C1CCCCN1
717,719,CHEMBL376852,CJUVIUZOUUBMJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,2800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.552841968657781,CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(c1ccc(Cl)cc1)C1CCCCN1
718,720,CHEMBL376852,CJUVIUZOUUBMJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,37.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.431798275933005,CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(c1ccc(Cl)cc1)C1CCCCN1
719,721,CHEMBL376852,CJUVIUZOUUBMJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,1800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.7447274948966935,CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(c1ccc(Cl)cc1)C1CCCCN1
720,722,CHEMBL198655,CJVNIBWRWXJTAF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,12.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,CNCCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCCCC1Cc2ccccc2N(c2ccccc2)C1=O
721,723,CHEMBL198655,CJVNIBWRWXJTAF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCCCC1Cc2ccccc2N(c2ccccc2)C1=O
722,724,CHEMBL2432060,CKFQOWSPJPMWEK-IINHSQADSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CCCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
723,725,CHEMBL1082723,CKLPLPZSUQEDRT-WPCRTTGESA-N,NITD609,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20813948.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant dopamine transporter,"Spiroindolones, a potent compound class for the treatment of malaria.",Science,PUBLICATION,,5.0,C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl,C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12
724,726,CHEMBL383081,CKPPJIQWWSHKBB-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,1300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693162,CN[C@H]1CC[C@H](C2=C1C=CC(=C2)C(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(C(N)=O)ccc21
725,727,CHEMBL469151,CKTXYRYJADRLRV-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,8.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=CC(=CC=C1)N(C)[C@@H](C2=CC=CC=C2)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1cccc(C)c1
726,728,CHEMBL572142,CLDXUDCHEILGJZ-GOTSBHOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1=CC=C(C=C1)[C@@H]([C@H](CNCC2=CC=NC=C2)O)N3C=CC4=CC=CC=C43,O[C@@H](CNCc1ccncc1)[C@H](c1ccccc1)n1ccc2ccccc21
727,729,CHEMBL1200558,CLKOFPXJLQSYAH-ABRJDSQDSA-N,BACITRACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4,CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1
728,730,CHEMBL1200558,CLKOFPXJLQSYAH-ABRJDSQDSA-N,BACITRACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4,CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1
729,731,CHEMBL2047567,CLPXEXYSIPWDMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,55.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,55.0,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CC=C(C=C3)[N+](=O)[O-])O,O=[N+]([O-])c1ccc(C(O)CCN2CC=C(Cc3ccccc3)CC2)cc1
730,732,CHEMBL1683882,CLQNHTVQVGGNMJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,9.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.045757490560675,CN(C)CC1(CCCC1)C2=CC(=C(C=C2)Cl)Cl,CN(C)CC1(c2ccc(Cl)c(Cl)c2)CCCC1
731,733,CHEMBL456223,CLSUYIGLXGEXLU-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,34300.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.464705879957228,COC1=C(C=C(C=C1)F)CC[C@@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CC[C@@H]1CC[C@H](CN)O1
732,734,CHEMBL456223,CLSUYIGLXGEXLU-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,30320.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.518270803039983,COC1=C(C=C(C=C1)F)CC[C@@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CC[C@@H]1CC[C@H](CN)O1
733,735,CHEMBL511500,CLSUYIGLXGEXLU-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,8555.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.067779986122881,COC1=C(C=C(C=C1)F)CC[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CC[C@H]1CC[C@H](CN)O1
734,736,CHEMBL511500,CLSUYIGLXGEXLU-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,14500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.838631997765026,COC1=C(C=C(C=C1)F)CC[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CC[C@H]1CC[C@H](CN)O1
735,737,CHEMBL1085959,CLUGYQSXBJPTPD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=CC=C1CC(C2=CC=CC=C2F)N3CCNCC3,COc1ccccc1CC(c1ccccc1F)N1CCNCC1
736,738,CHEMBL397889,CLVQITJMWWKDJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=C(C=CC(=C1)OCCCO)SC2=C(C=C(C=C2)Br)N,CN(C)Cc1cc(OCCCO)ccc1Sc1ccc(Br)cc1N
737,739,CHEMBL2171415,CLYPRUFOUBOJEJ-UHFFFAOYSA-N,"3-((3,4-DICHLOROPHENYL)(PROPOXY)METHYL)AZETIDINE HCL",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,32.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.494850021680094,CCCOC(C1CNC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCCOC(c1ccc(Cl)c(Cl)c1)C1CNC1
738,740,CHEMBL2171415,CLYPRUFOUBOJEJ-UHFFFAOYSA-N,"3-((3,4-DICHLOROPHENYL)(PROPOXY)METHYL)AZETIDINE HCL",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,74.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,74.0,CCCOC(C1CNC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCCOC(c1ccc(Cl)c(Cl)c1)C1CNC1
739,741,CHEMBL1515611,CMCCHHWTTBEZNM-UHFFFAOYSA-N,BROMISOVALUM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(C(=O)NC(=O)N)Br,CC(C)C(Br)C(=O)NC(N)=O
740,742,CHEMBL1515611,CMCCHHWTTBEZNM-UHFFFAOYSA-N,BROMISOVALUM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(C(=O)NC(=O)N)Br,CC(C)C(Br)C(=O)NC(N)=O
741,743,CHEMBL577272,CMGOBJCRHLBLJP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNCCC1NC(=O)C2=CC3=CC=CC=C3C=C2,O=C(NC1CCNCC1)c1ccc2ccccc2c1
742,744,CHEMBL1275709,CMJSIPQFDNXSOL-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20949929.0,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.161150909262744,CN(C)[C@@H]1CC[C@@H](C1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)[C@@H]1CC[C@H](c2c[nH]c3ccc(C#N)cc23)C1
743,745,CHEMBL1078743,CMNJEKBHBKVRME-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,1330.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.876148359032914,CC(C)CN([C@H]1CCNC1)C(=O)C2=CC(=CC=C2)Cl,CC(C)CN(C(=O)c1cccc(Cl)c1)[C@H]1CCNC1
744,746,CHEMBL88,CMSMOCZEIVJLDB-UHFFFAOYSA-N,CYCLOPHOSPHAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNP(=O)(OC1)N(CCCl)CCCl,O=P1(N(CCCl)CCCl)NCCCO1
745,747,CHEMBL88,CMSMOCZEIVJLDB-UHFFFAOYSA-N,CYCLOPHOSPHAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNP(=O)(OC1)N(CCCl)CCCl,O=P1(N(CCCl)CCCl)NCCCO1
746,748,CHEMBL402027,CMSMRUGCRICBLQ-WCQYABFASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CC(=C)F)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C=C(F)CN(C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
747,749,CHEMBL154,CMWTZPSULFXXJA-VIFPVBQESA-N,NAPROXEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
748,750,CHEMBL154,CMWTZPSULFXXJA-VIFPVBQESA-N,NAPROXEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
749,751,CHEMBL2432047,CNPQMMDLXZBMLB-KPCGFGSOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CN=CC=C6,c1cncc(CN[C@H]2C3C4CC5C6C4CC3C6C52)c1
750,752,CHEMBL200473,CNTBONUVPQEEGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,3980.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4001169279263115,CN1C2CCC1CC(C2)(C3=CC=CC=C3C4=CC=CC=C4)O,CN1C2CCC1CC(O)(c1ccccc1-c1ccccc1)C2
751,753,CHEMBL577138,CNZYWYSSMUKCGY-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,14.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,14.0,CNC[C@H]([C@H](C1=CC(=CC=C1)C(F)(F)F)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1cccc(C(F)(F)F)c1)n1ccc2ccccc21
752,754,CHEMBL1744190,COGUASSENRQBTI-KMIIZFTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.0,CN(CC1=CC=CC=C1)[C@H]2C[C@H](C3=CC=CC=C23)C4=CC(=C(C=C4)Cl)Cl.C(=C\C(=O)O)\C(=O)O,CN(Cc1ccccc1)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
753,755,CHEMBL820,COVZYZSDYWQREU-UHFFFAOYSA-N,BUSULFAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)OCCCCOS(=O)(=O)C,CS(=O)(=O)OCCCCOS(C)(=O)=O
754,756,CHEMBL820,COVZYZSDYWQREU-UHFFFAOYSA-N,BUSULFAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)OCCCCOS(=O)(=O)C,CS(=O)(=O)OCCCCOS(C)(=O)=O
755,757,CHEMBL421867,CPELCYRAOXWACY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,390.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.4089353929735005,C1CN(CCC1NCCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCNC2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
756,758,CHEMBL421867,CPELCYRAOXWACY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,160.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.795880017344076,C1CN(CCC1NCCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCNC2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
757,759,CHEMBL1454946,CPEUVMUXAHMANV-UHFFFAOYSA-N,FLUBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F,COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1
758,760,CHEMBL1454946,CPEUVMUXAHMANV-UHFFFAOYSA-N,FLUBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F,COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1
759,761,CHEMBL516094,CPFZMZOYHKWMOT-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2970.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.527243550682788,CN(C)C(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CN(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
760,762,CHEMBL16073,CPJSUEIXXCENMM-UHFFFAOYSA-N,PHENACETIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC=C(C=C1)NC(=O)C,CCOc1ccc(NC(C)=O)cc1
761,763,CHEMBL16073,CPJSUEIXXCENMM-UHFFFAOYSA-N,PHENACETIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC=C(C=C1)NC(=O)C,CCOc1ccc(NC(C)=O)cc1
762,764,CHEMBL2432051,CPLYGLAQLNAQOI-SEDVZXITSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,COC1=CC(=CC(=C1OC)OC)CN[C@H]2C3C4CC5C2C6C3CC4C56,COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC
763,765,CHEMBL404956,CPNTXNSOEZESIH-QZTJIDSGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.022276394711152,CC1=C(C=CC(=C1)F)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,Cc1cc(F)ccc1O[C@H](c1ccccc1)[C@H]1CNCCO1
764,766,CHEMBL427563,CPNTXNSOEZESIH-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1250.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.903089986991943,CC1=C(C=CC(=C1)F)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,Cc1cc(F)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
765,767,CHEMBL1784673,CPOQTXKWWFQYCF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21570838.0,INHIBITION,<,50.0,%,Not Active,,,,,,,,,,,,,,Inhibition of human recombinant DAT at 10 uM by radioligand binding assay,Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC1=C(C=CC(=C1)C(=O)N)C2=C(C=CN2CCC(=O)O)C3=CC=C(C=C3)N4C=CN=C4,Cc1cc(C(N)=O)ccc1-c1c(-c2ccc(-n3ccnc3)cc2)ccn1CCC(=O)O
766,768,CHEMBL1321,CPTBDICYNRMXFX-UHFFFAOYSA-N,PROCARBAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,CNNCc1ccc(C(=O)NC(C)C)cc1
767,769,CHEMBL1321,CPTBDICYNRMXFX-UHFFFAOYSA-N,PROCARBAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,CNNCc1ccc(C(=O)NC(C)C)cc1
768,770,CHEMBL510139,CQIUKKVOEOPUDV-IYSWYEEDSA-N,CITRININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,CC1=C2C(=CO[C@H](C)[C@H]2C)C(=O)C(C(=O)O)=C1O
769,771,CHEMBL510139,CQIUKKVOEOPUDV-IYSWYEEDSA-N,CITRININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,CC1=C2C(=CO[C@H](C)[C@H]2C)C(=O)C(C(=O)O)=C1O
770,772,CHEMBL405462,CQJCAOGPWRQORA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1(C)CN)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1(C)CN
771,773,CHEMBL1210154,CQUWKHKELQQYRI-KGENOOAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20591666.0,IC50,>,10000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]BTCP from human recombinant dopamine transporter expressed in CHO cells,A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C/C(=N\OC(=O)NC1=CC=CC=C1)/C2=CC=CC(=C2)C3=CC=CS3,C/C(=N\OC(=O)Nc1ccccc1)c1cccc(-c2cccs2)c1
772,774,CHEMBL1169622,CREVKPZAPMYUJW-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,7943.28,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.100000128334196,COC[C@]12C[C@]1(CCNC2)C3=CC=C(C=C3)OC(F)(F)F,COC[C@@]12CNCC[C@]1(c1ccc(OC(F)(F)F)cc1)C2
773,775,CHEMBL270791,CRLQFKMWDMUITC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2640.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.578396073130169,CC1=CC(=C(C=N1)CN(C)C)OC2=CC=CC=C2OC3=CC=CC=C3,Cc1cc(Oc2ccccc2Oc2ccccc2)c(CN(C)C)cn1
774,776,CHEMBL203741,CROGUKBPHFMYKB-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)C#N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(C#N)cc21
775,777,CHEMBL457931,CRTQNTKRJCYBET-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,18.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.744727494896693,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC(=C4)C(=O)N,NC(=O)c1cc2cc(C3(Cc4ccccc4)CCNC3)ccc2[nH]1
776,778,CHEMBL3673138,CSAJSGHGBPMKBX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,52.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.2839966563652,COC1=CC2=C(C=C1)C3(CCN(C2)CC3)C4=CC=C(C=C4)Cl,COc1ccc2c(c1)CN1CCC2(c2ccc(Cl)cc2)CC1
777,779,CHEMBL198177,CSIVTULLSFNYFC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,2.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,2.0,CC(C)C1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)(C)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccc(C(C)C)cc2)C1=O
778,780,CHEMBL198177,CSIVTULLSFNYFC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC(C)C1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)(C)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccc(C(C)C)cc2)C1=O
779,781,CHEMBL1914697,CSQWTWVZSNGFRN-IAFLDTSXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,17.9,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.747146969020108,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)CNC4=CN=C(C=C4)Br,CN1C2CCC1[C@@H](CNc1ccc(Br)nc1)[C@@H](c1ccc(Cl)cc1)C2
780,782,CHEMBL1950747,CSSVMZXGVYOUCF-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22290075.0,INHIBITION,=,13.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,13.0,C[C@H]1CC(=O)NN=C1C2=CC=C(C=C2)OC3CCN(CC3)C4CCC4,C[C@H]1CC(=O)NN=C1c1ccc(OC2CCN(C3CCC3)CC2)cc1
781,783,CHEMBL212763,CTAHXNUPBZTDFO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,COC1=CC=CC(=C1)CC(C2=CC=CC=C2)N3CCNCC3,COc1cccc(CC(c2ccccc2)N2CCNCC2)c1
782,784,CHEMBL1289,CTETYYAZBPJBHE-UHFFFAOYSA-N,HALOPROGIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1969.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.705754283861883,C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI,Clc1cc(Cl)c(OCC#CI)cc1Cl
783,785,CHEMBL1289,CTETYYAZBPJBHE-UHFFFAOYSA-N,HALOPROGIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1565.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.805485658117533,C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI,Clc1cc(Cl)c(OCC#CI)cc1Cl
784,786,CHEMBL2047568,CTGKEWQPUSZCPT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,66.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,66.0,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=C(C=C(C=C3)F)F)O,OC(CCN1CC=C(Cc2ccccc2)CC1)c1ccc(F)cc1F
785,787,CHEMBL206598,CTGMREDPJFWWBJ-LIRRHRJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,90.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)CNS(=O)(=O)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(CNS(C)(=O)=O)cc21
786,788,CHEMBL516933,CTNIUTSUTZHULD-JRTRGBLZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.823908740944319,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OCCC4=CC(=C(C(=C4)Br)N)Br.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OCCc2cc(Br)c(N)c(Br)c2)N3C)cc1
787,789,CHEMBL256970,CTPBZYGSXVZQMN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,1680.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.774690718274138,CC1=CC(=C(C=N1)CN(C)C)OC2=C(C=C(C=C2)Cl)C,Cc1cc(Oc2ccc(Cl)cc2C)c(CN(C)C)cn1
788,790,CHEMBL1068,CTRLABGOLIVAIY-UHFFFAOYSA-N,OXCARBAZEPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,NC(=O)N1c2ccccc2CC(=O)c2ccccc21
789,791,CHEMBL1068,CTRLABGOLIVAIY-UHFFFAOYSA-N,OXCARBAZEPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,NC(=O)N1c2ccccc2CC(=O)c2ccccc21
790,792,CHEMBL560877,CTVFQEBCIXRGTI-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,11.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,11.0,CCN1C2=C(C(=CC=C2)F)N(C1=O)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CCn1c(=O)n([C@@H](c2cccc(F)c2)[C@H](O)CNC)c2c(F)cccc21
791,793,CHEMBL3323102,CUFCKDTWFRBJEK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,12.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=CN4,CN1Cc2ccccc2C(c2ccc3cc[nH]c3c2)C1
792,794,CHEMBL3323102,CUFCKDTWFRBJEK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,19.8,NM,314454,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.703334809738469,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=CN4,CN1Cc2ccccc2C(c2ccc3cc[nH]c3c2)C1
793,795,CHEMBL1645600,CUHDMEXRHJPGHR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6460.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.189767482004916,C1C(CN1)OC2=C(C=CC=C2F)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1cccc(F)c1OC1CNC1
794,796,CHEMBL2205822,CUIQKJJPRAKRJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCCc1cccc(F)c1
795,797,CHEMBL2207388,CULSPSVPJXBZMJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23141912.0,INHIBITION,=,3.92,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM by radioligand displacement assay,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.92,CN1CCN(CC1)CC2=C3C=CN(C3=CC=C2)S(=O)(=O)C4=CC=CC=C4,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1
796,798,CHEMBL3334781,CUPOAMXQXTXPSU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,3.4,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,3.4,CN(CCC(C1=CC(=C(C=C1)Cl)Cl)N2CCOCC2)CC3=CC=CC=C3,CN(CCC(c1ccc(Cl)c(Cl)c1)N1CCOCC1)Cc1ccccc1
797,799,CHEMBL469887,CURALKDCIXHBQR-JTDONDQYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,1.57,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.804100347590767,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)C5=CC=C(C=C5)OC.Cl,COc1ccc(-c2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)on2)cc1
798,800,CHEMBL1123,CURUTKGFNZGFSE-UHFFFAOYSA-N,DICYCLOMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1
799,801,CHEMBL1123,CURUTKGFNZGFSE-UHFFFAOYSA-N,DICYCLOMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1
800,802,CHEMBL249134,CUZLSPYEHKUVQH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9586073148417755,CN(C)CC1CC1C2=CC3=C(C=C2)C=C(C=C3)C#N,CN(C)CC1CC1c1ccc2cc(C#N)ccc2c1
801,803,CHEMBL249134,CUZLSPYEHKUVQH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,41.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,41.0,CN(C)CC1CC1C2=CC3=C(C=C2)C=C(C=C3)C#N,CN(C)CC1CC1c1ccc2cc(C#N)ccc2c1
802,804,CHEMBL403441,CVFBVSUFNWOPLD-LJQANCHMSA-N,PF-526014,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,>,400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,CCOC1=CC=CC=C1C[C@H](C2=CC=CC=C2)N3CCNCC3,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1
803,805,CHEMBL403441,CVFBVSUFNWOPLD-LJQANCHMSA-N,PF-526014,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCOC1=CC=CC=C1C[C@H](C2=CC=CC=C2)N3CCNCC3,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1
804,806,CHEMBL403441,CVFBVSUFNWOPLD-LJQANCHMSA-N,PF-526014,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,2650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.576754126063192,CCOC1=CC=CC=C1C[C@H](C2=CC=CC=C2)N3CCNCC3,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1
805,807,CHEMBL386224,CVFBVSUFNWOPLD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CCOc1ccccc1CC(c1ccccc1)N1CCNCC1
806,808,CHEMBL386224,CVFBVSUFNWOPLD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CCOc1ccccc1CC(c1ccccc1)N1CCNCC1
807,809,CHEMBL218581,CVHOPXZORYBSMH-UNMCSNQZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,32.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.494850021680094,CC(=O)C1=CC(=CC=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2)CC3=CC=CC=C3,CC(=O)c1cccc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccccc3)CCN2)c1
808,810,CHEMBL3335556,CVKXGRRJHJHUFY-LJQANCHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221667.0,ACTIVITY,=,72.0,%,,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin) at 10 uM by radioligand binding assay,,ACS Med. Chem. Lett.,PUBLICATION,,72.0,C1CO[C@@H](CN1CC2=CC=C(C=C2)Cl)CCC3=CC=CC=C3,Clc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1
809,811,CHEMBL2030631,CWEGCQIIDCZZED-UHFFFAOYSA-N,N-BENZYLPYRROLIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCN(C1)CC2=CC=CC=C2,c1ccc(CN2CCCC2)cc1
810,812,CHEMBL1173701,CWQJTYANMLPKAM-IFXJQAMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,4.0,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=C(C=C2)C3=CC=CC=C3)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1ccc(-c2ccccc2)cc1
811,813,CHEMBL1231530,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,BETAMIPRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NCCC(=O)O,O=C(O)CCNC(=O)c1ccccc1
812,814,CHEMBL1231530,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,BETAMIPRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NCCC(=O)O,O=C(O)CCNC(=O)c1ccccc1
813,815,CHEMBL2326692,CWYBNSVSYKQGJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,11.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.9586073148417755,C1CCNCC(C1)C2=CC(=C(C=C2)Cl)Cl,Clc1ccc(C2CCCCNC2)cc1Cl
814,816,CHEMBL590615,CWYDYWFZPBTTIM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19954972.0,KI,=,137.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.863279432843593,C1C2C3C4C1C5C2C6C3C4C5(O6)NCCC7=CC(=CC=C7)F,Fc1cccc(CCNC23OC4C5C6CC(C7C6C4C72)C53)c1
815,817,CHEMBL257482,CXCHRIAFYHUSTE-MSRBBVSSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,28.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.552841968657781,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC(=O)CCCCC(=O)OC[C@H]4[C@H](CC5CCC4N5C)C6=CC(=C(C=C6)Cl)Cl,CN1C2CCC1[C@@H](COC(=O)CCCCC(=O)OC[C@@H]1C3CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N3C)[C@@H](c1ccc(Cl)c(Cl)c1)C2
816,818,CHEMBL577501,CXFKXPAAWKFBPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,5600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.251811972993798,CC(C(=O)C1=CC(=CC(=C1)F)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cc(F)cc(F)c1
817,819,CHEMBL577501,CXFKXPAAWKFBPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,5660.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.247183568811728,CC(C(=O)C1=CC(=CC(=C1)F)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cc(F)cc(F)c1
818,820,CHEMBL596796,CXJYZDWEGFRWPU-PSOPSSQASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,31.62,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.500038134403809,CC1=COC(=N1)[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1coc([C@H]2[C@@H]3CNC[C@@]32c2ccc(Cl)c(Cl)c2)n1
819,821,CHEMBL1829958,CXLPBBKWDIYIPK-UHFFFAOYSA-N,PSAMMOPEMMIN A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21907583.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT after 1.5 hrs by scintillation counting,CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1=CC2=C(C(=C1)O)C(=CN2)C3=CN=C(N=C3N)Br,Nc1nc(Br)ncc1-c1c[nH]c2cccc(O)c12
820,822,CHEMBL16,CXOFVDLJLONNDW-UHFFFAOYSA-N,PHENYTOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
821,823,CHEMBL16,CXOFVDLJLONNDW-UHFFFAOYSA-N,PHENYTOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
822,824,CHEMBL575753,CXPIEWAMVILDLK-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,9.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=C(C=C3)Cl)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2ccc(Cl)cc21
823,825,CHEMBL210578,CXQUOFVDYCOSEZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1
824,826,CHEMBL1201024,CXYRUNPLKGGUJF-XKTSLVMZSA-M,METHSCOPOLAMINE BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],C[N+]1(C)[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@H]1O[C@@H]21
825,827,CHEMBL1201024,CXYRUNPLKGGUJF-XKTSLVMZSA-M,METHSCOPOLAMINE BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],C[N+]1(C)[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@H]1O[C@@H]21
826,828,CHEMBL404520,CYDMQBQPVICBEU-XRNKAMNCSA-N,CHLORTETRACYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12
827,829,CHEMBL404520,CYDMQBQPVICBEU-XRNKAMNCSA-N,CHLORTETRACYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12
828,830,CHEMBL462410,CYHDCZGFQGQXJH-CLFYSBASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053782.0,KI,=,179.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]RTI-55 from human DAT transfected in human HEK293 cells,"Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,6.745451922891027,C1CC2C(C(CC1N2)C3=CC=CC(=C3)/C=C\I)C(=O)OCCCF,O=C(OCCCF)C1C2CCC(CC1c1cccc(/C=C\I)c1)N2
829,831,CHEMBL3094318,CYPDLWIUOMSUJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,76.8,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,76.8,C1=CC(=CC(=C1)F)COC2=CC=C(C=C2)CN.Cl,NCc1ccc(OCc2cccc(F)c2)cc1
830,832,CHEMBL75880,CYXKNKQEMFBLER-UHFFFAOYSA-N,PERHEXILINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
831,833,CHEMBL75880,CYXKNKQEMFBLER-UHFFFAOYSA-N,PERHEXILINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
832,834,CHEMBL197669,CYYQMAWUIRPCNW-UHFFFAOYSA-N,ST1535,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16250647.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Percent inhibition against Dopamine transporter at 1 uM,"2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.",J. Med. Chem.,PUBLICATION,,10.0,CCCCC1=NC(=C2C(=N1)N(C(=N2)N3N=CC=N3)C)N,CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1
833,835,CHEMBL202565,CZICWAXMIHSKKP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,CCCC(CN1CCCC1)C(=O)C2=CC=C(C=C2)C,CCCC(CN1CCCC1)C(=O)c1ccc(C)cc1
834,836,CHEMBL311469,CZIHNRWJTSTCEX-UHFFFAOYSA-N,2-ACETYLAMINOFLUORENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2
835,837,CHEMBL311469,CZIHNRWJTSTCEX-UHFFFAOYSA-N,2-ACETYLAMINOFLUORENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2
836,838,CHEMBL115253,CZMZTJBQMHRZQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,6.46,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.189767482004916,C1CC2CC(CC1N2CCNC(=O)C3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=C(NCCN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2)c1ccccc1
837,839,CHEMBL334508,CZOPILNHCQVMII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,INHIBITION,=,35.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane at a concentration of 10e-6 M,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,35.0,C1CCC2=C(C1)C=CC(=C2)C3(C4=CC=CC=C4C5=NCCN53)O,OC1(c2ccc3c(c2)CCCC3)c2ccccc2C2=NCCN21
838,840,CHEMBL334508,CZOPILNHCQVMII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,<,0.02,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,0.02,C1CCC2=C(C1)C=CC(=C2)C3(C4=CC=CC=C4C5=NCCN53)O,OC1(c2ccc3c(c2)CCCC3)c2ccccc2C2=NCCN21
839,841,CHEMBL1945252,CZPZQMXAJDWBFP-KZTBUPNPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,114.82,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.9399824574684,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=CC=C3,COC(=O)[C@H]1[C@@H](c2ccccc2)C[C@@H]2CC[C@H]1N2C/C=C/I
840,842,CHEMBL98350,CZQHHVNHHHRRDU-UHFFFAOYSA-N,LY-294002,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12
841,843,CHEMBL98350,CZQHHVNHHHRRDU-UHFFFAOYSA-N,LY-294002,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12
842,844,CHEMBL3323093,CZRBQWFOPMBTQM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,43.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.366531544420414,CN1CC(C2=CC=CC=C2C1)C3=C4C=COC4=CC=C3,CN1Cc2ccccc2C(c2cccc3occc23)C1
843,845,CHEMBL1080735,CZUGKEKGXKWONC-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5C(F)(F)F,C[C@H]1CN(C(=O)c2ccc(-c3ccccc3C(F)(F)F)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
844,846,CHEMBL560673,CZVBECXOXXYCQD-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)N([C@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(C1CCC1)[C@H]1CCNC1
845,847,CHEMBL3084884,DAAKBMHWKLVSKY-PMOLBWCYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,23.44,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.630042392653947,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl,CN1[C@H]2CC[C@@H]1CC(OC(c1ccc(Cl)cc1)c1ccc(Cl)cc1)C2
846,848,CHEMBL2419440,DAAWESBJYLHFAS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23837744.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) at 10 uM,"Atropisomeric 4-phenyl-4H-1,2,4-triazoles as selective glycine transporter 1 inhibitors.",J. Med. Chem.,PUBLICATION,,,CCC1=NN=C(N1C2=CC=CC(=C2C)C#N)C3=CN=C(C=C3)C4=CC=CC=C4,CCc1nnc(-c2ccc(-c3ccccc3)nc2)n1-c1cccc(C#N)c1C
847,849,CHEMBL380758,DACQOKGPDFDFGY-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,240.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.619788758288393,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)C(=O)OC)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(C(=O)OC)cc21
848,850,CHEMBL2430688,DARUNLRORREIKV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,8.14,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.089375595110798,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccccc1Cl
849,851,CHEMBL2430688,DARUNLRORREIKV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,93.9,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,93.9,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccccc1Cl
850,852,CHEMBL2430688,DARUNLRORREIKV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,100.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccccc1Cl
851,853,CHEMBL286991,DASHZBBQOARCMQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.97,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.97,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
852,854,CHEMBL286991,DASHZBBQOARCMQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.08,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.08,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
853,855,CHEMBL286991,DASHZBBQOARCMQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,8.38,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.38,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
854,856,CHEMBL286991,DASHZBBQOARCMQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.39,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.39,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
855,857,CHEMBL286991,DASHZBBQOARCMQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.76,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.76,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
856,858,CHEMBL286991,DASHZBBQOARCMQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.11,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.11,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
857,859,CHEMBL556299,DASUUHWEMHDMII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,199.53,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,CNCCC(C1=CC=CC=C1)C2=CC3=C(C=C2)NC=C3,CNCCC(c1ccccc1)c1ccc2[nH]ccc2c1
858,860,CHEMBL1914693,DAXFTWVNVGRVQC-AFNJWWOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,106.0,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9746941347352305,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NC4=CN=C(C=C4)Br,CN1C2CCC1[C@@H](C(=O)Nc1ccc(Br)nc1)[C@@H](c1ccc(Cl)cc1)C2
859,861,CHEMBL897,DBABZHXKTCFAPX-UHFFFAOYSA-N,PROBENECID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
860,862,CHEMBL897,DBABZHXKTCFAPX-UHFFFAOYSA-N,PROBENECID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
861,863,CHEMBL472253,DBDIPFBJGDKNIO-FZMZJTMJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.0,CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC=CS2,C#CCN(CC)C(=O)[C@@]1(c2cccs2)C[C@H]1CN
862,864,CHEMBL710,DBEPLOCGEIEOCV-WSBQPABSSA-N,FINASTERIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
863,865,CHEMBL710,DBEPLOCGEIEOCV-WSBQPABSSA-N,FINASTERIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
864,866,CHEMBL248702,DBGIVFWFUFKIQN-VIFPVBQESA-N,DEXFENFLURAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1
865,867,CHEMBL248702,DBGIVFWFUFKIQN-VIFPVBQESA-N,DEXFENFLURAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1
866,868,CHEMBL564445,DBNIRDAYCJINLF-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,30.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,30.0,CCN1C2=C(C=C(C=C2)F)N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CCn1c(=O)n([C@@H](c2ccccc2)[C@H](O)CNC)c2cc(F)ccc21
867,869,CHEMBL357322,DBOLXXRVIFGDTI-UHFFFAOYSA-N,4-BENZYLPYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Affinity to displace binding of [3H]WIN-35428 to dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C(C=C1)CC2=CC=NC=C2,c1ccc(Cc2ccncc2)cc1
868,870,CHEMBL357322,DBOLXXRVIFGDTI-UHFFFAOYSA-N,4-BENZYLPYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake evaluated at the dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C(C=C1)CC2=CC=NC=C2,c1ccc(Cc2ccncc2)cc1
869,871,CHEMBL2206518,DBOZEPCLJKANCL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.086186147616282,CN1CC(C2=C(C1)C=C(C=C2)OC)C3=CC=CC=C3,COc1ccc2c(c1)CN(C)CC2c1ccccc1
870,872,CHEMBL212328,DBPGONCPPLDYIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,1920.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,5.716698771296451,CN1C2CCC1C3COC(=O)CCCCCCCCC(=O)N(C4=CC=C(C3C2)C=C4)C,CN1C(=O)CCCCCCCCC(=O)OCC2C(CC3CCC2N3C)c2ccc1cc2
871,873,CHEMBL1062,DBPWSSGDRRHUNT-CEGNMAFCSA-N,HYDROXYPROGESTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,6905.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.16083631708535,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
872,874,CHEMBL1062,DBPWSSGDRRHUNT-CEGNMAFCSA-N,HYDROXYPROGESTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,5486.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.2607441967314905,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
873,875,CHEMBL420900,DBQULVOZIKDPMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,73.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.136677139879544,C1=CC=C(C=C1)CC(=O)NCCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(Cc1ccccc1)NCCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
874,876,CHEMBL420900,DBQULVOZIKDPMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,61.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.214670164989233,C1=CC=C(C=C1)CC(=O)NCCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(Cc1ccccc1)NCCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
875,877,CHEMBL420900,DBQULVOZIKDPMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,1.2,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,1.2,C1=CC=C(C=C1)CC(=O)NCCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(Cc1ccccc1)NCCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
876,878,CHEMBL871,DBVJJBKOTRCVKF-UHFFFAOYSA-N,ETIDRONIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(O)(P(=O)(O)O)P(=O)(O)O,CC(O)(P(=O)(O)O)P(=O)(O)O
877,879,CHEMBL871,DBVJJBKOTRCVKF-UHFFFAOYSA-N,ETIDRONIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(O)(P(=O)(O)O)P(=O)(O)O,CC(O)(P(=O)(O)O)P(=O)(O)O
878,880,CHEMBL574008,DBVKCFHUKVYYIQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,659.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1811145854059895,C1CNCCC1C2=C(C=CC(=C2)F)OCC3=CC=C(C=C3)F,Fc1ccc(COc2ccc(F)cc2C2CCNCC2)cc1
879,881,CHEMBL2407331,DBZNPAHUGJSVMH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,580.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.236572006437062,COCC(C1CCNCC1)C2=CC(=C(C=C2)F)Cl.Cl,COCC(c1ccc(F)c(Cl)c1)C1CCNCC1
880,882,CHEMBL3186763,DCAMTBFFNOHDAW-DYTRJAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25244572.0,INHIBITION,=,10.8,%,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT at 10 uM,"Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus.",J. Med. Chem.,PUBLICATION,,10.8,CN1CCN(C(=NC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC3=CC=CC=C3)C1)C,CN1CCN(C)C(=Nc2ccc([N+](=O)[O-])cc2C(=O)Nc2ccccc2)C1
881,883,CHEMBL426659,DCBHDYASYVFKAM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,21900.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6595558851598815,CN1C2CCC1CC(C2)(C3=CC=CC(=C3)C4=CC=CC=C4)O,CN1C2CCC1CC(O)(c1cccc(-c3ccccc3)c1)C2
882,884,CHEMBL2205833,DCGVCGVBZDMLGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CN=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccnc1
883,885,CHEMBL2205833,DCGVCGVBZDMLGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CN=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccnc1
884,886,CHEMBL173594,DCMSQGZJUOFZNO-DKIAHMRJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,IC50,=,28.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [3H]WIN-35428 as radioligand,Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,7.552841968657781,C/C=C/C1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3C,C/C=C/c1ccc([C@H]2CC3CCC([C@H]2C(=O)OC)N3C)cc1
885,887,CHEMBL435341,DCMSQGZJUOFZNO-REZDNEAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,IC50,=,32.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [3H]WIN-35428 as radioligand,Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,7.494850021680094,C/C=C\C1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3C,C/C=C\c1ccc([C@H]2CC3CCC([C@H]2C(=O)OC)N3C)cc1
886,888,CHEMBL139,DCOPUUMXTXDBNB-UHFFFAOYSA-N,DICLOFENAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
887,889,CHEMBL139,DCOPUUMXTXDBNB-UHFFFAOYSA-N,DICLOFENAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
888,890,CHEMBL1944643,DCRIIMMZVJPZAH-WKAQUBQDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,48.98,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.309981219211304,CN1[C@@H]2CC[C@H]1[C@@H]([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OCC5=CC=CC=C5,CN1[C@H]2CC[C@@H]1C[C@H](OC(c1ccc(F)cc1)c1ccc(F)cc1)[C@H]2C(=O)OCc1ccccc1
889,891,CHEMBL3310639,DCSFZFQYIIRZFM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,11.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,11.0,C1C(CN1)CC(C2=CC=CC=C2)OC3=CC=CC=C3Cl,Clc1ccccc1OC(CC1CNC1)c1ccccc1
890,892,CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
891,893,CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
892,894,CHEMBL40,DDBREPKUVSBGFI-UHFFFAOYSA-N,PHENOBARBITAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
893,895,CHEMBL40,DDBREPKUVSBGFI-UHFFFAOYSA-N,PHENOBARBITAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
894,896,CHEMBL194909,DDBXZYDSZVDTAS-ZJUUUORDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C(=CC=C3)F,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2cccc(F)c12
895,897,CHEMBL598026,DDDMGCMKOCLAAT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,>,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.0,CC(C(=O)C1=CC(=CC=C1)[N+](=O)[O-])NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc([N+](=O)[O-])c1
896,898,CHEMBL147040,DDKXNVHSNBNSEK-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,39.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.4089353929735005,CCN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
897,899,CHEMBL147040,DDKXNVHSNBNSEK-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,270.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.568636235841013,CCN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
898,900,CHEMBL147040,DDKXNVHSNBNSEK-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,6.9,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.9,CCN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
899,901,CHEMBL513248,DDNDQTODRFYZEU-WFASDCNBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.0,C#CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC=CS2,C#CCN(CC#C)C(=O)[C@@]1(c2cccs2)C[C@H]1CN
900,902,CHEMBL257280,DDPFMTCKLODLQM-GKBBYZSKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,-6.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,-6.0,CC1=CC2=C(C=C1)N(C(=N2)C(C)(C)O)[C@@H]3CCN(C[C@H]3OC)C[C@H]4CC5=C(C4)C=C(C=C5)C#N,CO[C@@H]1CN(C[C@H]2Cc3ccc(C#N)cc3C2)CC[C@H]1n1c(C(C)(C)O)nc2cc(C)ccc21
901,903,CHEMBL2367892,DDTDNCYHLGRFBM-YZEKDTGTSA-N,TEICOPLANIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1[C@H]([C@@H]([C@@H](O[C@H]1O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O[C@@H]5[C@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C6=C(C=CC(=C6)[C@H](C(=O)N3)NC(=O)[C@H]7C8=CC(=C(C(=C8)OC9=C(C=C2C=C9)Cl)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)CO)O)O)NC(=O)C)OC1=C(C=C(C[C@@H]2C(=O)N[C@@H](C3=CC(=CC(=C3)OC3=C(C=CC(=C3)[C@H](C(=O)N2)N)O)O)C(=O)N7)C=C1)Cl)O)C(=O)O)CO)O)O,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O
902,904,CHEMBL2367892,DDTDNCYHLGRFBM-YZEKDTGTSA-N,TEICOPLANIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1[C@H]([C@@H]([C@@H](O[C@H]1O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O[C@@H]5[C@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C6=C(C=CC(=C6)[C@H](C(=O)N3)NC(=O)[C@H]7C8=CC(=C(C(=C8)OC9=C(C=C2C=C9)Cl)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)CO)O)O)NC(=O)C)OC1=C(C=C(C[C@@H]2C(=O)N[C@@H](C3=CC(=CC(=C3)OC3=C(C=CC(=C3)[C@H](C(=O)N2)N)O)O)C(=O)N7)C=C1)Cl)O)C(=O)O)CO)O)O,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O
903,905,CHEMBL562,DDUHZTYCFQRHIY-RBHXEPJQSA-N,GRISEOFULVIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
904,906,CHEMBL562,DDUHZTYCFQRHIY-RBHXEPJQSA-N,GRISEOFULVIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
905,907,CHEMBL242011,DDWGQGZPYDSYEL-LSDHHAIUSA-N,HINOKININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24112084.0,ACTIVITY,,,,Not Active,,cell_based,,,,,,,,,,,,Activity at human DAT expressed in MDCK cells assessed as dopamine release at 0.5 to 500 uM after 10 mins using [3H]-dopamine pretreated for 1 hr before compound addition followed by wash out by reversed transport efflux assay,The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.,J. Nat. Prod.,PUBLICATION,,,C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
906,908,CHEMBL242011,DDWGQGZPYDSYEL-LSDHHAIUSA-N,HINOKININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24112084.0,IC50,=,8350.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in MDCK cells using [3H]-dopamine as substrate after 10 mins by scintillation counting,The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.,J. Nat. Prod.,PUBLICATION,,5.078313524516398,C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
907,909,CHEMBL242011,DDWGQGZPYDSYEL-LSDHHAIUSA-N,HINOKININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24112084.0,INHIBITION,,,,Active,,cell_based,,,,,,,,,,,,Non-competitive inhibition of human DAT expressed in MDCK cells using [3H]-dopamine as substrate,The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.,J. Nat. Prod.,PUBLICATION,,,C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
908,910,CHEMBL242011,DDWGQGZPYDSYEL-LSDHHAIUSA-N,HINOKININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24112084.0,INHIBITION,,,,Dose-dependent effect,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in MDCK cells using [3H]-dopamine as substrate after 10 mins by scintillation counting,The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.,J. Nat. Prod.,PUBLICATION,,,C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
909,911,CHEMBL3085023,DEBMLCCWWGKBJP-WKCHPHFGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,12.5,NM,,,,,,,,,,,,,,,Inhibition of DAT,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.903089986991943,C1C[C@H]2CC(C[C@@H]1N2CCN)NC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,NCCN1[C@H]2CC[C@@H]1CC(NC(c1ccc(F)cc1)c1ccc(F)cc1)C2
910,912,CHEMBL470903,DECJIAJUQYVNQV-KHQMHLGISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,6.45,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.190440285364733,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=NO4)C5=CC=C(C=C5)F)N3C.Cl,Cc1ccc([C@H]2CC3CCC([C@H]2c2cc(-c4ccc(F)cc4)no2)N3C)cc1
911,913,CHEMBL3323174,DELHGKQNJWIBFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,9.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.045757490560675,CN1CC(C2=C(C1)C=C(C=C2)OC)C3=CC4=C(C=C3)SC=C4,COc1ccc2c(c1)CN(C)CC2c1ccc2sccc2c1
912,914,CHEMBL196468,DEMWBYUAYXJYOC-NEPJUHHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2ccc(C#N)cc12
913,915,CHEMBL196468,DEMWBYUAYXJYOC-NEPJUHHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,KI,=,2100.0,NM,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.6777807052660805,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2ccc(C#N)cc12
914,916,CHEMBL196468,DEMWBYUAYXJYOC-NEPJUHHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560923.0,IC50,=,4200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602098,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2ccc(C#N)cc12
915,917,CHEMBL196468,DEMWBYUAYXJYOC-NEPJUHHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20034793.0,IC50,=,4200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [I125]RTI-55 from human DAT transfected in human HEK293 cells,Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602098,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2ccc(C#N)cc12
916,918,CHEMBL195774,DEMWBYUAYXJYOC-NWDGAFQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@@H]1C[C@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@@H]1C[C@H]1c1c[nH]c2ccc(C#N)cc12
917,919,CHEMBL194910,DEMWBYUAYXJYOC-RYUDHWBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@@H]1C[C@@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@@H]1C[C@@H]1c1c[nH]c2ccc(C#N)cc12
918,920,CHEMBL1162965,DEMWBYUAYXJYOC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)CC1CC1C2=CNC3=C2C=C(C=C3)C#N,CN(C)CC1CC1c1c[nH]c2ccc(C#N)cc12
919,921,CHEMBL373211,DEMWBYUAYXJYOC-VXGBXAGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@H]1C[C@H]1c1c[nH]c2ccc(C#N)cc12
920,922,CHEMBL2432053,DEOOAAFCKARVDM-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CCC1=CC=CC=N1)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(CCc1ccccn1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
921,923,CHEMBL3350037,DEQANNDTNATYII-JDBXKHNRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@@H](C)O)O,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
922,924,CHEMBL3350037,DEQANNDTNATYII-JDBXKHNRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@@H](C)O)O,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
923,925,CHEMBL595190,DEQWDXVSVPRQSI-PAASSLRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,3.9,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.4089353929735,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OCCCCCCCN4C=C(N=N4)COC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)OCc1cn(CCCCCCCOC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)nn1)[C@@H](c1ccc(Cl)cc1)C2
924,926,CHEMBL43064,DERZBLKQOCDDDZ-JLHYYAGUSA-N,CINNARIZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1641.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.7848914189469065,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
925,927,CHEMBL43064,DERZBLKQOCDDDZ-JLHYYAGUSA-N,CINNARIZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1304.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.884722408604098,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
926,928,CHEMBL314887,DEXKQDBBXIRFMK-IHXHZNKUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,477.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.3214816209598865,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC=C(C=C3)F)O,COC(=O)C1C(c2ccc(F)cc2)CC2[C@@H](O)CC1N2C
927,929,CHEMBL314887,DEXKQDBBXIRFMK-IHXHZNKUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,739.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.131355561605173,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC=C(C=C3)F)O,COC(=O)C1C(c2ccc(F)cc2)CC2[C@@H](O)CC1N2C
928,930,CHEMBL2407337,DEYDFIXCTXWVHT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,170.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.769551078621726,CCOCC(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCOCC(c1ccc(Cl)c(Cl)c1)C1CCNCC1
929,931,CHEMBL1873703,DFBKLUNHFCTMDC-PICURKEMSA-N,DIELDRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,ClC1=C(Cl)[C@]2(Cl)[C@@H]3[C@@H]4C[C@H]([C@@H]3[C@@]1(Cl)C2(Cl)Cl)[C@H]1O[C@@H]41
930,932,CHEMBL1873703,DFBKLUNHFCTMDC-PICURKEMSA-N,DIELDRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,ClC1=C(Cl)[C@]2(Cl)[C@@H]3[C@@H]4C[C@H]([C@@H]3[C@@]1(Cl)C2(Cl)Cl)[C@H]1O[C@@H]41
931,933,CHEMBL513884,DFLDZWQBWUBYFS-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@H]1N(CC2=C(C(=CC=C2)Cl)Cl)C(=O)C3CCOCC3,O=C(C1CCOCC1)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1
932,934,CHEMBL1140,DFPAKSUCGFBDDF-UHFFFAOYSA-N,NIACINAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)N,NC(=O)c1cccnc1
933,935,CHEMBL1140,DFPAKSUCGFBDDF-UHFFFAOYSA-N,NIACINAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)N,NC(=O)c1cccnc1
934,936,CHEMBL198033,DFPNKBKLTJXKDT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,19.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,19.0,CC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)CCCNC,CNCCCC1Cc2ccccc2N(c2ccc(C)cc2)C1=O
935,937,CHEMBL198033,DFPNKBKLTJXKDT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)CCCNC,CNCCCC1Cc2ccccc2N(c2ccc(C)cc2)C1=O
936,938,CHEMBL611990,DFPSUOZWGQDKPI-COPLHBTASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,630.96,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.19999817218203,CN(C)C[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CN(C)C[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
937,939,CHEMBL452,DGBIGWXXNGSACT-UHFFFAOYSA-N,CLONAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
938,940,CHEMBL452,DGBIGWXXNGSACT-UHFFFAOYSA-N,CLONAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
939,941,CHEMBL2012116,DGHBKKBHNLJPGA-JEGBIIHOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,487.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.3124710387853655,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC=C(S3)C4=CC=CC=C4,COC(=O)[C@H]1C2CCC(C[C@H]1c1ccc(-c3ccccc3)s1)O2
940,942,CHEMBL2012116,DGHBKKBHNLJPGA-JEGBIIHOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC=C(S3)C4=CC=CC=C4,COC(=O)[C@H]1C2CCC(C[C@H]1c1ccc(-c3ccccc3)s1)O2
941,943,CHEMBL1914694,DGHITSOFNGOFOI-AFNJWWOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,82.2,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0851281824599495,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NC4=CC(=NC=C4)Br,CN1C2CCC1[C@@H](C(=O)Nc1ccnc(Br)c1)[C@@H](c1ccc(Cl)cc1)C2
942,944,CHEMBL478836,DGKNIGATLZIOSX-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2470.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.607303046740334,C1CNC[C@H]1NCC2=CC=CC=C2C3=CC=CC=C3,c1ccc(-c2ccccc2CN[C@H]2CCNC2)cc1
943,945,CHEMBL441477,DGLUIONDYMRDKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,INHIBITION,=,12.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane at a concentration of 10e-6 M,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,12.0,C1C2=CC=CC=C2CN3C(=N1)C4=CC=CC=C4C3(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCc3ccccc3CN21
944,946,CHEMBL441477,DGLUIONDYMRDKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,<,0.02,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,0.02,C1C2=CC=CC=C2CN3C(=N1)C4=CC=CC=C4C3(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCc3ccccc3CN21
945,947,CHEMBL316561,DGMKFQYCZXERLX-UHFFFAOYSA-N,PROGLUMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1
946,948,CHEMBL316561,DGMKFQYCZXERLX-UHFFFAOYSA-N,PROGLUMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1
947,949,CHEMBL2113055,DGOLMTSTXLHVKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,=,969.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.013676222949233,CNC(=O)C1=CC=CC=C1SC2=CC=CC=C2[N+](=O)[O-],CNC(=O)c1ccccc1Sc1ccccc1[N+](=O)[O-]
948,950,CHEMBL603620,DGQVZUDAKWRJPY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,3620.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.441291429466834,CC(C(=O)C1=CC(=CC=C1)OC)NC(C)(C)C,COc1cccc(C(=O)C(C)NC(C)(C)C)c1
949,951,CHEMBL1172919,DGWDYSSUZQAJAQ-MISXGVKJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.900008766455317,COC[C@@H]1[C@H]2[C@@]1(CNCC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@H]1[C@@H]2CCNC[C@@]21c1ccc(Cl)c(Cl)c1
950,952,CHEMBL583113,DGZJTKQIMNNTQO-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CNC[C@H]([C@H](C1=CC=CC=C1Cl)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1Cl)n1ccc2ccccc21
951,953,CHEMBL2012079,DHGOPWYNAIGSII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,272.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.5654310959658,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CS4,COC(=O)C1=C(c2ccc(-c3cccs3)cc2)CC2CCC1O2
952,954,CHEMBL2012079,DHGOPWYNAIGSII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CS4,COC(=O)C1=C(c2ccc(-c3cccs3)cc2)CC2CCC1O2
953,955,CHEMBL2338044,DHKBDZKBBAEQNU-LRDDRELGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=CC(=C3F)F)F,Fc1ccc(F)c(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1F
954,956,CHEMBL577988,DHLSZOUSVZEAKZ-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1=CC=C(C=C1)[C@@H]([C@H](CN)O)N2C=CC3=C2C=CC(=C3)F,NC[C@H](O)[C@H](c1ccccc1)n1ccc2cc(F)ccc21
955,957,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N,NCC(=O)O
956,958,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N,NCC(=O)O
957,959,CHEMBL2205821,DHQYUPWRESNGBC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCCc1ccccc1
958,960,CHEMBL461571,DHUATBAZHILHIC-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18701276.0,IC50,=,3410.0,NM,,,,,,,,,,,,,,,Displacement of radioligand from DAT,Highly functionalized 7-azaindoles as selective PPAR gamma modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.467245621007502,CC1=C(C2=C(N1CC3=CC(=CC=C3)O[C@H](C)C(=O)O)C=C(C=C2)OC(F)(F)F)C(=O)C4=CC=C(C=C4)Cl,Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@H](C)C(=O)O)c1
959,961,CHEMBL390929,DHXANQGCRAVCSQ-DUHSPSEUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,3.3,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.481486060122112,COC(=O)[C@H]1[C@H](CC2CCC1O2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)O2
960,962,CHEMBL316342,DHXANQGCRAVCSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,2.34,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.630784142589858,COC(=O)C1C2CCC(O2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)c(Cl)c1)O2
961,963,CHEMBL316342,DHXANQGCRAVCSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,3.08,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.511449283499555,COC(=O)C1C2CCC(O2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)c(Cl)c1)O2
962,964,CHEMBL316342,DHXANQGCRAVCSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,3.27,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.485452247339714,COC(=O)C1C2CCC(O2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)c(Cl)c1)O2
963,965,CHEMBL316342,DHXANQGCRAVCSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,3.35,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.474955192963153,COC(=O)C1C2CCC(O2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)c(Cl)c1)O2
964,966,CHEMBL316342,DHXANQGCRAVCSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,47.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.327902142064282,COC(=O)C1C2CCC(O2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)c(Cl)c1)O2
965,967,CHEMBL316342,DHXANQGCRAVCSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,56.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.251811972993798,COC(=O)C1C2CCC(O2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)c(Cl)c1)O2
966,968,CHEMBL1173276,DHXSMGUKIICGAC-TVQRCGJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,3340.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.4762535331884346,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Br)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Br)c1
967,969,CHEMBL1173276,DHXSMGUKIICGAC-TVQRCGJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,44.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,7.356547323513813,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Br)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Br)c1
968,970,CHEMBL208070,DHYMNQOPOAQKFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,5.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)OCCN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2.C(C(C(=O)O)O)(C(=O)O)O,CC(C)OCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
969,971,CHEMBL48449,DHZBEENLJMYSHQ-XCVPVQRUSA-N,CANTHARIDIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3,C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1
970,972,CHEMBL48449,DHZBEENLJMYSHQ-XCVPVQRUSA-N,CANTHARIDIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3,C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1
971,973,CHEMBL253597,DHZBNHMEIOBPAE-JVVVGQRLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18067245.0,ACTIVITY,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT receptor at 10 uM,Synthesis and evaluation in monkey of two sensitive 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo.,J. Med. Chem.,PUBLICATION,,50.0,CC(=O)N(CC1=CC=CC=C1O[11CH3])C2=C(C=CN=C2)OC3=CC=CC=C3,COc1ccccc1CN(C(C)=O)c1cnccc1Oc1ccccc1
972,974,CHEMBL451105,DIEUHEQWLCVFKO-DNVCBOLYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CN(C)C,Cc1ccccc1O[C@H]1c2ccccc2OC[C@H]1CN(C)C
973,975,CHEMBL461148,DIIRBUSHKZQLRI-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,11.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,11.0,CC(C)N1C2=CC=CC=C2N(C1=O)[C@H](CCNC)C3=CC=CC=C3,CNCC[C@H](c1ccccc1)n1c(=O)n(C(C)C)c2ccccc21
974,976,CHEMBL2338351,DIKKTLPJDURHSW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,290.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,,ACS Med. Chem. Lett.,PUBLICATION,,6.5376020021010435,CN1CCC2=C(C1)C=CC=C2C(=O)NCC3(CCCCC3)N4CCN(CC4)C5=CC=CC=C5,CN1CCc2c(cccc2C(=O)NCC2(N3CCN(c4ccccc4)CC3)CCCCC2)C1
975,977,CHEMBL2338351,DIKKTLPJDURHSW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,INHIBITION,=,93.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 1 uM relative to control,,ACS Med. Chem. Lett.,PUBLICATION,,93.0,CN1CCC2=C(C1)C=CC=C2C(=O)NCC3(CCCCC3)N4CCN(CC4)C5=CC=CC=C5,CN1CCc2c(cccc2C(=O)NCC2(N3CCN(c4ccccc4)CC3)CCCCC2)C1
976,978,CHEMBL457866,DILAIXDPRRLKOQ-DXWGQUKGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.376750709602098,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OCCC4=CC=C(C=C4)[N+](=O)[O-].Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OCCc2ccc([N+](=O)[O-])cc2)N3C)cc1
977,979,CHEMBL395609,DIMAAAZZSSXDEH-DFBJGRDBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17127059.0,KI,=,102.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-uptake in human DAT expressed in CHO cells,Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.991399828238082,C[C@H]1COCCN1CCCOC2=CC3=C(C=C2)[C@@H](CN(C3)C)C4=CC=C(C=C4)OC,COc1ccc([C@@H]2CN(C)Cc3cc(OCCCN4CCOC[C@@H]4C)ccc32)cc1
978,980,CHEMBL469068,DINOQTNPFRDVRK-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,=,10200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.991399828238082,CC(C)(C)CC(=O)N(CC1=C(C=C(C=C1)Cl)Cl)[C@H]2CCNC2,CC(C)(C)CC(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
979,981,CHEMBL1684055,DIOWQSMFSBKMCS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,28.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.552841968657781,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)N(C)C,CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1
980,982,CHEMBL1684055,DIOWQSMFSBKMCS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,72.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.142667503568733,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)N(C)C,CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1
981,983,CHEMBL1684055,DIOWQSMFSBKMCS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,140.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321763,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)N(C)C,CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1
982,984,CHEMBL580,DIWRORZWFLOCLC-UHFFFAOYSA-N,LORAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
983,985,CHEMBL580,DIWRORZWFLOCLC-UHFFFAOYSA-N,LORAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
984,986,CHEMBL399831,DIYWRNLYKJKHAM-MDOVXXIYSA-N,(-)-CUBEBIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24112084.0,IC50,=,12000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in MDCK cells using [3H]-dopamine as substrate after 10 mins by scintillation counting,The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.,J. Nat. Prod.,PUBLICATION,,4.920818753952375,C1[C@@H]([C@H]([C@H](O1)O)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,O[C@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
985,987,CHEMBL399831,DIYWRNLYKJKHAM-MDOVXXIYSA-N,(-)-CUBEBIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24112084.0,INHIBITION,,,,Dose-dependent effect,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in MDCK cells using [3H]-dopamine as substrate after 10 mins by scintillation counting,The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.,J. Nat. Prod.,PUBLICATION,,,C1[C@@H]([C@H]([C@H](O1)O)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,O[C@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
986,988,CHEMBL1224318,DJFCVWKVRXLZFF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,63.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C(N=C2)N)Cl,CC(C)(C)CCC1(C(=O)c2cnc(N)c(Cl)c2)CCNC1
987,989,CHEMBL487894,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,DIPYRONE SODIUM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C
988,990,CHEMBL487894,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,DIPYRONE SODIUM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C
989,991,CHEMBL519240,DJKJVWJQAVGLHJ-YPMHNXCESA-N,A-987306,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18983139.0,ACTIVITY,=,74.5,%,,,,,,,,,,,,,,,Binding affinity to human DAT at 10 uM relative to control,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,74.5,C1CC[C@H]2[C@@H](C1)C3=C(O2)CCC4=C3N=C(N=C4N5CCNCC5)N,Nc1nc2c(c(N3CCNCC3)n1)CCC1=C2[C@@H]2CCCC[C@@H]2O1
990,992,CHEMBL519240,DJKJVWJQAVGLHJ-YPMHNXCESA-N,A-987306,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18983139.0,INHIBITION,=,25.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 uM,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,25.0,C1CC[C@H]2[C@@H](C1)C3=C(O2)CCC4=C3N=C(N=C4N5CCNCC5)N,Nc1nc2c(c(N3CCNCC3)n1)CCC1=C2[C@@H]2CCCC[C@@H]2O1
991,993,CHEMBL219116,DJLLHNLJLSEKHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,11.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.9586073148417755,COC(=O)C(C1CCCCN1)C2=CC=C(C=C2)Cl,COC(=O)C(c1ccc(Cl)cc1)C1CCCCN1
992,994,CHEMBL219116,DJLLHNLJLSEKHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,2700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.568636235841013,COC(=O)C(C1CCCCN1)C2=CC=C(C=C2)Cl,COC(=O)C(c1ccc(Cl)cc1)C1CCCCN1
993,995,CHEMBL219116,DJLLHNLJLSEKHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,25.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.602059991327962,COC(=O)C(C1CCCCN1)C2=CC=C(C=C2)Cl,COC(=O)C(c1ccc(Cl)cc1)C1CCCCN1
994,996,CHEMBL219116,DJLLHNLJLSEKHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,2000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.698970004336019,COC(=O)C(C1CCCCN1)C2=CC=C(C=C2)Cl,COC(=O)C(c1ccc(Cl)cc1)C1CCCCN1
995,997,CHEMBL469668,DJVJRXDBDBMWFD-JPKZNVRTSA-N,WAY-256805,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)C[C@H](C2=CC(=CC=C2)OC(F)(F)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(C[C@H](c2cccc(OC(F)(F)F)c2)C2(O)CCCCC2)CC1
996,998,CHEMBL511959,DJVJRXDBDBMWFD-NTEVMMBTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,5.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,CN1CCN(CC1)C[C@@H](C2=CC(=CC=C2)OC(F)(F)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(C[C@@H](c2cccc(OC(F)(F)F)c2)C2(O)CCCCC2)CC1
997,999,CHEMBL469667,DJVJRXDBDBMWFD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,3.0,CN1CCN(CC1)CC(C2=CC(=CC=C2)OC(F)(F)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(CC(c2cccc(OC(F)(F)F)c2)C2(O)CCCCC2)CC1
998,1000,CHEMBL1830891,DKFCBQMDHKALKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,23.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,23.0,C1COC(CN1)CCN2C3=C(C=C(C=C3)F)N(S2(=O)=O)C4=CC=CC=C4F,O=S1(=O)N(CCC2CNCCO2)c2ccc(F)cc2N1c1ccccc1F
999,1001,CHEMBL40416,DKLLAAOIWFKPBT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.01,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.01,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=C(C=C3)Br)C4=CC=C(C=C4)Br,Brc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccc(Br)cc2)cc1
1000,1002,CHEMBL1224227,DKLPATDCBOSBMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,1240.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.906578314837764,CNCCC(C1=CC2=CC=CC=C2C=C1)N3N=CN=N3,CNCCC(c1ccc2ccccc2c1)n1ncnn1
1001,1003,CHEMBL1224227,DKLPATDCBOSBMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,10.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CNCCC(C1=CC2=CC=CC=C2C=C1)N3N=CN=N3,CNCCC(c1ccc2ccccc2c1)n1ncnn1
1002,1004,CHEMBL498141,DKMITNDZRUDDGX-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@H]1[C@@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3C(F)(F)F,CNC[C@H]1OCc2ccccc2[C@H]1Oc1ccccc1C(F)(F)F
1003,1005,CHEMBL526270,DKMITNDZRUDDGX-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3C(F)(F)F,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1C(F)(F)F
1004,1006,CHEMBL526270,DKMITNDZRUDDGX-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3C(F)(F)F,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1C(F)(F)F
1005,1007,CHEMBL660,DKNWSYNQZKUICI-UHFFFAOYSA-N,AMANTADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2CC3CC1CC(C2)(C3)N,NC12CC3CC(CC(C3)C1)C2
1006,1008,CHEMBL660,DKNWSYNQZKUICI-UHFFFAOYSA-N,AMANTADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2CC3CC1CC(C2)(C3)N,NC12CC3CC(CC(C3)C1)C2
1007,1009,CHEMBL37513,DKXHNCOJPUVDIZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.28,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.28,C1CN(CCN1CCCC2=CC=CC=C2)CC(=O)N(CC3=CC=CC=C3)C4=CC=CC=C4,O=C(CN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccc1
1008,1010,CHEMBL37513,DKXHNCOJPUVDIZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,5.97,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.97,C1CN(CCN1CCCC2=CC=CC=C2)CC(=O)N(CC3=CC=CC=C3)C4=CC=CC=C4,O=C(CN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccc1
1009,1011,CHEMBL482295,DKXQXLBXXKLLSH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,6900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.161150909262744,CN(C)CC1=C(C=CC(=C1)NS(=O)(=O)C)SC2=CC=C(C=C2)C(F)(F)F,CN(C)Cc1cc(NS(C)(=O)=O)ccc1Sc1ccc(C(F)(F)F)cc1
1010,1012,CHEMBL75435,DKYWVDODHFEZIM-NSHDSACASA-N,DEXKETOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
1011,1013,CHEMBL75435,DKYWVDODHFEZIM-NSHDSACASA-N,DEXKETOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
1012,1014,CHEMBL571,DKYWVDODHFEZIM-UHFFFAOYSA-N,KETOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
1013,1015,CHEMBL571,DKYWVDODHFEZIM-UHFFFAOYSA-N,KETOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
1014,1016,CHEMBL1909050,DLDAZIVPAOLETE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
1015,1017,CHEMBL1909050,DLDAZIVPAOLETE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
1016,1018,CHEMBL513,DLGOEMSEDOSKAD-UHFFFAOYSA-N,CARMUSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCl)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NCCCl
1017,1019,CHEMBL513,DLGOEMSEDOSKAD-UHFFFAOYSA-N,CARMUSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCl)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NCCCl
1018,1020,CHEMBL3331505,DLJBWQLXARVMNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,406.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.391473966422807,C1C(CN1)N(CC2=CC=CC=C2)CC3=CC4=CC=CC=C4C=C3,c1ccc(CN(Cc2ccc3ccccc3c2)C2CNC2)cc1
1019,1021,CHEMBL61006,DLNKOYKMWOXYQA-UHFFFAOYSA-N,PHENYLPROPANOLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,68.3,NM,,,,,,,,,,,,,,,,,,,,7.165579296318468,CC(C(C1=CC=CC=C1)O)N,CC(N)C(O)c1ccccc1
1020,1022,CHEMBL61006,DLNKOYKMWOXYQA-UHFFFAOYSA-N,PHENYLPROPANOLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,294.0,NM,,,,,,,,,,,,,,,,,,,,6.531652669587842,CC(C(C1=CC=CC=C1)O)N,CC(N)C(O)c1ccccc1
1021,1023,CHEMBL61006,DLNKOYKMWOXYQA-UHFFFAOYSA-N,PHENYLPROPANOLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,302.0,NM,,,,,,,,,,,,,,,,,,,,6.519993057042849,CC(C(C1=CC=CC=C1)O)N,CC(N)C(O)c1ccccc1
1022,1024,CHEMBL61006,DLNKOYKMWOXYQA-UHFFFAOYSA-N,PHENYLPROPANOLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,1371.0,NM,,,,,,,,,,,,,,,,,,,,5.862962545210488,CC(C(C1=CC=CC=C1)O)N,CC(N)C(O)c1ccccc1
1023,1025,CHEMBL1945247,DLPVJOABBWHGLU-HZMVEIRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,30.2,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.519993057042849,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CC(=C)Br)C[C@@H]1C3=CC=C(C=C3)I,C=C(Br)CN1[C@H]2CC[C@@H]1[C@@H](C(=O)OC)[C@@H](c1ccc(I)cc1)C2
1024,1026,CHEMBL403078,DLQIUZVQSULILG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=N1)CNC)OC2=C(C=C(C=C2)Cl)OC,CNCc1cnc(C)cc1Oc1ccc(Cl)cc1OC
1025,1027,CHEMBL374769,DLVMQSXQUZPAKP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,60.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.221848749616356,CC(C)(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)(C)CC(c1ccc(Cl)cc1)C1CCCCN1
1026,1028,CHEMBL374769,DLVMQSXQUZPAKP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,670.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.173925197299173,CC(C)(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)(C)CC(c1ccc(Cl)cc1)C1CCCCN1
1027,1029,CHEMBL374769,DLVMQSXQUZPAKP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,120.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.920818753952375,CC(C)(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)(C)CC(c1ccc(Cl)cc1)C1CCCCN1
1028,1030,CHEMBL374769,DLVMQSXQUZPAKP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.221848749616356,CC(C)(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)(C)CC(c1ccc(Cl)cc1)C1CCCCN1
1029,1031,CHEMBL1173430,DLXDOKNGJXKCNQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,8250.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.0835460514500745,CC1C(OCC(N1)(C)C)(C2=CC(=CC(=C2)Cl)Cl)O,CC1NC(C)(C)COC1(O)c1cc(Cl)cc(Cl)c1
1030,1032,CHEMBL232069,DMFIBBAULMICJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,264000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.5783960731301687,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)C3=CC=CC=C3,COC(=O)C1=C(c2ccc(-c3ccccc3)cc2)CCCC1
1031,1033,CHEMBL232069,DMFIBBAULMICJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)C3=CC=CC=C3,COC(=O)C1=C(c2ccc(-c3ccccc3)cc2)CCCC1
1032,1034,CHEMBL232069,DMFIBBAULMICJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,3801893963205.61,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.58,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)C3=CC=CC=C3,COC(=O)C1=C(c2ccc(-c3ccccc3)cc2)CCCC1
1033,1035,CHEMBL217053,DMFOOUGJUFPBOG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17154491.0,INHIBITION,<,30.0,%,,,,,,,,,,,,,,,Inhibition of human DA transporter at 10 uM,Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.,J. Med. Chem.,PUBLICATION,,30.0,C1=CC=C(C=C1)N2C=C(C=N2)C(=O)C3=C(C=CC(=C3)Br)OCC(=O)O,O=C(O)COc1ccc(Br)cc1C(=O)c1cnn(-c2ccccc2)c1
1034,1036,CHEMBL127,DMJNNHOOLUXYBV-PQTSNVLCSA-N,MEROPENEM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
1035,1037,CHEMBL127,DMJNNHOOLUXYBV-PQTSNVLCSA-N,MEROPENEM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
1036,1038,CHEMBL403377,DMKNBJGZUPGVEW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,9000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,CNCC1=C(C=CC(=C1)C(=O)N2CCCN(CC2)C3CC3)OC4=CC=C(C=C4)C(F)(F)F,CNCc1cc(C(=O)N2CCCN(C3CC3)CC2)ccc1Oc1ccc(C(F)(F)F)cc1
1037,1039,CHEMBL2380979,DMOBQDGHIHODJN-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@H]1C[C@@H]1CC2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@H]1C[C@@H]1Cc1ccc2[nH]cc(C#N)c2c1
1038,1040,CHEMBL2380979,DMOBQDGHIHODJN-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,INHIBITION,=,17.0,%,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes at 1 uM,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,17.0,CN(C)C[C@H]1C[C@@H]1CC2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@H]1C[C@@H]1Cc1ccc2[nH]cc(C#N)c2c1
1039,1041,CHEMBL1095523,DMULXMAWQFEZSA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)(C(CN2CCNCC2)C3=C(SC(=C3)Cl)Cl)O,OC1(C(CN2CCNCC2)c2cc(Cl)sc2Cl)CCCCC1
1040,1042,CHEMBL519910,DNHPSSPWARRIMM-FOYRJYEQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,22.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.655607726314889,CC1=CC=C(C=C1)CC2=NOC(=C2)[C@H]3[C@H](CC4CCC3N4C)C5=CC=C(C=C5)Cl.Cl,Cc1ccc(Cc2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)on2)cc1
1041,1043,CHEMBL286398,DNIAPMSPPWPWGF-UHFFFAOYSA-N,PROPYLENE GLYCOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CO)O,CC(O)CO
1042,1044,CHEMBL286398,DNIAPMSPPWPWGF-UHFFFAOYSA-N,PROPYLENE GLYCOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CO)O,CC(O)CO
1043,1045,CHEMBL1643642,DNNGDLSNRHAHQR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,CC1=NOC(=C1)C2=C(CC3CCC2S3)C4=CC=CC=C4,Cc1cc(C2=C(c3ccccc3)CC3CCC2S3)on1
1044,1046,CHEMBL1641695,DNRTUAFNYBLJFW-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,1828.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.738023808602188,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)N=[N+]=[N-])C3=CC(=CC=C3)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1Cc1ccc(N=[N+]=[N-])cc1
1045,1047,CHEMBL1641695,DNRTUAFNYBLJFW-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,658.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,6.181774106386046,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)N=[N+]=[N-])C3=CC(=CC=C3)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1Cc1ccc(N=[N+]=[N-])cc1
1046,1048,CHEMBL477782,DNSFFPXOVPKGCT-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CCC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
1047,1049,CHEMBL1200709,DNTGGZPQPQTDQF-XBXARRHUSA-N,CROTAMITON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC=C1C)C(=O)/C=C/C,C/C=C/C(=O)N(CC)c1ccccc1C
1048,1050,CHEMBL1200709,DNTGGZPQPQTDQF-XBXARRHUSA-N,CROTAMITON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC=C1C)C(=O)/C=C/C,C/C=C/C(=O)N(CC)c1ccccc1C
1049,1051,CHEMBL494624,DNTKPSJIKIXCOA-BPNKVWISSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,8.853871964321762,CN1[C@H]2CC[C@@H]1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=C(Br)Br.Cl,CN1[C@H]2CC[C@@H]1[C@H](C=C(Br)Br)[C@@H](c1ccc(Cl)cc1)C2
1050,1052,CHEMBL494626,DNTKPSJIKIXCOA-VZXSFKIWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,0.32,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,9.494850021680094,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=C(Br)Br.Cl,CN1[C@H]2CC[C@@H]1[C@@H](C=C(Br)Br)[C@@H](c1ccc(Cl)cc1)C2
1051,1053,CHEMBL2338054,DNTVXLSMTRVFMZ-MBSDFSHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=CC(=C1O[C@H]([C@H]2CCNC2)C3=CC=CC=C3)C4=CC=CC=N4)Cl,Cc1cc(Cl)cc(-c2ccccn2)c1O[C@@H](c1ccccc1)[C@H]1CCNC1
1052,1054,CHEMBL599230,DNVMLFGJFSQQDE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,750.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.1249387366083,CC(C(=O)C1=CC(=CC=C1)Br)N2CCCCC2,CC(C(=O)c1cccc(Br)c1)N1CCCCC1
1053,1055,CHEMBL1405,DNXHEGUUPJUMQT-CBZIJGRNSA-N,ESTRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O
1054,1056,CHEMBL1405,DNXHEGUUPJUMQT-CBZIJGRNSA-N,ESTRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O
1055,1057,CHEMBL1466,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,DICUMAROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O
1056,1058,CHEMBL1466,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,DICUMAROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O
1057,1059,CHEMBL822,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,TERBINAFINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12
1058,1060,CHEMBL822,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,TERBINAFINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12
1059,1061,CHEMBL551473,DONMCIZYEUHXSH-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,12.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,12.0,CC(C)N1C2=C(C(=CC=C2)F)N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1ccccc1)n1c(=O)n(C(C)C)c2cccc(F)c21
1060,1062,CHEMBL3310481,DOQJYOJZNNPBRY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,13.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,13.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)OC(F)(F)F,FC(F)(F)Oc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
1061,1063,CHEMBL3310481,DOQJYOJZNNPBRY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,54.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,54.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)OC(F)(F)F,FC(F)(F)Oc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
1062,1064,CHEMBL3310481,DOQJYOJZNNPBRY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)OC(F)(F)F,FC(F)(F)Oc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
1063,1065,CHEMBL1204411,DOQYJYPXUDTPLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,23.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,CNCCCC1CC2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F.Cl,CNCCCC1Cc2ccccc2N(c2ccccc2F)S1(=O)=O
1064,1066,CHEMBL1282,DOUYETYNHWVLEO-UHFFFAOYSA-N,IMIQUIMOD,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,CC(C)Cn1cnc2c(N)nc3ccccc3c21
1065,1067,CHEMBL1282,DOUYETYNHWVLEO-UHFFFAOYSA-N,IMIQUIMOD,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,CC(C)Cn1cnc2c(N)nc3ccccc3c21
1066,1068,CHEMBL589178,DOYLLHOWPJQFPA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,=,6976.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.15639352807549,CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)OCCCF)CN(C)C)N,Cc1ccc(Oc2ccc(OCCCF)cc2CN(C)C)c(N)c1
1067,1069,CHEMBL248824,DPGZNUSUOPLFNV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,60.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,CC1=CC(=CC=C1)OC(=O)C2=C(CCC2)C3=CC(=C(C=C3)Cl)Cl,Cc1cccc(OC(=O)C2=C(c3ccc(Cl)c(Cl)c3)CCC2)c1
1068,1070,CHEMBL2338050,DPINDTNFGDXWLU-BLLLJJGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CNC[C@H]1[C@@H](C2=CC=CC=C2)OC3=C(C=CC(=C3Cl)F)F,Fc1ccc(F)c(O[C@H](c2ccccc2)[C@H]2CCNC2)c1Cl
1069,1071,CHEMBL2338048,DPINDTNFGDXWLU-LRDDRELGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,12.59,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=CC(=C3Cl)F)F,Fc1ccc(F)c(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1Cl
1070,1072,CHEMBL2338049,DPINDTNFGDXWLU-MLGOLLRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,7.94,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=C(C=CC(=C3Cl)F)F,Fc1ccc(F)c(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1Cl
1071,1073,CHEMBL2338051,DPINDTNFGDXWLU-WBMJQRKESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CNC[C@@H]1[C@H](C2=CC=CC=C2)OC3=C(C=CC(=C3Cl)F)F,Fc1ccc(F)c(O[C@@H](c2ccccc2)[C@@H]2CCNC2)c1Cl
1072,1074,CHEMBL597968,DPNWJTQXCYFUOT-VOMIJIAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,2.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.0,CC1=CC2=C(C=C1)N(CC2)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CCc2cc(C)ccc21
1073,1075,CHEMBL19019,DQCKKXVULJGBQN-XFWGSAIBSA-N,NALTREXONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
1074,1076,CHEMBL19019,DQCKKXVULJGBQN-XFWGSAIBSA-N,NALTREXONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
1075,1077,CHEMBL1198,DQKXQSGTHWVTAD-UHFFFAOYSA-N,PRAMOXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2,CCCCOc1ccc(OCCCN2CCOCC2)cc1
1076,1078,CHEMBL1198,DQKXQSGTHWVTAD-UHFFFAOYSA-N,PRAMOXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2,CCCCOc1ccc(OCCCN2CCOCC2)cc1
1077,1079,CHEMBL486538,DQMQNSKBKIYETN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,741.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1301817920206725,C1CNCC1(CC2=CC=CC=C2)C3=CN=C4C(=C3)C=CN4,c1ccc(CC2(c3cnc4[nH]ccc4c3)CCNC2)cc1
1078,1080,CHEMBL487691,DQMYTSCZLQLEID-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=C(C=C3)OC,COc1ccc(O[C@H]2C[C@@H](N(C)C)c3ccccc32)cc1
1079,1081,CHEMBL856,DQMZLTXERSFNPB-UHFFFAOYSA-N,PRIMIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NCNC1=O
1080,1082,CHEMBL856,DQMZLTXERSFNPB-UHFFFAOYSA-N,PRIMIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NCNC1=O
1081,1083,CHEMBL2206529,DQNPRNKGUDQMJY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,10.6,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.9746941347352305,CC1=CC=C(C=C1)C2CN(CC3=C(C=CC=C23)C)C,Cc1ccc(C2CN(C)Cc3c(C)cccc32)cc1
1082,1084,CHEMBL577597,DQPHXSWTVKEOEO-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,9.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=CC(=C3)F)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cc(F)ccc21
1083,1085,CHEMBL512878,DQRDMGPCIADVBP-ZSFQTYJUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,6.42,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.192464971931146,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)C5=CC=C(C=C5)Cl.Cl,CN1C2CCC1[C@@H](c1cc(-c3ccc(Cl)cc3)no1)[C@@H](c1ccc(Cl)cc1)C2
1084,1086,CHEMBL1097469,DRAQRLXEPIYYIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,INHIBITION,=,51.0,%,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human DAT expressed in CHO membranes at 1000 nM,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,51.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CSC4=CC=CC=C43)O,OC1(C(CN2CCNCC2)c2csc3ccccc23)CCCCC1
1085,1087,CHEMBL318592,DRIXPIWDZOXGSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,787.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.104025267640934,COC(=O)C1C2CCC(C2)CC1C3=CC=CC=C3,COC(=O)C1C2CCC(C2)CC1c1ccccc1
1086,1088,CHEMBL186306,DRKNLRWFPBQBFH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15482938.0,KI,=,5.0,NM,,,,,,,,,,,,,,,Inhibition of [18F]PET binding to dopamine transporter of human brain,Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,C1CC2C(C(CC1N2)C3=CC=C(C=C3)I)C(=O)OCCF,O=C(OCCF)C1C2CCC(CC1c1ccc(I)cc1)N2
1087,1089,CHEMBL45,DRLFMBDRBRZALE-UHFFFAOYSA-N,MELATONIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COc1ccc2[nH]cc(CCNC(C)=O)c2c1
1088,1090,CHEMBL45,DRLFMBDRBRZALE-UHFFFAOYSA-N,MELATONIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COc1ccc2[nH]cc(CCNC(C)=O)c2c1
1089,1091,CHEMBL227231,DRLOWUSIOOIRRD-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,63.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.200659450546419,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=CC=C5)Br,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3cccc(Br)c3)s1)[C@@H](c1ccc(Cl)cc1)C2
1090,1092,CHEMBL227231,DRLOWUSIOOIRRD-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,39.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.4089353929735005,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=CC=C5)Br,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3cccc(Br)c3)s1)[C@@H](c1ccc(Cl)cc1)C2
1091,1093,CHEMBL2337604,DRRQCYGCMNHHQK-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)Cl)Cl,Clc1ccc(O[C@@H](c2ccccc2)[C@H]2CCNC2)c(Cl)c1
1092,1094,CHEMBL332097,DRRXQCXSBONKPD-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,130000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter; Average of two experiments,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.886056647693163,CNCC[C@@H](C1=CC=CS1)OC2=CC=C(C3=CC=CC=C32)O,CNCC[C@H](Oc1ccc(O)c2ccccc12)c1cccs1
1093,1095,CHEMBL514560,DRWJMJVERMOJBX-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2910.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.536107011014093,CCOC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@@H]3CCNC3,CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@@H]1CCNC1
1094,1096,CHEMBL478834,DRWJMJVERMOJBX-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,3030.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.518557371497695,CCOC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
1095,1097,CHEMBL478834,DRWJMJVERMOJBX-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3030.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.518557371497695,CCOC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
1096,1098,CHEMBL258013,DRYNWXRVJSBMFJ-CPFSXVBKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=C(C(=C(S2)Cl)Cl)Cl,CCN(CC)C(=O)[C@@]1(c2sc(Cl)c(Cl)c2Cl)C[C@H]1CN
1097,1099,CHEMBL204199,DSAPXKWYVMTXKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)OC2=CC=CC=C2CN(C)C)N,Cc1ccc(Oc2ccccc2CN(C)C)c(N)c1
1098,1100,CHEMBL399429,DSBUEYRGXKHYAZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,30.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,C1CC(=C(C1)C(=O)NCC2=CC=CO2)C3=CC(=C(C=C3)Cl)Cl,O=C(NCc1ccco1)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
1099,1101,CHEMBL459391,DSDLGRNFGNGRFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,,COC1=C(C2=CC=CC=C2C=C1)CCC3CCC(O3)CCN,COc1ccc2ccccc2c1CCC1CCC(CCN)O1
1100,1102,CHEMBL459391,DSDLGRNFGNGRFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C2=CC=CC=C2C=C1)CCC3CCC(O3)CCN,COc1ccc2ccccc2c1CCC1CCC(CCN)O1
1101,1103,CHEMBL3331481,DSGFYRHAIBAWFX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,14.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,14.0,C1CC1N(CC2=CC3=CC=CC=C3C=C2)C4CNC4,c1ccc2cc(CN(C3CC3)C3CNC3)ccc2c1
1102,1104,CHEMBL379679,DSIUMNNVBQZCEG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,67.9,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.168130225719497,CCCC(C(=O)C1=CC=C(C=C1)NC(=O)C)N2CCCC2,CCCC(C(=O)c1ccc(NC(C)=O)cc1)N1CCCC1
1103,1105,CHEMBL379679,DSIUMNNVBQZCEG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,30.2,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.519993057042849,CCCC(C(=O)C1=CC=C(C=C1)NC(=O)C)N2CCCC2,CCCC(C(=O)c1ccc(NC(C)=O)cc1)N1CCCC1
1104,1106,CHEMBL379679,DSIUMNNVBQZCEG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,RATIO,=,3.0,,,,cell_based,,,,,,,,,,,,Ratio of IC50 for [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells to Ki for displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,3.0,CCCC(C(=O)C1=CC=C(C=C1)NC(=O)C)N2CCCC2,CCCC(C(=O)c1ccc(NC(C)=O)cc1)N1CCCC1
1105,1107,CHEMBL1783889,DSNALXIKDKGHLJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25893048.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to human DAT at 1 uM,,ACS Med. Chem. Lett.,PUBLICATION,,,CC(C)N1CCN(CC1)C(=O)C2=CC=C(C=C2)CN3CCCCC3,CC(C)N1CCN(C(=O)c2ccc(CN3CCCCC3)cc2)CC1
1106,1108,CHEMBL2252949,DSSYKIVIOFKYAU-OIBJUYFYSA-N,(-)-CAMPHOR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C1(C)C)CC2=O,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2
1107,1109,CHEMBL2252949,DSSYKIVIOFKYAU-OIBJUYFYSA-N,(-)-CAMPHOR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C1(C)C)CC2=O,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2
1108,1110,CHEMBL504760,DSSYKIVIOFKYAU-XCBNKYQSSA-N,CAMPHOR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CC[C@@H](C1(C)C)CC2=O,CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2
1109,1111,CHEMBL504760,DSSYKIVIOFKYAU-XCBNKYQSSA-N,CAMPHOR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CC[C@@H](C1(C)C)CC2=O,CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2
1110,1112,CHEMBL560999,DTBBOFHJHSCSAN-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)C(=O)N(CC2=CC=CC=C2C(F)(F)F)[C@H]3CCNC3,O=C(C1CCC1)N(Cc1ccccc1C(F)(F)F)[C@H]1CCNC1
1111,1113,CHEMBL290510,DTGCWKSRSZRKRD-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,13000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,4.886056647693163,COC(=O)[C@@H]([C@@H]1CCCCO1)C2=CC=CC=C2,COC(=O)[C@H](c1ccccc1)[C@@H]1CCCCO1
1112,1114,CHEMBL286937,DTGCWKSRSZRKRD-STQMWFEESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,3000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)[C@H]([C@@H]1CCCCO1)C2=CC=CC=C2,COC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCO1
1113,1115,CHEMBL2096877,DTGXSBMWMFLEGI-JRRMTSHWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,1.35,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,8.869666231504992,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC=C(C=C4)C)N3C,Cc1ccc([C@H]2CC3CCC([C@H]2c2ccc(C)cc2)N3C)cc1
1114,1116,CHEMBL426178,DTGXSBMWMFLEGI-OEXSPLCWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,340.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,6.468521082957745,CC1=CC=C(C=C1)[C@@H]2CC3CCC([C@@H]2C4=CC=C(C=C4)C)N3C,Cc1ccc([C@H]2C3CCC(C[C@H]2c2ccc(C)cc2)N3C)cc1
1115,1117,CHEMBL520735,DTIHRSKIBFPMSD-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=CC=C3,CN(C)[C@@H]1C[C@H](Oc2ccccc2)c2ccccc21
1116,1118,CHEMBL204759,DTNUPBSOODGRKW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,40.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.397940008672037,CCCC(C(=O)C1=CC2=CC=CC=C2C=C1)N3CCCC3,CCCC(C(=O)c1ccc2ccccc2c1)N1CCCC1
1117,1119,CHEMBL204759,DTNUPBSOODGRKW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,20.1,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.696803942579511,CCCC(C(=O)C1=CC2=CC=CC=C2C=C1)N3CCCC3,CCCC(C(=O)c1ccc2ccccc2c1)N1CCCC1
1118,1120,CHEMBL1683903,DTPYYGUOEBJVJL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,996.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.001740661576301,C1CCC(CC1)(CN)C2=CC=C(C=C2)C3=CC=CC=C3,NCC1(c2ccc(-c3ccccc3)cc2)CCCCC1
1119,1121,CHEMBL324269,DTPZQRWLIAELHU-YHZLUUAOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,,,,Not Determined,,,,,,,,,,,,,,In vitro ability of compound to inhibit DA re-uptake of radiolabeled [3H]-tritium transmitter into synaptosome; ND=not determined,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)F,CN(C)C[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(F)ccc2c1
1120,1122,CHEMBL324269,DTPZQRWLIAELHU-YHZLUUAOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,50.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)F,CN(C)C[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(F)ccc2c1
1121,1123,CHEMBL514447,DUCJOVLKXCHFKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,1260.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.8996294548824375,C1CNCC1(CC2=CC=CC=C2)C3=CNC4=CC=CC=C43,c1ccc(CC2(c3c[nH]c4ccccc34)CCNC2)cc1
1122,1124,CHEMBL827,DUGOZIWVEXMGBE-CHWSQXEVSA-N,DEXMETHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,88.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,7.055517327849832,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
1123,1125,CHEMBL827,DUGOZIWVEXMGBE-CHWSQXEVSA-N,DEXMETHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,156.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,6.806875401645539,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
1124,1126,CHEMBL827,DUGOZIWVEXMGBE-CHWSQXEVSA-N,DEXMETHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,25.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,7.602059991327962,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
1125,1127,CHEMBL827,DUGOZIWVEXMGBE-CHWSQXEVSA-N,DEXMETHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,16.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.795880017344076,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
1126,1128,CHEMBL290634,DUGOZIWVEXMGBE-STQMWFEESA-N,(SS)-METHYL-PHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,21.0,NM,,,,,,,,,,,,,,,,,,,,7.67778070526608,COC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
1127,1129,CHEMBL290634,DUGOZIWVEXMGBE-STQMWFEESA-N,(SS)-METHYL-PHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,42.0,NM,,,,,,,,,,,,,,,,,,,,7.376750709602098,COC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
1128,1130,CHEMBL290634,DUGOZIWVEXMGBE-STQMWFEESA-N,(SS)-METHYL-PHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,50.0,NM,,,,,,,,,,,,,,,,,,,,7.301029995663981,COC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
1129,1131,CHEMBL290634,DUGOZIWVEXMGBE-STQMWFEESA-N,(SS)-METHYL-PHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,61.0,NM,,,,,,,,,,,,,,,,,,,,7.214670164989233,COC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
1130,1132,CHEMBL290634,DUGOZIWVEXMGBE-STQMWFEESA-N,(SS)-METHYL-PHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,34.0,NM,,,,,,,,,,,,,,,,,,,,7.468521082957745,COC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
1131,1133,CHEMBL290634,DUGOZIWVEXMGBE-STQMWFEESA-N,(SS)-METHYL-PHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,5.920818753952375,COC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2,COC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
1132,1134,CHEMBL796,DUGOZIWVEXMGBE-UHFFFAOYSA-N,METHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,7.769551078621726,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,COC(=O)C(c1ccccc1)C1CCCCN1
1133,1135,CHEMBL796,DUGOZIWVEXMGBE-UHFFFAOYSA-N,METHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,79.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.102372908709557,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,COC(=O)C(c1ccccc1)C1CCCCN1
1134,1136,CHEMBL796,DUGOZIWVEXMGBE-UHFFFAOYSA-N,METHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,110.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.9586073148417755,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,COC(=O)C(c1ccccc1)C1CCCCN1
1135,1137,CHEMBL796,DUGOZIWVEXMGBE-UHFFFAOYSA-N,METHYLPHENIDATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,KI,=,34.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.468521082957745,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,COC(=O)C(c1ccccc1)C1CCCCN1
1136,1138,CHEMBL481526,DUKLUAWTTPYZNJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,6400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,CCOC1=CC=C(C=C1)OC2=CC=CC=C2CN(C)C,CCOc1ccc(Oc2ccccc2CN(C)C)cc1
1137,1139,CHEMBL3323106,DUMPPDQZUJJGKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,53.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.275724130399211,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)N=CS4,CN1Cc2ccccc2C(c2ccc3ncsc3c2)C1
1138,1140,CHEMBL410015,DUNLKPYMIRLCRM-IFXJQAMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CC2=C1SC=C2)C(=O)[C@]3(C[C@H]3CN)C4=CC5=C(C=C4)OCO5,NC[C@@H]1C[C@@]1(C(=O)N1CCc2sccc2C1)c1ccc2c(c1)OCO2
1139,1141,CHEMBL555491,DUNXFOYJTLLKNQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,IC50,=,7.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,8.154901959985743,CCCC(C(=O)C1=CC=C(C=C1)N)N2CCCC2,CCCC(C(=O)c1ccc(N)cc1)N1CCCC1
1140,1142,CHEMBL555491,DUNXFOYJTLLKNQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,KI,=,5.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,8.301029995663981,CCCC(C(=O)C1=CC=C(C=C1)N)N2CCCC2,CCCC(C(=O)c1ccc(N)cc1)N1CCCC1
1141,1143,CHEMBL213143,DUTXSEWRTZPJLR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784853.0,IC50,=,36.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at dopamine transporter,High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.443697499232713,C1CN(CCN1CCCC2=CC=C(C=C2)NC(=O)CCCCC3C4C(CS3)NC(=O)N4)CCOC(C5=CC=C(C=C5)F)C6=CC=C(C=C6)F,O=C(CCCCC1SCC2NC(=O)NC21)Nc1ccc(CCCN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
1142,1144,CHEMBL608560,DUZFRLZTNIIHKJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19954972.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccc(F)c1
1143,1145,CHEMBL608560,DUZFRLZTNIIHKJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19954972.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccc(F)c1
1144,1146,CHEMBL608560,DUZFRLZTNIIHKJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccc(F)c1
1145,1147,CHEMBL2432049,DUZKXKAAUHDBQA-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,1558.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.8074325466634535,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC=CC=N6,c1ccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)nc1
1146,1148,CHEMBL124854,DVAFIFWOFNIVEV-ADCDNAHGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,223.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,6.6516951369518384,COC(=O)C1[C@H](CC2CCC1N2CC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2Cc1ccccc1
1147,1149,CHEMBL550870,DVAFTUPEVMCRKD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,79.43,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,COC1=CC=CC(=C1)CN(C2CCNCC2)C3=CC4=C(C=C3)NC=C4,COc1cccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)c1
1148,1150,CHEMBL413562,DVAKZGWOGMMTDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,5000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,5.301029995663981,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CCCO)N,CN(C)Cc1ccccc1Sc1ccc(CCCO)cc1N
1149,1151,CHEMBL334255,DVBJBNKEBPCGSY-UHFFFAOYSA-M,CETYLPYRIDINIUM BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,6279.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.202109516941651,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Br-],CCCCCCCCCCCCCCCC[n+]1ccccc1
1150,1152,CHEMBL334255,DVBJBNKEBPCGSY-UHFFFAOYSA-M,CETYLPYRIDINIUM BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4989.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.3019864960608185,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Br-],CCCCCCCCCCCCCCCC[n+]1ccccc1
1151,1153,CHEMBL1642899,DVCQRBZBVYAGNZ-GDBMZVCRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,176.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.7544873321858505,CN(C)[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
1152,1154,CHEMBL1642901,DVCQRBZBVYAGNZ-GOEBONIOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,319.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.496209316942818,CN(C)[C@@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
1153,1155,CHEMBL1642898,DVCQRBZBVYAGNZ-HOCLYGCPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,454.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.342944147142896,CN(C)[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
1154,1156,CHEMBL1642900,DVCQRBZBVYAGNZ-ZBFHGGJFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,273.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.563837352959244,CN(C)[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
1155,1157,CHEMBL493264,DVFKWYNNNBWGRC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,5400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.267606240177033,CN(C)CC1=CC=CC=C1SC2=CC=C(C=C2)SC,CSc1ccc(Sc2ccccc2CN(C)C)cc1
1156,1158,CHEMBL3673137,DVONUWHZWNLFQL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,19.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.707743928643524,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)Cl)Cl)C=CC(=C3)C5=CC6=C(C=C5)NC(=O)O6,O=c1[nH]c2ccc(-c3ccc4c(c3)CN3CCC4(c4ccc(Cl)c(Cl)c4)C3)cc2o1
1157,1159,CHEMBL3673137,DVONUWHZWNLFQL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,50.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.301029995663981,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)Cl)Cl)C=CC(=C3)C5=CC6=C(C=C5)NC(=O)O6,O=c1[nH]c2ccc(-c3ccc4c(c3)CN3CCC4(c4ccc(Cl)c(Cl)c4)C3)cc2o1
1158,1160,CHEMBL3104091,DVSMVUMYJDOPJQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24365159.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin) by radioligand displacement assay,"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=CC=CC4=C3N2C5=CC=CC=C5CC4,CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1
1159,1161,CHEMBL577497,DWBBFNBXAKCWFH-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,12000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,CC(=O)N(CC1=CC2=CC=CC=C2C=C1)[C@@H]3CCNC3,CC(=O)N(Cc1ccc2ccccc2c1)[C@@H]1CCNC1
1160,1162,CHEMBL2380971,DWEUBXIQNVYDHT-HIFRSBDPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
1161,1163,CHEMBL2380971,DWEUBXIQNVYDHT-HIFRSBDPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,INHIBITION,=,56.0,%,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes at 1 uM,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,56.0,CN(C)C[C@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
1162,1164,CHEMBL2380980,DWEUBXIQNVYDHT-ZFWWWQNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
1163,1165,CHEMBL2380980,DWEUBXIQNVYDHT-ZFWWWQNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,INHIBITION,=,50.0,%,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes at 1 uM,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN(C)C[C@@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
1164,1166,CHEMBL3323103,DWFQMVGSQLUODG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,INHIBITION,=,40.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells at 100 nM after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,40.0,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4N3,CN1Cc2ccccc2C(c2cc3ccccc3[nH]2)C1
1165,1167,CHEMBL2012085,DWPZMURPWZHSTE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=CC=CC(=C3)C4=NC=CS4,COC(=O)C1=C(c2cccc(-c3nccs3)c2)CC2CCC1O2
1166,1168,CHEMBL2012085,DWPZMURPWZHSTE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=CC(=C3)C4=NC=CS4,COC(=O)C1=C(c2cccc(-c3nccs3)c2)CC2CCC1O2
1167,1169,CHEMBL1319362,DWSGTFTVBLXELC-RDYJJYPNSA-N,HOMATROPINE HYDROBROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O.Br,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(O)c1ccccc1)C2
1168,1170,CHEMBL1319362,DWSGTFTVBLXELC-RDYJJYPNSA-N,HOMATROPINE HYDROBROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O.Br,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(O)c1ccccc1)C2
1169,1171,CHEMBL3673150,DWTFUODFLDHIAT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,168.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.772370350428991,CC1=NN=C(S1)C2=CC3=C(C=C2)C4(CCN(C3)CC4)C5=CC=C(C=C5)Cl,Cc1nnc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)s1
1170,1172,CHEMBL475945,DWTJKIXZDHRVPT-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,1.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.0,CNCC[C@@H](C1=CC(=CC=C1)F)N2C3=CC=CC=C3C4(C2=O)CCCCC4,CNCC[C@@H](c1cccc(F)c1)N1C(=O)C2(CCCCC2)c2ccccc21
1171,1173,CHEMBL515614,DWTJKIXZDHRVPT-HXUWFJFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,20.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,20.0,CNCC[C@H](C1=CC(=CC=C1)F)N2C3=CC=CC=C3C4(C2=O)CCCCC4,CNCC[C@H](c1cccc(F)c1)N1C(=O)C2(CCCCC2)c2ccccc21
1172,1174,CHEMBL1651208,DWTYHCYVKJONSP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23009245.0,INHIBITION,=,40.0,%,,,,,,,,,,,,,,,Inhibition of radioligand binding to human DAT at 10 uM,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,40.0,C1CCC(C1)N2CC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl
1173,1175,CHEMBL506098,DXFWUAWSMRONLI-RXGFHJPUSA-N,HYDROPEROXYCADIFORIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17618015.0,IC50,=,0.05,UG.ML-1,,,,,,,,,,,,,,,Inhibition of dopamine uptake at DAT,Bioactive peroxides as potential therapeutic agents.,Eur. J. Med. Chem.,PUBLICATION,,0.05,CC(C)[C@H]1CC[C@@]([C@@H]2[C@@H]1C=C(CC2)C[C@@]3(C(=O)[C@@]4(C[C@@H]([C@@]([C@@](C4=O)(C3=O)C(=O)C(C)C)(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)CC=C(C)C)(C)OO,CC(C)=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@@]2(CC=C(C)C)C(=O)[C@@](CC=C(C)C)(CC3=C[C@H]4[C@H](CC3)[C@](C)(OO)CC[C@@H]4C(C)C)C(=O)[C@]1(C(=O)C(C)C)C2=O
1174,1176,CHEMBL569025,DXTDNUFZTNALDJ-SFTDATJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1COCCN1C[C@@H]([C@H](C2=CC=CC=C2)N3C=CC4=CC=CC=C43)O,O[C@@H](CN1CCOCC1)[C@H](c1ccccc1)n1ccc2ccccc21
1175,1177,CHEMBL2069411,DXYBEOOKXLMROC-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22832315.0,IC50,=,2000.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,C1[C@@H](COC2=CC=CC(=C21)C3=CN=C(C=C3)CO)NC(=O)C4=CN=C(C=C4)OCC(F)(F)F,O=C(N[C@@H]1COc2cccc(-c3ccc(CO)nc3)c2C1)c1ccc(OCC(F)(F)F)nc1
1176,1178,CHEMBL2069411,DXYBEOOKXLMROC-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22832315.0,INHIBITION,=,80.0,%,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT at 10 uM,Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,80.0,C1[C@@H](COC2=CC=CC(=C21)C3=CN=C(C=C3)CO)NC(=O)C4=CN=C(C=C4)OCC(F)(F)F,O=C(N[C@@H]1COc2cccc(-c3ccc(CO)nc3)c2C1)c1ccc(OCC(F)(F)F)nc1
1177,1180,CHEMBL482903,DYJBCVKMYPRGRR-BJUDXGSMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18487050.0,KI,=,2490.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.,Bioorg. Med. Chem.,PUBLICATION,,5.603800652904264,[11CH3]OC1=CC2=C(CN(CC2)CCCC3=CNC4=C3C=C(C=C4)F)C=C1,COc1ccc2c(c1)CCN(CCCc1c[nH]c3ccc(F)cc13)C2
1178,1181,CHEMBL3323105,DYQBWKPHLQJDJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,270.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.568636235841013,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=NN4,CN1Cc2ccccc2C(c2ccc3cn[nH]c3c2)C1
1179,1182,CHEMBL3323105,DYQBWKPHLQJDJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,300.0,NM,314456,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.522878745280337,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=NN4,CN1Cc2ccccc2C(c2ccc3cn[nH]c3c2)C1
1180,1183,CHEMBL3703738,DYQJFQKEXMXHKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,47.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.3251388592621876,CC1=C(C(=NO1)C)C2=CC3=C(C=C2)C(CNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1noc(C)c1-c1ccc2c(c1)CNCC2c1ccc(Cl)c(Cl)c1
1181,1184,CHEMBL40961,DYQUSDHMMXTDDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.93,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.93,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=N4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccn3)CC2)cc1
1182,1185,CHEMBL40961,DYQUSDHMMXTDDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.82,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.82,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=N4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccn3)CC2)cc1
1183,1186,CHEMBL40961,DYQUSDHMMXTDDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.97,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.97,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=N4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccn3)CC2)cc1
1184,1187,CHEMBL40961,DYQUSDHMMXTDDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.11,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.11,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=N4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccn3)CC2)cc1
1185,1188,CHEMBL429630,DYSBNPIZJYMHRA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,56000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,4.251811972993798,CC1=C(C=C(C=C1)C2=C(C3CCC2C3)C(=O)OC)F,COC(=O)C1=C(c2ccc(C)c(F)c2)C2CCC1C2
1186,1189,CHEMBL236046,DYUSEVKSEDICGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17616397.0,KI,=,700.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154901959985742,CNCC1=C(C=CC(=C1)C#CCCN2CCOCC2)OC3=CC=C(C=C3)SC,CNCc1cc(C#CCCN2CCOCC2)ccc1Oc1ccc(SC)cc1
1187,1190,CHEMBL1914698,DZCYWZREDUKUMT-IAFLDTSXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,7.9,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.102372908709556,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)CNC4=CC(=NC=C4)Br,CN1C2CCC1[C@@H](CNc1ccnc(Br)c1)[C@@H](c1ccc(Cl)cc1)C2
1188,1191,CHEMBL452429,DZEOBMAMUUMJNJ-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1COC2=CC=CC=C2[C@H]1OC3=CC=CC=C3Cl,CNC[C@H]1COc2ccccc2[C@H]1Oc1ccccc1Cl
1189,1192,CHEMBL497479,DZEOBMAMUUMJNJ-SJKOYZFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@H]1COC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3Cl,CNC[C@@H]1COc2ccccc2[C@@H]1Oc1ccccc1Cl
1190,1193,CHEMBL497479,DZEOBMAMUUMJNJ-SJKOYZFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@H]1COC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3Cl,CNC[C@@H]1COc2ccccc2[C@@H]1Oc1ccccc1Cl
1191,1194,CHEMBL346178,DZOJBGLFWINFBF-UMSFTDKQSA-N,OSANETANT,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25738882.0,INHIBITION,>=,50.0,%,,,cell_based,,,,,,,,,,,,Displacement of [3H]BTCP from recombinant human dopamine transporter expressed in CHO cells at 1 uM after 120 mins by scintillation counting analysis relative to control,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (part I).,J. Med. Chem.,PUBLICATION,,50.0,CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5,CC(=O)N(C)C1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1
1192,1195,CHEMBL103504,DZQDCXYKGIEDDJ-XBBDAYDNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,373.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.428291168191312,CCC[C@]1(CN2[C@@H]3CCC2C1[C@H](C3)C4=CC=C(C=C4)C)O,CCC[C@@]1(O)CN2C3CC[C@@H]2C[C@H](c2ccc(C)cc2)C31
1193,1197,CHEMBL201978,DZULEPZTNHLZTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,55.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.259637310505756,CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
1194,1198,CHEMBL201978,DZULEPZTNHLZTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,28.8,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.5406075122407685,CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
1195,1199,CHEMBL1258452,DZZIAERGLDKTBT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20812727.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,"Synthesis, structure--affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.",J. Med. Chem.,PUBLICATION,,5.0,CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C=C2)N)OC,CCCCN1CCC(COC(=O)c2ccc(N)c(OC)c2)CC1
1196,1200,CHEMBL850,DZZWHBIBMUVIIW-DTORHVGOSA-N,SPARFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F,C[C@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1
1197,1201,CHEMBL850,DZZWHBIBMUVIIW-DTORHVGOSA-N,SPARFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F,C[C@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1
1198,1202,CHEMBL211527,FABMPYBEKUUBIW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CN(CCN1)C(CC2=C(C=C(C=C2)Cl)Cl)C3=CC=CC=C3,Clc1ccc(CC(c2ccccc2)N2CCNCC2)c(Cl)c1
1199,1203,CHEMBL1560,FAKRSMQSSFJEIM-RQJHMYQMSA-N,CAPTOPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
1200,1204,CHEMBL1560,FAKRSMQSSFJEIM-RQJHMYQMSA-N,CAPTOPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
1201,1205,CHEMBL1200600,FAOZLTXFLGPHNG-KNAQIMQKSA-N,FLUOROMETHOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
1202,1206,CHEMBL1200600,FAOZLTXFLGPHNG-KNAQIMQKSA-N,FLUOROMETHOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
1203,1207,CHEMBL1173599,FAQPJNPOZWJWED-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,4.0,CC1C(OCC(N1)(C)C)(C2=CN=CC=C2)O,CC1NC(C)(C)COC1(O)c1cccnc1
1204,1208,CHEMBL2171408,FAVINESADHRZRB-UHFFFAOYSA-N,"3-((3,4-DICHLOROPHENYL)(ETHOXY)METHYL)AZETIDINE HCL",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,30.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,30.0,CCOC(C1CNC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCOC(c1ccc(Cl)c(Cl)c1)C1CNC1
1205,1209,CHEMBL1641694,FAWDXIDAVOHYQT-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,1232.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.909389292171594,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2N=[N+]=[N-])C3=CC=C(C=C3)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1Cc1ccccc1N=[N+]=[N-]
1206,1210,CHEMBL1641694,FAWDXIDAVOHYQT-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,517.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,6.286509456906058,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2N=[N+]=[N-])C3=CC=C(C=C3)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1Cc1ccccc1N=[N+]=[N-]
1207,1211,CHEMBL103919,FAWYJKWTZBQTRU-CIPDSAHDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.376750709602098,COC(=O)[C@@H]1C2CCC(C2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@@H]1C2CCC(C2)CC1c1ccc(Cl)c(Cl)c1
1208,1212,CHEMBL388545,FAWYJKWTZBQTRU-CMZCTZCXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,14.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.853871964321763,COC(=O)[C@H]1[C@H](CC2CCC1C2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@@H]1C2CCC(C2)C[C@@H]1c1ccc(Cl)c(Cl)c1
1209,1213,CHEMBL2111614,FAWYJKWTZBQTRU-XJFAFDKQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,9.6,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.017728766960431,COC(=O)[C@@H]1[C@H](CC2CCC1C2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@H]1C2CCC(C2)C[C@@H]1c1ccc(Cl)c(Cl)c1
1210,1214,CHEMBL2111614,FAWYJKWTZBQTRU-XJFAFDKQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.886056647693162,COC(=O)[C@@H]1[C@H](CC2CCC1C2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@H]1C2CCC(C2)C[C@@H]1c1ccc(Cl)c(Cl)c1
1211,1215,CHEMBL2171420,FBCBBHPWZDGQBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,29.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,29.0,C1C(CN1)C(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3F.Cl,Fc1cc(C(Oc2ccccc2F)C2CNC2)ccc1Cl
1212,1216,CHEMBL34259,FBOZXECLQNJBKD-ZDUSSCGKSA-N,METHOTREXATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
1213,1217,CHEMBL34259,FBOZXECLQNJBKD-ZDUSSCGKSA-N,METHOTREXATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
1214,1218,CHEMBL689,FBPFZTCFMRRESA-KVTDHHQDSA-N,MANNITOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
1215,1219,CHEMBL689,FBPFZTCFMRRESA-KVTDHHQDSA-N,MANNITOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
1216,1220,CHEMBL3703725,FBUHCPMYBAXIMM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,89.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.048662481204082,CNC1=NN=C(C=C1)C2=CC3=C(C=C2)C(CNC3)C4=CC=C(C=C4)F,CNc1ccc(-c2ccc3c(c2)CNCC3c2ccc(F)cc2)nn1
1217,1221,CHEMBL3703725,FBUHCPMYBAXIMM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,90.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.0433514207947985,CNC1=NN=C(C=C1)C2=CC3=C(C=C2)C(CNC3)C4=CC=C(C=C4)F,CNc1ccc(-c2ccc3c(c2)CNCC3c2ccc(F)cc2)nn1
1218,1222,CHEMBL270099,FBYDVYUKCVAEAU-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17983754.0,KI,>,30000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125]RTI35 from human DAT expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter.",Bioorg. Med. Chem.,PUBLICATION,,4.5228787452803365,COC(=O)C1=CC=CC=C1S[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COC(=O)c1ccccc1S[C@@H](c1ccccc1)[C@@H]1CNCCO1
1219,1223,CHEMBL199054,FBYZEHXPWUZCPM-KGLIPLIRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CCN1C=C(C2=C1C=CC(=C2)C#N)[C@H]3C[C@@H]3CN(C)C,CCn1cc([C@H]2C[C@@H]2CN(C)C)c2cc(C#N)ccc21
1220,1224,CHEMBL1084309,FCEXIPULXFOGIW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC=CC=C3F,Fc1ccccc1C(Cc1ccccc1OC(F)F)N1CCNCC1
1221,1225,CHEMBL213035,FCHUPCOGZXEFDS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=C2C#N)C3=CC=CC=C3,N#Cc1ccccc1CC(c1ccccc1)N1CCNCC1
1222,1226,CHEMBL204538,FCINLQHPPAWABH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,11.8,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.928117992693875,CCCC(C(=O)C1=CC=C(C=C1)C#CC)N2CCCC2,CC#Cc1ccc(C(=O)C(CCC)N2CCCC2)cc1
1223,1227,CHEMBL204538,FCINLQHPPAWABH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,61.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.214670164989233,CCCC(C(=O)C1=CC=C(C=C1)C#CC)N2CCCC2,CC#Cc1ccc(C(=O)C(CCC)N2CCCC2)cc1
1224,1228,CHEMBL1813306,FCMFWPCHZOKPLR-NHYWBVRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,1288.25,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.889999848866888,CN1C[C@@H]2CCCC[C@@]2(C1)C3=C(C=C(C=C3)Cl)Cl,CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)cc2Cl)C1
1225,1229,CHEMBL410055,FCURKYXBYVWDLH-FXAWDEMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCN(CC#CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,CC#CCN(CCC)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
1226,1230,CHEMBL256137,FCUSICKWCXJXBW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=N1)CNC)OC2=C(C=C(C=C2)Cl)C,CNCc1cnc(C)cc1Oc1ccc(Cl)cc1C
1227,1231,CHEMBL479410,FCXKPNHKJPFYSO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=C(C=CC(=C1)NS(=O)(=O)C)OC2=CC=C(C=C2)C(F)(F)F,CN(C)Cc1cc(NS(C)(=O)=O)ccc1Oc1ccc(C(F)(F)F)cc1
1228,1232,CHEMBL479410,FCXKPNHKJPFYSO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18782666.0,IC50,=,11000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.9586073148417755,CN(C)CC1=C(C=CC(=C1)NS(=O)(=O)C)OC2=CC=C(C=C2)C(F)(F)F,CN(C)Cc1cc(NS(C)(=O)=O)ccc1Oc1ccc(C(F)(F)F)cc1
1229,1233,CHEMBL256819,FCZCOULCVQEFCA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,421.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.375717904164333,CN(C)CC1=CC=CC=C1OC2=C(C=C(C=C2)Cl)F,CN(C)Cc1ccccc1Oc1ccc(Cl)cc1F
1230,1234,CHEMBL453062,FDBFTQAPQQWDDD-CRAIPNDOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2C[C@@H](CC3=CC=CC=C23)NC,CN[C@@H]1Cc2ccccc2[C@H](Oc2ccccc2C)C1
1231,1235,CHEMBL486045,FDBFTQAPQQWDDD-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,8000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008057,CC1=CC=CC=C1O[C@@H]2C[C@H](CC3=CC=CC=C23)NC,CN[C@H]1Cc2ccccc2[C@H](Oc2ccccc2C)C1
1232,1236,CHEMBL520736,FDBFTQAPQQWDDD-QAPCUYQASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,4500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,CC1=CC=CC=C1O[C@H]2C[C@@H](CC3=CC=CC=C23)NC,CN[C@@H]1Cc2ccccc2[C@@H](Oc2ccccc2C)C1
1233,1237,CHEMBL525249,FDBFTQAPQQWDDD-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,CC1=CC=CC=C1O[C@H]2C[C@H](CC3=CC=CC=C23)NC,CN[C@H]1Cc2ccccc2[C@@H](Oc2ccccc2C)C1
1234,1238,CHEMBL203562,FDCLNKXJEZCPEW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,44.3,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.35359627377693,CCCC(C(=O)C1=CC=C(C=C1)CO)N2CCCC2,CCCC(C(=O)c1ccc(CO)cc1)N1CCCC1
1235,1239,CHEMBL203562,FDCLNKXJEZCPEW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,48.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.312471038785365,CCCC(C(=O)C1=CC=C(C=C1)CO)N2CCCC2,CCCC(C(=O)c1ccc(CO)cc1)N1CCCC1
1236,1240,CHEMBL21,FDDDEECHVMSUSB-UHFFFAOYSA-N,SULFANILAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)N,Nc1ccc(S(N)(=O)=O)cc1
1237,1241,CHEMBL21,FDDDEECHVMSUSB-UHFFFAOYSA-N,SULFANILAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)N,Nc1ccc(S(N)(=O)=O)cc1
1238,1242,CHEMBL3593397,FDKMWPCRMXOEIV-NINOIYOQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CO[C@H]([C@@H](CN1)C(=O)N)C2=CC(=C(C=C2)Cl)Cl.Cl,NC(=O)[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1
1239,1243,CHEMBL476,FDKXTQMXEQVLRF-ZHACJKMWSA-N,DACARBAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)/N=N/C1=C(NC=N1)C(=O)N,CN(C)/N=N/c1nc[nH]c1C(N)=O
1240,1244,CHEMBL476,FDKXTQMXEQVLRF-ZHACJKMWSA-N,DACARBAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)/N=N/C1=C(NC=N1)C(=O)N,CN(C)/N=N/c1nc[nH]c1C(N)=O
1241,1245,CHEMBL446481,FDNFLRXXOIWCQA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,7100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1487416512809245,CN(C)CC1=C(C=CC(=C1)F)OC2=CC=C(C=C2)SC,CSc1ccc(Oc2ccc(F)cc2CN(C)C)cc1
1242,1246,CHEMBL67078,FDTFUBJUWHYSGU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,105.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.978810700930063,C1CC(CN(C1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CNCCCC4=CC=CC=C4,c1ccc(CCCNCC2CCCN(CCOC(c3ccccc3)c3ccccc3)C2)cc1
1243,1247,CHEMBL67078,FDTFUBJUWHYSGU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,70.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.154901959985742,C1CC(CN(C1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CNCCCC4=CC=CC=C4,c1ccc(CCCNCC2CCCN(CCOC(c3ccccc3)c3ccccc3)C2)cc1
1244,1248,CHEMBL232299,FDYWMYJFNNYCEI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,810.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.091514981121351,COC(=O)C1=C(CCCCC1)C2=CC=C(C=C2)C3=CC=CC=C3,COC(=O)C1=C(c2ccc(-c3ccccc3)cc2)CCCCC1
1245,1249,CHEMBL232299,FDYWMYJFNNYCEI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,2000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.698970004336019,COC(=O)C1=C(CCCCC1)C2=CC=C(C=C2)C3=CC=CC=C3,COC(=O)C1=C(c2ccc(-c3ccccc3)cc2)CCCCC1
1246,1250,CHEMBL2337597,FDZMWAFQMOJQFO-RHSMWYFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,158.49,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC=C(C=C3)Cl,Clc1ccc(O[C@H](c2ccccc2)[C@@H]2CCNC2)cc1
1247,1251,CHEMBL2337596,FDZMWAFQMOJQFO-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,15.85,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=CC=C(C=C3)Cl,Clc1ccc(O[C@@H](c2ccccc2)[C@H]2CCNC2)cc1
1248,1252,CHEMBL989,FEBLZLNTKCEFIT-VSXGLTOVSA-N,FLUOCINOLONE ACETONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
1249,1253,CHEMBL989,FEBLZLNTKCEFIT-VSXGLTOVSA-N,FLUOCINOLONE ACETONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
1250,1254,CHEMBL417035,FECMCOWJDSNXAS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,364.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.438898616350943,C1CC(CN(C1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CNCCC4=CC=C(C=C4)F,Fc1ccc(CCNCC2CCCN(CCOC(c3ccccc3)c3ccccc3)C2)cc1
1251,1255,CHEMBL417035,FECMCOWJDSNXAS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,87.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.0604807473813835,C1CC(CN(C1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CNCCC4=CC=C(C=C4)F,Fc1ccc(CCNCC2CCCN(CCOC(c3ccccc3)c3ccccc3)C2)cc1
1252,1256,CHEMBL1224239,FEFGXICFKQBCRL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.98,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,CC(C)(C)CCC1(CCNC1)C(=O)C2=NC3=CC=CC=C3C=C2,CC(C)(C)CCC1(C(=O)c2ccc3ccccc3n2)CCNC1
1253,1257,CHEMBL331334,FEIRROBBFMUCJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,3650.0,NM,,,,,,,,,,,,,,,Binding Affinity to cocaine site of dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol. ,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,5.437707135543525,CN1CCC(C(C1)C(=O)C2=C(C=C(C=C2)Cl)Cl)(C3=C(C=C(C=C3)Cl)Cl)O,CN1CCC(O)(c2ccc(Cl)cc2Cl)C(C(=O)c2ccc(Cl)cc2Cl)C1
1254,1258,CHEMBL1808432,FEJYXUSNDZMQOV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21724392.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 0.5 uM,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN1CC(=C(C1)Cl)C2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=CC=C4,COc1ccc2c(c1)c(C1=C(Cl)CN(C)C1)cn2S(=O)(=O)c1ccccc1
1255,1259,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
1256,1260,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
1257,1261,CHEMBL1813314,FEYNATNTSNGKKO-DOMZBBRYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,54.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.26003230324049,CN1C[C@H]2CCCC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1
1258,1262,CHEMBL1813315,FEYNATNTSNGKKO-SWLSCSKDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,14.13,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.849857838151442,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1
1259,1263,CHEMBL274119,FFEARJCKVFRZRR-UHFFFAOYSA-N,RACEMETHIONINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CSCCC(C(=O)O)N,CSCCC(N)C(=O)O
1260,1264,CHEMBL310604,FFFHZYDWPBMWHY-UHFFFAOYSA-N,HOMOCYSTEINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS)C(C(=O)O)N,NC(CCS)C(=O)O
1261,1265,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
1262,1266,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
1263,1267,CHEMBL1643898,FFHMGQOTHREMBZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,14.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321763,CCCCC1=C(C2CCN1CC2)C3=CC=C(C=C3)Cl,CCCCC1=C(c2ccc(Cl)cc2)C2CCN1CC2
1264,1268,CHEMBL481306,FFJCCOLDJHZNND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,85.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.070581074285707,CNCC1=C(C=CC(=C1)S(=O)(=O)N)CC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(S(N)(=O)=O)ccc1Cc1ccc(Cl)c(Cl)c1
1265,1269,CHEMBL516730,FFJNDOUWRPDJJX-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,3210.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.493494967595128,CCOC(=O)N(CC1=CC=CC=C1C(F)(F)F)[C@H]2CCNC2,CCOC(=O)N(Cc1ccccc1C(F)(F)F)[C@H]1CCNC1
1266,1270,CHEMBL576542,FFMLDCYSPNMTJA-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,52.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,52.0,CNCC[C@H](C1=CC(=CC=C1)F)N2C=CC3=CC=CC=C32,CNCC[C@H](c1cccc(F)c1)n1ccc2ccccc21
1267,1271,CHEMBL1683888,FFPZKPBDKMJMOH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.769551078621726,CN(C)CC1(CCCCC1)C2=CC(=C(C=C2)Cl)F,CN(C)CC1(c2ccc(Cl)c(F)c2)CCCCC1
1268,1272,CHEMBL256046,FFSGTXINCSICHG-BYGWLNTFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,12.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.920818753952375,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC(=O)CCC(=O)OC[C@H]4[C@H](CC5CCC4N5C)C6=CC(=C(C=C6)Cl)Cl,CN1C2CCC1[C@@H](COC(=O)CCC(=O)OC[C@@H]1C3CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N3C)[C@@H](c1ccc(Cl)c(Cl)c1)C2
1269,1273,CHEMBL3334794,FFTJRFHZXXMTTK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,863.1,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.063938883390012,CN(C)CCC(C1=CC2=CC=CC=C2S1)N3CCCC3,CN(C)CCC(c1cc2ccccc2s1)N1CCCC1
1270,1274,CHEMBL218997,FFTNCZSASXDDKK-FPOVZHCZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CN[C@H](C[C@@H]1CC2=CC=CC=C2)CCCNC(=O)NC3=CC=CC(=C3)C#N,N#Cc1cccc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccccc3)CCN2)c1
1271,1275,CHEMBL218997,FFTNCZSASXDDKK-FPOVZHCZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,34.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.468521082957745,C1CN[C@H](C[C@@H]1CC2=CC=CC=C2)CCCNC(=O)NC3=CC=CC(=C3)C#N,N#Cc1cccc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccccc3)CCN2)c1
1272,1276,CHEMBL477374,FFWMVMYKTQEBAE-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,=,5870.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.231361898752385,CC(C)C(=O)N(CC1=C(C(=C(C=C1)Cl)Cl)Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1ccc(Cl)c(Cl)c1Cl)[C@H]1CCNC1
1273,1277,CHEMBL122452,FFZXXMKWEGRDRF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,349.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.45717457304082,CN(CCCN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2)CCC3=CC=CC=C3,CN(CCCN(C)CCc1ccccc1)CCOC(c1ccccc1)c1ccccc1
1274,1278,CHEMBL122452,FFZXXMKWEGRDRF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,322.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.492144128304169,CN(CCCN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2)CCC3=CC=CC=C3,CN(CCCN(C)CCc1ccccc1)CCOC(c1ccccc1)c1ccccc1
1275,1279,CHEMBL122452,FFZXXMKWEGRDRF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,1.1,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,1.1,CN(CCCN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2)CCC3=CC=CC=C3,CN(CCCN(C)CCc1ccccc1)CCOC(c1ccccc1)c1ccccc1
1276,1280,CHEMBL1085567,FGLZNYXYSDQEEU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,4870.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3124710387853655,COC1=CC=CC=C1CC(C2=CC=C(C=C2)F)N3CCNCC3,COc1ccccc1CC(c1ccc(F)cc1)N1CCNCC1
1277,1281,CHEMBL1683889,FGMVBSZPVPCFKQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.9586073148417755,CN(C)CC1(CCCCC1)C2=CC(=C(C=C2)F)Cl,CN(C)CC1(c2ccc(F)c(Cl)c2)CCCCC1
1278,1282,CHEMBL235626,FGRCKQKQPFBUSG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,147910838816821.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-5.170000000000001,COC(=O)C1=C(C2CCC1C2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)C2CCC1C2
1279,1283,CHEMBL1940403,FGTGRXMIFIZGBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,=,497.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.303643611266668,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCSC3=CC=C(C=C3)F,OC1(c2ccc(Cl)cc2)CCN(CCCSc2ccc(F)cc2)CC1
1280,1284,CHEMBL550402,FGTRDYXFZBKEJR-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3470.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.459670525209127,CC(C)C1=CC=CC=C1C(=O)N(CC2CCCC2)[C@H]3CCNC3,CC(C)c1ccccc1C(=O)N(CC1CCCC1)[C@H]1CCNC1
1281,1285,CHEMBL3331498,FGVKRZJRXXZUHI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,150.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.823908740944319,C1CCC(C1)N(CC2CNC2)CC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(CN(CC2CNC2)C2CCCC2)cc1Cl
1282,1286,CHEMBL3331498,FGVKRZJRXXZUHI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,30.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,30.0,C1CCC(C1)N(CC2CNC2)CC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(CN(CC2CNC2)C2CCCC2)cc1Cl
1283,1287,CHEMBL219916,FGXWKSZFVQUSTL-UHFFFAOYSA-N,DOMPERIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
1284,1288,CHEMBL219916,FGXWKSZFVQUSTL-UHFFFAOYSA-N,DOMPERIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
1285,1289,CHEMBL2180073,FHBANDDJQJAZOQ-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23025719.0,KI,=,293.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors.",J. Med. Chem.,PUBLICATION,,6.533132379645891,C[C@H](C1=NC2=C(C=NN2C3CCOCC3)C(=O)N1)N4CC(C4)OC5=CC=CC=C5,C[C@H](c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1)N1CC(Oc2ccccc2)C1
1286,1290,CHEMBL267648,FHFYDNQZQSQIAI-UHFFFAOYSA-N,PEFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
1287,1291,CHEMBL267648,FHFYDNQZQSQIAI-UHFFFAOYSA-N,PEFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
1288,1292,CHEMBL513618,FHGGWRRIFBYBAE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCNCC1(CC2=CC=CC=C2C1OC3=CC=CC=C3C)O,CCNCC1(O)Cc2ccccc2C1Oc1ccccc1C
1289,1293,CHEMBL526669,FHNHVNKWEHYJDJ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,4100.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3872161432802645,CC1=CC=CC=C1O[C@@H]2[C@H](OCC3=CC=CC=C23)CNC,CNC[C@H]1OCc2ccccc2[C@@H]1Oc1ccccc1C
1290,1294,CHEMBL526669,FHNHVNKWEHYJDJ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@H](OCC3=CC=CC=C23)CNC,CNC[C@H]1OCc2ccccc2[C@@H]1Oc1ccccc1C
1291,1295,CHEMBL504606,FHNHVNKWEHYJDJ-QZTJIDSGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2[C@H](OCC3=CC=CC=C23)CNC,CNC[C@H]1OCc2ccccc2[C@H]1Oc1ccccc1C
1292,1296,CHEMBL505433,FHNHVNKWEHYJDJ-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1C
1293,1297,CHEMBL505433,FHNHVNKWEHYJDJ-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,2500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,CC1=CC=CC=C1O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1C
1294,1298,CHEMBL443952,FHNHVNKWEHYJDJ-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@H]1Oc1ccccc1C
1295,1299,CHEMBL381754,FHRNDZQBSORXCR-LIRRHRJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)(=O)NCCO)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(=O)(=O)NCCO)cc21
1296,1300,CHEMBL3663917,FHVZRKFXAWGVLU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,8.5,NM,314450,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.070581074285707,CN1CC(C2=C(C1)C=C(C=C2)C3=NN=CC=C3)C4=CC5=C(C=C4)SC=C5,CN1Cc2cc(-c3cccnn3)ccc2C(c2ccc3sccc3c2)C1
1297,1301,CHEMBL147983,FIGPOABEAKIBCL-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,8.1,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,8.09151498112135,CCN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1298,1302,CHEMBL147983,FIGPOABEAKIBCL-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,61.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.214670164989233,CCN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1299,1303,CHEMBL147983,FIGPOABEAKIBCL-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,7.5,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.5,CCN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1300,1304,CHEMBL356552,FIGPOABEAKIBCL-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,140.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.853871964321763,CCN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1301,1305,CHEMBL356552,FIGPOABEAKIBCL-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.0,CCN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1302,1306,CHEMBL356552,FIGPOABEAKIBCL-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,11.0,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,11.0,CCN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1303,1307,CHEMBL463585,FIIZGBLPZZYXCS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,60.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,CCCCC1(CCNC1)C2=CC3=C(C=C2)NC=C3,CCCCC1(c2ccc3[nH]ccc3c2)CCNC1
1304,1308,CHEMBL458019,FIKAKWIAUPDISJ-UHFFFAOYSA-L,PARAQUAT DICHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-],C[n+]1ccc(-c2cc[n+](C)cc2)cc1
1305,1309,CHEMBL458019,FIKAKWIAUPDISJ-UHFFFAOYSA-L,PARAQUAT DICHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-],C[n+]1ccc(-c2cc[n+](C)cc2)cc1
1306,1310,CHEMBL2308105,FJCIWANMQSLZNY-WLNZHLEZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,38.9,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.410050398674293,C1C[C@H]2CC(C[C@@H]1N2CCCCC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,Fc1ccc(C(OC2C[C@@H]3CC[C@H](C2)N3CCCCc2ccccc2)c2ccc(F)cc2)cc1
1307,1311,CHEMBL564285,FJFCTBPGJGVZBJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,794.33,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,C1CNCCC1N(CC2=CC=C(C=C2)C#N)C3=CC4=C(C=C3)NC=C4,N#Cc1ccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)cc1
1308,1312,CHEMBL3417585,FJHKZEVPGYADEG-XOKHGSTOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25827402.0,KI,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,4.991399828238082,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@H]4[C@@H]3C4,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1
1309,1313,CHEMBL3417586,FJHKZEVPGYADEG-XYPHTWIQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25827402.0,KI,=,6600.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,5.180456064458132,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@@H]4[C@H]3C4,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1
1310,1314,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
1311,1315,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
1312,1316,CHEMBL2220442,FJLGEFLZQAZZCD-VAWYXSNFSA-N,FLUVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1C2=CC=CC=C2C(=C1/C=C/C(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
1313,1317,CHEMBL2220442,FJLGEFLZQAZZCD-VAWYXSNFSA-N,FLUVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1C2=CC=CC=C2C(=C1/C=C/C(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
1314,1318,CHEMBL3310633,FJRHKFCLJYAKFM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,22.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,22.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC(=CC=C3)OC(F)(F)F,Fc1ccc(C(CC2CNC2)Oc2cccc(OC(F)(F)F)c2)cc1F
1315,1319,CHEMBL3323090,FKCXCDFQELSYLK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,7.5,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.1249387366083,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=CO4,CN1Cc2ccccc2C(c2ccc3ccoc3c2)C1
1316,1320,CHEMBL3323090,FKCXCDFQELSYLK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,7.5,NM,314441,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.1249387366083,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=CO4,CN1Cc2ccccc2C(c2ccc3ccoc3c2)C1
1317,1321,CHEMBL568096,FKDKUDMUXGCBLI-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNC[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=C2C=CC(=C3)F)O,CNC[C@H](O)[C@H](c1ccccc1)n1ccc2cc(F)ccc21
1318,1322,CHEMBL403,FKENQMMABCRJMK-RITPCOANSA-N,SULBACTAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C,CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
1319,1323,CHEMBL403,FKENQMMABCRJMK-RITPCOANSA-N,SULBACTAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C,CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
1320,1324,CHEMBL567482,FKPMMRLETAKLGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC1C(=O)C2=C(CN1C(C)(C)C)C=CC(=C2)Cl,CC1C(=O)c2cc(Cl)ccc2CN1C(C)(C)C
1321,1325,CHEMBL567482,FKPMMRLETAKLGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC1C(=O)C2=C(CN1C(C)(C)C)C=CC(=C2)Cl,CC1C(=O)c2cc(Cl)ccc2CN1C(C)(C)C
1322,1326,CHEMBL198176,FKPQTOXELNJTMQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,3.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)(C)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccc(C)cc2)C1=O
1323,1327,CHEMBL198176,FKPQTOXELNJTMQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)(C)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccc(C)cc2)C1=O
1324,1328,CHEMBL1683890,FLAQOJMPRHHQFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,CNCC1(CCCCC1)C2=CC(=C(C=C2)F)Cl,CNCC1(c2ccc(F)c(Cl)c2)CCCCC1
1325,1329,CHEMBL213030,FLCMZOWXDMNREV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=NC=CS3,Clc1ccccc1CC(c1nccs1)N1CCNCC1
1326,1330,CHEMBL1242923,FLGSUSWMWSZVMP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20684563.0,KI,>=,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to human dopamine transporter by radioligand displacement assay,"Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.",J. Med. Chem.,PUBLICATION,,6.0,C1CN(CCC1NC(=O)CC2=CC=CC=C2)CCCN3C(=O)COC4=CC=CC=C43,O=C(Cc1ccccc1)NC1CCN(CCCN2C(=O)COc3ccccc32)CC1
1327,1331,CHEMBL597134,FLHCVNZEHIWJGJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,EC50,=,6880.0,NM,,,,,,,,,,,,,,,Agonist activity at DAT,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.162411561764488,C1CNCCC1C2=C(N=CC=C2)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1ncccc1C1CCNCC1
1328,1332,CHEMBL597134,FLHCVNZEHIWJGJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6180.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.209011524911184,C1CNCCC1C2=C(N=CC=C2)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1ncccc1C1CCNCC1
1329,1333,CHEMBL597134,FLHCVNZEHIWJGJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6180.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.209011524911184,C1CNCCC1C2=C(N=CC=C2)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1ncccc1C1CCNCC1
1330,1334,CHEMBL363510,FLHXBXVOIUXMRL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,220.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,COC(=O)C1=C(CC2CCC1S2)C3=CC=C(C=C3)F,COC(=O)C1=C(c2ccc(F)cc2)CC2CCC1S2
1331,1335,CHEMBL557660,FLOGKESFYXJKPK-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3440.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.46344155742847,CSC1=CC=CC=C1C(=O)N([C@H]2CCNC2)C3=CC=CC=C3,CSc1ccccc1C(=O)N(c1ccccc1)[C@H]1CCNC1
1332,1336,CHEMBL3593405,FMBFPKABXNIGRK-SLHAJLBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=C(C=C(C=C1)[C@H]2[C@@H](CNCCO2)CNC(=O)C)Cl.Cl,CC(=O)NC[C@@H]1CNCCO[C@H]1c1ccc(C)c(Cl)c1
1333,1337,CHEMBL1475,FMHHVULEAZTJMA-UHFFFAOYSA-N,TRIOXSALEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
1334,1338,CHEMBL1475,FMHHVULEAZTJMA-UHFFFAOYSA-N,TRIOXSALEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
1335,1339,CHEMBL3673149,FMMKJZJKDJFMKF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,856.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.067272632698471,C1CN2CCC1(C3=C(C2)C=C(C=C3)N4C=CC=CC4=O)C5=CC=C(C=C5)Cl,O=c1ccccn1-c1ccc2c(c1)CN1CCC2(c2ccc(Cl)cc2)CC1
1336,1340,CHEMBL31184,FMMWHPNWAFZXNH-UHFFFAOYSA-N,BENZO[DEF]CHRYSENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34
1337,1341,CHEMBL31184,FMMWHPNWAFZXNH-UHFFFAOYSA-N,BENZO[DEF]CHRYSENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34
1338,1342,CHEMBL381373,FMVNGPGSZIETQV-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-63.9,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-63.9,CC(C)CN(CC1=CC(=CC=C1)C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1cccc(C(F)(F)F)c1)C1CCNCC1
1339,1343,CHEMBL3318586,FNHAFYQTHUKPIU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25037917.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989234,C1CC2CN(CC1N2C(=O)C3=CC=C(C=C3)C4=CC(=CC=C4)Cl)C5=NC=CC=N5,O=C(c1ccc(-c2cccc(Cl)c2)cc1)N1C2CCC1CN(c1ncccn1)C2
1340,1344,CHEMBL598168,FNQZKQRJZBPGQR-URBRKQAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,4.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2CCC3=C2C=CC(=C3)Cl)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CCc2cc(Cl)ccc21
1341,1345,CHEMBL1086275,FNRNKAMBXVROAU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,3160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,C1CN(CCN1)C(CC2=C(C=CC=C2F)OC(F)F)C3=CC=CC=C3,Fc1cccc(OC(F)F)c1CC(c1ccccc1)N1CCNCC1
1342,1346,CHEMBL2171414,FNYDYQPDDZMXFQ-UHFFFAOYSA-N,"3-((BENZYLOXY)(3,4-DICHLOROPHENYL)METHYL)AZETIDINE HCL",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,12.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,12.0,C1C(CN1)C(C2=CC(=C(C=C2)Cl)Cl)OCC3=CC=CC=C3.Cl,Clc1ccc(C(OCc2ccccc2)C2CNC2)cc1Cl
1343,1347,CHEMBL585,FNYLWPVRPXGIIP-UHFFFAOYSA-N,TRIAMTERENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
1344,1348,CHEMBL585,FNYLWPVRPXGIIP-UHFFFAOYSA-N,TRIAMTERENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
1345,1349,CHEMBL464422,FOEJRTWJHDIANT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,=,27850.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.555174800490252,COC1=C(C=C(C=C1)F)CCC2CCC(O2)CCN,COc1ccc(F)cc1CCC1CCC(CCN)O1
1346,1350,CHEMBL464422,FOEJRTWJHDIANT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,=,6500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,5.187086643357143,COC1=C(C=C(C=C1)F)CCC2CCC(O2)CCN,COc1ccc(F)cc1CCC1CCC(CCN)O1
1347,1351,CHEMBL462311,FOEJRTWJHDIANT-UONOGXRCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,27850.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.555174800490252,COC1=C(C=C(C=C1)F)CC[C@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1CC[C@H]1CC[C@H](CCN)O1
1348,1352,CHEMBL462311,FOEJRTWJHDIANT-UONOGXRCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,6500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.187086643357143,COC1=C(C=C(C=C1)F)CC[C@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1CC[C@H]1CC[C@H](CCN)O1
1349,1353,CHEMBL460406,FOEJRTWJHDIANT-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,36710.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.435215615496014,COC1=C(C=C(C=C1)F)CC[C@@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1CC[C@@H]1CC[C@H](CCN)O1
1350,1354,CHEMBL460406,FOEJRTWJHDIANT-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,16370.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.785951320588059,COC1=C(C=C(C=C1)F)CC[C@@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1CC[C@@H]1CC[C@H](CCN)O1
1351,1355,CHEMBL1945251,FOGCUXYHCCUINS-UNSMHXHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,30.2,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.519993057042849,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=C(C=C3)I,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
1352,1356,CHEMBL1945251,FOGCUXYHCCUINS-UNSMHXHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24262882.0,KI,=,1.72,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT after 2 hrs by liquid scintillation counting analysis,"Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [(11)C]IPCIT and [(18)F]FE@IPCIT.",Bioorg. Med. Chem.,PUBLICATION,,8.76447155309245,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=C(C=C3)I,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
1353,1357,CHEMBL1173429,FOKYJAFKMXEAJL-ISVAXAHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,1020.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.991399828238082,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC(=C2)F)F)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cc(F)cc(F)c1
1354,1358,CHEMBL376113,FOMAEAAMXSBAJG-LANGDILFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,469.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.328827157284918,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=C(C=C5)Cl)Cl)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(Cl)c(Cl)c4)s2)N3C)cc1
1355,1359,CHEMBL376113,FOMAEAAMXSBAJG-LANGDILFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,105.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.978810700930063,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=C(C=C5)Cl)Cl)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(Cl)c(Cl)c4)s2)N3C)cc1
1356,1360,CHEMBL257551,FOMBUMQDBKFBLB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(C(C1C2=CC=CC=C2)CN)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)C(CN)C1c1ccccc1
1357,1361,CHEMBL3318548,FORKQRVCGPWUGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25037917.0,IC50,=,3400.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,C1CN(CCN1C2=NC=CC=N2)C(=O)C3=CC=C(C=C3)C4=CC(=CC=C4)Cl,O=C(c1ccc(-c2cccc(Cl)c2)cc1)N1CCN(c2ncccn2)CC1
1358,1362,CHEMBL2205813,FOTUXOOYRRRHFQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=CC(=C1OC)CCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1OC
1359,1363,CHEMBL1173607,FOZZHOLQHJQMRY-SWLSCSKDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,12.59,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.899974269892138,C1C[C@@]2(CNCC[C@H]2C3=CC(=C(C=C3)Cl)Cl)COC1,Clc1ccc([C@@H]2CCNC[C@@]23CCCOC3)cc1Cl
1360,1364,CHEMBL1173607,FOZZHOLQHJQMRY-SWLSCSKDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.899974269892138,C1C[C@@]2(CNCC[C@H]2C3=CC(=C(C=C3)Cl)Cl)COC1,Clc1ccc([C@@H]2CCNC[C@@]23CCCOC3)cc1Cl
1361,1365,CHEMBL51,FPCCSQOGAWCVBH-UHFFFAOYSA-N,KETANSERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
1362,1366,CHEMBL232663,FPDIGUTXTUXSEH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,884000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.053547734986927,CC(C)(C)C1=CC=C(C=C1)C2=C(CCCCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)(C)C)cc2)CCCCC1
1363,1367,CHEMBL232663,FPDIGUTXTUXSEH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,CC(C)(C)C1=CC=C(C=C1)C2=C(CCCCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)(C)C)cc2)CCCCC1
1364,1368,CHEMBL2205835,FPHVMMXTLGSYHV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccc1
1365,1369,CHEMBL2205835,FPHVMMXTLGSYHV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccc1
1366,1370,CHEMBL1944830,FPNSLRWYOLCRFD-JJXSEGSLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,70.79,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.15002808767115,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCF)C[C@@H]1C3=CC=C(C=C3)F,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2CCF
1367,1371,CHEMBL439337,FPQRVMRURWGBHW-LIRRHRJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,220.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)N3C=CN=N3)C4=CC(=C(C=C4)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(-n3ccnn3)cc21
1368,1372,CHEMBL519609,FPUKGJMTLUQGFZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23707254.0,KI,=,6000.0,NM,,,,,,,,,,,,,,,Antagonist activity at DAT (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,CCN(CC)CCCOC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21
1369,1373,CHEMBL496913,FPXGGQHHZZOHQY-GAPKJMMISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,2.2,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,8.657577319177793,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C#CC4=CC=C(C=C4)N.Cl,CN1[C@H]2CC[C@@H]1[C@@H](C#Cc1ccc(N)cc1)[C@@H](c1ccc(Cl)cc1)C2
1370,1374,CHEMBL394585,FPYUHFVUAJRFHA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,2100.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.6777807052660805,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CCC1
1371,1375,CHEMBL394585,FPYUHFVUAJRFHA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,18000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.7447274948966935,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CCC1
1372,1376,CHEMBL582894,FQEQHKRYLKAFDD-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CNC[C@H]([C@H](C1=CC(=CC=C1)OC)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1cccc(OC)c1)n1ccc2ccccc21
1373,1377,CHEMBL2024087,FQIJPHXWIONJLF-JKOKRWQUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22171543.0,INHIBITION,=,43.7,%,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT at 10 uM,Chemistry and behavioral studies identify chiral cyclopropanes as selective a42-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,PUBLICATION,,43.7,C1CN[C@@H]1COC2=CN=CC(=C2)[C@H]3C[C@@H]3CCO,OCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1
1374,1378,CHEMBL1370561,FQPFAHBPWDRTLU-UHFFFAOYSA-N,AMINOPHYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,Cn1c(=O)c2[nH]cnc2n(C)c1=O
1375,1379,CHEMBL1370561,FQPFAHBPWDRTLU-UHFFFAOYSA-N,AMINOPHYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,Cn1c(=O)c2[nH]cnc2n(C)c1=O
1376,1380,CHEMBL1944976,FQPIVYZRQDXHIS-ISARSNTHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,371.54,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.429994423238213,CCCCC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)I,CCCCc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)cc1I
1377,1381,CHEMBL3310487,FQRVPUNOHDAYPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,164.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.785156151952302,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3Cl,Fc1cc(C(CC2CNC2)Oc2ccccc2Cl)ccc1Cl
1378,1382,CHEMBL3310487,FQRVPUNOHDAYPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,30.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,30.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3Cl,Fc1cc(C(CC2CNC2)Oc2ccccc2Cl)ccc1Cl
1379,1383,CHEMBL3310487,FQRVPUNOHDAYPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3Cl,Fc1cc(C(CC2CNC2)Oc2ccccc2Cl)ccc1Cl
1380,1384,CHEMBL3310487,FQRVPUNOHDAYPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3Cl,Fc1cc(C(CC2CNC2)Oc2ccccc2Cl)ccc1Cl
1381,1385,CHEMBL3311308,FQUAFMNPXPXOJE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24881566.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT by BacMam Binding SPA/summary (Abse5) assay,Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CC1=CC(=C(C(=C1)C)NS(=O)(=O)C2=CC=C(C=C2)OC)C,COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1
1382,1386,CHEMBL196368,FQUMMDVLHAIHNA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,10.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC(=CC=C3)F,CNCCCC1Cc2ccccc2N(c2cccc(F)c2)C1=O
1383,1387,CHEMBL196368,FQUMMDVLHAIHNA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC(=CC=C3)F,CNCCCC1Cc2ccccc2N(c2cccc(F)c2)C1=O
1384,1388,CHEMBL387117,FRKGVKAPAMAQSO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,13.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.886056647693162,CC(C)CC(C1CCCCN1C)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1C
1385,1389,CHEMBL387117,FRKGVKAPAMAQSO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,45.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.346787486224656,CC(C)CC(C1CCCCN1C)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1C
1386,1390,CHEMBL387117,FRKGVKAPAMAQSO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,6.6,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.180456064458129,CC(C)CC(C1CCCCN1C)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1C
1387,1391,CHEMBL387117,FRKGVKAPAMAQSO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,44.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.356547323513813,CC(C)CC(C1CCCCN1C)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1C
1388,1392,CHEMBL26477,FRNMVZXBCHKPGE-HHHXNRCGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,3.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.522878745280337,C1CN(CCN1CC[C@H](C2=CC=CC=C2)O)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,O[C@H](CCN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
1389,1393,CHEMBL26478,FRNMVZXBCHKPGE-MHZLTWQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,4.4,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.356547323513812,C1CN(CCN1CC[C@@H](C2=CC=CC=C2)O)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,O[C@@H](CCN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
1390,1394,CHEMBL327963,FRSLPZMBKYJWGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,390.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.4089353929735005,COC(=O)C1=C(CC2CCC1C2)C3=CC=C(C=C3)F,COC(=O)C1=C(c2ccc(F)cc2)CC2CCC1C2
1391,1395,CHEMBL478623,FRXKHOISTFCGOP-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCS(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCN(C3)C,CCS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCN(C)C1
1392,1396,CHEMBL1909049,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,COc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
1393,1397,CHEMBL1909049,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,COc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
1394,1398,CHEMBL1076211,FSKFPVLPFLJRQB-UHFFFAOYSA-N,TOLPERISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1
1395,1399,CHEMBL1076211,FSKFPVLPFLJRQB-UHFFFAOYSA-N,TOLPERISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1
1396,1400,CHEMBL596806,FSLROBKNJCTZIC-PYZFKAKLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,5.01,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.300162274132754,CCC(C)OCCC1([C@H]2[C@@H]1CNC2)C3=CC(=C(C=C3)Cl)Cl,CCC(C)OCCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CNC[C@H]21
1397,1401,CHEMBL189171,FSQKKOOTNAMONP-UHFFFAOYSA-N,ACEMETACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
1398,1402,CHEMBL189171,FSQKKOOTNAMONP-UHFFFAOYSA-N,ACEMETACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
1399,1403,CHEMBL285342,FSULAQVXMVICFX-DMRFDLNASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,125.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.903089986991943,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(C(F)(F)F)O,CN1C2CCC1[C@H](C(O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1400,1404,CHEMBL285342,FSULAQVXMVICFX-DMRFDLNASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,166.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.779891911959945,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(C(F)(F)F)O,CN1C2CCC1[C@H](C(O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1401,1405,CHEMBL285342,FSULAQVXMVICFX-DMRFDLNASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,525.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.279840696594043,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(C(F)(F)F)O,CN1C2CCC1[C@H](C(O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1402,1406,CHEMBL285342,FSULAQVXMVICFX-DMRFDLNASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1105.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.95663772197887,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(C(F)(F)F)O,CN1C2CCC1[C@H](C(O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1403,1407,CHEMBL27586,FSULAQVXMVICFX-FJGURNMVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,9.2,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.036212172654443,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)[C@H](C(F)(F)F)O,CN1C2CCC1[C@@H]([C@@H](O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1404,1408,CHEMBL27586,FSULAQVXMVICFX-FJGURNMVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,10.5,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.978810700930063,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)[C@H](C(F)(F)F)O,CN1C2CCC1[C@@H]([C@@H](O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1405,1409,CHEMBL285611,FSULAQVXMVICFX-PPJOZLOBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,not isolated,,,,,,,,,,,,,,Ability to displace [3H]mazindol to dopamine receptor; not being isolated,,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)[C@@H](C(F)(F)F)O,CN1C2CCC1[C@@H]([C@H](O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1406,1410,CHEMBL285611,FSULAQVXMVICFX-PPJOZLOBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,not isolated,,,,,,,,,,,,,,Inhibitory concentration required for [3H]dopamine uptake; not being isolated,,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)[C@@H](C(F)(F)F)O,CN1C2CCC1[C@@H]([C@H](O)C(F)(F)F)[C@@H](c1ccc(Cl)cc1)C2
1407,1411,CHEMBL146042,FSUVEHUIVCMLNZ-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,53.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.275724130399211,CCCN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1408,1412,CHEMBL146042,FSUVEHUIVCMLNZ-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,220.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.657577319177793,CCCN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1409,1413,CHEMBL146042,FSUVEHUIVCMLNZ-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,0.24,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,0.24,CCCN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1410,1414,CHEMBL146615,FSUVEHUIVCMLNZ-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,280.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.552841968657781,CCCN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1411,1415,CHEMBL146615,FSUVEHUIVCMLNZ-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,620.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.2076083105017466,CCCN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1412,1416,CHEMBL146615,FSUVEHUIVCMLNZ-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,2.2,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,2.2,CCCN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1413,1417,CHEMBL364146,FSVIUGSBUWZZTL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,6.7,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.173925197299173,COC(=O)C1=C(CC2CCC1S2)C3=CC=C(C=C3)I,COC(=O)C1=C(c2ccc(I)cc2)CC2CCC1S2
1414,1418,CHEMBL976,FSVJFNAIGNNGKK-UHFFFAOYSA-N,PRAZIQUANTEL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1
1415,1419,CHEMBL976,FSVJFNAIGNNGKK-UHFFFAOYSA-N,PRAZIQUANTEL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1
1416,1420,CHEMBL1683880,FSYUMFOIUHBSHI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,<,1.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CN1CCN(CC1)CC2(CCCCC2)C3=CC(=C(C=C3)Cl)Cl,CN1CCN(CC2(c3ccc(Cl)c(Cl)c3)CCCCC2)CC1
1417,1421,CHEMBL744,FTALBRSUTCGOEG-UHFFFAOYSA-N,RILUZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,Nc1nc2ccc(OC(F)(F)F)cc2s1
1418,1422,CHEMBL744,FTALBRSUTCGOEG-UHFFFAOYSA-N,RILUZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,Nc1nc2ccc(OC(F)(F)F)cc2s1
1419,1423,CHEMBL392927,FTHIFOZLTXZJMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,43651583224016.7,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.6400000000000015,COC(=O)C1=C(C2CCC1C2)C3=C(C=C(C=C3)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)cc2Cl)C2CCC1C2
1420,1424,CHEMBL1224092,FTQBIVFBXYAAQX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,CCCC1(CCCN1)C(=O)C2=CC3=C(C=C2)NN=C3,CCCC1(C(=O)c2ccc3[nH]ncc3c2)CCCN1
1421,1425,CHEMBL1818452,FTQFUQZSKDXZNW-ZYMOGRSISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,3.16,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.500312917381597,CC1=CC=NN1CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ccnn1CC12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
1422,1426,CHEMBL1818452,FTQFUQZSKDXZNW-ZYMOGRSISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,100.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.0,CC1=CC=NN1CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ccnn1CC12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
1423,1427,CHEMBL496285,FTQUSRCNRLUCRK-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCOC1=CC=CC=C1O[C@@H]2[C@H](OCC3=CC=CC=C23)CNC,CCOc1ccccc1O[C@H]1c2ccccc2CO[C@@H]1CNC
1424,1428,CHEMBL497846,FTTNLGGOMYVLOP-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C(=CC=C1)F)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1c(C)cccc1F
1425,1429,CHEMBL497846,FTTNLGGOMYVLOP-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C(=CC=C1)F)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1c(C)cccc1F
1426,1430,CHEMBL376737,FTVCCHUPUJEUIW-FIPFOOKPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,754.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.122628654130226,CC(=O)CN1CC[C@H](C[C@@H]1CCCNC(=O)NC2=CC(=CC(=C2)C(=O)C)C(=O)C)CC3=CC=C(C=C3)F,CC(=O)CN1CC[C@@H](Cc2ccc(F)cc2)C[C@@H]1CCCNC(=O)Nc1cc(C(C)=O)cc(C(C)=O)c1
1427,1431,CHEMBL3673161,FUDKVBNOVUMNRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,26.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.583359492661719,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=NN=CC=C4)C5=CC(=C(C=C5)Cl)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(-c4cccnn4)ccc23)cc1Cl
1428,1432,CHEMBL257481,FUFMKPBBSWMURG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,15700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.804100347590767,CNCC1=C(C=CC(=C1)C(=O)NC)OC2=C(C=C(C=C2)Cl)OC,CNCc1cc(C(=O)NC)ccc1Oc1ccc(Cl)cc1OC
1429,1433,CHEMBL263373,FUHOKNRCOVAKDB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCOC1=C(C=CC=C1Cl)OC(C2CNCCO2)C3=CC=CC=C3,CCOc1c(Cl)cccc1OC(c1ccccc1)C1CNCCO1
1430,1434,CHEMBL382248,FULUQLAFMOKDPE-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,4.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,COCCN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,COCCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
1431,1435,CHEMBL202907,FUNFIWMUTFWLPO-GTNSWQLSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,3600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,CN[C@H]1CC[C@H](C2=CC(=C(C=C12)NS(=O)(=O)C)C(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(C(N)=O)c(NS(C)(=O)=O)cc21
1432,1436,CHEMBL83668,FUSNMLFNXJSCDI-UHFFFAOYSA-N,TOLNAFTATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2,Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1
1433,1437,CHEMBL83668,FUSNMLFNXJSCDI-UHFFFAOYSA-N,TOLNAFTATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2,Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1
1434,1438,CHEMBL327055,FUXJAOQVDVQZMM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,18.62,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.730020323354676,C1CC2CC(CC1N2CCOCC3=CC=CS3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,Fc1ccc(C(OC2CC3CCC(C2)N3CCOCc2cccs2)c2ccc(F)cc2)cc1
1435,1439,CHEMBL214021,FVFURMJFTAJXRH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17234405.0,INHIBITION,=,26.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 10uM,"An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,26.0,C1CN(CCC1NC(=O)C2=CC(=O)C3=C(O2)C=C(C=C3)F)CC4=CC5=C(C=C4)OCO5,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1
1436,1440,CHEMBL1683904,FVJRSFJCTCDWPN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,739.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.131355561605173,CNCC1(CCCCC1)C2=CC=C(C=C2)C3=CC=CC=C3,CNCC1(c2ccc(-c3ccccc3)cc2)CCCCC1
1437,1441,CHEMBL213229,FVLUAITUNFZGCJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCOC1=CC=CC=C1CC(C2=CN=CC=C2)N3CCNCC3,CCOc1ccccc1CC(c1cccnc1)N1CCNCC1
1438,1442,CHEMBL12948,FVLVBPDQNARYJU-UHFFFAOYSA-N,SEMUSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CCC(CC1)NC(=O)N(CCCl)N=O,CC1CCC(NC(=O)N(CCCl)N=O)CC1
1439,1443,CHEMBL12948,FVLVBPDQNARYJU-UHFFFAOYSA-N,SEMUSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CCC(CC1)NC(=O)N(CCCl)N=O,CC1CCC(NC(=O)N(CCCl)N=O)CC1
1440,1444,CHEMBL377678,FVLVLFVHHIGOFZ-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-35.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-35.0,C1CNCCC1N(CCC(F)(F)F)CC2=CC=CC=C2C(F)(F)F.C(=C/C(=O)O)\C(=O)O,FC(F)(F)CCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
1441,1445,CHEMBL1683894,FVPYKEUHDWGTTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,125.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.903089986991943,CN(C)CC1(CCCCC1)C2=CC=C(C=C2)F,CN(C)CC1(c2ccc(F)cc2)CCCCC1
1442,1446,CHEMBL145994,FVVRXOHRSYEMTM-SIKLNZKXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,80.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.096910013008057,C1[C@H](C2=CC=CC=C2[C@@H]1NCC3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@H]2C[C@@H](NCc3ccccc3)c3ccccc32)cc1Cl
1443,1447,CHEMBL145994,FVVRXOHRSYEMTM-SIKLNZKXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.886056647693162,C1[C@H](C2=CC=CC=C2[C@@H]1NCC3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@H]2C[C@@H](NCc3ccccc3)c3ccccc32)cc1Cl
1444,1448,CHEMBL145994,FVVRXOHRSYEMTM-SIKLNZKXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,1.6,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,1.6,C1[C@H](C2=CC=CC=C2[C@@H]1NCC3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@H]2C[C@@H](NCc3ccccc3)c3ccccc32)cc1Cl
1445,1449,CHEMBL147544,FVVRXOHRSYEMTM-UGKGYDQZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,1100.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.9586073148417755,C1[C@H](C2=CC=CC=C2[C@H]1NCC3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@H]2C[C@H](NCc3ccccc3)c3ccccc32)cc1Cl
1446,1450,CHEMBL147544,FVVRXOHRSYEMTM-UGKGYDQZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,5300.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.275724130399211,C1[C@H](C2=CC=CC=C2[C@H]1NCC3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@H]2C[C@H](NCc3ccccc3)c3ccccc32)cc1Cl
1447,1451,CHEMBL220766,FVWTYUWMRRCCPG-CPJSRVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,31.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.508638306165728,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2C(=N)N)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2C(=N)N)cc(C(C)=O)c1
1448,1452,CHEMBL237512,FWJKAQILVAFVQQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17616397.0,KI,=,400.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,CNCC1=C(C=CC(=C1)C#CCCN(C)C2CC2)OC3=CC=C(C=C3)SC,CNCc1cc(C#CCCN(C)C2CC2)ccc1Oc1ccc(SC)cc1
1449,1453,CHEMBL562108,FWQBSLOVNYWJFZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNCCC1C(C2=CC=CC=N2)OC3=C(C=C(C=C3)Cl)Cl,Clc1ccc(OC(c2ccccn2)C2CCNCC2)c(Cl)c1
1450,1454,CHEMBL1645612,FWSGCKKLRWEEEX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,3880.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.411168274405791,C1CNCC1OC2=C(C=CC=C2F)OC3=CC=CC=C3F,Fc1ccccc1Oc1cccc(F)c1OC1CCNC1
1451,1455,CHEMBL1086274,FWSGTPZWDAUURJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,2370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6252516539898965,COC1=C(C(=CC=C1)F)CC(C2=CC=CC=C2)N3CCNCC3,COc1cccc(F)c1CC(c1ccccc1)N1CCNCC1
1452,1456,CHEMBL207860,FXACQNXCWARQOA-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,230.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.638272163982407,CC(C)CN(CC1=C(C=C(C=C1)Cl)Cl)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccc(Cl)cc1Cl)C1CCNCC1
1453,1457,CHEMBL2012117,FXAPJVBMDYZGRB-WZTMSUDTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC=C(O3)C4=CC=CC=C4,COC(=O)[C@H]1C2CCC(C[C@H]1c1ccc(-c3ccccc3)o1)O2
1454,1458,CHEMBL2012117,FXAPJVBMDYZGRB-WZTMSUDTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC=C(O3)C4=CC=CC=C4,COC(=O)[C@H]1C2CCC(C[C@H]1c1ccc(-c3ccccc3)o1)O2
1455,1459,CHEMBL1947100,FXIKVFNIIRHKBX-MBHMRJJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,0.398,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,9.400116927926312,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/CF)C[C@@H]1C3=CC=C(C=C3)Br,COC(=O)[C@H]1[C@@H](c2ccc(Br)cc2)C[C@@H]2CC[C@H]1N2C/C=C/CF
1456,1460,CHEMBL1214007,FXIKVFNIIRHKBX-PMWAWBRWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,=,0.4,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,9.397940008672037,COC(=O)[C@H]1[C@H](CC2CCC1N2C/C=C/CF)C3=CC=C(C=C3)Br,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Br)cc1)N2C/C=C/CF
1457,1461,CHEMBL409546,FXNBCHXTTZIOEI-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=CC(=C1)C#N)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1cc(C#N)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
1458,1462,CHEMBL186962,FXPKVPDERQMXMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,=,309.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.5100415205751645,CN(C)CC1=CC=CC=C1OC2=C(C=C(C=C2)I)N,CN(C)Cc1ccccc1Oc1ccc(I)cc1N
1459,1463,CHEMBL451460,FXQBHPKGRGPIKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CNCC1COC2=CC3=CC=CC=C3C=C2,c1ccc2cc(OCC3CCNC3)ccc2c1
1460,1464,CHEMBL469233,FXQFRAJLWAPPQJ-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@H]1N(CC2=C(C=C(C=C2)Cl)Cl)C(=O)C3=CC=CC=C3,O=C(c1ccccc1)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
1461,1465,CHEMBL1643652,FXYSWUQDXHEYNK-UMAGBFNSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,65.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.187086643357143,CC1=NOC(=C1)[C@H]2[C@@H](CC3CCC2S3)C4=CC=CC=C4,Cc1cc([C@@H]2C3CCC(C[C@H]2c2ccccc2)S3)on1
1462,1466,CHEMBL1643662,FXYSWUQDXHEYNK-VVBDHPJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CC1=NOC(=C1)[C@H]2[C@H](CC3CCC2S3)C4=CC=CC=C4,Cc1cc([C@@H]2C3CCC(C[C@@H]2c2ccccc2)S3)on1
1463,1467,CHEMBL476527,FYDXJUSDGLWNFV-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)C(=O)N(CC1=CC=CC=C1C(F)(F)F)[C@H]2CCNC2,CC(C)C(=O)N(Cc1ccccc1C(F)(F)F)[C@H]1CCNC1
1464,1468,CHEMBL402089,FYGDANPUVIMKMO-SUMWQHHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1[C@H]([C@@]1(C2=CSC=C2)C(=O)N3C=COC4=CC=CC=C43)CN,NC[C@@H]1C[C@@]1(C(=O)N1C=COc2ccccc21)c1ccsc1
1465,1469,CHEMBL602850,FYGREZKTJIXWIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19954972.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1cccc(F)c1
1466,1470,CHEMBL602850,FYGREZKTJIXWIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19954972.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1cccc(F)c1
1467,1471,CHEMBL602850,FYGREZKTJIXWIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1cccc(F)c1
1468,1472,CHEMBL3085020,FYMLZFJXJDKZKY-UQWUFBTJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,5.01,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1C[C@H]2CC(C[C@@H]1N2CCC(=O)NC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=C(CCN1[C@H]2CC[C@@H]1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2)Nc1ccccc1
1469,1473,CHEMBL608,FYPMFJGVHOHGLL-UHFFFAOYSA-N,PROBUCOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
1470,1474,CHEMBL608,FYPMFJGVHOHGLL-UHFFFAOYSA-N,PROBUCOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
1471,1475,CHEMBL264430,FYRQVFPRGMKFAC-LAUBAEHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,C1CN(CC2=CC=CC=C21)C(=O)[C@]3(C[C@H]3CN)C4=CC5=C(C=C4)OCO5,NC[C@@H]1C[C@@]1(C(=O)N1CCc2ccccc2C1)c1ccc2c(c1)OCO2
1472,1476,CHEMBL232870,FYXXKYRAPMHRTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,589.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.229884705212897,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CCCC1
1473,1477,CHEMBL232870,FYXXKYRAPMHRTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,85000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.070581074285707,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CCCC1
1474,1478,CHEMBL232870,FYXXKYRAPMHRTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,11748975549395.3,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.07,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CCCC1
1475,1479,CHEMBL1818455,FYXXTOJUMHTXEW-QRWMCTBCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,3.16,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.500312917381597,CC1=CC(=NN1CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C,Cc1cc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
1476,1480,CHEMBL1818455,FYXXTOJUMHTXEW-QRWMCTBCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,158.49,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.799998134593397,CC1=CC(=NN1CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C,Cc1cc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
1477,1481,CHEMBL1818454,FYXXTOJUMHTXEW-QZTJIDSGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.199970640755867,CC1=CC(=NN1C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C,Cc1cc(C)n(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
1478,1482,CHEMBL441864,FZAYBHQQLZFDLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.5376020021010435,C1CCNC(C1)C(CCCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCCc2ccccc2)C2CCCCN2)cc1
1479,1483,CHEMBL441864,FZAYBHQQLZFDLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,1400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.853871964321763,C1CCNC(C1)C(CCCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCCc2ccccc2)C2CCCCN2)cc1
1480,1484,CHEMBL441864,FZAYBHQQLZFDLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,440.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.356547323513813,C1CCNC(C1)C(CCCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCCc2ccccc2)C2CCCCN2)cc1
1481,1485,CHEMBL441864,FZAYBHQQLZFDLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,2900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.537602002101044,C1CCNC(C1)C(CCCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCCc2ccccc2)C2CCCCN2)cc1
1482,1486,CHEMBL3673140,FZFWHCGLHYASKK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,57.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.24184537803261,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=NN=C(C=C4)OC(F)F)C5=CC=C(C=C5)Cl,FC(F)Oc1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)nn1
1483,1487,CHEMBL1643900,FZIIBLBHXXRTMG-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,1684.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK cell membranes,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.773657912836369,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC(=CC=C6)F,Fc1cccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)c1
1484,1488,CHEMBL1643900,FZIIBLBHXXRTMG-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,1684.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.773657912836369,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC(=CC=C6)F,Fc1cccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)c1
1485,1489,CHEMBL2206525,FZJAPDJONFNIEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,44.7,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.349692476868062,CN1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)F,CN1Cc2ccccc2C(c2ccc(Cl)c(F)c2)C1
1486,1490,CHEMBL1173770,FZKVHQCDVIXSMY-QMHKHESXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.0,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC(=C2)C3=CC=CC4=CC=CC=C43)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(-c2cccc3ccccc23)c1
1487,1491,CHEMBL1258722,FZPKLZHGBRKKCP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20727749.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,"Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CCCOC1=CC=C(C=C1)C2=NN3C(=CC(=NC3=C2CC(=O)N(CC)CC)C)C,CCCOc1ccc(-c2nn3c(C)cc(C)nc3c2CC(=O)N(CC)CC)cc1
1488,1492,CHEMBL448912,FZRYLYZNENTFJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,565.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.247951552180562,C1CC(OC1CCN)CC2=CC=CC=C2,NCCC1CCC(Cc2ccccc2)O1
1489,1493,CHEMBL448912,FZRYLYZNENTFJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCN)CC2=CC=CC=C2,NCCC1CCC(Cc2ccccc2)O1
1490,1494,CHEMBL260440,GAARSROYUMPZLY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,C1CN(C2=CC=CC=C21)C(=O)C3(CC3CN)C4=CC=CC=C4,NCC1CC1(C(=O)N1CCc2ccccc21)c1ccccc1
1491,1495,CHEMBL260440,GAARSROYUMPZLY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,3900.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4089353929735005,C1CN(C2=CC=CC=C21)C(=O)C3(CC3CN)C4=CC=CC=C4,NCC1CC1(C(=O)N1CCc2ccccc21)c1ccccc1
1492,1496,CHEMBL1643901,GACBJAOXQGFNDL-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,1.2,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK cell membranes,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.920818753952375,CN(CC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
1493,1497,CHEMBL1643901,GACBJAOXQGFNDL-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,1.2,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,8.920818753952375,CN(CC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
1494,1498,CHEMBL116463,GALCSZPFCCZIBC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,781.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.1073489661227,C1CN(CCC1NC(=O)OCCC2=CC=C(C=C2)C#N)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,N#Cc1ccc(CCOC(=O)NC2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
1495,1499,CHEMBL380383,GAMXLCNZCZEZGS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784855.0,KI,=,8.48,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT transfected in HEK293 cells,Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.071604147743287,C=C1CN2C3CCC2C1C(C3)C4=CC=C(C=C4)I,C=C1CN2C3CCC2C1C(c1ccc(I)cc1)C3
1496,1500,CHEMBL1080069,GAOZHRLCFIUCBN-JTQLQIEISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,630.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.200659450546419,CCCN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CCCN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
1497,1501,CHEMBL436673,GAWWNBHCOINKBY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2660.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.575118363368933,CCC1=CC=CC=C1OC2=C(C=NC(=C2)C)CN(C)C,CCc1ccccc1Oc1cc(C)ncc1CN(C)C
1498,1502,CHEMBL3704749,GAWYDFHTJQSNCE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,5.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.244125144327509,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCOc1ccc(C2(C(CC(C)C)NCCOC(=O)CC)CCC2)cc1
1499,1503,CHEMBL3704749,GAWYDFHTJQSNCE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,80.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.094743951251549,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCOc1ccc(C2(C(CC(C)C)NCCOC(=O)CC)CCC2)cc1
1500,1504,CHEMBL3704749,GAWYDFHTJQSNCE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2340.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.6307841425898575,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCOc1ccc(C2(C(CC(C)C)NCCOC(=O)CC)CCC2)cc1
1501,1505,CHEMBL3704749,GAWYDFHTJQSNCE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,80.4,NM,317679,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.094743951251549,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCOc1ccc(C2(C(CC(C)C)NCCOC(=O)CC)CCC2)cc1
1502,1506,CHEMBL399284,GAZAGVAXNMLAKH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18242991.0,INHIBITION,=,28.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.,Bioorg. Med. Chem. Lett.,PUBLICATION,,28.0,CC1=C(C(=CC=C1)NC(=O)CCCS(=O)(=O)C)C2=CC(=CC=C2)S(=O)(=O)C3=C(SC(=C3)C(=N)N)SC,CSc1sc(C(=N)N)cc1S(=O)(=O)c1cccc(-c2c(C)cccc2NC(=O)CCCS(C)(=O)=O)c1
1503,1507,CHEMBL432394,GAZPWELASOLBPG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956218.0,KI,=,115.0,NM,,,,,,,,,,,,,,,In vitro binding affinity on cloned Dopamine transporter,"Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.",J. Med. Chem.,PUBLICATION,,6.939302159646387,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)Cl)N,CN(C)Cc1ccccc1Sc1ccc(Cl)cc1N
1504,1508,CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
1505,1509,CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
1506,1510,CHEMBL575199,GBDCEJWZYYZILX-CCRGXQTGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,112.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.950781977329817,COC(=O)[C@H]1[C@H](CC2CCC1N2CCCF)C3=CC=C(C=C3)SC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(SC)cc1)N2CCCF
1507,1511,CHEMBL248825,GBLKVAKAYJPCCZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,1500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,C1CC(=C(C1)C(=O)OCC2=CC=CO2)C3=CC(=C(C=C3)Cl)Cl,O=C(OCc1ccco1)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
1508,1512,CHEMBL1224238,GBLULAKVGYVWTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,2.51,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518963,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC3=CC=CC=C3N2,CC(C)(C)CCC1(C(=O)c2cc3ccccc3[nH]2)CCNC1
1509,1513,CHEMBL475527,GBPYXOBRYGPNKY-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,36.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,36.0,CNCC[C@H](C1=CC=CC=C1)N2C3=CC=CC=C3SC2=O,CNCC[C@H](c1ccccc1)n1c(=O)sc2ccccc21
1510,1514,CHEMBL401596,GBSPTFCPJIXLFF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,3230.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.490797477668897,CC1=C(C=CC(=C1)Cl)OC2=C(C=NC=C2)CN(C)C,Cc1cc(Cl)ccc1Oc1ccncc1CN(C)C
1511,1515,CHEMBL380191,GBWQTSFXTHVNTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-60.4,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-60.4,CC1=CC=C(C=C1)CN(CC(C)C)C2CCNCC2,Cc1ccc(CN(CC(C)C)C2CCNCC2)cc1
1512,1516,CHEMBL184807,GBXCFQBRUJWAGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15482938.0,KI,=,5.0,NM,,,,,,,,,,,,,,,Inhibition of [18F]PET binding to dopamine transporter of human brain,Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,C1CC2C(C(CC1N2)C3=CC=C(C=C3)Br)C(=O)OCCCF,O=C(OCCCF)C1C2CCC(CC1c1ccc(Br)cc1)N2
1513,1517,CHEMBL578,GBXSMTUPTTWBMN-XIRDDKMYSA-N,ENALAPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
1514,1518,CHEMBL578,GBXSMTUPTTWBMN-XIRDDKMYSA-N,ENALAPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
1515,1519,CHEMBL1395,GCKMFJBGXUYNAG-HLXURNFRSA-N,METHYLTESTOSTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
1516,1520,CHEMBL1395,GCKMFJBGXUYNAG-HLXURNFRSA-N,METHYLTESTOSTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
1517,1521,CHEMBL2047563,GCQYUVJKJNRUBX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,61.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,61.0,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CC=C(C=C3)Cl)O,OC(CCN1CC=C(Cc2ccccc2)CC1)c1ccc(Cl)cc1
1518,1522,CHEMBL323678,GDIDBVDYSJUGMI-NGKMOHNRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,,,,Not Determined,,,,,,,,,,,,,,In vitro ability of compound to inhibit DA re-uptake of radiolabeled [3H]-tritium transmitter into synaptosome; ND=not determined,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)OC,COc1ccc2cc([C@H]3C4CCC(C4)[C@@H]3CN(C)C)ccc2c1
1519,1523,CHEMBL323678,GDIDBVDYSJUGMI-NGKMOHNRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,64.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1938200260161125,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)OC,COc1ccc2cc([C@H]3C4CCC(C4)[C@@H]3CN(C)C)ccc2c1
1520,1524,CHEMBL181,GDLBFKVLRPITMI-UHFFFAOYSA-N,DIAZOXIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,CC1=NS(=O)(=O)c2cc(Cl)ccc2N1
1521,1525,CHEMBL181,GDLBFKVLRPITMI-UHFFFAOYSA-N,DIAZOXIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,CC1=NS(=O)(=O)c2cc(Cl)ccc2N1
1522,1526,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,2190.0,NM,,,,,,,,,,,,,,,,,,,,5.6595558851598815,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1523,1527,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11454918.0,KI,=,3020.0,NM,,,,,,,,,,,,,,,,,,,,5.519993057042849,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1524,1528,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14573386.0,KI,=,2190.0,NM,,,,,,,,,,,,,,,,,,,,5.6595558851598815,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1525,1529,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,2777.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.556424120249742,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1526,1530,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26372073.0,INHIBITION,=,14.0,%,,,,,,,,,,,,,,,Displacement of [3H]-BTCP from dopamine transporter (unknown origin) at 1 mM relative to control,Reengineered tricyclic anti-cancer agents.,Bioorg. Med. Chem.,PUBLICATION,,14.0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1527,1531,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26372073.0,INHIBITION,=,60.0,%,,,,,,,,,,,,,,,Displacement of [3H]-BTCP from dopamine transporter (unknown origin) at 10 mM relative to control,Reengineered tricyclic anti-cancer agents.,Bioorg. Med. Chem.,PUBLICATION,,60.0,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1528,1532,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2746.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.561299467099262,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1529,1533,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2182.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.6611452537476765,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1530,1534,CHEMBL471696,GDSLVFLGCFUFPN-KHQMHLGISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,8.74,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.058488567365597,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=NO4)C5=CC=C(C=C5)Cl)N3C.Cl,Cc1ccc([C@H]2CC3CCC([C@H]2c2cc(-c4ccc(Cl)cc4)no2)N3C)cc1
1531,1535,CHEMBL294733,GDTWDHOANPFJQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15080991.0,KI,=,8.83,NM,,,cell_based,,,,,,,,,,,,Binding affinity to dopamine transporter in membranes of cells selectively expressing the human genes for DAT,Synthesis and monoamine transporter affinity of 3'-analogs of 2-beta-carbomethoxy-3-beta-(4'-iodophenyl)tropane (beta-CIT).,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.054039296422431,CN1C2CCC1C(C(C2)C3=CC=CC(=C3)C4=CC=CC=C4)C(=O)OC,COC(=O)C1C(c2cccc(-c3ccccc3)c2)CC2CCC1N2C
1532,1536,CHEMBL205005,GEBDYHRDARRAJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.1,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.958607314841776,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC5=CC=CC=C5CC4.C(=O)(C(=O)O)O,Fc1ccc(C(OCCC2CCN(CC3=Cc4ccccc4CC3)CC2)c2ccc(F)cc2)cc1
1533,1537,CHEMBL492438,GEFDXUZHLNJUMR-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18800760.0,IC50,=,500.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.301029995663981,CS(=O)(=O)NC1=CC=C(C=C1)OC[C@H](CNCCC2=CC(=C(C=C2)Cl)Cl)O,CS(=O)(=O)Nc1ccc(OC[C@@H](O)CNCCc2ccc(Cl)c(Cl)c2)cc1
1534,1538,CHEMBL1084934,GESKFXJTJLLILS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,-5.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-5.0,CNCCN1CC2=C(C=CC(=C2)F)N(S1(=O)=O)C3=CC=CC=C3F,CNCCN1Cc2cc(F)ccc2N(c2ccccc2F)S1(=O)=O
1535,1539,CHEMBL3331476,GEZVEYCSABQEAF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,9.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,9.0,C1C(CN1)N(CC2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(N(Cc2ccccc2)C2CNC2)cc1Cl
1536,1540,CHEMBL2338035,GFBHUZKPXOPMMX-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)F)Cl,Fc1ccc(O[C@@H](c2ccccc2)[C@H]2CCNC2)c(Cl)c1
1537,1541,CHEMBL3310497,GFGPKOBHHRPKSF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,32.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,32.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3Cl,Clc1ccc(C(CC2CNC2)Oc2ccccc2Cl)cc1Cl
1538,1542,CHEMBL3310497,GFGPKOBHHRPKSF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3Cl,Clc1ccc(C(CC2CNC2)Oc2ccccc2Cl)cc1Cl
1539,1543,CHEMBL3310497,GFGPKOBHHRPKSF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3Cl,Clc1ccc(C(CC2CNC2)Oc2ccccc2Cl)cc1Cl
1540,1544,CHEMBL2048524,GFIQRJWRMJKKCT-AXTKMDLGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,18.3,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.73754891026957,CN(C)C[C@@H]1[C@H]2CC[C@H](N2CC[18F])C[C@@H]1C3=CC=C(C=C3)Cl,CN(C)C[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2CCF
1541,1545,CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
1542,1546,CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
1543,1547,CHEMBL451071,GFNCCLBUKZBTIA-LOPIXSETSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,7.9586073148417755,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C#C)N3C.Cl,C#C[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C
1544,1548,CHEMBL234928,GFNMZMSNUJYADM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,16.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,16.0,CN(C)C1CCC(=CC1)C2=CNC3=C2C=C(C=C3)Cl,CN(C)C1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1
1545,1549,CHEMBL2205817,GFQHCUYWLHSGJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CN=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1cccnc1
1546,1550,CHEMBL380056,GFWKSCDPOYKBDG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.823908740944319,CN1CCCCCCCCCC(=O)OCC2C3CCC(N3C)CC2C4=CC=C1C=C4,CN1CCCCCCCCCC(=O)OCC2C(CC3CCC2N3C)c2ccc1cc2
1547,1551,CHEMBL258063,GGDZOYZQDNYTKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,3010.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.521433504406158,CNCC1=C(C=CC(=C1)C#N)OC2=C(C=C(C=C2)Cl)Cl,CNCc1cc(C#N)ccc1Oc1ccc(Cl)cc1Cl
1548,1552,CHEMBL416409,GGGXMDDQIHPMRC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,IC50,=,7.2,NM,,,,,,,,,,,,,,,Compound was tested for the inhibition of dopamine (DA) reuptake,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.142667503568731,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC5=CC=CC=C5C=C4,Fc1ccc(C(OCCC2CCN(Cc3ccc4ccccc4c3)CC2)c2ccc(F)cc2)cc1
1549,1553,CHEMBL416409,GGGXMDDQIHPMRC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,0.71,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,9.148741651280924,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC5=CC=CC=C5C=C4,Fc1ccc(C(OCCC2CCN(Cc3ccc4ccccc4c3)CC2)c2ccc(F)cc2)cc1
1550,1554,CHEMBL1643667,GGNBFDVFZAGDEV-ACDROJECSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,157.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.804100347590767,C1CC2C([C@H](CC1S2)C3=CC=CC=C3)C4=CC(=NO4)C5=CC=CC=C5,c1ccc(-c2cc(C3C4CCC(C[C@@H]3c3ccccc3)S4)on2)cc1
1551,1555,CHEMBL1643657,GGNBFDVFZAGDEV-PBWJLWFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CC2C([C@@H](CC1S2)C3=CC=CC=C3)C4=CC(=NO4)C5=CC=CC=C5,c1ccc(-c2cc(C3C4CCC(C[C@H]3c3ccccc3)S4)on2)cc1
1552,1556,CHEMBL326713,GGNUKUMOMWBKFX-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,7275000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.1381670023420547,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3O)O,CNCC[C@H](Oc1cccc2c(O)c(O)ccc12)c1cccs1
1553,1557,CHEMBL326713,GGNUKUMOMWBKFX-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,>,10000000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.0,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3O)O,CNCC[C@H](Oc1cccc2c(O)c(O)ccc12)c1cccs1
1554,1558,CHEMBL1082211,GGUUYQBMWBFCFQ-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5,C[C@H]1CN(C(=O)c2ccc(-c3ccccc3)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
1555,1559,CHEMBL880,GGXKWVWZWMLJEH-UHFFFAOYSA-N,FAMCICLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O
1556,1560,CHEMBL880,GGXKWVWZWMLJEH-UHFFFAOYSA-N,FAMCICLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O
1557,1561,CHEMBL185,GHASVSINZRGABV-UHFFFAOYSA-N,FLUOROURACIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=O)NC(=O)N1)F,O=c1[nH]cc(F)c(=O)[nH]1
1558,1562,CHEMBL185,GHASVSINZRGABV-UHFFFAOYSA-N,FLUOROURACIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=O)NC(=O)N1)F,O=c1[nH]cc(F)c(=O)[nH]1
1559,1563,CHEMBL40530,GHFKTNDRKOPJLR-GIDUJCDVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.21,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.21,CC1=CC=C(C=C1)/C=C/C(=O)N2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Cc1ccc(/C=C/C(=O)N2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
1560,1564,CHEMBL40530,GHFKTNDRKOPJLR-GIDUJCDVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.1,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.1,CC1=CC=C(C=C1)/C=C/C(=O)N2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Cc1ccc(/C=C/C(=O)N2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
1561,1565,CHEMBL3238486,GHHRSTKFXHLNKT-QNGOZBTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1I)Cl)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(I)cc3Cl)c(O)c12
1562,1566,CHEMBL330250,GHLRGYOXQFGHEE-RUXDESIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,4.698970004336019,CN1C2C[C@@H](C1CC(=C2C(=O)OC)C3=CC=C(C=C3)F)O,COC(=O)C1=C(c2ccc(F)cc2)CC2[C@@H](O)CC1N2C
1563,1567,CHEMBL2012109,GICLXVPHVQLGJY-BHDPWAOGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC=CC(=C3)C4=NC=CS4,COC(=O)[C@H]1C2CCC(C[C@H]1c1cccc(-c3nccs3)c1)O2
1564,1568,CHEMBL2012109,GICLXVPHVQLGJY-BHDPWAOGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC=CC(=C3)C4=NC=CS4,COC(=O)[C@H]1C2CCC(C[C@H]1c1cccc(-c3nccs3)c1)O2
1565,1569,CHEMBL565396,GIDJZDYNVHMFAH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.022276394711152,CC(C(=O)C1=CC(=CC=C1)Br)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Br)c1
1566,1570,CHEMBL565396,GIDJZDYNVHMFAH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,4200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.376750709602098,CC(C(=O)C1=CC(=CC=C1)Br)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Br)c1
1567,1571,CHEMBL565396,GIDJZDYNVHMFAH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,511.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.291579099865287,CC(C(=O)C1=CC(=CC=C1)Br)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Br)c1
1568,1572,CHEMBL438257,GIENPXSUZALJHK-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,170.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)C(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(C(N)=O)cc21
1569,1573,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,312.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,6.505845405981558,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1[C@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2
1570,1574,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,312.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,6.505845405981558,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1[C@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2
1571,1575,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,243.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.614393726401688,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1[C@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2
1572,1576,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,193.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.714442690992227,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1[C@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2
1573,1577,CHEMBL2338036,GIKANUDLIOICAL-KSSFIOAISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,398.11,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,COC1=C(C=CC(=C1)Cl)O[C@H]([C@H]2CCNC2)C3=CC=CC=C3,COc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@H]1CCNC1
1574,1578,CHEMBL2338037,GIKANUDLIOICAL-RDTXWAMCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,COC1=C(C=CC(=C1)Cl)O[C@@H]([C@@H]2CCNC2)C3=CC=CC=C3,COc1cc(Cl)ccc1O[C@H](c1ccccc1)[C@@H]1CCNC1
1575,1579,CHEMBL563518,GISYFCKSYSNKHX-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,19.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,19.0,CC(C)N1C2=CC=CC=C2N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1ccccc1)n1c(=O)n(C(C)C)c2ccccc21
1576,1580,CHEMBL3310631,GIXNXFPSTUDIAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,28.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,28.0,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)F)F,Cc1cccc(OC(CC2CNC2)c2ccc(F)c(F)c2)c1
1577,1581,CHEMBL1201082,GIYXAJPCNFJEHY-UHFFFAOYSA-N,FLUOXETINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,18400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,4.735182176990463,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
1578,1582,CHEMBL1201082,GIYXAJPCNFJEHY-UHFFFAOYSA-N,FLUOXETINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,5.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.8,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
1579,1583,CHEMBL27490,GJDQYWYMCFMZIM-HHHXNRCGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,12.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.920818753952375,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CC4=CC=CC=C4)O,O[C@H](Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
1580,1584,CHEMBL27646,GJDQYWYMCFMZIM-MHZLTWQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,0.75,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,9.1249387366083,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H](CC4=CC=CC=C4)O,O[C@@H](Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
1581,1585,CHEMBL99946,GJJFMKBJSRMPLA-DZGCQCFKSA-N,LEVOMILNACIPRAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,3200.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN
1582,1586,CHEMBL99946,GJJFMKBJSRMPLA-DZGCQCFKSA-N,LEVOMILNACIPRAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,=,3200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN
1583,1587,CHEMBL252923,GJJFMKBJSRMPLA-HIFRSBDPSA-N,"1R,2S-MILNACIPRAN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14573386.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN
1584,1588,CHEMBL252923,GJJFMKBJSRMPLA-HIFRSBDPSA-N,"1R,2S-MILNACIPRAN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN
1585,1589,CHEMBL252923,GJJFMKBJSRMPLA-HIFRSBDPSA-N,"1R,2S-MILNACIPRAN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN
1586,1590,CHEMBL252923,GJJFMKBJSRMPLA-HIFRSBDPSA-N,"1R,2S-MILNACIPRAN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN
1587,1591,CHEMBL252923,GJJFMKBJSRMPLA-HIFRSBDPSA-N,"1R,2S-MILNACIPRAN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,>,854.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.068542129310996,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN
1588,1592,CHEMBL259209,GJJFMKBJSRMPLA-UHFFFAOYSA-N,MILNACIPRAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989234,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CN
1589,1593,CHEMBL259209,GJJFMKBJSRMPLA-UHFFFAOYSA-N,MILNACIPRAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,6100.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989234,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CN
1590,1594,CHEMBL259209,GJJFMKBJSRMPLA-UHFFFAOYSA-N,MILNACIPRAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,=,6100.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.214670164989234,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CN
1591,1595,CHEMBL259209,GJJFMKBJSRMPLA-UHFFFAOYSA-N,MILNACIPRAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,>,31622.78,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.499999953328897,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CN
1592,1596,CHEMBL471001,GJJFMKBJSRMPLA-ZFWWWQNUSA-N,"1S,2R-MILNACIPRAN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,=,3200.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.494850021680094,CCN(CC)C(=O)[C@@]1(C[C@H]1CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@H]1CN
1593,1597,CHEMBL493056,GJORZJNPTHLFPB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,2800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,CNCC1=CC=CC=C1SC2=CC=C(C=C2)C(F)(F)F,CNCc1ccccc1Sc1ccc(C(F)(F)F)cc1
1594,1598,CHEMBL134,GJSURZIOUXUGAL-UHFFFAOYSA-N,CLONIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,Clc1cccc(Cl)c1NC1=NCCN1
1595,1599,CHEMBL134,GJSURZIOUXUGAL-UHFFFAOYSA-N,CLONIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,Clc1cccc(Cl)c1NC1=NCCN1
1596,1600,CHEMBL3317694,GJZAPYUNMABLBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,420.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.376750709602098,C1CNCC(=O)N(C1)C2=CC(=C(C=C2)Cl)Cl.Cl,O=C1CNCCCN1c1ccc(Cl)c(Cl)c1
1597,1601,CHEMBL1744173,GJZWWIMXGJBWFD-HAEFCHRDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,530.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.275724130399211,CCN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.C(=C\C(=O)O)\C(=O)O,CCN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1598,1602,CHEMBL1744173,GJZWWIMXGJBWFD-HAEFCHRDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,660.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.180456064458133,CCN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.C(=C\C(=O)O)\C(=O)O,CCN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1599,1603,CHEMBL1744173,GJZWWIMXGJBWFD-HAEFCHRDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,0.8,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,0.8,CCN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.C(=C\C(=O)O)\C(=O)O,CCN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
1600,1604,CHEMBL698,GKCBAIGFKIBETG-UHFFFAOYSA-N,TETRACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,CCCCNc1ccc(C(=O)OCCN(C)C)cc1
1601,1605,CHEMBL698,GKCBAIGFKIBETG-UHFFFAOYSA-N,TETRACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,CCCCNc1ccc(C(=O)OCCN(C)C)cc1
1602,1606,CHEMBL243141,GKCCZGXUGNBNGL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,922.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.035269078946371,CCOC(=O)C1=C(CCNC1)C2=CC(=C(C=C2)Cl)Cl,CCOC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCNC1
1603,1607,CHEMBL194837,GKDBTHSYQZTDAJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16134937.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against dopamine transporter,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,PUBLICATION,,8.0,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)COC3=C(C=C(C=C3)Cl)Cl)OCCN(C)C,Cc1cc(OCCN(C)C)nc2ccc(NC(=O)COc3ccc(Cl)cc3Cl)cc12
1604,1608,CHEMBL954,GKIRPKYJQBWNGO-OCEACIFDSA-N,ENCLOMIPHENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,784.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.105683937315562,CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1
1605,1609,CHEMBL954,GKIRPKYJQBWNGO-OCEACIFDSA-N,ENCLOMIPHENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,623.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.205511953340831,CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1
1606,1610,CHEMBL598767,GKIYCLAZFANGKD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,2590.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.586700235918748,C1CNCCC1C2=C(N=CC=C2)OC3=C(C=C(C=C3)F)F,Fc1ccc(Oc2ncccc2C2CCNCC2)c(F)c1
1607,1611,CHEMBL592696,GKNLPWOESJYQTF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,=,1220.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.9136401693252525,CC1=CC(=C(C=C1)SC2=C(C=CC(=C2)F)CN(C)C)N,Cc1ccc(Sc2cc(F)ccc2CN(C)C)c(N)c1
1608,1612,CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C
1609,1613,CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C
1610,1614,CHEMBL199824,GKTQBPYMIGXPKG-JVVVGQRLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16392798.0,KI,=,407.4,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.",J. Med. Chem.,PUBLICATION,,6.389978975335856,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC4=C3C=C(C=C4)O[11CH3],COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1
1611,1615,CHEMBL1771,GKTWGGQPFAXNFI-HNNXBMFYSA-N,CLOPIDOGREL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
1612,1616,CHEMBL1771,GKTWGGQPFAXNFI-HNNXBMFYSA-N,CLOPIDOGREL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
1613,1617,CHEMBL396838,GKWNAKMFUGNGOE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,1548816618912.48,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.1899999999999995,COC(=O)C1=C(C2CCC1C2)C3=CC=CC=C3,COC(=O)C1=C(c2ccccc2)C2CCC1C2
1614,1618,CHEMBL3334787,GLFCAUWDGGEFFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,8.5,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,8.5,CN(C)CCC(C1=CC=C(C=C1)C(F)(F)F)N2CCOCC2,CN(C)CCC(c1ccc(C(F)(F)F)cc1)N1CCOCC1
1615,1619,CHEMBL511466,GLLHCTWOTAUGQC-ZSFQTYJUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,1.86,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.730487055782081,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)C5=CC=C(C=C5)F.Cl,CN1C2CCC1[C@@H](c1cc(-c3ccc(F)cc3)no1)[C@@H](c1ccc(Cl)cc1)C2
1616,1620,CHEMBL570781,GLMKIAAMEYVAIS-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)C1=CC=CC=C1C(=O)N([C@H]2CCNC2)C3CCC3,CC(C)c1ccccc1C(=O)N(C1CCC1)[C@H]1CCNC1
1617,1621,CHEMBL1425,GLVAUDGFNGKCSF-UHFFFAOYSA-N,MERCAPTOPURINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=CN2,S=c1nc[nH]c2nc[nH]c12
1618,1622,CHEMBL1425,GLVAUDGFNGKCSF-UHFFFAOYSA-N,MERCAPTOPURINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=CN2,S=c1nc[nH]c2nc[nH]c12
1619,1623,CHEMBL25719,GLZPCOQZEFWAFX-JXMROGBWSA-N,GERANIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=CCC/C(=C/CO)/C)C,CC(C)=CCC/C(C)=C/CO
1620,1624,CHEMBL25719,GLZPCOQZEFWAFX-JXMROGBWSA-N,GERANIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=CCC/C(=C/CO)/C)C,CC(C)=CCC/C(C)=C/CO
1621,1625,CHEMBL256818,GLZVSWBABDDJJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,19600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.707743928643524,CNCC1=CC=CC=C1OC2=C(C=C(C=C2)Cl)OC,CNCc1ccccc1Oc1ccc(Cl)cc1OC
1622,1626,CHEMBL3238496,GMJWWHDWSNWEBB-NFFVHWSESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)N)O)C)N,Cc1cc(-c2ccc(N=Nc3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(C)c2)ccc1N
1623,1627,CHEMBL3703731,GMTDFEZUDHTSAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,50.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.29929628285498,C1C(C2=C(CN1)C=C(C=C2)C3=NN=C(C=C3)OC(F)F)C4=CC(=C(C=C4)Cl)Cl,FC(F)Oc1ccc(-c2ccc3c(c2)CNCC3c2ccc(Cl)c(Cl)c2)nn1
1624,1628,CHEMBL202409,GMWFVXBLHOYMAG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,5.9,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.229147988357855,CC1=CC=C(C=C1)C(=O)C(CC(C)C)N2CCCC2,Cc1ccc(C(=O)C(CC(C)C)N2CCCC2)cc1
1625,1629,CHEMBL202409,GMWFVXBLHOYMAG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,13.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.863279432843593,CC1=CC=C(C=C1)C(=O)C(CC(C)C)N2CCCC2,Cc1ccc(C(=O)C(CC(C)C)N2CCCC2)cc1
1626,1630,CHEMBL36715,GMZVRMREEHBGGF-UHFFFAOYSA-N,PIRACETAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)N(C1)CC(=O)N,NC(=O)CN1CCCC1=O
1627,1631,CHEMBL36715,GMZVRMREEHBGGF-UHFFFAOYSA-N,PIRACETAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)N(C1)CC(=O)N,NC(=O)CN1CCCC1=O
1628,1632,CHEMBL451837,GNCUMPKNBKWCMB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCN)C2=CC=CO2,NCCC1CCC(c2ccco2)O1
1629,1633,CHEMBL451837,GNCUMPKNBKWCMB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCN)C2=CC=CO2,NCCC1CCC(c2ccco2)O1
1630,1634,CHEMBL599813,GNEJBSYNDIMJCO-BGUVMLPUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,23.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,23.0,C[C@@H]1CN(C2=CC=CC=C12)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1C[C@@H](C)c2ccccc21
1631,1635,CHEMBL599609,GNEJBSYNDIMJCO-MAOIFBLLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,0.0,CC1CN(C2=CC=CC=C12)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC(C)c2ccccc21
1632,1636,CHEMBL592167,GNEJBSYNDIMJCO-WKXZFPGYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,10.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,10.0,C[C@H]1CN(C2=CC=CC=C12)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1C[C@H](C)c2ccccc21
1633,1637,CHEMBL574081,GNESBMMZVPTREH-UHDQLFAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,6.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.187086643357143,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(OC)cc1)N2C
1634,1638,CHEMBL260439,GNGXSMDBVKAQSC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)C1(CC1CN)C2=CC=CC=C2,C=CCN(CC)C(=O)C1(c2ccccc2)CC1CN
1635,1639,CHEMBL260439,GNGXSMDBVKAQSC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)C1(CC1CN)C2=CC=CC=C2,C=CCN(CC)C(=O)C1(c2ccccc2)CC1CN
1636,1640,CHEMBL1201117,GNXFOGHNGIVQEH-UHFFFAOYSA-N,METHOCARBAMOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(COC(=O)N)O,COc1ccccc1OCC(O)COC(N)=O
1637,1641,CHEMBL1201117,GNXFOGHNGIVQEH-UHFFFAOYSA-N,METHOCARBAMOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(COC(=O)N)O,COc1ccccc1OCC(O)COC(N)=O
1638,1642,CHEMBL563404,GNYXJFDSZWNBKT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNCCC1C(C2=CC=CC=N2)OC3=CC=CC=C3C4=CC=CC=C4,c1ccc(-c2ccccc2OC(c2ccccn2)C2CCNCC2)cc1
1639,1643,CHEMBL642,GOEMGAFJFRBGGG-UHFFFAOYSA-N,ACEBUTOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
1640,1644,CHEMBL642,GOEMGAFJFRBGGG-UHFFFAOYSA-N,ACEBUTOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
1641,1645,CHEMBL3331503,GOHLFHFVKPDRNY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,330.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.481486060122112,CC(C)N(CC1CNC1)CC2=CC(=C(C=C2)Cl)Cl.Cl,CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1
1642,1646,CHEMBL3331503,GOHLFHFVKPDRNY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,22.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,22.0,CC(C)N(CC1CNC1)CC2=CC(=C(C=C2)Cl)Cl.Cl,CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1
1643,1647,CHEMBL2205819,GOYQRMVWIWPDFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCc1ccccc1
1644,1648,CHEMBL207407,GOZTZBHGDRHFET-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-10.3,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-10.3,CC(C)CN(CC1=CC=CC=C1C#N)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccccc1C#N)C1CCNCC1
1645,1649,CHEMBL458282,GPDDTDCIQUPUIA-MKRRPMGHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,92.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.036212172654443,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C(=C3)Br)OC)Br)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](c2cc(Br)c(OC)c(Br)c2)C[C@H]2CC[C@H]1N2C
1646,1650,CHEMBL2430691,GPFOQDAZAVIYMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,45.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,45.0,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccccc1Cl
1647,1651,CHEMBL2430691,GPFOQDAZAVIYMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,65.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,65.0,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccccc1Cl
1648,1652,CHEMBL206007,GPHQCFPKKILZDC-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,6.2,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2,C1CO[C@@H](CN1)[C@@](CC2=CC=CC=C2SC(F)(F)F)(C3=CC=CC=C3)O,O[C@](Cc1ccccc1SC(F)(F)F)(c1ccccc1)[C@@H]1CNCCO1
1649,1653,CHEMBL7568,GPKJTRJOBQGKQK-UHFFFAOYSA-N,QUINACRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12
1650,1654,CHEMBL7568,GPKJTRJOBQGKQK-UHFFFAOYSA-N,QUINACRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12
1651,1655,CHEMBL1730,GPRBEKHLDVQUJE-QSWIMTSFSA-N,CEFOTAXIME,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
1652,1656,CHEMBL1730,GPRBEKHLDVQUJE-QSWIMTSFSA-N,CEFOTAXIME,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
1653,1657,CHEMBL66068,GPTFOAJWBIXTMY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15080991.0,KI,=,438.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to dopamine transporter in membranes of cells selectively expressing the human genes for DAT,Synthesis and monoamine transporter affinity of 3'-analogs of 2-beta-carbomethoxy-3-beta-(4'-iodophenyl)tropane (beta-CIT).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.358525889495901,COC(=O)C1C2CCC(N2)CC1C3=CC(=CC=C3)I,COC(=O)C1C2CCC(CC1c1cccc(I)c1)N2
1654,1658,CHEMBL2031737,GPZMWOXSIRVXQW-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313227.0,KI,=,137.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant DAT,Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.,J. Med. Chem.,PUBLICATION,,6.863279432843593,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C(=O)C4=CC=C(C=C4)[N+](=O)[O-],C[C@@H]1CCCN1CCc1cc2cc(C(=O)c3ccc([N+](=O)[O-])cc3)ccc2o1
1655,1659,CHEMBL3334780,GPZZVYRXCADSAJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,46.2,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,46.2,CN(CCC(C1=C(C=C(C=C1)F)F)N2CCOCC2)CC3=CC=CC=C3,CN(CCC(c1ccc(F)cc1F)N1CCOCC1)Cc1ccccc1
1656,1660,CHEMBL514,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,LOMUSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NC1CCCCC1
1657,1661,CHEMBL514,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,LOMUSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NC1CCCCC1
1658,1662,CHEMBL607546,GRBWDTDDMWUOBH-DDZGMJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,710.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.1487416512809245,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCCC5=CC=C(C=C5)NC(=O)[C@H]6[C@H](CC7CCC6N7C)C8=CC=C(C=C8)C9=CSC=C9,CN1C2CCC1[C@@H](C(=O)Nc1ccc(CCNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(-c5ccsc5)cc3)N4C)cc1)[C@@H](c1ccc(-c3ccsc3)cc1)C2
1659,1663,CHEMBL1818441,GRCVTMNCDBAKJY-GFOWMXPYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,15.85,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.799970733446231,C1CNCC2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C5=CC=CC=C5C=N4,Clc1ccc([C@]23CCNCC2(Cn2ncc4ccccc42)C3)cc1Cl
1660,1664,CHEMBL1830888,GRFGQBNGPFNYCF-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,2040.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,5.690369832574102,C1CO[C@@H](CN1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=C(C=C(C=C4)F)F,O=S1(=O)N(CC[C@@H]2CNCCO2)c2ccccc2N1c1ccc(F)cc1F
1661,1665,CHEMBL402441,GRFLLIUZAGYUSO-HNAYVOBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C#CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C#CCN(CC#C)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
1662,1666,CHEMBL2171213,GRGFMFALKDYCBN-UHFFFAOYSA-N,3-((4-CHLOROPHENYL)(ETHOXY)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,7.3,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.3,CCOC(C1CNC1)C2=CC=C(C=C2)Cl.Cl,CCOC(c1ccc(Cl)cc1)C1CNC1
1663,1667,CHEMBL381914,GRHZPOKPBBOJOD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)S(=O)(=O)C2=CC=CC=C2CN(C)C)N,Cc1ccc(S(=O)(=O)c2ccccc2CN(C)C)c(N)c1
1664,1668,CHEMBL2029052,GRIXJAFEBWYBJE-ANUWOGMRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,>,10000000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.0,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,CNCC[C@H](Oc1cccc2cc(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)ccc12)c1cccs1
1665,1669,CHEMBL600854,GRMXPWKSNKSJGL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,310.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.508638306165728,C1CNCCC1C2=C(N=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(Oc2ncccc2C2CCNCC2)c1Cl
1666,1670,CHEMBL2012098,GRMYHCHFKYUZGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,CN1C(=CC=C1C2=CC=CC=C2)C3=C(C4CCC(C3)O4)C(=O)OC,COC(=O)C1=C(c2ccc(-c3ccccc3)n2C)CC2CCC1O2
1667,1671,CHEMBL2012098,GRMYHCHFKYUZGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,CN1C(=CC=C1C2=CC=CC=C2)C3=C(C4CCC(C3)O4)C(=O)OC,COC(=O)C1=C(c2ccc(-c3ccccc3)n2C)CC2CCC1O2
1668,1672,CHEMBL539564,GRNINAGHVYRWAO-HLRBRJAUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,140.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321763,C1=CC=C(C=C1)[C@@H]([C@@H](CN)C2=CC3=CC=CC=C3C=C2)O.Cl,NC[C@@H](c1ccc2ccccc2c1)[C@@H](O)c1ccccc1
1669,1673,CHEMBL520760,GRQBTYJVQQSMFR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CC1=C(C=CC(=C1)S(=O)(=O)N)SC2=CC=C(C=C2)SC,CSc1ccc(Sc2ccc(S(N)(=O)=O)cc2CN(C)C)cc1
1670,1674,CHEMBL1173428,GRQDILLJMSLURW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,70.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,7.154901959985742,CC1C(OCC(N1)(C)C)(C2=CC(=C(C=C2)Cl)Cl)O,CC1NC(C)(C)COC1(O)c1ccc(Cl)c(Cl)c1
1671,1675,CHEMBL469888,GRQJWLQCSDAJSU-MFYZWQBTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,3.93,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.405607449624574,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=NO4)C5=CC=C(C=C5)OC)N3C.Cl,COc1ccc(-c2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(C)cc3)N4C)on2)cc1
1672,1676,CHEMBL1099179,GRUIIAQNNWQJPW-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,=,175.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7569619513137065,CN1CCN(CC1)C[C@H](C2=CC(=CC=C2)Cl)C3(CCCCC3)O,CN1CCN(C[C@H](c2cccc(Cl)c2)C2(O)CCCCC2)CC1
1673,1677,CHEMBL1096495,GRUIIAQNNWQJPW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,=,247.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.607303046740334,CN1CCN(CC1)CC(C2=CC(=CC=C2)Cl)C3(CCCCC3)O,CN1CCN(CC(c2cccc(Cl)c2)C2(O)CCCCC2)CC1
1674,1678,CHEMBL567289,GSCMKUDZZALNHS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,1300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693162,C1CNCCC1N(CC2=CC3=CC=CC=C3C=C2)C4=NC=CC=N4,c1cnc(N(Cc2ccc3ccccc3c2)C2CCNCC2)nc1
1675,1679,CHEMBL81977,GSCPDZHWVNUUFI-UHFFFAOYSA-N,3-AMINOBENZAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)N)C(=O)N,NC(=O)c1cccc(N)c1
1676,1680,CHEMBL81977,GSCPDZHWVNUUFI-UHFFFAOYSA-N,3-AMINOBENZAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)N)C(=O)N,NC(=O)c1cccc(N)c1
1677,1681,CHEMBL33,GSDSWSVVBLHKDQ-JTQLQIEISA-N,LEVOFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1678,1682,CHEMBL33,GSDSWSVVBLHKDQ-JTQLQIEISA-N,LEVOFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1679,1683,CHEMBL4,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,OFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1680,1684,CHEMBL4,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,OFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1681,1685,CHEMBL392394,GSGVDKOCBKBMGG-UHFFFAOYSA-N,GS-39783,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,1988.0,NM,,,,,,,,,,,,,,,,,,,,5.701583619938706,CSC1=NC(=C(C(=N1)NC2CCCC2)[N+](=O)[O-])NC3CCCC3,CSc1nc(NC2CCCC2)c([N+](=O)[O-])c(NC2CCCC2)n1
1682,1686,CHEMBL1644607,GSHCBUDNKQJONH-OPVJXMOQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,481.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.317854923626168,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=C3)C4=CC=CC(=C4)C#N,N#Cc1cccc(-c2cccc(OC3C[C@@H]4CC[C@H](C3)N4)c2)c1
1683,1687,CHEMBL608704,GSKKFMDTLUPADS-PHBSMUBBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,690.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.161150909262744,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NC4=CC=C(C=C4)NC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)Nc1ccc(NC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)cc1)[C@@H](c1ccc(Cl)cc1)C2
1684,1688,CHEMBL1080790,GSMFLJBANXQXTM-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,273.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.563837352959244,CC(C)(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CC(C)(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
1685,1689,CHEMBL257338,GSMNVIUCCXHOLS-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,=,2400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288393,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=CC=CC=C3S2,CCN(CC)C(=O)[C@@]1(c2cc3ccccc3s2)C[C@H]1CN
1686,1690,CHEMBL207915,GSQLCOBXOUVYQV-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,4.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CC(C)CN(CC1=CC=CC=C1OC)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,COc1ccccc1CN(CC(C)C)C1CCNCC1
1687,1691,CHEMBL1204413,GSXGGZMCFSEFOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,IC50,=,4000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CNCCCC1CC2=C(C=CC(=C2)F)N(S1(=O)=O)C3=CC=CC=C3.Cl,CNCCCC1Cc2cc(F)ccc2N(c2ccccc2)S1(=O)=O
1688,1692,CHEMBL372318,GTKJFGPZQFGMLW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,12.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C(F)(F)F,CNCCCC1Cc2ccccc2N(c2ccc(C(F)(F)F)cc2)C1=O
1689,1693,CHEMBL372318,GTKJFGPZQFGMLW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C(F)(F)F,CNCCCC1Cc2ccccc2N(c2ccc(C(F)(F)F)cc2)C1=O
1690,1694,CHEMBL1818450,GTRIRKWLHVGYGS-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.899974269892138,CC1=C(OC=N1)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ncoc1C[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
1691,1695,CHEMBL136154,GTWLNJLBBONLRD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,1.01,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.995678626217357,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC5=CC=CC=C5O4,Fc1ccc(C(OCCC2CCN(Cc3cc4ccccc4o3)CC2)c2ccc(F)cc2)cc1
1692,1696,CHEMBL491408,GUEUKMXCMIUBEX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18782666.0,IC50,>,10.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=C(C=CC(=C1)OC2=C(C=C(C=C2)S(=O)(=O)N)CN(C)C)S(=O)C,Cc1cc(Oc2ccc(S(N)(=O)=O)cc2CN(C)C)ccc1[S+](C)[O-]
1693,1697,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,255.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.5934598195660445,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1694,1698,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,203.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.692503962086787,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1695,1699,CHEMBL1818464,GUIDCAHCXPHFSP-QZTJIDSGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.899974269892138,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=CC=C4C#N,N#Cc1cccn1C[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
1696,1700,CHEMBL3310623,GUVSOKCRWWGAEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,27.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,27.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)Cl,Fc1cc(C(CC2CNC2)Oc2ccc(Cl)cc2)ccc1Cl
1697,1701,CHEMBL3310623,GUVSOKCRWWGAEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)Cl,Fc1cc(C(CC2CNC2)Oc2ccc(Cl)cc2)ccc1Cl
1698,1702,CHEMBL3310623,GUVSOKCRWWGAEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)Cl,Fc1cc(C(CC2CNC2)Oc2ccc(Cl)cc2)ccc1Cl
1699,1703,CHEMBL492841,GVAGNJNCGNKLIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,5900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.229147988357856,CNCC1=CC=CC=C1CC2=CC=C(C=C2)SC,CNCc1ccccc1Cc1ccc(SC)cc1
1700,1704,CHEMBL517305,GVFNSRVEVUSCRN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,724.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.140261433802853,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4C#N,N#Cc1c[nH]c2ccc(C3(Cc4ccccc4)CCNC3)cc12
1701,1705,CHEMBL3310484,GVIKXRIOBFGDFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,63.9,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1944991418416,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3F,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl
1702,1706,CHEMBL3310484,GVIKXRIOBFGDFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,68.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,68.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3F,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl
1703,1707,CHEMBL3310484,GVIKXRIOBFGDFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3F,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl
1704,1708,CHEMBL3310484,GVIKXRIOBFGDFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3F,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl
1705,1709,CHEMBL47,GVJHHUAWPYXKBD-IEOSBIPESA-N,VITAMIN E,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
1706,1710,CHEMBL47,GVJHHUAWPYXKBD-IEOSBIPESA-N,VITAMIN E,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
1707,1711,CHEMBL3310486,GVURCJXFYIMVMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,143.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.8446639625349395,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
1708,1712,CHEMBL3310486,GVURCJXFYIMVMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,40.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,40.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
1709,1713,CHEMBL3310486,GVURCJXFYIMVMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
1710,1714,CHEMBL3310486,GVURCJXFYIMVMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
1711,1715,CHEMBL1813310,GVWVNROHWPGGAQ-GOEBONIOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,1000.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.0,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC=C(C=C3)OC,COc1ccc([C@]23CCCC[C@H]2CN(C)C3)cc1
1712,1716,CHEMBL313664,GWGUPRNQVJIAAS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,7.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.154901959985743,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)I,COC(=O)C1C2CCC(CC1c1ccc(I)cc1)O2
1713,1717,CHEMBL313664,GWGUPRNQVJIAAS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.376750709602098,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)I,COC(=O)C1C2CCC(CC1c1ccc(I)cc1)O2
1714,1718,CHEMBL3673127,GWMUISILSXOPNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,93.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.028260409112222,COC1=CC2=C(C=C1)C3(CCN(C2)C3)C4=CC=C(C=C4)Cl,COc1ccc2c(c1)CN1CCC2(c2ccc(Cl)cc2)C1
1715,1719,CHEMBL199093,GWNCELRRXGHFMX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,3.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CCC1(CC2=C(C=CC(=C2)Cl)N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCC1(CCCNC)Cc2cc(Cl)ccc2N(c2ccc(C)cc2)C1=O
1716,1720,CHEMBL199093,GWNCELRRXGHFMX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CCC1(CC2=C(C=CC(=C2)Cl)N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCC1(CCCNC)Cc2cc(Cl)ccc2N(c2ccc(C)cc2)C1=O
1717,1721,CHEMBL205505,GWNPJZXWVMSYBY-LIRRHRJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,920.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.036212172654443,CN[C@H]1CC[C@H](C2=C1C=CC(=C2)C(=O)N(C)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(C(=O)N(C)C)ccc21
1718,1722,CHEMBL13341,GWUSZQUVEVMBPI-UHFFFAOYSA-N,NIMETAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc21
1719,1723,CHEMBL13341,GWUSZQUVEVMBPI-UHFFFAOYSA-N,NIMETAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc21
1720,1724,CHEMBL3121096,GWVIOFUJTJGECV-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24513042.0,INHIBITION,=,63.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) at 10 uM,"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): Histamine H3 receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,63.0,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)[C@@H]5[C@H]4C5,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@@H]2C[C@H]12
1721,1725,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,998.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.0008694587126294,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
1722,1726,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,793.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.100726812682396,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
1723,1727,CHEMBL1684050,GXDMUUDAPHURSU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,66.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.180456064458133,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)N,CC(N)C1(c2ccc3ccccc3c2)CCCCC1
1724,1728,CHEMBL1684050,GXDMUUDAPHURSU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,110.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9586073148417755,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)N,CC(N)C1(c2ccc3ccccc3c2)CCCCC1
1725,1729,CHEMBL1684050,GXDMUUDAPHURSU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,120.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)N,CC(N)C1(c2ccc3ccccc3c2)CCCCC1
1726,1730,CHEMBL326538,GXLMYIVPJMIMFS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,2940.0,NM,,,,,,,,,,,,,,,Binding affinity against dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.531652669587842,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C(=O)OCC4=CC(=CC=C4)OC5=CC=CC=C5,O=C(OCc1cccc(Oc2ccccc2)c1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
1727,1731,CHEMBL408,GXPHKUHSUJUWKP-UHFFFAOYSA-N,TROGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
1728,1732,CHEMBL408,GXPHKUHSUJUWKP-UHFFFAOYSA-N,TROGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
1729,1733,CHEMBL598825,GXWUVPPXUBCALT-JMSVASOKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,12.59,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.899974269892138,CCCOC[C@@H]1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCCOC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1
1730,1734,CHEMBL599845,GXWUVPPXUBCALT-SLEUVZQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,19.95,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.700057099977232,CCCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
1731,1735,CHEMBL599845,GXWUVPPXUBCALT-SLEUVZQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,251.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.599997654072044,CCCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
1732,1736,CHEMBL877,GYDJEQRTZSCIOI-LJGSYFOKSA-N,TRANEXAMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)O,NCC1CCC(C(=O)O)CC1
1733,1737,CHEMBL877,GYDJEQRTZSCIOI-LJGSYFOKSA-N,TRANEXAMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)O,NCC1CCC(C(=O)O)CC1
1734,1738,CHEMBL498774,GYJUQRIRWMPONQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,9530.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.020907099361674,CCN(CCC1=CC=CC=C1OC(F)(F)F)CCN2CCCCC2,CCN(CCc1ccccc1OC(F)(F)F)CCN1CCCCC1
1735,1739,CHEMBL2205825,GYKFQDQFKGGVKD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,COC1=CC=C(C=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1
1736,1740,CHEMBL1644602,GYNVBZHVGBAXPA-IZZQQSIFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,5329.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.273354279759088,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC(=C3)C4=CC=CC=C4)Cl,Clc1cc(OC2C[C@@H]3CC[C@H](C2)N3)cc(-c2ccccc2)c1
1737,1741,CHEMBL133646,GYTGCOARTYXPAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,10.6,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.9746941347352305,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C=CC5=CC=CC=C53,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=NCCN21
1738,1742,CHEMBL133646,GYTGCOARTYXPAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,KI,=,27.2,NM,,,,,,,,,,,,,,,Inhibition of [125I]- RTI -55 binding at the Dopamine transporter sites on HEK-hDAT cells,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.5654310959658,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C=CC5=CC=CC=C53,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=NCCN21
1739,1743,CHEMBL133646,GYTGCOARTYXPAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,4.0,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,4.0,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C=CC5=CC=CC=C53,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=NCCN21
1740,1744,CHEMBL451165,GYURBKTVOWBCTD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,105.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.978810700930063,CNCC1=C(C=CC(=C1)C(=O)N)CC2=CC(=C(C=C2)Cl)Cl,CNCc1cc(C(N)=O)ccc1Cc1ccc(Cl)c(Cl)c1
1741,1745,CHEMBL375131,GYZLMHZBYPNULH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=CC=C3,FC(F)(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1
1742,1746,CHEMBL375131,GYZLMHZBYPNULH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=CC=C3,FC(F)(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1
1743,1747,CHEMBL422931,GZAMCYJCPQMIHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23477943.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.,Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CNCCC1(COCC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C3=CC=CC=C3,FC(F)(F)c1cc(COCC2(c3ccccc3)CCNCC2)cc(C(F)(F)F)c1
1744,1748,CHEMBL422931,GZAMCYJCPQMIHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23477943.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM,Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.,Bioorg. Med. Chem.,PUBLICATION,,,C1CNCCC1(COCC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C3=CC=CC=C3,FC(F)(F)c1cc(COCC2(c3ccccc3)CCNCC2)cc(C(F)(F)F)c1
1745,1749,CHEMBL1080789,GZAWVIWERRSMCS-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,404.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.393618634889394,C1CNC[C@H]1N(CCC2CC2)C(=O)C3=C(C(=CC=C3)Cl)Cl,O=C(c1cccc(Cl)c1Cl)N(CCC1CC1)[C@H]1CCNC1
1746,1750,CHEMBL1078076,GZJJRCVIVJXCPO-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,2540.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5951662833800615,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C=C(C=C2)F)Cl,CC(C)CN(C(=O)c1ccc(F)cc1Cl)[C@H]1CCNC1
1747,1751,CHEMBL597531,GZJLFOYGSNAXDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,6410.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.193141970481181,COC1=CC=CC=C1OC2=C(C=CC=N2)C3CCNCC3,COc1ccccc1Oc1ncccc1C1CCNCC1
1748,1752,CHEMBL1224163,GZMVATBMIADACI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,251.19,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,C1CCNCC(C1)(CC2=CC=CC=C2)C(=O)C3=CC4=C(C=C3)NC=C4,O=C(c1ccc2[nH]ccc2c1)C1(Cc2ccccc2)CCCCNC1
1749,1753,CHEMBL425010,GZRLZFDDKKLOGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,=,3549.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.449894000652408,CCCNCC1=CC=CC=C1SC2=C(C=C(C=C2)C)N,CCCNCc1ccccc1Sc1ccc(C)cc1N
1750,1754,CHEMBL81,GZUITABIAKMVPG-UHFFFAOYSA-N,RALOXIFENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1869.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.728390698621168,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
1751,1755,CHEMBL81,GZUITABIAKMVPG-UHFFFAOYSA-N,RALOXIFENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1485.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.828273546346768,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
1752,1756,CHEMBL103701,GZWGAKOZADNOEU-NPHMYQBISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,570.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2441251443275085,CCCC1[C@H](C[C@H]2CC3C1N2CC3)C4=CC=C(C=C4)C,CCCC1C2C3CCN2[C@H](C3)C[C@@H]1c1ccc(C)cc1
1753,1757,CHEMBL428706,GZWPHROGQGOESZ-HJWRWDBZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,3.5,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,8.455931955649724,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)/C=C\I,COC(=O)C1C2CCC(CC1c1ccc(/C=C\I)cc1)N2
1754,1758,CHEMBL428706,GZWPHROGQGOESZ-HJWRWDBZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,15.0,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,7.823908740944319,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)/C=C\I,COC(=O)C1C2CCC(CC1c1ccc(/C=C\I)cc1)N2
1755,1759,CHEMBL428706,GZWPHROGQGOESZ-HJWRWDBZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16451060.0,KI,=,6.0,NM,,,,,,,,,,,,,,,Displacement of [123I]RTI-55 from DAT,Evaluation of carbon-11-labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-iodoethenyl)phenyl]nortropane as a potential radioligand for imaging the serotonin transporter by PET.,J. Med. Chem.,PUBLICATION,,8.221848749616356,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)/C=C\I,COC(=O)C1C2CCC(CC1c1ccc(/C=C\I)cc1)N2
1756,1760,CHEMBL173427,GZWPHROGQGOESZ-PHHAAFCNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,1.88,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,8.72584215073632,COC(=O)[C@H]1[C@H](CC2CCC1N2)C3=CC=C(C=C3)/C=C/I,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(/C=C/I)cc1)N2
1757,1761,CHEMBL174088,GZWPHROGQGOESZ-SYEBVZJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,3.47,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,8.459670525209127,COC(=O)[C@H]1[C@H](CC2CCC1N2)C3=CC=C(C=C3)/C=C\I,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(/C=C\I)cc1)N2
1758,1762,CHEMBL481124,HACMDNQQWHUHKC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,16000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344076,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)CC3CC3,CN(C)Cc1ccccc1Oc1ccc(CC2CC2)cc1
1759,1763,CHEMBL574543,HAPMRZPBVFBVGL-UHDQLFAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)S(=O)(=O)C)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(S(C)(=O)=O)cc1)N2C
1760,1764,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CC(=O)NC1=O)C,CCC1(C)CC(=O)NC1=O
1761,1765,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CC(=O)NC1=O)C,CCC1(C)CC(=O)NC1=O
1762,1766,CHEMBL3663913,HAQQTPCJCLWUMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,33.0,NM,314446,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.481486060122112,CN1CC(C2=C(C1)C=C(C=C2)C3=CN=CN=C3)C4=CC5=CC=CC=C5S4,CN1Cc2cc(-c3cncnc3)ccc2C(c2cc3ccccc3s2)C1
1763,1767,CHEMBL257221,HASNZFFRDSPBMJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,7700.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827519,CC1=C(C=CC(=C1)OC2=C(C=C(C=C2)C(=O)N3CCCN(CC3)C4CC4)CNC)SC,CNCc1cc(C(=O)N2CCCN(C3CC3)CC2)ccc1Oc1ccc(SC)c(C)c1
1764,1768,CHEMBL2430693,HAUQQZNNDHTKIA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,36.3,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.440093374963888,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1cccc(Cl)c1
1765,1769,CHEMBL2430693,HAUQQZNNDHTKIA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,92.9,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,92.9,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1cccc(Cl)c1
1766,1770,CHEMBL2430693,HAUQQZNNDHTKIA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,99.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,99.0,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1cccc(Cl)c1
1767,1771,CHEMBL433257,HAVJATCHLFRDHY-KSZYUSJVSA-N,HARRINGTONINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O,COC(=O)C[C@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
1768,1772,CHEMBL433257,HAVJATCHLFRDHY-KSZYUSJVSA-N,HARRINGTONINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O,COC(=O)C[C@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
1769,1773,CHEMBL432482,HAXWFRNRCIQCDM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,127.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,6.896196279044043,C1CCC(CC1)C(C#N)C2=CC(=C(C=C2)Cl)Cl,N#CC(c1ccc(Cl)c(Cl)c1)C1CCCCC1
1770,1774,CHEMBL1944974,HBHKUPUWRATWLQ-IDCNUPLLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CCCC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)I,CCCc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)cc1I
1771,1775,CHEMBL129,HBOMLICNUCNMMY-XLPZGREQSA-N,ZIDOVUDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
1772,1776,CHEMBL129,HBOMLICNUCNMMY-XLPZGREQSA-N,ZIDOVUDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
1773,1777,CHEMBL555280,HBOXPGCKZVUQOF-ZVWHLABXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,7260.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.139063379299906,CC(C)(C)[C@@H]([C@@H](CN)C1=CC=CC=C1)O.Cl,CC(C)(C)[C@H](O)[C@@H](CN)c1ccccc1
1774,1778,CHEMBL409877,HBSKTTXZUZBHRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,7000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,CC1=C(C=CC(=C1)OC2=C(C=C(C=C2)C(=O)N3CCN(CC3)C4CC4)CNC)SC,CNCc1cc(C(=O)N2CCN(C3CC3)CC2)ccc1Oc1ccc(SC)c(C)c1
1775,1779,CHEMBL1568,HBUBKKRHXORPQB-FJFJXFQQSA-N,FLUDARABINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
1776,1780,CHEMBL1568,HBUBKKRHXORPQB-FJFJXFQQSA-N,FLUDARABINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
1777,1781,CHEMBL1818465,HBZMBTZPNQEKHQ-QRWMCTBCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.899974269892138,C1CNCC2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=CC(=C4)C#N,N#Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)c1
1778,1782,CHEMBL38468,HCIIUYRSYIGWIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.91,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.91,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=C(C=C3)F)C4=CC=CC=N4,Fc1ccc(CN(CCCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
1779,1783,CHEMBL38468,HCIIUYRSYIGWIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.95,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.95,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=C(C=C3)F)C4=CC=CC=N4,Fc1ccc(CN(CCCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
1780,1784,CHEMBL249951,HCOYSMZXQIWWOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288393,CN(C)CC1CC1C2=CC3=CC=CC=C3C=C2,CN(C)CC1CC1c1ccc2ccccc2c1
1781,1785,CHEMBL249951,HCOYSMZXQIWWOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,31.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,31.0,CN(C)CC1CC1C2=CC3=CC=CC=C3C=C2,CN(C)CC1CC1c1ccc2ccccc2c1
1782,1786,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,3190.0,NM,,,,,,,,,,,,,,,,,,,,5.496209316942818,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1783,1787,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10425082.0,KI,=,3000.0,NM,,,,,,,,,,,,,,,Compound was tested for inhibition of [3H]WIN-35428 binding to the human (DAT) dopamine transporter,Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.,J. Med. Chem.,PUBLICATION,,5.522878745280337,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1784,1788,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10425082.0,RATIO,=,11.5,,,,,,,,,,,,,,,,Ki uptake/Ki binding ratio was determined,Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.,J. Med. Chem.,PUBLICATION,,11.5,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1785,1789,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1786,1790,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,0.49,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,9.309803919971486,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1787,1791,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14573386.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1788,1792,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17690258.0,IC50,=,47900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in human wild type DAT transfected HEK293 cells,LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.,Science,PUBLICATION,,4.3196644865854354,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1789,1793,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,=,82000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,4.086186147616283,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1790,1794,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1791,1795,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1792,1796,CHEMBL255140,HDABHKBEYPDLDS-GKTUAVMOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,8.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.096910013008056,CCCCCCC(=O)OC[C@@H]1[C@H]2CCC(N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl,CCCCCCC(=O)OC[C@H]1[C@@H](c2ccc(Cl)c(Cl)c2)CC2CC[C@H]1N2C
1793,1797,CHEMBL1168,HDACQVRGBOVJII-JBDAPHQKSA-N,RAMIPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
1794,1798,CHEMBL1168,HDACQVRGBOVJII-JBDAPHQKSA-N,RAMIPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
1795,1799,CHEMBL37161,HDDSHPAODJUKPD-UHFFFAOYSA-N,FENBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1
1796,1800,CHEMBL37161,HDDSHPAODJUKPD-UHFFFAOYSA-N,FENBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1
1797,1801,CHEMBL456638,HDLNQDARKJUPIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,463.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.3344190089820485,C1CC(OC1CN)C2=CC=CC3=CC=CC=C32,NCC1CCC(c2cccc3ccccc23)O1
1798,1802,CHEMBL456638,HDLNQDARKJUPIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,8519.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.069611381755678,C1CC(OC1CN)C2=CC=CC3=CC=CC=C32,NCC1CCC(c2cccc3ccccc23)O1
1799,1803,CHEMBL3287654,HDOQLXMDBHVEMJ-SMWREMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24944746.0,INHIBITION,,,,Not Active,,cell_based,,,,,,,,,,,,"Inhibition of 2,5,6-[3H]-dopamine uptake at human DAT expressed in African green monkey COS7 cells at 10 uM incubated for 10 mins prior to radioligand addition measured after 5 mins by scintillation counting analysis",Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram.,ACS Med. Chem. Lett.,PUBLICATION,,,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCCCCN(C)CCC[C@@]5(C6=C(CO5)C=C(C=C6)C#N)C7=CC=C(C=C7)F)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCCCCN(C)CCC[C@@]4(c5ccc(F)cc5)OCc5cc(C#N)ccc54)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
1800,1804,CHEMBL1349,HDOVUKNUBWVHOX-QMMMGPOBSA-N,VALACYCLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21
1801,1805,CHEMBL1349,HDOVUKNUBWVHOX-QMMMGPOBSA-N,VALACYCLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21
1802,1806,CHEMBL40396,HDPHOPOIGUJUKC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.67,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.67,COC1=CC=C(C=C1)N(CCN2CCN(CC2)CCCC3=CC=CC=C3)CC4=CC=CC=C4,COc1ccc(N(CCN2CCN(CCCc3ccccc3)CC2)Cc2ccccc2)cc1
1803,1807,CHEMBL40396,HDPHOPOIGUJUKC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.04,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.04,COC1=CC=C(C=C1)N(CCN2CCN(CC2)CCCC3=CC=CC=C3)CC4=CC=CC=C4,COc1ccc(N(CCN2CCN(CCCc3ccccc3)CC2)Cc2ccccc2)cc1
1804,1808,CHEMBL2012094,HDQQOCQTLVPRHR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,CN1C=CC=C1C2=C(C3CCC(C2)O3)C(=O)OC,COC(=O)C1=C(c2cccn2C)CC2CCC1O2
1805,1809,CHEMBL2012094,HDQQOCQTLVPRHR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,CN1C=CC=C1C2=C(C3CCC(C2)O3)C(=O)OC,COC(=O)C1=C(c2cccn2C)CC2CCC1O2
1806,1810,CHEMBL562533,HDXRSCIIKGHXQP-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3130.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.504455662453552,C1CNC[C@H]1N(C2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(c1ccccc1)[C@H]1CCNC1
1807,1811,CHEMBL2205820,HDZWTAJVYGVJEQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCc1cccc(F)c1
1808,1812,CHEMBL2205820,HDZWTAJVYGVJEQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCc1cccc(F)c1
1809,1813,CHEMBL258271,HEBFKAQNVHADTH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,1210.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.917214629683549,CNCC1=C(C=CC(=C1)C(=O)N)OC2=C(C=C(C=C2)Cl)Cl,CNCc1cc(C(N)=O)ccc1Oc1ccc(Cl)cc1Cl
1810,1814,CHEMBL572927,HEBFYRLCWBRALV-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CC1=CC2=C(C=C1)N(C=C2)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cc(C)ccc21
1811,1815,CHEMBL44618,HEDRZPFGACZZDS-UHFFFAOYSA-N,CHLOROFORM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)Cl,ClC(Cl)Cl
1812,1816,CHEMBL44618,HEDRZPFGACZZDS-UHFFFAOYSA-N,CHLOROFORM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)Cl,ClC(Cl)Cl
1813,1817,CHEMBL369997,HEFDYDISPNHKAM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,539.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.268411234813263,CCCC(C(=O)C1=CC=C(C=C1)C2=CC=CS2)N3CCCC3,CCCC(C(=O)c1ccc(-c2cccs2)cc1)N1CCCC1
1814,1818,CHEMBL369997,HEFDYDISPNHKAM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,460.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.337242168318426,CCCC(C(=O)C1=CC=C(C=C1)C2=CC=CS2)N3CCCC3,CCCC(C(=O)c1ccc(-c2cccs2)cc1)N1CCCC1
1815,1819,CHEMBL175,HEFNNWSXXWATRW-JTQLQIEISA-N,DEXIBUPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
1816,1820,CHEMBL175,HEFNNWSXXWATRW-JTQLQIEISA-N,DEXIBUPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
1817,1821,CHEMBL427526,HEFNNWSXXWATRW-SNVBAGLBSA-N,(R)-IBUPROPHEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1
1818,1822,CHEMBL427526,HEFNNWSXXWATRW-SNVBAGLBSA-N,(R)-IBUPROPHEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1
1819,1823,CHEMBL521,HEFNNWSXXWATRW-UHFFFAOYSA-N,IBUPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)Cc1ccc(C(C)C(=O)O)cc1
1820,1824,CHEMBL521,HEFNNWSXXWATRW-UHFFFAOYSA-N,IBUPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)Cc1ccc(C(C)C(=O)O)cc1
1821,1825,CHEMBL2206516,HEKXQZYFIMYCKA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,112.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.950781977329817,CC1=CC2=C(C=C1)C(CN(C2)C)C3=CC=CC=C3,Cc1ccc2c(c1)CN(C)CC2c1ccccc1
1822,1826,CHEMBL457,HEMJJKBWTPKOJG-UHFFFAOYSA-N,GEMFIBROZIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1
1823,1827,CHEMBL457,HEMJJKBWTPKOJG-UHFFFAOYSA-N,GEMFIBROZIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1
1824,1828,CHEMBL1172525,HESFIOJTTFAYOC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,31.62,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CCCCC1CNCCN1C2=CC3=C(C=C2)NN=C3,CCCCC1CNCCN1c1ccc2[nH]ncc2c1
1825,1829,CHEMBL89662,HEYOUZKOHYRGEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,,,,,Not Determined,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen; Not available,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,,CN1C2CCC1C(=C(C2)C3=CC=CC=C3)C(=O)OC,COC(=O)C1=C(c2ccccc2)CC2CCC1N2C
1826,1830,CHEMBL89662,HEYOUZKOHYRGEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,2590.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,5.586700235918748,CN1C2CCC1C(=C(C2)C3=CC=CC=C3)C(=O)OC,COC(=O)C1=C(c2ccccc2)CC2CCC1N2C
1827,1831,CHEMBL3663907,HFAXMKVVLFVHBE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,5990.0,NM,314430,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,5.2225731776106885,CN1CC(C2=CC=CC=C2C1)C3=CC=CS3,CN1Cc2ccccc2C(c2cccs2)C1
1828,1832,CHEMBL256020,HFDKMRZLKAZCKK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,C1CCN(CC1)C(=O)C2(CC2CN)C3=CC=CC=C3,NCC1CC1(C(=O)N1CCCCC1)c1ccccc1
1829,1833,CHEMBL34139,HFGZFHCWKKQGIS-NOZJJQNGSA-N,GENACONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C,C[C@H]([C@](O)(Cn1cncn1)c1ccc(F)cc1F)S(C)(=O)=O
1830,1834,CHEMBL34139,HFGZFHCWKKQGIS-NOZJJQNGSA-N,GENACONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C,C[C@H]([C@](O)(Cn1cncn1)c1ccc(F)cc1F)S(C)(=O)=O
1831,1835,CHEMBL1230813,HFHDHCJBZVLPGP-RWMJIURBSA-N,ALFADEX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
1832,1836,CHEMBL1230813,HFHDHCJBZVLPGP-RWMJIURBSA-N,ALFADEX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
1833,1837,CHEMBL239301,HFHWEFNEZUUCLY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=C(C=CC(=C1)OCCCF)SC2=C(C=C(C=C2)F)N,CN(C)Cc1cc(OCCCF)ccc1Sc1ccc(F)cc1N
1834,1838,CHEMBL493384,HFIXKYCVEYCJOY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,12893.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,4.8896460173359975,CN(CCC1=CC=C(C=C1)OC)CCN2CCCCC2,COc1ccc(CCN(C)CCN2CCCCC2)cc1
1835,1839,CHEMBL1224091,HFJPQKBQGCFBQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.16,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381597,CC(C)OCC1(CCCN1)C(=O)C2=CC(=C(C=C2)N)Cl,CC(C)OCC1(C(=O)c2ccc(N)c(Cl)c2)CCCN1
1836,1840,CHEMBL3334783,HFKOIMHFPUBUFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,42.0,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,42.0,CNCCC(C1=C(C=C(C=C1)F)F)N2CCOCC2,CNCCC(c1ccc(F)cc1F)N1CCOCC1
1837,1841,CHEMBL550401,HGAHRPAUWSBEBM-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)C1=CC=CC=C1C(=O)N([C@H]2CCNC2)C3CCCC3,CC(C)c1ccccc1C(=O)N(C1CCCC1)[C@H]1CCNC1
1838,1842,CHEMBL382673,HGBGXSPIBLZGHS-PXAZEXFGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,<,1.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CN[C@H]1CC[C@@H](C2=C1C=C(C=C2)S(=O)(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(N)(=O)=O)cc21
1839,1843,CHEMBL383706,HGBGXSPIBLZGHS-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,90.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(N)(=O)=O)cc21
1840,1844,CHEMBL383706,HGBGXSPIBLZGHS-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,90.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(N)(=O)=O)cc21
1841,1845,CHEMBL203331,HGBGXSPIBLZGHS-SJKOYZFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,90.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,CN[C@@H]1CC[C@@H](C2=C1C=C(C=C2)S(=O)(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CC[C@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(N)(=O)=O)cc21
1842,1846,CHEMBL204323,HGBGXSPIBLZGHS-YVEFUNNKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,375.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.425968732272282,CN[C@@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(N)(=O)=O)cc21
1843,1847,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,32359.37,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.489999942195333,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1844,1848,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,17048.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.768326563293853,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1845,1849,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human recombinant dopamine transporter expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1846,1850,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26739781.0,Ki,=,3162.28,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1847,1851,CHEMBL2024089,HGSHFGWWOPXUPH-WHOFXGATSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22171543.0,INHIBITION,=,63.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT at 10 uM,Chemistry and behavioral studies identify chiral cyclopropanes as selective a42-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,PUBLICATION,,63.0,CNC(=O)OCC[C@H]1C[C@@H]1C2=CC(=CN=C2)OC[C@@H]3CCN3,CNC(=O)OCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1
1848,1852,CHEMBL3323092,HGTGGWUXBQZEBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,51.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.292429823902062,CN1CC(C2=CC=CC=C2C1)C3=COC4=CC=CC=C43,CN1Cc2ccccc2C(c2coc3ccccc23)C1
1849,1853,CHEMBL202644,HGUDCSBIBQSBGQ-BQAIUKQQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,3.8,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.42021640338319,C[C@@H](CC1=CC=CC=C1)CN2CCC(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.C(=O)(C(=O)O)O,C[C@@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
1850,1854,CHEMBL202644,HGUDCSBIBQSBGQ-BQAIUKQQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,8.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.096910013008056,C[C@@H](CC1=CC=CC=C1)CN2CCC(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.C(=O)(C(=O)O)O,C[C@@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
1851,1855,CHEMBL444540,HGUDCSBIBQSBGQ-GNAFDRTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,0.9,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,9.045757490560677,C[C@H](CC1=CC=CC=C1)CN2CCC(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.C(=O)(C(=O)O)O,C[C@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
1852,1856,CHEMBL30327,HGUFODBRKLSHSI-UHFFFAOYSA-N,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2
1853,1857,CHEMBL30327,HGUFODBRKLSHSI-UHFFFAOYSA-N,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2
1854,1858,CHEMBL149246,HGVLJGHVYCBNBB-UHFFFAOYSA-N,3-BENZHYDRYL-PYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,780.0,NM,,,,,,,,,,,,,,,Affinity to displace binding of [3H]WIN-35428 to dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.107905397309519,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CN=CC=C3,c1ccc(C(c2ccccc2)c2cccnc2)cc1
1855,1859,CHEMBL149246,HGVLJGHVYCBNBB-UHFFFAOYSA-N,3-BENZHYDRYL-PYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,860.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake evaluated at the dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0655015487564325,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CN=CC=C3,c1ccc(C(c2ccccc2)c2cccnc2)cc1
1856,1860,CHEMBL3331504,HGXZDFUNUJFDRQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,533.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.273272790973428,C1CCC(CC1)N(CC2=CC=C(C=C2)Cl)C3CNC3,Clc1ccc(CN(C2CCCCC2)C2CNC2)cc1
1857,1861,CHEMBL429759,HGZVDXQCKWQIFI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2150.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.667561540084394,CCOC1=CC=CC=C1OC2=C(C=NC(=C2)C)CN(C)C,CCOc1ccccc1Oc1cc(C)ncc1CN(C)C
1858,1862,CHEMBL219146,HHJUWIANJFBDHT-KOTLKJBCSA-N,VINDESINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
1859,1863,CHEMBL219146,HHJUWIANJFBDHT-KOTLKJBCSA-N,VINDESINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
1860,1864,CHEMBL218293,HHPPMJILBGAWHP-DOJYQVMGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17064081.0,ACTIVITY,,,,Active,,cell_based,,,,,HEK293,,,,,,,Photo labeling activity at human DAT expressed in HEK293 cells,Design and synthesis of a novel photoaffinity ligand for the dopamine and serotonin transporters based on 2beta-carbomethoxy-3beta-biphenyltropane.,J. Med. Chem.,PUBLICATION,,,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)C4=CC(=C(C=C4)N=[N+]=[N-])[125I])C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(-c3ccc(N=[N+]=[N-])c(I)c3)cc1)N2C
1861,1865,CHEMBL218293,HHPPMJILBGAWHP-DOJYQVMGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17064081.0,ACTIVITY,,,,Not Active,,cell_based,,,,,HEK293,,,,,,,Photo labeling activity at human DAT expressed in HEK293 cells in the presence of (-)cocaine,Design and synthesis of a novel photoaffinity ligand for the dopamine and serotonin transporters based on 2beta-carbomethoxy-3beta-biphenyltropane.,J. Med. Chem.,PUBLICATION,,,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)C4=CC(=C(C=C4)N=[N+]=[N-])[125I])C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(-c3ccc(N=[N+]=[N-])c(I)c3)cc1)N2C
1862,1866,CHEMBL1818443,HHRJGTNXMGSJLB-HZPDHXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,1.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,9.0,CC1=CN=C(O1)[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1cnc([C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)o1
1863,1867,CHEMBL204254,HHSYAWUBPBEDMP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,62.9,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.201349354554732,CCCC(C(=O)C1=CC=CC(=C1)C)N2CCCC2,CCCC(C(=O)c1cccc(C)c1)N1CCCC1
1864,1868,CHEMBL204254,HHSYAWUBPBEDMP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,51.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.292429823902062,CCCC(C(=O)C1=CC=CC(=C1)C)N2CCCC2,CCCC(C(=O)c1cccc(C)c1)N1CCCC1
1865,1869,CHEMBL565593,HHZNTCLXZVSLGW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,135.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.8696662315049934,CCCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCCCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
1866,1870,CHEMBL565593,HHZNTCLXZVSLGW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,510.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.292429823902062,CCCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCCCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
1867,1871,CHEMBL370110,HIBUHKNMTZCDMF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16219465.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Inhibitory activity against DAT upto 10 uM,Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)SC3=C2C(=O)N(C=N3)CCN4CCN(CC4)C5=CN=CC6=CC=CC=C65,CN1CCc2c(sc3ncn(CCN4CCN(c5cncc6ccccc56)CC4)c(=O)c23)C1
1868,1872,CHEMBL748,HIGSLXSBYYMVKI-UHFFFAOYSA-N,PRALIDOXIME CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=CC=C1/C=N/O.[Cl-],C[n+]1ccccc1/C=N/O
1869,1873,CHEMBL748,HIGSLXSBYYMVKI-UHFFFAOYSA-N,PRALIDOXIME CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=CC=C1/C=N/O.[Cl-],C[n+]1ccccc1/C=N/O
1870,1874,CHEMBL2338042,HIKRIVCRSDESKA-LRDDRELGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=CC(=C3Cl)Cl)Cl,Clc1ccc(Cl)c(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1Cl
1871,1875,CHEMBL2338043,HIKRIVCRSDESKA-MLGOLLRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=C(C=CC(=C3Cl)Cl)Cl,Clc1ccc(Cl)c(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1Cl
1872,1876,CHEMBL360901,HIOVXNATPKFXOD-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15664840.0,DISPLACEMENT,>,200.0,%,,,,,,,,,,,,,,,Displacement of dopamine by the compound against dopamine transporter was determined at 1000 nM,Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,200.0,CC1=CC(=CC=C1)S[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,Cc1cccc(S[C@@H](c2ccccc2)[C@@H]2CNCCO2)c1
1873,1877,CHEMBL41022,HIUIQYGAJIUXAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.12,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.12,C1CN(CCN1CCCC2=CC=CC=C2)CCCC(=O)N(CC3=CC=CC=C3)C4=CC=CC=C4,O=C(CCCN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccc1
1874,1878,CHEMBL41022,HIUIQYGAJIUXAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.56,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.56,C1CN(CCN1CCCC2=CC=CC=C2)CCCC(=O)N(CC3=CC=CC=C3)C4=CC=CC=C4,O=C(CCCN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccc1
1875,1879,CHEMBL1645599,HJCOGULOEUQZGT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,4700.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064284,C1C(CN1)OC2=C(C=CC=C2F)OC3=CC=CC=C3Cl,Fc1cccc(Oc2ccccc2Cl)c1OC1CNC1
1876,1880,CHEMBL2407329,HJKCBQAEYYPLHW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,2600.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,5.585026652029182,COCC(C1CCNCC1)C2=CC(=CC=C2)Cl.Cl,COCC(c1cccc(Cl)c1)C1CCNCC1
1877,1881,CHEMBL1779058,HJKLOGARPBXZTP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC(=O)C7=CC=C(C=C7)F)O,O=C(CCCN1C2C3C4CC5C6C4C2C6C1(O)C53)c1ccc(F)cc1
1878,1882,CHEMBL1220,HJLSLZFTEKNLFI-UHFFFAOYSA-N,TINIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
1879,1883,CHEMBL1220,HJLSLZFTEKNLFI-UHFFFAOYSA-N,TINIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
1880,1884,CHEMBL2030623,HJOLMLNXMCFYQQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CC2CCC1N2CC3=CC(=CC=C3)F,Fc1cccc(CN2C3CCC2CC3)c1
1881,1885,CHEMBL2177497,HJOWYZGUAOZDDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23025719.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,CC(C1=NC2=C(C=NN2C3CCOCC3)C(=O)N1)N4CC(C4)OC5=CC=C(C=C5)C#N,CC(c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1)N1CC(Oc2ccc(C#N)cc2)C1
1882,1886,CHEMBL2180070,HJXAXXUTIBEZHT-GFCCVEGCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23025719.0,INHIBITION,=,0.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 uM,"Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors.",J. Med. Chem.,PUBLICATION,,0.0,C[C@H](C1=NC2=C(C=NN2C3CCCC3)C(=O)N1)N4CC(C4)C5=NC=CC=N5,C[C@H](c1nc2c(cnn2C2CCCC2)c(=O)[nH]1)N1CC(c2ncccn2)C1
1883,1887,CHEMBL415523,HKALZDMFTTZJLT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,359.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.444905551421682,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C5=C(C=C3)OCO5,OC1(c2ccc(Cl)cc2)c2c(ccc3c2OCO3)C2=NCCN21
1884,1888,CHEMBL427904,HKERIGVYOINJIO-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C=CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
1885,1889,CHEMBL520301,HKMJCOCCPVLYPB-BJUDXGSMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18487050.0,KI,=,1485.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.,Bioorg. Med. Chem.,PUBLICATION,,5.828273546346768,[11CH3]OC1=CC=CC2=C1CCN(C2)CCCC3=CNC4=C3C=C(C=C4)F,COc1cccc2c1CCN(CCCc1c[nH]c3ccc(F)cc13)C2
1886,1890,CHEMBL551935,HKMZTVMDWMICAE-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,2340.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6307841425898575,CC1=CC=CC=C1C(=O)N(CC2CCC2)[C@H]3CCNC3,Cc1ccccc1C(=O)N(CC1CCC1)[C@H]1CCNC1
1887,1891,CHEMBL3085021,HKONLYZKJHOXAP-AERCQKQUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,25.7,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.590066876668706,C1C[C@H]2CC(C[C@@H]1N2CCN)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,NCCN1[C@H]2CC[C@@H]1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2
1888,1892,CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NN,NNc1ccccc1
1889,1893,CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NN,NNc1ccccc1
1890,1894,CHEMBL566418,HKOVZQZDXNHYOJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,258.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.58838029403677,CC(C(=O)C1=CC(=CC=C1)Cl)NC2CCC2,CC(NC1CCC1)C(=O)c1cccc(Cl)c1
1891,1895,CHEMBL566418,HKOVZQZDXNHYOJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,343.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.464705879957229,CC(C(=O)C1=CC(=CC=C1)Cl)NC2CCC2,CC(NC1CCC1)C(=O)c1cccc(Cl)c1
1892,1896,CHEMBL1454,HLFSDGLLUJUHTE-SNVBAGLBSA-N,LEVAMISOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSC2=N[C@H](CN21)C3=CC=CC=C3,c1ccc([C@H]2CN3CCSC3=N2)cc1
1893,1897,CHEMBL1454,HLFSDGLLUJUHTE-SNVBAGLBSA-N,LEVAMISOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSC2=N[C@H](CN21)C3=CC=CC=C3,c1ccc([C@H]2CN3CCSC3=N2)cc1
1894,1898,CHEMBL186501,HLHMTIRJTBORDU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,910.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.040958607678906,COC(=O)C1=C(CC2CCC1S2)C3=CC=CC=C3,COC(=O)C1=C(c2ccccc2)CC2CCC1S2
1895,1899,CHEMBL513367,HLQQIEZMTRFYMO-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,>,30000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5228787452803365,CCCCN([C@H]1CCNC1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2,CCCCN([C@H]1CCNC1)S(=O)(=O)c1ccc2ccccc2c1
1896,1900,CHEMBL602550,HMQMRPICUDGPQP-NSLUPJTDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,39.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,39.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2CC3(CCCCC3)C4=CC=CC=C42)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC2(CCCCC2)c2ccccc21
1897,1901,CHEMBL396840,HMRIQOVMDBATQK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,2691534803926.91,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.4299999999999997,COC(=O)C1=C(C2CCC1C2)C3=CC=CC=C3Cl,COC(=O)C1=C(c2ccccc2Cl)C2CCC1C2
1898,1902,CHEMBL598560,HMSJPIAQQVBQMP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6220.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.206209615309182,C1CNCCC1C2=C(N=CC=C2)OC3=C(C=CC(=C3)F)Cl,Fc1ccc(Cl)c(Oc2ncccc2C2CCNCC2)c1
1899,1903,CHEMBL1830892,HMXOXSKENXHTKZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,20.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,20.0,C1COC(CN1)CCN2C3=C(C(=CC=C3)F)N(S2(=O)=O)C4=CC=CC=C4F,O=S1(=O)N(CCC2CNCCO2)c2cccc(F)c2N1c1ccccc1F
1900,1904,CHEMBL307314,HNCXDNKKOJCVCN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,IC50,=,871.0,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [3H]DA binding to dopamine (DAT) transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.059981844992339,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
1901,1905,CHEMBL307314,HNCXDNKKOJCVCN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,KI,=,6.7,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [125I]RTI-55 binding to dopamine transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.173925197299173,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
1902,1906,CHEMBL307314,HNCXDNKKOJCVCN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,0.85,,,,,,,,,,,,,,,,Selectivity ratio determined of Ki human Dopamine transporter to Ki human Serotonin transporter,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.85,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
1903,1907,CHEMBL307314,HNCXDNKKOJCVCN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,130.0,,,,,,,,,,,,,,,,Ratio of uptake inhibition to binding affinity to human DAT (IC50/Ki),Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,130.0,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
1904,1908,CHEMBL1411979,HNJJXZKZRAWDPF-UHFFFAOYSA-N,METHAPYRILENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2757.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.5595632338942265,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2,CN(C)CCN(Cc1cccs1)c1ccccn1
1905,1909,CHEMBL1411979,HNJJXZKZRAWDPF-UHFFFAOYSA-N,METHAPYRILENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2190.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.6595558851598815,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2,CN(C)CCN(Cc1cccs1)c1ccccn1
1906,1910,CHEMBL283899,HNOKHIURIJOQKM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,56.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,56.0,CN1CCC(=CC1)C2=CNC3=C2C=C(C=C3)C#N,CN1CC=C(c2c[nH]c3ccc(C#N)cc23)CC1
1907,1911,CHEMBL2096859,HNVGNUVAMRLMSG-HXSCFSKGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,15.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.804100347590767,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Br)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@@H]1c1ccc(Br)cc1)N2C
1908,1912,CHEMBL218082,HNVGNUVAMRLMSG-JYVUQVBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,1.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,8.769551078621726,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Br)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Br)cc1)N2C
1909,1913,CHEMBL218082,HNVGNUVAMRLMSG-JYVUQVBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,3.5,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.455931955649724,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Br)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Br)cc1)N2C
1910,1914,CHEMBL224819,HNVGNUVAMRLMSG-SHWKFHJASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,1.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,8.769551078621726,CN1C2CCC1[C@H]([C@@H](C2)C3=CC=C(C=C3)Br)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(Br)cc1)N2C
1911,1915,CHEMBL557868,HNVLFSMNTLSQDR-RTWAWAEBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,11.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,11.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C3=C(C=CC=C3F)N(C2=O)C4=CC=CC=C4)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1c(=O)n(-c2ccccc2)c2cccc(F)c21
1912,1916,CHEMBL402000,HNYCNSONMUNSQM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,>,38000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.420216403383191,CCC1=C(C=CC(=C1)Cl)OC2=C(C=NC=C2)CN(C)C,CCc1cc(Cl)ccc1Oc1ccncc1CN(C)C
1913,1917,CHEMBL563214,HOLJKTPTYVYXQS-CHVRVKPSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,12.02,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.92009553233328,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OCCF)N3C/C=C/I,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OCCF)N3C/C=C/I)cc1
1914,1918,CHEMBL559741,HOLJKTPTYVYXQS-NWUNOEDWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,12.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OCC[18F])N3C/C=C/I,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OCCF)N3C/C=C/I)cc1
1915,1919,CHEMBL396386,HOMDNKBRXQHFOD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,912010839355912.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-5.960000000000001,COC(=O)C1=C(C2CCC1N2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)C2CCC1N2
1916,1920,CHEMBL1024,HOMGKSMUEGBAAB-UHFFFAOYSA-N,IFOSFAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(P(=O)(OC1)NCCCl)CCCl,O=P1(NCCCl)OCCCN1CCCl
1917,1921,CHEMBL1024,HOMGKSMUEGBAAB-UHFFFAOYSA-N,IFOSFAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(P(=O)(OC1)NCCCl)CCCl,O=P1(NCCCl)OCCCN1CCCl
1918,1922,CHEMBL1683885,HOXBFDRIDWJAEN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,395.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4034029043735385,CNCC1(CCCCC1)C2=CC=C(C=C2)Cl,CNCC1(c2ccc(Cl)cc2)CCCCC1
1919,1923,CHEMBL583676,HOYMQTQKCIHRHI-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CN(C)C[C@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
1920,1924,CHEMBL1444,HPJKCIUCZWXJDR-UHFFFAOYSA-N,LETROZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
1921,1925,CHEMBL1444,HPJKCIUCZWXJDR-UHFFFAOYSA-N,LETROZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
1922,1926,CHEMBL866,HPNSFSBZBAHARI-RUDMXATFSA-N,MYCOPHENOLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2
1923,1927,CHEMBL866,HPNSFSBZBAHARI-RUDMXATFSA-N,MYCOPHENOLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2
1924,1928,CHEMBL558651,HPPVWRRONLIBLV-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)CN([C@H]1CCNC1)C(=O)C2=CC=CC=C2OC3=CC=CC=C3,CC(C)CN(C(=O)c1ccccc1Oc1ccccc1)[C@H]1CCNC1
1925,1929,CHEMBL1643896,HPQILAIJSLHQQC-MLHJIOFPSA-N,RTI-229,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,IC50,=,0.37,NM,,,,,,,,,,,,,,,Inhibition of DAT,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.431798275933003,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)N4CCCC4,CN1[C@H]2CC[C@@H]1[C@@H](C(=O)N1CCCC1)[C@@H](c1ccc(I)cc1)C2
1926,1930,CHEMBL3310628,HQCGHDLCHPAWBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,94.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,94.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(F)c(F)c2)c1
1927,1931,CHEMBL129832,HQICEQOCYAITRP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.9586073148417755,COC1=CC=C(C=C1)C2(C3=CC=CC=C3C4=NCCN42)O,COc1ccc(C2(O)c3ccccc3C3=NCCN32)cc1
1928,1932,CHEMBL603920,HQJTZVWELLEYIW-VOMIJIAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,22.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,22.0,CC1(CN(C2=C1C=CC(=C2)F)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC(C)(C)c2ccc(F)cc21
1929,1933,CHEMBL420644,HQVQWOHDTVRIMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,23.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,23.0,CN(C)CC(C1=CC=C(C=C1)Cl)C2(CCCCC2)O,CN(C)CC(c1ccc(Cl)cc1)C1(O)CCCCC1
1930,1934,CHEMBL1644471,HQWOOKZKFBMBCD-PTEHBNRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,737.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.132532512140949,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC=C3,c1ccc(OC2C[C@@H]3CC[C@H](C2)N3)cc1
1931,1935,CHEMBL80515,HQXXRDHSJOKBAP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,33.7,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,7.472370099128661,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)F,COC(=O)C1C2CCC(CC1c1ccc(F)cc1)N2
1932,1936,CHEMBL493677,HQZBFDAIHIKVRO-CXAGYDPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18817368.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,"Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.",J. Med. Chem.,PUBLICATION,,50.0,CC(C)(C)CCN1CC[C@@H]([C@@H](C1)F)CNC(=O)C2=CC(=CC(=C2)Cl)Cl,CC(C)(C)CCN1CC[C@H](CNC(=O)c2cc(Cl)cc(Cl)c2)[C@H](F)C1
1933,1937,CHEMBL1818547,HRCVSENKVJEEJB-GFOWMXPYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,3.98,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.400116927926312,C1CNCC2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=C5C=CC=CC5=N4,Clc1ccc([C@]23CCNCC2(Cn2cc4ccccc4n2)C3)cc1Cl
1934,1938,CHEMBL385173,HRJQWACHSNEZEE-DBUDALRPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17154506.0,KI,=,32.6,NM,,,,,,,,,,,,,,,Displacement of [3H]RTI-55 from human DAT,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,7.4867823999320615,COC(=O)[C@H]1[C@H](CC2CCC1N2)C3=CC=CC(=C3)/C=C/Br,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1cccc(/C=C/Br)c1)N2
1935,1939,CHEMBL3331472,HRVOVTQQBGVYAV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,8.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,8.0,C1C(CN1)N(CCCC2=CC=CC=C2)C3=CC=CC=C3,c1ccc(CCCN(c2ccccc2)C2CNC2)cc1
1936,1940,CHEMBL1830883,HRZCVADZOIJDCK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,77.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,77.0,CN1CCOC(C1)CN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,CN1CCOC(CN2c3ccccc3N(c3ccccc3)S2(=O)=O)C1
1937,1941,CHEMBL432022,HSALZIQGHGTBLM-RYTUYPIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,,,,Not Determined,,,,,,,,,,,,,,In vitro ability of compound to inhibit DA re-uptake of radiolabeled [3H]-tritium transmitter into synaptosome; ND=not determined,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNC[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)F,CNC[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(F)ccc2c1
1938,1942,CHEMBL432022,HSALZIQGHGTBLM-RYTUYPIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,72.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.142667503568733,CNC[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)F,CNC[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(F)ccc2c1
1939,1943,CHEMBL1085066,HSMMZWQHSZFBQK-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,2326.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.63339028960757,CC1=CC=CC=C1N2C3=CC=CC=C3N(S2(=O)=O)CC[C@@H](CNC)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccccc2C)S1(=O)=O
1940,1944,CHEMBL1082292,HSMMZWQHSZFBQK-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,1872.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.727694155597915,CC1=CC=CC=C1N2C3=CC=CC=C3N(S2(=O)=O)CC[C@H](CNC)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccccc2C)S1(=O)=O
1941,1945,CHEMBL425961,HSPJWADLPHSZQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4,c1ccc(C(Cc2ccc3ccccc3c2)N2CCNCC2)cc1
1942,1946,CHEMBL980,HSRJKNPTNIJEKV-UHFFFAOYSA-N,GUAIFENESIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(CO)O,COc1ccccc1OCC(O)CO
1943,1947,CHEMBL980,HSRJKNPTNIJEKV-UHFFFAOYSA-N,GUAIFENESIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(CO)O,COc1ccccc1OCC(O)CO
1944,1948,CHEMBL1083405,HSRUEFWMMBYMIL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,3160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,CC(C)OC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CC(C)Oc1ccccc1CC(c1ccccc1)N1CCNCC1
1945,1949,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
1946,1950,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
1947,1951,CHEMBL403571,HTBZTZYEMXZZLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,C1CC(=C(C1)C(=O)OCC2=CC=CS2)C3=CC(=C(C=C3)Cl)Cl,O=C(OCc1cccs1)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
1948,1952,CHEMBL1491,HTIQEAQVCYTUBX-UHFFFAOYSA-N,AMLODIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,5521.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.257982252859862,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl
1949,1953,CHEMBL1491,HTIQEAQVCYTUBX-UHFFFAOYSA-N,AMLODIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4387.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.357832365595055,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl
1950,1954,CHEMBL2430685,HTKNCQZCINRNGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,280.6,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5519123333076585,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc(Cl)c(Cl)c1
1951,1955,CHEMBL2430685,HTKNCQZCINRNGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,89.4,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,89.4,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc(Cl)c(Cl)c1
1952,1956,CHEMBL2430685,HTKNCQZCINRNGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,96.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,96.0,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc(Cl)c(Cl)c1
1953,1957,CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
1954,1958,CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
1955,1959,CHEMBL1939222,HTSQRRQNKJNSLH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22191331.0,INHIBITION,=,11.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 10 uM by radioligand displacement assay,ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,J. Med. Chem.,PUBLICATION,,11.0,C1=C(C=C(C=C1Cl)Cl)OCC2=CC(=O)NN2,O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1
1956,1960,CHEMBL1830882,HTXNJLFLQDPRHG-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,792.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,6.1012748184105075,C1CO[C@@H](CN1)CN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,O=S1(=O)N(C[C@@H]2CNCCO2)c2ccccc2N1c1ccccc1
1957,1961,CHEMBL1830881,HTXNJLFLQDPRHG-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,341.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,6.467245621007503,C1CO[C@H](CN1)CN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,O=S1(=O)N(C[C@H]2CNCCO2)c2ccccc2N1c1ccccc1
1958,1962,CHEMBL1830880,HTXNJLFLQDPRHG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,32.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,32.0,C1COC(CN1)CN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,O=S1(=O)N(CC2CNCCO2)c2ccccc2N1c1ccccc1
1959,1963,CHEMBL40240,HTXTUFOZOVYDCP-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.86,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.86,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=C(C=C(C=C3)Cl)Cl)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(Cl)cc2Cl)cc1
1960,1964,CHEMBL40240,HTXTUFOZOVYDCP-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.18,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.18,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=C(C=C(C=C3)Cl)Cl)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(Cl)cc2Cl)cc1
1961,1965,CHEMBL232866,HTZRCXHILRRXTC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,2649000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,2.5769180417027693,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)OC(F)(F)F,COC(=O)C1=C(c2ccc(OC(F)(F)F)cc2)CCC1
1962,1966,CHEMBL232866,HTZRCXHILRRXTC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)OC(F)(F)F,COC(=O)C1=C(c2ccc(OC(F)(F)F)cc2)CCC1
1963,1967,CHEMBL232866,HTZRCXHILRRXTC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,380189396320.56,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-2.5799999999999987,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)OC(F)(F)F,COC(=O)C1=C(c2ccc(OC(F)(F)F)cc2)CCC1
1964,1968,CHEMBL476312,HUGQKIWTNMQGCP-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2670.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.573488738635424,CS(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
1965,1969,CHEMBL478622,HUGQKIWTNMQGCP-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2390.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.621602099051862,CS(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@@H]3CCNC3,CS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@@H]1CCNC1
1966,1970,CHEMBL1684052,HULJRWTYZFVYPA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,1520.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.818156412055227,CC(C1(CCCCC1)C2=CC=C(C=C2)OC(C)(C)C)N,CC(N)C1(c2ccc(OC(C)(C)C)cc2)CCCCC1
1967,1971,CHEMBL1521,HUNXMJYCHXQEGX-UHFFFAOYSA-N,ZALEPLON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
1968,1972,CHEMBL1521,HUNXMJYCHXQEGX-UHFFFAOYSA-N,ZALEPLON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
1969,1973,CHEMBL342055,HUOXUHKHSINJFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,99.0,NM,,,,,,,,,,,,,,,Affinity to displace binding of [3H]WIN-35428 to dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.00436480540245,C1=CC=C(C=C1)CC(C2=CC=CC=C2)C3=CC=NC=C3,c1ccc(CC(c2ccccc2)c2ccncc2)cc1
1970,1974,CHEMBL342055,HUOXUHKHSINJFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,263.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake evaluated at the dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.580044251510242,C1=CC=C(C=C1)CC(C2=CC=CC=C2)C3=CC=NC=C3,c1ccc(CC(c2ccccc2)c2ccncc2)cc1
1971,1975,CHEMBL898,HUPFGZXOMWLGNK-UHFFFAOYSA-N,DIFLUNISAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
1972,1976,CHEMBL898,HUPFGZXOMWLGNK-UHFFFAOYSA-N,DIFLUNISAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
1973,1977,CHEMBL3331494,HUXXUIUTUNPJTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,24.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,24.0,CC1=CC(=CC=C1)CN(CC2CNC2)C3=CC4=CC=CC=C4C=C3.C(=O)(C(F)(F)F)O,Cc1cccc(CN(CC2CNC2)c2ccc3ccccc3c2)c1
1974,1978,CHEMBL516088,HVJOIRMQZXEGPW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329329.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned DAT by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=CC=C1OCCF)C(=O)C2CCN(CC2)CCC3=CC=C(C=C3)F,COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1
1975,1979,CHEMBL1490,HWHLPVGTWGOCJO-UHFFFAOYSA-N,TRIHEXYPHENIDYL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1
1976,1980,CHEMBL1490,HWHLPVGTWGOCJO-UHFFFAOYSA-N,TRIHEXYPHENIDYL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1
1977,1981,CHEMBL1224025,HWJCHTVVHUINLQ-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,50.12,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CCC[C@]1(CCCN1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CCC[C@@]1(C(=O)c2ccc(Cl)c(Cl)c2)CCCN1
1978,1982,CHEMBL1224024,HWJCHTVVHUINLQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,CCCC1(CCCN1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CCCC1(C(=O)c2ccc(Cl)c(Cl)c2)CCCN1
1979,1983,CHEMBL1224024,HWJCHTVVHUINLQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,15.85,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,CCCC1(CCCN1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CCCC1(C(=O)c2ccc(Cl)c(Cl)c2)CCCN1
1980,1984,CHEMBL383422,HWLVSITUDAPLNE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)NC2=CC=CC=C2CN(C)C)N,Cc1ccc(Nc2ccccc2CN(C)C)c(N)c1
1981,1985,CHEMBL198706,HWOCKNMBFVXGDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,19.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,19.0,CC1(CC2=CC=CC=C2N(C1=O)C3=CC(=CC(=C3)F)F)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2cc(F)cc(F)c2)C1=O
1982,1986,CHEMBL198706,HWOCKNMBFVXGDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1(CC2=CC=CC=C2N(C1=O)C3=CC(=CC(=C3)F)F)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2cc(F)cc(F)c2)C1=O
1983,1987,CHEMBL218894,HWQHDSKQNMHWMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,25.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.602059991327962,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)OC,COc1ccc(C(CC(C)C)C2CCCCN2)cc1
1984,1988,CHEMBL218894,HWQHDSKQNMHWMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.3979400086720375,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)OC,COc1ccc(C(CC(C)C)C2CCCCN2)cc1
1985,1989,CHEMBL218894,HWQHDSKQNMHWMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,52.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.2839966563652,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)OC,COc1ccc(C(CC(C)C)C2CCCCN2)cc1
1986,1990,CHEMBL218894,HWQHDSKQNMHWMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,770.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.113509274827518,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)OC,COc1ccc(C(CC(C)C)C2CCCCN2)cc1
1987,1991,CHEMBL1643650,HWUDNPRGWFSDEO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,126.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.8996294548824375,C1CC2C(=C(CC1S2)C3=CC=C(C=C3)Br)C4=CC(=NO4)C5=CC=CC=C5,Brc1ccc(C2=C(c3cc(-c4ccccc4)no3)C3CCC(C2)S3)cc1
1988,1992,CHEMBL1527608,HWXIGFIVGWUZAO-UHFFFAOYSA-N,DOXOFYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
1989,1993,CHEMBL1527608,HWXIGFIVGWUZAO-UHFFFAOYSA-N,DOXOFYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
1990,1994,CHEMBL381127,HWYVHRCKBXGZLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,283.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.548213564475709,CCCC(C(=O)C1=CC=C(C=C1)OC)N2CCCC2,CCCC(C(=O)c1ccc(OC)cc1)N1CCCC1
1991,1995,CHEMBL381127,HWYVHRCKBXGZLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,329.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.482804102050027,CCCC(C(=O)C1=CC=C(C=C1)OC)N2CCCC2,CCCC(C(=O)c1ccc(OC)cc1)N1CCCC1
1992,1996,CHEMBL290901,HXGQGTYVLCWKMP-ONEGZZNKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.43,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.43,COC1=CC(=C(C=C1)OC)/C=C/CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COc1ccc(OC)c(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c1
1993,1997,CHEMBL290901,HXGQGTYVLCWKMP-ONEGZZNKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.42,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.42,COC1=CC(=C(C=C1)OC)/C=C/CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COc1ccc(OC)c(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c1
1994,1998,CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
1995,1999,CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
1996,2000,CHEMBL3323091,HXJTYROTEDEIBT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,16.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.795880017344076,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4O3,CN1Cc2ccccc2C(c2cc3ccccc3o2)C1
1997,2001,CHEMBL3323091,HXJTYROTEDEIBT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,13.5,NM,314436,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.8696662315049934,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4O3,CN1Cc2ccccc2C(c2cc3ccccc3o2)C1
1998,2002,CHEMBL3323091,HXJTYROTEDEIBT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,13.5,NM,314438,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.8696662315049934,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4O3,CN1Cc2ccccc2C(c2cc3ccccc3o2)C1
1999,2003,CHEMBL1824784,HXOMGUPFBWZKBK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21788137.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT transporter at 10 uM by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2CC3CC1CC(C2)N3CC4=CC=CC=C4.Cl,c1ccc(CN2C3CC4CC(C3)CC2C4)cc1
2000,2004,CHEMBL1830884,HXPJUTFPDVBIKT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,95.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,95.0,C1CC(CNC1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,O=S1(=O)N(CCC2CCCNC2)c2ccccc2N1c1ccccc1
2001,2005,CHEMBL339321,HXPZZXPNTMVGEC-GAIPOIILSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,INHIBITION,=,5.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane at a concentration of 10e-6 M,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.0,C1CC[C@H]2[C@H](C1)N=C3N2C(C4=C3C5=CC=CC=C5C=C4)(C6=CC=C(C=C6)Cl)O,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=N[C@H]3CCCC[C@@H]3N21
2002,2006,CHEMBL339321,HXPZZXPNTMVGEC-GAIPOIILSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,<,0.02,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,0.02,C1CC[C@H]2[C@H](C1)N=C3N2C(C4=C3C5=CC=CC=C5C=C4)(C6=CC=C(C=C6)Cl)O,OC1(c2ccc(Cl)cc2)c2ccc3ccccc3c2C2=N[C@H]3CCCC[C@@H]3N21
2003,2007,CHEMBL35411,HXSHKIDYCUOFFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,16.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.795880017344076,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC=CC5=CC=CC=C54,Fc1ccc(C(OCCC2CCN(Cc3cccc4ccccc34)CC2)c2ccc(F)cc2)cc1
2004,2009,CHEMBL3238478,HXTMSVQUJREQJC-QNGOZBTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1C(=O)O)Cl)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(C(=O)O)cc3Cl)c(O)c12
2005,2010,CHEMBL1224093,HXVMFBSINMZKRO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,CC(C)CC1(CCCN1)C(=O)C2=CC3=C(C=C2)NN=C3,CC(C)CC1(C(=O)c2ccc3[nH]ncc3c2)CCCN1
2006,2011,CHEMBL1945778,HXWLAJVUJSVENX-HZMVEIRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,28.18,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.550059011226662,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1C3=CC=C(C=C3)I,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2CCCF
2007,2012,CHEMBL595,HYAFETHFCAUJAY-UHFFFAOYSA-N,PIOGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
2008,2013,CHEMBL595,HYAFETHFCAUJAY-UHFFFAOYSA-N,PIOGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
2009,2014,CHEMBL2012108,HYHKAAKSUZBYDJ-KXWSQRDISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1C=CC=C1C2=CC(=CC=C2)[C@H]3CC4CCC([C@H]3C(=O)OC)O4,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1cccc(-c3cccn3C)c1)O2
2010,2015,CHEMBL2012108,HYHKAAKSUZBYDJ-KXWSQRDISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,CN1C=CC=C1C2=CC(=CC=C2)[C@H]3CC4CCC([C@H]3C(=O)OC)O4,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1cccc(-c3cccn3C)c1)O2
2011,2016,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
2012,2017,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
2013,2018,CHEMBL205028,HYMIOQDNASQILW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,1190.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.924453038607469,CCCCNC(CCC)C(=O)C1=CC(=C(C=C1)Cl)Cl,CCCCNC(CCC)C(=O)c1ccc(Cl)c(Cl)c1
2014,2019,CHEMBL205028,HYMIOQDNASQILW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,520.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.2839966563652006,CCCCNC(CCC)C(=O)C1=CC(=C(C=C1)Cl)Cl,CCCCNC(CCC)C(=O)c1ccc(Cl)c(Cl)c1
2015,2020,CHEMBL107077,HYOCZQPMJUZYKD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956218.0,KI,=,2651.0,NM,,,,,,,,,,,,,,,In vitro binding affinity on cloned Dopamine transporter,"Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.",J. Med. Chem.,PUBLICATION,,5.576590272266906,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)OC)N,COc1ccc(Sc2ccccc2CN(C)C)c(N)c1
2016,2021,CHEMBL56367,HYWYRSMBCFDLJT-UHFFFAOYSA-N,NIMESULIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,14884.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.827280338650503,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1
2017,2022,CHEMBL56367,HYWYRSMBCFDLJT-UHFFFAOYSA-N,NIMESULIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,11826.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.9271621253369124,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1
2018,2023,CHEMBL2206533,HYXFPJJRAOYSTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,21.5,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.667561540084394,CC1=C(C=C(C=C1)C2CN(CC3=C2C=CC(=C3)OC)C)F,COc1ccc2c(c1)CN(C)CC2c1ccc(C)c(F)c1
2019,2024,CHEMBL487763,HYXMIUGYZHSSJS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,>,1400.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321763,CNCCC(C1=CC=CC=C1)C2=CNC3=CC=CC=C32,CNCCC(c1ccccc1)c1c[nH]c2ccccc12
2020,2025,CHEMBL449235,HYXUARRYTJMRKQ-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2130.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.671620396561263,C1CNC[C@H]1N(CC2=CC=CC=C2C3=CC=CC=C3)C=O,O=CN(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
2021,2026,CHEMBL686,HYYBABOKPJLUIN-UHFFFAOYSA-N,MEFENAMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,Cc1cccc(Nc2ccccc2C(=O)O)c1C
2022,2027,CHEMBL686,HYYBABOKPJLUIN-UHFFFAOYSA-N,MEFENAMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,Cc1cccc(Nc2ccccc2C(=O)O)c1C
2023,2028,CHEMBL377057,HYYSFPWXVUOONL-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-31.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-31.0,CC(C)N(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)N(Cc1ccccc1C(F)(F)F)C1CCNCC1
2024,2029,CHEMBL1082459,HZFCYBLDOJMSFO-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3Cl)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccccc2Cl)S1(=O)=O
2025,2030,CHEMBL1086035,HZFCYBLDOJMSFO-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3Cl)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccccc2Cl)S1(=O)=O
2026,2031,CHEMBL260131,HZHJKYFUXCEIEP-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C#CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
2027,2032,CHEMBL3703745,HZPNLSFQNAKABD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,80.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.0958256317158375,CC1(C2=C(C=CC(=C2)C3=CN=C(C=N3)C(F)(F)F)C(CN1)C4=CC=C(C=C4)Cl)C,CC1(C)NCC(c2ccc(Cl)cc2)c2ccc(-c3cnc(C(F)(F)F)cn3)cc21
2028,2033,CHEMBL568350,HZPZVEJWTPAYPU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,4900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,CS(=O)(=O)N(CC1=CC2=CC=CC=C2C=C1)C3CCNCC3,CS(=O)(=O)N(Cc1ccc2ccccc2c1)C1CCNCC1
2029,2034,CHEMBL270625,HZRDBNNJLUYHJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,7300.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.136677139879544,CC(C)N1CCN(CC1)C(=O)C2=CC(=C(C=C2)OC3=CC=C(C=C3)SC)CNC,CNCc1cc(C(=O)N2CCN(C(C)C)CC2)ccc1Oc1ccc(SC)cc1
2030,2035,CHEMBL3673129,HZUHEVWACVPCEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,141.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.850165303284215,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=CN6C(=NC=N6)C=C5,Clc1ccc(C23CCN(Cc4cc(-c5ccc6ncnn6c5)ccc42)C3)cc1
2031,2036,CHEMBL3673129,HZUHEVWACVPCEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,339.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.469032318428085,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=CN6C(=NC=N6)C=C5,Clc1ccc(C23CCN(Cc4cc(-c5ccc6ncnn6c5)ccc42)C3)cc1
2032,2037,CHEMBL281288,IABCSXAJRAMENM-PWUWZPNHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1.2,NM,,,,,,,,,,,,,,,Ability to displace [3H]-Mazindol from dopamine receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.920818753952375,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=C,C=C[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C
2033,2038,CHEMBL281288,IABCSXAJRAMENM-PWUWZPNHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2.8,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.55284196865778,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=C,C=C[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C
2034,2039,CHEMBL103152,IAFRIOJGEFDYRR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,COC(=O)C1=C(CC2CCC1C2)C3=CC4=CC=CC=C4C=C3,COC(=O)C1=C(c2ccc3ccccc3c2)CC2CCC1C2
2035,2040,CHEMBL190937,IAGCXXVAWFKIDP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,=,3608.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.442733471130097,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CO)N,CN(C)Cc1ccccc1Sc1ccc(CO)cc1N
2036,2041,CHEMBL190937,IAGCXXVAWFKIDP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CO)N,CN(C)Cc1ccccc1Sc1ccc(CO)cc1N
2037,2042,CHEMBL190937,IAGCXXVAWFKIDP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18085744.0,KI,>,1000.0,NM,,,cell_based,,,,,MDCK,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in MDCK cells,"Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands.",J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CO)N,CN(C)Cc1ccccc1Sc1ccc(CO)cc1N
2038,2043,CHEMBL458639,IAIACGGIZWXQIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,147.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.832682665251824,C1CC(OC1CN)C2=CC=CC=C2,NCC1CCC(c2ccccc2)O1
2039,2044,CHEMBL458639,IAIACGGIZWXQIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,916.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.038104526332151,C1CC(OC1CN)C2=CC=CC=C2,NCC1CCC(c2ccccc2)O1
2040,2045,CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
2041,2046,CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
2042,2047,CHEMBL1083425,IAMMWWXBTYJBCX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,1760.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7544873321858505,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC=C(C=C3)F,Fc1ccc(C(Cc2ccccc2OC(F)F)N2CCNCC2)cc1
2043,2048,CHEMBL1079264,IAPNVLHDPZOUSQ-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,501.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.300162274132753,C1CNC[C@H]1N(C2=CC=CC=C2)C(=O)C3=C(C(=CC=C3)Cl)Cl,O=C(c1cccc(Cl)c1Cl)N(c1ccccc1)[C@H]1CCNC1
2044,2049,CHEMBL1950643,IAUVZRBJEZBOFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22290075.0,INHIBITION,=,63.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,63.0,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)C4=NNC(=O)C=C4,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1
2045,2050,CHEMBL344513,IAXQDXIYZZJWKO-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,130.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.886056647693162,CC(C)(C)N[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)(C)N[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
2046,2051,CHEMBL344513,IAXQDXIYZZJWKO-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,370.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.431798275933005,CC(C)(C)N[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)(C)N[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
2047,2052,CHEMBL344513,IAXQDXIYZZJWKO-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,2.8,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,2.8,CC(C)(C)N[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)(C)N[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
2048,2053,CHEMBL145940,IAXQDXIYZZJWKO-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,650.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.187086643357143,CC(C)(C)N[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)(C)N[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
2049,2054,CHEMBL145940,IAXQDXIYZZJWKO-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,1500.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.823908740944319,CC(C)(C)N[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)(C)N[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
2050,2055,CHEMBL145940,IAXQDXIYZZJWKO-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,2.3,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,2.3,CC(C)(C)N[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)(C)N[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
2051,2056,CHEMBL504,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,DIMETHYL SULFOXIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C,C[S+](C)[O-]
2052,2057,CHEMBL504,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,DIMETHYL SULFOXIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C,C[S+](C)[O-]
2053,2058,CHEMBL3310494,IBFDSAQZQXGCJT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,61.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,61.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC=CC=C3F,Fc1ccc(C(CC2CNC2)Oc2ccccc2F)cc1F
2054,2059,CHEMBL137020,IBKOZXQELVZJBY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,IC50,=,11.9,NM,,,,,,,,,,,,,,,Compound was tested for the inhibition of dopamine (DA) reuptake,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.924453038607469,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC5=CC=CC=C5S4,Fc1ccc(C(OCCC2CCN(Cc3cc4ccccc4s3)CC2)c2ccc(F)cc2)cc1
2055,2060,CHEMBL137020,IBKOZXQELVZJBY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,1.61,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.79317412396815,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC5=CC=CC=C5S4,Fc1ccc(C(OCCC2CCN(Cc3cc4ccccc4s3)CC2)c2ccc(F)cc2)cc1
2056,2061,CHEMBL452928,IBMMANZZPBFJNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,4589.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.338281942305341,C1CC(OC1CCC2=C(C(=C(C(=C2F)F)F)F)F)CN,NCC1CCC(CCc2c(F)c(F)c(F)c(F)c2F)O1
2057,2062,CHEMBL452928,IBMMANZZPBFJNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCC2=C(C(=C(C(=C2F)F)F)F)F)CN,NCC1CCC(CCc2c(F)c(F)c(F)c(F)c2F)O1
2058,2063,CHEMBL353333,IBOZZWGMZPMXBO-HHTDUIENSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,0.12,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,9.920818753952377,COC(=O)[C@H]1[C@H](CC2CCC1N2)C3=CC=C(C=C3)I,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(I)cc1)N2
2059,2064,CHEMBL398370,IBOZZWGMZPMXBO-RQJABVFESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446069.0,KI,=,2.25,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,"Synthesis and biological evaluation of 2beta,3alpha-(substituted phenyl)nortropanes as potential norepinephrine transporter imaging agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.647817481888637,COC(=O)[C@@H]1[C@H]2CC[C@@H](N2)C[C@H]1C3=CC=C(C=C3)I,COC(=O)[C@@H]1[C@H]2CC[C@H](C[C@H]1c1ccc(I)cc1)N2
2060,2065,CHEMBL14613,IBOZZWGMZPMXBO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,0.69,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,9.161150909262744,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)I,COC(=O)C1C2CCC(CC1c1ccc(I)cc1)N2
2061,2066,CHEMBL3215298,IBSREHMXUMOFBB-JFUDTMANSA-N,ABAMECTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
2062,2067,CHEMBL3215298,IBSREHMXUMOFBB-JFUDTMANSA-N,ABAMECTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
2063,2068,CHEMBL534942,IBUZSMCHAASZTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,1600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344076,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3.Cl,Clc1ccccc1CC(c1ccccc1)N1CCNCC1
2064,2069,CHEMBL534942,IBUZSMCHAASZTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,2900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.537602002101044,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3.Cl,Clc1ccccc1CC(c1ccccc1)N1CCNCC1
2065,2070,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,IC50,=,5.01,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in LLCPK cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.300162274132754,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
2066,2071,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,7.94,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.100179497572904,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
2067,2072,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.599980364934843,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
2068,2073,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,7.94,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.100179497572904,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
2069,2074,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,7.94,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.100179497572904,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
2070,2075,CHEMBL1200585,ICMWWNHDUZJFDW-DHODBPELSA-N,OXYMETHOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
2071,2076,CHEMBL1200585,ICMWWNHDUZJFDW-DHODBPELSA-N,OXYMETHOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
2072,2077,CHEMBL2386917,ICTBPKWPCGSFPZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23622982.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to human dopamine transporter by radioligand binding assay,"Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=CC2=NC(=CC(=O)N12)CN3C=NC4=CC=CC=C43,Cc1cccc2nc(Cn3cnc4ccccc43)cc(=O)n12
2073,2078,CHEMBL579254,ICUSSYNHQDIHBC-CCRGXQTGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.795880017344076,CC(C)SC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3C,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(SC(C)C)cc1)N2C
2074,2079,CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,IC50,=,2.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in pig LLCPK cells after 1 hr,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.698970004336019,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
2075,2080,CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,10.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.0,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
2076,2081,CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,12.02,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by SPA,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.92009553233328,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
2077,2082,CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.599980364934843,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
2078,2083,CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.0,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
2079,2084,CHEMBL1173532,ICXJGCSEMJXNQF-ZIAGYGMSSA-N,"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,10.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.0,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
2080,2085,CHEMBL589086,ICYDUOWTRYFBOY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,=,726.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.139063379299906,CC1=CC(=C(C=C1)OC2=C(C=CC(=C2)OCCF)CN(C)C)N,Cc1ccc(Oc2cc(OCCF)ccc2CN(C)C)c(N)c1
2081,2086,CHEMBL560050,ICZPNJDXXLLJEO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=C(N=CC=C1)C(C2CCNCC2)OC3=C(C(=CC=C3)Cl)Cl,Cc1cccnc1C(Oc1cccc(Cl)c1Cl)C1CCNCC1
2082,2087,CHEMBL394755,IDGMQHJPMVCZGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23707254.0,KI,=,3300.0,NM,,,,,,,,,,,,,,,Antagonist activity at DAT (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.481486060122113,C1=CC=C(C=C1)CCCC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42,O=C(CCCc1ccccc1)N1c2ccccc2Sc2ccccc21
2083,2088,CHEMBL2047575,IDGXKCMPBMPCQQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,49.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,49.0,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CC4=C(C=C3)OCC4)O,OC(CCN1CC=C(Cc2ccccc2)CC1)c1ccc2c(c1)CCO2
2084,2089,CHEMBL1079265,IDJLHSSQHKZAPT-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,2400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288393,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C=C(C=C2)Cl)Cl,CC(C)CN(C(=O)c1ccc(Cl)cc1Cl)[C@H]1CCNC1
2085,2090,CHEMBL403090,IDPUQOWVIAMLNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,47.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.327902142064282,CC1=C(C=CC(=C1)Cl)OC2=C(C=C(C=C2)N3CCCS3(=O)=O)CNC,CNCc1cc(N2CCCS2(=O)=O)ccc1Oc1ccc(Cl)cc1C
2086,2091,CHEMBL2432044,IDXFKHDXIHNWAI-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,1293.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.888401475119606,CN(CCC1=CC=CC=C1)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(CCc1ccccc1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
2087,2092,CHEMBL826,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,ENOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21
2088,2093,CHEMBL826,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,ENOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21
2089,2094,CHEMBL590472,IDZYJTXHWNKKBY-VIKVFOODSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,6.31,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.199970640755867,C1CC(C1)OCC2([C@H]3[C@@H]2CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(C2(COC3CCC3)[C@H]3CNC[C@H]32)cc1Cl
2090,2095,CHEMBL556888,IEAAUYDUGMCSHI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNCCC1C(C2=CC=NC=C2)OC3=C(C=C(C=C3)Cl)Cl,Clc1ccc(OC(c2ccncc2)C2CCNCC2)c(Cl)c1
2091,2096,CHEMBL1078741,IECZTWNGAWLQAQ-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,3070.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.512861624522814,CC(C)CN([C@H]1CCNC1)C(=O)C2=CC(=CC(=C2)Cl)Cl,CC(C)CN(C(=O)c1cc(Cl)cc(Cl)c1)[C@H]1CCNC1
2092,2097,CHEMBL3663906,IEHDEVXKWOALDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,128000.0,NM,314429,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,3.892790030352132,CC1=C(C(=NO1)C)C2CN(CC3=CC=CC=C23)C,Cc1noc(C)c1C1CN(C)Cc2ccccc21
2093,2098,CHEMBL566000,IELBAACIVCODPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,2319.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.634699251362012,CC(C(=O)C1=CC=C(C=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Cl)cc1
2094,2099,CHEMBL566000,IELBAACIVCODPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,2195.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.65856547542186,CC(C(=O)C1=CC=C(C=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Cl)cc1
2095,2100,CHEMBL566000,IELBAACIVCODPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,1090.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.962573502059376,CC(C(=O)C1=CC=C(C=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Cl)cc1
2096,2101,CHEMBL2106399,IEMDOFXTVAPVLX-YWQHLDGFSA-N,KITASAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O
2097,2102,CHEMBL2106399,IEMDOFXTVAPVLX-YWQHLDGFSA-N,KITASAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O
2098,2103,CHEMBL2,IENZQIKPVFGBNW-UHFFFAOYSA-N,PRAZOSIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
2099,2104,CHEMBL2,IENZQIKPVFGBNW-UHFFFAOYSA-N,PRAZOSIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
2100,2105,CHEMBL1097470,IFCHBQFBWRMERT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,INHIBITION,=,61.0,%,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human DAT expressed in CHO membranes at 1000 nM,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,61.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CC4=CC=CC=C4S3)O,OC1(C(CN2CCNCC2)c2cc3ccccc3s2)CCCCC1
2101,2106,CHEMBL1945244,IFHWCFRFKGCQMZ-GFDGQIBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,371.54,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.429994423238213,CC(C)C1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C=C/I,COC(=O)[C@H]1[C@@H](c2ccc(C(C)C)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
2102,2107,CHEMBL446260,IFOBTLHRUXGTFC-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2C3=CC=CC=C3C[C@]2(CNC)OC,CNC[C@]1(OC)Cc2ccccc2[C@@H]1Oc1ccccc1C
2103,2108,CHEMBL475965,IFWGJAXMPXZADJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19146417.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,"The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.",J. Med. Chem.,PUBLICATION,,10.0,CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C3=CN=C(C=C3)OC)CN4C(=O)C=C(C=N4)N5CCNCC5,COc1ccc(-c2ccc(C(=O)Nc3cccc(Cn4ncc(N5CCNCC5)cc4=O)c3C)cc2)cn1
2104,2109,CHEMBL1204009,IFWPZKFWNGLFCD-UFTMZEDQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821575.0,IC50,=,0.059,NM,,,,,,,,,,,,,,,Inhibition of DAT,Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,10.229147988357855,CCOC(=O)CCC1=CC(=C(C=C1)OC[C@@H](CNC(C)(C)CC2=CC3=CC=CC=C3C=C2)O)C#N.Cl,CCOC(=O)CCc1ccc(OC[C@H](O)CNC(C)(C)Cc2ccc3ccccc3c2)c(C#N)c1
2105,2110,CHEMBL153062,IGFHQQFPSIBGKE-UHFFFAOYSA-N,4-NONYLPHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1649.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.782779344355482,CCCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCCc1ccc(O)cc1
2106,2111,CHEMBL153062,IGFHQQFPSIBGKE-UHFFFAOYSA-N,4-NONYLPHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1310.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.8827287043442364,CCCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCCc1ccc(O)cc1
2107,2112,CHEMBL3309704,IGFZSDUARCFCFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,15.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,15.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
2108,2113,CHEMBL3309704,IGFZSDUARCFCFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,92.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,92.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
2109,2114,CHEMBL3309704,IGFZSDUARCFCFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
2110,2115,CHEMBL2326687,IGHNBPCIIFLLHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,25.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.602059991327962,C1C=CCNCC1C2=CC=C(C=C2)Cl,Clc1ccc(C2CC=CCNC2)cc1
2111,2116,CHEMBL520970,IGIFNSQJPOGUFY-BJUDXGSMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18487050.0,KI,=,3650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.,Bioorg. Med. Chem.,PUBLICATION,,5.437707135543525,[11CH3]OC1=CC2=C(CN(CC2)CCCC3=CNC4=C3C=C(C=C4)I)C=C1,COc1ccc2c(c1)CCN(CCCc1c[nH]c3ccc(I)cc13)C2
2112,2117,CHEMBL575700,IGKKFJKUWPDJDR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,>,2000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,C1CN(CCN1)C2=CC=CC=C2COC3=CC(=CC=C3)F,Fc1cccc(OCc2ccccc2N2CCNCC2)c1
2113,2118,CHEMBL563117,IGKPIVYFTICMLH-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3570.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.447331783887807,CCN([C@H]1CCNC1)C(=O)C2=CC=CC=C2OC3=CC=CC=C3,CCN(C(=O)c1ccccc1Oc1ccccc1)[C@H]1CCNC1
2114,2119,CHEMBL256511,IGNDYXSKELQDJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=C(C=CC(=C1)Cl)OC2=C(C=NC=C2)CNC,CNCc1cnccc1Oc1ccc(Cl)cc1C
2115,2120,CHEMBL210514,IGTBNUVMBDYPQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16722655.0,KI,=,1800.0,NM,,,,,,,,,,,,,,,Binding affinity to human DA transporter,"Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.",J. Med. Chem.,PUBLICATION,,5.7447274948966935,CC1=CC2=C(C=C1OC3=CC=C(O3)C(=O)NC4=C(N=C(N=C4OC)NCCCN5CCOCC5)OC)C(CC2)(C)C,COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1
2116,2121,CHEMBL404317,IHBJHLUWGRKAPP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,387.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.412289034981089,CC1=C(C=CC(=C1)Cl)OC2=C(C=C(C=C2)C(=O)NC)CNC,CNCc1cc(C(=O)NC)ccc1Oc1ccc(Cl)cc1C
2117,2122,CHEMBL219653,IHBJHYKTBCSULK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,21.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.67778070526608,C1CCC(C1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCC2)C2CCCCN2)cc1
2118,2123,CHEMBL219653,IHBJHYKTBCSULK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,180.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.7447274948966935,C1CCC(C1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCC2)C2CCCCN2)cc1
2119,2124,CHEMBL219653,IHBJHYKTBCSULK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,9.4,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.0268721464003,C1CCC(C1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCC2)C2CCCCN2)cc1
2120,2125,CHEMBL219653,IHBJHYKTBCSULK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,310.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.508638306165728,C1CCC(C1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCC2)C2CCCCN2)cc1
2121,2126,CHEMBL196751,IHBSSBISPQPZFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,11.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,11.0,CCC1(CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCC1(CCCNC)Cc2ccccc2N(c2ccc(C)cc2)C1=O
2122,2127,CHEMBL196751,IHBSSBISPQPZFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CCC1(CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCC1(CCCNC)Cc2ccccc2N(c2ccc(C)cc2)C1=O
2123,2128,CHEMBL2326690,IHFKHNCURWJDHC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,23.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.638272163982407,C1C=CCNCC1C2=CC3=CC=CC=C3O2,C1=CCC(c2cc3ccccc3o2)CNC1
2124,2131,CHEMBL1944977,IHNILTTUADKTCG-MXYBEHONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,112.2,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.950007143079858,CC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3)I,COC(=O)[C@H]1[C@@H](c2ccc(C)c(I)c2)C[C@@H]2CC[C@H]1N2
2125,2132,CHEMBL241115,IIBSAKGKZGFYNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23707254.0,KI,=,6600.0,NM,,,,,,,,,,,,,,,Antagonist activity at DAT (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,C1=CC=C2C=C(C=CC2=C1)CC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53,O=C(Cc1ccc2ccccc2c1)N1c2ccccc2Sc2ccccc21
2126,2133,CHEMBL264374,IIBYAHWJQTYFKB-UHFFFAOYSA-N,BEZAFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
2127,2134,CHEMBL264374,IIBYAHWJQTYFKB-UHFFFAOYSA-N,BEZAFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
2128,2135,CHEMBL923,IIDJRNMFWXDHID-UHFFFAOYSA-N,RISEDRONIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
2129,2136,CHEMBL923,IIDJRNMFWXDHID-UHFFFAOYSA-N,RISEDRONIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
2130,2137,CHEMBL401071,IIHVGQJVNJHAMA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,170.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,C1CC(=C(C1)C(=O)OC2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,O=C(Oc1ccccc1)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
2131,2138,CHEMBL418971,IISBACLAFKSPIT-UHFFFAOYSA-N,BISPHENOL A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,19015.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.720903670252398,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1
2132,2139,CHEMBL418971,IISBACLAFKSPIT-UHFFFAOYSA-N,BISPHENOL A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,15108.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.820793023844511,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1
2133,2140,CHEMBL1808425,IISCUUOMDCMADJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21724392.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 0.5 uM,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN1CC(=C(C1)Cl)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=C(C=C4)Br,CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccc(Br)cc3)c3ccccc23)C1
2134,2141,CHEMBL513206,IIVGYQYUSCHDRA-LIAHKDQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,135.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.8696662315049934,CC1=CC=C(C=C1)C2=C(ON=C2C)[C@H]3[C@H](CC4CCC3N4C)C5=CC=C(C=C5)Cl.Cl,Cc1ccc(-c2c(C)noc2[C@@H]2C3CCC(C[C@@H]2c2ccc(Cl)cc2)N3C)cc1
2135,2142,CHEMBL264418,IJMPFBJUROFOGZ-NVXWUHKLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,380.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.420216403383191,C1CO[C@H](CN1)[C@@H](C2=CC=CC=C2)OC3=C(C(=CC=C3)F)F,Fc1cccc(O[C@H](c2ccccc2)[C@H]2CNCCO2)c1F
2136,2143,CHEMBL264680,IJMPFBJUROFOGZ-RDJZCZTQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,2600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,C1CO[C@@H](CN1)[C@H](C2=CC=CC=C2)OC3=C(C(=CC=C3)F)F,Fc1cccc(O[C@@H](c2ccccc2)[C@@H]2CNCCO2)c1F
2137,2144,CHEMBL2180069,IJNPZLODDCNVFR-GFCCVEGCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23025719.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors.",J. Med. Chem.,PUBLICATION,,5.0,C[C@H](C1=NC2=C(C=NN2C3CCOCC3)C(=O)N1)N4CC(C4)OC5=NC=CC=N5,C[C@H](c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1)N1CC(Oc2ncccn2)C1
2138,2145,CHEMBL2338046,IJNSXDVGJQEXPC-BDJLRTHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,316.23,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=C(C(=CC(=C3Cl)F)F)Cl,Fc1cc(F)c(Cl)c(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1Cl
2139,2146,CHEMBL2338045,IJNSXDVGJQEXPC-ZBEGNZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C(=CC(=C3Cl)F)F)Cl,Fc1cc(F)c(Cl)c(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1Cl
2140,2147,CHEMBL2430680,IJNVPBUKXATNNR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,99.6,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.001740661576301,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc(Cl)cc1
2141,2148,CHEMBL2430680,IJNVPBUKXATNNR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,76.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,76.0,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc(Cl)cc1
2142,2149,CHEMBL2430680,IJNVPBUKXATNNR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,93.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,93.8,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc(Cl)cc1
2143,2150,CHEMBL407902,IJTFUKFRQQGBCF-LFWXXOGXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,2960.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.528708288941061,C1CC2[C@H]([C@H](CC1O2)C3=CC(=C(C=C3)Cl)Cl)COC(=O)CCC(=O)OC[C@H]4[C@H](CC5CCC4S5)C6=CC(=C(C=C6)Cl)Cl,O=C(CCC(=O)OC[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)S2)OC[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)O2
2144,2151,CHEMBL446809,IJZRPGINHKPXPE-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CC1(C2=C(C(=CC=C2)F)N(C1=O)[C@H](CCNC)C3=CC(=CC(=C3)F)F)C,CNCC[C@H](c1cc(F)cc(F)c1)N1C(=O)C(C)(C)c2cccc(F)c21
2145,2152,CHEMBL1949930,IKXSPLZKOZXPFB-RQBPZYBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22226656.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of DA transporter,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,CC(C)OC1=CC(=CC(=C1)OC)S(=O)(=O)C2=CC3=C(C=C2)[C@@H]4CCNC[C@@H]4O3.Cl,COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1
2146,2153,CHEMBL1949930,IKXSPLZKOZXPFB-RQBPZYBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22226656.0,INHIBITION,>,50.0,%,,,,,,,,,,,,,,,Inhibition of DA transporter at 10 uM,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC(C)OC1=CC(=CC(=C1)OC)S(=O)(=O)C2=CC3=C(C=C2)[C@@H]4CCNC[C@@H]4O3.Cl,COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1
2147,2154,CHEMBL258292,IKZQDEYILGZICZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,1980.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.703334809738469,CCCC1=CC=CC=C1OC2=C(C=NC(=C2)C)CNC,CCCc1ccccc1Oc1cc(C)ncc1CNC
2148,2155,CHEMBL514515,ILKQBHSHNTVIIC-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CNCC[C@@H](C1=CC=CC=C1)N2C3=CC=CC=C3C4(C2=O)CCCCC4,CNCC[C@@H](c1ccccc1)N1C(=O)C2(CCCCC2)c2ccccc21
2149,2156,CHEMBL476154,ILKQBHSHNTVIIC-HXUWFJFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,26.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,26.0,CNCC[C@H](C1=CC=CC=C1)N2C3=CC=CC=C3C4(C2=O)CCCCC4,CNCC[C@H](c1ccccc1)N1C(=O)C2(CCCCC2)c2ccccc21
2150,2157,CHEMBL411677,ILKYNXUJXDGZRH-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C#CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,C#CCN(CC#C)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
2151,2158,CHEMBL274525,ILLGYRJAYAAAEW-QMMMGPOBSA-N,ABT-418,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,7518514.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1=NOC(=C1)[C@@H]2CCCN2C,Cc1cc([C@@H]2CCCN2C)on1
2152,2159,CHEMBL562854,ILOAMTJMRVQTSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,1270.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.896196279044043,CC1=C(C(=CC=C1)OC(C2CCNCC2)C3=CN=CC=C3)C,Cc1cccc(OC(c2cccnc2)C2CCNCC2)c1C
2153,2160,CHEMBL595449,ILPANLYEJQKXKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19646882.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.,Bioorg. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)C2=NC(=NN2C3=CC(=CC=C3)O)CN(C)C,CN(C)Cc1nc(-c2ccc(C(C)(C)C)cc2)n(-c2cccc(O)c2)n1
2154,2161,CHEMBL3703726,ILPGXQBGCYEMTR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,138.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,6.858863909879261,C1CNC2=C(C1C3=CC=C(C=C3)Cl)C=CC(=C2)C4=NN=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(-c2ccc3c(c2)NCCC3c2ccc(Cl)cc2)nn1
2155,2162,CHEMBL451500,ILYANWOXFYOOPX-TUUXNKATSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,=,5340.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,5.272458742971444,COC1=CC(=C(C=C1)F)CCCC2CCC(O2)CCNCCCCCN3C(=O)[C@@H]4CC=CC[C@@H]4C(=N3)C5=CC(=C(C=C5)OC)OC,COc1ccc(F)c(CCCC2CCC(CCNCCCCCN3N=C(c4ccc(OC)c(OC)c4)[C@H]4CC=CC[C@H]4C3=O)O2)c1
2156,2163,CHEMBL451500,ILYANWOXFYOOPX-TUUXNKATSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,=,5340.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,5.272458742971444,COC1=CC(=C(C=C1)F)CCCC2CCC(O2)CCNCCCCCN3C(=O)[C@@H]4CC=CC[C@@H]4C(=N3)C5=CC(=C(C=C5)OC)OC,COc1ccc(F)c(CCCC2CCC(CCNCCCCCN3N=C(c4ccc(OC)c(OC)c4)[C@H]4CC=CC[C@H]4C3=O)O2)c1
2157,2164,CHEMBL487874,ILZIENIHITYFQQ-AEPIDVSQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,6.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.214670164989233,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)CC5=CC=C(C=C5)OC.Cl,COc1ccc(Cc2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)on2)cc1
2158,2165,CHEMBL233530,IMAGBMSOGGYLDK-CHWSQXEVSA-N,METHYL 2-PHENYLCYCLOHEXANECARBOXYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,975000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.0109953843014634,COC(=O)[C@@H]1CCCC[C@@H]1C2=CC=CC=C2,COC(=O)[C@@H]1CCCC[C@@H]1c1ccccc1
2159,2166,CHEMBL471035,IMESNXOOQNBNMN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COCC(C1CCNCC1)OC2=CC3=CC=CC=C3C=C2,COCC(Oc1ccc2ccccc2c1)C1CCNCC1
2160,2167,CHEMBL568372,IMHRUEORWKDPGA-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,5800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.236572006437063,C1CC(C1)N([C@@H]2CCNC2)C(=O)C3=CC4=CC=CC=C4C=C3,O=C(c1ccc2ccccc2c1)N(C1CCC1)[C@@H]1CCNC1
2161,2168,CHEMBL256557,IMHXBNROFRDAND-HNAYVOBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,C=CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C=CCN(CC=C)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
2162,2169,CHEMBL3334785,IMMKHFZNCWNBOD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,6.4,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.4,CN(C)CCC(C1=CC=C(C=C1)F)N2CCOCC2,CN(C)CCC(c1ccc(F)cc1)N1CCOCC1
2163,2170,CHEMBL1201146,IMONTRJLAWHYGT-ZCPXKWAGSA-N,NORETHINDRONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
2164,2171,CHEMBL1201146,IMONTRJLAWHYGT-ZCPXKWAGSA-N,NORETHINDRONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
2165,2172,CHEMBL1201151,IMSSROKUHAOUJS-MJCUULBUSA-N,MESTRANOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C
2166,2173,CHEMBL1201151,IMSSROKUHAOUJS-MJCUULBUSA-N,MESTRANOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C
2167,2174,CHEMBL574004,IMXJQWVQVSZOKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,EC50,=,498.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.302770657240282,C1CNCCC1C2=C(C=CC=C2F)OC3=CC(=CC=C3)F,Fc1cccc(Oc2cccc(F)c2C2CCNCC2)c1
2168,2175,CHEMBL574004,IMXJQWVQVSZOKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,139.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.856985199745905,C1CNCCC1C2=C(C=CC=C2F)OC3=CC(=CC=C3)F,Fc1cccc(Oc2cccc(F)c2C2CCNCC2)c1
2169,2176,CHEMBL428880,IMZMKUWMOSJXDT-UHFFFAOYSA-N,CROMOLYN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1
2170,2177,CHEMBL428880,IMZMKUWMOSJXDT-UHFFFAOYSA-N,CROMOLYN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1
2171,2178,CHEMBL3310491,INAKZKQNNCSLRZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,33.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,33.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)OC(F)(F)F,Fc1cc(C(CC2CNC2)Oc2cccc(OC(F)(F)F)c2)ccc1Cl
2172,2179,CHEMBL3310491,INAKZKQNNCSLRZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,99.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,99.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)OC(F)(F)F,Fc1cc(C(CC2CNC2)Oc2cccc(OC(F)(F)F)c2)ccc1Cl
2173,2180,CHEMBL3310491,INAKZKQNNCSLRZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)OC(F)(F)F,Fc1cc(C(CC2CNC2)Oc2cccc(OC(F)(F)F)c2)ccc1Cl
2174,2181,CHEMBL506,INDBQLZJXZLFIT-UHFFFAOYSA-N,PRIMAQUINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,COc1cc(NC(C)CCCN)c2ncccc2c1
2175,2182,CHEMBL506,INDBQLZJXZLFIT-UHFFFAOYSA-N,PRIMAQUINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,COc1cc(NC(C)CCCN)c2ncccc2c1
2176,2183,CHEMBL567288,INDDCTQFCFNYFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,339.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4698003017969175,CCC(=O)N(CC1=CC2=CC=CC=C2C=C1)C3CCNCC3,CCC(=O)N(Cc1ccc2ccccc2c1)C1CCNCC1
2177,2184,CHEMBL1224492,INEHYFAMZQPYDY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.98,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,CCCCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CCCCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
2178,2185,CHEMBL1224492,INEHYFAMZQPYDY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,CCCCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CCCCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
2179,2186,CHEMBL1642893,INFXKGQBKNZHOQ-GXTWGEPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,175.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.7569619513137065,C1[C@H](CC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl)N,N[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
2180,2187,CHEMBL1642890,INFXKGQBKNZHOQ-JSGCOSHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,350.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.455931955649724,C1[C@H](CC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N,N[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
2181,2188,CHEMBL1642892,INFXKGQBKNZHOQ-OCCSQVGLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,894.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.048662481204082,C1[C@@H](CC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N,N[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
2182,2189,CHEMBL1642891,INFXKGQBKNZHOQ-TZMCWYRMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,408.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.38933983691012,C1[C@@H](CC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl)N,N[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
2183,2190,CHEMBL862,INJOMKTZOLKMBF-UHFFFAOYSA-N,GUANFACINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,NC(N)=NC(=O)Cc1c(Cl)cccc1Cl
2184,2191,CHEMBL862,INJOMKTZOLKMBF-UHFFFAOYSA-N,GUANFACINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,NC(N)=NC(=O)Cc1c(Cl)cccc1Cl
2185,2192,CHEMBL2442940,INPPXFAIFVJMMD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24050790.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Binding affinity to human dopamine transporter at 10 uM by radioligand binding assay,"Identification of a novel benzoxazolone derivative as a selective, orally active 18 kDa translocator protein (TSPO) ligand.",J. Med. Chem.,PUBLICATION,,,CN(C1=CC=C(C=C1)C(F)(F)F)C(=O)CN2C3=C(C=CC(=C3)C4=CN=CC=C4)OC2=O,CN(C(=O)Cn1c(=O)oc2ccc(-c3cccnc3)cc21)c1ccc(C(F)(F)F)cc1
2186,2193,CHEMBL1087,INWLQCZOYSRPNW-UHFFFAOYSA-N,MEPIVACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,Cc1cccc(C)c1NC(=O)C1CCCCN1C
2187,2194,CHEMBL1087,INWLQCZOYSRPNW-UHFFFAOYSA-N,MEPIVACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,Cc1cccc(C)c1NC(=O)C1CCCCN1C
2188,2195,CHEMBL1830889,IODCZMRTDNJNCT-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,,C1CO[C@@H](CN1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=C(C=C(C=C4F)F)F,O=S1(=O)N(CC[C@@H]2CNCCO2)c2ccccc2N1c1c(F)cc(F)cc1F
2189,2196,CHEMBL451620,IOEFEBQWPLLQHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1CC2C3=CC=CC=C3CC2(CNC)O,CNCC1(O)Cc2ccccc2C1Cc1ccccc1C
2190,2197,CHEMBL378483,IOLBHHBTJKDZMF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,290.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.5376020021010435,CN1C2CCC1C3COC(=O)CCC4(CCC(=O)NC5=CC=C(C3C2)C=C5)C6=CC=CC=C6C7=CC=CC=C47,CN1C2CCC1C1COC(=O)CCC3(CCC(=O)Nc4ccc(cc4)C1C2)c1ccccc1-c1ccccc13
2191,2198,CHEMBL227757,IOQGJGXQSJIUOX-DUHSPSEUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,2.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.698970004336019,COC(=O)[C@H]1[C@H](CC2CCC1S2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)S2
2192,2199,CHEMBL567467,IPBRKYZIBYMQNY-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNC[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=C2C=CC(=C3)Cl)O,CNC[C@H](O)[C@H](c1ccccc1)n1ccc2cc(Cl)ccc21
2193,2200,CHEMBL401069,IPCUDCIZXKOOCV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,2600.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,CC(C)OC(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl,CC(C)OC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
2194,2201,CHEMBL614,IPEHBUMCGVEMRF-UHFFFAOYSA-N,PYRAZINAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(C=N1)C(=O)N,NC(=O)c1cnccn1
2195,2202,CHEMBL614,IPEHBUMCGVEMRF-UHFFFAOYSA-N,PYRAZINAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(C=N1)C(=O)N,NC(=O)c1cnccn1
2196,2203,CHEMBL214268,IPKZCLGGYKRDES-ZDUSSCGKSA-N,PHA-543613,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16821801.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Inhibition of dopamine uptake at human DA transporter at 1 uM,"Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.",J. Med. Chem.,PUBLICATION,,10.0,C1CN2CCC1[C@H](C2)NC(=O)C3=NC=C4C(=C3)C=CO4,O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1
2197,2204,CHEMBL1201346,IPOKCKJONYRRHP-FMQUCBEESA-N,BALSALAZID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1
2198,2205,CHEMBL1201346,IPOKCKJONYRRHP-FMQUCBEESA-N,BALSALAZID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1
2199,2206,CHEMBL257603,IQIONMXYTYNILR-WCQYABFASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C=CCN(C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
2200,2207,CHEMBL1644482,IQNGYWRUWKYNSE-GNXNZQSNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,2775.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.556737012541305,COC1=CC(=CC=C1)OC2C[C@H]3CC[C@@H](C2)N3,COc1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
2201,2208,CHEMBL1502,IQPSEEYGBUAQFF-UHFFFAOYSA-N,PANTOPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,COc1ccnc(C[S+]([O-])c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
2202,2209,CHEMBL1502,IQPSEEYGBUAQFF-UHFFFAOYSA-N,PANTOPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,COc1ccnc(C[S+]([O-])c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
2203,2210,CHEMBL67203,IQRFNUMAKGJEQR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,150.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.823908740944319,C1CC(CN(C1)CCCC2=CC=CC=C2)CNCCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCCC(CNCCOC(c3ccccc3)c3ccccc3)C2)cc1
2204,2211,CHEMBL67203,IQRFNUMAKGJEQR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,18.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.744727494896693,C1CC(CN(C1)CCCC2=CC=CC=C2)CNCCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCCC(CNCCOC(c3ccccc3)c3ccccc3)C2)cc1
2205,2212,CHEMBL563060,IQUFPTOFVDDVOF-UXHICEINSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,,CCNC[C@H]([C@H](C1=CC=CC=C1)N2C3=C(C=CC(=C3)F)N(C2=O)C(C)C)O,CCNC[C@@H](O)[C@H](c1ccccc1)n1c(=O)n(C(C)C)c2ccc(F)cc21
2206,2213,CHEMBL603109,IQUWBNFDLZZVRR-VOMIJIAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,14.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,14.0,CC1(CN(C2=C1C=C(C=C2)F)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC(C)(C)c2cc(F)ccc21
2207,2214,CHEMBL445794,IQZVBBALTJFFCB-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,15000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.823908740944318,C1CNC[C@H]1OCC2=CC3=CC=CC=C3C=C2,c1ccc2cc(CO[C@H]3CCNC3)ccc2c1
2208,2215,CHEMBL469809,IQZVBBALTJFFCB-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,3800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.420216403383191,C1CNC[C@@H]1OCC2=CC3=CC=CC=C3C=C2,c1ccc2cc(CO[C@@H]3CCNC3)ccc2c1
2209,2216,CHEMBL520035,IRDYKJUJFKVPBO-LIAHKDQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,17.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.7569619513137065,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)CC5=CC=C(C=C5)Cl.Cl,CN1C2CCC1[C@@H](c1cc(Cc3ccc(Cl)cc3)no1)[C@@H](c1ccc(Cl)cc1)C2
2210,2217,CHEMBL440110,IRFGAOJZUONKCE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.08,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.08,COC1=CC=C(C=C1)CN(CCCN2CCN(CC2)CCCC3=CC=CC=C3)C4=CC=CC=N4,COc1ccc(CN(CCCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
2211,2218,CHEMBL440110,IRFGAOJZUONKCE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.8,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.8,COC1=CC=C(C=C1)CN(CCCN2CCN(CC2)CCCC3=CC=CC=C3)C4=CC=CC=N4,COc1ccc(CN(CCCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
2212,2219,CHEMBL2338047,IRFOFLZPBFIIGA-LRDDRELGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,7.94,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=C(C=C3Cl)Cl)F,Fc1cc(Cl)cc(Cl)c1O[C@@H](c1ccccc1)[C@H]1CCNC1
2213,2220,CHEMBL493263,IRKCYPUGOBXCFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,36.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.443697499232713,CN(C)CC1=CC=CC=C1SC2=CC(=CC=C2)Cl,CN(C)Cc1ccccc1Sc1cccc(Cl)c1
2214,2221,CHEMBL3310641,IRQADABOPVURIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,24.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,24.0,C1C(CN1)CC(C2=CC=CC=C2)OC3=CC=CC=C3F,Fc1ccccc1OC(CC1CNC1)c1ccccc1
2215,2222,CHEMBL182,IRSCQMHQWWYFCW-UHFFFAOYSA-N,GANCICLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
2216,2223,CHEMBL182,IRSCQMHQWWYFCW-UHFFFAOYSA-N,GANCICLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
2217,2224,CHEMBL1944979,IRUCTNUIGISRRP-ABFRBSLYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CCCC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3)I,CCCc1ccc([C@H]2C[C@@H]3CC[C@@H](N3)[C@H]2C(=O)OC)cc1I
2218,2225,CHEMBL214209,IRVGZJHWMUWHKA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,3.8,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,8.42021640338319,CN1C2CCC1C3COC(=O)CCCCCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCCCCC(=O)Nc3ccc(cc3)C1C2
2219,2226,CHEMBL235625,IRXJTICYJMCEDR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,1659586907437.56,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.22,COC(=O)C1=C(C2CCC1C2)C3=CC=C(C=C3)C4=CC=CC=C4,COC(=O)C1=C(c2ccc(-c3ccccc3)cc2)C2CCC1C2
2220,2227,CHEMBL695,IRYJRGCIQBGHIV-UHFFFAOYSA-N,TRIMETHADIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C(=O)N(C(=O)O1)C)C,CN1C(=O)OC(C)(C)C1=O
2221,2228,CHEMBL695,IRYJRGCIQBGHIV-UHFFFAOYSA-N,TRIMETHADIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C(=O)N(C(=O)O1)C)C,CN1C(=O)OC(C)(C)C1=O
2222,2229,CHEMBL257809,ISKVOQJXBREYEF-ZANVPECISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,=,6300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200659450546418,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=C(S2)Br,CCN(CC)C(=O)[C@@]1(c2ccc(Br)s2)C[C@H]1CN
2223,2230,CHEMBL219334,ISSWMAXVWUPHQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,240.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.619788758288393,CCC(CC)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(CC)C(c1ccc(Cl)cc1)C1CCCCN1
2224,2231,CHEMBL219334,ISSWMAXVWUPHQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,1200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.920818753952375,CCC(CC)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(CC)C(c1ccc(Cl)cc1)C1CCCCN1
2225,2232,CHEMBL219334,ISSWMAXVWUPHQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.3979400086720375,CCC(CC)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(CC)C(c1ccc(Cl)cc1)C1CCCCN1
2226,2233,CHEMBL219334,ISSWMAXVWUPHQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,>,5700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.2441251443275085,CCC(CC)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CCC(CC)C(c1ccc(Cl)cc1)C1CCCCN1
2227,2234,CHEMBL333465,ISVBJSRQEBWKPB-SZPZYZBQSA-N,LOBELANE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15121762.0,KI,=,97.0,NM,,,,,,,,,,,,,,,,,,,,7.013228265733755,CN1[C@H](CCC[C@H]1CCC2=CC=CC=C2)CCC3=CC=CC=C3,CN1[C@H](CCc2ccccc2)CCC[C@@H]1CCc1ccccc1
2228,2235,CHEMBL14060,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,PHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)O,Oc1ccccc1
2229,2236,CHEMBL14060,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,PHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)O,Oc1ccccc1
2230,2237,CHEMBL2112915,ISWUXQKIYIOEJI-INJVKGPASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10691690.0,KI,=,3.2,NM,,,cell_based,,,,,,,,,,,,Inhibition constant against [N-methyl-3H]WIN-35428 in murine kidney cells transfected with human dopamine transporter.,"Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.",J. Med. Chem.,PUBLICATION,,8.494850021680094,C[C@H](CF)OC(=O)C1C2CCC(N2C)CC1C3=CC=C(C=C3)Cl,C[C@H](CF)OC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
2231,2238,CHEMBL1944827,ISWUXQKIYIOEJI-VGVPKUIYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,0.6759999999999999,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,9.170053304058364,C[C@@H](CF)OC(=O)[C@@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC=C(C=C3)Cl,C[C@@H](CF)OC(=O)[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C
2232,2239,CHEMBL1944828,ISWUXQKIYIOEJI-WTBGCVQCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,3.24,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,8.489454989793387,C[C@H](CF)OC(=O)[C@@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC=C(C=C3)Cl,C[C@H](CF)OC(=O)[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C
2233,2240,CHEMBL2112916,ISWUXQKIYIOEJI-XNQNRAEJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10691690.0,KI,=,0.67,NM,,,cell_based,,,,,,,,,,,,Inhibition constant against [N-methyl-3H]WIN-35428 in murine kidney cells transfected with human dopamine transporter.,"Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.",J. Med. Chem.,PUBLICATION,,9.173925197299171,C[C@@H](CF)OC(=O)C1C2CCC(N2C)CC1C3=CC=C(C=C3)Cl,C[C@@H](CF)OC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
2234,2241,CHEMBL526849,ISXTVMLLUKKPCR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,2389.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.6217838502501225,CCN(CCC1=CC=C(C=C1)OC(F)(F)F)CCN2CCCCC2,CCN(CCc1ccc(OC(F)(F)F)cc1)CCN1CCCCC1
2235,2242,CHEMBL560536,ISYQRUPHFNFRMZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,39.81,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1CC(CNC1)N(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CN(c2ccc3[nH]ccc3c2)C2CCCNC2)cc1
2236,2243,CHEMBL3593400,ITALTGDRMWXEDY-UOUQJYNVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,=,1500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.823908740944319,CC(=O)NC[C@@H]1CNCCO[C@H]1C2=CC(=C(C=C2)Cl)Cl.C(=C/C(=O)O)\C(=O)O,CC(=O)NC[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1
2237,2244,CHEMBL303494,ITEKLFIKJBIAEP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15080991.0,KI,=,54.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to dopamine transporter in membranes of cells selectively expressing the human genes for DAT,Synthesis and monoamine transporter affinity of 3'-analogs of 2-beta-carbomethoxy-3-beta-(4'-iodophenyl)tropane (beta-CIT).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.267606240177032,CN1C2CCC1C(C(C2)C3=CC=CC(=C3)C4=CC=CO4)C(=O)OC,COC(=O)C1C(c2cccc(-c3ccco3)c2)CC2CCC1N2C
2238,2245,CHEMBL318138,ITFWLAOOLMWNLG-LFVBFMBRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,0.57,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,9.244125144327509,CN1C2CCC1[C@H](C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC,COC(=O)[C@H]1C(c2ccc3ccccc3c2)CC2CCC1N2C
2239,2246,CHEMBL87567,ITFWLAOOLMWNLG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,0.49,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,9.309803919971486,CN1C2CCC1C(C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC,COC(=O)C1C(c2ccc3ccccc3c2)CC2CCC1N2C
2240,2247,CHEMBL87567,ITFWLAOOLMWNLG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,,,,,Not available,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the Dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen; Not available.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,,CN1C2CCC1C(C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC,COC(=O)C1C(c2ccc3ccccc3c2)CC2CCC1N2C
2241,2248,CHEMBL87567,ITFWLAOOLMWNLG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,0.49,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,9.309803919971486,CN1C2CCC1C(C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC,COC(=O)C1C(c2ccc3ccccc3c2)CC2CCC1N2C
2242,2249,CHEMBL87567,ITFWLAOOLMWNLG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,0.57,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,9.244125144327509,CN1C2CCC1C(C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC,COC(=O)C1C(c2ccc3ccccc3c2)CC2CCC1N2C
2243,2250,CHEMBL396540,ITHSRMGXDMLBTP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,95.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,95.0,CN(C)C1CCC(=CC1)C2=CNC3=C2C=C(C=C3)Br,CN(C)C1CC=C(c2c[nH]c3ccc(Br)cc23)CC1
2244,2251,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,30.0,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,7.522878745280337,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2245,2252,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.0,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2246,2253,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,2400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288393,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2247,2254,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,2400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288393,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2248,2255,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,1150.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.939302159646387,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2249,2256,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,9.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,9.8,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2250,2257,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,73.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,73.0,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2251,2258,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,1150.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.939302159646387,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2252,2259,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,10.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2253,2260,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,42.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,42.0,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2254,2261,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,73.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,73.0,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2255,2262,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,1150.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.939302159646387,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2256,2263,CHEMBL295467,ITJNARMNRKSWTA-UHFFFAOYSA-N,NISOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,10.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,10.0,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC,CNCCC(Oc1ccccc1OC)c1ccccc1
2257,2264,CHEMBL2407322,ITKQJLPIARUDPX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,220.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.657577319177793,COC(=O)C(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,COC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCNCC1
2258,2265,CHEMBL1813479,ITPUGBSWGNTRDI-SMDDNHRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,2818.38,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.5500004516890264,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC(=C(C=C3)F)F,CN1C[C@@H]2CCC[C@]2(c2ccc(F)c(F)c2)C1
2259,2266,CHEMBL1650,ITRJWOMZKQRYTA-RFZYENFJSA-N,CORTISONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
2260,2267,CHEMBL1650,ITRJWOMZKQRYTA-RFZYENFJSA-N,CORTISONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
2261,2268,CHEMBL2030622,ITUMTGGIBOPIJQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CC2CCC1N2CC3=CC=CC=C3,c1ccc(CN2C3CCC2CC3)cc1
2262,2269,CHEMBL378498,IUAVOMFUIPYCBG-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-39.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-39.0,CCC(CC)CN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CCC(CC)CN(Cc1ccccc1C(F)(F)F)C1CCNCC1
2263,2270,CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,COCCc1ccc(OCC(O)CNC(C)C)cc1
2264,2271,CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,COCCc1ccc(OCC(O)CNC(C)C)cc1
2265,2272,CHEMBL499815,IUCNQFHEWLYECJ-CXCSZTQTSA-L,ATRACTYLOSIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CCC4[C@@]3(C2)C)C(=C)[C@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+],C=C1[C@@H]2CCC3[C@]4(C)C[C@H](O[C@@H]5O[C@H](CO)[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]5OC(=O)CC(C)C)C[C@@H](C(=O)O)[C@H]4CC[C@]3(C2)[C@@H]1O
2266,2273,CHEMBL499815,IUCNQFHEWLYECJ-CXCSZTQTSA-L,ATRACTYLOSIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CCC4[C@@]3(C2)C)C(=C)[C@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+],C=C1[C@@H]2CCC3[C@]4(C)C[C@H](O[C@@H]5O[C@H](CO)[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]5OC(=O)CC(C)C)C[C@@H](C(=O)O)[C@H]4CC[C@]3(C2)[C@@H]1O
2267,2274,CHEMBL1258614,IUEKKZWRWOFGRT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20727749.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,"Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OCC)C)C,CCOc1ccc(-c2nn3c(C)cc(C)nc3c2CC(=O)N(CC)CC)cc1
2268,2275,CHEMBL1080788,IUTSKNRONKMGOS-QMMMGPOBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,3730.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.428291168191311,C1CNC[C@H]1N(CC(F)(F)F)C(=O)C2=C(C(=CC=C2)Cl)Cl,O=C(c1cccc(Cl)c1Cl)N(CC(F)(F)F)[C@H]1CCNC1
2269,2276,CHEMBL127516,IUWVALYLNVXWKX-UHFFFAOYSA-N,BUTAMBEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC(=O)C1=CC=C(C=C1)N,CCCCOC(=O)c1ccc(N)cc1
2270,2277,CHEMBL127516,IUWVALYLNVXWKX-UHFFFAOYSA-N,BUTAMBEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC(=O)C1=CC=C(C=C1)N,CCCCOC(=O)c1ccc(N)cc1
2271,2278,CHEMBL702,IVBHGBMCVLDMKU-GXNBUGAJSA-N,PIPERACILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O
2272,2279,CHEMBL702,IVBHGBMCVLDMKU-GXNBUGAJSA-N,PIPERACILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O
2273,2280,CHEMBL247538,IVMHSWRHRXAZNE-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,968.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.014124642691606,CC1=C(C=CC=C1OC)CN([C@H]2CCNC2)C3CCOCC3,COc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1C
2274,2281,CHEMBL3310625,IWAFLTUMYXUBBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,48.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,48.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC=CC=C3,Fc1ccc(C(CC2CNC2)Oc2ccccc2)cc1F
2275,2282,CHEMBL1173341,IWEJGKHITDGZSV-CABZTGNLSA-N,1-PHENYL-3-AZABICYCLO[4.1.0]HEPTANE (STRUCTURAL MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.400007822415903,C1CNC[C@]2([C@@H]1C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CNCC[C@H]2C3)cc1Cl
2276,2283,CHEMBL1173341,IWEJGKHITDGZSV-CABZTGNLSA-N,1-PHENYL-3-AZABICYCLO[4.1.0]HEPTANE (STRUCTURAL MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.100015437450608,C1CNC[C@]2([C@@H]1C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CNCC[C@H]2C3)cc1Cl
2277,2284,CHEMBL1173341,IWEJGKHITDGZSV-CABZTGNLSA-N,1-PHENYL-3-AZABICYCLO[4.1.0]HEPTANE (STRUCTURAL MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.0,C1CNC[C@]2([C@@H]1C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CNCC[C@H]2C3)cc1Cl
2278,2285,CHEMBL1087923,IWHDPHKISOJDMA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,24.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,24.0,CNCCN1CC2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCCN1Cc2ccccc2N(c2ccccc2F)S1(=O)=O
2279,2286,CHEMBL229699,IWJUZLMNKAYNPQ-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,181.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.742321425130816,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)F)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(F)cc4)s2)N3C)cc1
2280,2287,CHEMBL229699,IWJUZLMNKAYNPQ-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,61.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.214670164989233,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)F)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(F)cc4)s2)N3C)cc1
2281,2288,CHEMBL1643,IWUCXVSUMQZMFG-AFCXAGJDSA-N,RIBAVIRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
2282,2289,CHEMBL1643,IWUCXVSUMQZMFG-AFCXAGJDSA-N,RIBAVIRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
2283,2290,CHEMBL258451,IWUJCJJESBVFNA-HNAYVOBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=C(CN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3)F,C#CCN(CC(=C)F)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
2284,2291,CHEMBL1517,IWVCMVBTMGNXQD-PXOLEDIWSA-N,OXYTETRACYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12
2285,2292,CHEMBL1517,IWVCMVBTMGNXQD-PXOLEDIWSA-N,OXYTETRACYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12
2286,2293,CHEMBL539716,IWVPGLLZAJONSB-UXHICEINSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,6.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C4CCC4)O,CNC[C@@H](O)[C@H](c1ccccc1)n1c(=O)n(C2CCC2)c2ccccc21
2287,2294,CHEMBL3287653,IWWHJVANFFIWSJ-GNFJTHHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24944746.0,INHIBITION,,,,Not Active,,cell_based,,,,,,,,,,,,"Inhibition of 2,5,6-[3H]-dopamine uptake at human DAT expressed in African green monkey COS7 cells at 10 uM incubated for 10 mins prior to radioligand addition measured after 5 mins by scintillation counting analysis",Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram.,ACS Med. Chem. Lett.,PUBLICATION,,,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCCN(C)CCC[C@@]5(C6=C(CO5)C=C(C=C6)C#N)C7=CC=C(C=C7)F)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCCN(C)CCC[C@@]4(c5ccc(F)cc5)OCc5cc(C#N)ccc54)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
2288,2295,CHEMBL383734,IWWHZPZRJFBBJV-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-41.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-41.0,CCC(CC)N(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CCC(CC)N(Cc1ccccc1C(F)(F)F)C1CCNCC1
2289,2296,CHEMBL1097146,IWXNUOQJTVYMHH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)(C(CN2CCNCC2)C3=CC=CS3)O,OC1(C(CN2CCNCC2)c2cccs2)CCCCC1
2290,2297,CHEMBL470078,IWYMWKSOTYKSEE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,0.0,CN1CCN(CC1)CC(C2=CC=C(C=C2)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(CC(c2ccc(F)cc2)C2(O)CCCCC2)CC1
2291,2298,CHEMBL1201237,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,LEVOBUNOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
2292,2299,CHEMBL1201237,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,LEVOBUNOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
2293,2300,CHEMBL198463,IXHFUNSVBJAYHP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16219465.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Inhibitory activity against DAT upto 10 uM,Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)SC3=C2C(=O)N(C=N3)CCN4CCN(CC4)C5=CC=NC6=CC=CC=C65,CN1CCc2c(sc3ncn(CCN4CCN(c5ccnc6ccccc56)CC4)c(=O)c23)C1
2294,2301,CHEMBL234128,IXOXSNBFVBNEKC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1050000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,2.9788107009300617,COC(=O)C1=C(CCCC1)C2=CC(=CC=C2)C(F)(F)F,COC(=O)C1=C(c2cccc(C(F)(F)F)c2)CCCC1
2295,2302,CHEMBL234128,IXOXSNBFVBNEKC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCC1)C2=CC(=CC=C2)C(F)(F)F,COC(=O)C1=C(c2cccc(C(F)(F)F)c2)CCCC1
2296,2303,CHEMBL88986,IXQQMWIAXLMOHP-GHBBCFCZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.0,COC(=O)[C@H]1[C@H](CC2CCC1O2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COC(=O)[C@@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)O2
2297,2304,CHEMBL327868,IXQQMWIAXLMOHP-GUMHCPJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,20300.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.692503962086787,COC(=O)[C@@H]1[C@H](CC2CCC1O2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COC(=O)[C@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)O2
2298,2305,CHEMBL88163,IXQQMWIAXLMOHP-NTFDOXNWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,520.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.2839966563652006,COC(=O)[C@H]1[C@@H](CC2CCC1O2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COC(=O)[C@@H]1C2CCC(C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)O2
2299,2306,CHEMBL89324,IXQQMWIAXLMOHP-TUNPWDSISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,22300.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.6516951369518384,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COC(=O)[C@H]1C2CCC(C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)O2
2300,2307,CHEMBL206521,IXXMPCPWTWLRBY-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,24.1,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,24.1,C1CO[C@@H](CN1)[C@@](CC2=CC=CC=C2Br)(C3=CC=CC=C3)O,O[C@](Cc1ccccc1Br)(c1ccccc1)[C@@H]1CNCCO1
2301,2308,CHEMBL1947092,IYCQCLWRGXVAAB-KKXYHZGYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,10.96,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.9601894458516504,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OCCC4=CC=CC=C4,CN1[C@H]2CC[C@@H]1[C@@H](C(=O)OCCc1ccccc1)[C@@H](c1ccc(Cl)c(Cl)c1)C2
2302,2309,CHEMBL1224400,IYHIZUCENFBTJG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.98,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CC(C)(C)CCC1(C(=O)c2ccc(Cl)c(Cl)c2)CCNC1
2303,2310,CHEMBL1224400,IYHIZUCENFBTJG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CC(C)(C)CCC1(C(=O)c2ccc(Cl)c(Cl)c2)CCNC1
2304,2311,CHEMBL633,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,AMIODARONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2505.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.601192269796735,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
2305,2312,CHEMBL633,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,AMIODARONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1990.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.7011469235902945,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
2306,2313,CHEMBL219540,IYNBYQDXVFMDGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,190.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.721246399047171,CC(=O)C(C1CCCCN1)C2=CC=CC=C2,CC(=O)C(c1ccccc1)C1CCCCN1
2307,2314,CHEMBL219540,IYNBYQDXVFMDGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.431798275933005,CC(=O)C(C1CCCCN1)C2=CC=CC=C2,CC(=O)C(c1ccccc1)C1CCCCN1
2308,2315,CHEMBL559147,IYOZTVGMEWJPKR-IJLUTSLNSA-N,Y-27632,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N,C[C@@H](N)C1CCC(C(=O)Nc2ccncc2)CC1
2309,2316,CHEMBL559147,IYOZTVGMEWJPKR-IJLUTSLNSA-N,Y-27632,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N,C[C@@H](N)C1CCC(C(=O)Nc2ccncc2)CC1
2310,2317,CHEMBL3317699,IYQPFLICRCNMTK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCCN(C(=O)C1)C2=CC(=C(C=C2)Cl)Cl.Cl,CN1CCCN(c2ccc(Cl)c(Cl)c2)C(=O)C1
2311,2318,CHEMBL1224225,IYTKIEQZFQYQAC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN(C)CCC(C1=CC2=C(C=C1)C=C(C=C2)F)N3N=CN=N3,CN(C)CCC(c1ccc2cc(F)ccc2c1)n1ncnn1
2312,2319,CHEMBL504231,IYTYICIRVUHWDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,58.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.236572006437062,C1CNCC1(CCC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CCC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
2313,2320,CHEMBL1818544,IYUTUTQAPBTSKQ-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,63.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.199970640755867,CC(C)C1=NN=NN1C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,CC(C)c1nnnn1C[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
2314,2321,CHEMBL288914,IYWFOWPCJVOCMB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.41,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.41,C1CN(CCN1CCCC2=CC=C(C=C2)F)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,Fc1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
2315,2322,CHEMBL288914,IYWFOWPCJVOCMB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.4,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.4,C1CN(CCN1CCCC2=CC=C(C=C2)F)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,Fc1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
2316,2323,CHEMBL603495,IYXFYMMSRUEOGZ-BHDTVMLSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,3.0,CCC1(CN(C2=CC=CC=C21)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O)CC.Cl,CCC1(CC)CN([C@@H](c2cccc(F)c2)[C@H](O)CNC)c2ccccc21
2317,2324,CHEMBL1743259,IZBNNCFOBMGTQX-UHFFFAOYSA-N,ETOPERIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC
2318,2325,CHEMBL1641696,IZDPHHLEXGFTPC-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,4627.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.334700500500103,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC(=CC=C2)N=[N+]=[N-])C3=CC(=CC=C3)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1Cc1cccc(N=[N+]=[N-])c1
2319,2326,CHEMBL1641696,IZDPHHLEXGFTPC-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,2056.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.686976889676763,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC(=CC=C2)N=[N+]=[N-])C3=CC(=CC=C3)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1Cc1cccc(N=[N+]=[N-])c1
2320,2327,CHEMBL932,IZEKFCXSFNUWAM-UHFFFAOYSA-N,DIPYRIDAMOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
2321,2328,CHEMBL932,IZEKFCXSFNUWAM-UHFFFAOYSA-N,DIPYRIDAMOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
2322,2329,CHEMBL562767,IZHREGYJHUWQHR-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,3.0,CC(C)(C)N1C2=CC=CC=C2N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1ccccc1)n1c(=O)n(C(C)(C)C)c2ccccc21
2323,2330,CHEMBL486042,IZIPWOZWZWBTMH-FOYRJYEQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,22.2,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.653647025549362,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=NO4)CC5=CC=C(C=C5)Cl)N3C.Cl,Cc1ccc([C@H]2CC3CCC([C@H]2c2cc(Cc4ccc(Cl)cc4)no2)N3C)cc1
2324,2331,CHEMBL470690,IZMZEMAKFSYLMD-KHQMHLGISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,4.09,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.388276691992656,CC1=CC=C(C=C1)C2=NOC(=C2)[C@H]3[C@H](CC4CCC3N4C)C5=CC=C(C=C5)Cl.Cl,Cc1ccc(-c2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)on2)cc1
2325,2332,CHEMBL2048523,IZOYCGRRBKQLEO-AYBRLQTHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,135.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.8696662315049934,CN(C)C(=O)[C@@H]1[C@H]2CC[C@H](N2CCC[18F])C[C@@H]1C3=CC=C(C=C3)Cl,CN(C)C(=O)[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2CCCF
2326,2333,CHEMBL466670,IZYQNPOIOLPIRC-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,10.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CN(C1=CC=CC=C1)[C@@H](C2=CC=C(C=C2)OC)[C@@H](CN)O,COc1ccc([C@@H]([C@H](O)CN)N(C)c2ccccc2)cc1
2327,2334,CHEMBL3310485,JAJZURBQJLCEQE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,35.6,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.448550002027125,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
2328,2335,CHEMBL3310485,JAJZURBQJLCEQE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
2329,2336,CHEMBL3310485,JAJZURBQJLCEQE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
2330,2337,CHEMBL3310485,JAJZURBQJLCEQE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
2331,2338,CHEMBL559081,JAKBXJLCBFHUQX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,270.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,CC1=NC=C(C=C1)C(C2CCNCC2)OC3=C(C(=CC=C3)Cl)Cl,Cc1ccc(C(Oc2cccc(Cl)c2Cl)C2CCNCC2)cn1
2332,2339,CHEMBL559081,JAKBXJLCBFHUQX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,590.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.229147988357856,CC1=NC=C(C=C1)C(C2CCNCC2)OC3=C(C(=CC=C3)Cl)Cl,Cc1ccc(C(Oc2cccc(Cl)c2Cl)C2CCNCC2)cn1
2333,2340,CHEMBL559081,JAKBXJLCBFHUQX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,820.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.086186147616282,CC1=NC=C(C=C1)C(C2CCNCC2)OC3=C(C(=CC=C3)Cl)Cl,Cc1ccc(C(Oc2cccc(Cl)c2Cl)C2CCNCC2)cn1
2334,2341,CHEMBL2397268,JAKRIQWSQWQJHM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23627311.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) at 5 uM by psychoactive drug screening programme assay,Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors.,J. Med. Chem.,PUBLICATION,,50.0,COC1=CC=C(C=C1)OCC2C3=C(CCN2C(=O)C4=CC(=CC=C4)Br)C=C(C=C3)OCC5=CC=CC=C5,COc1ccc(OCC2c3ccc(OCc4ccccc4)cc3CCN2C(=O)c2cccc(Br)c2)cc1
2335,2342,CHEMBL204005,JAPHVUWBEYMUCG-ZBEGNZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,540.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.267606240177032,CN[C@H]1CC[C@H](C2=C1C(=CC=C2)C(=O)O)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cccc(C(=O)O)c21
2336,2343,CHEMBL611960,JAUMZHMWXNWFKB-PYNNCUBPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,6.6,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.180456064458129,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NCCC4=CC=C(C=C4)NC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)Nc1ccc(CCNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)cc1)[C@@H](c1ccc(Cl)cc1)C2
2337,2344,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,3879.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.411280220399943,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
2338,2345,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,3082.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.5111673656176,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
2339,2346,CHEMBL565386,JBABGZDZOMSKLX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC(C(=O)C1=CC=CS1)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccs1
2340,2347,CHEMBL565386,JBABGZDZOMSKLX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC(C(=O)C1=CC=CS1)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccs1
2341,2348,CHEMBL565386,JBABGZDZOMSKLX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,>,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.0,CC(C(=O)C1=CC=CS1)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccs1
2342,2349,CHEMBL153479,JBDGDEWWOUBZPM-XYPYZODXSA-N,AMBROXOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,Nc1c(Br)cc(Br)cc1CNC1CCC(O)CC1
2343,2350,CHEMBL153479,JBDGDEWWOUBZPM-XYPYZODXSA-N,AMBROXOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,Nc1c(Br)cc(Br)cc1CNC1CCC(O)CC1
2344,2351,CHEMBL1381098,JBDOSUUXMYMWQH-UHFFFAOYSA-N,1-NAPHTHYLISOTHIOCYANATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC=C2N=C=S,S=C=Nc1cccc2ccccc12
2345,2352,CHEMBL1381098,JBDOSUUXMYMWQH-UHFFFAOYSA-N,1-NAPHTHYLISOTHIOCYANATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC=C2N=C=S,S=C=Nc1cccc2ccccc12
2346,2353,CHEMBL1433,JBIWCJUYHHGXTC-AKNGSSGZSA-N,DOXYCYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
2347,2354,CHEMBL1433,JBIWCJUYHHGXTC-AKNGSSGZSA-N,DOXYCYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
2348,2355,CHEMBL477573,JBTZQUNHYUVAIK-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2550.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5934598195660445,CS(=O)(=O)N(CC1=CC=CC=C1OC2=CC=CC=C2)[C@H]3CCNC3,CS(=O)(=O)N(Cc1ccccc1Oc1ccccc1)[C@H]1CCNC1
2349,2356,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
2350,2357,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
2351,2358,CHEMBL233088,JCGZOWXIYHYCOD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,515.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.288192770958808,COC(=O)C1=C(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCCCC1
2352,2359,CHEMBL233088,JCGZOWXIYHYCOD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1360.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.866461091629782,COC(=O)C1=C(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCCCC1
2353,2360,CHEMBL3238480,JCIKAQSOEASANV-IWIPYMOSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1C(=O)O)C(F)(F)F)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(C(=O)O)cc3C(F)(F)F)c(O)c12
2354,2361,CHEMBL515,JCKYGMPEJWAADB-UHFFFAOYSA-N,CHLORAMBUCIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
2355,2362,CHEMBL515,JCKYGMPEJWAADB-UHFFFAOYSA-N,CHLORAMBUCIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
2356,2363,CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=NN2N,Nn1nnc2ccccc21
2357,2364,CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=NN2N,Nn1nnc2ccccc21
2358,2365,CHEMBL1812545,JDBSZVDIUIRSDG-DAFODLJHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21726069.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DA transporter at 10 uM relative to control,"Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.",J. Med. Chem.,PUBLICATION,,10.0,C1=CC2=C(C=C1F)NC=C2/C=C/C3=NNN=N3,Fc1ccc2c(/C=C/c3nn[nH]n3)c[nH]c2c1
2359,2366,CHEMBL3703748,JDEHEODNVULATB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,8.67778070526608,CC1(C2=C(C=CC(=C2)C3=CN4C(=NC=N4)C=C3)C(CN1)C5=CC(=C(C=C5)Cl)Cl)C,CC1(C)NCC(c2ccc(Cl)c(Cl)c2)c2ccc(-c3ccc4ncnn4c3)cc21
2360,2367,CHEMBL1643899,JDFBBZLNLYXHDC-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,3443.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK cell membranes,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.463062977295326,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC(=CC=C6)F,Fc1cccc(CN[C@H]2C3C4CC5C6C4CC3C6C52)c1
2361,2368,CHEMBL1643899,JDFBBZLNLYXHDC-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,3443.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.463062977295326,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC(=CC=C6)F,Fc1cccc(CN[C@H]2C3C4CC5C6C4CC3C6C52)c1
2362,2369,CHEMBL3334798,JDOZNEHOYKLUQH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,602.1,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.220331372792853,CN(C)CCC(C1=CC(=C(C=C1)Cl)Cl)N2CCCCC2,CN(C)CCC(c1ccc(Cl)c(Cl)c1)N1CCCCC1
2363,2370,CHEMBL194960,JDYWZWHJMGYGFK-SKDRFNHKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=CC(=C3)F,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2cc(F)ccc12
2364,2371,CHEMBL1078074,JEEXCFPOFSQJAA-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)F)C(F)(F)F,CC(C)CN(C(=O)c1cccc(F)c1C(F)(F)F)[C@H]1CCNC1
2365,2372,CHEMBL229436,JERGWFJDGWCPDJ-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,197.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.705533773838407,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)[N+](=O)[O-])N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc([N+](=O)[O-])cc4)s2)N3C)cc1
2366,2373,CHEMBL229436,JERGWFJDGWCPDJ-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,140.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.853871964321763,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)[N+](=O)[O-])N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc([N+](=O)[O-])cc4)s2)N3C)cc1
2367,2374,CHEMBL552341,JEUQNCNSWGGZRH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,25.12,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,C1CNCCC1N(CC2=CC(=CC=C2)S(=O)(=O)N)C3=CC4=C(C=C3)NC=C4,NS(=O)(=O)c1cccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)c1
2368,2375,CHEMBL403251,JEYCKWDBZTXTRQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,4350.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.361510743045363,CCC1=C(C=CC(=C1)Cl)OC2=C(C=NC(=C2)C)CNC,CCc1cc(Cl)ccc1Oc1cc(C)ncc1CNC
2369,2376,CHEMBL403251,JEYCKWDBZTXTRQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,34100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.467245621007502,CCC1=C(C=CC(=C1)Cl)OC2=C(C=NC(=C2)C)CNC,CCc1cc(Cl)ccc1Oc1cc(C)ncc1CNC
2370,2377,CHEMBL1808433,JEZVWAQXXDFILV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21724392.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 0.5 uM,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN1CC(=C(C1)Cl)C2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=CC=C4Br,COc1ccc2c(c1)c(C1=C(Cl)CN(C)C1)cn2S(=O)(=O)c1ccccc1Br
2371,2378,CHEMBL1170213,JFCGNEFWNWVNQD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,316.23,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,CCOCC1CNCCN1C2=CC3=C(C=C2)NN=C3,CCOCC1CNCCN1c1ccc2[nH]ncc2c1
2372,2379,CHEMBL2430700,JFHFWAQIJRRGSM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,159.7,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.796695083861518,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC=C(C=C4)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc2ccccc2c1
2373,2380,CHEMBL2430700,JFHFWAQIJRRGSM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,91.6,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,91.6,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC=C(C=C4)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc2ccccc2c1
2374,2381,CHEMBL2430700,JFHFWAQIJRRGSM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,97.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,97.0,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC=C(C=C4)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccc2ccccc2c1
2375,2382,CHEMBL290106,JFIOVJDNOJYLKP-UHFFFAOYSA-N,BITHIONOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2181.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.661344334421298,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
2376,2383,CHEMBL290106,JFIOVJDNOJYLKP-UHFFFAOYSA-N,BITHIONOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1733.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.761201437286083,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
2377,2384,CHEMBL47210,JFUNLJPTPCQLIR-DUHSPSEUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11425531.0,IC50,=,1.4,NM,,,cell_based,,,,,,,,,,,,Ability to inhibit human dopamine uptake by the human dopamine transporter in EM4 cells stably infected with Flag HA-hDAT,[3H]MFZ 2-12: a novel radioligand for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,COC(=O)[C@H]1[C@H](CC2CCC1N2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N2
2378,2385,CHEMBL169471,JFUNLJPTPCQLIR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,0.66,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,9.18045606445813,COC(=O)C1C2CCC(N2)CC1C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)c(Cl)c1)N2
2379,2386,CHEMBL3309701,JFZWFXQVYNCLJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,53.6,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.270835210307231,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3F,Fc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
2380,2387,CHEMBL3309701,JFZWFXQVYNCLJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,77.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,77.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3F,Fc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
2381,2388,CHEMBL3309701,JFZWFXQVYNCLJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3F,Fc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
2382,2389,CHEMBL3309701,JFZWFXQVYNCLJA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3F,Fc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(Cl)c1
2383,2390,CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
2384,2391,CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
2385,2392,CHEMBL1644608,JGPRTHDFGZBWFN-IZZQQSIFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,8066.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.093341782328401,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=C3)C4=CC=CC=C4C#N,N#Cc1ccccc1-c1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
2386,2393,CHEMBL29,JGSARLDLIJGVTE-MBNYWOFBSA-N,BENZYLPENICILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O
2387,2394,CHEMBL29,JGSARLDLIJGVTE-MBNYWOFBSA-N,BENZYLPENICILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O
2388,2395,CHEMBL419728,JGWXNVMXDBFNMX-KRCSLNALSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,44.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.356547323513813,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC4C2[C@](CN34)(C5=CC=C(C=C5)Cl)O,Cc1ccc([C@H]2C[C@H]3CCC4C2[C@@](O)(c2ccc(Cl)cc2)CN43)cc1
2389,2396,CHEMBL542746,JGYZGTZUFGVWMT-YYLIZZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,24000.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.619788758288394,C1=CC=C(C=C1)[C@H](CN)[C@H](C2=CC=CC=C2)O.Cl,NC[C@@H](c1ccccc1)[C@@H](O)c1ccccc1
2390,2397,CHEMBL2047564,JGZNMAIDTSSPBU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,30.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,30.0,CC1=CC=C(C=C1)C(CCN2CCC(=CC2)CC3=CC=CC=C3)O,Cc1ccc(C(O)CCN2CC=C(Cc3ccccc3)CC2)cc1
2391,2398,CHEMBL1224161,JHBXYVBNWXENQD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,63.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CC(CNC1)(CC2=CC=CC=C2)C(=O)C3=CC4=C(C=C3)NC=C4,O=C(c1ccc2[nH]ccc2c1)C1(Cc2ccccc2)CCCNC1
2392,2399,CHEMBL3126751,JHCKOEJURUJMLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24494745.0,KI,=,3700.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to wild type human DAT expressed in African green monkey COS7 cells assessed as inhibition of [3H]-dopamine uptake after 5 mins by beta-scintillation counting analysis,Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues.,J. Med. Chem.,PUBLICATION,,5.431798275933005,CNC(=O)CSC(C1=CC=C(C=C1)Cl)C2=CC=C(C=C2)Cl,CNC(=O)CSC(c1ccc(Cl)cc1)c1ccc(Cl)cc1
2393,2400,CHEMBL2432056,JHFKLSFCMAHSDK-LLOIJXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CC1=CC(=C(C=C1)OC)OC)[C@H]2C3C4CC5C2C6C3CC4C56,COc1ccc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc1OC
2394,2401,CHEMBL2012088,JHGBEMIRZAHFKB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=NC4=CC=CC=C4O3,COC(=O)C1=C(c2nc3ccccc3o2)CC2CCC1O2
2395,2402,CHEMBL2012088,JHGBEMIRZAHFKB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=NC4=CC=CC=C4O3,COC(=O)C1=C(c2nc3ccccc3o2)CC2CCC1O2
2396,2403,CHEMBL1643656,JHGFPQGHZNDWJN-KKZFSKEWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,101.3,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.994390554639718,CC1=NOC(=C1)[C@H]2[C@@H](CC3CCC2S3)C4=CC(=C(C=C4)Cl)Cl,Cc1cc([C@@H]2C3CCC(C[C@H]2c2ccc(Cl)c(Cl)c2)S3)on1
2397,2404,CHEMBL1643666,JHGFPQGHZNDWJN-LOGSSTAJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,43.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.361510743045362,CC1=NOC(=C1)[C@H]2[C@H](CC3CCC2S3)C4=CC(=C(C=C4)Cl)Cl,Cc1cc([C@@H]2C3CCC(C[C@@H]2c2ccc(Cl)c(Cl)c2)S3)on1
2398,2405,CHEMBL469459,JHIFTPLQHSGJLO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,4.0,CN1CCN(CC1)CC(C2=CC(=CC=C2)OC)C3(CCCCC3)O.Cl.Cl,COc1cccc(C(CN2CCN(C)CC2)C2(O)CCCCC2)c1
2399,2406,CHEMBL255957,JHJNQSMDFYVXBO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,5950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.22548303427145,CNCC1=CC=CC=C1OC2=C(C=C(C=C2)OC)Cl,CNCc1ccccc1Oc1ccc(OC)cc1Cl
2400,2407,CHEMBL1947091,JHKFTIBAMCJBQD-MLHJIOFPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CCCC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C,CCCc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)cc1
2401,2408,CHEMBL576758,JHNQGHUWSOJCOC-UXHICEINSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CCC1=CN(C2=CC=CC=C21)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CCc1cn([C@@H](c2cccc(F)c2)[C@H](O)CNC)c2ccccc12
2402,2409,CHEMBL334576,JHOCWSUEYIATGH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,67.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.173277479831008,CC1=CC(=C2C(=C1)C3=NCCN3C2(C4=CC=C(C=C4)Cl)O)C,Cc1cc(C)c2c(c1)C1=NCCN1C2(O)c1ccc(Cl)cc1
2403,2410,CHEMBL185169,JHRMJWNPQRPXKB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.698970004336019,COC(=O)C1=C(CC2CCC1O2)C3=CC4=CC=CC=C4C=C3,COC(=O)C1=C(c2ccc3ccccc3c2)CC2CCC1O2
2404,2411,CHEMBL125017,JHZOGWJGKSOSOG-WVEVRRLPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,33.5,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.4749551929631535,CN1C2CCC1C([C@H](C2)OC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccccc1)c1ccccc1)N2C
2405,2412,CHEMBL1200679,JIAARYAFYJHUJI-UHFFFAOYSA-L,ZINC CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,[Cl-].[Cl-].[Zn+2],[Zn+2]
2406,2413,CHEMBL1200679,JIAARYAFYJHUJI-UHFFFAOYSA-L,ZINC CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,[Cl-].[Cl-].[Zn+2],[Zn+2]
2407,2414,CHEMBL493027,JIIHYINDBVZYIB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=CC=C(C=C2)C(F)(F)F,CN(C)Cc1ccccc1Sc1ccc(C(F)(F)F)cc1
2408,2415,CHEMBL325669,JIMSUICOCSIKLE-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,353000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter; Average of two experiments,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.4522252946121776,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3OC)O,CNCC[C@H](Oc1cccc2c(OC)c(O)ccc12)c1cccs1
2409,2416,CHEMBL396318,JINIYXOBIKXUET-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,3780.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.422508200162776,COC(=O)C1=C(CCCCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCCCC1
2410,2417,CHEMBL396318,JINIYXOBIKXUET-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,22000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.657577319177793,COC(=O)C1=C(CCCCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCCCC1
2411,2418,CHEMBL2012103,JIQLOBNPZMPPDO-GRAKBVBRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=C(C=C3)C4=NC=CS4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3nccs3)cc1)O2
2412,2419,CHEMBL2012103,JIQLOBNPZMPPDO-GRAKBVBRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=C(C=C3)C4=NC=CS4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3nccs3)cc1)O2
2413,2420,CHEMBL512551,JIQNPRNQHOWEMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.420216403383191,CCOC(=O)C1=CC2=C(N1)C=CC(=C2)C3(CCNC3)CC4=CC=CC=C4,CCOC(=O)c1cc2cc(C3(Cc4ccccc4)CCNC3)ccc2[nH]1
2414,2421,CHEMBL187695,JIRFQBTTXOAYCT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,9.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.040958607678906,COC(=O)C1=C(CC2CCC1S2)C3=CC=C(C=C3)Br,COC(=O)C1=C(c2ccc(Br)cc2)CC2CCC1S2
2415,2422,CHEMBL336940,JIVIBEFNFXNPFI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,4.75,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.323306390375134,COC1=CC=CC2=C1C3=NCCN3C2(C4=CC=C(C=C4)Cl)O,COc1cccc2c1C1=NCCN1C2(O)c1ccc(Cl)cc1
2416,2423,CHEMBL336940,JIVIBEFNFXNPFI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,42.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.376750709602098,COC1=CC=CC2=C1C3=NCCN3C2(C4=CC=C(C=C4)Cl)O,COc1cccc2c1C1=NCCN1C2(O)c1ccc(Cl)cc1
2417,2424,CHEMBL336940,JIVIBEFNFXNPFI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,2.9,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.537602002101043,COC1=CC=CC2=C1C3=NCCN3C2(C4=CC=C(C=C4)Cl)O,COc1cccc2c1C1=NCCN1C2(O)c1ccc(Cl)cc1
2418,2425,CHEMBL1055,JIVPVXMEBJLZRO-UHFFFAOYSA-N,CHLORTHALIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl
2419,2426,CHEMBL1055,JIVPVXMEBJLZRO-UHFFFAOYSA-N,CHLORTHALIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl
2420,2427,CHEMBL104673,JJAUMTXFZLAGOI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956218.0,KI,=,2038.0,NM,,,,,,,,,,,,,,,In vitro binding affinity on cloned Dopamine transporter,"Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.",J. Med. Chem.,PUBLICATION,,5.690795820329592,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)C(F)(F)F)N,CN(C)Cc1ccccc1Sc1ccc(C(F)(F)F)cc1N
2421,2428,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
2422,2429,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
2423,2430,CHEMBL511950,JJFAOKMTNYBVNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,6.5,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.187086643357143,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC(=O)CC4=CC=CC=C4,O=C(Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
2424,2431,CHEMBL326263,JJKPSOUEWPDPFS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,996.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.001740661576301,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)C#N,N#Cc1ccc(CCOC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2425,2432,CHEMBL378379,JJMNVQSTRSYLOB-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,450.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.346787486224656,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)C(=O)NC)C3=CC(=C(C=C3)Cl)Cl,CNC(=O)c1ccc2c(c1)[C@@H](NC)CC[C@H]2c1ccc(Cl)c(Cl)c1
2426,2433,CHEMBL2030627,JJTSIVODPMDGBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CC2CCC1N2CCC3=CC=CC=C3,c1ccc(CCN2C3CCC2CC3)cc1
2427,2434,CHEMBL3593398,JJVNHIVTHFANPP-KATIXKQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CNC(=O)[C@@H]1CNCCO[C@H]1C2=CC(=C(C=C2)Cl)Cl.Cl,CNC(=O)[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1
2428,2435,CHEMBL406156,JJVUOKFSHYKOJS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CNC(C2=CC=CC=C21)C(=O)C3(CC3CNC(=O)CN)C4=CC=CC=C4,NCC(=O)NCC1CC1(C(=O)C1NCCc2ccccc21)c1ccccc1
2429,2436,CHEMBL493476,JKBJIWKBKAEYBB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,1800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,CN(C)CC1=CC=CC=C1C(C2=CC(=C(C=C2)Cl)Cl)O,CN(C)Cc1ccccc1C(O)c1ccc(Cl)c(Cl)c1
2430,2437,CHEMBL1006,JKOQGQFVAUAYPM-UHFFFAOYSA-N,AMIFOSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CN)CNCCSP(=O)(O)O,NCCCNCCSP(=O)(O)O
2431,2438,CHEMBL1006,JKOQGQFVAUAYPM-UHFFFAOYSA-N,AMIFOSTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CN)CNCCSP(=O)(O)O,NCCCNCCSP(=O)(O)O
2432,2439,CHEMBL1684043,JKRXUDRMEIXFBV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,29.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.5376020021010435,CCC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N,CCC(N)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
2433,2440,CHEMBL1083211,JLHRDEJKVFNGBV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,25.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,25.0,CNCCCCN1CC2=C(C=CC(=C2)F)N(S1(=O)=O)C3=CC=CC=C3F,CNCCCCN1Cc2cc(F)ccc2N(c2ccccc2F)S1(=O)=O
2434,2441,CHEMBL443,JLKIGFTWXXRPMT-UHFFFAOYSA-N,SULFAMETHOXAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
2435,2442,CHEMBL443,JLKIGFTWXXRPMT-UHFFFAOYSA-N,SULFAMETHOXAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
2436,2443,CHEMBL470082,JLLXWYHRIUISMQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,4.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CC(=CC=C3)C(F)(F)F)O.Cl.Cl,OC1(C(CN2CCNCC2)c2cccc(C(F)(F)F)c2)CCCCC1
2437,2444,CHEMBL1083707,JLTIELDULXFJCW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,3160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,C1COC2=C1C=CC=C2CC(C3=CC=CC=C3)N4CCNCC4,c1ccc(C(Cc2cccc3c2OCC3)N2CCNCC2)cc1
2438,2445,CHEMBL599608,JLWSMMAHZFKYJR-URBRKQAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,8.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2CCC3=CC=CC=C32)O.Cl,CNC[C@@H](O)[C@H](c1ccccc1)N1CCc2ccccc21
2439,2446,CHEMBL332506,JMAILUWJFFEWNB-XWTATZQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,6030.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,5.219682687859849,CN1C2CCC1C([C@H](C2)OC3C4=CC=CC=C4C5=CC=CC=C35)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC1c3ccccc3-c3ccccc31)N2C
2440,2447,CHEMBL194205,JMCFSRJDUZTPRD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,10.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC1(CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccccc2)C1=O
2441,2448,CHEMBL194205,JMCFSRJDUZTPRD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1(CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccccc2)C1=O
2442,2449,CHEMBL411033,JMLINUIVZHMJBT-GCZMORHFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,C1[C@H]([C@@]1(C2=CC3=C(C=C2)OCO3)C(=O)C4C5=CC=CC=C5CN4)CN,NC[C@@H]1C[C@@]1(C(=O)C1NCc2ccccc21)c1ccc2c(c1)OCO2
2443,2450,CHEMBL500629,JMOZPPPEEGAIOO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=C(C=CC(=C1)S(=O)(=O)N)SC2=CC=C(C=C2)C(F)(F)F,CN(C)Cc1cc(S(N)(=O)=O)ccc1Sc1ccc(C(F)(F)F)cc1
2444,2451,CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,4800.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.318758762624412,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O
2445,2452,CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,3800.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.420216403383191,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O
2446,2453,CHEMBL498482,JMYADEOPJFRDDM-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C(=CC=C1)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC)C,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1cccc(C)c1C
2447,2454,CHEMBL498120,JMYADEOPJFRDDM-RTBURBONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,2600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,CC1=C(C(=CC=C1)O[C@H]2[C@H](OCC3=CC=CC=C23)CNC)C,CNC[C@H]1OCc2ccccc2[C@H]1Oc1cccc(C)c1C
2448,2455,CHEMBL478833,JNLWAWMHYQYRKA-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,3500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,CC(C)C(=O)N(CC1=CC=CC=C1OC2=CC=CC=C2)[C@H]3CCNC3,CC(C)C(=O)N(Cc1ccccc1Oc1ccccc1)[C@H]1CCNC1
2449,2456,CHEMBL605209,JNLXUEPMJIMNHM-JMSVASOKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,5.01,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.300162274132754,CC(C)OC[C@@H]1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CC(C)OC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1
2450,2457,CHEMBL602235,JNLXUEPMJIMNHM-SLEUVZQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,7.94,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.100179497572904,CC(C)OC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CC(C)OC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
2451,2458,CHEMBL602235,JNLXUEPMJIMNHM-SLEUVZQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,251.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.599997654072044,CC(C)OC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CC(C)OC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
2452,2459,CHEMBL437,JNMRHUJNCSQMMB-UHFFFAOYSA-N,SULFATHIAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
2453,2460,CHEMBL437,JNMRHUJNCSQMMB-UHFFFAOYSA-N,SULFATHIAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
2454,2461,CHEMBL1540,JNTOCHDNEULJHD-UHFFFAOYSA-N,PENCICLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2CCC(CO)CO)c(=O)[nH]1
2455,2462,CHEMBL1540,JNTOCHDNEULJHD-UHFFFAOYSA-N,PENCICLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2CCC(CO)CO)c(=O)[nH]1
2456,2463,CHEMBL205025,JNVMCWLQXGNYMA-JCOPYZAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,0.9,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,9.045757490560677,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC[C@@H](C4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@@H](CCN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
2457,2464,CHEMBL383682,JNVMCWLQXGNYMA-LNLSOMNWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,0.8,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,9.096910013008056,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC[C@H](C4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@H](CCN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
2458,2465,CHEMBL1945248,JNVOFPVDNOCHFN-HZMVEIRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,14.13,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.849857838151442,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CC#C)C[C@@H]1C3=CC=C(C=C3)I,C#CCN1[C@H]2CC[C@@H]1[C@@H](C(=O)OC)[C@@H](c1ccc(I)cc1)C2
2459,2466,CHEMBL132955,JOBHARMVZDXCRY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,6.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.221848749616356,C1CN2C(=N1)C3=CC(=C(C=C3C2(C4=CC=C(C=C4)Cl)O)Cl)Cl,OC1(c2ccc(Cl)cc2)c2cc(Cl)c(Cl)cc2C2=NCCN21
2460,2467,CHEMBL132955,JOBHARMVZDXCRY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,1.05,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.978810700930062,C1CN2C(=N1)C3=CC(=C(C=C3C2(C4=CC=C(C=C4)Cl)O)Cl)Cl,OC1(c2ccc(Cl)cc2)c2cc(Cl)c(Cl)cc2C2=NCCN21
2461,2468,CHEMBL507806,JOHKRZVJVWMMNT-LRDDRELGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.0,C=CCN(CC1=NC=CS1)C(=O)[C@]2(C[C@H]2CN)C3=CC=CS3,C=CCN(Cc1nccs1)C(=O)[C@@]1(c2cccs2)C[C@H]1CN
2462,2469,CHEMBL322067,JOQQHMGSIKNGAF-HLFYOVGASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,28.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.552841968657781,CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl,CN(C)C[C@@H]1C2CCC(CC2)[C@@H]1c1ccc(Cl)c(Cl)c1
2463,2470,CHEMBL322067,JOQQHMGSIKNGAF-HLFYOVGASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,7.2,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.142667503568731,CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl,CN(C)C[C@@H]1C2CCC(CC2)[C@@H]1c1ccc(Cl)c(Cl)c1
2464,2471,CHEMBL173861,JOQQHMGSIKNGAF-NXDIHJKXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,7.2,NM,,,,,,,,,,,,,,,Inhibition of DAT,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.142667503568731,CN(C)C[C@@H]1[C@@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl,CN(C)C[C@H]1C2CCC(CC2)[C@H]1c1ccc(Cl)c(Cl)c1
2465,2472,CHEMBL523146,JOQTYFCRRMFQJX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18782666.0,IC50,>,10.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CN(C)CC1=C(C=CC(=C1)S(=O)(=O)N)OC2=CC=C(C=C2)S(=O)C,CN(C)Cc1cc(S(N)(=O)=O)ccc1Oc1ccc([S+](C)[O-])cc1
2466,2473,CHEMBL1224468,JORAUIMOUGISHQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,-21.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-21.0,CNCCC(C1=CC2=C(C=C1)C=C(C=C2)Cl)N3N=CN=N3,CNCCC(c1ccc2cc(Cl)ccc2c1)n1ncnn1
2467,2474,CHEMBL462547,JOYRKODLDBILNP-UHFFFAOYSA-N,URETHANE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N,CCOC(N)=O
2468,2475,CHEMBL462547,JOYRKODLDBILNP-UHFFFAOYSA-N,URETHANE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N,CCOC(N)=O
2469,2476,CHEMBL2207497,JPFBKWSBTOFTQU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23043306.0,INHIBITION,=,47.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DAT at 1 uM by CEREP assay,Systematic in Vivo Screening of a Series of 1-Propyl-4-arylpiperidines against Dopaminergic and Serotonergic Properties in Rat Brain: A Scaffold-Jumping Approach.,J. Med. Chem.,PUBLICATION,,47.0,CCCN1CCC(CC1)C2=CC3=CC=CC=C3C=C2,CCCN1CCC(c2ccc3ccccc3c2)CC1
2470,2477,CHEMBL3331499,JPHAIBIWRGTSEQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,16.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,16.0,C1CCC(CC1)N(CC2CNC2)CC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(CN(CC2CNC2)C2CCCCC2)cc1Cl
2471,2478,CHEMBL270366,JPMSOQZFFUMLIX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,1520.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.818156412055227,CC1=CC=CC=C1OC2=C(C=NC(=C2)C)CNC,CNCc1cnc(C)cc1Oc1ccccc1C
2472,2479,CHEMBL375179,JPMUIXQMIUSQNQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784853.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at dopamine transporter,High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CN(CCN1CCCC2=CC=C(C=C2)NC(=O)CCCCCCCCCCS)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,O=C(CCCCCCCCCCS)Nc1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
2473,2480,CHEMBL457655,JPRQFPVEGGQSSX-CLDCJMNLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,6.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,8.221848749616356,CC(=O)NC1=CC=C(C=C1)CCOC(=O)[C@@H]2[C@H]3CC[C@@H](N3C)C[C@@H]2C4=CC=C(C=C4)OC.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OCCc2ccc(NC(C)=O)cc2)N3C)cc1
2474,2481,CHEMBL1940404,JPTSMZMSIACDAD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCOC3=CC=C(C=C3)F,OC1(c2ccc(Cl)cc2)CCN(CCCOc2ccc(F)cc2)CC1
2475,2482,CHEMBL560049,JPUDXOCAZQSFHB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNCCC1C(C2=CN=CC=C2)OC3=C(C(=CC(=C3)Cl)Cl)Cl,Clc1cc(Cl)c(Cl)c(OC(c2cccnc2)C2CCNCC2)c1
2476,2483,CHEMBL3238476,JQKHFSNAKJULNT-PGMHBOJBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,CC1=C(C=CC(=C1)C(=O)O)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Cc1cc(C(=O)O)ccc1N=Nc1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
2477,2484,CHEMBL569699,JQNSRSIGKZYQAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,2310.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.636388020107857,CC(C(=O)C1=CC=CC=C1)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccccc1
2478,2485,CHEMBL569699,JQNSRSIGKZYQAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,5730.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.24184537803261,CC(C(=O)C1=CC=CC=C1)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccccc1
2479,2486,CHEMBL386223,JQQRBSOAFDAWGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC(=CC=C2)C#N)C3=CC=CC=C3,N#Cc1cccc(CC(c2ccccc2)N2CCNCC2)c1
2480,2487,CHEMBL1818462,JQQXRQMPNKINQO-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.199970640755867,CC(C)(C)C1=NN(C=C1)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,CC(C)(C)c1ccn(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
2481,2488,CHEMBL1885748,JQSJAVBMIMDUFO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23642479.0,INHIBITION,=,78.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 10 uM relative to control,Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.,Bioorg. Med. Chem. Lett.,PUBLICATION,,78.0,C1OC2=C(O1)C=C(C=C2)C3=CN=CN=C3NCC4=CC(=CC(=C4)Cl)Cl,Clc1cc(Cl)cc(CNc2ncncc2-c2ccc3c(c2)OCO3)c1
2482,2489,CHEMBL3334793,JQUXSYNGQWDWDG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,66.8,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,66.8,CN(C)CCC(C1=CC2=CC=CC=C2S1)N3CCOCC3,CN(C)CCC(c1cc2ccccc2s1)N1CCOCC1
2483,2490,CHEMBL374478,JQXXHWHPUNPDRT-WLSIYKJHSA-N,RIFAMPICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
2484,2491,CHEMBL374478,JQXXHWHPUNPDRT-WLSIYKJHSA-N,RIFAMPICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
2485,2492,CHEMBL202410,JREHJCKVQXOMFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,55.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.259637310505756,CC1=CC=C(C=C1)C(=O)C(CC=C)N2CCCC2,C=CCC(C(=O)c1ccc(C)cc1)N1CCCC1
2486,2493,CHEMBL202410,JREHJCKVQXOMFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,90.5,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.0433514207947985,CC1=CC=C(C=C1)C(=O)C(CC=C)N2CCCC2,C=CCC(C(=O)c1ccc(C)cc1)N1CCCC1
2487,2494,CHEMBL3663915,JRMIJYKTHQCXEO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,>,1000.0,NM,314448,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.0,CN1CC(C2=CC=CC=C2C1)C3=C(C4=C(C=C3)SC=C4)OC,COc1c(C2CN(C)Cc3ccccc32)ccc2sccc12
2488,2495,CHEMBL260039,JRNAGNLSMXSNPN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=N1)CNC)OC2=C(C=C(C=C2)F)C,CNCc1cnc(C)cc1Oc1ccc(F)cc1C
2489,2496,CHEMBL334596,JRNGIVHBMLVCBM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,390.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.4089353929735005,C1CN2C(=N1)C3=C(C=CC=C3C2(C4=CC=C(C=C4)Cl)O)C5=CC=CC=C5,OC1(c2ccc(Cl)cc2)c2cccc(-c3ccccc3)c2C2=NCCN21
2490,2497,CHEMBL578610,JRPWUGPYWRJACU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC(C(=O)C1=CC(=C(C=C1)F)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(F)c(F)c1
2491,2498,CHEMBL578610,JRPWUGPYWRJACU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC(C(=O)C1=CC(=C(C=C1)F)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(F)c(F)c1
2492,2499,CHEMBL578610,JRPWUGPYWRJACU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,7978.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.09810596802618,CC(C(=O)C1=CC(=C(C=C1)F)F)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(F)c(F)c1
2493,2500,CHEMBL3323104,JRUNWUCFSINWFW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,23.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.638272163982407,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)NN=C4,CN1Cc2ccccc2C(c2ccc3[nH]ncc3c2)C1
2494,2501,CHEMBL3323104,JRUNWUCFSINWFW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,29.4,NM,314455,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.531652669587842,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)NN=C4,CN1Cc2ccccc2C(c2ccc3[nH]ncc3c2)C1
2495,2502,CHEMBL926,JRWZLRBJNMZMFE-UHFFFAOYSA-N,DOBUTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,155.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.809668301829707,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1
2496,2503,CHEMBL926,JRWZLRBJNMZMFE-UHFFFAOYSA-N,DOBUTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,123.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.910094888560603,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1
2497,2504,CHEMBL1592,JSDRRTOADPPCHY-HSQYWUDLSA-N,QUINAPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
2498,2505,CHEMBL1592,JSDRRTOADPPCHY-HSQYWUDLSA-N,QUINAPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
2499,2506,CHEMBL566586,JSKNQLMFNCOKRW-PMACEKPBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)NC[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CC(C)NC[C@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
2500,2507,CHEMBL206211,JSMCJJAIEPJIIJ-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,120.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)(=O)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(C)(=O)=O)cc21
2501,2508,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
2502,2509,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
2503,2510,CHEMBL1078312,JSYQQBKBYKJHAO-VIFPVBQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,1090.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.962573502059376,CCN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CCN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
2504,2511,CHEMBL198215,JTBUWXHKRDNJAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,,,,Not Determined,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter; ND= not determined,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=C(C=C1)N2C3=C(CC(C2=O)(C)CCCNC)C=C(C=C3)Cl,CNCCCC1(C)Cc2cc(Cl)ccc2N(c2ccc(C)cc2)C1=O
2505,2512,CHEMBL411921,JTCQOAITNDJYSA-HKUYNNGSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1COC2=C1C=CC=C2O[C@H]([C@@H]3CNCCO3)C4=CC=CC=C4,c1ccc([C@H](Oc2cccc3c2OCC3)[C@@H]2CNCCO2)cc1
2506,2513,CHEMBL258930,JTCQOAITNDJYSA-IEBWSBKVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,5750.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2403321553103694,C1COC2=C1C=CC=C2O[C@@H]([C@H]3CNCCO3)C4=CC=CC=C4,c1ccc([C@@H](Oc2cccc3c2OCC3)[C@H]2CNCCO2)cc1
2507,2514,CHEMBL545557,JTDIXQXYTWHVIP-IDVLALEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,27000.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.568636235841012,CC(C)(C)[C@@H]([C@@H](CN)C1=CC2=CC=CC=C2C=C1)O.Cl,CC(C)(C)[C@H](O)[C@@H](CN)c1ccc2ccccc2c1
2508,2515,CHEMBL260036,JTDKALUSBWIJPG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,2430.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.614393726401689,CN(C)CC1=C(C=CN=C1)OC2=C(C=C(C=C2)Cl)Cl,CN(C)Cc1cnccc1Oc1ccc(Cl)cc1Cl
2509,2516,CHEMBL141,JTEGQNOMFQHVDC-NKWVEPMBSA-N,LAMIVUDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1
2510,2517,CHEMBL141,JTEGQNOMFQHVDC-NKWVEPMBSA-N,LAMIVUDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1
2511,2518,CHEMBL515936,JTFGLXWULCGHRY-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2760.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.559090917934784,CCS(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CCS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
2512,2519,CHEMBL505431,JTGBYRRUQUQVJF-UFADHCMUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,=,3556.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,5.449038247701823,COC1=C(C=C(C=C1)F)CCC2CCC(O2)CCNCCCCCN3C(=O)[C@@H]4CC=CC[C@@H]4C(=N3)C5=CC(=C(C=C5)OC)OC,COc1ccc(F)cc1CCC1CCC(CCNCCCCCN2N=C(c3ccc(OC)c(OC)c3)[C@H]3CC=CC[C@H]3C2=O)O1
2513,2520,CHEMBL505431,JTGBYRRUQUQVJF-UFADHCMUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,=,2478.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,5.6058986979599545,COC1=C(C=C(C=C1)F)CCC2CCC(O2)CCNCCCCCN3C(=O)[C@@H]4CC=CC[C@@H]4C(=N3)C5=CC(=C(C=C5)OC)OC,COc1ccc(F)cc1CCC1CCC(CCNCCCCCN2N=C(c3ccc(OC)c(OC)c3)[C@H]3CC=CC[C@H]3C2=O)O1
2514,2521,CHEMBL27336,JTJFHBTZULUOQN-PWUWZPNHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2.6,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.585026652029184,CC[C@H]1[C@H](CC2CCC1N2C)C3=CC=C(C=C3)Cl,CC[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C
2515,2522,CHEMBL27336,JTJFHBTZULUOQN-PWUWZPNHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,3.5,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.455931955649724,CC[C@H]1[C@H](CC2CCC1N2C)C3=CC=C(C=C3)Cl,CC[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C
2516,2523,CHEMBL411263,JTLPJEXKDFZLAY-HKUYNNGSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17983754.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125]RTI35 from human DAT expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CO[C@@H](CN1)[C@H](C2=CC=CC=C2)SC3=CC=CC=C3OCCF,FCCOc1ccccc1S[C@@H](c1ccccc1)[C@@H]1CNCCO1
2517,2524,CHEMBL1683871,JTOBXLVKTKGLSL-UHFFFAOYSA-N,"(1-(3,4-DICHLOROPHENYL)CYCLOHEXYL)METHANAMINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,C1CCC(CC1)(CN)C2=CC(=C(C=C2)Cl)Cl,NCC1(c2ccc(Cl)c(Cl)c2)CCCCC1
2518,2525,CHEMBL517978,JTVKAFWSBOMWKU-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,3190.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.496209316942818,COC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,COC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
2519,2526,CHEMBL84158,JTVPZMFULRWINT-UHFFFAOYSA-N,TIAPRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC,CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC
2520,2527,CHEMBL84158,JTVPZMFULRWINT-UHFFFAOYSA-N,TIAPRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC,CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC
2521,2528,CHEMBL1537,JTWOMNBEOCYFNV-NFFDBFGFSA-N,AZLOCILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
2522,2529,CHEMBL1537,JTWOMNBEOCYFNV-NFFDBFGFSA-N,AZLOCILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
2523,2530,CHEMBL611367,JTZODQOWHKXAGE-HALDLXJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,6.31,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.199970640755867,C1CC(C1)OCCC2([C@H]3[C@@H]2CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(C2(CCOC3CCC3)[C@H]3CNC[C@H]32)cc1Cl
2524,2531,CHEMBL40529,JUDLOGIXXXCULG-NSCUHMNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.43,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.43,CC1=CC=C(C=C1)/C=C/CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Cc1ccc(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2525,2532,CHEMBL40529,JUDLOGIXXXCULG-NSCUHMNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.32,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.32,CC1=CC=C(C=C1)/C=C/CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Cc1ccc(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2526,2533,CHEMBL257130,JUESHDJIQYYBKK-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(S2)C=CC(=C3)F,CCN(CC)C(=O)[C@@]1(c2cc3cc(F)ccc3s2)C[C@H]1CN
2527,2534,CHEMBL512189,JUFVWXGWKDEQTH-RRIHMMEISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,111.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.954677021213343,CC1=NOC(=C1C2=CC=C(C=C2)F)[C@H]3[C@H](CC4CCC3N4C)C5=CC=C(C=C5)Cl.Cl,Cc1noc([C@@H]2C3CCC(C[C@@H]2c2ccc(Cl)cc2)N3C)c1-c1ccc(F)cc1
2528,2535,CHEMBL1813312,JUHGVUXNNZSORA-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,1318.26,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.879998925531603,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC=CC4=CC=CC=C43,CN1C[C@@H]2CCCC[C@]2(c2cccc3ccccc23)C1
2529,2536,CHEMBL1813312,JUHGVUXNNZSORA-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,3311.31,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.480000159330324,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC=CC4=CC=CC=C43,CN1C[C@@H]2CCCC[C@]2(c2cccc3ccccc23)C1
2530,2537,CHEMBL1813318,JUHGVUXNNZSORA-VQIMIIECSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,2454.71,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.6099998081597775,CN1C[C@H]2CCCC[C@]2(C1)C3=CC=CC4=CC=CC=C43,CN1C[C@H]2CCCC[C@@]2(c2cccc3ccccc23)C1
2531,2538,CHEMBL1179011,JUKMAYKVHWKRKY-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1.8,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.744727494896694,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@H](c1ccc(Cl)c(Cl)c1)[C@H]1CCCCN1
2532,2539,CHEMBL220195,JUKMAYKVHWKRKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,23.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.638272163982407,COC(=O)C(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCCCN1
2533,2540,CHEMBL220195,JUKMAYKVHWKRKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.096910013008057,COC(=O)C(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCCCN1
2534,2541,CHEMBL220195,JUKMAYKVHWKRKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,1.4,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.853871964321762,COC(=O)C(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCCCN1
2535,2542,CHEMBL220195,JUKMAYKVHWKRKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,90.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.045757490560675,COC(=O)C(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCCCN1
2536,2543,CHEMBL1722,JUMYIBMBTDDLNG-UHFFFAOYSA-N,METHYLPHENIDATE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,19.9,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing human dopamine transporter,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,7.7011469235902945,COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,COC(=O)C(c1ccccc1)C1CCCCN1
2537,2544,CHEMBL1722,JUMYIBMBTDDLNG-UHFFFAOYSA-N,METHYLPHENIDATE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,121.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]-RTI-55 from Dopamine transporter expressed in HEK293 cells,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,6.914709421769935,COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,COC(=O)C(c1ccccc1)C1CCCCN1
2538,2545,CHEMBL512280,JUOTXFDGIKRFRE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,150.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.823908740944319,CC(CC1=CC=CC=C1)(CN2CCN(CC2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4)O,CC(O)(Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
2539,2546,CHEMBL429023,JUVIOZPCNVVQFO-HBGVWJBISA-N,ROTENONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1
2540,2547,CHEMBL429023,JUVIOZPCNVVQFO-HBGVWJBISA-N,ROTENONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1
2541,2548,CHEMBL2203551,JUWUZLUBIRHYMM-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,EFFICACY,=,59.4,%,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT at 10 uM after 1.5 hrs by microbeta scintillation counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,59.4,C1C[C@H](NC1)COC2=NOC(=C2)COC3=CC=CC=C3,c1ccc(OCc2cc(OC[C@@H]3CCCN3)no2)cc1
2542,2549,CHEMBL2203551,JUWUZLUBIRHYMM-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,373.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT after 1.5 hrs by microbeta scintillation counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.428291168191312,C1C[C@H](NC1)COC2=NOC(=C2)COC3=CC=CC=C3,c1ccc(OCc2cc(OC[C@@H]3CCCN3)no2)cc1
2543,2550,CHEMBL1645602,JVFNBOUZKYZEJE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6410.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.193141970481181,C1C(CN1)OC2=C(C=CC=C2F)OC3=C(C=CC=C3F)F,Fc1cccc(F)c1Oc1cccc(F)c1OC1CNC1
2544,2551,CHEMBL2030625,JVHYCBRRZUMPEJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCC(CC1)CN2C3CCC2CC3,C1CCC(CN2C3CCC2CC3)CC1
2545,2552,CHEMBL3673175,JVICAIHCMVKYNI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,78.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.107905397309519,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=CN5C(=NC=N5)C=C4)C6=CC(=C(C=C6)F)Cl,Fc1ccc(C23CCN(CC2)Cc2cc(-c4ccc5ncnn5c4)ccc23)cc1Cl
2546,2553,CHEMBL566240,JVIKPFIJPCEZJS-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,28000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5528419686577815,CC1=C(C=CC(=C1Cl)Cl)C(=O)N(CC(C)(C)C)[C@H]2CCNC2,Cc1c(C(=O)N(CC(C)(C)C)[C@H]2CCNC2)ccc(Cl)c1Cl
2547,2554,CHEMBL1200559,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,LACTIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)O)O,CC(O)C(=O)O
2548,2555,CHEMBL1200559,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,LACTIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)O)O,CC(O)C(=O)O
2549,2556,CHEMBL459332,JVTAHMMQYMBPEN-IYIFBUTFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,2.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,8.602059991327963,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OCCC4=CC(=C(C=C4)N)I.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OCCc2ccc(N)c(I)c2)N3C)cc1
2550,2557,CHEMBL1670,JWBOIMRXGHLCPP-UHFFFAOYSA-N,MITOTANE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1001.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.9995659225206825,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1
2551,2558,CHEMBL1670,JWBOIMRXGHLCPP-UHFFFAOYSA-N,MITOTANE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,795.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.0996328713435295,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1
2552,2559,CHEMBL2047565,JWEVRDWOVZZPKU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,52.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,52.0,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CC=CS3)O,OC(CCN1CC=C(Cc2ccccc2)CC1)c1cccs1
2553,2560,CHEMBL631,JWHAUXFOSRPERK-UHFFFAOYSA-N,PROPAFENONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1868.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.728623128105926,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1
2554,2561,CHEMBL631,JWHAUXFOSRPERK-UHFFFAOYSA-N,PROPAFENONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1484.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.828566099056991,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1
2555,2562,CHEMBL2171416,JWNKMCJAUXMBAD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,72.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.142667503568733,CCCOC(C1CNC1)C2=CC3=CC=CC=C3C=C2.Cl,CCCOC(c1ccc2ccccc2c1)C1CNC1
2556,2563,CHEMBL2171416,JWNKMCJAUXMBAD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,48.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,48.0,CCCOC(C1CNC1)C2=CC3=CC=CC=C3C=C2.Cl,CCCOC(c1ccc2ccccc2c1)C1CNC1
2557,2564,CHEMBL596795,JWSCWFWSMYRJBE-PSOPSSQASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.900008766455317,CC1=CN=C(O1)[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1cnc([C@H]2[C@@H]3CNC[C@@]32c2ccc(Cl)c(Cl)c2)o1
2558,2565,CHEMBL1084311,JWVNRZQALLUPMN-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,998.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,6.0008694587126294,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=C(C=C(C=C3)F)F)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccc(F)cc2F)S1(=O)=O
2559,2566,CHEMBL1084312,JWVNRZQALLUPMN-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,3185.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.496890563328631,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=C(C=C(C=C3)F)F)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccc(F)cc2F)S1(=O)=O
2560,2567,CHEMBL434,JWZZKOKVBUJMES-UHFFFAOYSA-N,ISOPROTERENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,CC(C)NCC(O)c1ccc(O)c(O)c1
2561,2568,CHEMBL434,JWZZKOKVBUJMES-UHFFFAOYSA-N,ISOPROTERENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,CC(C)NCC(O)c1ccc(O)c(O)c1
2562,2569,CHEMBL1224319,JXIHZLYRWFFHPQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,7.94,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC3=C(C=C2)NN=C3,CC(C)(C)CCC1(C(=O)c2ccc3[nH]ncc3c2)CCNC1
2563,2570,CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
2564,2571,CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
2565,2572,CHEMBL457635,JXMNHUDMPQBBLE-BAEQUSMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,6.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,8.221848749616356,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OC4CC4.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC2CC2)N3C)cc1
2566,2573,CHEMBL566208,JYBXLCIZWPNCMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,175.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.7569619513137065,CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CCC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
2567,2574,CHEMBL566208,JYBXLCIZWPNCMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,278.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.555955204081924,CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CCC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
2568,2575,CHEMBL566208,JYBXLCIZWPNCMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,118.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.928117992693875,CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CCC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
2569,2576,CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
2570,2577,CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
2571,2578,CHEMBL2047571,JYIMWQCCVNSNJW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,IC50,=,346.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.460923901207224,COC1=C(C2=C(C=C1)C=C(C=C2)C(CCN3CCC(=CC3)CC4=CC=CC=C4)O)Cl,COc1ccc2cc(C(O)CCN3CC=C(Cc4ccccc4)CC3)ccc2c1Cl
2572,2579,CHEMBL258291,JZCIRLJPOBBVMR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2250.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.647817481888637,CCCC1=CC=CC=C1OC2=C(C=NC(=C2)C)CN(C)C,CCCc1ccccc1Oc1cc(C)ncc1CN(C)C
2573,2580,CHEMBL63323,JZFPYUNJRRFVQU-UHFFFAOYSA-N,NIFLUMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1
2574,2581,CHEMBL63323,JZFPYUNJRRFVQU-UHFFFAOYSA-N,NIFLUMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1
2575,2582,CHEMBL2047573,JZHYJRPFUZJBQH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,IC50,=,564.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.248720896016657,C1CN(CCC1(CC2=CC=CC=C2)O)CCC(C3=CC(=C(C=C3)Cl)Cl)O,OC(CCN1CCC(O)(Cc2ccccc2)CC1)c1ccc(Cl)c(Cl)c1
2576,2583,CHEMBL2048520,JZIHRSHQGGBQMD-QUIJITIRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,2.64,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.578396073130168,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)CN(C)CCC[18F],CN(CCCF)C[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C
2577,2584,CHEMBL454770,JZKRUQHCKJXZSS-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,5000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CC1=C(C=CC(=C1)O)O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccc(O)cc1C
2578,2585,CHEMBL3310627,JZLLVPLMTCNSLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,49.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,49.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC=C(C=C3)Cl,Fc1ccc(C(CC2CNC2)Oc2ccc(Cl)cc2)cc1F
2579,2586,CHEMBL117405,JZQKKSLKJUAGIC-NSHDSACASA-N,S(-)-PINDOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=C1C=CN2)O,CC(C)NC[C@H](O)COc1cccc2[nH]ccc12
2580,2587,CHEMBL117405,JZQKKSLKJUAGIC-NSHDSACASA-N,S(-)-PINDOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=C1C=CN2)O,CC(C)NC[C@H](O)COc1cccc2[nH]ccc12
2581,2588,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CC(C)NCC(O)COc1cccc2[nH]ccc12
2582,2589,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CC(C)NCC(O)COc1cccc2[nH]ccc12
2583,2590,CHEMBL435,JZUFKLXOESDKRF-UHFFFAOYSA-N,HYDROCHLOROTHIAZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
2584,2591,CHEMBL435,JZUFKLXOESDKRF-UHFFFAOYSA-N,HYDROCHLOROTHIAZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
2585,2592,CHEMBL2012086,JZUOHICLNJQBTJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=CN=C(S3)C4=CC(=CC=C4)Br,COC(=O)C1=C(c2cnc(-c3cccc(Br)c3)s2)CC2CCC1O2
2586,2593,CHEMBL2012086,JZUOHICLNJQBTJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CN=C(S3)C4=CC(=CC=C4)Br,COC(=O)C1=C(c2cnc(-c3cccc(Br)c3)s2)CC2CCC1O2
2587,2594,CHEMBL1812741,JZWBQZKHNDUSFQ-XFKSJGNHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,0.75,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,9.1249387366083,CCC1=NOC(=C1)[C@@H]2[C@H]3CC[C@H](N3C)C[C@@H]2C4=CC=C(C=C4)C,CCc1cc([C@H]2[C@@H](c3ccc(C)cc3)C[C@@H]3CC[C@H]2N3C)on1
2588,2595,CHEMBL197643,JZXQQBOUEFCSBP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,50.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)Cl,CNCCCC1Cc2ccccc2N(c2ccc(Cl)cc2)C1=O
2589,2596,CHEMBL197643,JZXQQBOUEFCSBP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)Cl,CNCCCC1Cc2ccccc2N(c2ccc(Cl)cc2)C1=O
2590,2597,CHEMBL263770,KAEBWRHYUAKLED-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784853.0,IC50,=,18.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at dopamine transporter,High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.744727494896693,C1CN(CCN1CCCC2=CC=C(C=C2)NC(=O)CCCCCCCCCCS)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,O=C(CCCCCCCCCCS)Nc1ccc(CCCN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2591,2598,CHEMBL1818442,KAGBHVBIOJBGBD-NINOIYOQSA-N,AMITIFADINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,79.43,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.100015437450608,C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl.Cl,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
2592,2599,CHEMBL1818442,KAGBHVBIOJBGBD-NINOIYOQSA-N,AMITIFADINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,IC50,=,159.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.798602875679547,C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl.Cl,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
2593,2600,CHEMBL589177,KARYRXNBSOIGJH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,>,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC(=C(C=C1)OC2=C(C=CC(=C2)OCCCF)CN(C)C)N,Cc1ccc(Oc2cc(OCCCF)ccc2CN(C)C)c(N)c1
2594,2601,CHEMBL443090,KATOUFNMRLTTPE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,>,31000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.508638306165727,CC1=C(C=CC2=C1C=CC(=C2)F)CCN3CCNCC3,Cc1c(CCN2CCNCC2)ccc2cc(F)ccc12
2595,2602,CHEMBL245687,KAVHHDMCLXFYPS-NRFANRHFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CNC[C@H]1N(CC2=CC=CC=C2C3=CC=CC=C3)C4CCOCC4,c1ccc(-c2ccccc2CN(C2CCOCC2)[C@H]2CCNC2)cc1
2596,2603,CHEMBL245687,KAVHHDMCLXFYPS-NRFANRHFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CNC[C@H]1N(CC2=CC=CC=C2C3=CC=CC=C3)C4CCOCC4,c1ccc(-c2ccccc2CN(C2CCOCC2)[C@H]2CCNC2)cc1
2597,2604,CHEMBL2432048,KBAKPEFQDPCCTP-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,2016.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.6955094722265125,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC=CC=C6,c1ccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)cc1
2598,2605,CHEMBL270151,KBHALIJUSMYPCR-AFWDCEBSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,65.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,65.0,CC1=CC2=C(C=C1)N(C(=N2)C)[C@@H]3CCN(C[C@H]3OC)C[C@H]4CC5=C(C4)C=C(C=C5)NC(=O)OC,COC(=O)Nc1ccc2c(c1)C[C@@H](CN1CC[C@@H](n3c(C)nc4cc(C)ccc43)[C@H](OC)C1)C2
2599,2606,CHEMBL2337593,KBLODNDMWLXBEK-RHSMWYFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,50.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC=CC=C3Cl,Clc1ccccc1O[C@H](c1ccccc1)[C@@H]1CCNC1
2600,2607,CHEMBL2337592,KBLODNDMWLXBEK-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=CC=CC=C3Cl,Clc1ccccc1O[C@@H](c1ccccc1)[C@H]1CCNC1
2601,2608,CHEMBL2048521,KBXQOGFSLYHIJB-HXANBQKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,4.63,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.334419008982048,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)CN(C)CCOCC[18F],CN(CCOCCF)C[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C
2602,2609,CHEMBL504479,KCCUCFUQSYGPBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19492813.0,IC50,=,300.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,6.522878745280337,CC(C)(CC1=CC=C(C=C1)OC)NCC(COC2=CC=CC=C2C#N)O,COc1ccc(CC(C)(C)NCC(O)COc2ccccc2C#N)cc1
2603,2610,CHEMBL467512,KCFUXTYNOWCQBR-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,1.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC(=CC=C2)OC)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1cccc(OC)c1
2604,2611,CHEMBL1645619,KCIORJWXNLIEPL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,4260.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.370590400897282,C1C(CN1)OC2=C(N=CC=C2)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1ncccc1OC1CNC1
2605,2612,CHEMBL1196,KCLANYCVBBTKTO-UHFFFAOYSA-N,PROPARACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N
2606,2613,CHEMBL1196,KCLANYCVBBTKTO-UHFFFAOYSA-N,PROPARACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N
2607,2614,CHEMBL539050,KCLIFHPTVWHVGF-GUTACTQSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,70.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985742,CN(C)C[C@@H](C1=CC2=CC=CC=C2C=C1)[C@H](C3=CC=CC=C3)O.Cl,CN(C)C[C@@H](c1ccc2ccccc2c1)[C@@H](O)c1ccccc1
2608,2615,CHEMBL1083428,KCQQWPYAESYXHU-GFCCVEGCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,5500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.259637310505756,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=C(C=CC=C3F)F)O,CNC[C@H](O)CCN1c2ccccc2N(c2c(F)cccc2F)S1(=O)=O
2609,2616,CHEMBL1083429,KCQQWPYAESYXHU-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,2618.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.582030357785263,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=C(C=CC=C3F)F)O,CNC[C@@H](O)CCN1c2ccccc2N(c2c(F)cccc2F)S1(=O)=O
2610,2617,CHEMBL1829961,KCSUXNDYSCZCHV-UHFFFAOYSA-N,2'-CHLOROPSAMMOPEMMIN A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21907583.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT after 1.5 hrs by scintillation counting,CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1=CC2=C(C(=C1)O)C(=CN2)C3=CN=C(N=C3N)Cl,Nc1nc(Cl)ncc1-c1c[nH]c2cccc(O)c12
2611,2618,CHEMBL1642897,KDERKEZKMQCRPQ-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,72.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.142667503568733,CN[C@@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
2612,2619,CHEMBL1642897,KDERKEZKMQCRPQ-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,72.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.142667503568733,CN[C@@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
2613,2620,CHEMBL1642896,KDERKEZKMQCRPQ-HIFRSBDPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,281.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.55129368009492,CN[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
2614,2621,CHEMBL1642895,KDERKEZKMQCRPQ-UKRRQHHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,62.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.207608310501746,CN[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
2615,2622,CHEMBL1642894,KDERKEZKMQCRPQ-ZFWWWQNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,114.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.943095148663526,CN[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
2616,2623,CHEMBL577612,KDLATVNCFJVLBE-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,16.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,16.0,CNC[C@H]([C@H](C1=CC=C(C=C1)Cl)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccc(Cl)cc1)n1ccc2ccccc21
2617,2624,CHEMBL1753,KDLRVYVGXIQJDK-AWPVFWJPSA-N,CLINDAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
2618,2625,CHEMBL1753,KDLRVYVGXIQJDK-AWPVFWJPSA-N,CLINDAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
2619,2626,CHEMBL1215761,KDRRURQANSXWJL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23168018.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in COS7 cells after 3 mins by beta-counting,A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C3=CC(=CC=C3)N)C4=CC=C(C=C4)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(-c3cccc(N)c3)ccc21
2620,2627,CHEMBL2430689,KECBOARJOOAZSP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,81.5,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.088842391260022,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccccc1Cl
2621,2628,CHEMBL2430689,KECBOARJOOAZSP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,95.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,95.8,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccccc1Cl
2622,2629,CHEMBL2430689,KECBOARJOOAZSP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,97.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,97.0,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccccc1Cl
2623,2630,CHEMBL3334797,KEGBICCDHKITSP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,247.2,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.6069515335832225,CN(C)CCC(C1=CC(=C(C=C1)Cl)Cl)N2CCOCC2,CN(C)CCC(c1ccc(Cl)c(Cl)c1)N1CCOCC1
2624,2631,CHEMBL3334797,KEGBICCDHKITSP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,93.6,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DAT at 10 uM relative to control,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,93.6,CN(C)CCC(C1=CC(=C(C=C1)Cl)Cl)N2CCOCC2,CN(C)CCC(c1ccc(Cl)c(Cl)c1)N1CCOCC1
2625,2632,CHEMBL1813308,KEIRMFURGIUOGY-SWLSCSKDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,416.87,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.3799993576999325,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC(=C(C=C3)F)F,CN1C[C@@H]2CCCC[C@]2(c2ccc(F)c(F)c2)C1
2626,2633,CHEMBL3334789,KEQMEADCNMBAIF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,22.9,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,22.9,CN(C)CCC(C1=CC=C(C=C1)OC)N2CCOCC2,COc1ccc(C(CCN(C)C)N2CCOCC2)cc1
2627,2634,CHEMBL3640036,KESMMXPCOOCEDA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,25.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.602059991327962,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
2628,2635,CHEMBL3640036,KESMMXPCOOCEDA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,251.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.599634726650062,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
2629,2636,CHEMBL3640036,KESMMXPCOOCEDA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4728.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.325322532126801,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
2630,2637,CHEMBL3640036,KESMMXPCOOCEDA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,251.4,NM,317683,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.599634726650062,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC=C(C=C2)OCC,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(OCC)cc2)CCC1
2631,2638,CHEMBL575714,KETAEAPLSWORIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,470.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.327902142064282,C1CN(CCN1)C2=CC=CC=C2COC3=C(C(=CC=C3)F)F,Fc1cccc(OCc2ccccc2N2CCNCC2)c1F
2632,2639,CHEMBL3593274,KETAPAGKHJIKAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CC(CCNC1)(CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OCC1(c2ccc(Cl)c(Cl)c2)CCCNCC1
2633,2640,CHEMBL3310034,KEYZAWORGREMBZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,557.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT after 90 mins by microbeta counting analysis,,J. Nat. Prod.,PUBLICATION,,6.2541448048262716,CC1=CC2=CC(=C(C(=C2C(=O)O1)O)O)CCC(=O)O,Cc1cc2cc(CCC(=O)O)c(O)c(O)c2c(=O)o1
2634,2641,CHEMBL132683,KFDFKTMFADMFFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,IC50,=,406.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.391473966422807,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)O)O)C(=O)OC,COC(=O)C1C(c2ccc(O)c(O)c2)CC2CCC1N2C
2635,2642,CHEMBL132683,KFDFKTMFADMFFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,IC50,=,507.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2949920406666635,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)O)O)C(=O)OC,COC(=O)C1C(c2ccc(O)c(O)c2)CC2CCC1N2C
2636,2643,CHEMBL132683,KFDFKTMFADMFFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,=,970.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.013228265733755,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)O)O)C(=O)OC,COC(=O)C1C(c2ccc(O)c(O)c2)CC2CCC1N2C
2637,2644,CHEMBL132683,KFDFKTMFADMFFP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,=,1370.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.863279432843593,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)O)O)C(=O)OC,COC(=O)C1C(c2ccc(O)c(O)c2)CC2CCC1N2C
2638,2645,CHEMBL450907,KFFYQORCJDVDTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,16990.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.7698066211309555,COC1=C(C=C(C=C1)F)CCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCC1CCC(CCN)O1
2639,2646,CHEMBL450907,KFFYQORCJDVDTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,41260.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.384470776362868,COC1=C(C=C(C=C1)F)CCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCC1CCC(CCN)O1
2640,2647,CHEMBL450907,KFFYQORCJDVDTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,7307.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.136260892654783,COC1=C(C=C(C=C1)F)CCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCC1CCC(CCN)O1
2641,2648,CHEMBL450907,KFFYQORCJDVDTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,21190.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.673869043289206,COC1=C(C=C(C=C1)F)CCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCC1CCC(CCN)O1
2642,2649,CHEMBL450907,KFFYQORCJDVDTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,=,16987.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.76988331321378,COC1=C(C=C(C=C1)F)CCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCC1CCC(CCN)O1
2643,2650,CHEMBL450907,KFFYQORCJDVDTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,=,7307.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,5.136260892654783,COC1=C(C=C(C=C1)F)CCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCC1CCC(CCN)O1
2644,2651,CHEMBL279331,KFKKBZNZSBJESZ-LFWXXOGXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,1540.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.8124792791635365,C1CC2[C@H]([C@H](CC1S2)C3=CC(=C(C=C3)Cl)Cl)COC(=O)CCC(=O)OC[C@H]4[C@H](CC5CCC4S5)C6=CC(=C(C=C6)Cl)Cl,O=C(CCC(=O)OC[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)S2)OC[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)S2
2645,2652,CHEMBL1080926,KFUNLUIORXHBPH-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=C(C=C5)F,C[C@H]1CN(C(=O)c2ccc(-c3ccc(F)cc3)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
2646,2653,CHEMBL256021,KGCAQBRBCVWBSF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC(OC)OC)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCC(OC)OC
2647,2654,CHEMBL401878,KGLPNVVDPAVWHX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CNCC1=C(C=CC(=C1)C#N)OC2=C(C=C(C=C2)Cl)OC,CNCc1cc(C#N)ccc1Oc1ccc(Cl)cc1OC
2648,2655,CHEMBL381256,KGRXCESVCIYMSX-IMMIMJPRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,0.5,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,9.30102999566398,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H]4C[C@H]4C5=CC=CC=C5.C(=O)(C(=O)O)O,Fc1ccc(C(OCCC2CCN(C[C@@H]3C[C@H]3c3ccccc3)CC2)c2ccc(F)cc2)cc1
2649,2656,CHEMBL206128,KGRXCESVCIYMSX-OVWBULDYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.4,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.853871964321762,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H]4C[C@@H]4C5=CC=CC=C5.C(=O)(C(=O)O)O,Fc1ccc(C(OCCC2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c2ccc(F)cc2)cc1
2650,2657,CHEMBL3310635,KHACQPYREOXZTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,7.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC(=C(C=C3)Cl)Cl,Fc1ccc(C(CC2CNC2)Oc2ccc(Cl)c(Cl)c2)cc1F
2651,2658,CHEMBL511756,KHBBVPNKEBAUQS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,450.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.346787486224656,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC(=O)C4=CC=CC=C4,O=C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
2652,2659,CHEMBL258180,KHDOKCLXCQAKEX-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,C=CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
2653,2660,CHEMBL491753,KHFAFXFRTUHQNO-UHFFFAOYSA-N,KF-A3,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,5.0,CCN(CC)CCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31,CCN(CC)CCCn1c2ccccc2c(=O)c2ccccc21
2654,2661,CHEMBL218568,KHIUUVSTTUGPRZ-CUNXSJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,451.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.345823458122039,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CCO)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CCO)cc(C(C)=O)c1
2655,2662,CHEMBL447825,KHKLNHSDQIKVSU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,313.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.5044556624535526,C1CC(OC1CN)C2=CC=C(C=C2)Cl,NCC1CCC(c2ccc(Cl)cc2)O1
2656,2663,CHEMBL447825,KHKLNHSDQIKVSU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,6830.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.165579296318468,C1CC(OC1CN)C2=CC=C(C=C2)Cl,NCC1CCC(c2ccc(Cl)cc2)O1
2657,2664,CHEMBL942,KHOITXIGCFIULA-UHFFFAOYSA-N,BISACODYL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2208.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.656000930942839,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
2658,2665,CHEMBL942,KHOITXIGCFIULA-UHFFFAOYSA-N,BISACODYL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1755.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.755722879198157,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
2659,2666,CHEMBL1171260,KHVUFWSEOLNUFN-IINYFYTJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,3400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.468521082957745,C[C@H]1[C@@](OCC(N1C)(C)C)(C2=CC(=CC=C2)Cl)O,C[C@@H]1N(C)C(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
2660,2667,CHEMBL1171260,KHVUFWSEOLNUFN-IINYFYTJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,230.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,6.638272163982407,C[C@H]1[C@@](OCC(N1C)(C)C)(C2=CC(=CC=C2)Cl)O,C[C@@H]1N(C)C(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
2661,2668,CHEMBL394157,KHYFCJWXLVZFLY-QXSJWSMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446069.0,KI,=,10.09,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,"Synthesis and biological evaluation of 2beta,3alpha-(substituted phenyl)nortropanes as potential norepinephrine transporter imaging agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.996108833763089,COC(=O)[C@@H]1[C@H]2CC[C@@H](N2)C[C@H]1C3=CC=C(C=C3)C=C,C=Cc1ccc([C@@H]2C[C@H]3CC[C@@H](N3)[C@H]2C(=O)OC)cc1
2662,2669,CHEMBL1099178,KHYNNQYNYMSTIB-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,>,6000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,CN1CCN(CC1)C[C@@H](C2=CSC(=C2)Cl)C3(CCCCC3)O,CN1CCN(C[C@@H](c2csc(Cl)c2)C2(O)CCCCC2)CC1
2663,2670,CHEMBL1095850,KHYNNQYNYMSTIB-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,=,212.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6736641390712474,CN1CCN(CC1)C[C@H](C2=CSC(=C2)Cl)C3(CCCCC3)O,CN1CCN(C[C@H](c2csc(Cl)c2)C2(O)CCCCC2)CC1
2664,2671,CHEMBL1097148,KHYNNQYNYMSTIB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,=,389.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.410050398674293,CN1CCN(CC1)CC(C2=CSC(=C2)Cl)C3(CCCCC3)O,CN1CCN(CC(c2csc(Cl)c2)C2(O)CCCCC2)CC1
2665,2672,CHEMBL516507,KIAUBZBIKKPZNR-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=C(C=C1)F)O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1cc(F)ccc1C
2666,2673,CHEMBL196365,KIDMMWCQWSLXGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,5.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCCC1Cc2ccccc2N(c2ccccc2)C1=O
2667,2674,CHEMBL196365,KIDMMWCQWSLXGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,11.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,11.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCCC1Cc2ccccc2N(c2ccccc2)C1=O
2668,2675,CHEMBL196365,KIDMMWCQWSLXGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,24.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,24.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCCC1Cc2ccccc2N(c2ccccc2)C1=O
2669,2676,CHEMBL196365,KIDMMWCQWSLXGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCCC1Cc2ccccc2N(c2ccccc2)C1=O
2670,2677,CHEMBL3323173,KILGJUZHPOSPFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,12.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CC1=CC2=C(C=C1)C(CN(C2)C)C3=CC4=C(C=C3)SC=C4,Cc1ccc2c(c1)CN(C)CC2c1ccc2sccc2c1
2671,2678,CHEMBL3703736,KILSXJAEWHCKLW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,29.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.52432881167557,C1C(C2=C(CN1)C=C(C=C2)N3C(=O)C=CC=N3)C4=CC(=C(C=C4)Cl)Cl,O=c1cccnn1-c1ccc2c(c1)CNCC2c1ccc(Cl)c(Cl)c1
2672,2679,CHEMBL1224320,KIMRUTAJTDBFHO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CC(C)CCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CC(C)CCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
2673,2680,CHEMBL1224320,KIMRUTAJTDBFHO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,1.58,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.801342913045579,CC(C)CCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CC(C)CCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
2674,2681,CHEMBL3663912,KIRDSTWSOYAHOS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,119.0,NM,314445,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.924453038607469,CN1CC(C2=C(C1)C=C(C=C2)C3=NN=CC=C3)C4=CC5=CC=CC=C5S4,CN1Cc2cc(-c3cccnn3)ccc2C(c2cc3ccccc3s2)C1
2675,2683,CHEMBL427215,KIXBFSFRCBHKLN-INIZCTEOSA-N,(R)-SILA-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16513343.0,IC50,=,4900.0,NM,,,,,,,,,,,,,,,Inhibition of dopamine reuptake at human recombinant dopamine transporter,(R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,CN(C)C[C@@H](C1=CC=C(C=C1)OC)[Si]2(CCCCC2)O,COc1ccc([C@H](CN(C)C)[Si]2(O)CCCCC2)cc1
2676,2684,CHEMBL427215,KIXBFSFRCBHKLN-INIZCTEOSA-N,(R)-SILA-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21413808.0,IC50,=,5270.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,PUBLICATION,,5.278189384787454,CN(C)C[C@@H](C1=CC=C(C=C1)OC)[Si]2(CCCCC2)O,COc1ccc([C@H](CN(C)C)[Si]2(O)CCCCC2)cc1
2677,2685,CHEMBL427215,KIXBFSFRCBHKLN-INIZCTEOSA-N,(R)-SILA-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23061607.0,IC50,=,5270.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) assessed as dopamine reuptake,Organosilicon molecules with medicinal applications.,J. Med. Chem.,PUBLICATION,,5.278189384787454,CN(C)C[C@@H](C1=CC=C(C=C1)OC)[Si]2(CCCCC2)O,COc1ccc([C@H](CN(C)C)[Si]2(O)CCCCC2)cc1
2678,2686,CHEMBL2204342,KIXBFSFRCBHKLN-MRXNPFEDSA-N,(S)-SILA-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21413808.0,IC50,=,36350.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,PUBLICATION,,4.439495584804943,CN(C)C[C@H](C1=CC=C(C=C1)OC)[Si]2(CCCCC2)O,COc1ccc([C@@H](CN(C)C)[Si]2(O)CCCCC2)cc1
2679,2687,CHEMBL2204341,KIXBFSFRCBHKLN-UHFFFAOYSA-N,RAC-SILA-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21413808.0,IC50,=,2630.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,PUBLICATION,,5.580044251510242,CN(C)CC(C1=CC=C(C=C1)OC)[Si]2(CCCCC2)O,COc1ccc(C(CN(C)C)[Si]2(O)CCCCC2)cc1
2680,2688,CHEMBL2204341,KIXBFSFRCBHKLN-UHFFFAOYSA-N,RAC-SILA-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23061607.0,IC50,=,2630.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) assessed as dopamine reuptake,Organosilicon molecules with medicinal applications.,J. Med. Chem.,PUBLICATION,,5.580044251510242,CN(C)CC(C1=CC=C(C=C1)OC)[Si]2(CCCCC2)O,COc1ccc(C(CN(C)C)[Si]2(O)CCCCC2)cc1
2681,2689,CHEMBL486235,KJKJGUOGZBYCCJ-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,2500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,CCN[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=CC=C3C,CCN[C@@H]1C[C@H](Oc2ccccc2C)c2ccccc21
2682,2690,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
2683,2691,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
2684,2692,CHEMBL293492,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,CINNAMALDEHYDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)/C=C/C=O,O=C/C=C/c1ccccc1
2685,2693,CHEMBL293492,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,CINNAMALDEHYDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)/C=C/C=O,O=C/C=C/c1ccccc1
2686,2694,CHEMBL460204,KJRMGZKFHBXRRA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,37460.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.426432226960783,COC1=C(C=C(C=C1)F)CCCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCCC1CCC(CCN)O1
2687,2695,CHEMBL460204,KJRMGZKFHBXRRA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,3387.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.4701848033553695,COC1=C(C=C(C=C1)F)CCCCC2CCC(O2)CCN,COc1ccc(F)cc1CCCCC1CCC(CCN)O1
2688,2696,CHEMBL207867,KJSYAMNHDJSTMY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,227.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6439741428068775,CC1=C(C2=C(C=C1)C(CN(C2)C)C3=CC=CC=C3)C,Cc1ccc2c(c1C)CN(C)CC2c1ccccc1
2689,2697,CHEMBL493058,KKCKVAFKRSKQRE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CC1=CC=CC=C1SC2=CC=C(C=C2)Cl,CN(C)Cc1ccccc1Sc1ccc(Cl)cc1
2690,2698,CHEMBL1830887,KKELNYPZMKZDOL-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,211.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,6.675717544702308,C1CO[C@@H](CN1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=C(C=C4)F,O=S1(=O)N(CC[C@@H]2CNCCO2)c2ccccc2N1c1ccc(F)cc1
2691,2699,CHEMBL1078164,KKHPGFXTXRPZGB-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,2370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6252516539898965,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)F)Cl,CC(C)CN(C(=O)c1cccc(F)c1Cl)[C@H]1CCNC1
2692,2700,CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CN2C=CN=C2,c1ccc(Cn2ccnc2)cc1
2693,2701,CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CN2C=CN=C2,c1ccc(Cn2ccnc2)cc1
2694,2702,CHEMBL597967,KKLRTSAUACDUNQ-GTKSSXFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,20.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,20.0,CCC1CN(C2=CC=CC=C12)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CCC1CN([C@@H](c2cccc(F)c2)[C@H](O)CNC)c2ccccc21
2695,2703,CHEMBL202846,KKTUFJIEHNEGDF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,42.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.376750709602098,CCCC(C(=O)C1=CC(=C(C=C1)O)O)N2CCCC2,CCCC(C(=O)c1ccc(O)c(O)c1)N1CCCC1
2696,2704,CHEMBL202846,KKTUFJIEHNEGDF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,84.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.075720713938117,CCCC(C(=O)C1=CC(=C(C=C1)O)O)N2CCCC2,CCCC(C(=O)c1ccc(O)c(O)c1)N1CCCC1
2697,2705,CHEMBL3094312,KKYAPAJUTFYVRD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,50.7,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,50.7,C1=CC=C(C(=C1)COC2=CC=C(C=C2)CN)OC(F)(F)F.Cl,NCc1ccc(OCc2ccccc2OC(F)(F)F)cc1
2698,2706,CHEMBL396839,KKYCXUFOXFTJIV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,39810717055349.7,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.6,COC(=O)C1=C(C2CCC1C2)C3=CC=C(C=C3)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)C2CCC1C2
2699,2707,CHEMBL58,KKZJGLLVHKMTCM-UHFFFAOYSA-N,MITOXANTRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
2700,2708,CHEMBL58,KKZJGLLVHKMTCM-UHFFFAOYSA-N,MITOXANTRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
2701,2709,CHEMBL402090,KLAPRIKTPASOCO-GXTWGEPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC=CN(C1)C(=O)[C@]2(C[C@H]2CN)C3=CSC=C3,NC[C@@H]1C[C@@]1(C(=O)N1C=CCCC1)c1ccsc1
2702,2710,CHEMBL398009,KLBBBQNCHMPXRI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,2200.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.657577319177793,COC(=O)C1=C(CCCCC1)C2=CC=C(C=C2)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CCCCC1
2703,2711,CHEMBL398009,KLBBBQNCHMPXRI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,15000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.823908740944318,COC(=O)C1=C(CCCCC1)C2=CC=C(C=C2)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CCCCC1
2704,2712,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2376.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.624153563690844,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
2705,2713,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1888.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.72399801003795,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
2706,2714,CHEMBL40415,KLDSCOWYMZLTGO-SNAWJCMRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.86,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.86,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/CC4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
2707,2715,CHEMBL40415,KLDSCOWYMZLTGO-SNAWJCMRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.29,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.29,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/CC4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
2708,2716,CHEMBL1669669,KLFVWQCQUXXLOU-UHFFFAOYSA-N,RO-5212773,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21237643.0,INHIBITION,=,-7.0,%,,,,,,,,,,,,,,,Inhibition of human serotonin transporter at 10 uM,Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773).,Bioorg. Med. Chem. Lett.,PUBLICATION,,-7.0,CCOC1=CC=CC(=C1)NC(=O)C2=CC(=C(C=C2)N3CCCC3)C(F)(F)F,CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(C(F)(F)F)c2)c1
2709,2717,CHEMBL1669669,KLFVWQCQUXXLOU-UHFFFAOYSA-N,RO-5212773,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21237643.0,INHIBITION,=,43.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 10 uM,Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773).,Bioorg. Med. Chem. Lett.,PUBLICATION,,43.0,CCOC1=CC=CC(=C1)NC(=O)C2=CC(=C(C=C2)N3CCCC3)C(F)(F)F,CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(C(F)(F)F)c2)c1
2710,2718,CHEMBL511695,KLRJYPAUNJPVOA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,26.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,26.0,CN1CCN(CC1)CC(C2=CC=C(C=C2)Cl)C3(CCCCC3)O.Cl.Cl,CN1CCN(CC(c2ccc(Cl)cc2)C2(O)CCCCC2)CC1
2711,2719,CHEMBL337020,KLRMDPMJYLBCKY-IJXZTRCJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,2.7,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.568636235841014,C1CC[C@H]2[C@H](C1)N=C3N2C(C4=CC=CC=C43)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=N[C@H]3CCCC[C@@H]3N21
2712,2720,CHEMBL337020,KLRMDPMJYLBCKY-IJXZTRCJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,KI,=,152.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]- RTI -55 binding at the Dopamine transporter sites on HEK-hDAT cells,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.818156412055227,C1CC[C@H]2[C@H](C1)N=C3N2C(C4=CC=CC=C43)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=N[C@H]3CCCC[C@@H]3N21
2713,2721,CHEMBL337020,KLRMDPMJYLBCKY-IJXZTRCJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,15.8,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,15.8,C1CC[C@H]2[C@H](C1)N=C3N2C(C4=CC=CC=C43)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=N[C@H]3CCCC[C@@H]3N21
2714,2722,CHEMBL424627,KLRMDPMJYLBCKY-ZOVQDZKKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,8.4,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.075720713938116,C1CC[C@H]2[C@@H](C1)N=C3N2C(C4=CC=CC=C43)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=N[C@@H]3CCCC[C@@H]3N21
2715,2723,CHEMBL424627,KLRMDPMJYLBCKY-ZOVQDZKKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,5.1,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.1,C1CC[C@H]2[C@@H](C1)N=C3N2C(C4=CC=CC=C43)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=N[C@@H]3CCCC[C@@H]3N21
2716,2724,CHEMBL2030635,KLUCWWVQVUXBSE-UHFFFAOYSA-N,N-(2-PHENYLETHYL)PYRROLIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,KI,=,2731.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.563678299860267,C1CCN(C1)CCC2=CC=CC=C2,c1ccc(CCN2CCCC2)cc1
2717,2725,CHEMBL486237,KMLPWAMYQIJTNH-QUCCMNQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2C[C@H](C3=CC=CC=C23)N(C)C(C)C,Cc1ccccc1O[C@H]1C[C@@H](N(C)C(C)C)c2ccccc21
2718,2726,CHEMBL1818448,KMNJYBBPXRFSBY-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.199970640755867,CC1=CSC(=N1)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
2719,2727,CHEMBL1518,KNAHARQHSZJURB-UHFFFAOYSA-N,PROPYLTHIOURACIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=CC(=O)NC(=S)N1,CCCc1cc(=O)[nH]c(=S)[nH]1
2720,2728,CHEMBL1518,KNAHARQHSZJURB-UHFFFAOYSA-N,PROPYLTHIOURACIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=CC(=O)NC(=S)N1,CCCc1cc(=O)[nH]c(=S)[nH]1
2721,2729,CHEMBL2206531,KNAQCUBNCHCAPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,77.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.113509274827518,CN1CC(C2=C(C1)C=C(C=C2)OC)C3=CC(=C(C=C3)F)F,COc1ccc2c(c1)CN(C)CC2c1ccc(F)c(F)c1
2722,2730,CHEMBL2432046,KNBHNNRMMAKKFI-SEDVZXITSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,COC1=C(C=C(C=C1)CN[C@H]2C3C4CC5C2C6C3CC4C56)OC,COc1ccc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc1OC
2723,2731,CHEMBL2047566,KNEXRPBWIYIHRH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,61.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,61.0,COC1=C(C=C(C=C1)C(CCN2CCC(=CC2)CC3=CC=CC=C3)O)OC,COc1ccc(C(O)CCN2CC=C(Cc3ccccc3)CC2)cc1OC
2724,2732,CHEMBL565,KNHUKKLJHYUCFP-UHFFFAOYSA-N,CLOFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
2725,2733,CHEMBL565,KNHUKKLJHYUCFP-UHFFFAOYSA-N,CLOFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
2726,2734,CHEMBL445747,KNMQSIXWQIRNCP-NDXYWBNTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19284718.0,KI,=,5400.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,J. Med. Chem.,PUBLICATION,,5.267606240177033,CC1=CC(=CC=C1)[C@H]2C[C@@H]2CN.Cl,Cc1cccc([C@H]2C[C@@H]2CN)c1
2727,2735,CHEMBL461330,KNRWBQQXTOGVJT-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,12.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,CNCC[C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C,CNCC[C@H](c1ccccc1)n1c(=O)n(C)c2ccccc21
2728,2736,CHEMBL370063,KNTQYVICAJIRLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,9.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CC1=CC(=CC=C1)N2C3=CC=CC=C3CC(C2=O)(C)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2cccc(C)c2)C1=O
2729,2737,CHEMBL370063,KNTQYVICAJIRLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1=CC(=CC=C1)N2C3=CC=CC=C3CC(C2=O)(C)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2cccc(C)c2)C1=O
2730,2738,CHEMBL199053,KOGVQIODXLTVAN-OLZOCXBDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN1C=C(C2=C1C=CC(=C2)C#N)[C@H]3C[C@@H]3CN(C)C,CN(C)C[C@H]1C[C@@H]1c1cn(C)c2ccc(C#N)cc12
2731,2739,CHEMBL2012114,KOKBPPDCKPRXAM-OXOOOYADSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,110.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.9586073148417755,COC(=O)[C@H]1[C@H](CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1cc3ccccc3[nH]1)O2
2732,2740,CHEMBL2012114,KOKBPPDCKPRXAM-OXOOOYADSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@H](CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1cc3ccccc3[nH]1)O2
2733,2741,CHEMBL2012115,KOKBPPDCKPRXAM-RGODHZJXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,370.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.431798275933005,COC(=O)[C@@H]1[C@H](CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)[C@H]1C2CCC(C[C@@H]1c1cc3ccccc3[nH]1)O2
2734,2742,CHEMBL2012115,KOKBPPDCKPRXAM-RGODHZJXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@H](CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)[C@H]1C2CCC(C[C@@H]1c1cc3ccccc3[nH]1)O2
2735,2743,CHEMBL2012113,KOKBPPDCKPRXAM-UURUTEADSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,350.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.455931955649724,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)[C@H]1C2CCC(C[C@H]1c1cc3ccccc3[nH]1)O2
2736,2744,CHEMBL2012113,KOKBPPDCKPRXAM-UURUTEADSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@@H](CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)[C@H]1C2CCC(C[C@H]1c1cc3ccccc3[nH]1)O2
2737,2745,CHEMBL1813307,KOMUTRYSVZSJSV-LSDHHAIUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,1584.89,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.800000874803202,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC=CC=C3,CN1C[C@@H]2CCCC[C@]2(c2ccccc2)C1
2738,2746,CHEMBL1171391,KOPIUBJLSUXFHC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,6.31,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CC2CNCCN2c2ccc3[nH]ccc3c2)cc1
2739,2747,CHEMBL3613642,KORKKQLDGMHNKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26235950.0,INHIBITION,=,10.0,%,,,,,,,,,,,,,,,Binding affinity to human DA transporter assessed as inhibition of control specific binding at 10 uM,Identification of orally-bioavailable antagonists of the TRPV4 ion-channel.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC(C)N1CCN(CC1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=C(C=C3)C(F)(F)F)[N+](=O)[O-],CC(C)N1CCN(S(=O)(=O)c2ccc(NC(=O)c3ccc(C(F)(F)F)cc3[N+](=O)[O-])cc2)CC1
2740,2748,CHEMBL150932,KPDJDJHGSVDTMY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.431798275933005,C1CNCCC1C(C2=CC=CC=C2)OC3=CC=CC4=CC=CC=C43,c1ccc(C(Oc2cccc3ccccc23)C2CCNCC2)cc1
2741,2749,CHEMBL425589,KPESCGPEZLRTMM-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,201.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.696803942579511,CC(C)CN(CC1=CC(=CC=C1)C#N)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1cccc(C#N)c1)C1CCNCC1
2742,2750,CHEMBL1065,KPJZHOPZRAFDTN-ZRGWGRIASA-N,METHYSERGIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
2743,2751,CHEMBL1065,KPJZHOPZRAFDTN-ZRGWGRIASA-N,METHYSERGIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
2744,2752,CHEMBL23034,KPKLDBBNSFWOFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,=,840.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.075720713938117,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)I)N,CN(C)Cc1ccccc1Sc1ccc(I)cc1N
2745,2753,CHEMBL23034,KPKLDBBNSFWOFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)I)N,CN(C)Cc1ccccc1Sc1ccc(I)cc1N
2746,2754,CHEMBL23034,KPKLDBBNSFWOFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,=,840.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.075720713938117,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)I)N,CN(C)Cc1ccccc1Sc1ccc(I)cc1N
2747,2755,CHEMBL565638,KPOGSLKDEJXGPM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CCCN(C1CCNCC1)C(=O)C2=CC3=CC=CC=C3C=C2,CCCN(C(=O)c1ccc2ccccc2c1)C1CCNCC1
2748,2756,CHEMBL498847,KPQZUUQMTUIKBP-UHFFFAOYSA-N,SECNIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CC(C)O
2749,2757,CHEMBL498847,KPQZUUQMTUIKBP-UHFFFAOYSA-N,SECNIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CC(C)O
2750,2758,CHEMBL557555,KPSRODZRAIWAKH-UHFFFAOYSA-N,CIPROFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O
2751,2759,CHEMBL557555,KPSRODZRAIWAKH-UHFFFAOYSA-N,CIPROFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O
2752,2760,CHEMBL701,KPYSYYIEGFHWSV-UHFFFAOYSA-N,BACLOFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,NCC(CC(=O)O)c1ccc(Cl)cc1
2753,2761,CHEMBL701,KPYSYYIEGFHWSV-UHFFFAOYSA-N,BACLOFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,NCC(CC(=O)O)c1ccc(Cl)cc1
2754,2762,CHEMBL141343,KPZQRBACZSLMPH-UHFFFAOYSA-N,U-78517F,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,13352.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.87445367632881,CC1=C(C2=C(CCC(O2)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2
2755,2763,CHEMBL141343,KPZQRBACZSLMPH-UHFFFAOYSA-N,U-78517F,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,10609.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.974325550589656,CC1=C(C2=C(CCC(O2)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2
2756,2764,CHEMBL259694,KQAWRUCRTMUOJJ-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCO3,C=CCN(CC=C)C(=O)[C@@]1(c2ccc3c(c2)OCO3)C[C@H]1CN
2757,2765,CHEMBL556167,KQHYJWANORXMTF-GRTNUQQKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,4.6,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6,COC1=CC=CC=C1C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O.Cl,COc1ccccc1C[C@@](O)(c1ccccc1)[C@@H]1CNCCO1
2758,2766,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
2759,2767,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
2760,2768,CHEMBL391806,KQOBDZDVQFUADH-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,122.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9136401693252525,C1CNC[C@H]1N(CC2=C(C(=CC=C2)Cl)Cl)CC3=CC=CC=N3,Clc1cccc(CN(Cc2ccccn2)[C@H]2CCNC2)c1Cl
2761,2769,CHEMBL440230,KQOBDZDVQFUADH-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,125.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.903089986991943,C1CNC[C@@H]1N(CC2=C(C(=CC=C2)Cl)Cl)CC3=CC=CC=N3,Clc1cccc(CN(Cc2ccccn2)[C@@H]2CCNC2)c1Cl
2762,2770,CHEMBL447,KQPKPCNLIDLUMF-UHFFFAOYSA-N,SECOBARBITAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O
2763,2771,CHEMBL447,KQPKPCNLIDLUMF-UHFFFAOYSA-N,SECOBARBITAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O
2764,2772,CHEMBL1208572,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,SALINOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O,CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C
2765,2773,CHEMBL1208572,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,SALINOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O,CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C
2766,2774,CHEMBL2326501,KRCLPAGVJVBLJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23237837.0,INHIBITION,=,103.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]BTCP from human recombinant DA transporter expressed in CHO cells at 1 uM,Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,103.0,CCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC(=C2)N3CCNCC3,CCCCCCCOc1ccc(NC(=O)Oc2cccc(N3CCNCC3)c2)cc1
2767,2775,CHEMBL401550,KRJLGYVCEZYCEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,1160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.935542010773082,CC1=CC(=C(C=N1)CN(C)C)OC2=CC=CC=C2Cl,Cc1cc(Oc2ccccc2Cl)c(CN(C)C)cn1
2768,2776,CHEMBL1261,KRKNYBCHXYNGOX-UHFFFAOYSA-N,CITRIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,O=C(O)CC(O)(CC(=O)O)C(=O)O
2769,2777,CHEMBL1261,KRKNYBCHXYNGOX-UHFFFAOYSA-N,CITRIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,O=C(O)CC(O)(CC(=O)O)C(=O)O
2770,2778,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,3250.0,NM,,,,,,,,,,,,,,,,,,,,5.4881166390211265,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
2771,2779,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,2580.0,NM,,,,,,,,,,,,,,,,,,,,5.58838029403677,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
2772,2780,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,7500.0,NM,,,,,,,,,,,,,,,,,,,,5.1249387366083,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
2773,2781,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,12589.25,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.900000142057633,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
2774,2782,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,6203.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.207398218835033,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
2775,2783,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
2776,2784,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
2777,2785,CHEMBL2326685,KRNOLRHDBBTXOP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,24.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.619788758288393,CC1=C(C=CC(=C1)C2CC=CCNC2)Cl,Cc1cc(C2CC=CCNC2)ccc1Cl
2778,2786,CHEMBL234127,KRQBCJRFWIYJDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,630000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.2006594505464183,COC(=O)C1=C(CCCC1)C2=CC=CC=C2,COC(=O)C1=C(c2ccccc2)CCCC1
2779,2787,CHEMBL234127,KRQBCJRFWIYJDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCC1)C2=CC=CC=C2,COC(=O)C1=C(c2ccccc2)CCCC1
2780,2788,CHEMBL234127,KRQBCJRFWIYJDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,1584893192461.11,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.1999999999999997,COC(=O)C1=C(CCCC1)C2=CC=CC=C2,COC(=O)C1=C(c2ccccc2)CCCC1
2781,2789,CHEMBL2414911,KRSNVUPLMVRORR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23880542.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin) at 10 uM by ligand displacement assay,Neuroactive diol and acyloin metabolites from cone snail-associated bacteria.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1=CC=C2C(=C1)C(=CN2)CC(=O)C(CC3=CC=C(C=C3)O)O,O=C(Cc1c[nH]c2ccccc12)C(O)Cc1ccc(O)cc1
2782,2790,CHEMBL1752,KSCFJBIXMNOVSH-UHFFFAOYSA-N,DYPHYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
2783,2791,CHEMBL1752,KSCFJBIXMNOVSH-UHFFFAOYSA-N,DYPHYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
2784,2792,CHEMBL32749,KSEBMYQBYZTDHS-HWKANZROSA-N,FERULIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,COc1cc(/C=C/C(=O)O)ccc1O
2785,2793,CHEMBL32749,KSEBMYQBYZTDHS-HWKANZROSA-N,FERULIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,COc1cc(/C=C/C(=O)O)ccc1O
2786,2794,CHEMBL1224090,KSKOKUBPUSATCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.16,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381597,CC(C)CC1(CCCN1)C(=O)C2=CC(=C(C=C2)N)Cl,CC(C)CC1(C(=O)c2ccc(N)c(Cl)c2)CCCN1
2787,2795,CHEMBL35239,KSNRMBXMKXZRBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,1.23,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,1.23,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)C#N,N#Cc1ccc(CN2CCC(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
2788,2796,CHEMBL512967,KSQKTWNQJCTCMA-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCC(=O)N(CC1=C(C=C(C=C1)Cl)Cl)[C@H]2CCNC2,CCC(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
2789,2797,CHEMBL560535,KSQOUNJPKDJKKL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,50.12,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CNCCC1N(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)cc1
2790,2798,CHEMBL560535,KSQOUNJPKDJKKL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,50.12,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CNCCC1N(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)cc1
2791,2799,CHEMBL124222,KSRAFZQYEJWAQE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,>,10.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,8.0,C1CN(C(=O)CN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,O=C1CN(CCOC(c2ccccc2)c2ccccc2)CCN1CCCc1ccccc1
2792,2800,CHEMBL124222,KSRAFZQYEJWAQE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,8200.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,5.086186147616283,C1CN(C(=O)CN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,O=C1CN(CCOC(c2ccccc2)c2ccccc2)CCN1CCCc1ccccc1
2793,2801,CHEMBL124222,KSRAFZQYEJWAQE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,>,1.2,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,1.2,C1CN(C(=O)CN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,O=C1CN(CCOC(c2ccccc2)c2ccccc2)CCN1CCCc1ccccc1
2794,2802,CHEMBL566173,KSVISHYLWAYQCI-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCNC[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O,CCNC[C@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
2795,2803,CHEMBL236473,KTBNOMBPBJJANJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,232000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,3.6345120151091,COC(=O)C1=C(C2CCC1N2)C3=CC(=CC=C3)[N+](=O)[O-],COC(=O)C1=C(c2cccc([N+](=O)[O-])c2)C2CCC1N2
2796,2804,CHEMBL3238484,KTEXKENZUYDPAR-PGMHBOJBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,CC1=C(C=CC(=C1)I)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Cc1cc(I)ccc1N=Nc1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
2797,2805,CHEMBL540445,KTEXNACQROZXEV-SLXBATTESA-N,PARTHENOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CCC[C@@]2([C@@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,C=C1C(=O)O[C@H]2[C@H]1CCC(C)=CCC[C@@]1(C)O[C@@H]21
2798,2806,CHEMBL540445,KTEXNACQROZXEV-SLXBATTESA-N,PARTHENOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CCC[C@@]2([C@@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,C=C1C(=O)O[C@H]2[C@H]1CCC(C)=CCC[C@@]1(C)O[C@@H]21
2799,2807,CHEMBL192824,KTFFRYZZEFRULN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CC1=CC(=C(C=C1F)SC2=CC=CC=C2CN(C)C)N,Cc1cc(N)c(Sc2ccccc2CN(C)C)cc1F
2800,2808,CHEMBL1200322,KTGRHKOEFSJQNS-BDQAORGHSA-N,ESCITALOPRAM OXALATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,,,,Not Determined,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,,CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
2801,2809,CHEMBL1172744,KTJHVHZJTXJNIH-QZTJIDSGSA-N,1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,12.59,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.899974269892138,COC[C@]12C[C@]1(CCNC2)C3=CC4=CC=CC=C4C=C3,COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2
2802,2810,CHEMBL1172744,KTJHVHZJTXJNIH-QZTJIDSGSA-N,1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,31.62,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.500038134403809,COC[C@]12C[C@]1(CCNC2)C3=CC4=CC=CC=C4C=C3,COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2
2803,2811,CHEMBL1172744,KTJHVHZJTXJNIH-QZTJIDSGSA-N,1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.0,COC[C@]12C[C@]1(CCNC2)C3=CC4=CC=CC=C4C=C3,COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2
2804,2812,CHEMBL941,KTUFNOKKBVMGRW-UHFFFAOYSA-N,IMATINIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
2805,2813,CHEMBL941,KTUFNOKKBVMGRW-UHFFFAOYSA-N,IMATINIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
2806,2814,CHEMBL382810,KUDFJDYXEMEWNB-OAUVRVJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,90.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc([S+](C)[O-])cc21
2807,2815,CHEMBL1087924,KUHFOMDKXOTLGD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,-7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-7.0,CNCCCN1CC2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCCCN1Cc2ccccc2N(c2ccccc2F)S1(=O)=O
2808,2816,CHEMBL1818445,KUJKCGJIUCGPED-AAFJCEBUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,0.2,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,9.69897000433602,CC1=CSC(=N1)C23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc(C23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
2809,2817,CHEMBL1818445,KUJKCGJIUCGPED-AAFJCEBUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,19.95,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.700057099977232,CC1=CSC(=N1)C23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc(C23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
2810,2818,CHEMBL1818444,KUJKCGJIUCGPED-HZPDHXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,0.158,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,9.801342913045575,CC1=CSC(=N1)[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc([C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
2811,2819,CHEMBL2205814,KULMFBVVFDTVNX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,COC1=C(C=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O)OC,COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC
2812,2820,CHEMBL210116,KURNFMGUSYWHLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCOC1=CC=CC=C1CC(C2=NC=CS2)N3CCNCC3,CCOc1ccccc1CC(c1nccs1)N1CCNCC1
2813,2821,CHEMBL1645614,KUTIVIKNDVNVAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6460.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.189767482004916,CC1=C(C(=CC=C1)F)OC2=C(C(=CC=C2)F)OC3CCNC3,Cc1cccc(F)c1Oc1cccc(F)c1OC1CCNC1
2814,2822,CHEMBL391947,KUYNMYBNRQCGCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17616397.0,KI,=,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=C(C=CC(=C1)OC2=C(C=C(C=C2)C#CCCN3CCOCC3)CNC)SC,CNCc1cc(C#CCCN2CCOCC2)ccc1Oc1ccc(SC)c(C)c1
2815,2823,CHEMBL578219,KVHCMVHVGGEFGG-CCRGXQTGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,71.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.1487416512809245,COC(=O)[C@H]1[C@H](CC2CCC1N2CC=C)C3=CC=C(C=C3)SC,C=CCN1C2CCC1[C@@H](C(=O)OC)[C@@H](c1ccc(SC)cc1)C2
2816,2824,CHEMBL212452,KVHKGSIWONIENO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784855.0,KI,=,41.92,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT transfected in HEK293 cells,Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.377578726024329,C=C1CN2C3CCC2C1C(C3)C4=CC=C(C=C4)Br,C=C1CN2C3CCC2C1C(c1ccc(Br)cc1)C3
2817,2825,CHEMBL537196,KVIXRWQLEHRFLW-DPSPSOFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,3.7,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.7,COC1=CC=CC=C1C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O.Cl.Cl,COc1ccccc1C[C@@](O)(c1ccccc1)[C@@H]1CNCCO1
2818,2826,CHEMBL378418,KVNXQYJMNFSXRE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=C2Br)C3=CC=CC=C3,Brc1ccccc1CC(c1ccccc1)N1CCNCC1
2819,2827,CHEMBL511525,KVRIVKGFVFCJEI-JPKZNVRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,KI,=,73.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.136677139879544,CN1CCN(CC1)C[C@H](C2=CC(=CC=C2)Cl)C3(CCCCC3)O.Cl.Cl,CN1CCN(C[C@H](c2cccc(Cl)c2)C2(O)CCCCC2)CC1
2820,2828,CHEMBL459852,KVRIVKGFVFCJEI-NTEVMMBTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,KI,=,235.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.628932137728263,CN1CCN(CC1)C[C@@H](C2=CC(=CC=C2)Cl)C3(CCCCC3)O.Cl.Cl,CN1CCN(C[C@@H](c2cccc(Cl)c2)C2(O)CCCCC2)CC1
2821,2829,CHEMBL511347,KVRIVKGFVFCJEI-UHFFFAOYSA-N,WY-46824,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,KI,=,53.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.275724130399211,CN1CCN(CC1)CC(C2=CC(=CC=C2)Cl)C3(CCCCC3)O.Cl.Cl,CN1CCN(CC(c2cccc(Cl)c2)C2(O)CCCCC2)CC1
2822,2830,CHEMBL24944,KVSKGMLNBAPGKH-UHFFFAOYSA-N,TRIBROMSALAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br,O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O
2823,2831,CHEMBL24944,KVSKGMLNBAPGKH-UHFFFAOYSA-N,TRIBROMSALAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br,O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O
2824,2832,CHEMBL1813316,KVTPLEPXMVVCIZ-CJNGLKHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.599980364934843,CCN1C[C@H]2CCCC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,CCN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1
2825,2833,CHEMBL1813317,KVTPLEPXMVVCIZ-XJKSGUPXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,10.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,8.0,CCN1C[C@@H]2CCCC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,CCN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1
2826,2834,CHEMBL2430686,KVVQAOOISUGMSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,171.9,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.764724123312948,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccc(Cl)c(Cl)c1
2827,2835,CHEMBL2430686,KVVQAOOISUGMSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,89.7,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,89.7,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccc(Cl)c(Cl)c1
2828,2836,CHEMBL2430686,KVVQAOOISUGMSL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,99.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,99.0,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccc(Cl)c(Cl)c1
2829,2837,CHEMBL125140,KVVSZDPIQNKZIJ-AYXRGOPHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,49.5,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.305394801066433,CC1=CC=C(C=C1)C(C2=CC=CC=C2)O[C@H]3CC4CCC(C3C(=O)OC)N4C,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccccc1)c1ccc(C)cc1)N2C
2830,2838,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
2831,2839,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
2832,2840,CHEMBL504971,KWAYIPPRBHZSBU-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,9.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC=CC=C2)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccccc1
2833,2841,CHEMBL3673145,KWGNNADVFYRCOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,219.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.65856547542186,CC1=NN=C2N1C=C(C=C2)C3=CC4=C(C=C3)C5(CCN(C4)CC5)C6=CC=C(C=C6)Cl,Cc1nnc2ccc(-c3ccc4c(c3)CN3CCC4(c4ccc(Cl)cc4)CC3)cn12
2834,2842,CHEMBL279157,KWGRBVOPPLSCSI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,236.0,NM,,,,,,,,,,,,,,,,,,,,6.627087997029894,CC(C(C1=CC=CC=C1)O)NC,CNC(C)C(O)c1ccccc1
2835,2843,CHEMBL279157,KWGRBVOPPLSCSI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,2104.0,NM,,,,,,,,,,,,,,,,,,,,5.676954264518298,CC(C(C1=CC=CC=C1)O)NC,CNC(C)C(O)c1ccccc1
2836,2844,CHEMBL279157,KWGRBVOPPLSCSI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,9125.0,NM,,,,,,,,,,,,,,,,,,,,5.039767126871488,CC(C(C1=CC=CC=C1)O)NC,CNC(C)C(O)c1ccccc1
2837,2845,CHEMBL1818468,KWIJNWQXQHEXSP-RTBURBONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,7.94,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.100179497572904,CC1=CC(=CN1C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C,Cc1cc(C)n(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)c1
2838,2846,CHEMBL3331480,KWJCQQFIRORDRE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,13.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,13.0,C1C(CN1)N(CC2=CC=CC=C2)CC3=CC=C(C=C3)Cl,Clc1ccc(CN(Cc2ccccc2)C2CNC2)cc1
2839,2847,CHEMBL1643661,KWPJGSRDVFKINU-DUKDKBGRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,497.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.303643611266668,C1CC2C([C@@H](CC1S2)C3=CC(=C(C=C3)Cl)Cl)C4=CC(=NO4)C5=CC=CC=C5,Clc1ccc([C@@H]2CC3CCC(S3)C2c2cc(-c3ccccc3)no2)cc1Cl
2840,2848,CHEMBL1643669,KWPJGSRDVFKINU-JFNOIUHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,269.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.570247719997593,C1CC2C([C@H](CC1S2)C3=CC(=C(C=C3)Cl)Cl)C4=CC(=NO4)C5=CC=CC=C5,Clc1ccc([C@H]2CC3CCC(S3)C2c2cc(-c3ccccc3)no2)cc1Cl
2841,2849,CHEMBL612,KWTSXDURSIMDCE-QMMMGPOBSA-N,DEXTROAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22037049.0,EC50,=,24.8,NM,,,tissue,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT cloned in rat brain synaptosome by scintillation counting,Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.,Bioorg. Med. Chem.,PUBLICATION,,7.605548319173784,C[C@@H](CC1=CC=CC=C1)N,C[C@H](N)Cc1ccccc1
2842,2850,CHEMBL612,KWTSXDURSIMDCE-QMMMGPOBSA-N,DEXTROAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,288.4,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.540004743952608,C[C@@H](CC1=CC=CC=C1)N,C[C@H](N)Cc1ccccc1
2843,2851,CHEMBL612,KWTSXDURSIMDCE-QMMMGPOBSA-N,DEXTROAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,109.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.962573502059376,C[C@@H](CC1=CC=CC=C1)N,C[C@H](N)Cc1ccccc1
2844,2852,CHEMBL405,KWTSXDURSIMDCE-UHFFFAOYSA-N,AMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,116.0,NM,,,,,,,,,,,,,,,,,,,,6.935542010773082,CC(CC1=CC=CC=C1)N,CC(N)Cc1ccccc1
2845,2853,CHEMBL405,KWTSXDURSIMDCE-UHFFFAOYSA-N,AMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,190.0,NM,,,,,,,,,,,,,,,,,,,,6.721246399047171,CC(CC1=CC=CC=C1)N,CC(N)Cc1ccccc1
2846,2854,CHEMBL405,KWTSXDURSIMDCE-UHFFFAOYSA-N,AMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(CC1=CC=CC=C1)N,CC(N)Cc1ccccc1
2847,2855,CHEMBL405,KWTSXDURSIMDCE-UHFFFAOYSA-N,AMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,24.8,NM,,,,,,,,,,,,,,,,,,,,7.605548319173784,CC(CC1=CC=CC=C1)N,CC(N)Cc1ccccc1
2848,2856,CHEMBL563495,KWWVMVUZZJMGRZ-CHPOKUKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,1060.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9746941347352305,C1CNC[C@H]1C(C2=CC=CC=N2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2ccccn2)[C@H]2CCNC2)c1Cl
2849,2857,CHEMBL563495,KWWVMVUZZJMGRZ-CHPOKUKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,1530.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.815308569182402,C1CNC[C@H]1C(C2=CC=CC=N2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2ccccn2)[C@H]2CCNC2)c1Cl
2850,2858,CHEMBL551573,KWWVMVUZZJMGRZ-ZVDHGWRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,330.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.481486060122112,C1CNC[C@@H]1C(C2=CC=CC=N2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2ccccn2)[C@@H]2CCNC2)c1Cl
2851,2859,CHEMBL551573,KWWVMVUZZJMGRZ-ZVDHGWRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,720.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.142667503568733,C1CNC[C@@H]1C(C2=CC=CC=N2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2ccccn2)[C@@H]2CCNC2)c1Cl
2852,2860,CHEMBL505439,KXCIACPDRWQKBQ-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@H](CS(=O)(=O)C3=CC=CC=C23)CNC,CNC[C@H]1CS(=O)(=O)c2ccccc2[C@@H]1Oc1ccccc1C
2853,2861,CHEMBL1173415,KXJGGCUESGCVLH-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,1584.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.800000874803202,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)C(F)(F)F)Cl,COC[C@@]12CNCC[C@]1(c1ccc(C(F)(F)F)c(Cl)c1)C2
2854,2862,CHEMBL458488,KXLFAQOYCLVWOS-LJPFFJIGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,92.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.036212172654443,CCOC1=CC=C(C=C1)[C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC)N3C.Cl,CCOc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC)N3C)cc1
2855,2863,CHEMBL596805,KXLJVOFBGQNGTJ-VIKVFOODSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,6.31,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.199970640755867,CC(C)OCCC1([C@H]2[C@@H]1CNC2)C3=CC(=C(C=C3)Cl)Cl,CC(C)OCCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CNC[C@H]21
2856,2864,CHEMBL1813482,KXQVOLBRJCPHMW-HZMBPMFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,9772.37,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.010000098195094,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC(=CC(=C3)Cl)Cl,CN1C[C@@H]2CCC[C@]2(c2cc(Cl)cc(Cl)c2)C1
2857,2865,CHEMBL2338031,KXRRNOJECCYJIA-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,158.49,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)F)F,Fc1ccc(O[C@@H](c2ccccc2)[C@H]2CCNC2)c(F)c1
2858,2866,CHEMBL3092995,KXSAIQPPGSSNKX-ZETCQYMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24205976.0,INH,=,16000.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin),"Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).",J. Med. Chem.,PUBLICATION,,4.795880017344076,C1[C@@H](OC2=C(O1)C=C(C=C2)Cl)CNS(=O)(=O)N,NS(=O)(=O)NC[C@H]1COc2cc(Cl)ccc2O1
2859,2867,CHEMBL335423,KXYMHOPZXNZJHG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,IC50,=,1568.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.804653941651582,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)OC)OC)C(=O)OC,COC(=O)C1C(c2ccc(OC)c(OC)c2)CC2CCC1N2C
2860,2868,CHEMBL335423,KXYMHOPZXNZJHG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,=,1536.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.813608784304508,CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)OC)OC)C(=O)OC,COC(=O)C1C(c2ccc(OC)c(OC)c2)CC2CCC1N2C
2861,2869,CHEMBL1253735,KYFGACYORZGXNM-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,11.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,7.9586073148417755,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=C(C=C2)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1
2862,2870,CHEMBL1253735,KYFGACYORZGXNM-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,14.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,7.853871964321763,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=C(C=C2)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1
2863,2871,CHEMBL3309702,KYHMFLOOKCBLDX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,52.1,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.283162276700477,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3,Clc1ccc(C(CC2CNC2)Oc2ccccc2)cc1Cl
2864,2872,CHEMBL3309702,KYHMFLOOKCBLDX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,77.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,77.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3,Clc1ccc(C(CC2CNC2)Oc2ccccc2)cc1Cl
2865,2873,CHEMBL3309702,KYHMFLOOKCBLDX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3,Clc1ccc(C(CC2CNC2)Oc2ccccc2)cc1Cl
2866,2874,CHEMBL3309702,KYHMFLOOKCBLDX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3,Clc1ccc(C(CC2CNC2)Oc2ccccc2)cc1Cl
2867,2875,CHEMBL561598,KYMPTONVLFUIMS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,50.12,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CNCCC1N(CC2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4,c1ccc(CN(c2ccc3[nH]ncc3c2)C2CCNCC2)cc1
2868,2876,CHEMBL9514,KYRVNWMVYQXFEU-UHFFFAOYSA-N,NOCODAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,6232.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.205372555335492,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3,COC(=O)Nc1nc2ccc(C(=O)c3cccs3)cc2[nH]1
2869,2877,CHEMBL9514,KYRVNWMVYQXFEU-UHFFFAOYSA-N,NOCODAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4946.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.305745887974722,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3,COC(=O)Nc1nc2ccc(C(=O)c3cccs3)cc2[nH]1
2870,2878,CHEMBL466006,KYTHDBXSBSSRTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CC=C1)NC(=O)C2=CC(=C(C=C2)C3=CC=CC=C3)C#N,Cc1cccc(NC(=O)c2ccc(-c3ccccc3)c(C#N)c2)n1
2871,2879,CHEMBL466006,KYTHDBXSBSSRTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CC=C1)NC(=O)C2=CC(=C(C=C2)C3=CC=CC=C3)C#N,Cc1cccc(NC(=O)c2ccc(-c3ccccc3)c(C#N)c2)n1
2872,2880,CHEMBL2206532,KYUYTLMYZDCTDV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,25.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.602059991327962,CC1=CC(=CC=C1)C2CN(CC3=C2C=CC(=C3)OC)C,COc1ccc2c(c1)CN(C)CC2c1cccc(C)c1
2873,2881,CHEMBL1118,KYYIDSXMWOZKMP-UHFFFAOYSA-N,DESVENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16675639.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1
2874,2882,CHEMBL1118,KYYIDSXMWOZKMP-UHFFFAOYSA-N,DESVENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,>,854.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.068542129310996,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1
2875,2883,CHEMBL1813476,KZCROLYCBADBTI-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,33.88,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.470056598341332,C1C[C@H]2CNC[C@]2(C1)C3=CC4=CC=CC=C4C=C3,c1ccc2cc([C@]34CCC[C@H]3CNC4)ccc2c1
2876,2884,CHEMBL1813477,KZCROLYCBADBTI-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,30.2,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.519993057042849,C1C[C@@H]2CNC[C@@]2(C1)C3=CC4=CC=CC=C4C=C3,c1ccc2cc([C@@]34CCC[C@@H]3CNC4)ccc2c1
2877,2885,CHEMBL1641697,KZDQUVCATILJRB-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,2696.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.569280112136718,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2N=[N+]=[N-])C3=CC(=CC=C3)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1Cc1ccccc1N=[N+]=[N-]
2878,2886,CHEMBL1641697,KZDQUVCATILJRB-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,1112.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.953895212753961,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2N=[N+]=[N-])C3=CC(=CC=C3)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1Cc1ccccc1N=[N+]=[N-]
2879,2887,CHEMBL469810,KZMOSMDAUNHNBH-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,861.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.064996848546345,C1CNC[C@H]1OCC2=CC3=C(C=C2)C=C(C=C3)C#N,N#Cc1ccc2cc(CO[C@H]3CCNC3)ccc2c1
2880,2888,CHEMBL2165447,KZONDTNPVHWVKU-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,EFFICACY,=,91.8,%,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT at 10 uM after 1.5 hrs by microbeta scintillation counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,91.8,C1CN[C@@H]1COC2=NOC(=C2)COC3=CC=CC=C3,c1ccc(OCc2cc(OC[C@@H]3CCN3)no2)cc1
2881,2889,CHEMBL2165447,KZONDTNPVHWVKU-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,24.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT after 1.5 hrs by microbeta scintillation counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.619788758288393,C1CN[C@@H]1COC2=NOC(=C2)COC3=CC=CC=C3,c1ccc(OCc2cc(OC[C@@H]3CCN3)no2)cc1
2882,2890,CHEMBL249213,KZTLVKCVXWWSHF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,6400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,CN(C(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl)OC,CON(C)C(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
2883,2891,CHEMBL336827,KZVAORHWOZQQCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,INHIBITION,=,30.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane at a concentration of 10e-6 M,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,30.0,C1=CC=C2C(=C1)C3=NC4=CC=CC=C4N3C2(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2-c2nc3ccccc3n21
2884,2892,CHEMBL336827,KZVAORHWOZQQCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,<,0.02,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,0.02,C1=CC=C2C(=C1)C3=NC4=CC=CC=C4N3C2(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2-c2nc3ccccc3n21
2885,2893,CHEMBL379755,KZXIQLJNAIYPLZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,390.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.4089353929735005,CN1C2CCC1C3COC(=O)CCCCCCCCCCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCCCCCCCCCC(=O)Nc3ccc(cc3)C1C2
2886,2894,CHEMBL1080907,LADSERODBYZUAW-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5C,Cc1ccccc1-c1ccc(C(=O)N2CCN(C(=O)c3ccc4cc[nH]c4c3)[C@@H](C)C2)cc1
2887,2895,CHEMBL262357,LAMKUIMKGNOGQJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,4800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.318758762624412,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2OC,CNCc1cnc(C)cc1Oc1ccccc1OC
2888,2896,CHEMBL226933,LAVPLSGMUSPWHO-BQUSRXHISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,226.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.645891560852599,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)OC)N3C,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(C)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1
2889,2897,CHEMBL226933,LAVPLSGMUSPWHO-BQUSRXHISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,53.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.275724130399211,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)OC)N3C,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(C)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1
2890,2898,CHEMBL2031884,LBAKRWRQQGNMEB-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313242.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,CCNC(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=O)N(CC3)CCN4CCC[C@H]4C,CCNC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCC[C@H]2C)C3=O)cc1
2891,2899,CHEMBL202913,LBFUCVLJJXYYQF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)N)C2=CC=CC=C2CN(C)C,Cc1ccc(N)c(-c2ccccc2CN(C)C)c1
2892,2900,CHEMBL1812740,LBLVIDUIWXYVNG-AITUJVMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,4.8,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.318758762624412,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC4CCC4)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC2CCC2)N3C)cc1
2893,2901,CHEMBL2326689,LBMMBEDCUJAMIZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,60.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.221848749616356,CN1CC=CCC(C1)C2=CC3=CC=CC=C3O2,CN1CC=CCC(c2cc3ccccc3o2)C1
2894,2902,CHEMBL136057,LBRPERYKIZCGBR-HNQUOIGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,0.99,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,9.00436480540245,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CO4,Fc1ccc(C(OCCC2CCN(C/C=C/c3ccco3)CC2)c2ccc(F)cc2)cc1
2895,2903,CHEMBL383745,LBZCFIOVPDHQQT-JCOPYZAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,2.1,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.67778070526608,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC[C@@H](C4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@@H](CCN1CCC(CCOC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
2896,2904,CHEMBL204060,LBZCFIOVPDHQQT-LNLSOMNWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.8,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.744727494896694,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC[C@H](C4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@H](CCN1CCC(CCOC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
2897,2905,CHEMBL2030630,LCBQDWKMNGEPLD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CC2CCC1N2CCCC3=CC(=CC=C3)F,Fc1cccc(CCCN2C3CCC2CC3)c1
2898,2906,CHEMBL574126,LCJMOOYZLAZDBK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,87.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0604807473813835,C1CN(CCN1)C2=CC=CC=C2CC3C(=O)N(CCS3)C4=CC(=C(C=C4)Cl)Cl,O=C1C(Cc2ccccc2N2CCNCC2)SCCN1c1ccc(Cl)c(Cl)c1
2899,2907,CHEMBL2012087,LCUHMFPPMNYKDZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,349.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.45717457304082,COC(=O)C1=C(CC2CCC1O2)C3=CC4=CC=CC=C4O3,COC(=O)C1=C(c2cc3ccccc3o2)CC2CCC1O2
2900,2908,CHEMBL2012087,LCUHMFPPMNYKDZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC4=CC=CC=C4O3,COC(=O)C1=C(c2cc3ccccc3o2)CC2CCC1O2
2901,2909,CHEMBL508678,LCUQDUYHYRSPMJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCC2=CN=CC=C2)CN,NCC1CCC(CCc2cccnc2)O1
2902,2910,CHEMBL508678,LCUQDUYHYRSPMJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCC2=CN=CC=C2)CN,NCC1CCC(CCc2cccnc2)O1
2903,2911,CHEMBL132082,LCWPWPFSABPKJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,13.3,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.876148359032914,COC1=CC2=C(C=C1)C3=NCCN3C2(C4=CC=C(C=C4)Cl)O,COc1ccc2c(c1)C(O)(c1ccc(Cl)cc1)N1CCN=C21
2904,2912,CHEMBL132082,LCWPWPFSABPKJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,16.7,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.777283528852418,COC1=CC2=C(C=C1)C3=NCCN3C2(C4=CC=C(C=C4)Cl)O,COc1ccc2c(c1)C(O)(c1ccc(Cl)cc1)N1CCN=C21
2905,2913,CHEMBL132082,LCWPWPFSABPKJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,6.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.221848749616356,COC1=CC2=C(C=C1)C3=NCCN3C2(C4=CC=C(C=C4)Cl)O,COc1ccc2c(c1)C(O)(c1ccc(Cl)cc1)N1CCN=C21
2906,2914,CHEMBL348552,LCWYVYCRRLOAFG-FBNRMZCVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10691690.0,KI,=,0.48,NM,,,cell_based,,,,,,,,,,,,In vitro affinity determined using [3H]WIN-35428 in murine kidney cells transfected with human dopamine transporter (DAT),"Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.",J. Med. Chem.,PUBLICATION,,9.318758762624412,CN1CC2CCC1C([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1c1ccc(I)cc1)CN2C
2907,2915,CHEMBL498775,LCYYZQNDLDWZLI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.0,CN(CCC1=CC(=CC=C1)OC(F)(F)F)CCN2CCCC2,CN(CCc1cccc(OC(F)(F)F)c1)CCN1CCCC1
2908,2916,CHEMBL121460,LDCWRCFCYHTIGC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,830.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.080921907623925,CN(CCN(C)CCOC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CN(CCOC(c1ccc(F)cc1)c1ccc(F)cc1)CCN(C)CCOC(c1ccc(F)cc1)c1ccc(F)cc1
2909,2917,CHEMBL121460,LDCWRCFCYHTIGC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,26.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.585026652029183,CN(CCN(C)CCOC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CN(CCOC(c1ccc(F)cc1)c1ccc(F)cc1)CCN(C)CCOC(c1ccc(F)cc1)c1ccc(F)cc1
2910,2918,CHEMBL121460,LDCWRCFCYHTIGC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,32.4,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,32.4,CN(CCN(C)CCOC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CN(CCOC(c1ccc(F)cc1)c1ccc(F)cc1)CCN(C)CCOC(c1ccc(F)cc1)c1ccc(F)cc1
2911,2919,CHEMBL207837,LDELVNUHOAVIQP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-60.4,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-60.4,CC(C)CN(CC1=CC=CC=C1)C2CCNCC2,CC(C)CN(Cc1ccccc1)C1CCNCC1
2912,2920,CHEMBL3703728,LDGGSTOTUUPJPO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1.8,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,8.744727494896694,CC1(C2=C(C=CC(=C2)C3=NC=CN=C3)C(CN1)C4=CC(=C(C=C4)Cl)Cl)C,CC1(C)NCC(c2ccc(Cl)c(Cl)c2)c2ccc(-c3cnccn3)cc21
2913,2921,CHEMBL256816,LDPRCWPXDFHEJU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,506.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.295849483160201,CNCC1=CC=CC=C1OC2=C(C=C(C=C2)Cl)Cl,CNCc1ccccc1Oc1ccc(Cl)cc1Cl
2914,2922,CHEMBL1201193,LEBVLXFERQHONN-INIZCTEOSA-N,LEVOBUPIVACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
2915,2923,CHEMBL1201193,LEBVLXFERQHONN-INIZCTEOSA-N,LEVOBUPIVACAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
2916,2924,CHEMBL1914692,LEESYDIUWLXOSV-DXCLHELWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,86.7,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.061980902523791,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NC4=NC(=CC=C4)Br,CN1C2CCC1[C@@H](C(=O)Nc1cccc(Br)n1)[C@@H](c1ccc(Cl)cc1)C2
2917,2925,CHEMBL185608,LEEXJBMYTWENTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15482938.0,KI,=,5.0,NM,,,,,,,,,,,,,,,Inhibition of [18F]PET binding to dopamine transporter of human brain,Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Br)C(=O)OCCF,CN1C2CCC1C(C(=O)OCCF)C(c1ccc(Br)cc1)C2
2918,2926,CHEMBL332098,LEIFDHLVPBJTIV-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,163500.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter; Average of two experiments,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.7864822430036953,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3)O,CNCC[C@H](Oc1cccc2cc(O)ccc12)c1cccs1
2919,2927,CHEMBL34032,LEJRLSZVESQKJK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,35.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]WIN-35428 (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.455931955649724,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC=CC=C4,Fc1ccc(C(OCCC2CCN(Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
2920,2928,CHEMBL34032,LEJRLSZVESQKJK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]DA (radioligand) on Cloned human Dopamine transporter expressed in HEK cells; Not Determined,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC=CC=C4,Fc1ccc(C(OCCC2CCN(Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
2921,2929,CHEMBL1200391,LENZDBCJOHFCAS-UHFFFAOYSA-N,TROMETHAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(CO)(CO)N)O,NC(CO)(CO)CO
2922,2930,CHEMBL1200391,LENZDBCJOHFCAS-UHFFFAOYSA-N,TROMETHAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(CO)(CO)N)O,NC(CO)(CO)CO
2923,2931,CHEMBL437002,LEVTWCPGXIVKEH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F,O=C(c1ccccc1F)N1CCC(Cc2ccccc2)CC1
2924,2932,CHEMBL437002,LEVTWCPGXIVKEH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F,O=C(c1ccccc1F)N1CCC(Cc2ccccc2)CC1
2925,2933,CHEMBL366563,LEVWYRKDKASIDU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)SSCC(C(=O)O)N,NC(CSSCC(N)C(=O)O)C(=O)O
2926,2934,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,835.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.078313524516398,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
2927,2935,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,663.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.178486471595228,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
2928,2936,CHEMBL2012101,LFBAGZZBQAENDV-OQGULXLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,356.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.448550002027125,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CS4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3cccs3)cc1)O2
2929,2937,CHEMBL2012101,LFBAGZZBQAENDV-OQGULXLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CS4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3cccs3)cc1)O2
2930,2938,CHEMBL1095274,LFLUHLCPXQWQKW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19939513.0,ACTIVITY,,,,Active,,,,,,,,,,,,,,Binding affinity to dopamine transporter at 10 uM by radioligand displacement assay,"8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists.",Eur. J. Med. Chem.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2C)C=CC(=C3)S(=O)(=O)C4=CC=CC=C4.Cl,CN1CCc2c(c3cc(S(=O)(=O)c4ccccc4)ccc3n2C)C1
2931,2939,CHEMBL545,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,ALCOHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCO,CCO
2932,2940,CHEMBL545,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,ALCOHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCO,CCO
2933,2941,CHEMBL1830875,LFTRJEGVGRCFEP-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,1035.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,5.985059650207063,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3)OC,CNC[C@H](CCN1c2ccccc2N(c2ccccc2)S1(=O)=O)OC
2934,2942,CHEMBL1830876,LFTRJEGVGRCFEP-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,39.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,39.0,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3)OC,CNC[C@@H](CCN1c2ccccc2N(c2ccccc2)S1(=O)=O)OC
2935,2943,CHEMBL18797,LFWHFZJPXXOYNR-MFOYZWKCSA-N,SULINDAC SULFIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(=C2)F)CC(=O)O,CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1
2936,2944,CHEMBL18797,LFWHFZJPXXOYNR-MFOYZWKCSA-N,SULINDAC SULFIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(=C2)F)CC(=O)O,CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1
2937,2945,CHEMBL1224162,LGCPITGZBZPIIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CNCCC1(CC2=CC=CC=C2)C(=O)C3=CC4=C(C=C3)NC=C4,O=C(c1ccc2[nH]ccc2c1)C1(Cc2ccccc2)CCNCC1
2938,2946,CHEMBL41237,LGEBSRLTDNIQDY-OWOJBTEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.96,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.96,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=C(C=C4)F,Fc1ccc(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2939,2947,CHEMBL41237,LGEBSRLTDNIQDY-OWOJBTEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.41,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.41,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=C(C=C4)F,Fc1ccc(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2940,2948,CHEMBL3703749,LGHFQLREBMQWRS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,64.5,NM,198866,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 1.0 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 1.0 ul/well of 10 mM desipramine dissolved in DMSO. 50 ul/well of a 2x membrane preparation (0.4 mg/ml in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) and 50 ul/well of a 2x radioligand solution (4 nM [3H]nisoxetine in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.1904402853647325,CC1=CC=C(C=C1)C2CNCC3=C2C=CC(=C3)C4=NN=CC=C4,Cc1ccc(C2CNCc3cc(-c4cccnn4)ccc32)cc1
2941,2949,CHEMBL1082210,LGKIWGDJKNJYMG-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC(=CC=C5)F,C[C@H]1CN(C(=O)c2ccc(-c3cccc(F)c3)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
2942,2950,CHEMBL3673156,LGOLCLAISOMHIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,103.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.985059650207063,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NC=C(N=C4)N)C5=CC=C(C=C5)Cl,Nc1cnc(Oc2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)cn1
2943,2951,CHEMBL232867,LGPCFMYKDFHTOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,49000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.309803919971486,CC(=O)C1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)=O)cc2)CCC1
2944,2952,CHEMBL232867,LGPCFMYKDFHTOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,335000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.474955192963155,CC(=O)C1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)=O)cc2)CCC1
2945,2953,CHEMBL232867,LGPCFMYKDFHTOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,3019951720402.02,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.4800000000000004,CC(=O)C1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)=O)cc2)CCC1
2946,2954,CHEMBL1645608,LGPYPLZSWZJHBL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6370.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.195860567664648,C1CNCCC1OC2=C(C=CC=C2F)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1cccc(F)c1OC1CCNCC1
2947,2955,CHEMBL573766,LGSKMJOUAMVJKK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,461.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.336299074610353,C1CNCCC1C2=CC=CC=C2COC3=CC(=CC=C3)F,Fc1cccc(OCc2ccccc2C2CCNCC2)c1
2948,2956,CHEMBL156455,LGXVIGDEPROXKC-UHFFFAOYSA-N,"1,1-DICHLOROETHENE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=C(Cl)Cl,C=C(Cl)Cl
2949,2957,CHEMBL156455,LGXVIGDEPROXKC-UHFFFAOYSA-N,"1,1-DICHLOROETHENE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=C(Cl)Cl,C=C(Cl)Cl
2950,2958,CHEMBL3331468,LGYZPSJSJNXHOE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,498.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.302770657240282,C1CCC(CC1)N(CC2=CC3=CC=CC=C3C=C2)C4CNC4,c1ccc2cc(CN(C3CCCCC3)C3CNC3)ccc2c1
2951,2959,CHEMBL3331468,LGYZPSJSJNXHOE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1CCC(CC1)N(CC2=CC3=CC=CC=C3C=C2)C4CNC4,c1ccc2cc(CN(C3CCCCC3)C3CNC3)ccc2c1
2952,2960,CHEMBL1643902,LGZPNSXZRKGUES-DKSPCFMDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,101.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK cell membranes,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.995678626217357,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
2953,2961,CHEMBL1643902,LGZPNSXZRKGUES-DKSPCFMDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,101.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,6.995678626217357,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
2954,2962,CHEMBL3310626,LHDXSWGNSMXQLB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,86.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,86.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC=CC=C3Cl,Fc1ccc(C(CC2CNC2)Oc2ccccc2Cl)cc1F
2955,2963,CHEMBL256841,LHEVFGSJGDXFCO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,4600.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,CC(C)N(C(C)C)C(=O)C1(CC1CNC(=O)CN)C2=CC=CC=C2,CC(C)N(C(=O)C1(c2ccccc2)CC1CNC(=O)CN)C(C)C
2956,2964,CHEMBL573831,LHOOAMLZVNHXAN-IOXAMRCBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.920818753952375,CCSC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3CCCF,CCSc1ccc([C@H]2CC3CCC([C@H]2C(=O)OC)N3CCCF)cc1
2957,2965,CHEMBL264158,LHOSACAWSLTLQJ-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=CC(=C1)Cl)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3F,COc1cc(Cl)ccc1O[C@@H](c1ccccc1F)[C@@H]1CNCCO1
2958,2966,CHEMBL551818,LHPQIFURGZJMMZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,251.19,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,C1CNCCC1N(CC2=CC=C(C=C2)F)C3=CC4=C(C=C3)NC=C4,Fc1ccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)cc1
2959,2967,CHEMBL1173427,LHPUYZQFWLLHPT-ISVAXAHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,2140.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.669586226650809,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=C(C=C2)F)F)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1ccc(F)c(F)c1
2960,2968,CHEMBL1258723,LHSWZGXDIPQNGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20727749.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,"Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CCCCOC1=CC=C(C=C1)C2=NN3C(=CC(=NC3=C2CC(=O)N(CC)CC)C)C,CCCCOc1ccc(-c2nn3c(C)cc(C)nc3c2CC(=O)N(CC)CC)cc1
2961,2969,CHEMBL2205824,LIKZWSUAMNZHAE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,COC1=CC=CC(=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c1
2962,2970,CHEMBL3673164,LINSRJQQGQTFBQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,9.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.036212172654443,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=CN=C(C=N4)N)C5=CC(=C(C=C5)Cl)Cl,Nc1cnc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)c(Cl)c3)CC2)cn1
2963,2971,CHEMBL3673158,LITXWCJWLOYNDV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,65.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.182434630440218,C1CN2CCC1(C3=C(C2)C=C(C=C3)OCCCC4=CN=CC=C4)C5=CC=C(C=C5)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(OCCCc4cccnc4)ccc23)cc1
2964,2972,CHEMBL89208,LIYDQJCDMBBSPX-IHXHZNKUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,3530.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,5.452225294612178,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC=CC=C3)O,COC(=O)C1C(c2ccccc2)CC2[C@@H](O)CC1N2C
2965,2973,CHEMBL89208,LIYDQJCDMBBSPX-IHXHZNKUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,6150.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,5.211124884224583,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC=CC=C3)O,COC(=O)C1C(c2ccccc2)CC2[C@@H](O)CC1N2C
2966,2974,CHEMBL89208,LIYDQJCDMBBSPX-IHXHZNKUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,32600.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,4.4867823999320615,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC=CC=C3)O,COC(=O)C1C(c2ccccc2)CC2[C@@H](O)CC1N2C
2967,2975,CHEMBL1683872,LJALDWYVBOLBGW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,CCNCC1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,CCNCC1(c2ccc(Cl)c(Cl)c2)CCCCC1
2968,2976,CHEMBL600674,LJCOZBDBGBEZNJ-ZFNKBKEPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,2.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.0,CC1=C2C(=CC=C1)CCN2[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CCc2cccc(C)c21
2969,2977,CHEMBL2206535,LJEZBJASWTZZEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,27.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.568636235841013,CC1=CC=C(C=C1)C2CN(CC3=C2C=CC(=C3)C)C,Cc1ccc(C2CN(C)Cc3cc(C)ccc32)cc1
2970,2978,CHEMBL3323098,LJLKXARFBFJHOY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,INHIBITION,=,70.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells at 100 nM after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,70.0,CN1CC(C2=CC=CC=C2C1)C3=CSC4=CC=CC=C43,CN1Cc2ccccc2C(c2csc3ccccc23)C1
2971,2979,CHEMBL251576,LJOGQAFQXBMQQW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,=,44000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.356547323513813,CN(C)CC1CC1C2=C3C=C(C=CC3=NN2)C#N,CN(C)CC1CC1c1[nH]nc2ccc(C#N)cc12
2972,2980,CHEMBL251576,LJOGQAFQXBMQQW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,0.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CN(C)CC1CC1C2=C3C=C(C=CC3=NN2)C#N,CN(C)CC1CC1c1[nH]nc2ccc(C#N)cc12
2973,2981,CHEMBL203013,LJRLAJVWAFFRLV-IAQYHMDHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16361098.0,KI,>,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to DA transporter,"Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C[C@@H]1CNC[C@@H]2N1C3=C(C2)C=CC(=N3)COCC4CC4,C[C@@H]1CNC[C@H]2Cc3ccc(COCC4CC4)nc3N12
2974,2982,CHEMBL2079587,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,STANOZOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C,C[C@]12Cc3cn[nH]c3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
2975,2983,CHEMBL2079587,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,STANOZOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C,C[C@]12Cc3cn[nH]c3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
2976,2984,CHEMBL177,LKCWBDHBTVXHDL-RMDFUYIESA-N,AMIKACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
2977,2985,CHEMBL177,LKCWBDHBTVXHDL-RMDFUYIESA-N,AMIKACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
2978,2986,CHEMBL2432043,LKFSLMWAVKMONG-KPCGFGSOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CC1=CN=CC=C1)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(Cc1cccnc1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
2979,2987,CHEMBL41796,LKHJTNMKBCYRBQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.7,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.7,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(Cl)cc2)cc1
2980,2988,CHEMBL41796,LKHJTNMKBCYRBQ-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.41,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.41,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(Cl)cc2)cc1
2981,2989,CHEMBL63560,LKJPYSCBVHEWIU-KRWDZBQOSA-N,(R)-BICALUTAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
2982,2990,CHEMBL63560,LKJPYSCBVHEWIU-KRWDZBQOSA-N,(R)-BICALUTAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
2983,2991,CHEMBL3673152,LKORPZALGOFFBL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,134.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.869988050328097,[C-]#[N+]C1=CC=CC(=C1)C2=CC3=C(C=C2)C4(CCN(C3)CC4)C5=CC=C(C=C5)Cl,[C-]#[N+]c1cccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)c1
2984,2992,CHEMBL456639,LKTJWDXCFJJUGY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,513.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.2898826348881824,C1CC(OC1CCC2=CC=CC=C2)CN,NCC1CCC(CCc2ccccc2)O1
2985,2993,CHEMBL456639,LKTJWDXCFJJUGY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,1505.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.822463500070138,C1CC(OC1CCC2=CC=CC=C2)CN,NCC1CCC(CCc2ccccc2)O1
2986,2994,CHEMBL608148,LKVOLTSPLLAMPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,4310.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3655227298392685,C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3,c1ccc(Oc2ncccc2C2CCNCC2)cc1
2987,2995,CHEMBL3331497,LKWGTRCUUYXILW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,11.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,11.0,C1C(CN1)CN(CC2=CC=CC=C2)C3=CC=C(C=C3)OC4=CC=CC=C4.C(=O)(C(F)(F)F)O,c1ccc(CN(CC2CNC2)c2ccc(Oc3ccccc3)cc2)cc1
2988,2996,CHEMBL1641693,LKXBBIBINAVJJG-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,7966.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.098759697926691,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC(=CC=C2)N=[N+]=[N-])C3=CC=C(C=C3)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1Cc1cccc(N=[N+]=[N-])c1
2989,2997,CHEMBL1641693,LKXBBIBINAVJJG-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,2754.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.560036064079095,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC(=CC=C2)N=[N+]=[N-])C3=CC=C(C=C3)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1Cc1cccc(N=[N+]=[N-])c1
2990,2998,CHEMBL257810,LLAFUUNOXYVHHL-ZANVPECISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=C(S2)Cl,CCN(CC)C(=O)[C@@]1(c2ccc(Cl)s2)C[C@H]1CN
2991,2999,CHEMBL595638,LLOHGZFZQFVZTC-JLZXWRJPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,16.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.795880017344076,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OCCN4C=C(N=N4)COC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)OCc1cn(CCOC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)nn1)[C@@H](c1ccc(Cl)cc1)C2
2992,3000,CHEMBL493667,LLTVABOFFOVVKQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C1=CC(=C(C=C1)Cl)Cl)C2=CC=CC=C2CN(C)C,CC(c1ccc(Cl)c(Cl)c1)c1ccccc1CN(C)C
2993,3001,CHEMBL556093,LLXDSNCKQBRHMZ-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,2040.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.690369832574102,CC(C)C1=CC=CC=C1C(=O)N(CC2CCC2)[C@H]3CCNC3,CC(C)c1ccccc1C(=O)N(CC1CCC1)[C@H]1CCNC1
2994,3002,CHEMBL559319,LLXDSNCKQBRHMZ-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,3160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,CC(C)C1=CC=CC=C1C(=O)N(CC2CCC2)[C@@H]3CCNC3,CC(C)c1ccccc1C(=O)N(CC1CCC1)[C@@H]1CCNC1
2995,3003,CHEMBL380406,LMAWVKHKZVLUQO-JCOPYZAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,0.4,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,9.397940008672037,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H](CC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
2996,3004,CHEMBL204530,LMAWVKHKZVLUQO-LNLSOMNWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.769551078621726,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
2997,3005,CHEMBL204530,LMAWVKHKZVLUQO-LNLSOMNWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,5.1,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.292429823902062,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
2998,3006,CHEMBL1829959,LMBAMOXWCSVRLU-UHFFFAOYSA-N,4-METHOXYMERIDIANIN A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21907583.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT after 1.5 hrs by scintillation counting,CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.,Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=CC=CC2=C1C(=CN2)C3=NC(=NC=C3)N,COc1cccc2[nH]cc(-c3ccnc(N)n3)c12
2999,3007,CHEMBL1542,LMEKQMALGUDUQG-UHFFFAOYSA-N,AZATHIOPRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
3000,3008,CHEMBL1542,LMEKQMALGUDUQG-UHFFFAOYSA-N,AZATHIOPRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
3001,3009,CHEMBL469811,LMGLVWVNPWWAAK-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,2100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,C1CNC[C@@H]1OCC2=CC3=C(C=C2)C=C(C=C3)F,Fc1ccc2cc(CO[C@@H]3CCNC3)ccc2c1
3002,3010,CHEMBL1054,LMJSLTNSBFUCMU-UHFFFAOYSA-N,TRICHLORMETHIAZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
3003,3011,CHEMBL1054,LMJSLTNSBFUCMU-UHFFFAOYSA-N,TRICHLORMETHIAZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
3004,3012,CHEMBL288863,LMLWBSZZRXUBJX-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.62,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.62,C1CN(CCN1CCOC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C/C=C/C4=CC=CC=C4,Clc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(Cl)cc2)cc1
3005,3013,CHEMBL288863,LMLWBSZZRXUBJX-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.42,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.42,C1CN(CCN1CCOC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C/C=C/C4=CC=CC=C4,Clc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(Cl)cc2)cc1
3006,3014,CHEMBL1947099,LMVDJMCDHZLBFE-MBHMRJJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,0.603,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,9.219682687859848,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/CF)C[C@@H]1C3=CC=C(C=C3)Cl,COC(=O)[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C/C=C/CF
3007,3015,CHEMBL1214006,LMVDJMCDHZLBFE-PMWAWBRWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,=,0.6,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,9.221848749616356,COC(=O)[C@H]1[C@H](CC2CCC1N2C/C=C/CF)C3=CC=C(C=C3)Cl,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C/C=C/CF
3008,3016,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
3009,3017,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
3010,3018,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
3011,3019,CHEMBL576821,LNIDNIKEDAQTOW-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,28000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5528419686577815,CC1=C(C=CC2=C1C=CC(=C2)F)CN([C@@H]3CCNC3)S(=O)(=O)C,Cc1c(CN([C@@H]2CCNC2)S(C)(=O)=O)ccc2cc(F)ccc12
3012,3020,CHEMBL865,LNPDTQAFDNKSHK-UHFFFAOYSA-N,VALDECOXIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
3013,3021,CHEMBL865,LNPDTQAFDNKSHK-UHFFFAOYSA-N,VALDECOXIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
3014,3022,CHEMBL2432042,LNTMHZZRTAQEJQ-CPVTZQMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CC1=CC(=C(C=C1)OC)OC)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,COc1ccc(CN(C)[C@H]2C3C4CC5C3C(=O)C3C5C4C32)cc1OC
3015,3023,CHEMBL1170233,LNWGBLPMTUFHJM-HUUCEWRRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,31.62,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.500038134403809,CN1CC[C@@]2(C[C@@]2(C1)COC)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CN(C)CC[C@]1(c1ccc(Cl)c(Cl)c1)C2
3016,3024,CHEMBL54465,LOEPSYRVNXADMM-TYKWCNGQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18644726.0,KI,=,424.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,"3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.372634143407267,C1CC(CCC1C2=CNC3=C2C=C(C=C3)C#N)N4CCC5=CC=CC=C5C4,N#Cc1ccc2[nH]cc(C3CCC(N4CCc5ccccc5C4)CC3)c2c1
3017,3025,CHEMBL55505,LOEPSYRVNXADMM-XUTJKUGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18644726.0,KI,=,309.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,"3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5100415205751645,C1CC(CCC1C2=CNC3=C2C=C(C=C3)C#N)N4CCC5=CC=CC=C5C4,N#Cc1ccc2[nH]cc(C3CCC(N4CCc5ccccc5C4)CC3)c2c1
3018,3026,CHEMBL1744448,LOLFAJUUOFBGSF-KYIYJVAASA-N,BLEOMYCIN A2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@H]([C@@H](C)NC(=O)[C@H](C(C1=CN=CN1)O[C@H]2[C@H]([C@H]([C@@H]([C@@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)OC(=O)N)O)NC(=O)C4=CC(=NC(=N4)C(CC(=O)N)NCC(C(=O)N)N)N)O)C(=O)N[C@@H](C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.[Br-],CC(O)[C@H](NC(=O)[C@@H](C)[C@@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1cc(N)nc(C(CC(N)=O)NCC(N)C(N)=O)n1)C(O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1
3019,3027,CHEMBL1744448,LOLFAJUUOFBGSF-KYIYJVAASA-N,BLEOMYCIN A2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@H]([C@@H](C)NC(=O)[C@H](C(C1=CN=CN1)O[C@H]2[C@H]([C@H]([C@@H]([C@@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)OC(=O)N)O)NC(=O)C4=CC(=NC(=N4)C(CC(=O)N)NCC(C(=O)N)N)N)O)C(=O)N[C@@H](C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.[Br-],CC(O)[C@H](NC(=O)[C@@H](C)[C@@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1cc(N)nc(C(CC(N)=O)NCC(N)C(N)=O)n1)C(O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1
3020,3028,CHEMBL188964,LOONKLFFRKQSJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CCF)N,CN(C)Cc1ccccc1Sc1ccc(CCF)cc1N
3021,3029,CHEMBL188964,LOONKLFFRKQSJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,5000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,5.301029995663981,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CCF)N,CN(C)Cc1ccccc1Sc1ccc(CCF)cc1N
3022,3030,CHEMBL566420,LOWDJVQAZMFOLZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,1033.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.985899678480378,CC(C(=O)C1=CC(=CC=C1)Cl)N2CCCCC2,CC(C(=O)c1cccc(Cl)c1)N1CCCCC1
3023,3031,CHEMBL566420,LOWDJVQAZMFOLZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,1148.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.940058111938045,CC(C(=O)C1=CC(=CC=C1)Cl)N2CCCCC2,CC(C(=O)c1cccc(Cl)c1)N1CCCCC1
3024,3032,CHEMBL566420,LOWDJVQAZMFOLZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,852.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.069560405233299,CC(C(=O)C1=CC(=CC=C1)Cl)N2CCCCC2,CC(C(=O)c1cccc(Cl)c1)N1CCCCC1
3025,3033,CHEMBL1824778,LPAMOYXJLQSGRI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21788137.0,INHIBITION,,,,Not Determined,,,,,,,,,,,,,,Inhibition of DAT transporter at 10 uM by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2CC3CC1CC(C2)(N3CC4=CC(=CC=C4)F)O.Cl,OC12CC3CC(CC(C3)N1Cc1cccc(F)c1)C2
3026,3034,CHEMBL3323172,LPEVXVVSNBJGCU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,INHIBITION,=,28.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells at 100 nM after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,28.0,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4OC3,CN1Cc2ccccc2C(C2=Cc3ccccc3OC2)C1
3027,3035,CHEMBL1224160,LPLLJFFJYKVRLO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,39.81,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1CC(NC1)(CC2=CC=CC=C2)C(=O)C3=CC4=C(C=C3)NC=C4,O=C(c1ccc2[nH]ccc2c1)C1(Cc2ccccc2)CCCN1
3028,3037,CHEMBL441687,LPLVUJXQOOQHMX-QWBHMCJMSA-N,GLYCYRRHIZIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C
3029,3038,CHEMBL441687,LPLVUJXQOOQHMX-QWBHMCJMSA-N,GLYCYRRHIZIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C
3030,3039,CHEMBL222863,LPMXVESGRSUGHW-HBYQJFLCSA-N,OUABAIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O
3031,3040,CHEMBL222863,LPMXVESGRSUGHW-HBYQJFLCSA-N,OUABAIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O
3032,3041,CHEMBL493130,LPQAVKPTKBXDEY-GHXDPTCOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19284718.0,KI,=,3261.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,J. Med. Chem.,PUBLICATION,,5.4866492011940435,C1[C@@H]([C@H]1C2=CC=C(C=C2)F)CN.Cl,NC[C@H]1C[C@@H]1c1ccc(F)cc1
3033,3042,CHEMBL404,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,TAZOBACTAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
3034,3043,CHEMBL404,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,TAZOBACTAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
3035,3044,CHEMBL111861,LPYXTAPPNYMYOP-XDBTXSBWSA-N,CORTISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
3036,3045,CHEMBL111861,LPYXTAPPNYMYOP-XDBTXSBWSA-N,CORTISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
3037,3046,CHEMBL3673128,LQAFCQOIRLFSLX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,53.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.268411234813263,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)O,Oc1ccc2c(c1)CN1CCC2(c2ccc(Cl)cc2)C1
3038,3047,CHEMBL397787,LQAVUHFNJFDFLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)S(=O)(=O)C,COC(=O)C1=C(c2ccc(S(C)(=O)=O)cc2)CCC1
3039,3048,CHEMBL397787,LQAVUHFNJFDFLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCC1)C2=CC=C(C=C2)S(=O)(=O)C,COC(=O)C1=C(c2ccc(S(C)(=O)=O)cc2)CCC1
3040,3049,CHEMBL487875,LQBFAZFBAPGPPM-PHGOYLPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,9.6,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.017728766960431,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=NO4)CC5=CC=C(C=C5)OC)N3C.Cl,COc1ccc(Cc2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(C)cc3)N4C)on2)cc1
3041,3050,CHEMBL130593,LQCWQIGQIHPKEY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,218.0,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.661543506395395,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C5=CC=CC=C5C=C3,OC1(c2ccc(Cl)cc2)c2c(ccc3ccccc23)C2=NCCN21
3042,3051,CHEMBL130593,LQCWQIGQIHPKEY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,0.2,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,0.2,C1CN2C(=N1)C3=C(C2(C4=CC=C(C=C4)Cl)O)C5=CC=CC=C5C=C3,OC1(c2ccc(Cl)cc2)c2c(ccc3ccccc23)C2=NCCN21
3043,3052,CHEMBL222787,LQDARHFLRKPAMM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17367122.0,INHIBITION,=,-62.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of radiolabeled BTCP from human recombinant DAT expressed in CHO cells at 10 uM,Designing active template molecules by combining computational de novo design and human chemist's expertise.,J. Med. Chem.,PUBLICATION,,-62.0,C1=CC(=CC(=C1)N)C2=COC=C2,Nc1cccc(-c2ccoc2)c1
3044,3053,CHEMBL891,LQOLIRLGBULYKD-JKIFEVAISA-N,CLOXACILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12
3045,3054,CHEMBL891,LQOLIRLGBULYKD-JKIFEVAISA-N,CLOXACILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12
3046,3055,CHEMBL198960,LQONCZWYZLNINV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,3.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CCCC1(CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC,CCCC1(CCCNC)Cc2ccccc2N(c2ccccc2)C1=O
3047,3056,CHEMBL198960,LQONCZWYZLNINV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CCCC1(CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC,CCCC1(CCCNC)Cc2ccccc2N(c2ccccc2)C1=O
3048,3057,CHEMBL457865,LQPCABVKUZFZCC-GNQYJHKCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,0.82,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,9.086186147616283,CC1=C(C=CC(=C1)[C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC)N3C)Cl.Cl,COC(=O)[C@H]1[C@@H](c2ccc(Cl)c(C)c2)C[C@H]2CC[C@H]1N2C
3049,3058,CHEMBL566376,LQXLMIBCEDZZFC-SFTDATJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C[C@@H]([C@H](C2=CC=CC=C2)N3C=CC4=CC=CC=C43)O,O[C@@H](CN1CCNCC1)[C@H](c1ccccc1)n1ccc2ccccc21
3050,3059,CHEMBL475936,LQYWRHPJMNCEEY-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1(C2=C(C(=CC=C2)F)N(C1=O)[C@H](CCNC)C3=CC(=CC=C3)F)C,CNCC[C@H](c1cccc(F)c1)N1C(=O)C(C)(C)c2cccc(F)c21
3051,3060,CHEMBL232879,LQZNMKWOFOJVOS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,239000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.6216020990518634,COC(=O)C1=C(CCCC1)C2=CC(=CC=C2)[N+](=O)[O-],COC(=O)C1=C(c2cccc([N+](=O)[O-])c2)CCCC1
3052,3061,CHEMBL232879,LQZNMKWOFOJVOS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCC1)C2=CC(=CC=C2)[N+](=O)[O-],COC(=O)C1=C(c2cccc([N+](=O)[O-])c2)CCCC1
3053,3062,CHEMBL180630,LRAFIWLBFGAPRJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)CCCC1=CNC2=C1C=C(C=C2)C#N,CN(C)CCCc1c[nH]c2ccc(C#N)cc12
3054,3063,CHEMBL180630,LRAFIWLBFGAPRJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20034793.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Displacement of [I125]RTI-55 from human DAT transfected in human HEK293 cells,Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CCCC1=CNC2=C1C=C(C=C2)C#N,CN(C)CCCc1c[nH]c2ccc(C#N)cc12
3055,3064,CHEMBL506247,LRBQNJMCXXYXIU-PPKXGCFTSA-N,TANNIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1
3056,3065,CHEMBL506247,LRBQNJMCXXYXIU-PPKXGCFTSA-N,TANNIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1
3057,3066,CHEMBL455937,LRISBEQMFXITND-HEHWQVRWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.886056647693162,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OC4CCC4.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC2CCC2)N3C)cc1
3058,3067,CHEMBL1083427,LRKGVRWKYSKWQW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,4900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.309803919971486,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC(=CC=C3)F,Fc1cccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)c1
3059,3068,CHEMBL204449,LRQBXHMVEXEFBO-GFCCVEGCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16263279.0,ACTIVITY,=,23.0,%,,,,,,,,,,,,,,,Binding affinity to dopamine transporter at 10 uM,A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.,Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,C[C@H](C1=CC=CS1)NC(=O)C2=C(N=CC=C2)OC3=CC=C(C=C3)F,C[C@@H](NC(=O)c1cccnc1Oc1ccc(F)cc1)c1cccs1
3060,3069,CHEMBL269799,LRQFAGSCSIOKKB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,2400.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288393,CCN(C)C(=O)C1(CC1CN)C2=CC=CC=C2,CCN(C)C(=O)C1(c2ccccc2)CC1CN
3061,3070,CHEMBL1275791,LRSVJJWABVMKRA-PWSUYJOCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20949929.0,IC50,=,2100.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.6777807052660805,CN(C)[C@H]1CC[C@H](C1)C2=CNC3=C2C=C(C=C3)F,CN(C)[C@H]1CC[C@@H](c2c[nH]c3ccc(F)cc23)C1
3062,3071,CHEMBL257964,LRXREOMAEUNNPU-GWCFXTLKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CS2,CCN(CC)C(=O)[C@@]1(c2cccs2)C[C@H]1CN
3063,3072,CHEMBL1945245,LRZIIDDMLMCOJY-LUVSFPRASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,371.54,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.429994423238213,CCCC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C=C/I,CCCc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C=C/I)cc1
3064,3073,CHEMBL207755,LSDAXRLUBRBZQK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-7.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-7.0,COCCCN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2.C(C(C(=O)O)O)(C(=O)O)O,COCCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
3065,3074,CHEMBL1643668,LSHLQBBAJNMIOH-ACDROJECSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,49.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.309803919971486,C1CC2C([C@H](CC1S2)C3=CC=C(C=C3)F)C4=CC(=NO4)C5=CC=CC=C5,Fc1ccc([C@H]2CC3CCC(S3)C2c2cc(-c3ccccc3)no2)cc1
3066,3075,CHEMBL1643658,LSHLQBBAJNMIOH-PBWJLWFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,456.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.341035157335565,C1CC2C([C@@H](CC1S2)C3=CC=C(C=C3)F)C4=CC(=NO4)C5=CC=CC=C5,Fc1ccc([C@@H]2CC3CCC(S3)C2c2cc(-c3ccccc3)no2)cc1
3067,3076,CHEMBL1566249,LSNWBKACGXCGAJ-UHFFFAOYSA-N,AMPIROXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3,CCOC(=O)OC(C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21
3068,3077,CHEMBL1566249,LSNWBKACGXCGAJ-UHFFFAOYSA-N,AMPIROXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3,CCOC(=O)OC(C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21
3069,3078,CHEMBL1173414,LSPLQALBHLTUIH-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,3162.28,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.4999996786570655,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)C(F)(F)F,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(C(F)(F)F)c1)C2
3070,3079,CHEMBL1082,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,AMOXICILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
3071,3080,CHEMBL1082,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,AMOXICILLIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
3072,3081,CHEMBL497140,LTDVATHIGODXNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18793858.0,KI,>,1500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]GBR-12935 from human cloned DAT expressed in HEK293 cells,"Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.",Bioorg. Med. Chem.,PUBLICATION,,5.823908740944319,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)NCC3=CC=C(C=C3)F,Cc1ccc(Sc2ccccc2CN(C)C)c(NCc2ccc(F)cc2)c1
3073,3082,CHEMBL2386163,LTFSJEXVJFCDEL-SLHAJLBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,354.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.450996737974213,CC1=C(C=CC(=N1)OC)O[C@@H](CC(C)C)[C@H]2CCNC2.C(C(C(=O)O)O)(C(=O)O)O,COc1ccc(O[C@@H](CC(C)C)[C@H]2CCNC2)c(C)n1
3074,3083,CHEMBL2386163,LTFSJEXVJFCDEL-SLHAJLBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,475.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.323306390375134,CC1=C(C=CC(=N1)OC)O[C@@H](CC(C)C)[C@H]2CCNC2.C(C(C(=O)O)O)(C(=O)O)O,COc1ccc(O[C@@H](CC(C)C)[C@H]2CCNC2)c(C)n1
3075,3084,CHEMBL517423,LTGCAGJRXIORIR-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,3000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,CC1=C(C=CC=C1F)O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1cccc(F)c1C
3076,3085,CHEMBL494786,LTKIILYBJZQLLW-PEVLCXCCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,7.638272163982407,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](c2ccccc2)C[C@@H]2CC[C@H]1N2C
3077,3086,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,65.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,7.187086643357143,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3078,3087,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8691489.0,IC50,=,373.0,NM,,,,,,,,,,,,,,,Inhibitory activity against [3H]-Dopamine uptake from Dopamine transporter in rat caudate putamen tissue,Synthesis and ligand binding of eta(6)-(2beta-carbomethoxy-3beta-phenyltropane) transition metal complexes.,J. Med. Chem.,PUBLICATION,,6.428291168191312,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3079,3088,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8691489.0,KI,=,33.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter using [3H]WIN-35428 as radioligand from rat caudate putamen tissue (high affinity),Synthesis and ligand binding of eta(6)-(2beta-carbomethoxy-3beta-phenyltropane) transition metal complexes.,J. Med. Chem.,PUBLICATION,,7.481486060122112,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3080,3089,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8691489.0,KI,=,314.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter using [3H]WIN-35428 as radioligand from rat caudate putamen tissue (low affinity),Synthesis and ligand binding of eta(6)-(2beta-carbomethoxy-3beta-phenyltropane) transition metal complexes.,J. Med. Chem.,PUBLICATION,,6.503070351926786,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3081,3090,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.638272163982407,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3082,3091,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,101.0,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.995678626217357,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3083,3092,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,,,,,Not Determined,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the Dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen; Not available.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3084,3093,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,65.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.187086643357143,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3085,3094,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,,,,Not Active,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen.,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3086,3095,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3087,3096,CHEMBL1790051,LTKIILYBJZQLLW-QNIIYNMLSA-N,WIN-35065-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.638272163982407,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3088,3097,CHEMBL214240,LTKQGPSHVUGDKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC(=CC=C2)Cl)C3=CC=CC=C3,Clc1cccc(CC(c2ccccc2)N2CCNCC2)c1
3089,3098,CHEMBL599233,LTLFRBMKBHQUTH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.0,CC(C(=O)C1=CC(=CC=C1)[N+](=O)[O-])N2CCCCC2,CC(C(=O)c1cccc([N+](=O)[O-])c1)N1CCCCC1
3090,3099,CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
3091,3100,CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
3092,3101,CHEMBL2430695,LTOCWIOHTZQZEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,36.6,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.436518914605589,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccccc1
3093,3102,CHEMBL2430695,LTOCWIOHTZQZEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,83.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,83.0,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccccc1
3094,3103,CHEMBL2430695,LTOCWIOHTZQZEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,93.2,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,93.2,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccccc1
3095,3104,CHEMBL2012728,LTQWNQOQFFXHAJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22342142.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM by radioligand displacement assay,Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: carboxamide modification.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=C(C=CC(=C1)NS(=O)(=O)C)N2C(=CC=C2C3=CC=C(S3)N4C=CN=C4C)CCC(=O)O,Cc1cc(NS(C)(=O)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2C)s1
3096,3105,CHEMBL3310478,LTRGRJOIAIYRCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,129.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.889410289700751,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
3097,3106,CHEMBL3310478,LTRGRJOIAIYRCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,33.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,33.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
3098,3107,CHEMBL3310478,LTRGRJOIAIYRCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
3099,3108,CHEMBL3310478,LTRGRJOIAIYRCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
3100,3109,CHEMBL3113642,LUDBNRIKUAJOOY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24393810.0,INHIBITION,=,8.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human dopamine transporter at 1 uM relative to control,A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,8.0,C1CCN(C1)CC2=CC3=C(C=CC(=C3)C(F)(F)F)OC2=O,O=c1oc2ccc(C(F)(F)F)cc2cc1CN1CCCC1
3101,3110,CHEMBL2207484,LUENAZOOIPSKQU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23043306.0,INHIBITION,=,1.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DAT at 1 uM by CEREP assay,Systematic in Vivo Screening of a Series of 1-Propyl-4-arylpiperidines against Dopaminergic and Serotonergic Properties in Rat Brain: A Scaffold-Jumping Approach.,J. Med. Chem.,PUBLICATION,,1.0,CCCN1CCC(CC1)C2=CNC3=C2C=CC(=C3)F,CCCN1CCC(c2c[nH]c3cc(F)ccc23)CC1
3102,3111,CHEMBL1909051,LUHHARLTABWBTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1
3103,3112,CHEMBL1909051,LUHHARLTABWBTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1
3104,3113,CHEMBL567041,LUIWHKVXZYFQLW-CJRXIRLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,18.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,18.0,CNC[C@@H]([C@@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32)O.Cl,CNC[C@H](O)[C@@H](c1ccccc1)n1ccc2ccccc21
3105,3114,CHEMBL257909,LUJLISGGFLGFKZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,770.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.113509274827518,CNCC1=C(C=CC(=C1)C(=O)N2CCCN(CC2)C3CC3)OC4=CC=C(C=C4)Cl,CNCc1cc(C(=O)N2CCCN(C3CC3)CC2)ccc1Oc1ccc(Cl)cc1
3106,3115,CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
3107,3116,CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
3108,3117,CHEMBL54126,LULNWZDBKTWDGK-UHFFFAOYSA-M,NEOSTIGMINE BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-],CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
3109,3118,CHEMBL54126,LULNWZDBKTWDGK-UHFFFAOYSA-M,NEOSTIGMINE BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-],CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
3110,3119,CHEMBL2206530,LULUPYXXDWTNNO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,687.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.16304326294045,CN1CC(C2=C(C1)C=C(C=C2)F)C3=CC=CC=C3,CN1Cc2cc(F)ccc2C(c2ccccc2)C1
3111,3120,CHEMBL2430684,LUQRHZHXLQQJTM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,284.7,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5456125328530455,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc(Cl)c(Cl)c1
3112,3121,CHEMBL2430684,LUQRHZHXLQQJTM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,85.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,85.0,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc(Cl)c(Cl)c1
3113,3122,CHEMBL2430684,LUQRHZHXLQQJTM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,86.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,86.8,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc(Cl)c(Cl)c1
3114,3123,CHEMBL3317698,LUYDHJNQCRADNJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1CCN(C(=O)CN1)C2=CC(=C(C=C2)Cl)Cl.Cl,CC1CCN(c2ccc(Cl)c(Cl)c2)C(=O)CN1
3115,3124,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
3116,3125,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
3117,3126,CHEMBL601880,LVFOKOCPQCOYER-VOMIJIAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,0.0,CC1(CN(C2=CC=CC=C21)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC(C)(C)c2ccccc21
3118,3127,CHEMBL338566,LVODOGNPKDFXNV-ISRILLDMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,13.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.87942606879415,CN1C2CCC1C([C@H](C2)OC(C3=CC=CC=C3)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccccc1)c1ccc(F)cc1)N2C
3119,3128,CHEMBL1231107,LVQDKIWDGQRHTE-UHFFFAOYSA-N,CYROMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1NC2=NC(=NC(=N2)N)N,Nc1nc(N)nc(NC2CC2)n1
3120,3129,CHEMBL1231107,LVQDKIWDGQRHTE-UHFFFAOYSA-N,CYROMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1NC2=NC(=NC(=N2)N)N,Nc1nc(N)nc(NC2CC2)n1
3121,3130,CHEMBL3238482,LVRWTVAZVIJYDH-PGMHBOJBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,COC1=C(C=CC(=C1)C(=O)O)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,COc1cc(C(=O)O)ccc1N=Nc1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
3122,3131,CHEMBL599593,LVSZWRFDLAUNPF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6320.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.199282921717615,C1CN(CCN1)C2=C(N=CC=C2)OC3=CC=CC=C3Cl,Clc1ccccc1Oc1ncccc1N1CCNCC1
3123,3132,CHEMBL2337600,LVUBCLOONUNZAC-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,PKI,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@H]1[C@@H](C2=CC=CC=C2)OC3=CC=C(C=C3)C(F)(F)F,FC(F)(F)c1ccc(O[C@H](c2ccccc2)[C@H]2CCNC2)cc1
3124,3133,CHEMBL1672288,LVXAMCKZCLWWTF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21207959.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.,J. Med. Chem.,PUBLICATION,,5.0,C1=C(C=C(C=C1C#N)F)C#CC2=CSC(=N2)F,N#Cc1cc(F)cc(C#Cc2csc(F)n2)c1
3125,3134,CHEMBL41027,LWDROUBWOBOGMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.92,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.92,C1CN(CCN1CCCCC(=O)N(CC2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,O=C(CCCCN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccc1
3126,3135,CHEMBL41027,LWDROUBWOBOGMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.24,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.24,C1CN(CCN1CCCCC(=O)N(CC2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,O=C(CCCCN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccc1
3127,3136,CHEMBL1818456,LWFZPUPJSMFIKP-HZPDHXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,1.58,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.801342913045579,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C(=CC=N4)C(F)(F)F,FC(F)(F)c1ccnn1C[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
3128,3137,CHEMBL3310482,LWGULHIUMBMSRR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,33.1,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.480172006224282,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3,Fc1cc(C(CC2CNC2)Oc2ccccc2)ccc1Cl
3129,3138,CHEMBL3310482,LWGULHIUMBMSRR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,98.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,98.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3,Fc1cc(C(CC2CNC2)Oc2ccccc2)ccc1Cl
3130,3139,CHEMBL3310482,LWGULHIUMBMSRR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3,Fc1cc(C(CC2CNC2)Oc2ccccc2)ccc1Cl
3131,3140,CHEMBL3310482,LWGULHIUMBMSRR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3,Fc1cc(C(CC2CNC2)Oc2ccccc2)ccc1Cl
3132,3141,CHEMBL1224562,LWIZTBGDAFNFMW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,7.94,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CNCC1(CC2=CC=CC=C2)C(=O)C3=CC4=C(C=C3)NC=C4,O=C(c1ccc2[nH]ccc2c1)C1(Cc2ccccc2)CCNC1
3133,3142,CHEMBL333476,LWMFMZKTEROARR-KBWCOIMZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,10650.0,NM,,,,,,,,,,,,,,,Binding Affinity to cocaine site of dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol. ,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,4.972650392225243,CC1=CC=C(C=C1)[C@@H](C2CN(CCC2(C3=CC=C(C=C3)C)O)C)O,Cc1ccc([C@H](O)C2CN(C)CCC2(O)c2ccc(C)cc2)cc1
3134,3143,CHEMBL3331491,LWYKHCJDYWFVCG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,1.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,1.0,C1CCC(CC1)N(CC2CNC2)CC3=CC=C(C=C3)Cl,Clc1ccc(CN(CC2CNC2)C2CCCCC2)cc1
3135,3144,CHEMBL1643653,LXAGRMZFEDEAAM-UMAGBFNSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.657577319177793,CC1=NOC(=C1)[C@H]2[C@@H](CC3CCC2S3)C4=CC=C(C=C4)F,Cc1cc([C@@H]2C3CCC(C[C@H]2c2ccc(F)cc2)S3)on1
3136,3145,CHEMBL1643663,LXAGRMZFEDEAAM-VVBDHPJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,7.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.154901959985743,CC1=NOC(=C1)[C@H]2[C@H](CC3CCC2S3)C4=CC=C(C=C4)F,Cc1cc([C@@H]2C3CCC(C[C@@H]2c2ccc(F)cc2)S3)on1
3137,3146,CHEMBL325372,LXCFILQKKLGQFO-UHFFFAOYSA-N,METHYLPARABEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=C(C=C1)O,COC(=O)c1ccc(O)cc1
3138,3147,CHEMBL325372,LXCFILQKKLGQFO-UHFFFAOYSA-N,METHYLPARABEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=C(C=C1)O,COC(=O)c1ccc(O)cc1
3139,3148,CHEMBL378243,LXDSBNMMECZLMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.769551078621726,CN1C2CCC1C3COC(=O)CCSCCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCSCCC(=O)Nc3ccc(cc3)C1C2
3140,3149,CHEMBL406789,LXFLYTRXPWVMTB-SUMWQHHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCO3,C=CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCO3)C[C@H]1CN
3141,3150,CHEMBL1908355,LXIKEPCNDFVJKC-QXMHVHEDSA-N,TENIDAP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O,NC(=O)n1c(O)c(C(=O)c2cccs2)c2cc(Cl)ccc21
3142,3151,CHEMBL1908355,LXIKEPCNDFVJKC-QXMHVHEDSA-N,TENIDAP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O,NC(=O)n1c(O)c(C(=O)c2cccs2)c2cc(Cl)ccc21
3143,3152,CHEMBL1644477,LXIOTZOSBNBEKN-PTEHBNRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,804.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.094743951251549,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC=C3)I,Ic1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
3144,3153,CHEMBL461322,LXKDYSGDYBBTJV-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CNCC[C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C4CC4,CNCC[C@H](c1ccccc1)n1c(=O)n(C2CC2)c2ccccc21
3145,3154,CHEMBL1393,LXMSZDCAJNLERA-ZHYRCANASA-N,SPIRONOLACTONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21
3146,3155,CHEMBL1393,LXMSZDCAJNLERA-ZHYRCANASA-N,SPIRONOLACTONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21
3147,3156,CHEMBL204285,LXNRWPBVYRKZDQ-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,2500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,CN[C@H]1CC[C@H](C2=C1C=CC(=C2)S(=O)(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(S(N)(=O)=O)ccc21
3148,3157,CHEMBL3673130,LXQRBRXJAMSDSI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,603.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.219466674683597,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=CN6C(=NN=C6C(F)(F)F)C=C5,FC(F)(F)c1nnc2ccc(-c3ccc4c(c3)CN3CCC4(c4ccc(Cl)cc4)C3)cn12
3149,3158,CHEMBL509446,LXXOMHAIVSCBSY-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2C3=CC=CC=C3C[C@]2(CN)O,Cc1ccccc1O[C@H]1c2ccccc2C[C@@]1(O)CN
3150,3159,CHEMBL509373,LXXOMHAIVSCBSY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1OC2C3=CC=CC=C3CC2(CN)O,Cc1ccccc1OC1c2ccccc2CC1(O)CN
3151,3160,CHEMBL512677,LYBIOYSWEAGQEQ-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,23.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,CNCC[C@@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C4=CC=CC=C4,CNCC[C@@H](c1ccccc1)n1c(=O)n(-c2ccccc2)c2ccccc21
3152,3161,CHEMBL471519,LYBIOYSWEAGQEQ-HXUWFJFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,33.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,33.0,CNCC[C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C4=CC=CC=C4,CNCC[C@H](c1ccccc1)n1c(=O)n(-c2ccccc2)c2ccccc21
3153,3162,CHEMBL457299,LYCAIKOWRPUZTN-UHFFFAOYSA-N,ETHYLENE GLYCOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CO)O,OCCO
3154,3163,CHEMBL457299,LYCAIKOWRPUZTN-UHFFFAOYSA-N,ETHYLENE GLYCOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CO)O,OCCO
3155,3164,CHEMBL1944970,LYCULYABSZPOPO-MLHJIOFPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CC(C)C1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C,COC(=O)[C@H]1[C@@H](c2ccc(C(C)C)cc2)C[C@@H]2CC[C@H]1N2C
3156,3165,CHEMBL1173772,LYDZRRKPDGFEON-JSGCOSHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,204.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,6.690369832574103,CC[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,CC[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
3157,3166,CHEMBL1173772,LYDZRRKPDGFEON-JSGCOSHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,23.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CC[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,CC[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
3158,3167,CHEMBL3298876,LYMHIBZGTAPASQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24944732.0,KI,=,1014.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin)-mediated dopamine reuptake,Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.,ACS Med. Chem. Lett.,PUBLICATION,,5.993962045002682,CCNC(C)C(=O)C1=CC=CC=C1,CCNC(C)C(=O)c1ccccc1
3159,3168,CHEMBL401677,LYVNVEXOLQKXSZ-SUMWQHHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(C=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C=CN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
3160,3169,CHEMBL258260,LZBZURMZSQMQEB-KPGYKUMBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,10.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC1=CC2=C(C=C1)N(C(=N2)C)[C@@H]3CCN(C[C@H]3OC)C[C@@H]4CC5=C(C4)C=C(C=C5)NC(=O)C(C)C,CO[C@@H]1CN(C[C@@H]2Cc3ccc(NC(=O)C(C)C)cc3C2)CC[C@H]1n1c(C)nc2cc(C)ccc21
3161,3170,CHEMBL302795,LZNWYQJJBLGYLT-UHFFFAOYSA-N,TENOXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O
3162,3171,CHEMBL302795,LZNWYQJJBLGYLT-UHFFFAOYSA-N,TENOXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O
3163,3172,CHEMBL403956,LZPBAUCREIASQQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,1750.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7569619513137065,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2SC,CNCc1cnc(C)cc1Oc1ccccc1SC
3164,3173,CHEMBL2112594,LZTYLQCFLVOYDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,90.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.045757490560675,C1=CC=C(C=C1)CCC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(CCc1ccccc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
3165,3174,CHEMBL2112594,LZTYLQCFLVOYDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,51.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.292429823902062,C1=CC=C(C=C1)CCC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(CCc1ccccc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
3166,3175,CHEMBL2112594,LZTYLQCFLVOYDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,1.8,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,1.8,C1=CC=C(C=C1)CCC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(CCc1ccccc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
3167,3176,CHEMBL2206526,LZYIBOJIMRPXNJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,30.1,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.521433504406158,CC1=C(C=C(C=C1)C2CN(CC3=CC=CC=C23)C)F,Cc1ccc(C2CN(C)Cc3ccccc32)cc1F
3168,3177,CHEMBL3317703,MASFTFKGBFXWJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,130.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693162,CCC1C(=O)N(CCCN1)C2=CC3=CC=CC=C3C=C2.Cl,CCC1NCCCN(c2ccc3ccccc3c2)C1=O
3169,3178,CHEMBL313493,MBABOKRGFJTBAE-UHFFFAOYSA-N,METHANESULFONIC ACID METHYL ESTER,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COS(=O)(=O)C,COS(C)(=O)=O
3170,3179,CHEMBL313493,MBABOKRGFJTBAE-UHFFFAOYSA-N,METHANESULFONIC ACID METHYL ESTER,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COS(=O)(=O)C,COS(C)(=O)=O
3171,3180,CHEMBL516825,MBCIBUXZJAIISR-SOFGYWHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053782.0,KI,=,274.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]RTI-55 from human DAT transfected in human HEK293 cells,"Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,6.562249437179612,C1CC2C(C(CC1N2)C3=CC=CC(=C3)/C=C/I)C(=O)OCCF,O=C(OCCF)C1C2CCC(CC1c1cccc(/C=C/I)c1)N2
3172,3181,CHEMBL1944832,MBCIBUXZJAIISR-UEBMMIFQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,275.42,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.5600045260461926,C1C[C@@H]2[C@H]([C@H](C[C@H]1N2)C3=CC=CC(=C3)/C=C/I)C(=O)OCCF,O=C(OCCF)[C@H]1[C@@H](c2cccc(/C=C/I)c2)C[C@@H]2CC[C@H]1N2
3173,3182,CHEMBL462431,MBCIBUXZJAIISR-VURMDHGXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053782.0,KI,=,87.6,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]RTI-55 from human DAT transfected in human HEK293 cells,"Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,7.057495893831919,C1CC2C(C(CC1N2)C3=CC=CC(=C3)/C=C\I)C(=O)OCCF,O=C(OCCF)C1C2CCC(CC1c1cccc(/C=C\I)c1)N2
3174,3183,CHEMBL1944831,MBCIBUXZJAIISR-XAMFQDPGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,89.13,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.0499760934766735,C1C[C@@H]2[C@H]([C@H](C[C@H]1N2)C3=CC=CC(=C3)/C=C\I)C(=O)OCCF,O=C(OCCF)[C@H]1[C@@H](c2cccc(/C=C\I)c2)C[C@@H]2CC[C@H]1N2
3175,3184,CHEMBL2207382,MBFLODNVCSXSKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23141912.0,INHIBITION,=,3.53,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM by radioligand displacement assay,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.53,CN1CCN(CC1)CC2=C3C(=CC=C2)N(C=C3Br)S(=O)(=O)C4=CC=CC=C4,CN1CCN(Cc2cccc3c2c(Br)cn3S(=O)(=O)c2ccccc2)CC1
3176,3185,CHEMBL832,MBGGBVCUIVRRBF-UHFFFAOYSA-N,SULFINPYRAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
3177,3186,CHEMBL832,MBGGBVCUIVRRBF-UHFFFAOYSA-N,SULFINPYRAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
3178,3187,CHEMBL324967,MBVKPOXXMWDHKB-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,240500.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter; Average of two experiments,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.618884919290149,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC=C3O,CNCC[C@H](Oc1cccc2c(O)cccc12)c1cccs1
3179,3188,CHEMBL2337603,MCHVXQNUHBOZIA-CXAGYDPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,3.16,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381597,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1Cl
3180,3189,CHEMBL2337602,MCHVXQNUHBOZIA-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1Cl
3181,3190,CHEMBL310555,MCJGNVYPOGVAJF-UHFFFAOYSA-N,OXYQUINOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)O)N=CC=C2,Oc1cccc2cccnc12
3182,3191,CHEMBL310555,MCJGNVYPOGVAJF-UHFFFAOYSA-N,OXYQUINOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)O)N=CC=C2,Oc1cccc2cccnc12
3183,3192,CHEMBL466187,MCNALKIPDZCJNZ-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19067522.0,KI,>,6000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT receptor expressed in canine kidney cells,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter.",J. Med. Chem.,PUBLICATION,,5.221848749616356,C1CO[C@@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC=CC=C3CCF,FCCc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
3184,3193,CHEMBL2012112,MCODPXUUCUIDSE-AZGFUHLJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,18.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,7.744727494896693,COC(=O)[C@@H]1[C@H](CC2CCC1O2)C3=CC4=CC=CC=C4S3,COC(=O)[C@H]1C2CCC(C[C@@H]1c1cc3ccccc3s1)O2
3185,3194,CHEMBL2012112,MCODPXUUCUIDSE-AZGFUHLJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]1[C@H](CC2CCC1O2)C3=CC4=CC=CC=C4S3,COC(=O)[C@H]1C2CCC(C[C@@H]1c1cc3ccccc3s1)O2
3186,3195,CHEMBL2012111,MCODPXUUCUIDSE-UWTNAYQSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,9.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,8.045757490560675,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC4=CC=CC=C4S3,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cc3ccccc3s1)O2
3187,3196,CHEMBL2012111,MCODPXUUCUIDSE-UWTNAYQSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC4=CC=CC=C4S3,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cc3ccccc3s1)O2
3188,3197,CHEMBL89754,MDCYMBSNGHLBLC-GLWUULTISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,5.0,CN1C2C[C@H](C1C(=C(C2)C3=CC=CC=C3)C(=O)OC)O,COC(=O)C1=C(c2ccccc2)CC2C[C@@H](O)C1N2C
3189,3198,CHEMBL1224095,MDLYPVGOCJZPGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,794.33,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,C1C(CN1)(CC2=CC=CC=C2)C(=O)C3=CC4=C(C=C3)NC=C4,O=C(c1ccc2[nH]ccc2c1)C1(Cc2ccccc2)CNC1
3190,3199,CHEMBL395931,MDQSOSLERPCADB-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,44.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.356547323513813,C1CNC[C@@H]1N(CC2CC2)CC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(CN(CC2CC2)[C@@H]2CCNC2)c1Cl
3191,3200,CHEMBL246920,MDQSOSLERPCADB-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,206.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6861327796308485,C1CNC[C@H]1N(CC2CC2)CC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(CN(CC2CC2)[C@H]2CCNC2)c1Cl
3192,3201,CHEMBL513090,MDTSUTPVPDPVGP-CHKHYCHESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,47.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.327902142064282,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C=C3)OC)Br)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](c2ccc(OC)c(Br)c2)C[C@H]2CC[C@H]1N2C
3193,3202,CHEMBL1813489,MEAWOAPXKTVYPU-IUODEOHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,158.49,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.799998134593397,C1CC[C@]2(CNC[C@H]2C1)CC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C[C@@]23CCCC[C@@H]2CNC3)cc1Cl
3194,3203,CHEMBL1813488,MEAWOAPXKTVYPU-WFASDCNBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,501.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.299997602857746,C1CC[C@@]2(CNC[C@@H]2C1)CC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C[C@]23CCCC[C@H]2CNC3)cc1Cl
3195,3204,CHEMBL1650844,MEBYDATXPNEUSM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20875743.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 1 uM relative to control,"Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships.",Bioorg. Med. Chem.,PUBLICATION,,10.0,C1CCCC(CCC1)(CO)N2CCC(CC2)N3C4=CC=CC=C4N=C3N5CC6CNCC6C5,OCC1(N2CCC(n3c(N4CC5CNCC5C4)nc4ccccc43)CC2)CCCCCCC1
3196,3205,CHEMBL1536,MECHNRXZTMCUDQ-RKHKHRCZSA-N,ERGOCALCIFEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C
3197,3206,CHEMBL1536,MECHNRXZTMCUDQ-RKHKHRCZSA-N,ERGOCALCIFEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C
3198,3207,CHEMBL201977,MEMCHWOZQTXCNY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,2900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.537602002101044,CCCC(CN1CCCC1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CCCC(CN1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1
3199,3208,CHEMBL201977,MEMCHWOZQTXCNY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,1530.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.815308569182402,CCCC(CN1CCCC1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CCCC(CN1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1
3200,3209,CHEMBL2430683,MEPVQYBSRCKVHV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,51.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,51.0,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccc(Cl)cc1
3201,3210,CHEMBL2430683,MEPVQYBSRCKVHV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,61.2,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,61.2,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccc(Cl)cc1
3202,3211,CHEMBL2029054,MERKGGYYOYLGCB-ROPJLGIWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,>,10000000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.0,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,CNCC[C@H](Oc1cccc2c(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)c(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)ccc12)c1cccs1
3203,3212,CHEMBL1080389,MESZSUFNQDICOD-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5F,C[C@H]1CN(C(=O)c2ccc(-c3ccccc3F)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
3204,3213,CHEMBL24,METKIMKYRPQLGS-UHFFFAOYSA-N,ATENOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
3205,3214,CHEMBL24,METKIMKYRPQLGS-UHFFFAOYSA-N,ATENOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
3206,3215,CHEMBL972,MEZLKOACVSPNER-GFCCVEGCSA-N,SELEGILINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C#CCN(C)[C@H](C)Cc1ccccc1
3207,3216,CHEMBL972,MEZLKOACVSPNER-GFCCVEGCSA-N,SELEGILINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C#CCN(C)[C@H](C)Cc1ccccc1
3208,3217,CHEMBL381071,MFCNYVIQGJNQQJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)N(CC2=CC=CC=C2)C3=CC=CC=C3CN(C)C)N,Cc1ccc(N(Cc2ccccc2)c2ccccc2CN(C)C)c(N)c1
3209,3218,CHEMBL569,MFDFERRIHVXMIY-UHFFFAOYSA-N,PROCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,CCN(CC)CCOC(=O)c1ccc(N)cc1
3210,3219,CHEMBL569,MFDFERRIHVXMIY-UHFFFAOYSA-N,PROCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,CCN(CC)CCOC(=O)c1ccc(N)cc1
3211,3220,CHEMBL3703734,MFFCMNOKOQHLPH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,77.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.113509274827518,CS(=O)(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C(CNC3)C4=CC(=C(C=C4)Cl)Cl,CS(=O)(=O)c1ccc(-c2ccc3c(c2)CNCC3c2ccc(Cl)c(Cl)c2)cc1
3212,3221,CHEMBL1173354,MFHSHFDIBPWOJA-TVQRCGJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,285.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,6.54515513999149,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=C(C=C2)Cl)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1ccc(Cl)cc1
3213,3222,CHEMBL269939,MFKHVNDQMBWBBI-PISWEHOVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,80.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,80.0,CC1=CC2=C(C=C1)N(C(=N2)C)[C@@H]3CCN(C[C@H]3OC)C[C@H]4CC5=C(C4)C=C(C=C5)Br,CO[C@@H]1CN(C[C@H]2Cc3ccc(Br)cc3C2)CC[C@H]1n1c(C)nc2cc(C)ccc21
3214,3223,CHEMBL2030624,MFKYGKXYJBKSQN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,COC1=C(C=C(C=C1)CN2C3CCC2CC3)OC,COc1ccc(CN2C3CCC2CC3)cc1OC
3215,3224,CHEMBL206599,MFRFEHWQLFFQLQ-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,3300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.481486060122113,CN[C@H]1CC[C@H](C2=C1C=CC(=C2)C(=O)NC)C3=CC(=C(C=C3)Cl)Cl,CNC(=O)c1ccc2c(c1)[C@H](c1ccc(Cl)c(Cl)c1)CC[C@@H]2NC
3216,3225,CHEMBL1085338,MFTRIVHFDLRKDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,512.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,6.29073003902417,CNCCCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCCCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
3217,3226,CHEMBL126100,MFVHRXXVTQSVAV-LWCMGDNJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,20.3,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.692503962086787,COC(=O)C1[C@H](CC2CCC1N2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2
3218,3227,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
3219,3228,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
3220,3229,CHEMBL208251,MFXWGMNUZKYAND-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,83.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.080921907623925,CC(C)CN(CC1=CC=CC=C1Cl)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccccc1Cl)C1CCNCC1
3221,3230,CHEMBL1097660,MGCWVDDXPPKNQT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)(C(CN2CCNCC2)C3=CC4=CC=CC=C4N=C3)O,OC1(C(CN2CCNCC2)c2cnc3ccccc3c2)CCCCC1
3222,3231,CHEMBL493568,MGEYXYRIODCARZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CC=C1)NC(=O)C2=CC(=C(C=C2)C3=CC(=CC=C3)F)C#N,Cc1cccc(NC(=O)c2ccc(-c3cccc(F)c3)c(C#N)c2)n1
3223,3232,CHEMBL493568,MGEYXYRIODCARZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CC=C1)NC(=O)C2=CC(=C(C=C2)C3=CC(=CC=C3)F)C#N,Cc1cccc(NC(=O)c2ccc(-c3cccc(F)c3)c(C#N)c2)n1
3224,3233,CHEMBL415522,MGJPPQVRSBEOEX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,1260.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.8996294548824375,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC5=C(C=C4)OCCO5)O,OC1(c2ccc3c(c2)OCCO3)c2ccccc2C2=NCCN21
3225,3234,CHEMBL469946,MGQRODBGBVCRHA-FZMZJTMJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.0,CCN(CC(=C)F)C(=O)[C@]1(C[C@H]1CN)C2=CC=CS2,C=C(F)CN(CC)C(=O)[C@@]1(c2cccs2)C[C@H]1CN
3226,3235,CHEMBL209969,MGQYROXWDORYIL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=C2C(=O)N)C3=CC=CC=C3,NC(=O)c1ccccc1CC(c1ccccc1)N1CCNCC1
3227,3236,CHEMBL1224301,MGURNBDIUXGJTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,10.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC1=NN(N=N1)C(CCNC)C2=CC3=C(C=C2)C=C(C=C3)F,CNCCC(c1ccc2cc(F)ccc2c1)n1nnc(C)n1
3228,3237,CHEMBL550779,MGXQLLRKRSAUPY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,60.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,C1CNCCC1C(C2=CC=NC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2ccncc2)C2CCNCC2)c1Cl
3229,3238,CHEMBL2205827,MGYAQEPRQTVZOM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,COC1=C(C=C(C=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC
3230,3239,CHEMBL2205827,MGYAQEPRQTVZOM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,COC1=C(C=C(C=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC
3231,3240,CHEMBL3323095,MHFUBIDIXOMIAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,5.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,8.292429823902062,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)SC=C4,CN1Cc2ccccc2C(c2ccc3sccc3c2)C1
3232,3241,CHEMBL3323095,MHFUBIDIXOMIAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,190.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,6.721246399047171,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)SC=C4,CN1Cc2ccccc2C(c2ccc3sccc3c2)C1
3233,3242,CHEMBL3323095,MHFUBIDIXOMIAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,3.8,NM,314435,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.42021640338319,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)SC=C4,CN1Cc2ccccc2C(c2ccc3sccc3c2)C1
3234,3243,CHEMBL3323095,MHFUBIDIXOMIAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,3.8,NM,314443,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.42021640338319,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)SC=C4,CN1Cc2ccccc2C(c2ccc3sccc3c2)C1
3235,3244,CHEMBL3238500,MHGBDWVFNLUSGF-ZXSNDDASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)N)O)C(F)(F)F)C(F)(F)F)N,Nc1ccc(-c2ccc(N=Nc3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(C(F)(F)F)c2)cc1C(F)(F)F
3236,3245,CHEMBL381331,MHJZXDDQSMFDMW-ZBEGNZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN[C@H]1CC[C@H](C2=C1C(=CC(=C2)C(=O)N)C(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(C(N)=O)cc(C(N)=O)c21
3237,3246,CHEMBL288152,MHMSJQGEVKUFEQ-JXMROGBWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,5.66,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.66,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)C/C=C/C3=CC=CC=C3)C4=CC=CC=N4,COc1ccc(CN(CCN2CCN(C/C=C/c3ccccc3)CC2)c2ccccn2)cc1
3238,3247,CHEMBL317757,MHNSOBBJZCWUGS-UHFFFAOYSA-N,DIFLUOROBENZTROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,44.6,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.350665141287857,CN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2
3239,3248,CHEMBL317757,MHNSOBBJZCWUGS-UHFFFAOYSA-N,DIFLUOROBENZTROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,13.8,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.860120913598763,CN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2
3240,3249,CHEMBL404474,MHSMLXPGKSUMMH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(C1=CC=CC=C1)C(=O)C2(CC2CN)C3=CC=CC=C3,CCN(C(=O)C1(c2ccccc2)CC1CN)c1ccccc1
3241,3250,CHEMBL119605,MHWRJCBZOCBFBD-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,2814000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.5506759069012728,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3O)OC,CNCC[C@H](Oc1cccc2c(O)c(OC)ccc12)c1cccs1
3242,3251,CHEMBL1687,MHXYWXHKLBMJKL-QBYKQQEBSA-N,TUBOCURARINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.[Cl-],COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
3243,3252,CHEMBL1687,MHXYWXHKLBMJKL-QBYKQQEBSA-N,TUBOCURARINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.[Cl-],COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
3244,3253,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,2.42,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.616184634019568,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3245,3254,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,190.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.721246399047171,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3246,3255,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,29.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,29.0,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3247,3256,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,14.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321763,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3248,3257,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,89.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,89.0,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3249,3258,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,190.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3250,3259,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,29.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,29.0,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3251,3260,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,86.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,86.0,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3252,3261,CHEMBL543876,MIBSKSYCRFWIRU-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,89.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,89.0,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3253,3262,CHEMBL407030,MIFVTYPADKEWAV-HGRQBIKSSA-N,GAMMA-CYCLODEXTRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)O)OC6[C@H](OC([C@@H]([C@H]6O)O)C7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CO)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1OC2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)OC(OC9[C@@H](CO)OC(C1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
3254,3263,CHEMBL407030,MIFVTYPADKEWAV-HGRQBIKSSA-N,GAMMA-CYCLODEXTRIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)O)OC6[C@H](OC([C@@H]([C@H]6O)O)C7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CO)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1OC2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)OC(OC9[C@@H](CO)OC(C1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
3255,3264,CHEMBL1080755,MIJPHKXHAZCAQK-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=C(C=C5)OC(F)(F)F,C[C@H]1CN(C(=O)c2ccc(-c3ccc(OC(F)(F)F)cc3)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
3256,3265,CHEMBL340978,MITFXPHMIHQXPI-UHFFFAOYSA-N,BENOXAPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
3257,3266,CHEMBL340978,MITFXPHMIHQXPI-UHFFFAOYSA-N,BENOXAPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
3258,3267,CHEMBL2030633,MIZXZRHARATZMK-UHFFFAOYSA-N,"N-(3,4-DIMETHOXYBENZYL)PYRROLIDINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,COC1=C(C=C(C=C1)CN2CCCC2)OC,COc1ccc(CN2CCCC2)cc1OC
3259,3268,CHEMBL1224321,MJCKYDPFUPMINT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,0.631,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.199970640755863,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CC(C)(C)CCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
3260,3269,CHEMBL1224321,MJCKYDPFUPMINT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,0.794,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.100179497572904,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CC(C)(C)CCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
3261,3270,CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
3262,3271,CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
3263,3272,CHEMBL305660,MJJALKDDGIKVBE-UHFFFAOYSA-N,EBASTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,98.7,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.0056828473303625,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
3264,3273,CHEMBL305660,MJJALKDDGIKVBE-UHFFFAOYSA-N,EBASTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,78.4,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.105683937315562,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
3265,3274,CHEMBL471036,MJJDYOLPMGIWND-UHFFFAOYSA-N,LITOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,1300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693162,C1CNCCC1OCC2=CC3=CC=CC=C3C=C2,c1ccc2cc(COC3CCNCC3)ccc2c1
3266,3275,CHEMBL471036,MJJDYOLPMGIWND-UHFFFAOYSA-N,LITOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,6700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.173925197299173,C1CNCCC1OCC2=CC3=CC=CC=C3C=C2,c1ccc2cc(COC3CCNCC3)ccc2c1
3267,3276,CHEMBL476839,MJKRYUCQHJLOIV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329329.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned DAT by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,5.0,CC1=CC=C(C=C1)CCN2CCC(CC2)C(C3=C(C(=CC=C3)OCCF)OC)O,COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(C)cc2)CC1
3268,3277,CHEMBL2337608,MJNJOFYBUSUCSO-CXAGYDPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,158.49,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC(=CC(=C3)Cl)Cl,Clc1cc(Cl)cc(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1
3269,3278,CHEMBL2337607,MJNJOFYBUSUCSO-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,316.23,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=CC(=CC(=C3)Cl)Cl,Clc1cc(Cl)cc(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1
3270,3279,CHEMBL2432058,MJOVYQVAQIHDSE-DKSPCFMDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CCC1=CC=CC=C1)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CCc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41
3271,3280,CHEMBL1644475,MJWXDPDEDHUUJV-JGPRNRPPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,1318.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.880084589742008,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC=C3Cl,Clc1ccccc1OC1C[C@@H]2CC[C@H](C1)N2
3272,3281,CHEMBL409715,MJXIPRPHBIFHJC-MGPUTAFESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,640.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1938200260161125,C1CN(C2=CC=CC=C21)C(=O)[C@]3(C[C@H]3CN)C4=CC5=C(C=C4)OCO5,NC[C@@H]1C[C@@]1(C(=O)N1CCc2ccccc21)c1ccc2c(c1)OCO2
3273,3282,CHEMBL551471,MJXRIUSTMWJDCG-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,2650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.576754126063192,CCOC1=CC=CC=C1C(=O)N(CC2CCC2)[C@H]3CCNC3,CCOc1ccccc1C(=O)N(CC1CCC1)[C@H]1CCNC1
3274,3283,CHEMBL2207376,MJYQMQCVUXOIFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23141912.0,INHIBITION,=,20.39,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM by radioligand displacement assay,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,20.39,CN1CCN(CC1)CC2=C3C(=CC=C2)N(C=C3Cl)S(=O)(=O)C4=CC(=CC=C4)Cl,CN1CCN(Cc2cccc3c2c(Cl)cn3S(=O)(=O)c2cccc(Cl)c2)CC1
3275,3284,CHEMBL1683883,MKEIWZZHDFWQBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,82.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.086186147616282,CN(C)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CN(C)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3276,3285,CHEMBL396083,MKGVCSJCNPSLPB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,302000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.519993057042849,CC(C)(C)C1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)(C)C)cc2)CCC1
3277,3286,CHEMBL396083,MKGVCSJCNPSLPB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,CC(C)(C)C1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)(C)C)cc2)CCC1
3278,3287,CHEMBL396083,MKGVCSJCNPSLPB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,3311311214825.91,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.52,CC(C)(C)C1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(C(C)(C)C)cc2)CCC1
3279,3288,CHEMBL1645596,MKIMQSUJTXVNED-UHFFFAOYSA-N,3-(2-PHENOXYPHENOXY)AZETIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,2090.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.679853713888947,C1C(CN1)OC2=CC=CC=C2OC3=CC=CC=C3,c1ccc(Oc2ccccc2OC2CNC2)cc1
3280,3289,CHEMBL247341,MKNCFIMZZSMFIK-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,196.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.707743928643524,CC1=C(C=CC=C1Cl)CN([C@H]2CCNC2)C3CCOCC3,Cc1c(Cl)cccc1CN(C1CCOCC1)[C@H]1CCNC1
3281,3290,CHEMBL184,MKUXAQIIEYXACX-UHFFFAOYSA-N,ACYCLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Nc1nc2c(ncn2COCCO)c(=O)[nH]1
3282,3291,CHEMBL184,MKUXAQIIEYXACX-UHFFFAOYSA-N,ACYCLOVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Nc1nc2c(ncn2COCCO)c(=O)[nH]1
3283,3292,CHEMBL806,MKXKFYHWDHIYRV-UHFFFAOYSA-N,FLUTAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
3284,3293,CHEMBL806,MKXKFYHWDHIYRV-UHFFFAOYSA-N,FLUTAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
3285,3294,CHEMBL52440,MKXZASYAUGDDCJ-NJAFHUGGSA-N,DEXTROMETHORPHAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
3286,3295,CHEMBL52440,MKXZASYAUGDDCJ-NJAFHUGGSA-N,DEXTROMETHORPHAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
3287,3296,CHEMBL3334772,MLGACOKYDQJTGD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,83.9,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,83.9,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CSC4=CC=CC=C43)N5CCNCC5,C1=C(Cc2ccccc2)CCN(CCC(c2csc3ccccc23)N2CCNCC2)C1
3288,3297,CHEMBL15770,MLKXDPUZXIRXEP-MFOYZWKCSA-N,SULINDAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
3289,3298,CHEMBL15770,MLKXDPUZXIRXEP-MFOYZWKCSA-N,SULINDAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
3290,3299,CHEMBL2430682,MLLKPBZCMWKIND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,33.1,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.480172006224282,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
3291,3300,CHEMBL2430682,MLLKPBZCMWKIND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,94.6,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,94.6,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
3292,3301,CHEMBL2430682,MLLKPBZCMWKIND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,95.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,95.0,C1C(C(C(=O)N1)C2=CC=C(C=C2)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1
3293,3302,CHEMBL416433,MLLNVAJYLMHYEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.24,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.24,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=C(C=C3)F)C4=CC=CC=N4,Fc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
3294,3303,CHEMBL416433,MLLNVAJYLMHYEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.19,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.19,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=C(C=C3)F)C4=CC=CC=N4,Fc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
3295,3304,CHEMBL202810,MLTWEZLEOAHOAA-SMWAQBJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,89.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0506099933550885,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)CS(=O)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(C[S+](C)[O-])cc21
3296,3305,CHEMBL506789,MLXZSGRSLJXYNT-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,7700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113509274827519,CN(CC1=CC2=CC=CC=C2C=C1)[C@H]3CCNC3,CN(Cc1ccc2ccccc2c1)[C@H]1CCNC1
3297,3306,CHEMBL469607,MLXZSGRSLJXYNT-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,3000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,CN(CC1=CC2=CC=CC=C2C=C1)[C@@H]3CCNC3,CN(Cc1ccc2ccccc2c1)[C@@H]1CCNC1
3298,3307,CHEMBL2326684,MMBDWDAKDCKUAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,23.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.638272163982407,CC1=C(C=CC(=C1)C2CC=CCN(C2)C)Cl,Cc1cc(C2CC=CCN(C)C2)ccc1Cl
3299,3308,CHEMBL373385,MMKZDDDDODERSJ-GRAKBVBRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,10.2,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.991399828238082,CC1=CC=C(C=C1)[C@@H]2CC3CCC([C@H]2C(=O)OC)N3C,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(C)cc1)N2C
3300,3309,CHEMBL312037,MMKZDDDDODERSJ-GXRBRPDZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,1.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,8.769551078621726,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC([C@H]2C(=O)OC)N3C,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccc(C)cc1)N2C
3301,3310,CHEMBL312037,MMKZDDDDODERSJ-GXRBRPDZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,1.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,8.769551078621726,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC([C@H]2C(=O)OC)N3C,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccc(C)cc1)N2C
3302,3311,CHEMBL312037,MMKZDDDDODERSJ-GXRBRPDZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,23.4,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,7.6307841425898575,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC([C@H]2C(=O)OC)N3C,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccc(C)cc1)N2C
3303,3312,CHEMBL2096861,MMKZDDDDODERSJ-GYTBAZASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,207.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,6.684029654543082,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@@H]2C(=O)OC)N3C,COC(=O)[C@H]1C2CCC(C[C@@H]1c1ccc(C)cc1)N2C
3304,3313,CHEMBL221993,MMKZDDDDODERSJ-JAAVRUMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,23.4,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.6307841425898575,CC1=CC=C(C=C1)[C@@H]2CC3CC[C@H]([C@@H]2C(=O)OC)N3C,COC(=O)[C@@H]1[C@H](c2ccc(C)cc2)CC2CC[C@H]1N2C
3305,3314,CHEMBL1947089,MMKZDDDDODERSJ-JJXSEGSLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,32.36,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.489991487059766,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C
3306,3315,CHEMBL322605,MMQIRPMTFUSCNV-JZIDCSOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,25.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.602059991327962,COC(=O)[C@@H]1C2CCC(C2)CC1C3=CC4=CC=CC=C4C=C3,COC(=O)[C@@H]1C2CCC(C2)CC1c1ccc2ccccc2c1
3307,3316,CHEMBL2111613,MMQIRPMTFUSCNV-NZFXJPAUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.920818753952375,COC(=O)[C@@H]1[C@H](CC2CCC1C2)C3=CC4=CC=CC=C4C=C3,COC(=O)[C@H]1C2CCC(C2)C[C@@H]1c1ccc2ccccc2c1
3308,3317,CHEMBL2111613,MMQIRPMTFUSCNV-NZFXJPAUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.769551078621726,COC(=O)[C@@H]1[C@H](CC2CCC1C2)C3=CC4=CC=CC=C4C=C3,COC(=O)[C@H]1C2CCC(C2)C[C@@H]1c1ccc2ccccc2c1
3309,3318,CHEMBL2112412,MMQIRPMTFUSCNV-QAZKEQNZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.568636235841013,COC(=O)[C@H]1[C@H](CC2CCC1C2)C3=CC4=CC=CC=C4C=C3,COC(=O)[C@@H]1C2CCC(C2)C[C@@H]1c1ccc2ccccc2c1
3310,3319,CHEMBL256646,MMSNYIQZTXLKBV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC1=CC=CC=C1)C(=O)C2(CC2CN)C3=CC=CC=C3,CCN(Cc1ccccc1)C(=O)C1(c2ccccc2)CC1CN
3311,3320,CHEMBL347772,MMXYNKLYVRNTCK-UHFFFAOYSA-N,2-BENZHYDRYL-PYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,742.0,NM,,,,,,,,,,,,,,,Affinity to displace binding of [3H]WIN-35428 to dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.129596094720973,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=CC=N3,c1ccc(C(c2ccccc2)c2ccccn2)cc1
3312,3321,CHEMBL347772,MMXYNKLYVRNTCK-UHFFFAOYSA-N,2-BENZHYDRYL-PYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,1067.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake evaluated at the dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.97183558057553,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=CC=N3,c1ccc(C(c2ccccc2)c2ccccn2)cc1
3313,3322,CHEMBL93645,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,ACECLOFENAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
3314,3323,CHEMBL93645,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,ACECLOFENAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
3315,3324,CHEMBL599592,MNKYSXOLQYNYNU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.195860567664648,CC1=C(C(=CC=C1)F)OC2=C(C=CC=N2)C3CCNCC3,Cc1cccc(F)c1Oc1ncccc1C1CCNCC1
3316,3325,CHEMBL3673144,MNVQGSYZEJNUAT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,47.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.322393047279506,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=CN=C(C=N4)N)C5=CC=C(C=C5)Cl,Nc1cnc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)cn1
3317,3326,CHEMBL559654,MNXBENJELVJIHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CNCCC1C(C2=CN=CC=C2)OC3=C(C=CC(=C3)Cl)Cl,Clc1ccc(Cl)c(OC(c2cccnc2)C2CCNCC2)c1
3318,3327,CHEMBL494807,MNZCWNRZRKZOCQ-PQEADEMYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,0.8,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,9.096910013008056,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C#CC4=CC=CC=C4)N3C.Cl,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C#Cc2ccccc2)N3C)cc1
3319,3328,CHEMBL567943,MOEMPBAHOJKXBG-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,2800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,CS(=O)(=O)N(CC1=CC2=CC=CC=C2C=C1)[C@H]3CCNC3,CS(=O)(=O)N(Cc1ccc2ccccc2c1)[C@H]1CCNC1
3320,3329,CHEMBL566576,MOEMPBAHOJKXBG-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,68000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.167491087293763,CS(=O)(=O)N(CC1=CC2=CC=CC=C2C=C1)[C@@H]3CCNC3,CS(=O)(=O)N(Cc1ccc2ccccc2c1)[C@@H]1CCNC1
3321,3330,CHEMBL481695,MOEZDBSMUWWXGO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=C(C=CC(=C1)C(=O)N)OC2=CC=C(C=C2)OC(F)(F)F,CN(C)Cc1cc(C(N)=O)ccc1Oc1ccc(OC(F)(F)F)cc1
3322,3331,CHEMBL220765,MOOPIJCZPWGNKW-FIPFOOKPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,621.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.20690839982342,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CC#C)CC3=CC=C(C=C3)F)C(=O)C,C#CCN1CC[C@@H](Cc2ccc(F)cc2)C[C@@H]1CCCNC(=O)Nc1cc(C(C)=O)cc(C(C)=O)c1
3323,3332,CHEMBL215236,MOULTCTZAHHVRO-WQLSENKSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784855.0,KI,=,4.54,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT transfected in HEK293 cells,Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.342944147142896,COC(=O)/C=C\1/CN2C3CCC2C1C(C3)C4=CC=C(C=C4)Cl,COC(=O)/C=C1/CN2C3CCC2C1C(c1ccc(Cl)cc1)C3
3324,3333,CHEMBL2432040,MPBJQDFYALBXED-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CC1=CC=CC=C1)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(Cc1ccccc1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
3325,3334,CHEMBL578841,MPFXFPLOFFDVSF-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,11.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,11.0,CC1=CC=CC=C1[C@@H]([C@@H](CNC)O)N2C=CC3=CC=CC=C32,CNC[C@@H](O)[C@H](c1ccccc1C)n1ccc2ccccc21
3326,3335,CHEMBL1080968,MPGDFMOXIHFZSL-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,983.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0074464821678655,C1CCC(C1)N([C@H]2CCNC2)C(=O)C3=C(C(=CC=C3)Cl)Cl,O=C(c1cccc(Cl)c1Cl)N(C1CCCC1)[C@H]1CCNC1
3327,3336,CHEMBL259136,MPTXQMSURVDICU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNCC1=C(C=CN=C1)OC2=C(C=C(C=C2)Cl)Cl,CNCc1cnccc1Oc1ccc(Cl)cc1Cl
3328,3337,CHEMBL3321790,MPWWGTFDWDZHRM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,=,1081.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.966174306046691,C1CC2CC(CC1N2CCCSC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccc(F)cc1
3329,3338,CHEMBL205837,MQFDETILCHDOAZ-ZBEGNZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5376020021010435,CN[C@H]1CC[C@H](C2=C1C(=CC=C2)C(=O)N)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cccc(C(N)=O)c21
3330,3339,CHEMBL564059,MQFMYYCALRUDSV-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3040.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.517126416391246,CSC1=CC=CC=C1C(=O)N(CC2CCC2)[C@H]3CCNC3,CSc1ccccc1C(=O)N(CC1CCC1)[C@H]1CCNC1
3331,3340,CHEMBL562802,MQFMYYCALRUDSV-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3470.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.459670525209127,CSC1=CC=CC=C1C(=O)N(CC2CCC2)[C@@H]3CCNC3,CSc1ccccc1C(=O)N(CC1CCC1)[C@@H]1CCNC1
3332,3341,CHEMBL388612,MQFVMWBVJNBDJG-CIBWYJFOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,416.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.380906669373259,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=C(C=C5)Cl)Cl,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(Cl)c(Cl)c3)s1)[C@@H](c1ccc(Cl)cc1)C2
3333,3342,CHEMBL388612,MQFVMWBVJNBDJG-CIBWYJFOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,66.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.180456064458133,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=C(C=C5)Cl)Cl,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(Cl)c(Cl)c3)s1)[C@@H](c1ccc(Cl)cc1)C2
3334,3343,CHEMBL210027,MQGLAASXHMCXDS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CN(CCN1)C(CC2=CC=CC=C2C(F)(F)F)C3=CC=CC=C3,FC(F)(F)c1ccccc1CC(c1ccccc1)N1CCNCC1
3335,3344,CHEMBL404885,MQNROJMRVKETEZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,1410.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.85078088734462,CC1=CC=CC=C1OC2=C(C=NC(=C2)C)CN(C)C,Cc1cc(Oc2ccccc2C)c(CN(C)C)cn1
3336,3345,CHEMBL3703729,MQRPDUHCJZKKNO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,28.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.552841968657781,CC1(C2=C(C=CC(=C2)C3=NN=C(C=C3)C(F)(F)F)C(CN1)C4=CC(=C(C=C4)Cl)Cl)C,CC1(C)NCC(c2ccc(Cl)c(Cl)c2)c2ccc(-c3ccc(C(F)(F)F)nn3)cc21
3337,3346,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
3338,3347,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
3339,3348,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
3340,3349,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
3341,3350,CHEMBL440878,MRBFFQVXMIGKST-NWDGAFQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NNC(=O)[C@H]3[C@@H]2CC=CC3)OC,COc1ccc(C2=NNC(=O)[C@@H]3CC=CC[C@H]23)cc1OC
3342,3351,CHEMBL440878,MRBFFQVXMIGKST-NWDGAFQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NNC(=O)[C@H]3[C@@H]2CC=CC3)OC,COc1ccc(C2=NNC(=O)[C@@H]3CC=CC[C@H]23)cc1OC
3343,3352,CHEMBL313041,MRBFFQVXMIGKST-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NNC(=O)C3C2CC=CC3)OC,COc1ccc(C2=NNC(=O)C3CC=CCC23)cc1OC
3344,3353,CHEMBL313041,MRBFFQVXMIGKST-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NNC(=O)C3C2CC=CC3)OC,COc1ccc(C2=NNC(=O)C3CC=CCC23)cc1OC
3345,3354,CHEMBL313041,MRBFFQVXMIGKST-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NNC(=O)C3C2CC=CC3)OC,COc1ccc(C2=NNC(=O)C3CC=CCC23)cc1OC
3346,3355,CHEMBL313041,MRBFFQVXMIGKST-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.0,COC1=C(C=C(C=C1)C2=NNC(=O)C3C2CC=CC3)OC,COc1ccc(C2=NNC(=O)C3CC=CCC23)cc1OC
3347,3356,CHEMBL388832,MRPLQNITIUKVEG-SMOZNVCYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,212.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.6736641390712474,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=C(C=C5)OC)OC,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(Cl)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1OC
3348,3357,CHEMBL388832,MRPLQNITIUKVEG-SMOZNVCYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,234.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.6307841425898575,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=C(C=C5)OC)OC,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(Cl)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1OC
3349,3358,CHEMBL3577957,MRTJHEDYFUFHHQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25893048.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to human DAT at 1 uM,,ACS Med. Chem. Lett.,PUBLICATION,,,C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4.Cl,O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1
3350,3359,CHEMBL207067,MRYGKPHUQVMAJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-22.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-22.0,C1CC1CN(CC2=C(C=C(C=C2)F)C(F)(F)F)C3CCNCC3.C(C(C(=O)O)O)(C(=O)O)O,Fc1ccc(CN(CC2CC2)C2CCNCC2)c(C(F)(F)F)c1
3351,3360,CHEMBL40358,MRYOBMPKEQQIMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.57,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.57,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)CCCC3=CC=CC=C3)C4=CC=CC=N4,COc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
3352,3361,CHEMBL40358,MRYOBMPKEQQIMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.66,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.66,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)CCCC3=CC=CC=C3)C4=CC=CC=N4,COc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccccn2)cc1
3353,3362,CHEMBL359025,MSLSPRSRIMVUAY-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,32.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.494850021680094,CC(C)N[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3354,3363,CHEMBL359025,MSLSPRSRIMVUAY-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,51.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.292429823902062,CC(C)N[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3355,3364,CHEMBL359025,MSLSPRSRIMVUAY-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,1.6,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,1.6,CC(C)N[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3356,3365,CHEMBL424496,MSLSPRSRIMVUAY-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,450.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.346787486224656,CC(C)N[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3357,3366,CHEMBL424496,MSLSPRSRIMVUAY-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,1400.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.853871964321763,CC(C)N[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3358,3367,CHEMBL424496,MSLSPRSRIMVUAY-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,3.1,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,3.1,CC(C)N[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CC(C)N[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3359,3368,CHEMBL1683874,MSRLFKAAHSYYJT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CN(C)CC1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,CN(C)CC1(c2ccc(Cl)c(Cl)c2)CCCCC1
3360,3369,CHEMBL451232,MSSKZLHARRXFKT-VNUWRVCDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19284718.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,J. Med. Chem.,PUBLICATION,,5.0,C1[C@@H]([C@H]1C2=C(C=C(C=C2)F)Cl)CN.Cl,NC[C@H]1C[C@@H]1c1ccc(F)cc1Cl
3361,3370,CHEMBL2432041,MSTPNDDVMWUDFF-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,4523.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.344573412254081,CN(CC1=CC(=CC=C1)F)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
3362,3371,CHEMBL3215892,MTATYSOUXXNXHF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23141912.0,INHIBITION,=,5.23,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM by radioligand displacement assay,"Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N(1)-arylsulfonyl indole derivatives as 5-HT(6) receptor ligands.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.23,C1CN(CCN1)CC2=C3C=CN(C3=CC=C2)S(=O)(=O)C4=CC=CC=C4Br.Cl.Cl,O=S(=O)(c1ccccc1Br)n1ccc2c(CN3CCNCC3)cccc21
3363,3372,CHEMBL484952,MTEFLXYKMHWTNG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19338356.0,ACTIVITY,<,50.0,%,Active,,,,,,,,,,,,,,Binding affinity to DAT,Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.,J. Med. Chem.,PUBLICATION,,50.0,CCCCNC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3C(=N2)C4=CC=C(C=C4)Cl,CCCCNC(=O)c1ccc2c(c1)N=C(c1ccc(Cl)cc1)c1ccccc1S2
3364,3373,CHEMBL408329,MTFGWQIUGWXBJK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2390.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.621602099051862,CCOC1=CC=CC=C1OC2=C(C=NC(=C2)C)CNC,CCOc1ccccc1Oc1cc(C)ncc1CNC
3365,3374,CHEMBL1173280,MTLOYHNBLPYTSE-TVQRCGJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,12000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,4.920818753952375,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)[N+](=O)[O-])O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc([N+](=O)[O-])c1
3366,3375,CHEMBL211396,MTTQVAJJGOFFBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,5.698970004336019,CN1C2CCC1C3COC(=O)CC4=CC=C(CC(=O)NC5=CC=C(C3C2)C=C5)C=C4,CN1C2CCC1C1COC(=O)Cc3ccc(cc3)CC(=O)Nc3ccc(cc3)C1C2
3367,3376,CHEMBL3317695,MTYNQRLUWCXWLL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,4000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CC1CNCC(=O)N(C1)C2=CC(=C(C=C2)Cl)Cl.Cl,CC1CNCC(=O)N(c2ccc(Cl)c(Cl)c2)C1
3368,3377,CHEMBL116735,MUAYITOFLINYIL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,1280.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.892790030352131,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCC4=CC=C(C=C4)F,O=C(CCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
3369,3378,CHEMBL1224237,MUCOWQIQUFKAFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,1.26,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.899629454882437,CC(C)(C)CCC1(CCNC1)C(=O)C2=CC3=CC=CC=C3S2,CC(C)(C)CCC1(C(=O)c2cc3ccccc3s2)CCNC1
3370,3379,CHEMBL133551,MUEXSYLRFIXODP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,INHIBITION,=,5.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane at a concentration of 10 e -6 M,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.0,COCC1(C2=CC=CC=C2C3=NCCCN31)C4=CC=C(C=C4)Cl,COCC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
3371,3380,CHEMBL402924,MUJXFBPLIVKRBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,9000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.045757490560675,C1CC(C1)NC(=O)C2=C(CCC2)C3=CC(=C(C=C3)Cl)Cl,O=C(NC1CCC1)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
3372,3381,CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
3373,3382,CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
3374,3383,CHEMBL453996,MUOXAGUZMVATIC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,>,7000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,C1CNCCC1COC2=CC3=CC=CC=C3C=C2,c1ccc2cc(OCC3CCNCC3)ccc2c1
3375,3384,CHEMBL574347,MUPPOMFFBLBAKT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1680.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.774690718274138,CC1=CC(=C(C=C1)C2CCNCC2)OC3=CC=C(C=C3)F,Cc1ccc(C2CCNCC2)c(Oc2ccc(F)cc2)c1
3376,3385,CHEMBL1200845,MUQNGPZZQDCDFT-JNQJZLCISA-N,HALCINONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
3377,3386,CHEMBL1200845,MUQNGPZZQDCDFT-JNQJZLCISA-N,HALCINONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
3378,3387,CHEMBL3218985,MUQXFOQLDSJMCX-YADHBBJMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,INHIBITION,=,50.0,%,,,,,,,,,,,,,,,Binding affinity to DA transporter (unknown origin) at 10 uM by displacement assay relative to control,,MedChemComm,PUBLICATION,,50.0,C1CN(CCN1CCNC(=O)[C@H]2C[C@@H]2C3=CC=CC=C3)CC4=CC=CC=C4,O=C(NCCN1CCN(Cc2ccccc2)CC1)[C@H]1C[C@@H]1c1ccccc1
3379,3388,CHEMBL1812742,MUVQRHMVRFZUGP-IKJKNFHUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,11.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=CC(=NO4)C5=CC=C(C=C5)Cl)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2cc(-c4ccc(Cl)cc4)no2)N3C)cc1
3380,3389,CHEMBL189367,MUWHGPWUJGZMPM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,2000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,5.698970004336019,CCC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)N,CCc1ccc(Sc2ccccc2CN(C)C)c(N)c1
3381,3390,CHEMBL595766,MVCBKJMODFGYDE-LOKCHCMISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,540.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.267606240177032,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCCCCCCNC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)C8=CSC=C8,CN1C2CCC1[C@@H](C(=O)NCCCCCCNC(=O)[C@H]1C3CCC(C[C@@H]1c1ccc(-c4ccsc4)cc1)N3C)[C@@H](c1ccc(-c3ccsc3)cc1)C2
3382,3391,CHEMBL211412,MVELXQAMQGKSIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3F,Fc1ccccc1C(Cc1ccccc1Cl)N1CCNCC1
3383,3392,CHEMBL1194,MVFGUOIZUNYYSO-UHFFFAOYSA-N,PRILOCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(C)C(=O)NC1=CC=CC=C1C,CCCNC(C)C(=O)Nc1ccccc1C
3384,3393,CHEMBL1194,MVFGUOIZUNYYSO-UHFFFAOYSA-N,PRILOCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(C)C(=O)NC1=CC=CC=C1C,CCCNC(C)C(=O)Nc1ccccc1C
3385,3394,CHEMBL488025,MVGSNCBCUWPVDA-MFOYZWKCSA-N,EXISULIND,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)(=O)=O)cc1
3386,3395,CHEMBL488025,MVGSNCBCUWPVDA-MFOYZWKCSA-N,EXISULIND,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)(=O)=O)cc1
3387,3396,CHEMBL476108,MVKKLGNVARQKRP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18595716.0,KI,=,1150.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,5.939302159646387,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
3388,3397,CHEMBL362783,MVOUTMRHQVFORJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.0,CNCC1=CC=CC=C1SC2=C(C=C(C=C2)CO)N,CNCc1ccccc1Sc1ccc(CO)cc1N
3389,3398,CHEMBL549965,MVRJFCQZNCIBPF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CNCCC1C(C2=CN=CC=C2)OC3=CC=CC=C3OC4=CC=CC=C4,c1ccc(Oc2ccccc2OC(c2cccnc2)C2CCNCC2)cc1
3390,3399,CHEMBL523475,MVYOBBWPCHPRSG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19492813.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,5.9586073148417755,CC(C)(CC1=CC=C(C=C1)OC)NCC(COC2=C(C(=CC=C2)Cl)C#N)O,COc1ccc(CC(C)(C)NCC(O)COc2cccc(Cl)c2C#N)cc1
3391,3400,CHEMBL109097,MWGRXFWGMDSMNI-UKRRQHHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10576690.0,IC50,=,3.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT),Synthesis and biological evaluation of two novel DAT-binding technetium complexes containing a piperidine based analogue of cocaine.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.522878745280337,CCC[C@@H]1CN(CC[C@@H]1C2=CC=C(C=C2)Cl)C,CCC[C@@H]1CN(C)CC[C@@H]1c1ccc(Cl)cc1
3392,3401,CHEMBL39241,MWISMDNUXLOMTQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,128.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,6.892790030352131,C1CCC(C1)C(C#N)C2=CC(=C(C=C2)Cl)Cl,N#CC(c1ccc(Cl)c(Cl)c1)C1CCCC1
3393,3402,CHEMBL283416,MWJUXAHARLFJAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,73.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,73.0,CN1CCC(=CC1)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-],CN1CC=C(c2c[nH]c3ccc([N+](=O)[O-])cc23)CC1
3394,3403,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,CC(c1cc2ccccc2s1)N(O)C(N)=O
3395,3404,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,CC(c1cc2ccccc2s1)N(O)C(N)=O
3396,3405,CHEMBL218999,MXBQNIQYUCTYND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,5.5,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.259637310505756,CC(C)CC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
3397,3406,CHEMBL218999,MXBQNIQYUCTYND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,13.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.886056647693162,CC(C)CC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
3398,3407,CHEMBL218999,MXBQNIQYUCTYND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,1.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,9.0,CC(C)CC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
3399,3408,CHEMBL218999,MXBQNIQYUCTYND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,31.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.508638306165728,CC(C)CC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CC(C)CC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
3400,3409,CHEMBL215988,MXCAKGCIGZRYGJ-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,323.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.490797477668897,CN1CC[C@@H]([C@@H](C1)C(=O)OC)C2=CC=C(C=C2)I,COC(=O)[C@@H]1CN(C)CC[C@@H]1c1ccc(I)cc1
3401,3410,CHEMBL242920,MXCAKGCIGZRYGJ-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1250.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.903089986991943,CN1CC[C@H]([C@@H](C1)C(=O)OC)C2=CC=C(C=C2)I,COC(=O)[C@@H]1CN(C)CC[C@H]1c1ccc(I)cc1
3402,3411,CHEMBL503234,MXNHEKIHSVXJPG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)CCC2=CC3=CC=CC=C3C=C2,c1ccc2cc(CCN3CCNCC3)ccc2c1
3403,3412,CHEMBL595540,MXPYLJDZHAVWJM-DKOHEDPJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,180.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.7447274948966935,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NCCC4CCN(CC4)C(=O)[C@@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)NCCC1CCN(C(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)CC1)[C@@H](c1ccc(Cl)cc1)C2
3404,3413,CHEMBL568140,MXUDEADPGZWZCH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,271.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.5670307091255955,CC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
3405,3414,CHEMBL568140,MXUDEADPGZWZCH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,472.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.3260580013659125,CC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
3406,3415,CHEMBL568140,MXUDEADPGZWZCH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,463.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.3344190089820485,CC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
3407,3416,CHEMBL15476,MXYUKLILVYORSK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15121762.0,KI,=,5400.0,NM,,,,,,,,,,,,,,,,,,,,5.267606240177033,CN1C(CCCC1CC(=O)C2=CC=CC=C2)CC(C3=CC=CC=C3)O,CN1C(CC(=O)c2ccccc2)CCCC1CC(O)c1ccccc1
3408,3417,CHEMBL566958,MYBQVBFITHURNS-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=CC(=C3)Cl)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cc(Cl)ccc21
3409,3418,CHEMBL600325,MYEJFUXQJGHEQK-ALRJYLEOSA-N,PROSCILLARIDIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,C[C@@H]1O[C@@H](O[C@@H]2C=C3CC[C@@H]4[C@H](CC[C@]5(C)[C@@H](c6ccc(=O)oc6)CC[C@]45O)[C@@]3(C)CC2)[C@H](O)[C@H](O)[C@H]1O
3410,3419,CHEMBL600325,MYEJFUXQJGHEQK-ALRJYLEOSA-N,PROSCILLARIDIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,C[C@@H]1O[C@@H](O[C@@H]2C=C3CC[C@@H]4[C@H](CC[C@]5(C)[C@@H](c6ccc(=O)oc6)CC[C@]45O)[C@@]3(C)CC2)[C@H](O)[C@H](O)[C@H]1O
3411,3420,CHEMBL405349,MYIGEQURFWGOFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1540.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.8124792791635365,CCOC1=C(C=CC(=C1)Cl)OC(C2CNCCO2)C3=CC=CC=C3,CCOc1cc(Cl)ccc1OC(c1ccccc1)C1CNCCO1
3412,3421,CHEMBL405349,MYIGEQURFWGOFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1670.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.777283528852418,CCOC1=C(C=CC(=C1)Cl)OC(C2CNCCO2)C3=CC=CC=C3,CCOc1cc(Cl)ccc1OC(c1ccccc1)C1CNCCO1
3413,3422,CHEMBL262777,MYPYJXKWCTUITO-LYRMYLQWSA-N,VANCOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
3414,3423,CHEMBL262777,MYPYJXKWCTUITO-LYRMYLQWSA-N,VANCOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
3415,3424,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
3416,3425,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
3417,3426,CHEMBL454798,MYUDLLKSAURVGJ-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC=CC=C2Cl)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccccc1Cl
3418,3427,CHEMBL598644,MYVJXQAAFVJXRY-VIKVFOODSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,10.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.0,C1CC1COCC2([C@H]3[C@@H]2CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(C2(COCC3CC3)[C@H]3CNC[C@H]32)cc1Cl
3419,3429,CHEMBL1082209,MYYHPWVXRPLYMD-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC(=CC=C5)C(F)(F)F,C[C@H]1CN(C(=O)c2ccc(-c3cccc(C(F)(F)F)c3)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
3420,3430,CHEMBL2205815,MYZBXDLMEOAPIJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC8=C(C=C7)OCO8)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccc2c(c1)OCO2
3421,3431,CHEMBL1812743,MZBDCJWEXVZTQQ-AYEZKCMBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,3.9,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.4089353929735,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)C5=CC=C(C=C5)OC,COc1ccc(-c2cc([C@H]3[C@@H](c4ccc(Cl)cc4)C[C@@H]4CC[C@H]3N4C)on2)cc1
3422,3432,CHEMBL223166,MZGJHBJKODTIQM-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17983754.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125]RTI35 from human DAT expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
3423,3433,CHEMBL223166,MZGJHBJKODTIQM-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19067522.0,KI,=,2000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT receptor expressed in canine kidney cells,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter.",J. Med. Chem.,PUBLICATION,,5.698970004336019,COC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
3424,3434,CHEMBL1224399,MZGJPVOTOHUEGK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,CC1=C(C=C(C=C1)C(=O)C2(CCNC2)CCC(C)(C)C)Cl,Cc1ccc(C(=O)C2(CCC(C)(C)C)CCNC2)cc1Cl
3425,3435,CHEMBL552938,MZIGEEZFAITPCB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,79.43,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CN1C=CC2=C1C=CC(=C2)N(CC3=CC=CC=C3)C4CCNCC4,Cn1ccc2cc(N(Cc3ccccc3)C3CCNCC3)ccc21
3426,3436,CHEMBL3331492,MZSBLTQPEGPTAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1CCC(C1)N(CC2CNC2)CC3=CC4=CC=CC=C4C=C3,c1ccc2cc(CN(CC3CNC3)C3CCCC3)ccc2c1
3427,3437,CHEMBL1828653,MZTLLFJYLUUPPP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,50.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,50.0,C1COC(CN1)CCN2C3=C(C=CC=C3F)N(S2(=O)=O)C4=CC=CC=C4F,O=S1(=O)N(CCC2CNCCO2)c2c(F)cccc2N1c1ccccc1F
3428,3438,CHEMBL39282,MZWVASMORMKPEJ-JXMROGBWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.1,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.1,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc2)cc1
3429,3439,CHEMBL39282,MZWVASMORMKPEJ-JXMROGBWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.48,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.48,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc2)cc1
3430,3440,CHEMBL1095699,MZZGOOYMKKIOOX-VKHMYHEASA-N,AZASERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-],[N-]=[N+]=CC(=O)OC[C@H](N)C(=O)O
3431,3441,CHEMBL1095699,MZZGOOYMKKIOOX-VKHMYHEASA-N,AZASERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-],[N-]=[N+]=CC(=O)OC[C@H](N)C(=O)O
3432,3442,CHEMBL379446,NAHZCGQMXZCULW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,1110.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.954677021213343,CCCC(C(=O)C1=CC=C(C=C1)[N+](=O)[O-])N2CCCC2,CCCC(C(=O)c1ccc([N+](=O)[O-])cc1)N1CCCC1
3433,3443,CHEMBL379446,NAHZCGQMXZCULW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,266.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.575118363368933,CCCC(C(=O)C1=CC=C(C=C1)[N+](=O)[O-])N2CCCC2,CCCC(C(=O)c1ccc([N+](=O)[O-])cc1)N1CCCC1
3434,3444,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,1.4,NM,,,,,,,,,,,,,,,,,,,,8.853871964321762,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3435,3445,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,3.8,NM,,,,,,,,,,,,,,,,,,,,8.42021640338319,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3436,3446,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,14.0,NM,,,,,,,,,,,,,,,,,,,,7.853871964321763,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3437,3447,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,30.6,NM,,,,,,,,,,,,,,,,,,,,7.51427857351842,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3438,3448,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,26.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]DA (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.585026652029183,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3439,3449,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,43.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]WIN-35428 (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.366531544420414,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3440,3450,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10691690.0,KI,=,0.36,NM,,,cell_based,,,,,,,,,,,,Competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with human dopamine transporter,"Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.",J. Med. Chem.,PUBLICATION,,9.443697499232712,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3441,3451,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,0.62,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,0.62,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3442,3452,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,IC50,=,4.3,NM,,,,,,,,,,,,,,,The inhibition of reuptake against dopamine transporter,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.366531544420411,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3443,3453,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,3.7,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.431798275933005,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3444,3454,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12747792.0,SELECTIVITY RATIO,=,0.62,,,,,,,,,,,,,,,,Ratio of [3H]- DA uptake to DAT binding was determined,"Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.",J. Med. Chem.,PUBLICATION,,0.62,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3445,3455,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,3.7,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.431798275933005,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3446,3456,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18588282.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,PUBLICATION,,7.568636235841013,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3447,3457,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19791802.0,KI,=,5.07,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.",J. Med. Chem.,PUBLICATION,,8.294992040666664,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3448,3458,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20875743.0,IC50,=,7.2,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,"Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships.",Bioorg. Med. Chem.,PUBLICATION,,8.142667503568731,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3449,3459,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21907583.0,KI,=,22.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT after 1.5 hrs by scintillation counting,CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.,Bioorg. Med. Chem.,PUBLICATION,,7.657577319177793,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3450,3460,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,190.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.721246399047171,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3451,3461,CHEMBL281594,NAUWTFJOPJWYOT-UHFFFAOYSA-N,VANOXERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,29.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,29.0,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3452,3462,CHEMBL1644600,NAZAMXVJDAUZNQ-IZZQQSIFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC(=C3)C(F)(F)F)C4=CC=CC=C4,FC(F)(F)c1cc(OC2C[C@@H]3CC[C@H](C2)N3)cc(-c2ccccc2)c1
3453,3463,CHEMBL2047561,NBIWTPBSAFCSRX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,IC50,=,491.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.308918507877031,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CC4=CC=CC=C4S3)O,OC(CCN1CC=C(Cc2ccccc2)CC1)c1cc2ccccc2s1
3454,3464,CHEMBL1813309,NBIXVIPZQQXWBM-GOEBONIOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,3388.44,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.470000200122707,CN1C[C@@H]2CCCC[C@@]2(C1)C3=CC(=CC=C3)OC,COc1cccc([C@]23CCCC[C@H]2CN(C)C3)c1
3455,3465,CHEMBL521392,NBLMTDPDGYITGF-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2C[C@H](C3=CC=CC=C23)N(C)C,Cc1ccccc1O[C@H]1C[C@@H](N(C)C)c2ccccc21
3456,3466,CHEMBL520201,NBLMTDPDGYITGF-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,3400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,CC1=CC=CC=C1O[C@H]2C[C@@H](C3=CC=CC=C23)N(C)C,Cc1ccccc1O[C@H]1C[C@H](N(C)C)c2ccccc21
3457,3467,CHEMBL1586,NBMKJKDGKREAPL-DVTGEIKXSA-N,BECLOMETHASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
3458,3468,CHEMBL1586,NBMKJKDGKREAPL-DVTGEIKXSA-N,BECLOMETHASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
3459,3469,CHEMBL205313,NBVSCHGTCFRUCS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)N(C2=CC=CC=C2)C3=CC=CC=C3CN(C)C)N,Cc1ccc(N(c2ccccc2)c2ccccc2CN(C)C)c(N)c1
3460,3470,CHEMBL2012095,NBWNRWXBZFXLJY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=NC=CS3,COC(=O)C1=C(c2nccs2)CC2CCC1O2
3461,3471,CHEMBL2012095,NBWNRWXBZFXLJY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=NC=CS3,COC(=O)C1=C(c2nccs2)CC2CCC1O2
3462,3472,CHEMBL208420,NCBUFRZNBFLCMW-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,160.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344076,CC(C)(C)CN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)(C)CN(Cc1ccccc1C(F)(F)F)C1CCNCC1
3463,3473,CHEMBL2337598,NCBYCBRHLYXVNZ-RHSMWYFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC=CC=C3F,Fc1ccccc1O[C@H](c1ccccc1)[C@@H]1CCNC1
3464,3474,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
3465,3475,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
3466,3476,CHEMBL421,NCEXYHBECQHGNR-QZQOTICOSA-N,SULFASALAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
3467,3477,CHEMBL421,NCEXYHBECQHGNR-QZQOTICOSA-N,SULFASALAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
3468,3478,CHEMBL2430677,NCPFSSICYASJEG-KBAYOESNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,5.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC2=C(C=CC=C2Cl)[C@H]3[C@@H]1NC[C@@H]3C4=CC=CC=C4,Clc1cccc2c1CC[C@H]1NC[C@H](c3ccccc3)[C@@H]21
3469,3479,CHEMBL256408,NCRFMJNGTNNKEE-UHFFFAOYSA-N,N-(2-OXAZOLEMETHYL)MILNACIPRAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC2=NC=CO2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCc1ncco1
3470,3480,CHEMBL1200656,NCXMLFZGDNKEPB-FFPOYIOWSA-N,NATAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O
3471,3481,CHEMBL1200656,NCXMLFZGDNKEPB-FFPOYIOWSA-N,NATAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O
3472,3482,CHEMBL714,NDAUXUAQIAJITI-UHFFFAOYSA-N,ALBUTEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
3473,3483,CHEMBL714,NDAUXUAQIAJITI-UHFFFAOYSA-N,ALBUTEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
3474,3484,CHEMBL1642909,NDCNHLIWHOBKGK-BLLLJJGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,484.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.315154638355588,CNC[C@@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
3475,3485,CHEMBL1642906,NDCNHLIWHOBKGK-LRDDRELGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,125.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.903089986991943,CNC[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
3476,3486,CHEMBL1642907,NDCNHLIWHOBKGK-MLGOLLRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,103.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.987162775294827,CNC[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
3477,3487,CHEMBL1642908,NDCNHLIWHOBKGK-WBMJQRKESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,111.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.954677021213343,CNC[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CNC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
3478,3488,CHEMBL406,NDDAHWYSQHTHNT-UHFFFAOYSA-N,INDAPAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
3479,3489,CHEMBL406,NDDAHWYSQHTHNT-UHFFFAOYSA-N,INDAPAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
3480,3490,CHEMBL488049,NDHNYVIKBFYSGN-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2C[C@H](CC3=CC=CC=C23)N(C)C,Cc1ccccc1O[C@@H]1C[C@@H](N(C)C)Cc2ccccc21
3481,3491,CHEMBL1683870,NDMODESSMWGHBK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,21.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.67778070526608,CNCC1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,CNCC1(c2ccc(Cl)c(Cl)c2)CCCCC1
3482,3492,CHEMBL1683870,NDMODESSMWGHBK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,21.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.67778070526608,CNCC1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,CNCC1(c2ccc(Cl)c(Cl)c2)CCCCC1
3483,3493,CHEMBL383611,NEDZBDOBZLQEFI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-15.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-15.0,C1CNCCC1N(CCCC#N)CC2=CC=CC=C2C(F)(F)F.C(C(C(=O)O)O)(C(=O)O)O,N#CCCCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
3484,3494,CHEMBL287904,NEHPFNBRZYFWFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,47.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,7.327902142064282,COC(=O)C(C1CCCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCCC1
3485,3495,CHEMBL3238499,NEPJZLPUPYBVNM-HFTWOUSFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)N)O)F)F)N,Nc1ccc(-c2ccc(N=Nc3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(F)c2)cc1F
3486,3496,CHEMBL3673168,NEPZBEGINWEWDI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,55.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.2580609222708015,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC(F)F)C4=CC(=C(C=C4)Cl)Cl,FC(F)Oc1ccc2c(c1)CN1CCC2(c2ccc(Cl)c(Cl)c2)CC1
3487,3497,CHEMBL461706,NESUISGAACOCQG-RMRYJAPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,KI,=,340.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.468521082957745,C1CCC(CC1)([C@@H](CN2CCNCC2)C3=CC(=CC=C3)Cl)O.Cl.Cl,OC1([C@@H](CN2CCNCC2)c2cccc(Cl)c2)CCCCC1
3488,3498,CHEMBL461705,NESUISGAACOCQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,KI,=,45.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.346787486224656,C1CCC(CC1)(C(CN2CCNCC2)C3=CC(=CC=C3)Cl)O.Cl.Cl,OC1(C(CN2CCNCC2)c2cccc(Cl)c2)CCCCC1
3489,3499,CHEMBL461707,NESUISGAACOCQG-ZEECNFPPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,KI,=,135.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.8696662315049934,C1CCC(CC1)([C@H](CN2CCNCC2)C3=CC(=CC=C3)Cl)O.Cl.Cl,OC1([C@H](CN2CCNCC2)c2cccc(Cl)c2)CCCCC1
3490,3500,CHEMBL895,NETZHAKZCGBWSS-CEDHKZHLSA-N,NALBUPHINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
3491,3501,CHEMBL895,NETZHAKZCGBWSS-CEDHKZHLSA-N,NALBUPHINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
3492,3502,CHEMBL325516,NEUFWHZAVWYYSZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,1650.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.782516055786092,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)F,O=C(OCCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
3493,3503,CHEMBL3287656,NEVFWHLXCFNVPG-DTSDQNDWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24944746.0,INHIBITION,,,,Not Active,,cell_based,,,,,,,,,,,,"Inhibition of 2,5,6-[3H]-dopamine uptake at human DAT expressed in African green monkey COS7 cells at 10 uM incubated for 10 mins prior to radioligand addition measured after 5 mins by scintillation counting analysis",Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram.,ACS Med. Chem. Lett.,PUBLICATION,,,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCC5=CC6=C(C=C5)[C@](OC6)(CCCN(C)C)C7=CC=C(C=C7)F)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCc4ccc5c(c4)CO[C@@]5(CCCN(C)C)c4ccc(F)cc4)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
3494,3504,CHEMBL569014,NEVVQGBYHRTAEI-ZEQRLZLVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)CNC[C@@H]([C@H](C2=CC=CC=C2)N3C=CC4=CC=CC=C43)O,O[C@@H](CNCC1CCCCC1)[C@H](c1ccccc1)n1ccc2ccccc21
3495,3505,CHEMBL711,NFBAXHOPROOJAW-UHFFFAOYSA-N,PHENINDIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,O=C1c2ccccc2C(=O)C1c1ccccc1
3496,3506,CHEMBL711,NFBAXHOPROOJAW-UHFFFAOYSA-N,PHENINDIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,O=C1c2ccccc2C(=O)C1c1ccccc1
3497,3507,CHEMBL113956,NFBNIRNKYJTDIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,994.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.002613615602686,CCOC1=CC=C(C=C1)CCNC(=O)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CCOc1ccc(CCNC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
3498,3508,CHEMBL2321991,NFEQUCGNNCYRCD-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,9.3,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.031517051446064,C1C[C@](CNC1)(CCO)C2=CC(=C(C=C2)Cl)Cl,OCC[C@]1(c2ccc(Cl)c(Cl)c2)CCCNC1
3499,3509,CHEMBL2321992,NFEQUCGNNCYRCD-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,140.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,6.853871964321763,C1C[C@@](CNC1)(CCO)C2=CC(=C(C=C2)Cl)Cl,OCC[C@@]1(c2ccc(Cl)c(Cl)c2)CCCNC1
3500,3510,CHEMBL2012737,NFEVAAXMHCVVQF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22342142.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM by radioligand displacement assay,Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: carboxamide modification.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=C(C=CC(=C1)NS(=O)(=O)C)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O,Cc1cc(NS(C)(=O)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1
3501,3511,CHEMBL1200406,NFLLKCVHYJRNRH-UHFFFAOYSA-N,DIMENHYDRINATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2245.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.648783654660658,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
3502,3512,CHEMBL1200406,NFLLKCVHYJRNRH-UHFFFAOYSA-N,DIMENHYDRINATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1784.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.7486051499598965,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
3503,3513,CHEMBL130668,NFNRNOMETYDQMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,59.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.229147988357856,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)O)O,Oc1ccc(C2(O)c3ccccc3C3=NCCCN32)cc1
3504,3514,CHEMBL130668,NFNRNOMETYDQMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,87.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.059981844992339,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)O)O,Oc1ccc(C2(O)c3ccccc3C3=NCCCN32)cc1
3505,3515,CHEMBL1078163,NFOLOYSQMPQIMO-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,1610.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.793174123968151,CC1=C(C=CC=C1F)C(=O)N(CC(C)C)[C@H]2CCNC2,Cc1c(F)cccc1C(=O)N(CC(C)C)[C@H]1CCNC1
3506,3516,CHEMBL3310490,NFVMXEOTEJTNLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,110.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9586073148417755,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
3507,3517,CHEMBL3310490,NFVMXEOTEJTNLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,41.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,41.0,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
3508,3518,CHEMBL3310490,NFVMXEOTEJTNLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
3509,3519,CHEMBL3310490,NFVMXEOTEJTNLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC=C(C=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1
3510,3520,CHEMBL518276,NFXSKGKGQACNCS-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,1380.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.860120913598763,CC(C)C(=O)N(CC1=CC=CC=C1SC)[C@H]2CCNC2,CSc1ccccc1CN(C(=O)C(C)C)[C@H]1CCNC1
3511,3521,CHEMBL6731,NGBBVGZWCFBOGO-UHFFFAOYSA-N,TENAMFETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19717215.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.,Eur. J. Med. Chem.,PUBLICATION,,6.0506099933550885,CC(CC1=CC2=C(C=C1)OCO2)N,CC(N)Cc1ccc2c(c1)OCO2
3512,3522,CHEMBL6731,NGBBVGZWCFBOGO-UHFFFAOYSA-N,TENAMFETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20466553.0,IC50,=,890.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,"Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines.",Bioorg. Med. Chem.,PUBLICATION,,6.0506099933550885,CC(CC1=CC2=C(C=C1)OCO2)N,CC(N)Cc1ccc2c(c1)OCO2
3513,3523,CHEMBL6731,NGBBVGZWCFBOGO-UHFFFAOYSA-N,TENAMFETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,6165.95,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.210000001311122,CC(CC1=CC2=C(C=C1)OCO2)N,CC(N)Cc1ccc2c(c1)OCO2
3514,3524,CHEMBL6731,NGBBVGZWCFBOGO-UHFFFAOYSA-N,TENAMFETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,2425.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.615288257061716,CC(CC1=CC2=C(C=C1)OCO2)N,CC(N)Cc1ccc2c(c1)OCO2
3515,3525,CHEMBL1148,NGBFQHCMQULJNZ-UHFFFAOYSA-N,TORSEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
3516,3526,CHEMBL1148,NGBFQHCMQULJNZ-UHFFFAOYSA-N,TORSEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
3517,3527,CHEMBL1173274,NGHJSSNVKXEBAB-GXFFZTMASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,1065.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.972650392225241,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC=C2)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1ccccc1
3518,3528,CHEMBL260336,NGJYHUYANNRTCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,CCN(CC)C(=O)C1(C(C1(C)C)CN)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)C(CN)C1(C)C
3519,3529,CHEMBL2012091,NGQDNGWLIHIVFJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,336.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.473660722610156,COC(=O)C1=C(CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)C1=C(c2cc3ccccc3[nH]2)CC2CCC1O2
3520,3530,CHEMBL2012091,NGQDNGWLIHIVFJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC4=CC=CC=C4N3,COC(=O)C1=C(c2cc3ccccc3[nH]2)CC2CCC1O2
3521,3531,CHEMBL609023,NGRIUVQYFBDXMT-JYAVWHMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,15.85,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.799970733446231,CCOCCC1([C@H]2[C@@H]1CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOCCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CNC[C@H]21
3522,3532,CHEMBL579056,NGSZLOCYHZRIMB-UHDQLFAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,9.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.045757490560675,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)SC)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(SC)cc1)N2C
3523,3533,CHEMBL403660,NHLHLDRELLISCL-LSJNQNCOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,115.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.939302159646387,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC(=O)CCCCCCCCCCC(=O)OC[C@H]4[C@H](CC5CCC4N5C)C6=CC(=C(C=C6)Cl)Cl,CN1C2CCC1[C@@H](COC(=O)CCCCCCCCCCC(=O)OC[C@@H]1C3CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N3C)[C@@H](c1ccc(Cl)c(Cl)c1)C2
3524,3534,CHEMBL1200862,NHTGHBARYWONDQ-JTQLQIEISA-N,METYROSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)cc1)C(=O)O
3525,3535,CHEMBL1200862,NHTGHBARYWONDQ-JTQLQIEISA-N,METYROSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)cc1)C(=O)O
3526,3536,CHEMBL453,NHUHCSRWZMLRLA-UHFFFAOYSA-N,SULFISOXAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C
3527,3537,CHEMBL453,NHUHCSRWZMLRLA-UHFFFAOYSA-N,SULFISOXAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C
3528,3538,CHEMBL3094311,NHUZHVAPAIJQRS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,75.7,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,75.7,C1=CC(=CC=C1CN)OCC2=CC=C(C=C2)Cl.Cl,NCc1ccc(OCc2ccc(Cl)cc2)cc1
3529,3539,CHEMBL2048526,NHXMCNVSIJECMD-BSQFXFRVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KD,=,1.2,NM,,,,,,,,,,,,,,,Binding affinity to DAT,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.920818753952375,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/[125I])C[C@@H]1C3=CC=C(C=C3)Cl,COC(=O)[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
3530,3540,CHEMBL214237,NIBIYLDNVMUKNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CN(CCN1)C(CC2=CC=CC=C2)C3=CC=CC=C3,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3531,3541,CHEMBL89906,NIHJLAAYMSHMKG-IOWXEBBTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,448.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.348721986001856,CN1C2C[C@@H](C1CC(C2C(=O)OC)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O,COC(=O)C1C(OC(c2ccc(F)cc2)c2ccc(F)cc2)CC2[C@@H](O)CC1N2C
3532,3542,CHEMBL109,NIJJYAXOARWZEE-UHFFFAOYSA-N,VALPROIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(CCC)C(=O)O,CCCC(CCC)C(=O)O
3533,3543,CHEMBL109,NIJJYAXOARWZEE-UHFFFAOYSA-N,VALPROIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(CCC)C(=O)O,CCCC(CCC)C(=O)O
3534,3544,CHEMBL323348,NIQCNGHVCWTJSM-UHFFFAOYSA-N,DIMETHYL PHTHALATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.0,COC(=O)C1=CC=CC=C1C(=O)OC,COC(=O)c1ccccc1C(=O)OC
3535,3545,CHEMBL2206397,NIRASHDWADNQJU-UHFFFAOYSA-N,RO-4992479,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22795332.0,INHIBITION,=,0.0,%,,,,,,,,,,,,,,,Inhibition of human DA transporter at 10 uM by CEREP assay,Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CCC1=C(C(=CC=C1)CC)CC2=NC=CN2,CCc1cccc(CC)c1Cc1ncc[nH]1
3536,3546,CHEMBL3703740,NIXMEJRSHLSZKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,78.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.1062382379420574,C1C(C2=CC(=C(C=C2CN1)C3=NN=C(C=C3)C(F)(F)F)F)C4=CC(=C(C=C4)Cl)Cl,Fc1cc2c(cc1-c1ccc(C(F)(F)F)nn1)CNCC2c1ccc(Cl)c(Cl)c1
3537,3547,CHEMBL214159,NJCGBANIMWAYHY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCOC1=CC=CC=C1CC(C2=CC=C(C=C2)F)N3CCNCC3,CCOc1ccccc1CC(c1ccc(F)cc1)N1CCNCC1
3538,3548,CHEMBL606930,NJIWTVLWXIINMO-DEOINHEYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,7.37,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.132532512140948,CN1[C@@H]2C[C@H](C1C(=C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)C[C@H]2C[C@@H](O)C1N2C
3539,3549,CHEMBL86710,NJIWTVLWXIINMO-KWCGZIOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,19.4,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.712198270069773,CN1C2C[C@H](C1C(=C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC)O,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)C1N2C
3540,3550,CHEMBL606928,NJIWTVLWXIINMO-QOEIZOLYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,265.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.576754126063192,CN1[C@@H]2[C@H](CC1CC(=C2C(=O)OC)C3=CC(=C(C=C3)Cl)Cl)O,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2C[C@H](O)[C@H]1N2C
3541,3551,CHEMBL202055,NJZIWQLWRVISOP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,CCCC(C(C1=CC=C(C=C1)C)O)N2CCCC2,CCCC(C(O)c1ccc(C)cc1)N1CCCC1
3542,3552,CHEMBL3673173,NJZNVVTVUJDMET-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,42.8,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.368556230986828,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC=C(C=C5)F,Fc1ccc(C23CCN(CC2)Cc2cc(Oc4ccc(C(F)(F)F)nn4)ccc23)cc1
3543,3553,CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1841.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.734946211495985,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
3544,3554,CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1462.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.8350526273781576,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
3545,3555,CHEMBL600424,NKULKNQOSDDCTA-VOMIJIAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,4.0,CC1(CN(C2=CC=CC=C21)[C@@H](C3=CC(=CC(=C3)F)F)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1cc(F)cc(F)c1)N1CC(C)(C)c2ccccc21
3546,3556,CHEMBL1944640,NLEJNOPBICEOTA-HZMVEIRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,47.86,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.320027305722581,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1C3=CC=C(C=C3)F,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2CCCF
3547,3557,CHEMBL3094314,NLGKYLSBSOGION-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,70.5,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,70.5,C1=CC(=CC=C1CN)OCC2=CC=C(C=C2)OC(F)(F)F.Cl,NCc1ccc(OCc2ccc(OC(F)(F)F)cc2)cc1
3548,3558,CHEMBL477783,NLRQPOSSIBJNGG-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2010.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.696803942579511,CC(C)OC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CC(C)OC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
3549,3559,CHEMBL1747,NLVFBUXFDBBNBW-PBSUHMDJSA-N,TOBRAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
3550,3560,CHEMBL1747,NLVFBUXFDBBNBW-PBSUHMDJSA-N,TOBRAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
3551,3561,CHEMBL1683881,NMFAKPRDDDKVBP-UHFFFAOYSA-N,"(1-(3,4-DICHLOROPHENYL)CYCLOHEPTYL)METHANAMINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,75.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1249387366083,C1CCCC(CC1)(CN)C2=CC(=C(C=C2)Cl)Cl,NCC1(c2ccc(Cl)c(Cl)c2)CCCCCC1
3552,3562,CHEMBL402371,NMHWBLJSIIETCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=N1)CNC)OC2=C(C=C(C=C2)Cl)Br,CNCc1cnc(C)cc1Oc1ccc(Cl)cc1Br
3553,3563,CHEMBL2024094,NMIIKXFGCKOYRV-WHOFXGATSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22171543.0,INHIBITION,=,21.7,%,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT at 10 uM,Chemistry and behavioral studies identify chiral cyclopropanes as selective a42-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,PUBLICATION,,21.7,COCC[C@H]1C[C@@H]1C2=CC(=CN=C2)OC[C@@H]3CCN3,COCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1
3554,3564,CHEMBL257048,NMRSWXVEITZBIQ-UHFFFAOYSA-N,"N,N-DIMETHYL MILNACIPRAN",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,4500.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,CCN(CC)C(=O)C1(CC1CN(C)C)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CN(C)C
3555,3565,CHEMBL1489,NMUSYJAQQFHJEW-KVTDHHQDSA-N,AZACITIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
3556,3566,CHEMBL1489,NMUSYJAQQFHJEW-KVTDHHQDSA-N,AZACITIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
3557,3567,CHEMBL257906,NNGIOOYYOUWXAP-PISWEHOVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,68.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,68.0,CC1=CC2=C(C=C1)N(C(=N2)C(C)(C)O)[C@@H]3CCN(C[C@H]3OC)C[C@H]4CC5=C(C4)C=C(C=C5)Br,CO[C@@H]1CN(C[C@H]2Cc3ccc(Br)cc3C2)CC[C@H]1n1c(C(C)(C)O)nc2cc(C)ccc21
3558,3568,CHEMBL79,NNJVILVZKWQKPM-UHFFFAOYSA-N,LIDOCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CCN(CC)CC(=O)Nc1c(C)cccc1C
3559,3569,CHEMBL79,NNJVILVZKWQKPM-UHFFFAOYSA-N,LIDOCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CCN(CC)CC(=O)Nc1c(C)cccc1C
3560,3570,CHEMBL145810,NNNDXILSDZTFTR-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.0,CCCN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3561,3571,CHEMBL145810,NNNDXILSDZTFTR-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,1200.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.920818753952375,CCCN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3562,3572,CHEMBL145810,NNNDXILSDZTFTR-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,0.83,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,0.83,CCCN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3563,3573,CHEMBL344116,NNNDXILSDZTFTR-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,250.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.6020599913279625,CCCN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3564,3574,CHEMBL344116,NNNDXILSDZTFTR-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.468521082957745,CCCN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3565,3575,CHEMBL344116,NNNDXILSDZTFTR-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,1.4,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,1.4,CCCN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CCCN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3566,3576,CHEMBL386073,NNOWQHZNUGOGEV-FIPFOOKPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,157.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.804100347590767,CCCN1CC[C@H](C[C@@H]1CCCNC(=O)NC2=CC(=CC(=C2)C(=O)C)C(=O)C)CC3=CC=C(C=C3)F,CCCN1CC[C@@H](Cc2ccc(F)cc2)C[C@@H]1CCCNC(=O)Nc1cc(C(C)=O)cc(C(C)=O)c1
3567,3577,CHEMBL487690,NNOXYEGAVKKWOL-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,7000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,CN(C)[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=C(C=C3)Cl,CN(C)[C@@H]1C[C@H](Oc2ccc(Cl)cc2)c2ccccc21
3568,3578,CHEMBL2206510,NNPFARQTHIIRJL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,40.5,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.392544976785332,CC1=CC2=C(C=C1)C(CN(C2)C)C3=CC=C(C=C3)Cl,Cc1ccc2c(c1)CN(C)CC2c1ccc(Cl)cc1
3569,3579,CHEMBL578419,NNQDGWJXUJCRBF-MENKECLHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,10.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.995678626217357,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)SC)Br)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(SC)c(Br)c1)N2C
3570,3580,CHEMBL1173275,NNTJAYKRPQPBCZ-TVQRCGJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,1380.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.860120913598763,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)F)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(F)c1
3571,3581,CHEMBL1173275,NNTJAYKRPQPBCZ-TVQRCGJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,61.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,7.214670164989233,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)F)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(F)c1
3572,3582,CHEMBL2206515,NNVATDBGKYTMIL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,371.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.430626090384954,CN1CC(C2=CC=CC=C2C1)C3=CC=CC=C3,CN1Cc2ccccc2C(c2ccccc2)C1
3573,3583,CHEMBL622,NNYBQONXHNTVIJ-UHFFFAOYSA-N,ETODOLAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
3574,3584,CHEMBL622,NNYBQONXHNTVIJ-UHFFFAOYSA-N,ETODOLAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
3575,3585,CHEMBL257047,NOZPULFYDFZTCM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC2=CC=NC=C2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCc1ccncc1
3576,3586,CHEMBL757,NPAGDVCDWIYMMC-IZPLOLCNSA-N,NANDROLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O
3577,3587,CHEMBL757,NPAGDVCDWIYMMC-IZPLOLCNSA-N,NANDROLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O
3578,3588,CHEMBL514759,NPBACWUTGOBPGG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,39.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.4089353929735005,COC1=CC=CC(=C1)CC2(CCNC2)C3=CC4=C(C=C3)NC=C4,COc1cccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)c1
3579,3589,CHEMBL1169733,NPBFISOTLZPTLN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,199.53,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,C1CN(C(CN1)C2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4,c1ccc(C2CNCCN2c2ccc3[nH]ncc3c2)cc1
3580,3590,CHEMBL3039597,NPEFREDMMVQEPL-RWPARATISA-N,GENTAMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1
3581,3591,CHEMBL3039597,NPEFREDMMVQEPL-RWPARATISA-N,GENTAMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1
3582,3592,CHEMBL3663909,NPFSYWQNMCUQFC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,5640.0,NM,314432,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,5.248720896016658,CC1=CC=C(O1)C2CN(CC3=CC=CC=C23)C,Cc1ccc(C2CN(C)Cc3ccccc32)o1
3583,3593,CHEMBL2012093,NPIGZCKXEPXDPK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=CC=CO3,COC(=O)C1=C(c2ccco2)CC2CCC1O2
3584,3594,CHEMBL2012093,NPIGZCKXEPXDPK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=CO3,COC(=O)C1=C(c2ccco2)CC2CCC1O2
3585,3595,CHEMBL1644603,NPRIIPJXYKFSOJ-IZZQQSIFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,8710.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.059981844992337,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC(=C3)C4=CC=CC=C4)F,Fc1cc(OC2C[C@@H]3CC[C@H](C2)N3)cc(-c2ccccc2)c1
3586,3596,CHEMBL383220,NQBLHHIYFYAVRB-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,4.3,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3,COC1=CC=CC(=C1)C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O,COc1cccc(C[C@@](O)(c2ccccc2)[C@@H]2CNCCO2)c1
3587,3597,CHEMBL550289,NQBQXWBCVCHJSE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCC1=CC=CC=C1OC(C2CCNCC2)C3=CN=CC=C3,CCc1ccccc1OC(c1cccnc1)C1CCNCC1
3588,3598,CHEMBL57,NQDJXKOVJZTUJA-UHFFFAOYSA-N,NEVIRAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1
3589,3599,CHEMBL57,NQDJXKOVJZTUJA-UHFFFAOYSA-N,NEVIRAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1
3590,3600,CHEMBL120490,NQHSMRHMUBKGPZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,10.9,NM,,,,,,,,,,,,,,,Binding Affinity to cocaine site of dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol. ,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,7.962573502059376,CN1CCC(C(C1)C(=O)C2=CC(=C(C=C2)Cl)Cl)(C3=CC(=C(C=C3)Cl)Cl)O,CN1CCC(O)(c2ccc(Cl)c(Cl)c2)C(C(=O)c2ccc(Cl)c(Cl)c2)C1
3591,3601,CHEMBL362269,NQJQLWDYMNUNBE-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15664840.0,DISPLACEMENT,>,200.0,%,,,,,,,,,,,,,,,Displacement of dopamine by the compound against dopamine transporter was determined at 1000 nM,Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,200.0,CC1=CC=C(C=C1)S[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,Cc1ccc(S[C@@H](c2ccccc2)[C@@H]2CNCCO2)cc1
3592,3602,CHEMBL559802,NQUQUDJZIDCEFJ-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CNC[C@H]1N(CC2CC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(CC1CC1)[C@H]1CCNC1
3593,3603,CHEMBL207914,NQWIZKWCQGEVLT-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-16.4,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-16.4,CC(C)CN(CC1=CC=CC=C1OC(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccccc1OC(F)(F)F)C1CCNCC1
3594,3604,CHEMBL2047574,NQXSFBZVBLPNCG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,IC50,=,689.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.161780778092374,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CC(=C(C=C3)Cl)Cl)O,OC(CCN1CC=C(Cc2ccccc2)CC1)c1ccc(Cl)c(Cl)c1
3595,3605,CHEMBL3673133,NQZVQAKLVZGMOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,16.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.779891911959945,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=NNC(=O)C=C5,O=c1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)C2)n[nH]1
3596,3606,CHEMBL3673133,NQZVQAKLVZGMOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,148.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.828858848971617,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=NNC(=O)C=C5,O=c1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)C2)n[nH]1
3597,3607,CHEMBL577565,NREAZRDUCYUONQ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,12.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=C(C=C3)Br)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2ccc(Br)cc21
3598,3608,CHEMBL41606,NRFRVJIPDSIXRE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.8,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.8,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccccc2)cc1
3599,3609,CHEMBL41606,NRFRVJIPDSIXRE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.69,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.69,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccccc2)cc1
3600,3610,CHEMBL551135,NRIPPOKFEABEPU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,31.62,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CNCC1N(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CN(c2ccc3[nH]ccc3c2)C2CCNC2)cc1
3601,3611,CHEMBL1644605,NRKLSKYRBUUDLU-BJWYYQGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC(=N3)C4=CC=CC=C4)C#N,N#Cc1cc(OC2C[C@@H]3CC[C@H](C2)N3)nc(-c2ccccc2)c1
3602,3612,CHEMBL247340,NRMWWURWZRGVIQ-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,115.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.939302159646387,CC1=C(C(=CC=C1)CN([C@H]2CCNC2)C3CCOCC3)Cl,Cc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1Cl
3603,3613,CHEMBL1177,NRNCYVBFPDDJNE-UHFFFAOYSA-N,PEMOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,521.3,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.282912275072981,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,NC1=NC(=O)C(c2ccccc2)O1
3604,3614,CHEMBL1177,NRNCYVBFPDDJNE-UHFFFAOYSA-N,PEMOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,414.2,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.382789905442567,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,NC1=NC(=O)C(c2ccccc2)O1
3605,3615,CHEMBL345689,NRQIOYJXOKSZCR-MFWMIFASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10691690.0,KI,=,0.9,NM,,,cell_based,,,,,,,,,,,,Inhibition constant against [N-methyl-3H]WIN-35428 in murine kidney cells transfected with human dopamine transporter.,"Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.",J. Med. Chem.,PUBLICATION,,9.045757490560677,CC(C)OC(=O)C1[C@H](CC2CCC1N(C2)C)C3=CC=C(C=C3)Cl,CC(C)OC(=O)C1C2CCC(C[C@@H]1c1ccc(Cl)cc1)CN2C
3606,3616,CHEMBL3703743,NRTIHDQHAKWSTG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,15.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.812479279163537,C1C(C2=C(CN1)C=C(C=C2)C3=NN=CC=C3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(C2CNCc3cc(-c4cccnn4)ccc32)cc1Cl
3607,3617,CHEMBL598228,NRTIMMZNHIFNOB-IJOPVONJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,7.94,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.100179497572904,CCC(C)OCC1([C@H]2[C@@H]1CNC2)C3=CC(=C(C=C3)Cl)Cl,CCC(C)OCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CNC[C@H]21
3608,3618,CHEMBL3310630,NRVOSXXQMRKXOI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,93.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,93.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC(=C(C=C3)F)F,Cc1ccccc1OC(CC1CNC1)c1ccc(F)c(F)c1
3609,3619,CHEMBL232672,NRWFUCFNIMDFPX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,6300.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.200659450546418,COC1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(OC)cc2)CCC1
3610,3620,CHEMBL232672,NRWFUCFNIMDFPX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,140000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.853871964321762,COC1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(OC)cc2)CCC1
3611,3621,CHEMBL232672,NRWFUCFNIMDFPX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,7079457843841.37,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.85,COC1=CC=C(C=C1)C2=C(CCC2)C(=O)OC,COC(=O)C1=C(c2ccc(OC)cc2)CCC1
3612,3622,CHEMBL202755,NSIMWGJISYLRDI-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)C(=O)O)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(C(=O)O)cc21
3613,3623,CHEMBL574629,NSKFLKQWPVFAAE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,5530.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.257274868695301,C1CNCCC1C2=C(C=CC(=C2)Cl)OCC3=CC=C(C=C3)F,Fc1ccc(COc2ccc(Cl)cc2C2CCNCC2)cc1
3614,3624,CHEMBL3331506,NSLNAFLIDKTSFM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,415.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.381951903287908,C1C(CN1)N(CC2=CC=C(C=C2)Cl)C3=CC=CC=C3F,Fc1ccccc1N(Cc1ccc(Cl)cc1)C1CNC1
3615,3625,CHEMBL1224300,NSQVIEVBUSYQLK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CNCCC(C1=CC2=C(C=C1)C=C(C=C2)F)N3N=CN=N3,CNCCC(c1ccc2cc(F)ccc2c1)n1ncnn1
3616,3626,CHEMBL2407326,NSTTWNJKAWCIFK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,100.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,7.0,CCC(=O)C(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCNCC1
3617,3627,CHEMBL1083705,NSVJPFSJIISEIG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,1390.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.856985199745905,C1CC1OC2=CC=CC=C2CC(C3=CC=CC=C3)N4CCNCC4,c1ccc(C(Cc2ccccc2OC2CC2)N2CCNCC2)cc1
3618,3628,CHEMBL3238490,NSVQKMPNMQIXNW-PGMHBOJBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,COC1=C(C=CC(=C1)Br)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,COc1cc(Br)ccc1N=Nc1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
3619,3629,CHEMBL559456,NTBRVAZZXJHBGJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,71.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1487416512809245,C1CNCCC1C(C2=CN=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2cccnc2)C2CCNCC2)c1Cl
3620,3630,CHEMBL559456,NTBRVAZZXJHBGJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,150.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,C1CNCCC1C(C2=CN=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2cccnc2)C2CCNCC2)c1Cl
3621,3631,CHEMBL559456,NTBRVAZZXJHBGJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,375.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.425968732272282,C1CNCCC1C(C2=CN=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2cccnc2)C2CCNCC2)c1Cl
3622,3632,CHEMBL195437,NTDQQZYCCIDJRK-UHFFFAOYSA-N,4-OCTYLPHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,8491.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.0710411591191695,CCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCc1ccc(O)cc1
3623,3633,CHEMBL195437,NTDQQZYCCIDJRK-UHFFFAOYSA-N,4-OCTYLPHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6746.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.1709536631468165,CCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCc1ccc(O)cc1
3624,3634,CHEMBL243712,NTJOBXMMWNYJFB-UHFFFAOYSA-N,AMISULPRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19337725.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC,CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC
3625,3635,CHEMBL445743,NTKCCYPDVMIZQP-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC=CC=C2OC)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccccc1OC
3626,3636,CHEMBL538053,NTMVOPDZLWZAQO-APTPAJQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,3500.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,CN(C)C[C@@H](C1=CC=C(C=C1)OC)[C@H](C2CCCCC2)O.Cl,COc1ccc([C@H](CN(C)C)[C@@H](O)C2CCCCC2)cc1
3627,3637,CHEMBL258060,NTOHKBIOUPYUFZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,320.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,CC1=C(C=CC(=C1)Cl)OC2=C(C=C(C=C2)NS(=O)(=O)C)CNC,CNCc1cc(NS(C)(=O)=O)ccc1Oc1ccc(Cl)cc1C
3628,3638,CHEMBL2205830,NTRDOPDLDNCOHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=CC(=C1OC)OC)CN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc(OC)c1OC
3629,3639,CHEMBL2205830,NTRDOPDLDNCOHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,COC1=CC(=CC(=C1OC)OC)CN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc(OC)c1OC
3630,3640,CHEMBL3334801,NTSASDUHAQEZEA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,8192.5,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,5.086583549945587,CN(C)CCC(C1=CC2=C(C=C1)C(=C(C=C2)OC)Cl)N3CCCC3,COc1ccc2cc(C(CCN(C)C)N3CCCC3)ccc2c1Cl
3631,3641,CHEMBL2321997,NTSBDQLGAZMMFC-LLVKDONJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,13.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.886056647693162,CN1CC=CC[C@H](C1)C2=CC(=C(C=C2)Cl)Cl,CN1CC=CC[C@@H](c2ccc(Cl)c(Cl)c2)C1
3632,3642,CHEMBL2321996,NTSBDQLGAZMMFC-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,3.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.522878745280337,CN1CC=CC[C@@H](C1)C2=CC(=C(C=C2)Cl)Cl,CN1CC=CC[C@H](c2ccc(Cl)c(Cl)c2)C1
3633,3643,CHEMBL2321995,NTSBDQLGAZMMFC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,5.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.301029995663981,CN1CC=CCC(C1)C2=CC(=C(C=C2)Cl)Cl,CN1CC=CCC(c2ccc(Cl)c(Cl)c2)C1
3634,3644,CHEMBL473966,NTTIJAHCUAQKMW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.0,CNCCC1CCC(O1)CCC2=C(C=CC(=C2)F)OC,CNCCC1CCC(CCc2cc(F)ccc2OC)O1
3635,3645,CHEMBL473966,NTTIJAHCUAQKMW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,=,66988.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.174002988352055,CNCCC1CCC(O1)CCC2=C(C=CC(=C2)F)OC,CNCCC1CCC(CCc2cc(F)ccc2OC)O1
3636,3646,CHEMBL442272,NUAORYLXEWKQRZ-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CNC[C@H]1N(CC2=CC=CC=C2C(F)(F)F)C3CCOCC3,FC(F)(F)c1ccccc1CN(C1CCOCC1)[C@H]1CCNC1
3637,3647,CHEMBL415098,NUAPUMDPHIFPBC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC2=CC=CC=C2N(C1)C(=O)C3(CC3CN)C4=CC=CC=C4,NCC1CC1(C(=O)N1CCCc2ccccc21)c1ccccc1
3638,3648,CHEMBL263920,NUGRPPXOWJFLKG-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=CC=C1)[C@@H]([C@@H]2CNCCO2)OC3=C(C=C(C=C3)Cl)OC,COc1cc(Cl)ccc1O[C@@H](c1cccc(C)c1)[C@@H]1CNCCO1
3639,3649,CHEMBL3663920,NUMHOXGZNHJTHF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,79.4,NM,314458,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.100179497572904,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)SN=C4,CN1Cc2ccccc2C(c2ccc3sncc3c2)C1
3640,3650,CHEMBL207635,NUNBGFOIBBDTEC-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-7.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-7.0,C1CNCCC1N(CCO)CC2=C(C=C(C=C2)F)C(F)(F)F.C(=C/C(=O)O)\C(=O)O,OCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
3641,3651,CHEMBL404345,NUQCHJVIHOGEMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(C1CCCCC1)C(=O)C2(CC2CN)C3=CC=CC=C3,CCN(C(=O)C1(c2ccccc2)CC1CN)C1CCCCC1
3642,3652,CHEMBL1644473,NUQHQIXAXZDZPW-PTEHBNRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,2261.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.645699437654639,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=C(C=C3)Cl,Clc1ccc(OC2C[C@@H]3CC[C@H](C2)N3)cc1
3643,3653,CHEMBL1784671,NVCJMYLJSSPEKR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21570838.0,INHIBITION,<,50.0,%,Not Active,,,,,,,,,,,,,,Inhibition of human recombinant DAT at 10 uM by radioligand binding assay,Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC1=C(C=CC(=C1)C(=O)N)C2=C(C=CN2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O,Cc1cc(C(N)=O)ccc1-c1c(CCC(=O)O)ccn1-c1ccc(-n2ccnc2)cc1
3644,3654,CHEMBL3673153,NVDYVZGABKJWFJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,5263.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,5.278766629982722,C1CN2CCC1(C3=C(C2)C=C(C=C3)N4CCOCC4)C5=CC=C(C=C5)N6CCOCC6,c1cc(C23CCN(CC2)Cc2cc(N4CCOCC4)ccc23)ccc1N1CCOCC1
3645,3655,CHEMBL1224402,NVHLQOKZIFFNOX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,15.85,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,CCCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CCCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
3646,3656,CHEMBL440584,NVIWIEFWADBWQX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,834.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.078833949362261,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2Cl,CNCc1cnc(C)cc1Oc1ccccc1Cl
3647,3657,CHEMBL121027,NVIYCTHUJATAOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,119.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.924453038607469,CN(CCC1=CC=C(C=C1)F)CCN(C)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,CN(CCOC(c1ccccc1)c1ccccc1)CCN(C)CCc1ccc(F)cc1
3648,3658,CHEMBL121027,NVIYCTHUJATAOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,30.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.522878745280337,CN(CCC1=CC=C(C=C1)F)CCN(C)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,CN(CCOC(c1ccccc1)c1ccccc1)CCN(C)CCc1ccc(F)cc1
3649,3659,CHEMBL121027,NVIYCTHUJATAOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,4.0,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,4.0,CN(CCC1=CC=C(C=C1)F)CCN(C)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,CN(CCOC(c1ccccc1)c1ccccc1)CCN(C)CCc1ccc(F)cc1
3650,3660,CHEMBL27769,NVKAWKQGWWIWPM-ABEVXSGRSA-N,STANOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
3651,3661,CHEMBL27769,NVKAWKQGWWIWPM-ABEVXSGRSA-N,STANOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
3652,3662,CHEMBL14924,NVNZDUXXKQYTHC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,6.73,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,8.171984935776024,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)C=C(Br)Br)C(=O)OC,COC(=O)C1C(c2ccc(C=C(Br)Br)cc2)CC2CCC1N2C
3653,3663,CHEMBL109517,NWCPOGFPLUASJD-PEVDHWGLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,93.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.031517051446066,CN(C)C[C@H]1[C@@H](C2CCC1C2)C3=CC4=CC=CC=C4C=C3,CN(C)C[C@@H]1C2CCC(C2)[C@H]1c1ccc2ccccc2c1
3654,3664,CHEMBL109517,NWCPOGFPLUASJD-PEVDHWGLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,38.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.420216403383191,CN(C)C[C@H]1[C@@H](C2CCC1C2)C3=CC4=CC=CC=C4C=C3,CN(C)C[C@@H]1C2CCC(C2)[C@H]1c1ccc2ccccc2c1
3655,3665,CHEMBL326466,NWCPOGFPLUASJD-QUDVFMAMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,76.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1191864077192095,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=CC=CC=C4C=C3,CN(C)C[C@H]1C2CCC(C2)[C@@H]1c1ccc2ccccc2c1
3656,3666,CHEMBL326466,NWCPOGFPLUASJD-QUDVFMAMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,25.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.602059991327962,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=CC=CC=C4C=C3,CN(C)C[C@H]1C2CCC(C2)[C@@H]1c1ccc2ccccc2c1
3657,3667,CHEMBL326466,NWCPOGFPLUASJD-QUDVFMAMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16220969.0,IC50,=,76.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against dopamine transporter,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.1191864077192095,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=CC=CC=C4C=C3,CN(C)C[C@H]1C2CCC(C2)[C@@H]1c1ccc2ccccc2c1
3658,3668,CHEMBL109571,NWCPOGFPLUASJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,95.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.022276394711152,CN(C)CC1C2CCC(C2)C1C3=CC4=CC=CC=C4C=C3,CN(C)CC1C2CCC(C2)C1c1ccc2ccccc2c1
3659,3669,CHEMBL109571,NWCPOGFPLUASJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,18.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.744727494896693,CN(C)CC1C2CCC(C2)C1C3=CC4=CC=CC=C4C=C3,CN(C)CC1C2CCC(C2)C1c1ccc2ccccc2c1
3660,3670,CHEMBL105,NWIBSHFKIJFRCO-WUDYKRTCSA-N,MITOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
3661,3671,CHEMBL105,NWIBSHFKIJFRCO-WUDYKRTCSA-N,MITOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
3662,3672,CHEMBL270607,NWKCIVHGGAEYQL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,7000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,CNCC1=C(C=CC(=C1)C(=O)N2CCN(CC2)C3CC3)OC4=CC(=CC=C4)Cl,CNCc1cc(C(=O)N2CCN(C3CC3)CC2)ccc1Oc1cccc(Cl)c1
3663,3673,CHEMBL254283,NWNAJZAIHGZXNI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18242991.0,INHIBITION,=,5.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C(=CC=C1)NC(=O)NCCC2=NNN=N2)C3=CC(=CC=C3)S(=O)(=O)C4=C(SC(=C4)C(=N)N)SC,CSc1sc(C(=N)N)cc1S(=O)(=O)c1cccc(-c2c(C)cccc2NC(=O)NCCc2nn[nH]n2)c1
3664,3674,CHEMBL102018,NWRMTPHQJUHLJH-NOZYUVCASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,538.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.269217724333612,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC4C2C(=O)CN34,Cc1ccc([C@H]2C[C@H]3CCC4C2C(=O)CN43)cc1
3665,3675,CHEMBL2326688,NWTJKIVXQLVNCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,240.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,6.619788758288393,C1C=CCNCC1C2=CC(=CC=C2)Cl,Clc1cccc(C2CC=CCNC2)c1
3666,3676,CHEMBL394089,NWZPRTYDJDHZJI-HZPDHXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,766000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.1157712303673963,CC(C)(C)C1=CC=C(C=C1)[C@H]2CCCC[C@H]2C(=O)OC,COC(=O)[C@@H]1CCCC[C@@H]1c1ccc(C(C)(C)C)cc1
3667,3677,CHEMBL290267,NXEIIWOLSIXINJ-DHZHZOJOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.46,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.46,COC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN3CCN(CC3)C/C=C/C4=CC=CC=C4,COc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc2)cc1
3668,3678,CHEMBL290267,NXEIIWOLSIXINJ-DHZHZOJOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.47,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.47,COC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN3CCN(CC3)C/C=C/C4=CC=CC=C4,COc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc2)cc1
3669,3679,CHEMBL404475,NXELRJXDBIVZKB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC2CCCC2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCC1CCCC1
3670,3680,CHEMBL572,NXFQHRVNIOXGAQ-YCRREMRBSA-N,NITROFURANTOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
3671,3681,CHEMBL572,NXFQHRVNIOXGAQ-YCRREMRBSA-N,NITROFURANTOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
3672,3682,CHEMBL2113054,NXQVAVZAULOMGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,=,698.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.156144577376839,CC1=CC(=C(C=C1)SC2=CC=CC=C2C(=O)NC)[N+](=O)[O-],CNC(=O)c1ccccc1Sc1ccc(C)cc1[N+](=O)[O-]
3673,3683,CHEMBL214056,NXRPSLBPUSCIJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=C(C(=CC=C2)Cl)Cl)C3=CC=CC=C3,Clc1cccc(CC(c2ccccc2)N2CCNCC2)c1Cl
3674,3684,CHEMBL208069,NXRRKZLGAMZHCY-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-2.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-2.0,CCN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
3675,3685,CHEMBL88246,NXVJVSJZXNWIHP-ARQQBVMPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,33.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.478861916295964,CN1C2C[C@H](C1CC(C2C(=O)OC)C3=CC(=C(C=C3)Cl)Cl)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2[C@H](O)CC1N2C
3676,3686,CHEMBL421167,NXVJVSJZXNWIHP-LKKSUFESSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,3.02,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.51999305704285,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC(=C(C=C3)Cl)Cl)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2[C@@H](O)CC1N2C
3677,3687,CHEMBL421167,NXVJVSJZXNWIHP-LKKSUFESSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,6.09,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.215382707367125,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC(=C(C=C3)Cl)Cl)O,COC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2[C@@H](O)CC1N2C
3678,3688,CHEMBL2326691,NYADKXRJISYHGA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,8.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.096910013008056,CN1CCCCC(C1)C2=CC(=C(C=C2)Cl)Cl,CN1CCCCC(c2ccc(Cl)c(Cl)c2)C1
3679,3689,CHEMBL216773,NYBAGOILAMMUMR-NCHKHCDFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,436.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]dopamine from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.360513510731415,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCC5CCC(CC5)C(=O)NCCN6C7CCC6[C@H]([C@H](C7)C8=CC(=C(C=C8)Cl)Cl)C(=O)OC)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCC4CCC(C(=O)NCCN5C6CCC5[C@@H](C(=O)OC)[C@@H](c5ccc(Cl)c(Cl)c5)C6)CC4)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
3680,3690,CHEMBL3334802,NYBUFVNFJIAWTL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,362.8,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.440332721611942,CCN(CC)CCC(C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CCN(CC)CCC(c1ccc(Cl)c(Cl)c1)N1CCCC1
3681,3691,CHEMBL207894,NYDRNGXEWTVMOM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-8.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-8.0,C1CNCCC1N(CCOC(F)(F)F)CC2=CC=CC=C2C(F)(F)F.C(C(C(=O)O)O)(C(=O)O)O,FC(F)(F)OCCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
3682,3692,CHEMBL426304,NYDUTEZMPZHSRY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,52.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.2839966563652,CCCC(C(=O)C1=CC(=CC=C1)I)N2CCCC2,CCCC(C(=O)c1cccc(I)c1)N1CCCC1
3683,3693,CHEMBL426304,NYDUTEZMPZHSRY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,109.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.962573502059376,CCCC(C(=O)C1=CC(=CC=C1)I)N2CCCC2,CCCC(C(=O)c1cccc(I)c1)N1CCCC1
3684,3694,CHEMBL70586,NYKCGQQJNVPOLU-ONTIZHBOSA-N,SPIRADOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
3685,3695,CHEMBL70586,NYKCGQQJNVPOLU-ONTIZHBOSA-N,SPIRADOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
3686,3696,CHEMBL92401,NYMGNSNKLVNMIA-UHFFFAOYSA-N,IPRONIAZID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C)NNC(=O)C1=CC=NC=C1,CC(C)NNC(=O)c1ccncc1
3687,3697,CHEMBL92401,NYMGNSNKLVNMIA-UHFFFAOYSA-N,IPRONIAZID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NNC(=O)C1=CC=NC=C1,CC(C)NNC(=O)c1ccncc1
3688,3698,CHEMBL92401,NYMGNSNKLVNMIA-UHFFFAOYSA-N,IPRONIAZID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NNC(=O)C1=CC=NC=C1,CC(C)NNC(=O)c1ccncc1
3689,3699,CHEMBL257602,NYOJDMQJBPXCHG-GXTWGEPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C=CCN(CC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
3690,3700,CHEMBL1645618,NYOUEYCHUPCVGU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,4620.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.335358024443875,C1CNCC1OC2=C(N=CC=C2)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1ncccc1OC1CCNC1
3691,3701,CHEMBL2171209,NYTOPNHZBPMVJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,2.1,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.1,C1C(CN1)C(C2=CC=C(C=C2)Cl)O.Cl,OC(c1ccc(Cl)cc1)C1CNC1
3692,3702,CHEMBL338313,NYWOLUGCSRCGJB-ISRILLDMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,15.8,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.801342913045577,CN1C2CCC1C([C@H](C2)OC(C3=CC=CC=C3)C4=CC=C(C=C4)Cl)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccccc1)c1ccc(Cl)cc1)N2C
3693,3703,CHEMBL440554,NYXHSNJGOQCTBS-MQMFKJKRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15012999.0,IC50,=,3600.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human dopamine transporter at 10 uM,Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,CC[C@H](C)[C@H](C(=O)O)N1C[C@@H]([C@H](C1)C2=CC(=CC=C2)F)CN3CCC(CC3)C4=CC(=NN4CC)CC5=CC=C(C=C5)OC(F)(F)F,CC[C@H](C)[C@H](C(=O)O)N1C[C@H](CN2CCC(c3cc(Cc4ccc(OC(F)(F)F)cc4)nn3CC)CC2)[C@@H](c2cccc(F)c2)C1
3694,3704,CHEMBL408206,NZBRXUBKIJFZOJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,330.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.481486060122112,CC(C)N1CCN(CC1)C(=O)C2=CC(=C(C=C2)OC3=CC(=C(C=C3)Cl)Cl)CNC,CNCc1cc(C(=O)N2CCN(C(C)C)CC2)ccc1Oc1ccc(Cl)c(Cl)c1
3695,3705,CHEMBL461268,NZCDMSTWUUULEH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,167.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.777283528852418,C1CC(OC1CN)C2=CC=C(C=C2)Br,NCC1CCC(c2ccc(Br)cc2)O1
3696,3706,CHEMBL461268,NZCDMSTWUUULEH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,6117.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.213461519502197,C1CC(OC1CN)C2=CC=C(C=C2)Br,NCC1CCC(c2ccc(Br)cc2)O1
3697,3707,CHEMBL415324,NZHGWWWHIYHZNX-CSKARUKUSA-N,TRANILAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC,COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC
3698,3708,CHEMBL415324,NZHGWWWHIYHZNX-CSKARUKUSA-N,TRANILAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC,COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC
3699,3709,CHEMBL201223,OAASRUWEEIXAQF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,9350.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.029188389127482,CN1C2CCC1C=C(C2)C3C4=CC=CC=C4C5=CC=CC=C35,CN1C2C=C(C3c4ccccc4-c4ccccc43)CC1CC2
3700,3710,CHEMBL3323097,OADBNBUTUOPDJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,38.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.420216403383191,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4S3,CN1Cc2ccccc2C(c2cc3ccccc3s2)C1
3701,3711,CHEMBL3323097,OADBNBUTUOPDJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,14.3,NM,314434,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.8446639625349395,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4S3,CN1Cc2ccccc2C(c2cc3ccccc3s2)C1
3702,3712,CHEMBL3323097,OADBNBUTUOPDJD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,128.0,NM,314442,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.892790030352131,CN1CC(C2=CC=CC=C2C1)C3=CC4=CC=CC=C4S3,CN1Cc2ccccc2C(c2cc3ccccc3s2)C1
3703,3713,CHEMBL1237174,OAKJQQAXSVQMHS-UHFFFAOYSA-N,HYDRAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,NN,NN
3704,3714,CHEMBL1237174,OAKJQQAXSVQMHS-UHFFFAOYSA-N,HYDRAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,NN,NN
3705,3715,CHEMBL512685,OAUPYPVBPTVZBM-CQMVAQQKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.886056647693162,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=NO4)C5=CC=C(C=C5)C)N3C.Cl,Cc1ccc(-c2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(C)cc3)N4C)on2)cc1
3706,3716,CHEMBL2012122,OAYRUVPNHCONEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,4.3979400086720375,C1CC2C=C(CC1O2)C3=CC4=CC5=CC=CC=C5C=C4C=C3,C1=C(c2ccc3cc4ccccc4cc3c2)CC2CCC1O2
3707,3717,CHEMBL2206513,OBCHZURPAABPDI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,157.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.804100347590767,CN1CC(C2=C(C1)C(=CC=C2)OC)C3=CC=CC=C3,COc1cccc2c1CN(C)CC2c1ccccc1
3708,3718,CHEMBL2012081,OBDQYTHBVATJAH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)C4=NC=CS4,COC(=O)C1=C(c2ccc(-c3nccs3)cc2)CC2CCC1O2
3709,3719,CHEMBL2012081,OBDQYTHBVATJAH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)C4=NC=CS4,COC(=O)C1=C(c2ccc(-c3nccs3)cc2)CC2CCC1O2
3710,3720,CHEMBL2029053,OBIZFSZXDHWUJZ-ANUWOGMRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,3509000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.4548166317845936,CNCC[C@@H](C1=CC=CS1)OC2=CC=C(C3=CC=CC=C32)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,CNCC[C@H](Oc1ccc(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)c2ccccc12)c1cccs1
3711,3721,CHEMBL1643512,OBKCQTGBMZHBFE-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,C1CN(C2=CC=CC=C2[C@@H]1N)C3=CC(=C(C=C3)Cl)Cl,N[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
3712,3722,CHEMBL1643509,OBKCQTGBMZHBFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,246.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.609064892896622,C1CN(C2=CC=CC=C2C1N)C3=CC(=C(C=C3)Cl)Cl,NC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
3713,3723,CHEMBL233532,OBKUWTMFPMVPNX-RTBURBONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,830000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.0809219076239263,COC(=O)[C@@H]1CCCC[C@@H]1C2=CC=C(C=C2)C3=CC=CC=C3,COC(=O)[C@@H]1CCCC[C@@H]1c1ccc(-c2ccccc2)cc1
3714,3724,CHEMBL2206527,OBNBMYWZKYYXNS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,61.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.214670164989233,CC1=C(C=CC(=C1)C2CN(CC3=CC=CC=C23)C)F,Cc1cc(C2CN(C)Cc3ccccc32)ccc1F
3715,3725,CHEMBL522065,OBPAJKUDOWNRDR-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=CC=CC=C1O[C@@H]2[C@H](OCC3=CC=CC=C23)CNC,CCc1ccccc1O[C@H]1c2ccccc2CO[C@@H]1CNC
3716,3726,CHEMBL498687,OBPAJKUDOWNRDR-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=CC=CC=C1O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CCc1ccccc1O[C@H]1c2ccccc2CO[C@H]1CNC
3717,3727,CHEMBL1684047,OBWKCACUZGJXHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,36.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.443697499232713,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N(C)C,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
3718,3728,CHEMBL1684047,OBWKCACUZGJXHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,64.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1938200260161125,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N(C)C,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
3719,3729,CHEMBL1684047,OBWKCACUZGJXHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,220.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N(C)C,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
3720,3730,CHEMBL1684047,OBWKCACUZGJXHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26935940.0,IC50,=,36.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human DA transporter assessed as reduction in [3H]-DA reuptake,Emerging targets and new small molecule therapies in Parkinson's disease treatment.,Bioorg. Med. Chem.,PUBLICATION,,7.443697499232713,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N(C)C,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
3721,3731,CHEMBL2012089,OBYJJYCAMUYQRV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)C1=C(CC2CCC1O2)C3=NC4=CC=CC=C4S3,COC(=O)C1=C(c2nc3ccccc3s2)CC2CCC1O2
3722,3732,CHEMBL2012089,OBYJJYCAMUYQRV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=NC4=CC=CC=C4S3,COC(=O)C1=C(c2nc3ccccc3s2)CC2CCC1O2
3723,3733,CHEMBL290365,OCAZYHPPOVXLLX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.28,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.28,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
3724,3734,CHEMBL3673148,OCDDZWTUNAXZEY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,37.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.425968732272282,C1CN2CCC1(C3=C(C2)C=C(C=C3)N4C(=O)N5C=CC=CC5=N4)C6=CC=C(C=C6)Cl,O=c1n(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)nc2ccccn12
3725,3735,CHEMBL403370,OCFADYHICWCDMN-ZBEGNZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=NC3=CC=CC=C3S2,CCN(CC)C(=O)[C@@]1(c2nc3ccccc3s2)C[C@H]1CN
3726,3736,CHEMBL553937,OCJJDONQQSQZLT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,IC50,=,175.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,6.7569619513137065,CCCC(C(=O)C1=CC(=C(C=C1)N)I)N2CCCC2,CCCC(C(=O)c1ccc(N)c(I)c1)N1CCCC1
3727,3737,CHEMBL553937,OCJJDONQQSQZLT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,KI,=,28.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,7.552841968657781,CCCC(C(=O)C1=CC(=C(C=C1)N)I)N2CCCC2,CCCC(C(=O)c1ccc(N)c(I)c1)N1CCCC1
3728,3738,CHEMBL553937,OCJJDONQQSQZLT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,RATIO,=,3.0,,,,cell_based,,,,,,,,,,,,Ratio of IC50 for [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells to Ki for displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,3.0,CCCC(C(=O)C1=CC(=C(C=C1)N)I)N2CCCC2,CCCC(C(=O)c1ccc(N)c(I)c1)N1CCCC1
3729,3739,CHEMBL561739,OCXCCNYHGSRYEK-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,2680.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.571865205971212,CCC1=CC=CC=C1C(=O)N(CC2CCC2)[C@H]3CCNC3,CCc1ccccc1C(=O)N(CC1CCC1)[C@H]1CCNC1
3730,3740,CHEMBL583411,OCYLDAPFNOMBGQ-MJGOQNOKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=C2C(=CC=C1)C=CN2[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cccc(C)c21
3731,3741,CHEMBL402365,OCYYUEJRVUGFGH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNC)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CNC
3732,3742,CHEMBL2326693,ODFLDWCDMOARBM-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,37.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.431798275933005,C1C=CCN(C[C@H]1C2=CC(=C(C=C2)Cl)Cl)CCO,OCCN1CC=CC[C@H](c2ccc(Cl)c(Cl)c2)C1
3733,3743,CHEMBL917,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,FLOXURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F
3734,3744,CHEMBL917,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,FLOXURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F
3735,3745,CHEMBL1632174,ODMLUIATXKBXOW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21075638.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CN2C3=CC=CC=C3C(=C2OC1)C(=O)NCC4CCN(CC4)CCCCCC(=O)O,O=C(O)CCCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1
3736,3746,CHEMBL3331496,ODNZYCPQFKDYJF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,4.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,C1C(CN1)CN(CC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC4=CC=CC=C4.C(=O)(C(F)(F)F)O,Clc1ccc(CN(CC2CNC2)c2ccc(Oc3ccccc3)cc2)cc1
3737,3747,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CC/C=C1/c2ccccc2COc2ccccc21
3738,3748,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2COc2ccccc21
3739,3749,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2COc2ccccc21
3740,3750,CHEMBL399430,ODQZUOPUJDCECI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,12000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,C1CCC(CC1)OC(=O)C2=C(CCC2)C3=CC(=C(C=C3)Cl)Cl,O=C(OC1CCCCC1)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
3741,3751,CHEMBL3334774,ODTKQPAQIAKYDZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,68.1,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,68.1,C1CCN(CC1)CCC(C2=CC(=C(C=C2)Cl)Cl)N3CCOCC3,Clc1ccc(C(CCN2CCCCC2)N2CCOCC2)cc1Cl
3742,3752,CHEMBL208535,ODVLOSXWFXUKAY-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-22.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-22.0,CC(C)CN(CC1=C(C=CC(=C1)Cl)Cl)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1cc(Cl)ccc1Cl)C1CCNCC1
3743,3753,CHEMBL190860,ODXYYPIOITXURW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)F)N,CN(C)Cc1ccccc1Sc1ccc(F)cc1N
3744,3754,CHEMBL167911,OEBRKCOSUFCWJD-UHFFFAOYSA-N,DICHLORVOS,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COP(=O)(OC)OC=C(Cl)Cl,COP(=O)(OC)OC=C(Cl)Cl
3745,3755,CHEMBL167911,OEBRKCOSUFCWJD-UHFFFAOYSA-N,DICHLORVOS,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COP(=O)(OC)OC=C(Cl)Cl,COP(=O)(OC)OC=C(Cl)Cl
3746,3756,CHEMBL303232,OECDZVROWVHNGS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15080991.0,KI,=,29.8,NM,,,cell_based,,,,,,,,,,,,Binding affinity to dopamine transporter in membranes of cells selectively expressing the human genes for DAT,Synthesis and monoamine transporter affinity of 3'-analogs of 2-beta-carbomethoxy-3-beta-(4'-iodophenyl)tropane (beta-CIT).,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.525783735923746,CN1C2CCC1C(C(C2)C3=CC=CC(=C3)C4=CSC=C4)C(=O)OC,COC(=O)C1C(c2cccc(-c3ccsc3)c2)CC2CCC1N2C
3747,3757,CHEMBL197913,OECITYWBFXTMBT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,7220.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.141462802430362,CN1C2CCC1C=C(C2)C3=CC=CC(=C3)C4=CC=CC=C4,CN1C2C=C(c3cccc(-c4ccccc4)c3)CC1CC2
3748,3758,CHEMBL1946574,OEKZFTKHYIDUOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22119468.0,KI,=,3071.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in N2A cells after 15 mins by photoaffinity labeling","()-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.512720183556932,CC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])I)NC(C)(C)C.Cl,CC(NC(C)(C)C)C(=O)c1ccc(N=[N+]=[N-])c(I)c1
3749,3759,CHEMBL783,OELFLUMRDSZNSF-BRWVUGGUSA-N,NATEGLINIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,CC(C)C1CCC(C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
3750,3760,CHEMBL783,OELFLUMRDSZNSF-BRWVUGGUSA-N,NATEGLINIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,CC(C)C1CCC(C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
3751,3761,CHEMBL209094,OEPVPUNMOOHWKG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-8.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-8.0,CC(C)(CN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2)O.C(C(C(=O)O)O)(C(=O)O)O,CC(C)(O)CN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
3752,3762,CHEMBL40797,OEZGWIMXRXRLRR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.42,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.42,C1CN(CCN1CCCC2=CC=C(C=C2)F)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(CCCN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
3753,3763,CHEMBL40797,OEZGWIMXRXRLRR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.25,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.25,C1CN(CCN1CCCC2=CC=C(C=C2)F)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(CCCN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
3754,3764,CHEMBL407,OFBIFZUFASYYRE-UHFFFAOYSA-N,FLUMAZENIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
3755,3765,CHEMBL407,OFBIFZUFASYYRE-UHFFFAOYSA-N,FLUMAZENIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
3756,3766,CHEMBL186488,OFBWJOISMRTYCR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,62.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.207608310501746,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)Br,COC(=O)C1=C(c2ccc(Br)cc2)CC2CCC1O2
3757,3767,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NNC2=C1C(=O)NC=N2,O=c1[nH]cnc2[nH]ncc12
3758,3768,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NNC2=C1C(=O)NC=N2,O=c1[nH]cnc2[nH]ncc12
3759,3769,CHEMBL187935,OFFZXSBVSKRSFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CCO)N,CN(C)Cc1ccccc1Sc1ccc(CCO)cc1N
3760,3770,CHEMBL1601669,OFHCOWSQAMBJIW-AVJTYSNKSA-N,ALFACALCIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
3761,3771,CHEMBL1601669,OFHCOWSQAMBJIW-AVJTYSNKSA-N,ALFACALCIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
3762,3772,CHEMBL3331479,OFHFGOZYBFKXKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,696.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.157390760389438,CC1=CC=C(C=C1)N(CC2=CC3=CC=CC=C3C=C2)C4CNC4,Cc1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
3763,3773,CHEMBL3331479,OFHFGOZYBFKXKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,7.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC=C(C=C1)N(CC2=CC3=CC=CC=C3C=C2)C4CNC4,Cc1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
3764,3774,CHEMBL3262896,OFHXXBRBGWUOHR-NYYWCZLTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24678947.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) at 10 uM,Identification and characterization of small molecule modulators of the Epstein-Barr virus-induced gene 2 (EBI2) receptor.,J. Med. Chem.,PUBLICATION,,,COC1=CC=C(C=C1)C(=O)N2CCN(CC2)C(=O)/C=C/C3=CC=C(C=C3)Br,COc1ccc(C(=O)N2CCN(C(=O)/C=C/c3ccc(Br)cc3)CC2)cc1
3765,3775,CHEMBL1641691,OFLGSFKBBRGLOC-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,14.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,7.853871964321763,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=CC=C2)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1
3766,3776,CHEMBL1641691,OFLGSFKBBRGLOC-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,4.5,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,8.346787486224656,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=CC=C2)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1
3767,3777,CHEMBL1641691,OFLGSFKBBRGLOC-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4.5,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.346787486224656,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=CC=C2)I,COC(=O)[C@H](c1cccc(I)c1)[C@H]1CCCCN1
3768,3778,CHEMBL1071,OFPXSFXSNFPTHF-UHFFFAOYSA-N,OXAPROZIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
3769,3779,CHEMBL1071,OFPXSFXSNFPTHF-UHFFFAOYSA-N,OXAPROZIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
3770,3780,CHEMBL1440,OFVLGDICTFRJMM-WESIUVDSSA-N,TETRACYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
3771,3781,CHEMBL1440,OFVLGDICTFRJMM-WESIUVDSSA-N,TETRACYCLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
3772,3782,CHEMBL2407324,OFVYRZBLIGHUKA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.301029995663981,CN(C)OC(=O)C(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CN(C)OC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCNCC1
3773,3783,CHEMBL41797,OFYUHBGVPIWBBK-OWOJBTEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.66,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.66,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=C(C=C4)Cl,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccc(Cl)cc3)CC2)c2ccc(F)cc2)cc1
3774,3784,CHEMBL41797,OFYUHBGVPIWBBK-OWOJBTEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.65,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.65,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=C(C=C4)Cl,Fc1ccc(C(OCCN2CCN(C/C=C/c3ccc(Cl)cc3)CC2)c2ccc(F)cc2)cc1
3775,3785,CHEMBL936,OGAKLTJNUQRZJU-UHFFFAOYSA-N,DIPHENIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
3776,3786,CHEMBL936,OGAKLTJNUQRZJU-UHFFFAOYSA-N,DIPHENIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
3777,3787,CHEMBL323447,OGDCBGGLUZRVAG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,1514.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.8198741248359465,CN(C)CC1C2CCC(C2)C1C3=CC=CC4=CC=CC=C43,CN(C)CC1C2CCC(C2)C1c1cccc2ccccc12
3778,3788,CHEMBL323447,OGDCBGGLUZRVAG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,430.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.366531544420414,CN(C)CC1C2CCC(C2)C1C3=CC=CC4=CC=CC=C43,CN(C)CC1C2CCC(C2)C1c1cccc2ccccc12
3779,3789,CHEMBL384687,OGFNNMZMCOBWPR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,C1CN(CCN1)C(CCC2=CC=CC=C2)CC3=CC=CC=C3,c1ccc(CCC(Cc2ccccc2)N2CCNCC2)cc1
3780,3790,CHEMBL723,OGHNVEJMJSYVRP-UHFFFAOYSA-N,CARVEDILOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,845.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.073143291050307,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
3781,3791,CHEMBL723,OGHNVEJMJSYVRP-UHFFFAOYSA-N,CARVEDILOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,671.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.173277479831008,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
3782,3792,CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
3783,3793,CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
3784,3794,CHEMBL585708,OGJYXTXOUOYPDQ-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CC1=CN(C2=CC=CC=C12)[C@@H](C3=CC=CC=C3)[C@H](CNC)O,CNC[C@H](O)[C@H](c1ccccc1)n1cc(C)c2ccccc21
3785,3795,CHEMBL1644483,OGKOSOTXSHSDIP-DABQJJPHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,1404.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.852632892206214,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=C3)C#N,N#Cc1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
3786,3796,CHEMBL870,OGSPWJRAVKPPFI-UHFFFAOYSA-N,ALENDRONIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,NCCCC(O)(P(=O)(O)O)P(=O)(O)O
3787,3797,CHEMBL870,OGSPWJRAVKPPFI-UHFFFAOYSA-N,ALENDRONIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,NCCCC(O)(P(=O)(O)O)P(=O)(O)O
3788,3798,CHEMBL409277,OGUCJMOATTVEME-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=CC(=C1)Cl)O[C@H]([C@@H]2CNCCO2)C3=CC=C(C=C3)F,COc1cc(Cl)ccc1O[C@@H](c1ccc(F)cc1)[C@@H]1CNCCO1
3789,3799,CHEMBL192528,OGVZXKWRLUGGKA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,=,4426.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.353988590408761,CC1=CC(=C(C=C1)SC2=CC=CC=C2CNCCF)N,Cc1ccc(Sc2ccccc2CNCCF)c(N)c1
3790,3800,CHEMBL90555,OGWKCGZFUXNPDA-XQKSVPLYSA-N,VINCRISTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
3791,3801,CHEMBL90555,OGWKCGZFUXNPDA-XQKSVPLYSA-N,VINCRISTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
3792,3802,CHEMBL520349,OHOQFGDSEWQDAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19338356.0,ACTIVITY,<,50.0,%,Active,,,,,,,,,,,,,,Binding affinity to DAT,Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.,J. Med. Chem.,PUBLICATION,,50.0,CCCCNC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3C(=N2)C4=CC(=C(C=C4)F)Cl,CCCCNC(=O)c1ccc2c(c1)N=C(c1ccc(F)c(Cl)c1)c1ccccc1S2
3793,3803,CHEMBL235189,OHPFLCHMYPRGPV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,37153522909717.3,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.57,COC(=O)C1=C(C2CCC1N2)C3=CC=C(C=C3)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)C2CCC1N2
3794,3804,CHEMBL524188,OHTMMULBWQHGBT-AAPAXJHYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,3.6,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,8.443697499232712,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@@H]2C=C(Br)Br)N3C.Cl,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@@H]2C=C(Br)Br)N3C)cc1
3795,3805,CHEMBL495464,OHTMMULBWQHGBT-JRJWNBDDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,0.23,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,9.638272163982409,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C=C(Br)Br)N3C.Cl,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C=C(Br)Br)N3C)cc1
3796,3806,CHEMBL218847,OICPVJMMZDEJMO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,7.4,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.130768280269024,CCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCC(c1ccc(Cl)cc1)C1CCCCN1
3797,3807,CHEMBL218847,OICPVJMMZDEJMO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,450.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.346787486224656,CCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCC(c1ccc(Cl)cc1)C1CCCCN1
3798,3808,CHEMBL218847,OICPVJMMZDEJMO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,11.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.9586073148417755,CCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCC(c1ccc(Cl)cc1)C1CCCCN1
3799,3809,CHEMBL218847,OICPVJMMZDEJMO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,380.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.420216403383191,CCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCC(c1ccc(Cl)cc1)C1CCCCN1
3800,3810,CHEMBL1083409,OIFBYCGNUDQJBL-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,2113.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.675100502947687,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccccc2)S1(=O)=O
3801,3811,CHEMBL1083408,OIFBYCGNUDQJBL-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccccc2)S1(=O)=O
3802,3812,CHEMBL131,OIGNJSKKLXVSLS-VWUMJDOOSA-N,PREDNISOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
3803,3813,CHEMBL131,OIGNJSKKLXVSLS-VWUMJDOOSA-N,PREDNISOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
3804,3814,CHEMBL1084042,OIHGHECQZMOUEI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,=,74.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,74.0,CC(CCNC)N1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCCC(C)N1c2ccccc2N(c2ccccc2F)S1(=O)=O
3805,3815,CHEMBL477587,OIJZGDHTGREJNF-JKIUYZKVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18644726.0,KI,=,343.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,"3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.464705879957229,C1CC(CCC1C2=CNC3=C2C=C(C=C3)C#N)N4CCC5=C(C4)C=CC(=C5)OCCCF,N#Cc1ccc2[nH]cc(C3CCC(N4CCc5cc(OCCCF)ccc5C4)CC3)c2c1
3806,3816,CHEMBL449277,OIJZGDHTGREJNF-UHGJSFDGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18644726.0,KI,=,366.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,"3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.436518914605589,C1CC(CCC1C2=CNC3=C2C=C(C=C3)C#N)N4CCC5=C(C4)C=CC(=C5)OCCCF,N#Cc1ccc2[nH]cc(C3CCC(N4CCc5cc(OCCCF)ccc5C4)CC3)c2c1
3807,3817,CHEMBL2338040,OIMUKKZXUMOQAB-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,794.33,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C(=CC(=C3)Cl)Cl)Cl,Clc1cc(Cl)c(Cl)c(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1
3808,3818,CHEMBL2338041,OIMUKKZXUMOQAB-SJKOYZFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,398.11,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=C(C(=CC(=C3)Cl)Cl)Cl,Clc1cc(Cl)c(Cl)c(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1
3809,3819,CHEMBL2012084,OIPFYRVEIJOREG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,CN1C=CC=C1C2=CC(=CC=C2)C3=C(C4CCC(C3)O4)C(=O)OC,COC(=O)C1=C(c2cccc(-c3cccn3C)c2)CC2CCC1O2
3810,3820,CHEMBL2012084,OIPFYRVEIJOREG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,CN1C=CC=C1C2=CC(=CC=C2)C3=C(C4CCC(C3)O4)C(=O)OC,COC(=O)C1=C(c2cccc(-c3cccn3C)c2)CC2CCC1O2
3811,3821,CHEMBL1237064,OIRCMLIIRQJBKA-CABZTGNLSA-N,"RAC-1-(3,4-DICHLO ROPHENYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERS)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.599980364934843,C1CNC[C@H]2[C@@]1(C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@@]23CCNC[C@@H]2C3)cc1Cl
3812,3822,CHEMBL1237064,OIRCMLIIRQJBKA-CABZTGNLSA-N,"RAC-1-(3,4-DICHLO ROPHENYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERS)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,50.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CNC[C@H]2[C@@]1(C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@@]23CCNC[C@@H]2C3)cc1Cl
3813,3823,CHEMBL575289,OIRUCIGVEPJTON-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,C1CC1C2=CC=CC=C2OCC3=CC=CC=C3N4CCNCC4,c1ccc(N2CCNCC2)c(COc2ccccc2C2CC2)c1
3814,3824,CHEMBL204490,OIZUHURZTLEFGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.0,CCCC(C(=O)C1=CC=C(C=C1)C(F)(F)F)N2CCCC2,CCCC(C(=O)c1ccc(C(F)(F)F)cc1)N1CCCC1
3815,3825,CHEMBL231684,OJEXZTOASHOTIX-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,313000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.504455662453552,COC(=O)[C@@H]1CCCCC[C@@H]1C2=CC=C(C=C2)C3=CC=CC=C3,COC(=O)[C@@H]1CCCCC[C@@H]1c1ccc(-c2ccccc2)cc1
3816,3826,CHEMBL253376,OJGDCBLYJGHCIH-UHFFFAOYSA-N,BROMHEXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
3817,3827,CHEMBL253376,OJGDCBLYJGHCIH-UHFFFAOYSA-N,BROMHEXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
3818,3828,CHEMBL3673169,OJMJJCYLOPIDKJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,9.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.045757490560675,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC(=C(C=C5)F)Cl,Fc1ccc(C23CCN(CC2)Cc2cc(Oc4ccc(C(F)(F)F)nn4)ccc23)cc1Cl
3819,3829,CHEMBL1447,OJMMVQQUTAEWLP-KIDUDLJLSA-N,LINCOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
3820,3830,CHEMBL1447,OJMMVQQUTAEWLP-KIDUDLJLSA-N,LINCOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
3821,3831,CHEMBL94739,OJSFTALXCYKKFQ-YLJYHZDGSA-N,FEMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,2050.0,NM,,,,,,,,,,,,,,,,,,,,5.688246138944246,CN1CC[C@@H]([C@H](C1)COC2=CC=C(C=C2)OC)C3=CC=CC=C3,COc1ccc(OC[C@H]2CN(C)CC[C@@H]2c2ccccc2)cc1
3822,3832,CHEMBL206580,OJTUQCJDORIBOX-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-28.5,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-28.5,CC(C)CN(CC1=CC=C(C=C1)C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccc(C(F)(F)F)cc1)C1CCNCC1
3823,3833,CHEMBL471518,OJWLQAQJTIVAQB-HXUWFJFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,24.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,24.0,CNCC[C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C4CCCCC4,CNCC[C@H](c1ccccc1)n1c(=O)n(C2CCCCC2)c2ccccc21
3824,3834,CHEMBL2432038,OKCSFONJDXUZOU-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,C1CCC(CC1)CN[C@H]2C3C4CC5C2C6C3CC4C56,C1CCC(CN[C@H]2C3C4CC5C6C4CC3C6C52)CC1
3825,3835,CHEMBL86654,OKISLTVQJOBHIW-DBMMPTTLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,1.26,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.899629454882437,CN1C2C[C@H](C1C(C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC)O,COC(=O)C1C(c2ccc3ccccc3c2)CC2C[C@@H](O)C1N2C
3826,3836,CHEMBL86654,OKISLTVQJOBHIW-DBMMPTTLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,2.8,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.55284196865778,CN1C2C[C@H](C1C(C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC)O,COC(=O)C1C(c2ccc3ccccc3c2)CC2C[C@@H](O)C1N2C
3827,3837,CHEMBL408384,OKJDGNKVEJTMBB-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.366531544420414,C#CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCO3,C#CCN(CC#C)C(=O)[C@@]1(c2ccc3c(c2)OCO3)C[C@H]1CN
3828,3838,CHEMBL386281,OKJKIOJUDZFVDL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17234405.0,INHIBITION,=,67.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 10uM,"An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,67.0,C1CN(CCC1NC(=O)C2=CC(=O)C3=C(O2)C=C(C=C3)F)CC4=CC5=C(C=C4)C=CC(=O)O5,O=C(NC1CCN(Cc2ccc3ccc(=O)oc3c2)CC1)c1cc(=O)c2ccc(F)cc2o1
3829,3839,CHEMBL1644601,OKLKBYAVPPRKEG-IZZQQSIFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC(=C3)C4=CC=CC=C4)Br,Brc1cc(OC2C[C@@H]3CC[C@H](C2)N3)cc(-c2ccccc2)c1
3830,3840,CHEMBL513859,OKVPTUOBHHHDDX-HHHXNRCGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,110.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.9586073148417755,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)[C@H](CC4=CC=CC=C4)CF,FC[C@@H](Cc1ccccc1)N1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
3831,3841,CHEMBL468208,OKVPTUOBHHHDDX-MHZLTWQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,140.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.853871964321763,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)[C@@H](CC4=CC=CC=C4)CF,FC[C@H](Cc1ccccc1)N1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
3832,3842,CHEMBL526,OLBCVFGFOZPWHH-UHFFFAOYSA-N,PROPOFOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=CC=C1)C(C)C)O,CC(C)c1cccc(C(C)C)c1O
3833,3843,CHEMBL526,OLBCVFGFOZPWHH-UHFFFAOYSA-N,PROPOFOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=CC=C1)C(C)C)O,CC(C)c1cccc(C(C)C)c1O
3834,3844,CHEMBL231809,OLBSGDZXLHSPOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,67.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,67.0,CN(C)C1CCC(=CC1)C2=CNC3=CC=CC=C32,CN(C)C1CC=C(c2c[nH]c3ccccc23)CC1
3835,3845,CHEMBL609904,OLCRHPXGKWMFIP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,5150.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.288192770958808,C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3Cl,Clc1ccccc1Oc1ncccc1C1CCNCC1
3836,3846,CHEMBL6467,OLEWMKVPSUCNLG-UHFFFAOYSA-N,4-METHYLTHIOAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19717215.0,EC50,=,22908.68,NM,,,cell_based,,,,,HEK293,,,,,,,Induction of human DAT-dependent cytotoxicity in DAT expressing HEK293 cells after 48 hrs by neutral red assay,Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.,Eur. J. Med. Chem.,PUBLICATION,,4.6399999341729625,CC(CC1=CC=C(C=C1)SC)N,CSc1ccc(CC(C)N)cc1
3837,3847,CHEMBL6467,OLEWMKVPSUCNLG-UHFFFAOYSA-N,4-METHYLTHIOAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19717215.0,IC50,=,3073.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.,Eur. J. Med. Chem.,PUBLICATION,,5.512437439743622,CC(CC1=CC=C(C=C1)SC)N,CSc1ccc(CC(C)N)cc1
3838,3848,CHEMBL478835,OLINBEUJWKQKCV-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,CC(C)S(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CC(C)S(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
3839,3849,CHEMBL260863,OLIZEOZRLLYHDY-HNAYVOBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC#CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCO3,C=CCN(CC#CC)C(=O)[C@@]1(c2ccc3c(c2)OCO3)C[C@H]1CN
3840,3850,CHEMBL2012121,OLJSMOSQGDQUGA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,20.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,7.698970004336019,C1CC2C=C(CC1O2)C3=CC4=CC=CC=C4C=C3,C1=C(c2ccc3ccccc3c2)CC2CCC1O2
3841,3851,CHEMBL1684053,OLMZNNJAFQDNIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,1000.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC(C1(CCCCC1)C2=CC=CS2)N,CC(N)C1(c2cccs2)CCCCC1
3842,3852,CHEMBL367169,OLUONKODHNDKJM-HQRWHSCBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15012999.0,INHIBITION,=,17.0,%,,,,,,,,,,,,,,,Inhibitory activity against human dopamine transporter at 10 uM,Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.,Bioorg. Med. Chem. Lett.,PUBLICATION,,17.0,CCN1C(=CC(=N1)CC2=CC=C(C=C2)C#N)C3CCN(CC3)C[C@H]4CN(C[C@@H]4C5=CC(=CC=C5)F)[C@@H](C(=O)O)C(C)(C)C,CCn1nc(Cc2ccc(C#N)cc2)cc1C1CCN(C[C@H]2CN([C@@H](C(=O)O)C(C)(C)C)C[C@@H]2c2cccc(F)c2)CC1
3843,3853,CHEMBL3703750,OLXVUIIXACCIHX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,37.0,NM,198869,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 1.0 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 1.0 ul/well of 10 mM desipramine dissolved in DMSO. 50 ul/well of a 2x membrane preparation (0.4 mg/ml in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) and 50 ul/well of a 2x radioligand solution (4 nM [3H]nisoxetine in 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.431798275933005,C1C(C2=CC(=C(C=C2CN1)C3=NNC(=O)C=C3)F)C4=CC(=C(C=C4)Cl)Cl,O=c1ccc(-c2cc3c(cc2F)C(c2ccc(Cl)c(Cl)c2)CNC3)n[nH]1
3844,3854,CHEMBL452376,OLYZEORLRJZNQC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,640.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1938200260161125,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)Br,CN(C)Cc1ccccc1Oc1ccc(Br)cc1
3845,3855,CHEMBL2096856,OMBOXYLBBHNWHL-HXSCFSKGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,6.173925197299173,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@@H]1c1ccccc1)N2C
3846,3856,CHEMBL376899,OMBOXYLBBHNWHL-SHWKFHJASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,101.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,6.995678626217357,CN1C2CCC1[C@H]([C@@H](C2)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccccc1)N2C
3847,3857,CHEMBL83729,OMBOXYLBBHNWHL-VOFREWHGSA-N,WIN-35066-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3848,3858,CHEMBL83729,OMBOXYLBBHNWHL-VOFREWHGSA-N,WIN-35066-2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,23.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C
3849,3859,CHEMBL390742,OMBOXYLBBHNWHL-YJNKXOJESA-N,TROPARIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,33.11,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.4800408192479315,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccccc2)C[C@@H]2CC[C@H]1N2C
3850,3860,CHEMBL198011,OMMZYEKKLHJLJY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,50.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC1(CC2=CC=CC=C2N(C1=O)C3=CC(=C(C=C3)F)F)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccc(F)c(F)c2)C1=O
3851,3861,CHEMBL198011,OMMZYEKKLHJLJY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1(CC2=CC=CC=C2N(C1=O)C3=CC(=C(C=C3)F)F)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2ccc(F)c(F)c2)C1=O
3852,3862,CHEMBL574020,OMORUWMYPOOINH-YNYQRCFRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,76.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.1191864077192095,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)S(=O)C)Br)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc([S+](C)[O-])c(Br)c1)N2C
3853,3863,CHEMBL255450,OMTGXKFSSPIPRK-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C#CCN(CC=C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
3854,3864,CHEMBL1200624,ONKUMRGIYFNPJW-KIEAKMPYSA-N,ETHYNODIOL DIACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C
3855,3865,CHEMBL1200624,ONKUMRGIYFNPJW-KIEAKMPYSA-N,ETHYNODIOL DIACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C
3856,3866,CHEMBL3334792,ONLLHTKWUBCLOO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,50.7,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,50.7,CN(C)CCC(C1=C(C=C(C=C1)F)F)N2CCOCC2,CN(C)CCC(c1ccc(F)cc1F)N1CCOCC1
3857,3867,CHEMBL583750,ONPYWJJNTLFDAR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,7370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1325325121409495,C1CNCCC1C2=C(C(=CC=C2)F)OCC3=CC=CC=C3,Fc1cccc(C2CCNCC2)c1OCc1ccccc1
3858,3868,CHEMBL596989,ONSLZFSSJGOMSK-CPUCHLNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.0,C1CCC(C1)OC[C@@H]2[C@@H]3[C@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@]23CNC[C@@H]2[C@H]3COC2CCCC2)cc1Cl
3859,3869,CHEMBL596987,ONSLZFSSJGOMSK-GRDNDAEWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,2.51,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.600326278518963,C1CCC(C1)OC[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2[C@@H]3COC2CCCC2)cc1Cl
3860,3870,CHEMBL596987,ONSLZFSSJGOMSK-GRDNDAEWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,6.31,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.199970640755867,C1CCC(C1)OC[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2[C@@H]3COC2CCCC2)cc1Cl
3861,3871,CHEMBL510855,ONSNNWXLUHKPDE-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,8.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=CC=C(C=C1)N(C)[C@@H](C2=CC=CC=C2)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccc(C)cc1
3862,3872,CHEMBL602305,ONWOFJCPRAZRKC-BOPFTXTBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20020710.0,ACTIVITY,=,0.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by displacement assay,Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.,J. Med. Chem.,PUBLICATION,,0.0,CC(C)OC(=O)N/N=C\1/N(C2=C(S1)C=C(C=C2)OC(F)(F)F)C,CC(C)OC(=O)N/N=c1\sc2cc(OC(F)(F)F)ccc2n1C
3863,3873,CHEMBL564935,OOCIRVSPZDCFHT-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,4650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.332547047110047,C1CNC[C@H]1N(C2=CC=CC=C2)C(=O)C3=CC=CC=C3OC4=CC=CC=C4,O=C(c1ccccc1Oc1ccccc1)N(c1ccccc1)[C@H]1CCNC1
3864,3874,CHEMBL337609,OOCXBILTCDDTIT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,INHIBITION,=,5.7,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane at a concentration of 10 E-6 M,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.7,COC1=CC(=CC(=C1OC)OC)C2(C3=CC=CC=C3C4=NCCN42)O,COc1cc(C2(O)c3ccccc3C3=NCCN32)cc(OC)c1OC
3865,3875,CHEMBL378447,OOJWGIFGXZKDHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCOC1=CC=CC=C1CC(C2=CC=CC=C2F)N3CCNCC3,CCOc1ccccc1CC(c1ccccc1F)N1CCNCC1
3866,3876,CHEMBL450184,OORQAYQYEWAQJS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18793858.0,KI,>,2000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]GBR-12935 from human cloned DAT expressed in HEK293 cells,"Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.",Bioorg. Med. Chem.,PUBLICATION,,5.698970004336019,CC1=CC(=C(C=C1)SC2=CC=CC=C2CNC)NCC3=CC=C(C=C3)F,CNCc1ccccc1Sc1ccc(C)cc1NCc1ccc(F)cc1
3867,3877,CHEMBL198842,OOXDSSIGOMBXFF-WKIMUTGTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,50.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]CFT from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.301029995663981,CC1(C2=CC3=[N+](CCCC3=CC2=CC4=C1C=C(C=C4)N(C)C)CCCC(=O)NCCN5C6CCC5[C@H]([C@H](C6)C7=CC(=C(C=C7)Cl)Cl)C(=O)OC)C.[O-]Cl(=O)(=O)=O,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N2CCNC(=O)CCC[N+]1=c2cc3c(cc2CCC1)=Cc1ccc(N(C)C)cc1C3(C)C
3868,3878,CHEMBL198842,OOXDSSIGOMBXFF-WKIMUTGTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,250.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]dopamine from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.6020599913279625,CC1(C2=CC3=[N+](CCCC3=CC2=CC4=C1C=C(C=C4)N(C)C)CCCC(=O)NCCN5C6CCC5[C@H]([C@H](C6)C7=CC(=C(C=C7)Cl)Cl)C(=O)OC)C.[O-]Cl(=O)(=O)=O,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N2CCNC(=O)CCC[N+]1=c2cc3c(cc2CCC1)=Cc1ccc(N(C)C)cc1C3(C)C
3869,3879,CHEMBL502379,OOXPOUDWMPWCQG-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=CC=CC=C1O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O,CCc1ccccc1O[C@H]1c2ccccc2C[C@@]1(O)CNC
3870,3880,CHEMBL1170373,OOXRIQOVBUMMQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,31.62,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CN(C(CN1)CCC2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4,c1ccc(CCC2CNCCN2c2ccc3[nH]ncc3c2)cc1
3871,3881,CHEMBL447750,OOZOQFAQHUVOAM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,4301.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.366430557445908,CC(C)(C)C1=CC=C(C=C1)C2CCC(O2)CN,CC(C)(C)c1ccc(C2CCC(CN)O2)cc1
3872,3882,CHEMBL447750,OOZOQFAQHUVOAM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)C2CCC(O2)CN,CC(C)(C)c1ccc(C2CCC(CN)O2)cc1
3873,3883,CHEMBL470488,OPHKAGKHRDCCTP-DPYJAVKESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,81.6,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.088309841246139,CC1=NOC(=C1C2=CC=C(C=C2)OC)[C@H]3[C@H](CC4CCC3N4C)C5=CC=C(C=C5)Cl.Cl,COc1ccc(-c2c(C)noc2[C@@H]2C3CCC(C[C@@H]2c2ccc(Cl)cc2)N3C)cc1
3874,3884,CHEMBL3593275,OPTPKUISFYHAGF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CNCCOC1(CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OCC1(c2ccc(Cl)c(Cl)c2)CCNCCO1
3875,3885,CHEMBL3593392,OPTPKUISFYHAGF-UTONKHPSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CNCCO[C@]1(CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OC[C@@]1(c2ccc(Cl)c(Cl)c2)CCNCCO1
3876,3886,CHEMBL3593391,OPTPKUISFYHAGF-YDALLXLXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CNCCO[C@@]1(CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OC[C@]1(c2ccc(Cl)c(Cl)c2)CCNCCO1
3877,3887,CHEMBL685,OPXLLQIJSORQAM-UHFFFAOYSA-N,MEBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
3878,3888,CHEMBL685,OPXLLQIJSORQAM-UHFFFAOYSA-N,MEBENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
3879,3889,CHEMBL1944975,OPYJLQBLPXEIHM-NZPGVSJUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CC(C)C1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)I,COC(=O)[C@H]1[C@@H](c2ccc(C(C)C)c(I)c2)C[C@@H]2CC[C@H]1N2C
3880,3890,CHEMBL446321,OPZIFOOJYWJNSE-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@]1(CC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3Cl)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccccc1Cl
3881,3891,CHEMBL3287655,OQGUIOWSTCLFME-GNFJTHHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24944746.0,INHIBITION,,,,Not Active,,cell_based,,,,,,,,,,,,"Inhibition of 2,5,6-[3H]-dopamine uptake at human DAT expressed in African green monkey COS7 cells at 10 uM incubated for 10 mins prior to radioligand addition measured after 5 mins by scintillation counting analysis",Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram.,ACS Med. Chem. Lett.,PUBLICATION,,,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCCC5=CC6=C(C=C5)[C@](OC6)(CCCN(C)C)C7=CC=C(C=C7)F)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCCc4ccc5c(c4)CO[C@@]5(CCCN(C)C)c4ccc(F)cc4)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
3882,3892,CHEMBL459730,OQIBXTHHXDTIBJ-OAQYLSRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18754613.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT,"Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.",J. Med. Chem.,PUBLICATION,,50.0,C1[C@@H](C(=NN1/C(=N/S(=O)(=O)C2=CC=C(C=C2)C#N)/N)C3=CC=C(C=C3)Cl)C4=CC=CC=C4,N#Cc1ccc(S(=O)(=O)/N=C(\N)N2C[C@H](c3ccccc3)C(c3ccc(Cl)cc3)=N2)cc1
3883,3893,CHEMBL1697694,OQIQSTLJSLGHID-WNWIJWBNSA-N,AFLATOXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2
3884,3894,CHEMBL1697694,OQIQSTLJSLGHID-WNWIJWBNSA-N,AFLATOXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2
3885,3895,CHEMBL1813480,OQMBCBJEQWFPSN-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,>,10000.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.0,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC=C(C=C3)OC,COc1ccc([C@]23CCC[C@H]2CN(C)C3)cc1
3886,3896,CHEMBL200906,OQMLSKSSPKAKJQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16275071.0,ACTIVITY,=,11.0,%,,,,,,,,,,,,,,,Activity against dopamine uptake at 10 uM,A new chemical tool for exploring the physiological function of the PDE2 isozyme.,Bioorg. Med. Chem. Lett.,PUBLICATION,,11.0,CN1C2=C(C=C3C(=C2)C=CO3)C(C1=O)C(=O)NC4=NN=CS4,CN1C(=O)C(C(=O)Nc2nncs2)c2cc3occc3cc21
3887,3897,CHEMBL207480,OQNFDJJNTQSMQQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-45.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-45.0,C1CC(C1)CN(CC2=C(C=C(C=C2)F)C(F)(F)F)C3CCNCC3.C(C(C(=O)O)O)(C(=O)O)O,Fc1ccc(CN(CC2CCC2)C2CCNCC2)c(C(F)(F)F)c1
3888,3898,CHEMBL396537,OQPMHMPOPMZPGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,74.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,74.0,CN(C)C1CCC(=CC1)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-],CN(C)C1CC=C(c2c[nH]c3ccc([N+](=O)[O-])cc23)CC1
3889,3899,CHEMBL497665,OQRZMLVFIJAOKO-CRAIPNDOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@H](CC3=CC=CC=C23)CNC,CNC[C@H]1Cc2ccccc2[C@@H]1Oc1ccccc1C
3890,3900,CHEMBL455447,OQRZMLVFIJAOKO-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,5300.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.275724130399211,CC1=CC=CC=C1O[C@@H]2[C@@H](CC3=CC=CC=C23)CNC,CNC[C@@H]1Cc2ccccc2[C@@H]1Oc1ccccc1C
3891,3901,CHEMBL455447,OQRZMLVFIJAOKO-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,3500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,CC1=CC=CC=C1O[C@@H]2[C@@H](CC3=CC=CC=C23)CNC,CNC[C@@H]1Cc2ccccc2[C@@H]1Oc1ccccc1C
3892,3902,CHEMBL435787,OQUHNYSLWMRNBE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,113.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.946921556516581,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC5=C(C=C4)OCO5)O,OC1(c2ccc3c(c2)OCO3)c2ccccc2C2=NCCN21
3893,3903,CHEMBL521179,OQWZIAVXCYIZNN-UHFFFAOYSA-N,SR-3677,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18834107.0,INHIBITION,=,37.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 3 uM,Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.,J. Med. Chem.,PUBLICATION,,37.0,CN(C)CCOC1=C(C=CC(=C1)C2=CNN=C2)NC(=O)C3COC4=CC=CC=C4O3,CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1
3894,3904,CHEMBL3113644,ORDPXOCNLOPGLX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24393810.0,INHIBITION,=,0.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human dopamine transporter at 1 uM relative to control,A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,0.0,C1CCN(C1)CC2=CC3=C(C=CC(=C3)N)OC2=O,Nc1ccc2oc(=O)c(CN3CCCC3)cc2c1
3895,3905,CHEMBL171106,ORJOVSLDGBGQAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,7.93,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,8.100726812682396,CN1C2CCC1C(C(C2)C3=CC(=CC=C3)Br)C(=O)OC,COC(=O)C1C(c2cccc(Br)c2)CC2CCC1N2C
3896,3906,CHEMBL565382,OROOSQVGDDDAFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,1570.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.804100347590767,CCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
3897,3907,CHEMBL565382,OROOSQVGDDDAFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,709.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.149353764816934,CCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
3898,3908,CHEMBL562244,ORQNDGDHUCGODU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,C1CNCCC1C(C2=CN=CC=C2)OC3=CC=CC=C3C4=CC=CC=C4,c1ccc(-c2ccccc2OC(c2cccnc2)C2CCNCC2)cc1
3899,3909,CHEMBL3238491,ORQRPDYJEIXKPA-XLNRJJMWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,CC1=CC(=CC(=C1N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O)C)Br,Cc1cc(Br)cc(C)c1N=Nc1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
3900,3910,CHEMBL599639,ORUPHFRKUPILCN-HEHGZKQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.599980364934843,C1CC1COC[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2[C@@H]3COCC2CC2)cc1Cl
3901,3911,CHEMBL599639,ORUPHFRKUPILCN-HEHGZKQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,199.53,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.699991797446188,C1CC1COC[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2[C@@H]3COCC2CC2)cc1Cl
3902,3912,CHEMBL610795,ORUPHFRKUPILCN-IOASZLSFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,12.59,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.899974269892138,C1CC1COC[C@@H]2[C@@H]3[C@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@]23CNC[C@@H]2[C@H]3COCC2CC2)cc1Cl
3903,3913,CHEMBL607871,ORUPHFRKUPILCN-WOSRLPQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,501.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.299997602857746,C1CC1COC[C@@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2[C@H]3COCC2CC2)cc1Cl
3904,3914,CHEMBL457930,OSAULANLOUKVQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,83.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.080921907623925,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC(=C4)C#N,N#Cc1cc2cc(C3(Cc4ccccc4)CCNC3)ccc2[nH]1
3905,3915,CHEMBL398440,OSDLLIBGSJNGJE-UHFFFAOYSA-N,CHLOROXYLENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC(=C1Cl)C)O,Cc1cc(O)cc(C)c1Cl
3906,3916,CHEMBL398440,OSDLLIBGSJNGJE-UHFFFAOYSA-N,CHLOROXYLENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC(=C1Cl)C)O,Cc1cc(O)cc(C)c1Cl
3907,3917,CHEMBL469458,OSFVTFVGHYSFBU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,9.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,9.0,COC1=CC=C(C=C1)C(CN2CCNCC2)C3(CCCCC3)O.Cl.Cl,COc1ccc(C(CN2CCNCC2)C2(O)CCCCC2)cc1
3908,3918,CHEMBL567712,OSHSXYCWEWJREH-LJQANCHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,7400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.130768280269023,C1CCC(C1)N([C@@H]2CCNC2)C(=O)C3=CC4=CC=CC=C4C=C3,O=C(c1ccc2ccccc2c1)N(C1CCCC1)[C@@H]1CCNC1
3909,3919,CHEMBL1909072,OSJJYEUEJRVVOD-UHFFFAOYSA-N,PIPAMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3910,3920,CHEMBL1909072,OSJJYEUEJRVVOD-UHFFFAOYSA-N,PIPAMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3911,3921,CHEMBL577598,OSJVAFCFAQCABQ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNC[C@H]([C@H](C1=CC=CC=C1F)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1F)n1ccc2ccccc21
3912,3922,CHEMBL283662,OSLVNNRVAWCDKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,48.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.3187587626244115,C1CN(CCN1CCC(=O)C2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,O=C(CCN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
3913,3923,CHEMBL132713,OSQPMWKFNVZHBI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,1841.0,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.734946211495985,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=CC5=CC=CC=C54)O,OC1(c2cccc3ccccc23)c2ccccc2C2=NCCN21
3914,3924,CHEMBL132713,OSQPMWKFNVZHBI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,0.02,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,0.02,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=CC5=CC=CC=C54)O,OC1(c2cccc3ccccc23)c2ccccc2C2=NCCN21
3915,3925,CHEMBL108545,OSWPMRLSEDHDFF-UHFFFAOYSA-N,METHYL SALICYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=CC=C1O,COC(=O)c1ccccc1O
3916,3926,CHEMBL108545,OSWPMRLSEDHDFF-UHFFFAOYSA-N,METHYL SALICYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=CC=C1O,COC(=O)c1ccccc1O
3917,3927,CHEMBL459176,OSXVIZKTSFAUPG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CN1C=CC2=C1C=CC(=C2)C3(CCNC3)CC4=CC=CC=C4,Cn1ccc2cc(C3(Cc4ccccc4)CCNC3)ccc21
3918,3928,CHEMBL143707,OTCJLGGVKHCDCO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CF)N,CN(C)Cc1ccccc1Sc1ccc(CF)cc1N
3919,3929,CHEMBL3317696,OTPNPTZDWITNTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,8100.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.091514981121351,C1C(=O)N(CC(CN1)(F)F)C2=CC(=C(C=C2)Cl)Cl.Cl,O=C1CNCC(F)(F)CN1c1ccc(Cl)c(Cl)c1
3920,3930,CHEMBL597530,OTTUCFBNHXCUBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6180.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.209011524911184,C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3F,Fc1ccccc1Oc1ncccc1C1CCNCC1
3921,3931,CHEMBL1236282,OTVAEFIXJLOWRX-NXEZZACHSA-N,THIAMPHENICOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O,CS(=O)(=O)c1ccc([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)cc1
3922,3932,CHEMBL1236282,OTVAEFIXJLOWRX-NXEZZACHSA-N,THIAMPHENICOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O,CS(=O)(=O)c1ccc([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)cc1
3923,3933,CHEMBL1644470,OTYQXOHDRTWMJY-MUJYYYPQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=N3)C4=CC=CC=C4,c1ccc(-c2cccc(OC3C[C@@H]4CC[C@H](C3)N4)n2)cc1
3924,3934,CHEMBL817,OUDSBRTVNLOZBN-UHFFFAOYSA-N,TOLAZAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
3925,3935,CHEMBL817,OUDSBRTVNLOZBN-UHFFFAOYSA-N,TOLAZAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
3926,3936,CHEMBL26260,OUGIDAPQYNCXRA-UHFFFAOYSA-N,BETA-NAPHTHOFLAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43,O=c1cc(-c2ccccc2)oc2ccc3ccccc3c12
3927,3937,CHEMBL26260,OUGIDAPQYNCXRA-UHFFFAOYSA-N,BETA-NAPHTHOFLAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43,O=c1cc(-c2ccccc2)oc2ccc3ccccc3c12
3928,3938,CHEMBL410286,OULZYJCJGXXRLZ-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=CC(=C1)C(F)(F)F)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1cc(C(F)(F)F)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
3929,3939,CHEMBL248932,OUMLAORSIFDYJV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,=,260.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.585026652029183,CN(C)CC1CC1C2=CC3=C(C=CC(=C3)C#N)C=C2,CN(C)CC1CC1c1ccc2ccc(C#N)cc2c1
3930,3940,CHEMBL248932,OUMLAORSIFDYJV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,83.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,83.0,CN(C)CC1CC1C2=CC3=C(C=CC(=C3)C#N)C=C2,CN(C)CC1CC1c1ccc2ccc(C#N)cc2c1
3931,3941,CHEMBL571443,OUQIHZQQYQPARR-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)C1=CC=CC=C1C(=O)N(CC2CC2)[C@H]3CCNC3,CC(C)c1ccccc1C(=O)N(CC1CC1)[C@H]1CCNC1
3932,3942,CHEMBL203776,OUQMYOZRLIWPPV-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,270.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)(=O)NC)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(=O)(=O)NC)cc21
3933,3943,CHEMBL3099773,OUZUXYQXCXYGMX-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24332089.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),Imidazole-derived agonists for the neurotensin 1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)C[C@@H](C(=O)O)NC(=O)C1=CN(C(=N1)C2=C(C=CC=C2OC)OC)C3=C4C=CC(=CC4=NC=C3)Cl,COc1cccc(OC)c1-c1nc(C(=O)N[C@@H](CC(C)C)C(=O)O)cn1-c1ccnc2cc(Cl)ccc12
3934,3944,CHEMBL204288,OVEGFFRUJIZDSI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,666.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.1765257708296994,CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCCC2,CCCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCCC1
3935,3945,CHEMBL204288,OVEGFFRUJIZDSI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,144.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.841637507904752,CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCCC2,CCCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCCC1
3936,3946,CHEMBL118794,OVHJBARWJMLZJX-OBONGRFPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,4350.0,NM,,,,,,,,,,,,,,,Binding Affinity to cocaine site of dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol. ,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,5.361510743045363,CN1CCC(C(C1)[C@H](C2=C(C=C(C=C2)Cl)Cl)O)(C3=C(C=C(C=C3)Cl)Cl)O,CN1CCC(O)(c2ccc(Cl)cc2Cl)C([C@@H](O)c2ccc(Cl)cc2Cl)C1
3937,3947,CHEMBL88915,OVLMCLBVTLFJPW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,1.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.920818753952375,CN1C2CCC1C(=C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
3938,3948,CHEMBL88915,OVLMCLBVTLFJPW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,1.16,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.935542010773082,CN1C2CCC1C(=C(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
3939,3949,CHEMBL316862,OVSAXOVRTVDPOU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,9.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,9.0,CN(C)CC(C1=CC=CC=C1Cl)C2(CCCCC2)O,CN(C)CC(c1ccccc1Cl)C1(O)CCCCC1
3940,3950,CHEMBL1818447,OVVOKUDGMQGUQG-HUUCEWRRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,0.794,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,9.100179497572904,CC1=NOC(=N1)[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1noc([C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
3941,3951,CHEMBL391143,OVZCYWBNBLGMMB-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CC1=C(C=CC=C1C(F)(F)F)CN([C@H]2CCNC2)C3CCOCC3,Cc1c(CN(C2CCOCC2)[C@H]2CCNC2)cccc1C(F)(F)F
3942,3952,CHEMBL498680,OWDDBNVCYYHRPW-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CS1)OC3=CC=CC=C3Cl,CNC[C@@H]1SCc2ccccc2[C@@H]1Oc1ccccc1Cl
3943,3953,CHEMBL1084933,OWEYOMCWVMSOQF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,18.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,18.0,CNCCCCN1CC2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCCCCN1Cc2ccccc2N(c2ccccc2F)S1(=O)=O
3944,3954,CHEMBL1915725,OWEZURWNYQWWNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21777010.0,IC50,=,2800.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,5.552841968657781,CC1=CC(=C(N=C1)COC2=CC=C(C=C2)C3=NN(C=C3C4=CC=NC=C4)CCF)C,Cc1cnc(COc2ccc(-c3nn(CCF)cc3-c3ccncc3)cc2)c(C)c1
3945,3955,CHEMBL1915725,OWEZURWNYQWWNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21777010.0,INHIBITION,=,69.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 '-5 M,"Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,69.0,CC1=CC(=C(N=C1)COC2=CC=C(C=C2)C3=NN(C=C3C4=CC=NC=C4)CCF)C,Cc1cnc(COc2ccc(-c3nn(CCF)cc3-c3ccncc3)cc2)c(C)c1
3946,3956,CHEMBL611962,OWLDNNYJJFSQJU-LOKCHCMISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,210.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.6777807052660805,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NC5=CC=C(C=C5)NC(=O)[C@H]6[C@H](CC7CCC6N7C)C8=CC=C(C=C8)C9=CSC=C9,CN1C2CCC1[C@@H](C(=O)Nc1ccc(NC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(-c5ccsc5)cc3)N4C)cc1)[C@@H](c1ccc(-c3ccsc3)cc1)C2
3947,3957,CHEMBL595674,OWRBWLIVQNSHAQ-DDZGMJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,690.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.161150909262744,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCCCCCCCCNC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)C8=CSC=C8,CN1C2CCC1[C@@H](C(=O)NCCCCCCCCNC(=O)[C@H]1C3CCC(C[C@@H]1c1ccc(-c4ccsc4)cc1)N3C)[C@@H](c1ccc(-c3ccsc3)cc1)C2
3948,3958,CHEMBL77675,OWRCNXZUPFZXOS-UHFFFAOYSA-N,"N,N'-DIPHENYL-GUANIDINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)N,NC(=Nc1ccccc1)Nc1ccccc1
3949,3959,CHEMBL77675,OWRCNXZUPFZXOS-UHFFFAOYSA-N,"N,N'-DIPHENYL-GUANIDINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)N,NC(=Nc1ccccc1)Nc1ccccc1
3950,3960,CHEMBL1173751,OWTIWTHXBDWNDV-HUUCEWRRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,5.01,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.300162274132754,CCOC(=O)[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC(=O)[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
3951,3961,CHEMBL556268,OWUWJHDPUJMAGB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,3470.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.459670525209127,CC1=CN=C(C=C1)C(C2CCNCC2)OC3=C(C(=CC=C3)Cl)Cl,Cc1ccc(C(Oc2cccc(Cl)c2Cl)C2CCNCC2)nc1
3952,3962,CHEMBL188921,OWYLAEYXIQKAOL-UHFFFAOYSA-N,BUFLOMEDIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1
3953,3963,CHEMBL188921,OWYLAEYXIQKAOL-UHFFFAOYSA-N,BUFLOMEDIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1
3954,3964,CHEMBL250000,OXDQCMPUWXORTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,11000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.9586073148417755,C1CC(=C(C1)C(=O)N2CCOCC2)C3=CC(=C(C=C3)Cl)Cl,O=C(C1=C(c2ccc(Cl)c(Cl)c2)CCC1)N1CCOCC1
3955,3965,CHEMBL270595,OXEFHEYEQUISKC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCN(C1)CCC2=CC=CC=N2,c1ccc(CCN2CCCC2)nc1
3956,3966,CHEMBL3663911,OXERSMRQMIRNOS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,>,300.0,NM,314439,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.522878745280337,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(O3)C(=CC=C4)OC,COc1cccc2cc(C3CN(C)Cc4ccccc43)oc12
3957,3967,CHEMBL2206445,OXFCYNMUHYQEJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22992024.0,ACTIVITY,=,52.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by CEREP assay,"Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,52.0,COC1=C(C=CC(=C1C2CCN(CC2)C3=C(C4=NN=C(N4C=C3)CC5CC5)Cl)F)F,COc1c(F)ccc(F)c1C1CCN(c2ccn3c(CC4CC4)nnc3c2Cl)CC1
3958,3968,CHEMBL2206445,OXFCYNMUHYQEJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22992024.0,KI,>,8500.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,5.070581074285707,COC1=C(C=CC(=C1C2CCN(CC2)C3=C(C4=NN=C(N4C=C3)CC5CC5)Cl)F)F,COc1c(F)ccc(F)c1C1CCN(c2ccn3c(CC4CC4)nnc3c2Cl)CC1
3959,3969,CHEMBL2070953,OXQNLLVUVDAEHC-OAQYLSRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22910039.0,INHIBITION,=,54.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 uM,"Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.",Bioorg. Med. Chem. Lett.,PUBLICATION,,54.0,CC1=CC=C(C=C1)S(=O)(=O)N2CCCC[C@@H]2C(=O)NC3=NC(=CS3)C4=CC=C(C=C4)OC,COc1ccc(-c2csc(NC(=O)[C@H]3CCCCN3S(=O)(=O)c3ccc(C)cc3)n2)cc1
3960,3970,CHEMBL457415,OXWLQFOLXMGQTM-CHKHYCHESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,6.769551078621726,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C=C3)OC)I)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](c2ccc(OC)c(I)c2)C[C@H]2CC[C@H]1N2C
3961,3971,CHEMBL403949,OXXNPMVLHAHIKP-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
3962,3972,CHEMBL502707,OXYQNDFARIFPMG-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCOC(=O)N(CC1=CC=CC=C1SC)[C@H]2CCNC2,CCOC(=O)N(Cc1ccccc1SC)[C@H]1CCNC1
3963,3973,CHEMBL404729,OYNDMWYYCBLSSM-HNAYVOBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.537602002101044,C=CCN(CC(=C)F)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C=CCN(CC(=C)F)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
3964,3974,CHEMBL37744,OYPPVKRFBIWMSX-SXGWCWSVSA-N,ZIMELDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)C/C=C(/C1=CC=C(C=C1)Br)\C2=CN=CC=C2,CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1
3965,3975,CHEMBL218193,OYPZJIHQZRPSNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.3979400086720375,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)C(C)C,CC(C)CC(c1ccc(C(C)C)cc1)C1CCCCN1
3966,3976,CHEMBL218193,OYPZJIHQZRPSNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,>,9100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.040958607678906,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)C(C)C,CC(C)CC(c1ccc(C(C)C)cc1)C1CCCCN1
3967,3977,CHEMBL218193,OYPZJIHQZRPSNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,3300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.481486060122113,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)C(C)C,CC(C)CC(c1ccc(C(C)C)cc1)C1CCCCN1
3968,3978,CHEMBL218193,OYPZJIHQZRPSNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,>,6500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,5.187086643357143,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)C(C)C,CC(C)CC(c1ccc(C(C)C)cc1)C1CCCCN1
3969,3979,CHEMBL203488,OYYFMZJTKZIRQM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,43.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.366531544420414,CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CCCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
3970,3980,CHEMBL203488,OYYFMZJTKZIRQM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,11.5,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.939302159646387,CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CCCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
3971,3981,CHEMBL1945250,OZEKSHNBMDIPKA-CBPXPLCBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,93.33,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.0299787341716335,CC1=CC=CC=C1CN2[C@H]3CC[C@@H]2[C@H]([C@H](C3)C4=CC=C(C=C4)I)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2Cc1ccccc1C
3972,3982,CHEMBL256136,OZGYIQFKTKLWDA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,1970.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.705533773838407,CN(C)CC1=C(C=CN=C1)OC2=C(C=C(C=C2)Cl)Br,CN(C)Cc1cnccc1Oc1ccc(Cl)cc1Br
3973,3983,CHEMBL2430694,OZKUXEIZXWPRFX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,38.7,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.412289034981089,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1cccc(Cl)c1
3974,3984,CHEMBL2430694,OZKUXEIZXWPRFX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,94.6,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,94.6,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1cccc(Cl)c1
3975,3985,CHEMBL2430694,OZKUXEIZXWPRFX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,98.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,98.0,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1cccc(Cl)c1
3976,3986,CHEMBL3704754,OZLLUGNMXJLQIE-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,0.91,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,9.040958607678906,C[C@@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3977,3987,CHEMBL3704754,OZLLUGNMXJLQIE-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.638272163982407,C[C@@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3978,3988,CHEMBL3704754,OZLLUGNMXJLQIE-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,30.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.518557371497695,C[C@@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3979,3989,CHEMBL3704754,OZLLUGNMXJLQIE-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,0.91,NM,317685,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,9.040958607678906,C[C@@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3980,3990,CHEMBL3704755,OZLLUGNMXJLQIE-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,126.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.899284913426919,C[C@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3981,3991,CHEMBL3704755,OZLLUGNMXJLQIE-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,299.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.523313257054356,C[C@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3982,3992,CHEMBL3704755,OZLLUGNMXJLQIE-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,3415.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.466609291982449,C[C@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3983,3993,CHEMBL3704755,OZLLUGNMXJLQIE-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,126.1,NM,317686,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.899284913426919,C[C@H](CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,C[C@H](CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3984,3994,CHEMBL3704753,OZLLUGNMXJLQIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.823908740944319,CC(CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CC(CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3985,3995,CHEMBL3704753,OZLLUGNMXJLQIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,8.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.09151498112135,CC(CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CC(CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3986,3996,CHEMBL3704753,OZLLUGNMXJLQIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,50.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.300162274132753,CC(CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CC(CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3987,3997,CHEMBL3704753,OZLLUGNMXJLQIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,1.5,NM,317684,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.823908740944319,CC(CCNCCCC(=O)N)CC1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CC(CCNCCCC(N)=O)CC1(c2ccc(Cl)c(Cl)c2)CCC1
3988,3998,CHEMBL2012099,OZMCGVGCODUDNU-UHFFFAOYSA-N,RACEMIC O-2862,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,C1CC2C3=C(CC1O2)C4=CC5=CC=CC=C5N4C3=O,O=C1C2=C(CC3CCC2O3)c2cc3ccccc3n21
3989,3999,CHEMBL2012099,OZMCGVGCODUDNU-UHFFFAOYSA-N,RACEMIC O-2862,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,C1CC2C3=C(CC1O2)C4=CC5=CC=CC=C5N4C3=O,O=C1C2=C(CC3CCC2O3)c2cc3ccccc3n21
3990,4000,CHEMBL469947,OZOIMHBDGJFSOJ-NHYWBVRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.0,C=CCN(C1CC1)C(=O)[C@]2(C[C@H]2CN)C3=CC=CS3,C=CCN(C(=O)[C@@]1(c2cccs2)C[C@H]1CN)C1CC1
3991,4001,CHEMBL471855,OZOVADGYFYTOAE-LJQANCHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,66.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.180456064458133,CC(C)CN(CC1=CC2=CC=CC=C2C=C1)[C@@H]3CCNC3,CC(C)CN(Cc1ccc2ccccc2c1)[C@@H]1CCNC1
3992,4002,CHEMBL294481,OZUHPVAODZNQKI-RVWIWJKTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18644726.0,KI,=,370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,"3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.431798275933005,COC1=CC2=C(CN(CC2)C3CCC(CC3)C4=CNC5=C4C=C(C=C5)C#N)C=C1,COc1ccc2c(c1)CCN(C1CCC(c3c[nH]c4ccc(C#N)cc34)CC1)C2
3993,4003,CHEMBL293583,OZUHPVAODZNQKI-XGAFWQRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18644726.0,KI,=,462.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,"3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.335358024443876,COC1=CC2=C(CN(CC2)C3CCC(CC3)C4=CNC5=C4C=C(C=C5)C#N)C=C1,COc1ccc2c(c1)CCN(C1CCC(c3c[nH]c4ccc(C#N)cc34)CC1)C2
3994,4004,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
3995,4005,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
3996,4006,CHEMBL469,OZWKMVRBQXNZKK-UHFFFAOYSA-N,KETOROLAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
3997,4007,CHEMBL469,OZWKMVRBQXNZKK-UHFFFAOYSA-N,KETOROLAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
3998,4008,CHEMBL353643,PAHPPCVLEUXOFZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,0.36,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,0.36,CS(=O)(=O)NC1=CC=C(C=C1)CN2CCC(CC2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,CS(=O)(=O)Nc1ccc(CN2CCC(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
3999,4009,CHEMBL526670,PATATAHKRVWCHN-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3F,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1F
4000,4010,CHEMBL264678,PAYGGRIFYBKVNJ-SUMWQHHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
4001,4011,CHEMBL219703,PAZWPXLTYQROKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,45.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.346787486224656,CCCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCCC(c1ccc(Cl)cc1)C1CCCCN1
4002,4012,CHEMBL219703,PAZWPXLTYQROKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.187086643357143,CCCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCCC(c1ccc(Cl)cc1)C1CCCCN1
4003,4013,CHEMBL219703,PAZWPXLTYQROKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,23.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CCCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCCC(c1ccc(Cl)cc1)C1CCCCN1
4004,4014,CHEMBL219703,PAZWPXLTYQROKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,870.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.0604807473813835,CCCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCCC(c1ccc(Cl)cc1)C1CCCCN1
4005,4015,CHEMBL2171210,PBCQYBZENRQFON-UHFFFAOYSA-N,3-(METHOXY(PHENYL)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,2.2,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.2,COC(C1CNC1)C2=CC=CC=C2.Cl,COC(c1ccccc1)C1CNC1
4006,4016,CHEMBL1243,PBCZLFBEBARBBI-UHFFFAOYSA-N,SULFABENZAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1
4007,4017,CHEMBL1243,PBCZLFBEBARBBI-UHFFFAOYSA-N,SULFABENZAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1
4008,4018,CHEMBL486278,PBDMWGSHTOZGOM-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19492813.0,IC50,=,1200.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,5.920818753952375,CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](COC2=CC=CC3=C2NC(=O)N3)O,COc1ccc(CC(C)(C)NC[C@H](O)COc2cccc3[nH]c(=O)[nH]c23)cc1
4009,4019,CHEMBL486278,PBDMWGSHTOZGOM-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821575.0,IC50,=,1.2,NM,,,,,,,,,,,,,,,Inhibition of DAT,Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,8.920818753952375,CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](COC2=CC=CC3=C2NC(=O)N3)O,COc1ccc(CC(C)(C)NC[C@H](O)COc2cccc3[nH]c(=O)[nH]c23)cc1
4010,4020,CHEMBL256168,PBERLNCGGCSXEK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,6510.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.186419011431808,CNCC1=CC=CC=C1OC2=C(C=C(C=C2)F)Cl,CNCc1ccccc1Oc1ccc(F)cc1Cl
4011,4021,CHEMBL544633,PBPZAEYGFWGLBT-VKLKMBQZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,42000.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.376750709602098,CC1=CC(=C(C(=C1)C)[C@@H]([C@@H](CN(C)C)C2=CC=CC=C2)O)C.Cl,Cc1cc(C)c([C@H](O)[C@@H](CN(C)C)c2ccccc2)c(C)c1
4012,4022,CHEMBL3310637,PCSGUMGUIACOPL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,23.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC4=CC=CC=C4C=C3,Cc1ccccc1OC(CC1CNC1)c1ccc2ccccc2c1
4013,4023,CHEMBL375685,PCXXVJSJWKSKBZ-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,810.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.091514981121351,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)Br)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(Br)cc4)s2)N3C)cc1
4014,4024,CHEMBL375685,PCXXVJSJWKSKBZ-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,130.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.886056647693162,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC=C(C=C5)Br)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4ccc(Br)cc4)s2)N3C)cc1
4015,4025,CHEMBL1224385,PCXZFUGPNRGVAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNCCC(C1=CC2=C(C=C1)C=C(C=C2)OC)N3N=CN=N3,CNCCC(c1ccc2cc(OC)ccc2c1)n1ncnn1
4016,4026,CHEMBL272493,PCZHCTVLCPQAAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,172.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.764471553092451,CC1=C(C=CC(=C1)Cl)OC2=C(C=C(C=C2)C(=O)N(C)C)CNC,CNCc1cc(C(=O)N(C)C)ccc1Oc1ccc(Cl)cc1C
4017,4027,CHEMBL503,PCZOHLXUXFIOCF-BXMDZJJMSA-N,LOVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,10104.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.9955066624527245,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
4018,4028,CHEMBL503,PCZOHLXUXFIOCF-BXMDZJJMSA-N,LOVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,8028.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.095392636184552,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
4019,4029,CHEMBL255303,PDGMXEUBNYMTST-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693162,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)SC=C3,CCN(CC)C(=O)[C@@]1(c2ccc3sccc3c2)C[C@H]1CN
4020,4030,CHEMBL2012096,PDIDAKJNGBZUJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(O3)C4=CC=CC=C4,COC(=O)C1=C(c2ccc(-c3ccccc3)o2)CC2CCC1O2
4021,4031,CHEMBL2012096,PDIDAKJNGBZUJB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(O3)C4=CC=CC=C4,COC(=O)C1=C(c2ccc(-c3ccccc3)o2)CC2CCC1O2
4022,4032,CHEMBL18701,PDMUULPVBYQBBK-UHFFFAOYSA-N,RO-201724,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC
4023,4033,CHEMBL18701,PDMUULPVBYQBBK-UHFFFAOYSA-N,RO-201724,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC
4024,4035,CHEMBL1516176,PDNJLMZEGXHSCU-VKHMYHEASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCS(=O)O)C(=O)O
4025,4036,CHEMBL3246857,PDPLBVIQNAZCAX-NWDGAFQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,448684.0,INHIBITION,=,3.0,%,,,,,,,,,,,,,,,Inhibition of dopamine reuptake at DAT (unknown origin) at 10'-5 M,"Synthesis and biological activity of cocaine analogues. 2. 6H-[2]Benzopyrano[4,3-c]pyridin-6-ones.",J. Med. Chem.,PUBLICATION,,3.0,CN1CC[C@@H]2[C@@H](C1)C3=CC=CC=C3C(=O)O2,CN1CC[C@H]2OC(=O)c3ccccc3[C@@H]2C1
4026,4037,CHEMBL2349533,PDUYPEOJRTWPFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23434029.0,INHIBITION,=,60.0,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM,Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.,Bioorg. Med. Chem. Lett.,PUBLICATION,,60.0,CC1=NC(=CC=C1)NC(=O)C2=NN(C(=C2C)C3=CC=CC=C3)C,Cc1cccc(NC(=O)c2nn(C)c(-c3ccccc3)c2C)n1
4027,4038,CHEMBL1645616,PDVOMSJUMYNNBT-JTQLQIEISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,5870.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.231361898752385,C1CNC[C@H]1OC2=C(C=CC=C2F)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1cccc(F)c1O[C@H]1CCNC1
4028,4039,CHEMBL1645617,PDVOMSJUMYNNBT-SNVBAGLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,5870.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.231361898752385,C1CNC[C@@H]1OC2=C(C=CC=C2F)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1cccc(F)c1O[C@@H]1CCNC1
4029,4040,CHEMBL1645615,PDVOMSJUMYNNBT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6460.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.189767482004916,C1CNCC1OC2=C(C=CC=C2F)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1cccc(F)c1OC1CCNC1
4030,4041,CHEMBL366170,PEFLMXJNQRODSP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,=,5296.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.276052023568357,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN)N,Cc1ccc(Sc2ccccc2CN)c(N)c1
4031,4042,CHEMBL288109,PEISWOHNLQWAFV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.12,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.12,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
4032,4043,CHEMBL288109,PEISWOHNLQWAFV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.01,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.01,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC=CC=C4,Fc1ccc(C(OCCN2CCN(Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
4033,4044,CHEMBL446230,PEOZAOHZZSCNEV-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,>,30000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5228787452803365,CCN([C@@H]1CCNC1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2,CCN([C@@H]1CCNC1)S(=O)(=O)c1ccc2ccccc2c1
4034,4045,CHEMBL14531,PETAHELMBJGYJY-HJWRWDBZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,3.9,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,8.4089353929735,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)/C=C\Br,COC(=O)C1C2CCC(CC1c1ccc(/C=C\Br)cc1)N2
4035,4046,CHEMBL471899,PEUIEZIOUGCTOJ-RRIHMMEISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,68.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.16304326294045,CC1=NOC(=C1C2=CC=C(C=C2)Cl)[C@H]3[C@H](CC4CCC3N4C)C5=CC=C(C=C5)Cl.Cl,Cc1noc([C@@H]2C3CCC(C[C@@H]2c2ccc(Cl)cc2)N3C)c1-c1ccc(Cl)cc1
4036,4047,CHEMBL401554,PFAAQRLRJQZICN-PXJINDFSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,67.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.173925197299173,CN1[C@@H]2CCC1C[C@@H]([C@@H]2COC(=O)CCC(=O)OC[C@@H]3[C@H]4CCC(O4)C[C@@H]3C5=CC(=C(C=C5)Cl)Cl)C6=CC(=C(C=C6)Cl)Cl,CN1C2CC[C@@H]1[C@@H](COC(=O)CCC(=O)OC[C@H]1[C@@H](c3ccc(Cl)c(Cl)c3)CC3CC[C@H]1O3)[C@@H](c1ccc(Cl)c(Cl)c1)C2
4037,4048,CHEMBL2115225,PFDGXJOTTDWOFC-DZKFTUMYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,14.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.847711655616942,CN1C2C[C@H]([C@H](C1C(=O)C2)C(=O)OC)C3=CC(=C(C=C3)Cl)Cl,COC(=O)[C@H]1C2C(=O)CC(C[C@H]1c1ccc(Cl)c(Cl)c1)N2C
4038,4049,CHEMBL565845,PFEJBPNFLAFPKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.022276394711152,CC1=C(C=CC(=C1)C(=O)C(C)NC(C)(C)C)Br,Cc1cc(C(=O)C(C)NC(C)(C)C)ccc1Br
4039,4050,CHEMBL565845,PFEJBPNFLAFPKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,1740.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.7594507517174005,CC1=C(C=CC(=C1)C(=O)C(C)NC(C)(C)C)Br,Cc1cc(C(=O)C(C)NC(C)(C)C)ccc1Br
4040,4051,CHEMBL565845,PFEJBPNFLAFPKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,2810.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.55129368009492,CC1=C(C=CC(=C1)C(=O)C(C)NC(C)(C)C)Br,Cc1cc(C(=O)C(C)NC(C)(C)C)ccc1Br
4041,4052,CHEMBL1945782,PFEYQHAJVMQAQQ-KKXYHZGYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,14.13,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.849857838151442,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OCCC4=CC(=C(C=C4)N=[N+]=[N-])I,CN1[C@H]2CC[C@@H]1[C@@H](C(=O)OCCc1ccc(N=[N+]=[N-])c(I)c1)[C@@H](c1ccc(Cl)cc1)C2
4042,4053,CHEMBL169429,PFFMWFZKIJIGTL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,COC(=O)C1=C(CC2CCC1O2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2CCC1O2
4043,4054,CHEMBL2407327,PFPDWJWOZCMTIS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,26.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,7.585026652029183,CCCC(=O)C(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCCC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCNCC1
4044,4055,CHEMBL214335,PFTJCYRHNKTTTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,=,11000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.9586073148417755,COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,COc1ccccc1CC(c1ccccc1)N1CCNCC1
4045,4056,CHEMBL214335,PFTJCYRHNKTTTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,2940.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.531652669587842,COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,COc1ccccc1CC(c1ccccc1)N1CCNCC1
4046,4057,CHEMBL214335,PFTJCYRHNKTTTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,4950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.305394801066432,COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,COc1ccccc1CC(c1ccccc1)N1CCNCC1
4047,4058,CHEMBL214335,PFTJCYRHNKTTTO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,COc1ccccc1CC(c1ccccc1)N1CCNCC1
4048,4059,CHEMBL184618,PGBHMTALBVVCIT-VCIWKGPPSA-N,NEOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
4049,4060,CHEMBL184618,PGBHMTALBVVCIT-VCIWKGPPSA-N,NEOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
4050,4061,CHEMBL426317,PGGCRGAETLNAJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16458504.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT by radioligand binding assay,"Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC(=CC=C3)OC,COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1
4051,4062,CHEMBL207214,PGIUKOCTZQBZIO-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-26.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-26.0,C1CC1CN(CC2=C(C=C(C=C2)F)C(F)(F)F)C3CCNCC3.C(=C/C(=O)O)\C(=O)O,Fc1ccc(CN(CC2CC2)C2CCNCC2)c(C(F)(F)F)c1
4052,4063,CHEMBL2171411,PGJNAAAPLQPFLU-UHFFFAOYSA-N,"3-((3,4-DICHLOROPHENYL)(PHENOXY)METHYL)AZETIDINE HCL",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,58.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,58.0,C1C(CN1)C(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=CC=C3.Cl,Clc1ccc(C(Oc2ccccc2)C2CNC2)cc1Cl
4053,4064,CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N,CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS
4054,4065,CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N,CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS
4055,4066,CHEMBL272286,PGQYZXSMJFWTHI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC2=CN=CO2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCc1cnco1
4056,4067,CHEMBL3401350,PGSGWIDQXZCHJL-FYSMJZIKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25728416.0,INHIBITION,=,51.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 10 uM,Iminopyrimidinones: A novel pharmacophore for the development of orally active renin inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,51.0,C[C@@H](C1=CC=CC=C1)NC(=O)C2=CC(=CC(=C2)CN3C(=O)C[C@@](N=C3N)(C)C(C)C)F,CC(C)[C@]1(C)CC(=O)N(Cc2cc(F)cc(C(=O)N[C@@H](C)c3ccccc3)c2)C(N)=N1
4057,4068,CHEMBL566886,PGTPXIBBHIHMQS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,31.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,7.508638306165728,CCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
4058,4069,CHEMBL566886,PGTPXIBBHIHMQS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,459.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.338187314462738,CCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
4059,4070,CHEMBL566886,PGTPXIBBHIHMQS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,209.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.679853713888947,CCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
4060,4071,CHEMBL214273,PGYQPHBCJVVZFQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC(=CC=C2)C(F)(F)F)C3=CC=CC=C3,FC(F)(F)c1cccc(CC(c2ccccc2)N2CCNCC2)c1
4061,4072,CHEMBL2012080,PGZFTWRXWCVBCF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,CN1C=CC=C1C2=CC=C(C=C2)C3=C(C4CCC(C3)O4)C(=O)OC,COC(=O)C1=C(c2ccc(-c3cccn3C)cc2)CC2CCC1O2
4062,4073,CHEMBL2012080,PGZFTWRXWCVBCF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,CN1C=CC=C1C2=CC=C(C=C2)C3=C(C4CCC(C3)O4)C(=O)OC,COC(=O)C1=C(c2ccc(-c3cccn3C)cc2)CC2CCC1O2
4063,4074,CHEMBL1149,PHIQHXFUZVPYII-ZCFIWIBFSA-N,LEVOCARNITINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,C[N+](C)(C)C[C@H](O)CC(=O)[O-]
4064,4075,CHEMBL1149,PHIQHXFUZVPYII-ZCFIWIBFSA-N,LEVOCARNITINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,C[N+](C)(C)C[C@H](O)CC(=O)[O-]
4065,4076,CHEMBL1105,PHJFLPMVEFKEPL-UHFFFAOYSA-N,6-METHOXY-2-NAPHTHYLACETIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O,COc1ccc2cc(CC(=O)O)ccc2c1
4066,4077,CHEMBL1105,PHJFLPMVEFKEPL-UHFFFAOYSA-N,6-METHOXY-2-NAPHTHYLACETIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O,COc1ccc2cc(CC(=O)O)ccc2c1
4067,4078,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,7400.0,NM,,,,,,,,,,,,,,,,,,,,5.130768280269023,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
4068,4079,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
4069,4080,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
4070,4081,CHEMBL574920,PHMNKJGYIDQICY-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,13.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,13.0,CNC[C@H]([C@H](C1=CC(=CC=C1)Br)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1cccc(Br)c1)n1ccc2ccccc21
4071,4082,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,NC(=O)N1c2ccccc2CCc2ccccc21
4072,4083,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,NC(=O)N1c2ccccc2CCc2ccccc21
4073,4084,CHEMBL1644479,PHOVKMVBVOKTKB-DABQJJPHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,2427.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6149302236680665,CC1=CC(=CC=C1)OC2C[C@H]3CC[C@@H](C2)N3,Cc1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
4074,4085,CHEMBL1818545,PHRHUWNKARHRNO-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,25.12,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.599980364934843,CC(C)C1=NN(N=N1)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,CC(C)c1nnn(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
4075,4086,CHEMBL383128,PHROHJIYKYCBCW-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN[C@H]1CC[C@H](C2=C1C(=CC=C2)C(=O)N(C)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cccc(C(=O)N(C)C)c21
4076,4087,CHEMBL552046,PHRPRBMCXLFXOY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,353.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.452225294612178,C1CNCCC1C(C2=CC=CC=N2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2ccccn2)C2CCNCC2)c1Cl
4077,4088,CHEMBL1083410,PHSDSMUCNUCJGQ-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,2409.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.618163200001657,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
4078,4089,CHEMBL1083410,PHSDSMUCNUCJGQ-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
4079,4090,CHEMBL1083083,PHSDSMUCNUCJGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,=,78.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,78.0,CNCC(CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F)O,CNCC(O)CCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
4080,4091,CHEMBL1082458,PHSDSMUCNUCJGQ-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,3617.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.441651491238379,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
4081,4092,CHEMBL1082458,PHSDSMUCNUCJGQ-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,2113.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,5.675100502947687,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
4082,4093,CHEMBL108947,PHTUQLWOUWZIMZ-BOPFTXTBSA-N,DOTHIEPIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,5310.0,NM,,,,,,,,,,,,,,,,,,,,5.274905478918532,CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31,CN(C)CC/C=C1/c2ccccc2CSc2ccccc21
4083,4094,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,1140.0,NM,,,,,,,,,,,,,,,,,,,,5.943095148663526,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
4084,4095,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,1200.0,NM,,,,,,,,,,,,,,,,,,,,5.920818753952375,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
4085,4096,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,5000.0,NM,,,,,,,,,,,,,,,,,,,,5.301029995663981,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
4086,4097,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1678.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.775208043507319,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
4087,4098,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1333.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.875169850586142,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
4088,4099,CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,Clc1ccccc1CN1CCc2sccc2C1
4089,4100,CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,Clc1ccccc1CN1CCc2sccc2C1
4090,4101,CHEMBL438450,PHZZSZDDGUPIKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,7.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)(CCCNC)C(C)C,CNCCCC1(C(C)C)Cc2ccccc2N(c2ccc(C)cc2)C1=O
4091,4102,CHEMBL438450,PHZZSZDDGUPIKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)(CCCNC)C(C)C,CNCCCC1(C(C)C)Cc2ccccc2N(c2ccc(C)cc2)C1=O
4092,4103,CHEMBL3334779,PIBFRRUEZPEANJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,41.9,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,41.9,CN(CCC(C1=CC2=CC=CC=C2S1)N3CCOCC3)CC4=CC=CC=C4,CN(CCC(c1cc2ccccc2s1)N1CCOCC1)Cc1ccccc1
4093,4104,CHEMBL1644476,PICCBNDESXQSTL-PTEHBNRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,201.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.696803942579511,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC=C3)Br,Brc1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
4094,4105,CHEMBL94,PIJVFDBKTWXHHD-HIFRSBDPSA-N,PHYSOSTIGMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C
4095,4106,CHEMBL94,PIJVFDBKTWXHHD-HIFRSBDPSA-N,PHYSOSTIGMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C
4096,4107,CHEMBL1078170,PIKCALBGLDBAKK-LLVKDONJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,3090.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5100415205751645,CC(C)CN([C@@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@@H]1CCNC1
4097,4108,CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,544.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2644011003018205,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
4098,4109,CHEMBL1080787,PIKCALBGLDBAKK-NSHDSACASA-N,PF-184298,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,544.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2644011003018205,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
4099,4110,CHEMBL3703735,PILUFBWYZBSMTQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,84.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.072116589669293,C1C(C2=C(CN1)C=C(C=C2)N3C=CC=CC3=O)C4=CC(=C(C=C4)Cl)Cl,O=c1ccccn1-c1ccc2c(c1)CNCC2c1ccc(Cl)c(Cl)c1
4100,4111,CHEMBL245880,PIMIZGGCAMLEJJ-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,89.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0506099933550885,C1CNC[C@H]1N(CC2=C(C(=CC=C2)Cl)Cl)C3CCOCC3,Clc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1Cl
4101,4112,CHEMBL245880,PIMIZGGCAMLEJJ-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,IC50,=,89.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0506099933550885,C1CNC[C@H]1N(CC2=C(C(=CC=C2)Cl)Cl)C3CCOCC3,Clc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1Cl
4102,4113,CHEMBL47244,PIMZUZSSNYHVCU-YKWPQBAZSA-N,PICROTOXININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,C=C(C)[C@H]1[C@@H]2C(=O)O[C@H]1[C@H]1OC(=O)[C@@]34O[C@@H]3C[C@]2(O)[C@@]14C
4103,4114,CHEMBL47244,PIMZUZSSNYHVCU-YKWPQBAZSA-N,PICROTOXININ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,C=C(C)[C@H]1[C@@H]2C(=O)O[C@H]1[C@H]1OC(=O)[C@@]34O[C@@H]3C[C@]2(O)[C@@]14C
4104,4115,CHEMBL529437,PIQVDUKEQYOJNR-VZXSFKIWSA-N,COCAINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,89.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.050122295963125,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
4105,4116,CHEMBL529437,PIQVDUKEQYOJNR-VZXSFKIWSA-N,COCAINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,89.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.050122295963125,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
4106,4117,CHEMBL529437,PIQVDUKEQYOJNR-VZXSFKIWSA-N,COCAINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,=,46.3,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,7.3344190089820485,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
4107,4118,CHEMBL1083210,PITDIXLZXHYFAC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,2.5,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.5,CNCCCN1CC2=C(C=CC(=C2)F)N(S1(=O)=O)C3=CC=CC=C3F,CNCCCN1Cc2cc(F)ccc2N(c2ccccc2F)S1(=O)=O
4108,4119,CHEMBL401867,PIVRFBAMCBQCDZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,8000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.096910013008057,CNCC1=C(C=CC(=C1)C(=O)N2CCCN(CC2)C3CC3)OC4=CC(=CC=C4)F,CNCc1cc(C(=O)N2CCCN(C3CC3)CC2)ccc1Oc1cccc(F)c1
4109,4120,CHEMBL456222,PJDWTDSVCNJUGD-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,38440.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.415216621003492,COC1=C(C=C(C=C1)F)C[C@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1C[C@H]1CC[C@H](CCN)O1
4110,4121,CHEMBL456222,PJDWTDSVCNJUGD-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,51020.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.292259545726228,COC1=C(C=C(C=C1)F)C[C@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1C[C@H]1CC[C@H](CCN)O1
4111,4122,CHEMBL450769,PJDWTDSVCNJUGD-OLZOCXBDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,36340.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.439615077027986,COC1=C(C=C(C=C1)F)C[C@@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1C[C@@H]1CC[C@H](CCN)O1
4112,4123,CHEMBL450769,PJDWTDSVCNJUGD-OLZOCXBDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,34790.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.458545571252411,COC1=C(C=C(C=C1)F)C[C@@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1C[C@@H]1CC[C@H](CCN)O1
4113,4124,CHEMBL1224240,PJIMUTYPWDGKIC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CC1=C2C=CC(=NC2=CC=C1)C(=O)C3(CCNC3)CCC(C)(C)C,Cc1cccc2nc(C(=O)C3(CCC(C)(C)C)CCNC3)ccc12
4114,4125,CHEMBL1712923,PJLVTVAIERNDEQ-BTJKTKAUSA-N,IRSOGLADINE MALEATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O,Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1
4115,4126,CHEMBL1712923,PJLVTVAIERNDEQ-BTJKTKAUSA-N,IRSOGLADINE MALEATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O,Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1
4116,4127,CHEMBL1539,PJSFRIWCGOHTNF-UHFFFAOYSA-N,SULFADOXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC
4117,4128,CHEMBL1539,PJSFRIWCGOHTNF-UHFFFAOYSA-N,SULFADOXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC
4118,4129,CHEMBL567480,PJSOCXYIJJIWHO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CCCNC(C)C(=O)C1=CC(=CC=C1)Cl,CCCNC(C)C(=O)c1cccc(Cl)c1
4119,4130,CHEMBL567480,PJSOCXYIJJIWHO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CCCNC(C)C(=O)C1=CC(=CC=C1)Cl,CCCNC(C)C(=O)c1cccc(Cl)c1
4120,4131,CHEMBL1464,PJVWKTKQMONHTI-UHFFFAOYSA-N,WARFARIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
4121,4132,CHEMBL1464,PJVWKTKQMONHTI-UHFFFAOYSA-N,WARFARIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
4122,4133,CHEMBL3334770,PJXULSBRZWCAJP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,77.4,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,77.4,C1CCN(CC1)C(CCN2CCC(=CC2)CC3=CC=CC=C3)C4=CSC5=CC=CC=C54,C1=C(Cc2ccccc2)CCN(CCC(c2csc3ccccc23)N2CCCCC2)C1
4123,4134,CHEMBL569364,PJZPOQITFNSOGK-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCN([C@H]1CCNC1)C(=O)C2=CC=CC=C2C(C)C,CCCN(C(=O)c1ccccc1C(C)C)[C@H]1CCNC1
4124,4135,CHEMBL3673180,PKEMWWJRFYCMFJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,4017.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,5.3960981682683276,CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)C34CCN(CC3)CC5=C4C=CC(=C5)N6CCN(CC6)S(=O)(=O)CC,CCS(=O)(=O)N1CCN(c2ccc(C34CCN(CC3)Cc3cc(N5CCN(S(=O)(=O)CC)CC5)ccc34)cc2)CC1
4125,4136,CHEMBL1224491,PKEWUQPHEKJOIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,79.43,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CCOCC1(CCNC1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CCOCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCNC1
4126,4137,CHEMBL1684048,PKNHHRUELROULR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,350.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.455931955649724,CC(C)CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N(C)C,CC(C)CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
4127,4138,CHEMBL1085323,PKVDODLSCSUTRW-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,2570.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.590066876668706,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC(=CC=C3)OC)O,CNC[C@@H](O)CCN1c2ccccc2N(c2cccc(OC)c2)S1(=O)=O
4128,4139,CHEMBL1085322,PKVDODLSCSUTRW-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,267.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,6.573488738635424,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC(=CC=C3)OC)O,CNC[C@H](O)CCN1c2ccccc2N(c2cccc(OC)c2)S1(=O)=O
4129,4140,CHEMBL207719,PKVYOVHKHCWTDE-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,200.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC(C)CN(CC1=CC=C(C=C1)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccc(F)cc1)C1CCNCC1
4130,4141,CHEMBL2407336,PLAKLZGCXGCZCY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,190.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.721246399047171,COCC(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,COCC(c1ccc(Cl)c(Cl)c1)C1CCNCC1
4131,4142,CHEMBL2407333,PLAKLZGCXGCZCY-UTONKHPSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,470.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.327902142064282,COC[C@H](C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,COC[C@@H](c1ccc(Cl)c(Cl)c1)C1CCNCC1
4132,4143,CHEMBL2407332,PLAKLZGCXGCZCY-YDALLXLXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,180.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.7447274948966935,COC[C@@H](C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,COC[C@H](c1ccc(Cl)c(Cl)c1)C1CCNCC1
4133,4144,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2053.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.687611050629407,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
4134,4145,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1631.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.787546038959723,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
4135,4146,CHEMBL1103,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,FURAZOLIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1
4136,4147,CHEMBL1103,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,FURAZOLIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1
4137,4148,CHEMBL126224,PLIGPBGDXASWPX-UHFFFAOYSA-N,IPRINDOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,6530.0,NM,,,,,,,,,,,,,,,,,,,,5.185086818724925,CN(C)CCCN1C2=C(CCCCCC2)C3=CC=CC=C31,CN(C)CCCn1c2c(c3ccccc31)CCCCCC2
4138,4149,CHEMBL3310802,PLIHWCCORFZAAL-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24856064.0,INHIBITION,=,-2.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 3 uM by radioligand binding assay,"Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,-2.0,CCOC(=O)N1CCC(CC1)CN2CCC3(CC2)CN(C4=C3C=CC=N4)C(=O)N(C)C.C(=C/C(=O)O)\C(=O)O,CCOC(=O)N1CCC(CN2CCC3(CC2)CN(C(=O)N(C)C)c2ncccc23)CC1
4139,4150,CHEMBL1641698,PLSLYUFKIKYVII-GUXLZLHYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,ACTIVITY,,,,Active,,cell_based,,,,,,,,,,,,Binding affinity to human DAT expressed in UV irradiated mouse N2A cells by photoaffinity labeling assay,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)N=[N+]=[N-])C3=CC=C(C=C3)[125I],COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1Cc1ccc(N=[N+]=[N-])cc1
4140,4151,CHEMBL1641692,PLSLYUFKIKYVII-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,IC50,=,2764.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in mouse N2A cells,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,5.558461961297839,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)N=[N+]=[N-])C3=CC=C(C=C3)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1Cc1ccc(N=[N+]=[N-])cc1
4141,4152,CHEMBL1641692,PLSLYUFKIKYVII-WOJBJXKFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21129986.0,KI,=,363.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT stably expressed in mouse N2A cells by scintillation countnig,"Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.",Bioorg. Med. Chem.,PUBLICATION,,6.440093374963888,COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)N=[N+]=[N-])C3=CC=C(C=C3)I,COC(=O)[C@H](c1ccc(I)cc1)[C@H]1CCCCN1Cc1ccc(N=[N+]=[N-])cc1
4142,4153,CHEMBL468207,PLTVEFQGFXRXRM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,54.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.267606240177032,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC(=O)C4=CC=CC=C4,O=C(CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
4143,4154,CHEMBL1170441,PLVMDZQEFNUCOF-SMDDNHRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,832.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,6.079876673709277,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=C(C=C2)C)O,Cc1ccc([C@]2(O)OCC(C)(C)N[C@H]2C)cc1
4144,4155,CHEMBL232498,PLVZUCHZVZCSGX-GORDUTHDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,11000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.9586073148417755,C/C=C/C1=C(CCCC1)C2=CC(=C(C=C2)Cl)Cl,C/C=C/C1=C(c2ccc(Cl)c(Cl)c2)CCCC1
4145,4156,CHEMBL232498,PLVZUCHZVZCSGX-GORDUTHDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,42000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.376750709602098,C/C=C/C1=C(CCCC1)C2=CC(=C(C=C2)Cl)Cl,C/C=C/C1=C(c2ccc(Cl)c(Cl)c2)CCCC1
4146,4157,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
4147,4158,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
4148,4159,CHEMBL3310489,PMFYWAOJTSDFLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,80.4,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.094743951251549,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
4149,4160,CHEMBL3310489,PMFYWAOJTSDFLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,58.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,58.0,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
4150,4161,CHEMBL3310489,PMFYWAOJTSDFLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
4151,4162,CHEMBL3310489,PMFYWAOJTSDFLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)F,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1
4152,4163,CHEMBL103138,PMIPVYUBFZZBSH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,16000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.795880017344076,COC(=O)C1=CC=CC=C1C2=CC=C(C=C2)F,COC(=O)c1ccccc1-c1ccc(F)cc1
4153,4164,CHEMBL2321999,PMLBVCPRUZMORG-JTQLQIEISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.221848749616356,C1C=CCNC[C@H]1C2=CC(=C(C=C2)Cl)Cl,Clc1ccc([C@H]2CC=CCNC2)cc1Cl
4154,4165,CHEMBL2322000,PMLBVCPRUZMORG-SNVBAGLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,8.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.096910013008056,C1C=CCNC[C@@H]1C2=CC(=C(C=C2)Cl)Cl,Clc1ccc([C@@H]2CC=CCNC2)cc1Cl
4155,4166,CHEMBL2321998,PMLBVCPRUZMORG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.221848749616356,C1C=CCNCC1C2=CC(=C(C=C2)Cl)Cl,Clc1ccc(C2CC=CCNC2)cc1Cl
4156,4167,CHEMBL477148,PMNGGGSGAMTCOG-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,4190.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.377785977033705,C1CCN(C1)C(=O)N(CC2=CC=CC=C2C3=CC=CC=C3)[C@H]4CCNC4,O=C(N1CCCC1)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
4157,4168,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=CNC1=S,Cn1cc[nH]c1=S
4158,4169,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=CNC1=S,Cn1cc[nH]c1=S
4159,4170,CHEMBL208121,PMVYNXPSCGXPRM-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-12.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-12.0,CCCN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CCCN(Cc1ccccc1C(F)(F)F)C1CCNCC1
4160,4171,CHEMBL1224164,PMWJXJVDUJHXHT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,2.51,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518963,CCCC1(CCCN1)C(=O)C2=CC3=C(C=C2)NC=C3,CCCC1(C(=O)c2ccc3[nH]ccc3c2)CCCN1
4161,4172,CHEMBL517963,PMWLMRLBVALWMX-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)C(=O)N(CC1=CC=CC=C1Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1ccccc1Cl)[C@H]1CCNC1
4162,4173,CHEMBL1080969,PMZYRKGBQBCWOA-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,2600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,CCC(CC)N([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl,CCC(CC)N(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
4163,4174,CHEMBL463389,PNEAEOHMGHCGPC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,363.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.440093374963888,CCCC1(CCNC1)C2=CC3=C(C=C2)NC=C3,CCCC1(c2ccc3[nH]ccc3c2)CCNC1
4164,4175,CHEMBL84680,PNEHBGJVHOWVCT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,2.9,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.537602002101043,CN1C2CCC1C(=C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC,COC(=O)C1=C(c2ccc3ccccc3c2)CC2CCC1N2C
4165,4176,CHEMBL84680,PNEHBGJVHOWVCT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,2.94,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.531652669587842,CN1C2CCC1C(=C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC,COC(=O)C1=C(c2ccc3ccccc3c2)CC2CCC1N2C
4166,4177,CHEMBL272530,PNHQUTMNPCBPOX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(C(=O)C1(CC1CN)C2=CC=CC=C2)C(C)(C)C,CCN(C(=O)C1(c2ccccc2)CC1CN)C(C)(C)C
4167,4178,CHEMBL251694,PNVNVHUZROJLTJ-INIZCTEOSA-N,(R)-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21413808.0,IC50,=,19600.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,PUBLICATION,,4.707743928643524,CN(C)C[C@@H](C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc([C@H](CN(C)C)C2(O)CCCCC2)cc1
4168,4179,CHEMBL252720,PNVNVHUZROJLTJ-MRXNPFEDSA-N,(S)-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21413808.0,IC50,=,6670.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,PUBLICATION,,5.175874166083451,CN(C)C[C@H](C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1
4169,4180,CHEMBL252720,PNVNVHUZROJLTJ-MRXNPFEDSA-N,(S)-VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23061607.0,IC50,=,4430.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) assessed as dopamine reuptake,Organosilicon molecules with medicinal applications.,J. Med. Chem.,PUBLICATION,,5.3535962737769305,CN(C)C[C@H](C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1
4170,4181,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,9300.0,NM,,,,,,,,,,,,,,,,,,,,5.031517051446065,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4171,4182,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,9300.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4172,4183,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11454918.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4173,4184,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11750180.0,KI,=,7647.0,NM,,,,,,,,,,,,,,,,,,,,5.1165089098110705,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4174,4185,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14573386.0,KI,=,7647.0,NM,,,,,,,,,,,,,,,,,,,,5.1165089098110705,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4175,4186,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,3070.0,NM,,,,,,,,,,,,,,,,,,,,5.512861624522814,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4176,4187,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,6050.0,NM,,,,,,,,,,,,,,,,,,,,5.218244625347531,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4177,4188,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,45.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 10000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,45.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4178,4189,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4179,4190,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,7340.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.13430394008393,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4180,4191,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21413808.0,IC50,=,4430.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Synopsis of some recent tactical application of bioisosteres in drug design.,J. Med. Chem.,PUBLICATION,,5.3535962737769305,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4181,4192,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,9120.11,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.039999923502187,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4182,4193,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,3620.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.441291429466834,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4183,4194,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,15767.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.802250932377388,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4184,4195,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,6.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4185,4196,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,16.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,16.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4186,4197,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,56.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,56.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4187,4198,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4188,4199,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,>,890.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.0506099933550885,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4189,4200,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4190,4201,CHEMBL255663,POGCTVQQHWBYLG-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,=,8300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.080921907623925,C=CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C=CCN(CC=C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
4191,4202,CHEMBL1684046,POKCWLLPLOIIOW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,9.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.045757490560675,CC(C)CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)NC,CNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
4192,4203,CHEMBL1201012,POPFMWWJOGLOIF-XWCQMRHXSA-N,FLURANDRENOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
4193,4204,CHEMBL1201012,POPFMWWJOGLOIF-XWCQMRHXSA-N,FLURANDRENOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
4194,4205,CHEMBL111128,PORDAYLSLHLTRQ-FYOYPEGLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,86.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0655015487564325,CNC[C@@H]1[C@H](C2CCC1C2)C3=CC4=CC=CC=C4C=C3,CNC[C@H]1C2CCC(C2)[C@@H]1c1ccc2ccccc2c1
4195,4206,CHEMBL111128,PORDAYLSLHLTRQ-FYOYPEGLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,41.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.387216143280264,CNC[C@@H]1[C@H](C2CCC1C2)C3=CC4=CC=CC=C4C=C3,CNC[C@H]1C2CCC(C2)[C@@H]1c1ccc2ccccc2c1
4196,4207,CHEMBL331799,PORDAYLSLHLTRQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,87.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0604807473813835,CNCC1C2CCC(C2)C1C3=CC4=CC=CC=C4C=C3,CNCC1C2CCC(C2)C1c1ccc2ccccc2c1
4197,4208,CHEMBL331799,PORDAYLSLHLTRQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,25.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.602059991327962,CNCC1C2CCC(C2)C1C3=CC4=CC=CC=C4C=C3,CNCC1C2CCC(C2)C1c1ccc2ccccc2c1
4198,4209,CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,6842.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.164816930150956,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
4199,4210,CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,5436.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.264720551939544,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
4200,4211,CHEMBL1818218,PPANZCQXFYBGHN-UHFFFAOYSA-N,PF-4840154,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21741838.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 1.6 uM,"Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel.",Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC(C)CNC1=NC(=NC=C1C(=O)NCC2=CC=CC=C2)N3CCN(CC3)CC4CCCOC4,CC(C)CNc1nc(N2CCN(CC3CCCOC3)CC2)ncc1C(=O)NCc1ccccc1
4201,4212,CHEMBL408230,PPEMPAPSRLGSIO-RDJZCZTQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,420.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.376750709602098,C1CO[C@@H](CN1)[C@H](C2=CC=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(O[C@@H](c2ccccc2)[C@@H]2CNCCO2)c1Cl
4202,4213,CHEMBL572163,PPLVDBKGJPKXLH-HSZRJFAPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821575.0,IC50,=,3.7,NM,,,,,,,,,,,,,,,Inhibition of DAT,Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,8.431798275933005,CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=CC=C(C=C3)CCC(=O)O)O,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1ccc(CCC(=O)O)cc1
4203,4214,CHEMBL3331493,PPMWMFQRUQSBNK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,25.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,25.0,C1CC1N(CC2CNC2)CC3=CC4=CC=CC=C4C=C3,c1ccc2cc(CN(CC3CNC3)C3CC3)ccc2c1
4204,4215,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
4205,4216,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
4206,4217,CHEMBL582928,PPQUPQGZDGZYJI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,EC50,=,5210.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.283162276700477,C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3,c1ccc(COc2ccccc2N2CCNCC2)cc1
4207,4218,CHEMBL582928,PPQUPQGZDGZYJI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,>,8720.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0594835150674315,C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3,c1ccc(COc2ccccc2N2CCNCC2)cc1
4208,4219,CHEMBL120951,PPQZABOURJVKNI-UHFFFAOYSA-N,FLAZALONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,5700.0,NM,,,,,,,,,,,,,,,Binding Affinity to cocaine site of dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol.,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,5.2441251443275085,CN1CCC(C(C1)C(=O)C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)O,CN1CCC(O)(c2ccc(F)cc2)C(C(=O)c2ccc(F)cc2)C1
4209,4220,CHEMBL2062933,PPUPWUDKXPTAMV-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,35.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.455931955649724,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=C(C=C2)N=[N+]=[N-],COC(=O)[C@H](c1ccc(N=[N+]=[N-])cc1)[C@H]1CCCCN1
4210,4221,CHEMBL2206517,PPWGBAKMSRMGKP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,233.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.632644078973981,CCC1=CC2=C(C=C1)C(CN(C2)C)C3=CC=CC=C3,CCc1ccc2c(c1)CN(C)CC2c1ccccc1
4211,4222,CHEMBL490632,PPXOTGGYVKBLCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329329.0,KI,,,,Not Determined,,,,,,,,,,,,,,Inhibition of human cloned DAT by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,,CC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=C(C(=CC=C3)OCCF)OC,COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1
4212,4223,CHEMBL497679,PQCPVVBGHDVKFV-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,1400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321763,CC1=C(C=CC=C1Cl)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1cccc(Cl)c1C
4213,4224,CHEMBL206153,PQGGSLAVULAHLP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,10.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,C1CNCCC1N(CCCC#N)CC2=C(C=C(C=C2)F)C(F)(F)F.C(C(C(=O)O)O)(C(=O)O)O,N#CCCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
4214,4225,CHEMBL2047569,PQGQRUUEBWORMY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,57.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,57.0,COC1=CC=C(C=C1)C(CCN2CCC(=CC2)CC3=CC=CC=C3)O,COc1ccc(C(O)CCN2CC=C(Cc3ccccc3)CC2)cc1
4215,4226,CHEMBL2021583,PQMJWYCYCSXLGZ-JJLQDPRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,6309.57,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.200000237109354,CCOCC1([C@H]2[C@@H]1CCC2)C3=CC(=C(C=C3)Cl)Cl,CCOCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CCC[C@H]21
4216,4227,CHEMBL2021582,PQMJWYCYCSXLGZ-JYAVWHMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,19.95,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.700057099977232,CCOCC1([C@H]2[C@@H]1CCC2)C3=CC(=C(C=C3)Cl)Cl,CCOCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CCC[C@H]21
4217,4228,CHEMBL416245,PQQCDVZHCORTDJ-NTEUORMPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.24,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.24,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)/C=C/C4=CC=CC=C4Cl,O=C(/C=C/c1ccccc1Cl)N1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4218,4229,CHEMBL416245,PQQCDVZHCORTDJ-NTEUORMPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.14,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.14,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)/C=C/C4=CC=CC=C4Cl,O=C(/C=C/c1ccccc1Cl)N1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4219,4230,CHEMBL1808424,PQQHOBXFKJXQAU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21724392.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 0.5 uM,Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN1CC(=C(C1)Cl)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4,CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)C1
4220,4231,CHEMBL227233,PQQIGLGAWBKHRP-NQAVQENRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,38.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.420216403383191,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)OC,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(Cl)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1
4221,4232,CHEMBL227233,PQQIGLGAWBKHRP-NQAVQENRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,8.6,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,8.065501548756432,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)OC,COc1ccc(-c2cnc([C@H]3[C@@H](c4ccc(Cl)cc4)C[C@@H]4CC[C@H]3N4C)s2)cc1
4222,4233,CHEMBL41061,PQUSJGFLYJZNNR-XNTDXEJSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.74,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.74,C1CN(CCN1CCN(CC2=CC=CC=C2)C3=CC=CC=C3)C/C=C/C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(CCN(Cc2ccccc2)c2ccccc2)CC1
4223,4234,CHEMBL41061,PQUSJGFLYJZNNR-XNTDXEJSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.35,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.35,C1CN(CCN1CCN(CC2=CC=CC=C2)C3=CC=CC=C3)C/C=C/C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(CCN(Cc2ccccc2)c2ccccc2)CC1
4224,4235,CHEMBL609908,PQVFTFGHDAAJKQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20034793.0,IC50,=,620.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [I125]RTI-55 from human DAT transfected in human HEK293 cells,Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2076083105017466,CN1CCC2=CC=CC=C2C1CCC3=CNC4=C3C=C(C=C4)C#N,CN1CCc2ccccc2C1CCc1c[nH]c2ccc(C#N)cc12
4225,4236,CHEMBL3289656,PQVQCEDGSJVHMK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24800940.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human DAT by PDSP assay,Identification of a new selective dopamine D4 receptor ligand.,Bioorg. Med. Chem.,PUBLICATION,,50.0,C1CN(CCN1CCCC2=NC3=CC=CC=C3S2)C4=NC=CC=N4,c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1
4226,4237,CHEMBL569465,PREYWAJYVTVVPE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,33.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,7.481486060122112,CCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
4227,4238,CHEMBL569465,PREYWAJYVTVVPE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,96.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,7.017728766960433,CCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
4228,4239,CHEMBL569465,PREYWAJYVTVVPE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,56.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.251811972993798,CCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
4229,4240,CHEMBL3673170,PRHCBLDIFFVLSZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,10.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.995678626217357,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC(=C(C=C5)Cl)F,Fc1cc(C23CCN(CC2)Cc2cc(Oc4ccc(C(F)(F)F)nn4)ccc23)ccc1Cl
4230,4241,CHEMBL2030632,PRKCBGIXZFUCEF-UHFFFAOYSA-N,N-(3-FLUOROBENZYL)PYRROLIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCN(C1)CC2=CC(=CC=C2)F,Fc1cccc(CN2CCCC2)c1
4231,4242,CHEMBL193482,PROQIPRRNZUXQM-ZXXIGWHRSA-N,ESTRIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O
4232,4243,CHEMBL193482,PROQIPRRNZUXQM-ZXXIGWHRSA-N,ESTRIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O
4233,4244,CHEMBL202910,PRPQDTYJTKSLKO-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,16700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.777283528852417,CN[C@H]1CC[C@H](C2=C1C=CC(=C2)C(=O)O)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(C(=O)O)ccc21
4234,4245,CHEMBL81525,PRQICMQRAXJOCP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,1.43,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,8.844663962534938,COC(=O)C1C2CCC(N2)CC1C3=CC=C(C=C3)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)cc1)N2
4235,4246,CHEMBL260988,PRTQZTFEHWCKDF-BLLLJJGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCO3,CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCO3)C[C@H]1CN
4236,4247,CHEMBL2205836,PSBBAGWMKGXQRW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1CCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53
4237,4248,CHEMBL2012083,PSBDCZZMKYJTOI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.0,COC(=O)C1=C(CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CS4,COC(=O)C1=C(c2cccc(-c3cccs3)c2)CC2CCC1O2
4238,4249,CHEMBL2012083,PSBDCZZMKYJTOI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CS4,COC(=O)C1=C(c2cccc(-c3cccs3)c2)CC2CCC1O2
4239,4250,CHEMBL717,PSGAAPLEWMOORI-PEINSRQWSA-N,MEDROXYPROGESTERONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
4240,4251,CHEMBL717,PSGAAPLEWMOORI-PEINSRQWSA-N,MEDROXYPROGESTERONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
4241,4252,CHEMBL191,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,LOSARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
4242,4253,CHEMBL191,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,LOSARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
4243,4254,CHEMBL213754,PSIGDYKJTYBHDY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CCCOc1ccccc1CC(c1ccccc1)N1CCNCC1
4244,4255,CHEMBL213754,PSIGDYKJTYBHDY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,1950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.709965388637482,CCCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CCCOc1ccccc1CC(c1ccccc1)N1CCNCC1
4245,4256,CHEMBL2407323,PSMAIUZEWLCYGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,97.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,7.013228265733755,CCOC(=O)C(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCOC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCNCC1
4246,4257,CHEMBL63703,PSNHNKLTGOOICN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,270.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.568636235841013,C1CN(CCC1NCCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=CC=C4,c1ccc(CN2CCC(NCCOC(c3ccccc3)c3ccccc3)CC2)cc1
4247,4258,CHEMBL63703,PSNHNKLTGOOICN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,83.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.080921907623925,C1CN(CCC1NCCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=CC=C4,c1ccc(CN2CCC(NCCOC(c3ccccc3)c3ccccc3)CC2)cc1
4248,4259,CHEMBL378039,PSOLLAWKFQBNIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784853.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at dopamine transporter,High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.9586073148417755,C1CN(CCN1CCCC2=CC=C(C=C2)NC(=O)CCCCC3C4C(CS3)NC(=O)N4)CCOC(C5=CC=CC=C5)C6=CC=CC=C6,O=C(CCCCC1SCC2NC(=O)NC21)Nc1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
4249,4260,CHEMBL387758,PSPJUVHWZINCFD-KOQKOIQBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,22.4,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,7.649751981665838,CC1=CC=C(C=C1)[C@H]2[C@H](CC3CCC2N3C)C4=CC=CC=C4,Cc1ccc([C@@H]2C3CCC(C[C@@H]2c2ccccc2)N3C)cc1
4250,4261,CHEMBL2096876,PSPJUVHWZINCFD-KWJLTHHISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,540.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,6.267606240177032,CC1=CC=C(C=C1)[C@@H]2[C@@H](CC3CCC2N3C)C4=CC=CC=C4,Cc1ccc([C@H]2C3CCC(C[C@H]2c2ccccc2)N3C)cc1
4251,4262,CHEMBL1807053,PSUFQBRCUSJTDO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21618986.0,INHIBITION,>,16.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 4 uM,Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.,J. Med. Chem.,PUBLICATION,,16.0,CCC(CC)NC1=NC(=C(N=C1OC)C2=C(C=C(C=C2)OC(F)(F)F)OC)C,CCC(CC)Nc1nc(C)c(-c2ccc(OC(F)(F)F)cc2OC)nc1OC
4252,4263,CHEMBL1649,PTJADDMMFYXMMG-UHFFFAOYSA-N,DEMETHYL-CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CNCCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CNCCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
4253,4264,CHEMBL2326686,PTKQUPHPZRJQRH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,68.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.167491087293763,C1C=CCNCC1C2=CC(=C(C=C2)F)Cl,Fc1ccc(C2CC=CCNC2)cc1Cl
4254,4265,CHEMBL1909078,PTLRDCMBXHILCL-UHFFFAOYSA-M,SODIUM ARSENITE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][As]=O.[Na+],O=[As][O-]
4255,4266,CHEMBL1909078,PTLRDCMBXHILCL-UHFFFAOYSA-M,SODIUM ARSENITE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][As]=O.[Na+],O=[As][O-]
4256,4267,CHEMBL1619,PTOAARAWEBMLNO-KVQBGUIXSA-N,CLADRIBINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
4257,4268,CHEMBL1619,PTOAARAWEBMLNO-KVQBGUIXSA-N,CLADRIBINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
4258,4269,CHEMBL574428,PTVWULKTBHSTNS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,45.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.346787486224656,C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3,Fc1cccc(Oc2ccccc2)c1C1CCNCC1
4259,4270,CHEMBL2206522,PUACBDCIAIMRLD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,1840.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.735182176990462,CC1=C2C(CN(CC2=CC=C1)C)C3=CC=CC=C3,Cc1cccc2c1C(c1ccccc1)CN(C)C2
4260,4271,CHEMBL1124,PUAQLLVFLMYYJJ-UHFFFAOYSA-N,DEALKYLATED DIETHYLPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12954796.0,KI,=,18.5,NM,,,,,,,,,,,,,,,,,,,,7.732828271596986,CC(C(=O)C1=CC=CC=C1)N,CC(N)C(=O)c1ccccc1
4261,4272,CHEMBL1683891,PUCWXLYHLYMUCG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,57.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.244125144327507,CN(C)CC1(CCCCC1)C2=CC(=C(C=C2)F)F,CN(C)CC1(c2ccc(F)c(F)c2)CCCCC1
4262,4273,CHEMBL2380975,PUIPTRFLVUMEKQ-JSGCOSHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,IC50,=,750.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1249387366083,CNC[C@@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CNC[C@@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
4263,4274,CHEMBL2380975,PUIPTRFLVUMEKQ-JSGCOSHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,INHIBITION,=,49.0,%,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes at 1 uM,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,49.0,CNC[C@@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CNC[C@@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
4264,4275,CHEMBL2380972,PUIPTRFLVUMEKQ-OCCSQVGLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,IC50,=,660.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.180456064458133,CNC[C@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CNC[C@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
4265,4276,CHEMBL2380972,PUIPTRFLVUMEKQ-OCCSQVGLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,INHIBITION,=,53.0,%,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes at 1 uM,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,53.0,CNC[C@H]1CCC[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CNC[C@H]1CCC[C@H]1c1ccc2[nH]cc(C#N)c2c1
4266,4277,CHEMBL255449,PUKHAHUSCTVYAW-SWLSCSKDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(C1CC1)C(=O)[C@]2(C[C@H]2CN)C3=CSC=C3,C=CCN(C(=O)[C@@]1(c2ccsc2)C[C@H]1CN)C1CC1
4267,4278,CHEMBL381056,PUKYDIKEMQFSPQ-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,98.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.008773924307505,CC1=CC(=CC=C1)CN(CC(C)C)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,Cc1cccc(CN(CC(C)C)C2CCNCC2)c1
4268,4279,CHEMBL563852,PUMRLCALOZDUIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,C1CNCCC1C(C2=CN=CC=C2)OC3=CC=CC=C3OC(F)(F)F,FC(F)(F)Oc1ccccc1OC(c1cccnc1)C1CCNCC1
4269,4280,CHEMBL559490,PUQYZIQIINNNTQ-RTWAWAEBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,20.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,20.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C4CCCC4)O,CNC[C@@H](O)[C@H](c1ccccc1)n1c(=O)n(C2CCCC2)c2ccccc21
4270,4281,CHEMBL3673174,PUYNZNIAZURARP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,120.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.9193735130781935,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=NN=C(C=C4)C(F)(F)F)C5=CC(=C(C=C5)F)Cl,Fc1ccc(C23CCN(CC2)Cc2cc(-c4ccc(C(F)(F)F)nn4)ccc23)cc1Cl
4271,4282,CHEMBL2206519,PUZGOXIAHPOFIX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,210.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6777807052660805,CCOC1=CC2=C(C=C1)C(CN(C2)C)C3=CC=CC=C3,CCOc1ccc2c(c1)CN(C)CC2c1ccccc1
4272,4283,CHEMBL3310624,PVENMTZFPWNCAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,30.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,30.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3OC(F)(F)F,Fc1cc(C(CC2CNC2)Oc2ccccc2OC(F)(F)F)ccc1Cl
4273,4284,CHEMBL3310624,PVENMTZFPWNCAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,69.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,69.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3OC(F)(F)F,Fc1cc(C(CC2CNC2)Oc2ccccc2OC(F)(F)F)ccc1Cl
4274,4285,CHEMBL3310624,PVENMTZFPWNCAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3OC(F)(F)F,Fc1cc(C(CC2CNC2)Oc2ccccc2OC(F)(F)F)ccc1Cl
4275,4286,CHEMBL475534,PVHUJELLJLJGLN-UHFFFAOYSA-N,NITRENDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1
4276,4287,CHEMBL475534,PVHUJELLJLJGLN-UHFFFAOYSA-N,NITRENDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1
4277,4288,CHEMBL408868,PVISFTMIHRDVDS-QZTJIDSGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1790.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.747146969020108,COC1=C(C=CC(=C1)Cl)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,COc1cc(Cl)ccc1O[C@H](c1ccccc1)[C@H]1CNCCO1
4278,4289,CHEMBL260259,PVISFTMIHRDVDS-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1570.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.804100347590767,COC1=C(C=CC(=C1)Cl)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
4279,4290,CHEMBL261076,PVISFTMIHRDVDS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,2200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.657577319177793,COC1=C(C=CC(=C1)Cl)OC(C2CNCCO2)C3=CC=CC=C3,COc1cc(Cl)ccc1OC(c1ccccc1)C1CNCCO1
4280,4291,CHEMBL261076,PVISFTMIHRDVDS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,5050.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.296708621881338,COC1=C(C=CC(=C1)Cl)OC(C2CNCCO2)C3=CC=CC=C3,COc1cc(Cl)ccc1OC(c1ccccc1)C1CNCCO1
4281,4292,CHEMBL325826,PVLOMLBAVRLZPH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,22.39,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.64994590642097,C1CC2CC(CC1N2CCOCC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,Fc1ccc(C(OC2CC3CCC(C2)N3CCOCc2ccccc2)c2ccc(F)cc2)cc1
4282,4293,CHEMBL3331473,PVNIHODJFUFJAX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1C(CN1)N(CCC2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(N(CCc2ccccc2)C2CNC2)cc1Cl
4283,4294,CHEMBL573,PVNIIMVLHYAWGP-UHFFFAOYSA-N,NIACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)O,O=C(O)c1cccnc1
4284,4295,CHEMBL573,PVNIIMVLHYAWGP-UHFFFAOYSA-N,NIACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)O,O=C(O)c1cccnc1
4285,4296,CHEMBL3673131,PVPLKGUBRLAGAF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,74.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.129596094720973,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=NN=C(C=C5)C(F)(F)F,FC(F)(F)c1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)C2)nn1
4286,4297,CHEMBL2392692,PVTFEAGMCGMRRS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23664879.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 1 uM relative to control,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC1=NC(=NC(=N1)N2CCC(CC2)C(=O)NCC3=C(C=C(C=C3)Br)OC(F)(F)F)NC,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccc(Br)cc3OC(F)(F)F)CC2)n1
4287,4298,CHEMBL1224303,PVTZQLSVJXEDHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,78.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.107905397309519,CN(C)CCC(C1=CC(=C(C=C1)Cl)Cl)N2N=CN=N2,CN(C)CCC(c1ccc(Cl)c(Cl)c1)n1ncnn1
4288,4299,CHEMBL1224303,PVTZQLSVJXEDHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,58.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,58.0,CN(C)CCC(C1=CC(=C(C=C1)Cl)Cl)N2N=CN=N2,CN(C)CCC(c1ccc(Cl)c(Cl)c1)n1ncnn1
4289,4300,CHEMBL238867,PWAQSKSFOYUNMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,=,340.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.468521082957745,CN(C)CC1=C(C=CC(=C1)OCCF)SC2=CC=CC=C2N,CN(C)Cc1cc(OCCF)ccc1Sc1ccccc1N
4290,4301,CHEMBL562691,PWCRFPCCCWITCB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,644.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.191114132640188,CC1=CC(=NC=C1)C(C2CCNCC2)OC3=C(C(=CC=C3)Cl)Cl,Cc1ccnc(C(Oc2cccc(Cl)c2Cl)C2CCNCC2)c1
4291,4302,CHEMBL3577955,PWDBREUBRYUEGC-BTJKTKAUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25893048.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to human DAT at 1 uM,,ACS Med. Chem. Lett.,PUBLICATION,,,CC(C)N1CCN(CC1)C(=O)C2=CC=C(C=C2)CN3CCOCC3.C(=C\C(=O)O)\C(=O)O,CC(C)N1CCN(C(=O)c2ccc(CN3CCOCC3)cc2)CC1
4292,4303,CHEMBL1173533,PWRNDGOMCQHVRL-HUUCEWRRSA-N,"6-(3,4-DICHLOROPHENYL)-1-[(ETHYLOXY)METHYL]-3-AZABICYCLO[4.1.0]-HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,3.98,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.400116927926312,CCOC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4293,4304,CHEMBL1173533,PWRNDGOMCQHVRL-HUUCEWRRSA-N,"6-(3,4-DICHLOROPHENYL)-1-[(ETHYLOXY)METHYL]-3-AZABICYCLO[4.1.0]-HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,6.31,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.199970640755867,CCOC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4294,4305,CHEMBL1173533,PWRNDGOMCQHVRL-HUUCEWRRSA-N,"6-(3,4-DICHLOROPHENYL)-1-[(ETHYLOXY)METHYL]-3-AZABICYCLO[4.1.0]-HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.199970640755867,CCOC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4295,4306,CHEMBL498367,PWVMDDIYWPUTLR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18793858.0,KI,>,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]GBR-12935 from human cloned DAT expressed in HEK293 cells,"Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-],Cc1ccc(Sc2ccccc2CN(C)C)c(NC(=O)c2ccc([N+](=O)[O-])cc2)c1
4296,4307,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
4297,4308,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
4298,4309,CHEMBL206649,PXASTWDWEDJFAW-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,360.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.443697499232713,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)O)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(O)cc21
4299,4310,CHEMBL2030636,PXBKRGXXBYALIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,KI,=,2309.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.636576067082824,C1CCN(C1)CCC2=CC(=CC=C2)F,Fc1cccc(CCN2CCCC2)c1
4300,4311,CHEMBL249807,PXCLIXMWUZNIDA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,58000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.236572006437063,C1CCN(C1)C(=O)C2=C(CCC2)C3=CC(=C(C=C3)Cl)Cl,O=C(C1=C(c2ccc(Cl)c(Cl)c2)CCC1)N1CCCC1
4301,4312,CHEMBL523574,PXFCLZUOFIJVNC-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,7500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1249387366083,CC1=CC=CC=C1O[C@@H]2[C@H](CSC3=CC=CC=C23)CNC,CNC[C@H]1CSc2ccccc2[C@@H]1Oc1ccccc1C
4302,4313,CHEMBL450435,PXHGECKMKPJNDM-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2920.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5346171485515825,CC(C)C(=O)N(CC1=CC=CC=C1C2CC2)[C@H]3CCNC3,CC(C)C(=O)N(Cc1ccccc1C1CC1)[C@H]1CCNC1
4303,4314,CHEMBL469475,PXVMYRXIGXGAFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)CC(C2=CC(=CC=C2)C(F)(F)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(CC(c2cccc(C(F)(F)F)c2)C2(O)CCCCC2)CC1
4304,4315,CHEMBL2407330,PXYULNPULNZYHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,1700.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,5.769551078621726,COCC(C1CCNCC1)C2=CC=C(C=C2)Cl.Cl,COCC(c1ccc(Cl)cc1)C1CCNCC1
4305,4316,CHEMBL513360,PXZVEYWSVBEKRN-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC(C1)C(=O)N(CC2=C(C=C(C=C2)Cl)Cl)[C@H]3CCNC3,O=C(C1CCC1)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
4306,4317,CHEMBL506397,PYEILVKGQDUINV-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@@H]1COC2=CC3=C(C=C2)C=C(C=C3)C#N,N#Cc1ccc2cc(OC[C@@H]3CCNC3)ccc2c1
4307,4318,CHEMBL469551,PYEILVKGQDUINV-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@H]1COC2=CC3=C(C=C2)C=C(C=C3)C#N,N#Cc1ccc2cc(OC[C@H]3CCNC3)ccc2c1
4308,4319,CHEMBL102144,PYFSWHDVAVZUTG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,9.0,COC(=O)C1=CC=CC=C1C2=CC=C(C=C2)C3=CC=C(C=C3)Br,COC(=O)c1ccccc1-c1ccc(-c2ccc(Br)cc2)cc1
4309,4320,CHEMBL597000,PYIBCEOJEPANCH-MKBNYLNASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,IC50,=,19.95,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in LLCPK cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.700057099977232,CC1=CSC(=N1)C[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc(C[C@H]2[C@@H]3CNC[C@@]32c2ccc(Cl)c(Cl)c2)n1
4310,4321,CHEMBL597000,PYIBCEOJEPANCH-MKBNYLNASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,19.95,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.700057099977232,CC1=CSC(=N1)C[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc(C[C@H]2[C@@H]3CNC[C@@]32c2ccc(Cl)c(Cl)c2)n1
4311,4322,CHEMBL603480,PYIBCEOJEPANCH-XHBSWPGZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,50.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.299988937677887,CC1=CSC(=N1)C[C@@H]2[C@@H]3[C@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1csc(C[C@@H]2[C@H]3CNC[C@]32c2ccc(Cl)c(Cl)c2)n1
4312,4323,CHEMBL599376,PYPVCBLWSWFYNN-MOSHPQCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20020710.0,ACTIVITY,=,0.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by displacement assay,Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.,J. Med. Chem.,PUBLICATION,,0.0,CC(C)(C)CC(=O)N/N=C\1/N(C2=C(S1)C=C(C=C2)OC(F)(F)F)C,Cn1/c(=N/NC(=O)CC(C)(C)C)sc2cc(OC(F)(F)F)ccc21
4313,4324,CHEMBL196258,PYUBHJHQYILWFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16250647.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Percent inhibition against Dopamine transporter at 1 uM,"2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.",J. Med. Chem.,PUBLICATION,,10.0,CCCCCC1=NC(=C2C(=N1)N(C(=N2)N3N=CC=N3)C)N,CCCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1
4314,4325,CHEMBL741,PYZRQGJRPPTADH-UHFFFAOYSA-N,LAMOTRIGINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
4315,4326,CHEMBL741,PYZRQGJRPPTADH-UHFFFAOYSA-N,LAMOTRIGINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
4316,4327,CHEMBL436132,PZHJZKURLFYNOX-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,98.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.008773924307505,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=CC=C5)Br)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4cccc(Br)c4)s2)N3C)cc1
4317,4328,CHEMBL436132,PZHJZKURLFYNOX-GNXKAVGDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,12.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.920818753952375,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=CC=C5)Br)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4cccc(Br)c4)s2)N3C)cc1
4318,4329,CHEMBL189,PZRHRDRVRGEVNW-UHFFFAOYSA-N,MILRINONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1
4319,4330,CHEMBL189,PZRHRDRVRGEVNW-UHFFFAOYSA-N,MILRINONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1
4320,4331,CHEMBL180672,PZUJQWHTIRWCID-HXUWFJFHSA-N,SB-262470,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821575.0,IC50,=,0.2,NM,,,,,,,,,,,,,,,Inhibition of DAT,Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,9.69897000433602,CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=C(C(=CC=C3)Cl)C#N)O,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N
4321,4332,CHEMBL272285,PZVMCTLCQFNWSD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CCCN(CC1)C(=O)C2(CC2CN)C3=CC=CC=C3,NCC1CC1(C(=O)N1CCCCCC1)c1ccccc1
4322,4333,CHEMBL3331489,QABBWHVPVTUKOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,12.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,12.0,C1C(CN1)CN(CC2=CC=C(C=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(CN(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
4323,4334,CHEMBL2171211,QADQXQPJDYRHHG-UHFFFAOYSA-N,3-(ETHOXY(PHENYL)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,3.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,3.0,CCOC(C1CNC1)C2=CC=CC=C2.Cl,CCOC(c1ccccc1)C1CNC1
4324,4335,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,15525.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.808968391151383,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
4325,4336,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,12335.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.908860846174245,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
4326,4337,CHEMBL1224467,QANXQNKYGWZPJQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CC1=NN(N=N1)C(CCNC)C2=CC3=C(C=C2)C=C(C=C3)OC,CNCCC(c1ccc2cc(OC)ccc2c1)n1nnc(C)n1
4327,4338,CHEMBL1173355,QAPDCFXYLMIQOK-IINYFYTJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,4.0,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=C(C=C2)OC)O,COc1ccc([C@]2(O)OCC(C)(C)N[C@H]2C)cc1
4328,4339,CHEMBL16068,QARVLSVVCXYDNA-UHFFFAOYSA-N,BROMOBENZENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)Br,Brc1ccccc1
4329,4340,CHEMBL16068,QARVLSVVCXYDNA-UHFFFAOYSA-N,BROMOBENZENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)Br,Brc1ccccc1
4330,4341,CHEMBL235408,QAWMAJZYTBWZOZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,54954087385762.5,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.74,COC(=O)C1=C(C2CCC1O2)C3=CC=C(C=C3)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)C2CCC1O2
4331,4342,CHEMBL2385886,QBCRLDPMQHPGIM-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23718281.0,INHIBITION,=,71.0,%,,,,,,,,,,,,,,,Binding affinity to human DAT at 10 uM by radioligand displacement assay relative to control,"Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu3 Selective and CNS Penetrant Negative Allosteric Modulator (NAM).",J. Med. Chem.,PUBLICATION,,71.0,COC1=CC=C(C=C1)C#CC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C3)O)F,COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](O)C3)c(F)c2)cc1
4332,4343,CHEMBL469812,QBEXADKSFJNYHO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(C1CCNCC1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2,CCN(C1CCNCC1)S(=O)(=O)c1ccc2ccccc2c1
4333,4344,CHEMBL381046,QBMUMECEHYHKPP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,9240.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0343280287798935,CN1C2CCC1C=C(C2)C3=CC=CC=C3C4=CC=CC=C4,CN1C2C=C(c3ccccc3-c3ccccc3)CC1CC2
4334,4345,CHEMBL492842,QBOITYXCKDGUNE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,11000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.9586073148417755,CN(C)CC1=CC=CC=C1CC2=CC=C(C=C2)SC,CSc1ccc(Cc2ccccc2CN(C)C)cc1
4335,4346,CHEMBL120901,QBYGRJQJEUUFHI-CDFKWJNJSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,350.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.455931955649724,CN1C2CCC1[C@H]([C@H](C2)C(=O)OC3=CC=CC=C3)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1C(=O)Oc1ccccc1)N2C
4336,4347,CHEMBL120901,QBYGRJQJEUUFHI-CDFKWJNJSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,490.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,CN1C2CCC1[C@H]([C@H](C2)C(=O)OC3=CC=CC=C3)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1C(=O)Oc1ccccc1)N2C
4337,4348,CHEMBL1779059,QCBXRMVDVAHCPR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O)OCCC8=CC=CC=C8,COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OCCc1ccccc1
4338,4349,CHEMBL515472,QCFZUTYIUYQTPW-JOCHJYFZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329329.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned DAT by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=CC=C1OCCF)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O,COc1c(OCCF)cccc1[C@H](O)C1CCN(CCc2ccc(F)cc2)CC1
4339,4350,CHEMBL402143,QCFZUTYIUYQTPW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329329.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned DAT by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=CC=C1OCCF)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O,COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(F)cc2)CC1
4340,4351,CHEMBL574427,QCGAHDLRCVBZHH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,C1CNCCC1C2=CC(=C(C=C2OC3=CC=C(C=C3)F)F)F,Fc1ccc(Oc2cc(F)c(F)cc2C2CCNCC2)cc1
4341,4352,CHEMBL430840,QDDIKUPXWGQLSU-SIUPQYRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,3320.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.478861916295964,C1CC2C3[C@H](C[C@@H]1N2CC3=O)C4=CC=C(C=C4)F,O=C1CN2C3CC[C@@H]2C[C@H](c2ccc(F)cc2)C13
4342,4353,CHEMBL249329,QDLBXJOPGVUQLI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,=,12000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,CN(C)CC1CC1C2=CC=CC3=C(C=CC=C32)C#N,CN(C)CC1CC1c1cccc2c(C#N)cccc12
4343,4354,CHEMBL249329,QDLBXJOPGVUQLI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,9.5,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.5,CN(C)CC1CC1C2=CC=CC3=C(C=CC=C32)C#N,CN(C)CC1CC1c1cccc2c(C#N)cccc12
4344,4355,CHEMBL101250,QDNMERQLRWGGDY-AXRJEEMOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,390.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC4C2[C@](CN34)(C)O,Cc1ccc([C@H]2C[C@H]3CCC4C2[C@](C)(O)CN43)cc1
4345,4356,CHEMBL315172,QDTQQCFRNAKULP-NNGLDNROSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,7.7,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.113509274827518,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC4=CC=CC=C4C=C3)O,COC(=O)C1C(c2ccc3ccccc3c2)CC2[C@@H](O)CC1N2C
4346,4357,CHEMBL315172,QDTQQCFRNAKULP-NNGLDNROSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,32.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.494850021680094,CN1C2C[C@@H](C1CC(C2C(=O)OC)C3=CC4=CC=CC=C4C=C3)O,COC(=O)C1C(c2ccc3ccccc3c2)CC2[C@@H](O)CC1N2C
4347,4358,CHEMBL3310492,QDXMLWBTDCCUTJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,12.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC=CC=C3OC(F)(F)F,Fc1ccc(C(CC2CNC2)Oc2ccccc2OC(F)(F)F)cc1F
4348,4359,CHEMBL391864,QDZIBQWKRRRXAL-OSRDXIQISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446069.0,KI,=,6.42,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,"Synthesis and biological evaluation of 2beta,3alpha-(substituted phenyl)nortropanes as potential norepinephrine transporter imaging agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.192464971931146,CC1=C(C=C(C=C1)[C@@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC)N3)F,COC(=O)[C@@H]1[C@H]2CC[C@H](C[C@H]1c1ccc(C)c(F)c1)N2
4349,4360,CHEMBL1812750,QDZIBQWKRRRXAL-VIRABCJISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,6.4,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.193820026016112,CC1=C(C=C(C=C1)[C@@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3)F,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@H]1c1ccc(C)c(F)c1)N2
4350,4361,CHEMBL379107,QEEDIXLXNLXRBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784853.0,IC50,=,5.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at dopamine transporter,High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,C1CN(CCN1CCCC2=CC=C(C=C2)NC(=O)CCCCCCCCCCNC(=O)CCCCC3C4C(CS3)NC(=O)N4)CCOC(C5=CC=C(C=C5)F)C6=CC=C(C=C6)F,O=C(CCCCC1SCC2NC(=O)NC21)NCCCCCCCCCCC(=O)Nc1ccc(CCCN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
4351,4362,CHEMBL507723,QEHHRDFKZARORR-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2610.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.583359492661719,CCCC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CCCC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
4352,4363,CHEMBL377552,QEKVURATSAPTGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,1.3,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.3,CC(C)(CCN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2)O.C(C(C(=O)O)O)(C(=O)O)O,CC(C)(O)CCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
4353,4364,CHEMBL290916,QELUYTUMUWHWMC-UHFFFAOYSA-N,EDARAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN(C(=O)C1)C2=CC=CC=C2,CC1=NN(c2ccccc2)C(=O)C1
4354,4365,CHEMBL290916,QELUYTUMUWHWMC-UHFFFAOYSA-N,EDARAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN(C(=O)C1)C2=CC=CC=C2,CC1=NN(c2ccccc2)C(=O)C1
4355,4366,CHEMBL393625,QEMMIBZQGYYMNU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,=,299.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.52432881167557,CN(C)CC1=C(C=CC(=C1)OCCCF)SC2=CC=CC=C2N,CN(C)Cc1cc(OCCCF)ccc1Sc1ccccc1N
4356,4367,CHEMBL3673163,QEQQILAAIUZZEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,5.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.292429823902062,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=NNC(=O)C=C4)C5=CC(=C(C=C5)Cl)Cl,O=c1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)c(Cl)c3)CC2)n[nH]1
4357,4368,CHEMBL772,QEVHRUUCFGRFIF-MDEJGZGSSA-N,RESERPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
4358,4369,CHEMBL772,QEVHRUUCFGRFIF-MDEJGZGSSA-N,RESERPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
4359,4370,CHEMBL772,QEVHRUUCFGRFIF-MDEJGZGSSA-N,RESERPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
4360,4371,CHEMBL1945783,QFEVQBUJEXGMJH-NLEAXPPASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,34.67,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.460046158343602,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)OCC4=CC=CC=C4,CN1[C@H]2CC[C@@H]1[C@@H](C(=O)OCc1ccccc1)[C@@H](c1ccc(Cl)c(Cl)c1)C2
4361,4372,CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
4362,4373,CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
4363,4374,CHEMBL2205834,QFMGHZDEZHDVJJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=NC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccncc1
4364,4375,CHEMBL2436555,QFNMPNWOYBWECY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24035337.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant sodium-dependent dopamine transporter expressed in HEK cells after 90 mins by scintillation counting analysis,"2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2=C(C=CC(=C2)Cl)NC(=N1)N.Cl,NC1=NCc2cc(Cl)ccc2N1
4365,4376,CHEMBL2338034,QFQJPPPPEDIVLD-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,31.62,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)Cl)F,Fc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@H]1CCNC1
4366,4377,CHEMBL396082,QGGSNXQBFWAFCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,4100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.3872161432802645,COC(=O)C1=C(CCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCC1
4367,4378,CHEMBL396082,QGGSNXQBFWAFCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,7000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.154901959985743,COC(=O)C1=C(CCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCC1
4368,4379,CHEMBL396082,QGGSNXQBFWAFCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,239883291901949.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-5.38,COC(=O)C1=C(CCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCC1
4369,4380,CHEMBL1812748,QGJBJCQWBZDANK-WGWURMLHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,15.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,7.823908740944319,CC1=C(C=CC(=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=CC(=NO4)C5=CC=CC=C5)N3C)Cl,Cc1cc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2cc(-c4ccccc4)no2)N3C)ccc1Cl
4370,4381,CHEMBL136249,QGSJJLSDNPKNBC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,5.3,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.275724130399214,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC#CC4=CC=CC=C4,Fc1ccc(C(OCCC2CCN(CC#Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
4371,4382,CHEMBL87285,QGXBDMJGAMFCBF-HLUDHZFRSA-N,ANDROSTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@@]43C)[C@@H]1CCC2=O
4372,4383,CHEMBL87285,QGXBDMJGAMFCBF-HLUDHZFRSA-N,ANDROSTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@@]43C)[C@@H]1CCC2=O
4373,4384,CHEMBL575290,QHHWSRAVBLCPAI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,EC50,=,1880.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.72584215073632,C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)Cl,Clc1cccc(Oc2ccccc2C2CCNCC2)c1
4374,4385,CHEMBL575290,QHHWSRAVBLCPAI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,310.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.508638306165728,C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)Cl,Clc1cccc(Oc2ccccc2C2CCNCC2)c1
4375,4386,CHEMBL445800,QHIKEMVZWMXQMI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,22.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,22.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CC=C(C=C3)F)O.Cl.Cl,OC1(C(CN2CCNCC2)c2ccc(F)cc2)CCCCC1
4376,4387,CHEMBL3321792,QHLAPIQLWATZKM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,=,354.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.450996737974213,C1CC2CC(CC1N2CCCSC3=CC=CC=C3F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccccc1F
4377,4388,CHEMBL1645601,QHOAGSGZOCDBGO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6460.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.189767482004916,CC1=C(C(=CC=C1)F)OC2=C(C(=CC=C2)F)OC3CNC3,Cc1cccc(F)c1Oc1cccc(F)c1OC1CNC1
4378,4389,CHEMBL2432057,QHQJBDOHEUWLBB-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CC1=CN=CC=C1)[C@H]2C3C4CC5C2C6C3CC4C56,CN(Cc1cccnc1)[C@H]1C2C3CC4C5C3CC2C5C41
4379,4390,CHEMBL3334796,QHRPNPFRUGWUJT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,986.1,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.0060790411987135,CN(C)CCC(C1=CSC2=CC=CC=C21)N3CCCC3,CN(C)CCC(c1csc2ccccc12)N1CCCC1
4380,4391,CHEMBL562444,QHSQRSCEVZFFIU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,7830.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.106238237942057,CCC1=CC=C(C=C1)OC(C2CCNCC2)C3=CN=CC=C3,CCc1ccc(OC(c2cccnc2)C2CCNCC2)cc1
4381,4392,CHEMBL523652,QHSXELZOXIQJEU-UHFFFAOYSA-N,KF-A4,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,5.0,CCN(CC)CCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31,CCN(CC)CCCCn1c2ccccc2c(=O)c2ccccc21
4382,4393,CHEMBL43629,QICHBHLWZOHDPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.61,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.61,C1CN(CCN1CCCC2=CC=CC=C2)CCCC(=O)N(CC3=CC=CC=C3)C4=CC=CC=N4,O=C(CCCN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccn1
4383,4394,CHEMBL43629,QICHBHLWZOHDPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.25,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.25,C1CN(CCN1CCCC2=CC=CC=C2)CCCC(=O)N(CC3=CC=CC=C3)C4=CC=CC=N4,O=C(CCCN1CCN(CCCc2ccccc2)CC1)N(Cc1ccccc1)c1ccccn1
4384,4395,CHEMBL257808,QIEUXXFCMLEYMI-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CSC3=CC=CC=C32,CCN(CC)C(=O)[C@@]1(c2csc3ccccc23)C[C@H]1CN
4385,4396,CHEMBL334491,QIHLUZAFSSMXHQ-UHFFFAOYSA-N,BUDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1
4386,4397,CHEMBL3334775,QIIDHPUHHXZNJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,54.4,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,54.4,C1COCCN1CCC(C2=CC(=C(C=C2)Cl)Cl)N3CCOCC3,Clc1ccc(C(CCN2CCOCC2)N2CCOCC2)cc1Cl
4387,4398,CHEMBL40169,QILYLJIMDLIORW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,146.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,6.835647144215562,COC(=O)C(C1CCCCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCCCC1
4388,4399,CHEMBL1681810,QIYANFXIRPCCFR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,268.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.571865205971212,CN(C)CC1(CCCCC1)C2=CC=C(C=C2)C(F)(F)F,CN(C)CC1(c2ccc(C(F)(F)F)cc2)CCCCC1
4389,4400,CHEMBL2164350,QJFWBEXGRNKZIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22738628.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by radioligand binding assay,Moderate chemical modifications of WAY-100635 improve the selectivity for 5-HT1A versus D4 receptors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCC(CC1)C(=O)N(CCN2CCN(CC2)C3=CC=CC=C3)C4=CC=CC=N4,O=C(C1CCCCC1)N(CCN1CCN(c2ccccc2)CC1)c1ccccn1
4390,4401,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
4391,4402,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
4392,4403,CHEMBL213632,QJMPSMDQYHMYSR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CS(=O)(=O)C1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CS(=O)(=O)c1ccccc1CC(c1ccccc1)N1CCNCC1
4393,4404,CHEMBL573531,QJRQNVRAJVCSDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,9120.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.040005161671584,C1CNCCC1C2=CC=CC=C2OCC3=CC=C(C=C3)F,Fc1ccc(COc2ccccc2C2CCNCC2)cc1
4394,4405,CHEMBL124278,QJWIKJQDFYXPFY-WVEVRRLPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,72.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.142667503568733,CN1C2CCC1C([C@H](C2)OC(C3=CC=C(C=C3)Br)C4=CC=C(C=C4)Br)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(Br)cc1)c1ccc(Br)cc1)N2C
4395,4406,CHEMBL277100,QKDHBVNJCZBTMR-UHFFFAOYSA-N,TEMAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F,CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1
4396,4407,CHEMBL277100,QKDHBVNJCZBTMR-UHFFFAOYSA-N,TEMAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F,CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1
4397,4408,CHEMBL454675,QKJSLGBMXQASRH-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@]1(CC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3OC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccccc1OC
4398,4409,CHEMBL2031877,QKNQLRSRULGFBA-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313242.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,C[C@H]1CCCN1C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5,C[C@H]1CCCN1C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
4399,4410,CHEMBL2031876,QKNQLRSRULGFBA-HXUWFJFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313242.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5,C[C@@H]1CCCN1C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
4400,4411,CHEMBL2338053,QLILSXLCYHMHMR-BDJLRTHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=C(C(=CC(=C3F)F)F)F,Fc1cc(F)c(F)c(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1F
4401,4412,CHEMBL2338052,QLILSXLCYHMHMR-ZBEGNZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C(=CC(=C3F)F)F)F,Fc1cc(F)c(F)c(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1F
4402,4413,CHEMBL239302,QLIVPGJLVJVMJT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=C(C=CC(=C1)OCCCF)SC2=C(C=C(C=C2)Br)N,CN(C)Cc1cc(OCCCF)ccc1Sc1ccc(Br)cc1N
4403,4414,CHEMBL379333,QLJHRHJFUIHEAT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,160.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.795880017344076,CN1C2CCC1C3COC(=O)CCC(=O)CCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCC(=O)CCC(=O)Nc3ccc(cc3)C1C2
4404,4415,CHEMBL575546,QLJOCRJOIIVENA-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,15.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,15.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=C(C=C3)F)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2ccc(F)cc21
4405,4416,CHEMBL9419,QLNWXBAGRTUKKI-UHFFFAOYSA-N,METACETAMOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC(=CC=C1)O,CC(=O)Nc1cccc(O)c1
4406,4417,CHEMBL9419,QLNWXBAGRTUKKI-UHFFFAOYSA-N,METACETAMOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC(=CC=C1)O,CC(=O)Nc1cccc(O)c1
4407,4418,CHEMBL385359,QLPRIWAESOJKJS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,70.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,7.154901959985742,CN1C2CCC1C3COC(=O)CCCCCCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCCCCCC(=O)Nc3ccc(cc3)C1C2
4408,4419,CHEMBL3323181,QLQQUDCJVQOCBW-OAQYLSRUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,3.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,8.508638306165727,CN1C[C@@H](C2=C(C1)C=C(C=C2)N3CCOCC3)C4=CC5=C(C=C4)SC=C5,CN1Cc2cc(N3CCOCC3)ccc2[C@@H](c2ccc3sccc3c2)C1
4409,4420,CHEMBL3323182,QLQQUDCJVQOCBW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,140.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.853871964321763,CN1CC(C2=C(C1)C=C(C=C2)N3CCOCC3)C4=CC5=C(C=C4)SC=C5,CN1Cc2cc(N3CCOCC3)ccc2C(c2ccc3sccc3c2)C1
4410,4421,CHEMBL3323182,QLQQUDCJVQOCBW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,53.4,NM,314451,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.272458742971443,CN1CC(C2=C(C1)C=C(C=C2)N3CCOCC3)C4=CC5=C(C=C4)SC=C5,CN1Cc2cc(N3CCOCC3)ccc2C(c2ccc3sccc3c2)C1
4411,4422,CHEMBL2321994,QLSUBNPMUSWHLS-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,C1C[C@@](CNC1)(CCO)C2=CC3=CC=CC=C3O2,OCC[C@@]1(c2cc3ccccc3o2)CCCNC1
4412,4423,CHEMBL2321993,QLSUBNPMUSWHLS-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.221848749616356,C1C[C@](CNC1)(CCO)C2=CC3=CC=CC=C3O2,OCC[C@]1(c2cc3ccccc3o2)CCCNC1
4413,4424,CHEMBL511163,QLXIMJBRAWACSR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCC2=CC=CC3=CC=CC=C32)CN,NCC1CCC(CCc2cccc3ccccc23)O1
4414,4425,CHEMBL511163,QLXIMJBRAWACSR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CC(OC1CCC2=CC=CC3=CC=CC=C32)CN,NCC1CCC(CCc2cccc3ccccc23)O1
4415,4426,CHEMBL110691,QMBJSIBWORFWQT-DFXBJWIESA-N,CHLORMADINONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
4416,4427,CHEMBL110691,QMBJSIBWORFWQT-DFXBJWIESA-N,CHLORMADINONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
4417,4428,CHEMBL227934,QMGVPVSNSZLJIA-FVWCLLPLSA-N,STRYCHNINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75,O=C1C[C@@H]2OCC=C3CN4CC[C@]56c7ccccc7N1[C@H]5[C@H]2[C@H]3C[C@H]46
4418,4429,CHEMBL227934,QMGVPVSNSZLJIA-FVWCLLPLSA-N,STRYCHNINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75,O=C1C[C@@H]2OCC=C3CN4CC[C@]56c7ccccc7N1[C@H]5[C@H]2[C@H]3C[C@H]46
4419,4430,CHEMBL157548,QMLVECGLEOSESV-RYUDHWBXSA-N,DANOFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F,CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1
4420,4431,CHEMBL157548,QMLVECGLEOSESV-RYUDHWBXSA-N,DANOFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F,CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1
4421,4432,CHEMBL264174,QMMAMXVYCMLPGH-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=CC=C1[C@@H]([C@@H]2CNCCO2)OC3=C(C=C(C=C3)Cl)OC,COc1cc(Cl)ccc1O[C@@H](c1ccccc1C)[C@@H]1CNCCO1
4422,4433,CHEMBL111928,QMNLHOYOYRYELH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,229.09,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.639993867770902,C1CC2CC(CC1N2CCCOC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,Fc1ccc(C(OC2CC3CCC(C2)N3CCCOc2ccccc2)c2ccc(F)cc2)cc1
4423,4434,CHEMBL3663914,QMOZFCXYKWWVFV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,35.4,NM,314447,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.450996737974213,CN1CC(C2=C(C1)C=C(C=C2)CN3CCOCC3)C4=CC5=CC=CC=C5S4,CN1Cc2cc(CN3CCOCC3)ccc2C(c2cc3ccccc3s2)C1
4424,4435,CHEMBL403363,QMRGFFVBWTXOKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2880.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5406075122407685,CC1=CC(=C(C=N1)CN(C)C)OC2=CC=CC=C2C(C)C,Cc1cc(Oc2ccccc2C(C)C)c(CN(C)C)cn1
4425,4436,CHEMBL599371,QNOVJSGRCXZVAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6140.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.211831628858833,CC1=CC(=C(C=C1)OC2=C(C=CC=N2)C3CCNCC3)F,Cc1ccc(Oc2ncccc2C2CCNCC2)c(F)c1
4426,4437,CHEMBL408016,QNPLPYOQHFFYGC-HNAYVOBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC1CC1)C(=O)[C@]2(C[C@H]2CN)C3=CC4=C(C=C3)OCCO4,CCN(CC1CC1)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
4427,4438,CHEMBL2144958,QNRODODTMXCRKU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22172704.0,INHIBITION,=,87.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 uM by radioligand displacement assay,Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway.,Bioorg. Med. Chem. Lett.,PUBLICATION,,87.0,C1=CC=C(C=C1)C2=CC=C(C=C2)CNC3=C(N=NC(=N3)C4=CC=CC=N4)C5=CC=CC=C5,c1ccc(-c2ccc(CNc3nc(-c4ccccn4)nnc3-c3ccccc3)cc2)cc1
4428,4439,CHEMBL2171409,QNUHQFJRHPIXTE-UHFFFAOYSA-N,3-(PHENOXY(PHENYL)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,9.3,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,9.3,C1C(CN1)C(C2=CC=CC=C2)OC3=CC=CC=C3.Cl,c1ccc(OC(c2ccccc2)C2CNC2)cc1
4429,4440,CHEMBL2206521,QNWBLRHWGDFQHE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,173.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.761953896871206,CN1CC(C2=C(C1)C=CC(=C2)OC)C3=CC=CC=C3,COc1ccc2c(c1)C(c1ccccc1)CN(C)C2
4430,4441,CHEMBL3321791,QOECKZUXJGSVMP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,=,285.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.54515513999149,C1CC2CC(CC1N2CCCSC3=CC=CC(=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1cccc(F)c1
4431,4442,CHEMBL596175,QOGSMHDQGODXBS-BEJSXWRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,=,1793.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.746419710437817,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCNCC[C@H](C4=CC=CS4)OC5=CC=CC6=CC=CC=C65)OC,COc1ccc(C2=NN(CCCCCNCC[C@@H](Oc3cccc4ccccc34)c3cccs3)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
4432,4443,CHEMBL596175,QOGSMHDQGODXBS-BEJSXWRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,=,857.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,6.0670191780768015,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCNCC[C@H](C4=CC=CS4)OC5=CC=CC6=CC=CC=C65)OC,COc1ccc(C2=NN(CCCCCNCC[C@@H](Oc3cccc4ccccc34)c3cccs3)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
4433,4444,CHEMBL596185,QOGSMHDQGODXBS-HHMOXRITSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,=,6630.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.178486471595226,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCNCC[C@@H](C4=CC=CS4)OC5=CC=CC6=CC=CC=C65)OC,COc1ccc(C2=NN(CCCCCNCC[C@H](Oc3cccc4ccccc34)c3cccs3)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
4434,4445,CHEMBL596185,QOGSMHDQGODXBS-HHMOXRITSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,=,4598.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.33743103306674,COC1=C(C=C(C=C1)C2=NN(C(=O)[C@H]3[C@@H]2CC=CC3)CCCCCNCC[C@@H](C4=CC=CS4)OC5=CC=CC6=CC=CC=C65)OC,COc1ccc(C2=NN(CCCCCNCC[C@H](Oc3cccc4ccccc34)c3cccs3)C(=O)[C@@H]3CC=CC[C@H]23)cc1OC
4435,4446,CHEMBL1644610,QOSPLNXOHCYGSB-BJWYYQGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC(=N3)C4=CC=CC=C4C#N)C#N,N#Cc1cc(OC2C[C@@H]3CC[C@H](C2)N3)nc(-c2ccccc2C#N)c1
4436,4447,CHEMBL2430701,QOTGNPSPQIIZKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,23.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4Cl,O=C1NCC(c2ccccc2Cl)C1c1ccc2ccccc2c1
4437,4448,CHEMBL2430701,QOTGNPSPQIIZKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,40.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,40.8,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4Cl,O=C1NCC(c2ccccc2Cl)C1c1ccc2ccccc2c1
4438,4449,CHEMBL2012078,QOWAEFJRYGURMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,102.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.991399828238082,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CO4,COC(=O)C1=C(c2ccc(-c3ccco3)cc2)CC2CCC1O2
4439,4450,CHEMBL2012078,QOWAEFJRYGURMT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CO4,COC(=O)C1=C(c2ccc(-c3ccco3)cc2)CC2CCC1O2
4440,4451,CHEMBL378377,QPAFLDILQMKTGS-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,4.7,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.7,COC1=CC=CC=C1C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O,COc1ccccc1C[C@@](O)(c1ccccc1)[C@@H]1CNCCO1
4441,4452,CHEMBL438,QPPBRPIAZZHUNT-UHFFFAOYSA-N,SULFAMERAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1
4442,4453,CHEMBL438,QPPBRPIAZZHUNT-UHFFFAOYSA-N,SULFAMERAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1
4443,4454,CHEMBL583332,QPPDVPUFQFPJKK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1080.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.966576244513051,CC1=CC(=C(C=C1)F)OC2=CC=CC=C2C3CCNCC3,Cc1ccc(F)c(Oc2ccccc2C2CCNCC2)c1
4444,4455,CHEMBL483749,QPUXUSUONDVIKY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19338356.0,ACTIVITY,<,50.0,%,Active,,,,,,,,,,,,,,Binding affinity to DAT,Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.,J. Med. Chem.,PUBLICATION,,50.0,C1CCC(CC1)C2=NC3=C(C=CC(=C3)C(=O)NN4CCCCC4)SC5=CC=CC=C52,O=C(NN1CCCCC1)c1ccc2c(c1)N=C(C1CCCCC1)c1ccccc1S2
4445,4456,CHEMBL272986,QPWPMQLSJRESDN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC(C)C)C2=CC=CC=C2,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCC(C)C
4446,4457,CHEMBL3331482,QQERQVYKVSFETA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,21.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,21.0,C1CCC(C1)N(CC2=CC3=CC=CC=C3C=C2)C4CNC4,c1ccc2cc(CN(C3CCCC3)C3CNC3)ccc2c1
4447,4458,CHEMBL264173,QQHREAWMTUYOBO-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.782516055786092,CC1=CC=C(C=C1)[C@@H]([C@@H]2CNCCO2)OC3=C(C=C(C=C3)Cl)OC,COc1cc(Cl)ccc1O[C@@H](c1ccc(C)cc1)[C@@H]1CNCCO1
4448,4459,CHEMBL1683878,QQKNLGCYRCQFQP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,C1CCC(CC1)(CN2CCCCC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C2(CN3CCCCC3)CCCCC2)cc1Cl
4449,4460,CHEMBL2338055,QQMFCCASOIUAMW-KKSFZXQISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=C(C=C3Cl)Cl)C4=CC=CC=N4,Clc1cc(Cl)c(O[C@@H](c2ccccc2)[C@H]2CCNC2)c(-c2ccccn2)c1
4450,4461,CHEMBL515914,QQOBRRFOVWGIMD-OJAKKHQRSA-N,AZARIBINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
4451,4462,CHEMBL515914,QQOBRRFOVWGIMD-OJAKKHQRSA-N,AZARIBINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
4452,4463,CHEMBL2432054,QQUOSDRKLSIRED-DKSPCFMDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CCCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
4453,4464,CHEMBL216015,QRBFMQFAEQGJIW-ZROIWOOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784855.0,KI,=,13.25,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT transfected in HEK293 cells,Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.877784121727173,CC1=CC=C(C=C1)C2CC3CCC4C2/C(=C\C(=O)OC)/CN34,COC(=O)/C=C1/CN2C3CCC2C1C(c1ccc(C)cc1)C3
4454,4465,CHEMBL257390,QRBKUYBUQLQJEH-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COCCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C#CCN(CCOC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
4455,4466,CHEMBL2206511,QREUWDKINMWLMS-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,291.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.536107011014093,CC1=CC2=C(C=C1)[C@@H](CN(C2)C)C3=CC(=CC=C3)F,Cc1ccc2c(c1)CN(C)C[C@H]2c1cccc(F)c1
4456,4467,CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2655.5,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.575853694244843,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
4457,4468,CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2109.8,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.675758712007131,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
4458,4469,CHEMBL514424,QRNLLMHKIXCFGM-IYIFBUTFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,3.3,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,8.481486060122112,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OCCC4=CC(=C(C=C4)N)Br.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OCCc2ccc(N)c(Br)c2)N3C)cc1
4459,4470,CHEMBL14305,QRRDJSMVPRYYBA-KTKRTIGZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,3.1,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,8.508638306165727,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)/C=C\Br)C(=O)OC,COC(=O)C1C(c2ccc(/C=C\Br)cc2)CC2CCC1N2C
4460,4471,CHEMBL1644604,QRRQVHBNSBQIBJ-OPVJXMOQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,9550.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.019996628416254,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC(=C3)C4=CC=CC=C4)C#N,N#Cc1cc(OC2C[C@@H]3CC[C@H](C2)N3)cc(-c2ccccc2)c1
4461,4472,CHEMBL64,QRXWMOHMRWLFEY-UHFFFAOYSA-N,ISONIAZID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C(=O)NN,NNC(=O)c1ccncc1
4462,4473,CHEMBL64,QRXWMOHMRWLFEY-UHFFFAOYSA-N,ISONIAZID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C(=O)NN,NNC(=O)c1ccncc1
4463,4474,CHEMBL413965,QRZAKQDHEVVFRX-UHFFFAOYSA-N,FELBINAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O,O=C(O)Cc1ccc(-c2ccccc2)cc1
4464,4475,CHEMBL413965,QRZAKQDHEVVFRX-UHFFFAOYSA-N,FELBINAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O,O=C(O)Cc1ccc(-c2ccccc2)cc1
4465,4476,CHEMBL256667,QSCRGZVJRUUPPV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CNC(C2=CC=CC=C21)C(=O)C3(CC3CN)C4=CC=CC=C4,NCC1CC1(C(=O)C1NCCc2ccccc21)c1ccccc1
4466,4477,CHEMBL391911,QSIGRHGXIDLKCT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,40738027780411.2,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.6099999999999985,COC(=O)C1=C(C2CCC1N2)C3=CC=C(C=C3)C4=CC=CC=C4,COC(=O)C1=C(c2ccc(-c3ccccc3)cc2)C2CCC1N2
4467,4478,CHEMBL1170795,QSIIURGKHNVJBN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,158.49,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4C(=O)N,NC(=O)c1c[nH]c2ccc(N3CCNCC3Cc3ccccc3)cc12
4468,4479,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,1000.0,NM,,,,,,,,,,,,,,,,,,,,6.0,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
4469,4480,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2910.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.536107011014093,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
4470,4481,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2312.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.636012170251509,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
4471,4482,CHEMBL1813485,QSOVYEIFTQKDEW-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,28.84,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.540004743952608,CN1C[C@H]2CCC[C@]2(C1)C3=CC4=CC=CC=C4C=C3,CN1C[C@H]2CCC[C@@]2(c2ccc3ccccc3c2)C1
4472,4483,CHEMBL1813483,QSOVYEIFTQKDEW-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,100.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.0,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC4=CC=CC=C4C=C3,CN1C[C@@H]2CCC[C@]2(c2ccc3ccccc3c2)C1
4473,4484,CHEMBL1813483,QSOVYEIFTQKDEW-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,181.97,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.740000204918113,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC4=CC=CC=C4C=C3,CN1C[C@@H]2CCC[C@]2(c2ccc3ccccc3c2)C1
4474,4485,CHEMBL30713,QSQQQURBVYWZKJ-UHFFFAOYSA-N,ALPHA-METHYLTRYPTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,1862.09,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7299993321845495,CC(CC1=CNC2=CC=CC=C21)N,CC(N)Cc1c[nH]c2ccccc12
4475,4486,CHEMBL30713,QSQQQURBVYWZKJ-UHFFFAOYSA-N,ALPHA-METHYLTRYPTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,666.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1765257708296994,CC(CC1=CNC2=CC=CC=C21)N,CC(N)Cc1c[nH]c2ccccc12
4476,4487,CHEMBL30713,QSQQQURBVYWZKJ-UHFFFAOYSA-N,ALPHA-METHYLTRYPTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human recombinant dopamine transporter expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(CC1=CNC2=CC=CC=C21)N,CC(N)Cc1c[nH]c2ccccc12
4477,4488,CHEMBL255246,QSSYRFOLGZMPLN-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC2=CC=CC=C2N(C1)C(=O)[C@]3(C[C@H]3CN)C4=CSC=C4,NC[C@@H]1C[C@@]1(C(=O)N1CCCc2ccccc21)c1ccsc1
4478,4489,CHEMBL1200748,QTAOMKOIBXZKND-PPHPATTJSA-N,CARBIDOPA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
4479,4490,CHEMBL1200748,QTAOMKOIBXZKND-PPHPATTJSA-N,CARBIDOPA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
4480,4491,CHEMBL174304,QTGSINBFNYAXSI-HYRLGQOJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15012999.0,INHIBITION,=,15.0,%,,,,,,,,,,,,,,,Inhibitory activity against human dopamine transporter at 10 uM,Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.,Bioorg. Med. Chem. Lett.,PUBLICATION,,15.0,CCN1C(=CC(=N1)CC2=CC=CC=C2)C3CCN(CC3)C[C@H]4CN(C[C@@H]4C5=CC(=CC=C5)F)[C@H](C(C)C)C(=O)O,CCn1nc(Cc2ccccc2)cc1C1CCN(C[C@H]2CN([C@@H](C(=O)O)C(C)C)C[C@@H]2c2cccc(F)c2)CC1
4481,4492,CHEMBL434063,QTQMRBZOBKYXCG-MHZLTWQESA-N,GW1929,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,13551.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.868028654718943,CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1
4482,4493,CHEMBL434063,QTQMRBZOBKYXCG-MHZLTWQESA-N,GW1929,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,10767.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.967905286947098,CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1
4483,4494,CHEMBL498564,QTWYMQIZRRTWFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,4123.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.384786665198642,CN(CCC1=CC=C(C=C1)OC(F)(F)F)CCN2CCCCC2,CN(CCc1ccc(OC(F)(F)F)cc1)CCN1CCCCC1
4484,4495,CHEMBL1173753,QUJMNYWULZSJDX-HZPDHXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,158.49,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.799998134593397,CC#CNC(=O)[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,CC#CNC(=O)[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4485,4496,CHEMBL404027,QUKVPZYBMYBTQO-FUHWJXTLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CC2=CC=CC=C21)C(=O)[C@]3(C[C@H]3CN)C4=CSC=C4,NC[C@@H]1C[C@@]1(C(=O)N1CCc2ccccc2C1)c1ccsc1
4486,4497,CHEMBL2205828,QUMVESOWCHBEEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=CC(=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC,COc1cc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc(OC)c1
4487,4498,CHEMBL511718,QUOVWZCNMCSUEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,17.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.769551078621726,CC(CC1=CC=CC=C1)CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CC(Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4488,4499,CHEMBL2096857,QUSLQENMLDRCTO-HXSCFSKGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,325.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,6.4881166390211265,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@@H]1c1ccc(F)cc1)N2C
4489,4500,CHEMBL222705,QUSLQENMLDRCTO-SHWKFHJASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,21.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.67778070526608,CN1C2CCC1[C@H]([C@@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(F)cc1)N2C
4490,4501,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,12.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,7.889410289700751,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4491,4502,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,7.9586073148417755,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4492,4503,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4493,4504,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,21.0,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.67778070526608,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4494,4505,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9804682.0,IC50,=,2.62,NM,,,,,,,,,,,,,,,The compound was tested in vitro for high binding affinity for the Dopamine transporter (DAT) using competitive binding assay.,TROTEC-1: a new high-affinity ligand for labeling of the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.581698708680255,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4495,4506,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9804682.0,IC50,=,139.0,NM,,,,,,,,,,,,,,,The compound was tested in vitro for low binding affinity for the Dopamine transporter (DAT) using competitive binding assay.,TROTEC-1: a new high-affinity ligand for labeling of the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.856985199745905,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4496,4507,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4497,4508,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,633.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.198596289982644,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4498,4509,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4499,4510,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,17.9,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.747146969020108,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4500,4511,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,13.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.856985199745905,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4501,4512,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,=,10.6,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,7.9746941347352305,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4502,4513,CHEMBL2079586,QUSLQENMLDRCTO-TUVASFSCSA-N,WIN-35428,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,14.7,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.832682665251823,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@H]2CC[C@H]1N2C
4503,4514,CHEMBL1944829,QUSLQENMLDRCTO-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10.0,NM,,,,,,,,,,,,,,,,,,,,8.0,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C
4504,4515,CHEMBL1944829,QUSLQENMLDRCTO-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10.4,NM,,,,,,,,,,,,,,,,,,,,7.982966660701218,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C
4505,4516,CHEMBL1944829,QUSLQENMLDRCTO-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,13.0,NM,,,,,,,,,,,,,,,,,,,,7.886056647693162,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C
4506,4517,CHEMBL1944829,QUSLQENMLDRCTO-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,13.4,NM,,,,,,,,,,,,,,,,,,,,7.872895201635193,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C
4507,4518,CHEMBL1944829,QUSLQENMLDRCTO-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,1900.0,NM,,,,,,,,,,,,,,,,,,,,5.721246399047171,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C
4508,4519,CHEMBL1944829,QUSLQENMLDRCTO-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,35.48,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.450016388840312,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C
4509,4520,CHEMBL3331483,QUVBNJDESLRYDS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,22.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,22.0,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4F,Fc1ccccc1N(Cc1ccc2ccccc2c1)C1CNC1
4510,4521,CHEMBL219281,QUVNADBNAUIISW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.795880017344076,C1CCNC(C1)C(CCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCc2ccccc2)C2CCCCN2)cc1
4511,4522,CHEMBL219281,QUVNADBNAUIISW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,420.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.376750709602098,C1CCNC(C1)C(CCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCc2ccccc2)C2CCCCN2)cc1
4512,4523,CHEMBL219281,QUVNADBNAUIISW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,24.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.619788758288393,C1CCNC(C1)C(CCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCc2ccccc2)C2CCCCN2)cc1
4513,4524,CHEMBL219281,QUVNADBNAUIISW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.154901959985742,C1CCNC(C1)C(CCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CCc2ccccc2)C2CCCCN2)cc1
4514,4525,CHEMBL109776,QUXIGJBRICTBKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,3213.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]WIN-35428 (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,5.493089274448482,C1CN(CCC1CC(=O)NC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,O=C(CC1CCN(Cc2ccc(F)cc2)CC1)NC(c1ccccc1)c1ccccc1
4515,4526,CHEMBL109776,QUXIGJBRICTBKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]DA (radioligand) on Cloned human Dopamine transporter expressed in HEK cells; not determined,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,,C1CN(CCC1CC(=O)NC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,O=C(CC1CCN(Cc2ccc(F)cc2)CC1)NC(c1ccccc1)c1ccccc1
4516,4527,CHEMBL272699,QUZXTJYADOYRDB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,2500.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,CNCC1=C(C=CC(=C1)C(=O)N2CCCN(CC2)C3CC3)OC4=CC(=CC=C4)Cl,CNCc1cc(C(=O)N2CCCN(C3CC3)CC2)ccc1Oc1cccc(Cl)c1
4517,4528,CHEMBL1830878,QVFGNQQNMCPCBY-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,479.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,6.319664486585437,C1CO[C@H](CN1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,O=S1(=O)N(CC[C@H]2CNCCO2)c2ccccc2N1c1ccccc1
4518,4529,CHEMBL1830879,QVFGNQQNMCPCBY-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,599.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,6.2225731776106885,C1CO[C@@H](CN1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,O=S1(=O)N(CC[C@@H]2CNCCO2)c2ccccc2N1c1ccccc1
4519,4530,CHEMBL1830877,QVFGNQQNMCPCBY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,964.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,6.015922966097169,C1COC(CN1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4,O=S1(=O)N(CCC2CNCCO2)c2ccccc2N1c1ccccc1
4520,4531,CHEMBL2046455,QVIAHGYFYZASCH-GAJHUEQPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,77.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,77.0,C[C@@H]([C@H](C1=CSC2=CC=CC=C21)O)N3CCC(=CC3)CC4=CC=CC=C4,C[C@@H]([C@@H](O)c1csc2ccccc12)N1CC=C(Cc2ccccc2)CC1
4521,4532,CHEMBL2047576,QVIAHGYFYZASCH-UZUQRXQVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,75.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,75.0,C[C@H]([C@H](C1=CSC2=CC=CC=C21)O)N3CCC(=CC3)CC4=CC=CC=C4,C[C@H]([C@@H](O)c1csc2ccccc12)N1CC=C(Cc2ccccc2)CC1
4522,4533,CHEMBL1683905,QVLGCILLMAUJBI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,>,10.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CCC(CC1)(CN)C2=CC=CS2,NCC1(c2cccs2)CCCCC1
4523,4534,CHEMBL214004,QVONDVLKKQSPCH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=NC=C2)C3=CC=CC=C3,c1ccc(C(Cc2ccncc2)N2CCNCC2)cc1
4524,4535,CHEMBL1097147,QVVYUPDVPHVIPQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)(C(CN2CCNCC2)C3=CC=C(S3)Cl)O,OC1(C(CN2CCNCC2)c2ccc(Cl)s2)CCCCC1
4525,4536,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Cc1ccccc1C(OCCN(C)C)c1ccccc1
4526,4537,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Cc1ccccc1C(OCCN(C)C)c1ccccc1
4527,4538,CHEMBL77867,QWAAKIRPIKMRGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,1.1,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.958607314841776,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CCCC4=CC=CC=C4,Fc1ccc(C(OCCC2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
4528,4539,CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,35097.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.454730004307044,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
4529,4540,CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,27885.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.554629351172419,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
4530,4541,CHEMBL1109,QWCJHSGMANYXCW-UHFFFAOYSA-N,SULFAPHENAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1
4531,4542,CHEMBL1109,QWCJHSGMANYXCW-UHFFFAOYSA-N,SULFAPHENAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1
4532,4543,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
4533,4544,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
4534,4545,CHEMBL564786,QWDPOYBOJIBHAD-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,6.0,CCCN1C2=CC=CC=C2N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CCCn1c(=O)n([C@@H](c2ccccc2)[C@H](O)CNC)c2ccccc21
4535,4546,CHEMBL110530,QWEUHAMEWHLOTG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,30.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]WIN-35428 (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.522878745280337,C1CN(CCC1CCNC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CCNC(c3ccccc3)c3ccccc3)CC2)cc1
4536,4547,CHEMBL110530,QWEUHAMEWHLOTG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,32.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]DA (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.494850021680094,C1CN(CCC1CCNC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CCNC(c3ccccc3)c3ccccc3)CC2)cc1
4537,4548,CHEMBL110530,QWEUHAMEWHLOTG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,1.33,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,1.33,C1CN(CCC1CCNC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CCNC(c3ccccc3)c3ccccc3)CC2)cc1
4538,4549,CHEMBL1085830,QWFUAOOOLIDWBY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,=,85.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,85.0,CNCC(CN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F)(F)F,CNCC(F)(F)CN1c2ccccc2N(c2ccccc2F)S1(=O)=O
4539,4550,CHEMBL1113,QWGDMFLQWFTERH-UHFFFAOYSA-N,AMOXAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,4310.0,NM,,,,,,,,,,,,,,,,,,,,5.3655227298392685,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
4540,4551,CHEMBL1113,QWGDMFLQWFTERH-UHFFFAOYSA-N,AMOXAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
4541,4552,CHEMBL1113,QWGDMFLQWFTERH-UHFFFAOYSA-N,AMOXAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
4542,4553,CHEMBL1914699,QWGVIOYTQRTWPO-UMQBVGHOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,4.1,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.387216143280265,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)CNC4=NC(=CC=C4)F,CN1C2CCC1[C@@H](CNc1cccc(F)n1)[C@@H](c1ccc(Cl)cc1)C2
4543,4554,CHEMBL3622360,QWHKGOUNYNQXJA-FEHRVWHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25801931.0,INHIBITION,=,37.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 uM relative to control,Pseudosaccharin amines as potent and selective KV1.5 blockers.,Bioorg. Med. Chem. Lett.,PUBLICATION,,37.0,CC(C)OC(=O)NC1CCC(CC1)(CN=C2C3=C(C=CC=C3S(=O)(=O)N2)OC)C4=CC=CC=C4,COc1cccc2c1C(=NCC1(c3ccccc3)CCC(NC(=O)OC(C)C)CC1)NS2(=O)=O
4544,4555,CHEMBL236422,QWJBNDKIQHTZLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,29512092266663.8,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.469999999999999,COC(=O)C1=C(C2CCC1N2)C3=CC(=CC=C3)Cl,COC(=O)C1=C(c2cccc(Cl)c2)C2CCC1N2
4545,4556,CHEMBL1170210,QWWBXRLAEPLMHV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC(=C4C(=C3)C=CN4)Cl,Clc1cc(N2CCNCC2Cc2ccccc2)cc2cc[nH]c12
4546,4557,CHEMBL40967,QWXFIIPWQOCDPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.85,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.85,CN(CCC1=CC=CC=C1)CCN2CCN(CC2)CCCC3=CC=CC=C3,CN(CCc1ccccc1)CCN1CCN(CCCc2ccccc2)CC1
4547,4558,CHEMBL40967,QWXFIIPWQOCDPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.26,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.26,CN(CCC1=CC=CC=C1)CCN2CCN(CC2)CCCC3=CC=CC=C3,CN(CCc1ccccc1)CCN1CCN(CCCc2ccccc2)CC1
4548,4559,CHEMBL1365675,QXAITBQSYVNQDR-ZIOPAAQOSA-N,AMITRAZ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Cc1ccc(N=CN(C)C=Nc2ccc(C)cc2C)c(C)c1
4549,4560,CHEMBL1365675,QXAITBQSYVNQDR-ZIOPAAQOSA-N,AMITRAZ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Cc1ccc(N=CN(C)C=Nc2ccc(C)cc2C)c(C)c1
4550,4561,CHEMBL202479,QXBWECFEEZMKTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,32.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.494850021680094,CCCC(C(=O)C1=CC=C(C=C1)I)N2CCCC2,CCCC(C(=O)c1ccc(I)cc1)N1CCCC1
4551,4562,CHEMBL202479,QXBWECFEEZMKTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,81.4,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.0893755951107975,CCCC(C(=O)C1=CC=C(C=C1)I)N2CCCC2,CCCC(C(=O)c1ccc(I)cc1)N1CCCC1
4552,4563,CHEMBL2047570,QXCOEFGWAUGVTR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,IC50,=,566.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.247183568811729,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CSC4=CC=CC=C43)O,OC(CCN1CC=C(Cc2ccccc2)CC1)c1csc2ccccc12
4553,4564,CHEMBL214395,QXDADQKWVQYGSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCOC1=CC=CC=C1CC(C2=CC(=CC=C2)F)N3CCNCC3,CCOc1ccccc1CC(c1cccc(F)c1)N1CCNCC1
4554,4565,CHEMBL499461,QXJNTMSGRQZRFO-DQZOQLMQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,>,7001.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.154839922348054,COC1=C(C=C(C=C1)C2=NN(C(=O)C3C2CC=CC3)CCCCCNCC[C@H](C4=CC=CC=C4)OC5=CC=C(C=C5)C(F)(F)F)OC,COc1ccc(C2=NN(CCCCCNCC[C@@H](Oc3ccc(C(F)(F)F)cc3)c3ccccc3)C(=O)C3CC=CCC23)cc1OC
4555,4566,CHEMBL499461,QXJNTMSGRQZRFO-DQZOQLMQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,=,4492.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.34756025241058,COC1=C(C=C(C=C1)C2=NN(C(=O)C3C2CC=CC3)CCCCCNCC[C@H](C4=CC=CC=C4)OC5=CC=C(C=C5)C(F)(F)F)OC,COc1ccc(C2=NN(CCCCCNCC[C@@H](Oc3ccc(C(F)(F)F)cc3)c3ccccc3)C(=O)C3CC=CCC23)cc1OC
4556,4567,CHEMBL454507,QXJNTMSGRQZRFO-PDZHLSQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,=,5983.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.223080997157954,COC1=C(C=C(C=C1)C2=NN(C(=O)C3C2CC=CC3)CCCCCNCC[C@@H](C4=CC=CC=C4)OC5=CC=C(C=C5)C(F)(F)F)OC,COc1ccc(C2=NN(CCCCCNCC[C@H](Oc3ccc(C(F)(F)F)cc3)c3ccccc3)C(=O)C3CC=CCC23)cc1OC
4557,4568,CHEMBL454507,QXJNTMSGRQZRFO-PDZHLSQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,=,2716.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.566070234391537,COC1=C(C=C(C=C1)C2=NN(C(=O)C3C2CC=CC3)CCCCCNCC[C@@H](C4=CC=CC=C4)OC5=CC=C(C=C5)C(F)(F)F)OC,COc1ccc(C2=NN(CCCCCNCC[C@H](Oc3ccc(C(F)(F)F)cc3)c3ccccc3)C(=O)C3CC=CCC23)cc1OC
4558,4569,CHEMBL416,QXKHYNVANLEOEG-UHFFFAOYSA-N,METHOXSALEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,COc1c2occc2cc2ccc(=O)oc12
4559,4570,CHEMBL416,QXKHYNVANLEOEG-UHFFFAOYSA-N,METHOXSALEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,COc1c2occc2cc2ccc(=O)oc12
4560,4571,CHEMBL199598,QXKRLFHQZJJIMH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,16800.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.774690718274138,CN1C2CCC1CC(C2)(C3C4=CC=CC=C4C5=C3C=C(C=C5)Br)O,CN1C2CCC1CC(O)(C1c3ccccc3-c3ccc(Br)cc31)C2
4561,4572,CHEMBL395649,QXYYDFAFOMWDHD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,231000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.636388020107856,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)O,COC(=O)C1=C(c2ccc(O)cc2)CCCC1
4562,4573,CHEMBL395649,QXYYDFAFOMWDHD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)O,COC(=O)C1=C(c2ccc(O)cc2)CCCC1
4563,4574,CHEMBL1818460,QYAZFPSPLQVWMZ-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,2.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.698970004336019,CC1=CC(=NN1C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl)C(F)(F)F,Cc1cc(C(F)(F)F)nn1C[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4564,4575,CHEMBL443797,QYIDZGIRYRGUNF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,210.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.6777807052660805,CN(CCCC1=CC=CC=C1)C2CCN(CC2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,CN(CCCc1ccccc1)C1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
4565,4576,CHEMBL443797,QYIDZGIRYRGUNF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,340.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.468521082957745,CN(CCCC1=CC=CC=C1)C2CCN(CC2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,CN(CCCc1ccccc1)C1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
4566,4577,CHEMBL1643648,QYKXDVOUDRSNAP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,>,2000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,C1CC2C(=C(CC1S2)C3=CC=C(C=C3)F)C4=CC(=NO4)C5=CC=CC=C5,Fc1ccc(C2=C(c3cc(-c4ccccc4)no3)C3CCC(C2)S3)cc1
4567,4578,CHEMBL566001,QYLKSFXBRALDIS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,1295.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.8877302315827285,CC(C(=O)C1=CC=C(C=C1)Br)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Br)cc1
4568,4579,CHEMBL566001,QYLKSFXBRALDIS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,1918.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.717151397165356,CC(C(=O)C1=CC=C(C=C1)Br)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Br)cc1
4569,4580,CHEMBL566001,QYLKSFXBRALDIS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,689.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.161780778092374,CC(C(=O)C1=CC=C(C=C1)Br)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(Br)cc1
4570,4581,CHEMBL3612693,QYOJMNDDVVEPFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26372073.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Displacement of [3H]-BTCP from dopamine transporter (unknown origin) at 1 to 10 mM,Reengineered tricyclic anti-cancer agents.,Bioorg. Med. Chem.,PUBLICATION,,,C1CC2=CC=CC=C2N(C3=C1C=CC(=C3)Cl)CCCNS(=O)(=O)C4=CC=C(C=C4)OC(F)(F)F,O=S(=O)(NCCCN1c2ccccc2CCc2ccc(Cl)cc21)c1ccc(OC(F)(F)F)cc1
4571,4582,CHEMBL214259,QYPSCQLKEMPYGY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,970.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.013228265733755,C1CN(CCN1)C(CC2=C(C=CC=C2Cl)Cl)C3=CC=CC=C3,Clc1cccc(Cl)c1CC(c1ccccc1)N1CCNCC1
4572,4583,CHEMBL1201066,QYRYFNHXARDNFZ-UHFFFAOYSA-N,VENLAFAXINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,15700.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,4.804100347590767,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O.Cl,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4573,4584,CHEMBL1201066,QYRYFNHXARDNFZ-UHFFFAOYSA-N,VENLAFAXINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,6.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O.Cl,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
4574,4585,CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
4575,4586,CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
4576,4587,CHEMBL1042,QYSXJUFSXHHAJI-YRZJJWOYSA-N,CHOLECALCIFEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C
4577,4588,CHEMBL1042,QYSXJUFSXHHAJI-YRZJJWOYSA-N,CHOLECALCIFEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C
4578,4589,CHEMBL39,QZAYGJVTTNCVMB-UHFFFAOYSA-N,SEROTONIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC2=C(C=C1O)C(=CN2)CCN,NCCc1c[nH]c2ccc(O)cc12
4579,4590,CHEMBL197315,QZFLFWOTDWFGFO-GXSJLCMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@@H]1C[C@H]1C2=CNC3=C2C=C(C=C3)F,CN(C)C[C@@H]1C[C@H]1c1c[nH]c2ccc(F)cc12
4580,4591,CHEMBL198019,QZFLFWOTDWFGFO-KOLCDFICSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=C(C=C3)F,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2ccc(F)cc12
4581,4592,CHEMBL383347,QZFLFWOTDWFGFO-MWLCHTKSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter; nt is not tested,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,,CN(C)C[C@H]1C[C@H]1C2=CNC3=C2C=C(C=C3)F,CN(C)C[C@H]1C[C@H]1c1c[nH]c2ccc(F)cc12
4582,4593,CHEMBL196513,QZFLFWOTDWFGFO-ONGXEEELSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@@H]1C[C@@H]1C2=CNC3=C2C=C(C=C3)F,CN(C)C[C@@H]1C[C@@H]1c1c[nH]c2ccc(F)cc12
4583,4594,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
4584,4595,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
4585,4596,CHEMBL598614,QZVQFWATMTZJGK-URBRKQAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,IC50,=,22834.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,4.641418003281486,CC1(CN(C2=C1C=CC=C2F)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC(C)(C)c2cccc(F)c21
4586,4597,CHEMBL598614,QZVQFWATMTZJGK-URBRKQAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,2.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.0,CC1(CN(C2=C1C=CC=C2F)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC(C)(C)c2cccc(F)c21
4587,4598,CHEMBL159128,QZYPZMPVLWCVLI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,4.5,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.5,C1CN(CCC1CCNC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=CC=C4,c1ccc(CN2CCC(CCNC(c3ccccc3)c3ccccc3)CC2)cc1
4588,4599,CHEMBL132614,QZZUDVMQVVGVGN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1C2CCC1C(=C(C2)C3=CC(=C(C=C3)O)O)C(=O)OC,COC(=O)C1=C(c2ccc(O)c(O)c2)CC2CCC1N2C
4589,4600,CHEMBL404247,RAEJZLUTUUNZSA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,3000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,CNCC1=C(C=CC(=C1)C(=O)N2CCN(CC2)C3CC3)OC4=CC=C(C=C4)Cl,CNCc1cc(C(=O)N2CCN(C3CC3)CC2)ccc1Oc1ccc(Cl)cc1
4590,4601,CHEMBL202420,RAHKQMUBMIJUFG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,39.5,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.4034029043735385,CCCC(C(=O)C1=CC=C(C=C1)Br)N2CCCC2,CCCC(C(=O)c1ccc(Br)cc1)N1CCCC1
4591,4602,CHEMBL202420,RAHKQMUBMIJUFG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,51.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.292429823902062,CCCC(C(=O)C1=CC=C(C=C1)Br)N2CCCC2,CCCC(C(=O)c1ccc(Br)cc1)N1CCCC1
4592,4603,CHEMBL1086273,RANMCMHHAKTCAZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,6810.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.166852888087215,COC1=C(C=CC=C1F)CC(C2=CC=CC=C2)N3CCNCC3,COc1c(F)cccc1CC(c1ccccc1)N1CCNCC1
4593,4604,CHEMBL3323183,RAPYOTFVDQSFNZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,88.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.055517327849832,CN1CC(C2=C(C1)C=C(C=C2)N3CCOCC3)C4=CC5=C(C=C4)C=CS5,CN1Cc2cc(N3CCOCC3)ccc2C(c2ccc3ccsc3c2)C1
4594,4605,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
4595,4606,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
4596,4607,CHEMBL26320,RAQPOZGWANIDQT-UHFFFAOYSA-N,GBR-12935,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,DISCRIMINATION RATIO,=,0.25,,,,,,,,,,,,,,,,Discrimination ratio of [3H]DA reuptake/DAT binding,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,0.25,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
4597,4608,CHEMBL26320,RAQPOZGWANIDQT-UHFFFAOYSA-N,GBR-12935,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,18.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.744727494896693,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
4598,4609,CHEMBL26320,RAQPOZGWANIDQT-UHFFFAOYSA-N,GBR-12935,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,73.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.136677139879544,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
4599,4610,CHEMBL26320,RAQPOZGWANIDQT-UHFFFAOYSA-N,GBR-12935,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,3.7,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.431798275933005,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
4600,4611,CHEMBL1641622,RAQYAPJFZWPJNL-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,465.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.332547047110047,C1[C@@H](CN(C2=CC=CC=C21)C3=CC(=C(C=C3)Cl)Cl)N,N[C@H]1Cc2ccccc2N(c2ccc(Cl)c(Cl)c2)C1
4601,4612,CHEMBL1643515,RAQYAPJFZWPJNL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,605.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2182446253475305,C1C(CN(C2=CC=CC=C21)C3=CC(=C(C=C3)Cl)Cl)N,NC1Cc2ccccc2N(c2ccc(Cl)c(Cl)c2)C1
4602,4613,CHEMBL339352,RBCQCVSMIQCOMN-PCQZLOAOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,99.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.00436480540245,COC(=O)C1[C@H](CC2CCC1N2CCCCCC3=CC=CC=C3)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2CCCCCc1ccccc1
4603,4614,CHEMBL1909048,RBCUCXILXJXLTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl,O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1
4604,4615,CHEMBL1909048,RBCUCXILXJXLTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl,O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1
4605,4616,CHEMBL27907,RBFITAWVAXQBNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,210.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.6777807052660805,C1CN(CCN1CCC(=O)C2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,O=C(CCN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
4606,4617,CHEMBL272074,RBGQVIWIAYEYFG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC2=CC=CO2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCc1ccco1
4607,4618,CHEMBL1630578,RBKASMJPSJDQKY-RBFSKHHSSA-N,TIRILIZAD,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@H]1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1
4608,4619,CHEMBL1630578,RBKASMJPSJDQKY-RBFSKHHSSA-N,TIRILIZAD,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@H]1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1
4609,4620,CHEMBL403616,RBKMRYYKCJETLF-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COCCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C=CCN(CCOC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
4610,4621,CHEMBL488422,RBLJKXZFEKSSRK-AEPIDVSQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,119.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.924453038607469,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=C(C(=NO4)C)C5=CC=C(C=C5)OC)N3C.Cl,COc1ccc(-c2c(C)noc2[C@@H]2C3CCC(C[C@@H]2c2ccc(C)cc2)N3C)cc1
4611,4622,CHEMBL513258,RBNFIIOAQFISLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,79.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.102372908709557,C1CNCC1(CC2=CC=C(C=C2)F)C3=CC4=C(C=C3)NC=C4,Fc1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
4612,4623,CHEMBL382241,RBZDTFXHCQBMRR-OAUVRVJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,1100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9586073148417755,CN[C@H]1CC[C@H](C2=C1C=CC(=C2)S(=O)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc([S+](C)[O-])ccc21
4613,4624,CHEMBL172806,RCAXDUZVJIMXJF-UFZHQWOOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15012999.0,INHIBITION,=,9.0,%,,,,,,,,,,,,,,,Inhibitory activity against human dopamine transporter at 10 uM,Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CCN1C(=CC(=N1)CC2=CC(=C(C=C2)OC)OC)C3CCN(CC3)C[C@H]4CN(C[C@@H]4C5=CC(=CC=C5)F)[C@@H](C(=O)O)C(C)(C)C,CCn1nc(Cc2ccc(OC)c(OC)c2)cc1C1CCN(C[C@H]2CN([C@@H](C(=O)O)C(C)(C)C)C[C@@H]2c2cccc(F)c2)CC1
4614,4625,CHEMBL311350,RCIMBBZXSXFZBV-UHFFFAOYSA-N,PIROMIDIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCCC3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCCC3)nc21
4615,4626,CHEMBL311350,RCIMBBZXSXFZBV-UHFFFAOYSA-N,PIROMIDIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCCC3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCCC3)nc21
4616,4627,CHEMBL428647,RCINICONZNJXQF-MZXODVADSA-N,PACLITAXEL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
4617,4628,CHEMBL428647,RCINICONZNJXQF-MZXODVADSA-N,PACLITAXEL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
4618,4629,CHEMBL1813484,RCJIOMDJRBCHJE-RISCZKNCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,147.91,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.83000246293343,CN1C[C@H]2CCC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1C[C@H]2CCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1
4619,4630,CHEMBL1813478,RCJIOMDJRBCHJE-SMDDNHRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,47.86,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.320027305722581,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1
4620,4631,CHEMBL1813478,RCJIOMDJRBCHJE-SMDDNHRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,67.61,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.169989064063883,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1
4621,4632,CHEMBL576036,RCMGBZYHSPTETA-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,266.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.575118363368933,CCC(=O)N(CC1=CC2=CC=CC=C2C=C1)[C@@H]3CCNC3,CCC(=O)N(Cc1ccc2ccccc2c1)[C@@H]1CCNC1
4622,4633,CHEMBL450813,RCMVHXAYSDWNBI-GFCCVEGCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,=,1120.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.950781977329817,CC(C)C(=O)N(CC1=C(C(=CC=C1)Cl)Cl)[C@@H]2CCNC2,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@@H]1CCNC1
4623,4634,CHEMBL476954,RCMVHXAYSDWNBI-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,IC50,=,1250.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.903089986991943,CC(C)C(=O)N(CC1=C(C(=CC=C1)Cl)Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1
4624,4635,CHEMBL476954,RCMVHXAYSDWNBI-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,=,1270.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.896196279044043,CC(C)C(=O)N(CC1=C(C(=CC=C1)Cl)Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1
4625,4636,CHEMBL476954,RCMVHXAYSDWNBI-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,640.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1938200260161125,CC(C)C(=O)N(CC1=C(C(=CC=C1)Cl)Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1
4626,4637,CHEMBL1172929,RCOBKSKAZMVBHT-RNCFNFMXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,630.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,6.200659450546419,C[C@@H]1[C@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,C[C@H]1NC(C)(C)CO[C@]1(O)c1cccc(Cl)c1
4627,4638,CHEMBL1172929,RCOBKSKAZMVBHT-RNCFNFMXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,1600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,5.795880017344076,C[C@@H]1[C@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,C[C@H]1NC(C)(C)CO[C@]1(O)c1cccc(Cl)c1
4628,4639,CHEMBL1172928,RCOBKSKAZMVBHT-TVQRCGJNSA-N,RADAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,4.0,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
4629,4640,CHEMBL1172928,RCOBKSKAZMVBHT-TVQRCGJNSA-N,RADAFAXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,220.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,6.657577319177793,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
4630,4641,CHEMBL1297,RDJGLLICXDHJDY-UHFFFAOYSA-N,FENOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
4631,4642,CHEMBL1297,RDJGLLICXDHJDY-UHFFFAOYSA-N,FENOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
4632,4643,CHEMBL476941,RDLDWTPNWMTWKO-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)CC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CC(C)CC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
4633,4644,CHEMBL379181,RDLXBTKNMZJTIX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,490.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.309803919971486,CN1CCCCCCCCCCCC(=O)OCC2C3CCC(N3C)CC2C4=CC=C1C=C4,CN1CCCCCCCCCCCC(=O)OCC2C(CC3CCC2N3C)c2ccc1cc2
4634,4645,CHEMBL841,RDOIQAHITMMDAJ-UHFFFAOYSA-N,LOPERAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
4635,4646,CHEMBL841,RDOIQAHITMMDAJ-UHFFFAOYSA-N,LOPERAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
4636,4647,CHEMBL1083430,RDRQTGHODUVHMX-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,291.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,6.536107011014093,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC(=C(C=C3)F)F)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccc(F)c(F)c2)S1(=O)=O
4637,4648,CHEMBL1082611,RDRQTGHODUVHMX-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC(=C(C=C3)F)F)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccc(F)c(F)c2)S1(=O)=O
4638,4649,CHEMBL1200993,REEUVFCVXKWOFE-UHFFFAOYSA-K,GALLAMINE TRIETHIODIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC
4639,4650,CHEMBL1200993,REEUVFCVXKWOFE-UHFFFAOYSA-K,GALLAMINE TRIETHIODIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC
4640,4651,CHEMBL3323178,REFDLFNZTJITBX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,11.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,7.9586073148417755,CN1CC(C2=C(C1)C=C(C=C2)CN)C3=CC4=C(C=C3)SC=C4,CN1Cc2cc(CN)ccc2C(c2ccc3sccc3c2)C1
4641,4652,CHEMBL343534,REFWYZSDWMHZTK-HNQUOIGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,1.3,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.886056647693161,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CS4,Fc1ccc(C(OCCC2CCN(C/C=C/c3cccs3)CC2)c2ccc(F)cc2)cc1
4642,4653,CHEMBL3238501,REQCUEVODFVEBU-UCMJSZAQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=C2C=C(C(=C(C2=C(C=C1S(=O)(=O)O)N)O)N=NC3=C(C(=C(C(=C3F)F)C4=C(C(=C(C(=C4F)F)N)F)F)F)F)S(=O)(=O)O,Nc1c(F)c(F)c(-c2c(F)c(F)c(N=Nc3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(F)c2F)c(F)c1F
4643,4654,CHEMBL640,REQCZEXYDRLIBE-UHFFFAOYSA-N,PROCAINAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CCN(CC)CCNC(=O)c1ccc(N)cc1
4644,4655,CHEMBL640,REQCZEXYDRLIBE-UHFFFAOYSA-N,PROCAINAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CCN(CC)CCNC(=O)c1ccc(N)cc1
4645,4656,CHEMBL28079,REZGGXNDEMKIQB-UHFFFAOYSA-N,ZAPRINAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,CCCOc1ccccc1-c1nc2n[nH]nc2c(=O)[nH]1
4646,4657,CHEMBL28079,REZGGXNDEMKIQB-UHFFFAOYSA-N,ZAPRINAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,CCCOc1ccccc1-c1nc2n[nH]nc2c(=O)[nH]1
4647,4658,CHEMBL393701,RFECIGQVKKOIMS-CHWSQXEVSA-N,METHYL 2-(3-(TRIFLUOROMETHYL)PHENYL)CYCLOHEXANECARBOXYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,569000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.2448877336049287,COC(=O)[C@@H]1CCCC[C@@H]1C2=CC(=CC=C2)C(F)(F)F,COC(=O)[C@@H]1CCCC[C@@H]1c1cccc(C(F)(F)F)c1
4648,4659,CHEMBL246388,RFEHSKWKBMZDQP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19926484.0,KI,=,503.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human cloned DAT expressed in HEK293 cells,Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.298432014944072,CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)CN(C)C)N,Cc1ccc(Oc2ccc(F)cc2CN(C)C)c(N)c1
4649,4660,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
4650,4661,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
4651,4662,CHEMBL258062,RFJRYJRDVNGNCX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,275.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.560667306169737,CNCC1=C(C=CC(=C1)C(=O)N(C)C)OC2=C(C=C(C=C2)Cl)Cl,CNCc1cc(C(=O)N(C)C)ccc1Oc1ccc(Cl)cc1Cl
4652,4663,CHEMBL564100,RFKSUPOWTRFCKG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3979400086720375,C1CNCCC1C(C2=CN=CC=C2)OC3=CC=CC=C3Cl,Clc1ccccc1OC(c1cccnc1)C1CCNCC1
4653,4664,CHEMBL447598,RFOPOIPYLVKPSZ-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=CC=C1O[C@H]2CC[C@H](C3=CC=CC=C23)NC,CN[C@@H]1CC[C@H](Oc2ccccc2C)c2ccccc21
4654,4665,CHEMBL1173752,RFTBXAYWUQYHOQ-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,251.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.599997654072044,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)C(=O)N,NC(=O)[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4655,4666,CHEMBL1201216,RFWZESUMWJKKRN-UHFFFAOYSA-N,DAPIPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
4656,4667,CHEMBL1201216,RFWZESUMWJKKRN-UHFFFAOYSA-N,DAPIPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
4657,4668,CHEMBL503609,RFZOKJQQTZLOBO-BJUDXGSMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18487050.0,KI,=,1030.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.,Bioorg. Med. Chem.,PUBLICATION,,5.987162775294827,[11CH3]OC1=CC2=C(CN(CC2)CCCC3=CNC4=C3C=C(C=C4)Br)C=C1,COc1ccc2c(c1)CCN(CCCc1c[nH]c3ccc(Br)cc13)C2
4658,4669,CHEMBL1644606,RGCRPWWXLBCYBL-OPVJXMOQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,173.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.761953896871206,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=C3)C4=CC=C(C=C4)C#N,N#Cc1ccc(-c2cccc(OC3C[C@@H]4CC[C@H](C3)N4)c2)cc1
4659,4670,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
4660,4671,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
4661,4672,CHEMBL411,RGLYKWWBQGJZGM-ISLYRVAYSA-N,DIETHYLSTILBESTROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1071.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.970210529168145,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
4662,4673,CHEMBL411,RGLYKWWBQGJZGM-ISLYRVAYSA-N,DIETHYLSTILBESTROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,851.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.070070439915413,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
4663,4674,CHEMBL257348,RGPDAGIHVSVOQP-BDBMTWCYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,=,6900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.161150909262744,C1[C@H]([C@@]1(C2=CSC=C2)C(=O)C3C4=CC=CC=C4CN3)CN,NC[C@@H]1C[C@@]1(C(=O)C1NCc2ccccc21)c1ccsc1
4664,4675,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18588282.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,PUBLICATION,,7.920818753952375,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4665,4676,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18983139.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Displacement of radiolabeled BTCP from human DAT,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,7.769551078621726,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4666,4677,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18983139.0,KI,=,8.9,NM,,,,,,,,,,,,,,,Displacement of radiolabeled BTCP from human DAT,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,8.050609993355089,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4667,4678,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21726069.0,KI,=,2.2,NM,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DA transporter,"Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.",J. Med. Chem.,PUBLICATION,,8.657577319177793,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4668,4679,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23466604.0,IC50,=,5.1,NM,,,,,,,,,,,,,,,Binding affinity to human dopamine transporter by radioligand displacement assay,Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.,Eur. J. Med. Chem.,PUBLICATION,,8.292429823902062,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4669,4680,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23466604.0,KI,=,2.7,NM,,,,,,,,,,,,,,,Binding affinity to human dopamine transporter by radioligand displacement assay,Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.,Eur. J. Med. Chem.,PUBLICATION,,8.568636235841014,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4670,4681,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23582449.0,IC50,=,2.6,NM,,,,,,,,,,,,,,,Binding affinity to human dopamine transporter by radioligand displacement assay,Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.,Bioorg. Med. Chem.,PUBLICATION,,8.585026652029184,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4671,4682,CHEMBL279556,RGSVXQJPSWZXOP-UHFFFAOYSA-N,BTCP,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26988801.0,IC50,=,2.8,NM,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human recombinant dopamine transporter expressed in CHO cells,"Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.",Bioorg. Med. Chem.,PUBLICATION,,8.55284196865778,C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1
4672,4683,CHEMBL411655,RGXBRYANHNSPHQ-VBKZILBWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,5100.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,C1COC2=CC=CC=C2N1C(=O)[C@]3(C[C@H]3CN)C4=CC5=C(C=C4)OCO5,NC[C@@H]1C[C@@]1(C(=O)N1CCOc2ccccc21)c1ccc2c(c1)OCO2
4673,4684,CHEMBL1643659,RHCGODMTXRAWCK-PBWJLWFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.886056647693162,C1CC2C([C@@H](CC1S2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)C5=CC=CC=C5,Clc1ccc([C@@H]2CC3CCC(S3)C2c2cc(-c3ccccc3)no2)cc1
4674,4685,CHEMBL498510,RHFJKUASNIKDKP-SJKOYZFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@H]1CSC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3Cl,CNC[C@@H]1CSc2ccccc2[C@@H]1Oc1ccccc1Cl
4675,4686,CHEMBL410062,RHHBTYFKWRRJPP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1(C(C1(C2=CC=CC=C2)C(=O)N3CCC4=CC=CC=C43)CN)C,CC1(C)C(CN)C1(C(=O)N1CCc2ccccc21)c1ccccc1
4676,4687,CHEMBL3703732,RHVRAPZNMRRCCU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,8.619788758288394,CC1(C2=C(C=CC(=C2)C3=NN=C(C=C3)N)C(CN1)C4=CC(=C(C=C4)Cl)Cl)C,CC1(C)NCC(c2ccc(Cl)c(Cl)c2)c2ccc(-c3ccc(N)nn3)cc21
4677,4688,CHEMBL574546,RHZULZDFMYQLIX-UHDQLFAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,177.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.752026733638194,CCSC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3,CCSc1ccc([C@H]2CC3CCC(N3)[C@H]2C(=O)OC)cc1
4678,4689,CHEMBL1308,RIKMMFOAQPJVMX-UHFFFAOYSA-N,FOMEPIZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CNN=C1,Cc1cn[nH]c1
4679,4690,CHEMBL1308,RIKMMFOAQPJVMX-UHFFFAOYSA-N,FOMEPIZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CNN=C1,Cc1cn[nH]c1
4680,4691,CHEMBL563030,RILKVQPDTVTHBN-CWQZNGJJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,36.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.443697499232713,C1C[C@@H](CNC1)C(C2=CN=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2cccnc2)[C@H]2CCCNC2)c1Cl
4681,4692,CHEMBL563030,RILKVQPDTVTHBN-CWQZNGJJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,53.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.275724130399211,C1C[C@@H](CNC1)C(C2=CN=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2cccnc2)[C@H]2CCCNC2)c1Cl
4682,4693,CHEMBL549825,RILKVQPDTVTHBN-FWJOYPJLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,6.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,C1C[C@H](CNC1)C(C2=CN=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2cccnc2)[C@@H]2CCCNC2)c1Cl
4683,4694,CHEMBL549825,RILKVQPDTVTHBN-FWJOYPJLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,99.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.00436480540245,C1C[C@H](CNC1)C(C2=CN=CC=C2)OC3=C(C(=CC=C3)Cl)Cl,Clc1cccc(OC(c2cccnc2)[C@@H]2CCCNC2)c1Cl
4684,4695,CHEMBL394373,RILPYESNVZTTIN-CHWSQXEVSA-N,METHYL 2-(4-(TRIFLUOROMETHYL)PHENYL)CYCLOHEXANECARBOXYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,222000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.653647025549361,COC(=O)[C@@H]1CCCC[C@@H]1C2=CC=C(C=C2)C(F)(F)F,COC(=O)[C@@H]1CCCC[C@@H]1c1ccc(C(F)(F)F)cc1
4685,4696,CHEMBL550932,RIMYGAIUGCFOTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,501.19,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CNCCN(C1=CC=CC=C1)C2=CC3=C(C=C2)NC=C3,CNCCN(c1ccccc1)c1ccc2[nH]ccc2c1
4686,4697,CHEMBL444412,RINBNPPEMJIWTC-UHFFFAOYSA-N,KF-A2,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,5.0,CCN(CC)CCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31,CCN(CC)CCn1c2ccccc2c(=O)c2ccccc21
4687,4698,CHEMBL203453,RISBSIZJBWBMEB-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,1400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321763,CN[C@H]1CC[C@H](C2=C1C=CC(=C2)S(=O)(=O)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(S(C)(=O)=O)ccc21
4688,4699,CHEMBL103,RJKFOVLPORLFTN-LEKSSAKUSA-N,PROGESTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
4689,4700,CHEMBL103,RJKFOVLPORLFTN-LEKSSAKUSA-N,PROGESTERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
4690,4701,CHEMBL1554,RJURFGZVJUQBHK-IIXSONLDSA-N,DACTINOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O
4691,4702,CHEMBL1554,RJURFGZVJUQBHK-IIXSONLDSA-N,DACTINOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O
4692,4703,CHEMBL172090,RJVRDLDDCGQDGE-GTRCSXEUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15012999.0,INHIBITION,=,-4.0,%,,,,,,,,,,,,,,,Inhibitory activity against human dopamine transporter at 10 uM,Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-4.0,CC[C@H](C)[C@H](C(=O)O)N1C[C@@H]([C@H](C1)C2=CC(=CC=C2)F)CN3CCC(CC3)C4=CC(=NN4CC)CC5=CC(=C(C=C5)OC)OC,CC[C@H](C)[C@H](C(=O)O)N1C[C@H](CN2CCC(c3cc(Cc4ccc(OC)c(OC)c4)nn3CC)CC2)[C@@H](c2cccc(F)c2)C1
4693,4704,CHEMBL132676,RKCUTIXVCFBEGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,4.1,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.387216143280265,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC5=CC=CC=C5C=C4)O,OC1(c2ccc3ccccc3c2)c2ccccc2C2=NCCN21
4694,4705,CHEMBL132676,RKCUTIXVCFBEGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,KI,=,45.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]- RTI -55 binding at the Dopamine transporter sites on HEK-hDAT cells,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.346787486224656,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC5=CC=CC=C5C=C4)O,OC1(c2ccc3ccccc3c2)c2ccccc2C2=NCCN21
4695,4706,CHEMBL132676,RKCUTIXVCFBEGE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,10.4,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,10.4,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC5=CC=CC=C5C=C4)O,OC1(c2ccc3ccccc3c2)c2ccccc2C2=NCCN21
4696,4707,CHEMBL217987,RKHFLVYZXJYWKW-RDPSFJRHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,119.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.924453038607469,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2)cc(C(C)=O)c1
4697,4708,CHEMBL517712,RKUNBYITZUJHSG-SPUOUPEWSA-N,ATROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(CO)c1ccccc1)C2
4698,4709,CHEMBL517712,RKUNBYITZUJHSG-SPUOUPEWSA-N,ATROPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(CO)c1ccccc1)C2
4699,4710,CHEMBL498,RKWGIWYCVPQPMF-UHFFFAOYSA-N,CHLORPROPAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
4700,4711,CHEMBL498,RKWGIWYCVPQPMF-UHFFFAOYSA-N,CHLORPROPAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
4701,4712,CHEMBL1237,RLAWWYSOJDYHDC-BZSNNMDCSA-N,LISINOPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
4702,4713,CHEMBL1237,RLAWWYSOJDYHDC-BZSNNMDCSA-N,LISINOPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
4703,4714,CHEMBL3673179,RLLIIRDYLONSJW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,13.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.866461091629782,CCS(=O)(=O)N1CCN(CC1)C2=CC3=C(C=C2)C4(CCN(C3)CC4)C5=CC=C(C=C5)Cl,CCS(=O)(=O)N1CCN(c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)CC1
4704,4715,CHEMBL402999,RLOLTHVCQCDNSF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CCOC)C(=O)C1(CC1CN)C2=CC=CC=C2,CCN(CCOC)C(=O)C1(c2ccccc2)CC1CN
4705,4716,CHEMBL3323099,RLPCKFFTXOAFOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,200.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CN1CC(C2=CC=CC=C2C1)C3=C4C=CSC4=CC=C3,CN1Cc2ccccc2C(c2cccc3sccc23)C1
4706,4717,CHEMBL3317697,RLSDCBVRAGSYCJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,4500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,CC1CCNCC(=O)N1C2=CC(=C(C=C2)Cl)Cl.Cl,CC1CCNCC(=O)N1c1ccc(Cl)c(Cl)c1
4707,4718,CHEMBL607548,RLTILGBQVNXKRQ-DDZGMJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,230.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.638272163982407,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCC5=CC(=CC=C5)CNC(=O)[C@H]6[C@H](CC7CCC6N7C)C8=CC=C(C=C8)C9=CSC=C9,CN1C2CCC1[C@@H](C(=O)NCc1cccc(CNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(-c5ccsc5)cc3)N4C)c1)[C@@H](c1ccc(-c3ccsc3)cc1)C2
4708,4719,CHEMBL506874,RLUHSIYRINOGAT-RTWAWAEBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,10.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1cccc2ccccc12
4709,4720,CHEMBL1173277,RLZACOPBIXSOEX-SMDDNHRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,2600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.585026652029182,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC(=C2)C)O,Cc1cccc([C@]2(O)OCC(C)(C)N[C@H]2C)c1
4710,4721,CHEMBL249215,RLZDYYKLMOPCMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,3400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.468521082957745,C1CC(=C(C1)C(=O)OCC(F)(F)F)C2=CC(=C(C=C2)Cl)Cl,O=C(OCC(F)(F)F)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
4711,4722,CHEMBL1108,RMEDXOLNCUSCGS-UHFFFAOYSA-N,DROPERIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
4712,4723,CHEMBL1108,RMEDXOLNCUSCGS-UHFFFAOYSA-N,DROPERIDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
4713,4724,CHEMBL599638,RMFDASBXQBLDIL-BREBYQMCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,512.86,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.290001171974812,COC[C@@H]1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1
4714,4725,CHEMBL603540,RMFDASBXQBLDIL-OPQQBVKSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,660.69,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.180002266489224,COC[C@@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
4715,4726,CHEMBL596809,RMFDASBXQBLDIL-OUJBWJOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,56.23,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.250031916490598,COC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
4716,4727,CHEMBL596809,RMFDASBXQBLDIL-OUJBWJOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,85.11,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in LLCPK cells by liquid scintillation counting,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.070019409484487,COC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
4717,4728,CHEMBL596809,RMFDASBXQBLDIL-OUJBWJOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,109.65,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.9599913639864575,COC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
4718,4729,CHEMBL481696,RMKQQVTXLRWNDV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC(=O)C1=CC(=C(C=C1)OC2=CC=C(C=C2)OC(F)(F)F)CN(C)C,CNC(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)c(CN(C)C)c1
4719,4730,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,8400.0,NM,,,,,,,,,,,,,,,,,,,,5.075720713938118,C1=CC=C(C=C1)CCNN,NNCCc1ccccc1
4720,4731,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCNN,NNCCc1ccccc1
4721,4732,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCNN,NNCCc1ccccc1
4722,4733,CHEMBL551646,RMVVWYWHBYZSBH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNCCC1C(C2=CN=CC=C2)OC3=CC(=CC(=C3)Cl)Cl,Clc1cc(Cl)cc(OC(c2cccnc2)C2CCNCC2)c1
4723,4734,CHEMBL469165,RMWQLXLFYHDPRH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,7.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.154901959985743,CC(CCN1CCN(CC1)CCOC(C2=CC=CC=C2)C3=CC=CC=C3)(C4=CC=CC=C4)O,CC(O)(CCN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
4724,4735,CHEMBL556714,RNLDMCBNMHSZQI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,199.53,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,C1CNCCC1N(CC2=CC=CC=C2)C3=CC4=C(C=C3)SC=C4,c1ccc(CN(c2ccc3sccc3c2)C2CCNCC2)cc1
4725,4736,CHEMBL12856,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,INAMRINONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,Nc1cc(-c2ccncc2)c[nH]c1=O
4726,4737,CHEMBL12856,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,INAMRINONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,Nc1cc(-c2ccncc2)c[nH]c1=O
4727,4738,CHEMBL524153,RNPCOHCWKNMBRI-QHCPKHFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18799310.0,ACTIVITY,=,3480.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,"Identification and SAR around N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-[1,4]diazepan-1-yl]-ethyl}-2-phenoxy-nicotinamide, a selective alpha2C adrenergic receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.458420756053419,C1CN(CCN(C1)C[C@H]2COC3=CC=CC=C3O2)CCNC(=O)C4=C(N=CC=C4)OC5=CC=CC=C5,O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1
4728,4739,CHEMBL1173519,RNWPCCAJXHTPIS-BFHYXJOUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.0,COC[C@]12C[C@]1([C@H](CNC2)F)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNC[C@H](F)[C@]1(c1ccc(Cl)c(Cl)c1)C2
4729,4740,CHEMBL1173520,RNWPCCAJXHTPIS-MGPQQGTHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.0,COC[C@]12C[C@]1([C@@H](CNC2)F)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNC[C@@H](F)[C@]1(c1ccc(Cl)c(Cl)c1)C2
4730,4741,CHEMBL1632158,RNXYMZNGMNWKMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21075638.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,COC(=O)CCCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42,COC(=O)CCCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1
4731,4742,CHEMBL597135,RNYJGXWCOXRLAG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6630.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.178486471595226,C1CNCCC1C2=C(N=CC=C2)OC3=C(C=CC=C3F)F,Fc1cccc(F)c1Oc1ncccc1C1CCNCC1
4732,4743,CHEMBL190703,ROARIPXQVCVHPS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,=,962.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.016824927962188,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)C=C)N,C=Cc1ccc(Sc2ccccc2CN(C)C)c(N)c1
4733,4744,CHEMBL488,ROBVIMPUHSLWNV-UHFFFAOYSA-N,AMINOGLUTETHIMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O
4734,4745,CHEMBL488,ROBVIMPUHSLWNV-UHFFFAOYSA-N,AMINOGLUTETHIMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O
4735,4746,CHEMBL184238,ROFVXGGUISEHAM-UHFFFAOYSA-N,URB597,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16352709.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N,NC(=O)c1cccc(-c2cccc(OC(=O)NC3CCCCC3)c2)c1
4736,4747,CHEMBL654,RONZAEMNMFQXRA-UHFFFAOYSA-N,MIRTAZAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2c3ncccc3Cc3ccccc3C2C1
4737,4748,CHEMBL505592,ROTDEDNYANYXDF-PMACEKPBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19067522.0,KI,>,6000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT receptor expressed in canine kidney cells,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter.",J. Med. Chem.,PUBLICATION,,5.221848749616356,C1CO[C@@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC=CC=C3CCCF,FCCCc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
4738,4749,CHEMBL510484,ROTSFLNCGRVNJJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18782666.0,IC50,=,13.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693162,CNS(=O)(=O)C1=CC(=C(C=C1)OC2=CC=C(C=C2)S(=O)C)CN(C)C,CNS(=O)(=O)c1ccc(Oc2ccc([S+](C)[O-])cc2)c(CN(C)C)c1
4739,4750,CHEMBL377510,ROXOOMBIDGERBZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,5400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.267606240177033,CCCC(C(=O)C1=CC=C(C=C1)C2=CC=CN2C)N3CCCC3,CCCC(C(=O)c1ccc(-c2cccn2C)cc1)N1CCCC1
4740,4751,CHEMBL377510,ROXOOMBIDGERBZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,3850.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.414539270491499,CCCC(C(=O)C1=CC=C(C=C1)C2=CC=CN2C)N3CCCC3,CCCC(C(=O)c1ccc(-c2cccn2C)cc1)N1CCCC1
4741,4752,CHEMBL573971,ROZQUSZIXUCKCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,452.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3448615651886175,C1CNCCC1C2=C(C=CC(=C2)F)OCC3=CC(=C(C=C3)Cl)Cl,Fc1ccc(OCc2ccc(Cl)c(Cl)c2)c(C2CCNCC2)c1
4742,4753,CHEMBL198038,RPAXLFKEFIYMPQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,9.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CCC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)CCCNC,CCc1ccc(N2C(=O)C(CCCNC)Cc3ccccc32)cc1
4743,4754,CHEMBL198038,RPAXLFKEFIYMPQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CCC1=CC=C(C=C1)N2C3=CC=CC=C3CC(C2=O)CCCNC,CCc1ccc(N2C(=O)C(CCCNC)Cc3ccccc32)cc1
4744,4755,CHEMBL3310477,RPBPOTIIGUEQSZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,45.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,45.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=C(C=C3)F)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1F
4745,4756,CHEMBL3310477,RPBPOTIIGUEQSZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=C(C=C3)F)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1F
4746,4757,CHEMBL3310477,RPBPOTIIGUEQSZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=C(C=C3)F)F,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1F
4747,4758,CHEMBL2207488,RPDHXGXUGMGVAU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23043306.0,INHIBITION,=,34.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DAT at 1 uM by CEREP assay,Systematic in Vivo Screening of a Series of 1-Propyl-4-arylpiperidines against Dopaminergic and Serotonergic Properties in Rat Brain: A Scaffold-Jumping Approach.,J. Med. Chem.,PUBLICATION,,34.0,CCCN1CCC(CC1)C2=COC3=CC=CC=C32,CCCN1CCC(c2coc3ccccc23)CC1
4748,4759,CHEMBL322348,RPEDEMBGNMELBV-YHZLUUAOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,,,,Not Determined,,,,,,,,,,,,,,In vitro ability of compound to inhibit DA re-uptake of radiolabeled [3H]-tritium transmitter into synaptosome; ND=not determined,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNC[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)OC,CNC[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(OC)ccc2c1
4749,4760,CHEMBL322348,RPEDEMBGNMELBV-YHZLUUAOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,60.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.221848749616356,CNC[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)OC,CNC[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(OC)ccc2c1
4750,4761,CHEMBL566618,RPHSTODYKZLNFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,980.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.008773924307505,CC(C(=O)C1=CC(=CC=C1)Cl)NC2CCCC2,CC(NC1CCCC1)C(=O)c1cccc(Cl)c1
4751,4762,CHEMBL566618,RPHSTODYKZLNFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,2200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.657577319177793,CC(C(=O)C1=CC(=CC=C1)Cl)NC2CCCC2,CC(NC1CCCC1)C(=O)c1cccc(Cl)c1
4752,4763,CHEMBL566618,RPHSTODYKZLNFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,>,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.0,CC(C(=O)C1=CC(=CC=C1)Cl)NC2CCCC2,CC(NC1CCCC1)C(=O)c1cccc(Cl)c1
4753,4764,CHEMBL514937,RPJFGKOZZHLXFS-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,4000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CC1=C(C=CC=C1O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1cccc(O)c1C
4754,4765,CHEMBL3673139,RPNWMLLBQPFWML-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,21.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.675717544702308,C1CN2CCC1(C3=C(C2)C=C(C=C3)O)C4=CC=C(C=C4)Cl,Oc1ccc2c(c1)CN1CCC2(c2ccc(Cl)cc2)CC1
4755,4766,CHEMBL276832,RPTUSVTUFVMDQK-UHFFFAOYSA-N,HYDRALAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=NN=C2NN,NNc1nncc2ccccc12
4756,4767,CHEMBL276832,RPTUSVTUFVMDQK-UHFFFAOYSA-N,HYDRALAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=NN=C2NN,NNc1nncc2ccccc12
4757,4768,CHEMBL2407321,RPURJJSUIZKBOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,2200.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,5.657577319177793,CS(=O)(=O)CC(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CS(=O)(=O)CC(c1ccc(Cl)c(Cl)c1)C1CCNCC1
4758,4769,CHEMBL1794855,RPZYOWNZYQHSLJ-SPIKMXEPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15203136.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding towards dopamine transporter; NA- Not active,"(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCN(C1C2=C(C=CN=C2)CCC1)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,CCN(C)C1CCCc2ccncc21
4759,4770,CHEMBL3104092,RQBRUGMHSQYCNU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24365159.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin) by radioligand displacement assay,"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=CC=CC4=C3N2CC5=CC=CC=C5C4,CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1
4760,4771,CHEMBL380559,RQBVJCCLVRZSFV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,41.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,41.0,CC1(CC2=CC=CC=C2N(C1=O)C3=CC(=CC(=C3)Cl)Cl)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2cc(Cl)cc(Cl)c2)C1=O
4761,4772,CHEMBL380559,RQBVJCCLVRZSFV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CC1(CC2=CC=CC=C2N(C1=O)C3=CC(=CC(=C3)Cl)Cl)CCCNC,CNCCCC1(C)Cc2ccccc2N(c2cc(Cl)cc(Cl)c2)C1=O
4762,4773,CHEMBL549510,RQCXDPJNIVTCJD-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,4770.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3214816209598865,CSC1=CC=CC=C1C(=O)N([C@H]2CCNC2)C3CCCC3,CSc1ccccc1C(=O)N(C1CCCC1)[C@H]1CCNC1
4763,4774,CHEMBL2012092,RQDKDYRGZLTUMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=CC=CS3,COC(=O)C1=C(c2cccs2)CC2CCC1O2
4764,4775,CHEMBL2012092,RQDKDYRGZLTUMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=CS3,COC(=O)C1=C(c2cccs2)CC2CCC1O2
4765,4776,CHEMBL481941,RQDOQYXVLGVVBA-UHFFFAOYSA-N,4-(2-((DIMETHYLAMINO)METHYL)PHENOXY)BENZONITRILE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)C#N,CN(C)Cc1ccccc1Oc1ccc(C#N)cc1
4766,4777,CHEMBL3323176,RQGSUGDPXICJIV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,66.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.180456064458133,CN1CC(C2=C(C1)C=C(C=C2)F)C3=CC4=C(C=C3)SC=C4,CN1Cc2cc(F)ccc2C(c2ccc3sccc3c2)C1
4767,4778,CHEMBL3310035,RQPAEAIGXOANQF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,ACTIVITY,,,,Not Active,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT expressed in HEK cells at 10 uM after 90 mins by microbeta counting analysis,,J. Nat. Prod.,PUBLICATION,,,CC1=CC2=CC(=C(C(=C2C(=O)O1)O)O)CCC(=O)OC,COC(=O)CCc1cc2cc(C)oc(=O)c2c(O)c1O
4768,4779,CHEMBL567944,RQQIFQXOKVSJMS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,=,1500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,CC(=O)N(CC1=CC2=CC=CC=C2C=C1)C3CCNCC3,CC(=O)N(Cc1ccc2ccccc2c1)C1CCNCC1
4769,4780,CHEMBL498509,RQRGTZIPGLRQOJ-CXAGYDPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CN,Cc1ccccc1O[C@H]1c2ccccc2OC[C@H]1CN
4770,4781,CHEMBL498509,RQRGTZIPGLRQOJ-CXAGYDPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CN,Cc1ccccc1O[C@H]1c2ccccc2OC[C@H]1CN
4771,4782,CHEMBL510352,RQRGTZIPGLRQOJ-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@H]2[C@H](COC3=CC=CC=C23)CN,Cc1ccccc1O[C@@H]1c2ccccc2OC[C@@H]1CN
4772,4783,CHEMBL304656,RQTWPNKOATVIPT-CFXFOKGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,=,3320.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for binding affinity to dopamine transporter using [125I]RTI-55 as a radioligand in HEK cells expressing human transporters.,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,5.478861916295964,COC(=O)[C@@H]1[C@@H]\2C[C@H]3CCC1N3C/C2=C\C4=CC(=C(C=C4)Cl)Cl,COC(=O)[C@H]1C2CC[C@@H]3C[C@@H]1/C(=C/c1ccc(Cl)c(Cl)c1)CN23
4773,4784,CHEMBL304656,RQTWPNKOATVIPT-CFXFOKGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for inhibition of [3H]DA uptake in HEK-hDAT cells expressing Human dopamine Transporter,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,5.0,COC(=O)[C@@H]1[C@@H]\2C[C@H]3CCC1N3C/C2=C\C4=CC(=C(C=C4)Cl)Cl,COC(=O)[C@H]1C2CC[C@@H]3C[C@@H]1/C(=C/c1ccc(Cl)c(Cl)c1)CN23
4774,4785,CHEMBL1201139,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,MEGESTROL ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
4775,4786,CHEMBL1201139,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,MEGESTROL ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
4776,4787,CHEMBL42710,RRAFCDWBNXTKKO-UHFFFAOYSA-N,EUGENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)CC=C)O,C=CCc1ccc(O)c(OC)c1
4777,4788,CHEMBL42710,RRAFCDWBNXTKKO-UHFFFAOYSA-N,EUGENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)CC=C)O,C=CCc1ccc(O)c(OC)c1
4778,4789,CHEMBL2205831,RRBNCHNWWUXYEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCC(CC1)CN2C3C4C5CC6C4C2(C7C6C5C73)O,OC12C3C4CC5C6C4C1C6C(C53)N2CC1CCCCC1
4779,4790,CHEMBL2205831,RRBNCHNWWUXYEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,C1CCC(CC1)CN2C3C4C5CC6C4C2(C7C6C5C73)O,OC12C3C4CC5C6C4C1C6C(C53)N2CC1CCCCC1
4780,4791,CHEMBL2113217,RRFLDGUEDAERPR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,231.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.636388020107857,CC1=CC=C(C=C1)C(=O)C(CC#C)N2CCCC2,C#CCC(C(=O)c1ccc(C)cc1)N1CCCC1
4781,4792,CHEMBL2113217,RRFLDGUEDAERPR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,2310.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.636388020107857,CC1=CC=C(C=C1)C(=O)C(CC#C)N2CCCC2,C#CCC(C(=O)c1ccc(C)cc1)N1CCCC1
4782,4793,CHEMBL2337601,RRGCJEHCXSKPFY-RHSMWYFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,PKI,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC=CC=C3[N+](=O)[O-],O=[N+]([O-])c1ccccc1O[C@H](c1ccccc1)[C@@H]1CCNC1
4783,4794,CHEMBL799,RRGUKTPIGVIEKM-UHFFFAOYSA-N,CILOSTAZOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1
4784,4795,CHEMBL799,RRGUKTPIGVIEKM-UHFFFAOYSA-N,CILOSTAZOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1
4785,4796,CHEMBL1643519,RRPWTJMHWMGFPI-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,309.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5100415205751645,CN(C)[C@H]1CC2=CC=CC=C2N(C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@H]1Cc2ccccc2N(c2ccc(Cl)c(Cl)c2)C1
4786,4797,CHEMBL1643516,RRPWTJMHWMGFPI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,122.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9136401693252525,CN(C)C1CC2=CC=CC=C2N(C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)C1Cc2ccccc2N(c2ccc(Cl)c(Cl)c2)C1
4787,4798,CHEMBL333280,RRWQOIKRLCJAFP-SZSCYUJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,4140.0,NM,,,,,,,,,,,,,,,Binding Affinity to cocaine site of dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol. ,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,5.382999658879101,CN1CCC(C(C1)[C@H](C2=CC(=C(C=C2)Cl)Cl)O)(C3=CC(=C(C=C3)Cl)Cl)O,CN1CCC(O)(c2ccc(Cl)c(Cl)c2)C([C@@H](O)c2ccc(Cl)c(Cl)c2)C1
4788,4799,CHEMBL2338032,RSAGNBIVUSOUTP-BBRMVZONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=CC=C3F)F,Fc1cccc(F)c1O[C@@H](c1ccccc1)[C@H]1CCNC1
4789,4800,CHEMBL234706,RSNYUBDIPFPZKJ-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,IC50,=,290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5376020021010435,CN(C)[C@@H]1CCC(=CC1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)[C@H]1CC=C(c2c[nH]c3ccc(C#N)cc23)CC1
4790,4801,CHEMBL234706,RSNYUBDIPFPZKJ-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560923.0,IC50,=,290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5376020021010435,CN(C)[C@@H]1CCC(=CC1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)[C@H]1CC=C(c2c[nH]c3ccc(C#N)cc23)CC1
4791,4802,CHEMBL234706,RSNYUBDIPFPZKJ-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20034793.0,IC50,=,290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [I125]RTI-55 from human DAT transfected in human HEK293 cells,Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5376020021010435,CN(C)[C@@H]1CCC(=CC1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)[C@H]1CC=C(c2c[nH]c3ccc(C#N)cc23)CC1
4792,4803,CHEMBL234705,RSNYUBDIPFPZKJ-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,IC50,=,80.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.096910013008057,CN(C)[C@H]1CCC(=CC1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)[C@@H]1CC=C(c2c[nH]c3ccc(C#N)cc23)CC1
4793,4804,CHEMBL390432,RSNYUBDIPFPZKJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,IC50,=,97.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.013228265733755,CN(C)C1CCC(=CC1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)C1CC=C(c2c[nH]c3ccc(C#N)cc23)CC1
4794,4805,CHEMBL390432,RSNYUBDIPFPZKJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,71.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,71.0,CN(C)C1CCC(=CC1)C2=CNC3=C2C=C(C=C3)C#N,CN(C)C1CC=C(c2c[nH]c3ccc(C#N)cc23)CC1
4795,4806,CHEMBL1909076,RSTSYGXUDMJEFP-SECBINFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CNC(=S)SC[C@H](C(=O)O)N,N[C@H](CSC(=S)NCc1ccccc1)C(=O)O
4796,4807,CHEMBL1909076,RSTSYGXUDMJEFP-SECBINFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CNC(=S)SC[C@H](C(=O)O)N,N[C@H](CSC(=S)NCc1ccccc1)C(=O)O
4797,4808,CHEMBL404145,RSWULBWZZJNURY-SWLSCSKDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC(=CC=C2)F,CCN(CC)C(=O)[C@@]1(c2cccc(F)c2)C[C@H]1CN
4798,4809,CHEMBL3094316,RSZFCDGHJLBYEB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,72.2,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,72.2,C1=CC=C(C=C1)COC2=CC=C(C=C2)CN.Cl,NCc1ccc(OCc2ccccc2)cc1
4799,4810,CHEMBL1456,RTGDFNSFWBGLEC-SYZQJQIISA-N,MYCOPHENOLATE MOFETIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2
4800,4811,CHEMBL1456,RTGDFNSFWBGLEC-SYZQJQIISA-N,MYCOPHENOLATE MOFETIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2
4801,4812,CHEMBL1169388,RTHCYVBBDHJXIQ-INIZCTEOSA-N,(S)-FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,3097.0,NM,,,,,,,,,,,,,,,,,,,,5.509058794643212,CNCC[C@@H](C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4802,4813,CHEMBL1169388,RTHCYVBBDHJXIQ-INIZCTEOSA-N,(S)-FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,4974.0,NM,,,,,,,,,,,,,,,,,,,,5.303294219066083,CNCC[C@@H](C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4803,4814,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,3600.0,NM,,,,,,,,,,,,,,,,,,,,5.443697499232713,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4804,4815,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,3600.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4805,4816,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,3764.0,NM,,,,,,,,,,,,,,,,,,,,5.4243503852447805,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4806,4817,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,5960.0,NM,,,,,,,,,,,,,,,,,,,,5.224753740259764,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4807,4818,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,4752.0,NM,,,,,,,,,,,,,,,,,,,,5.323123568026864,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4808,4819,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,KI,=,1900.0,NM,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.721246399047171,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4809,4820,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16220969.0,KI,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition constant against dopamine transporter,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4810,4821,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,=,4400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513811,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4811,4822,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,4400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513811,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4812,4823,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4813,4824,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,6000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4814,4825,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,=,19500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,4.709965388637482,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4815,4826,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,=,6670.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.175874166083451,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4816,4827,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,=,19500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,4.709965388637482,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4817,4828,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,=,6670.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,5.175874166083451,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4818,4829,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4819,4830,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,9120.11,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.039999923502187,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4820,4831,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,3764.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4243503852447805,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4821,4832,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,31.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,31.0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4822,4833,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,18400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.735182176990463,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4823,4834,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4824,4835,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,6.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4825,4836,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,31.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,31.0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4826,4837,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,18400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,4.735182176990463,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4827,4838,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,6.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4828,4839,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4829,4840,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
4830,4841,CHEMBL3334800,RTJQGAYVHIKRGT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,356.6,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.447818661160665,CN(C)CCC(C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,CN(C)CCC(c1ccc(Cl)c(Cl)c1)N1CCCC1
4831,4842,CHEMBL564229,RTKAHBPTWDBIEJ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,-2.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,-2.0,CCN1C2=CC=CC=C2N(C1=O)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CCn1c(=O)n([C@@H](c2cccc(F)c2)[C@H](O)CNC)c2ccccc21
4832,4843,CHEMBL1173412,RTLOWGFIODTOMO-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,251.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.599997654072044,COC[C@]12C[C@]1(CCNC2)C3=CC=C(C=C3)Cl,COC[C@@]12CNCC[C@]1(c1ccc(Cl)cc1)C2
4833,4844,CHEMBL257549,RTMQOOCMZQWPBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)C1(C(C1C2=CC=CC=C2)CN)C3=CC=CC=C3,C=CCN(CC)C(=O)C1(c2ccccc2)C(CN)C1c1ccccc1
4834,4845,CHEMBL1915726,RTNYSNRMZBOTJO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21777010.0,IC50,=,870.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,6.0604807473813835,COC1=CN=C(C=C1)COC2=CC=C(C=C2)C3=NN(C=C3C4=CC=NC=C4)CCF,COc1ccc(COc2ccc(-c3nn(CCF)cc3-c3ccncc3)cc2)nc1
4835,4846,CHEMBL1915726,RTNYSNRMZBOTJO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21777010.0,INHIBITION,=,92.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 '-5 M,"Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,92.0,COC1=CN=C(C=C1)COC2=CC=C(C=C2)C3=NN(C=C3C4=CC=NC=C4)CCF,COc1ccc(COc2ccc(-c3nn(CCF)cc3-c3ccncc3)cc2)nc1
4836,4847,CHEMBL3673157,RTZINNBUTTZVCY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,205.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.687611050629407,C1CN2CCC1(C3=C(C2)C=C(C=C3)OCCCC4=CC=NC=C4)C5=CC=C(C=C5)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(OCCCc4ccncc4)ccc23)cc1
4837,4848,CHEMBL252203,RUBGVYPHZJSWTD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18242991.0,INHIBITION,=,1.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.0,CC1=C(C(=CC=C1)NC(=O)CCCCC(=O)O)C2=CC(=CC=C2)S(=O)(=O)C3=C(SC(=C3)C(=N)N)SC,CSc1sc(C(=N)N)cc1S(=O)(=O)c1cccc(-c2c(C)cccc2NC(=O)CCCCC(=O)O)c1
4838,4849,CHEMBL2206528,RUBLHLUAVCRNAN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,58.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.236572006437062,CC1=C2CN(CC(C2=CC=C1)C3=CC(=C(C=C3)F)F)C,Cc1cccc2c1CN(C)CC2c1ccc(F)c(F)c1
4839,4850,CHEMBL513313,RUCURZAOXQKURR-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCCCC(=O)N(CC1=C(C=C(C=C1)Cl)Cl)[C@H]2CCNC2,CCCCC(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
4840,4851,CHEMBL201666,RUCXEVOCSDADAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,154.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.812479279163537,CCCC(C(=O)C1=CC=C(C=C1)C(=O)OC)N2CCCC2,CCCC(C(=O)c1ccc(C(=O)OC)cc1)N1CCCC1
4841,4852,CHEMBL201666,RUCXEVOCSDADAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,360.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.443697499232713,CCCC(C(=O)C1=CC=C(C=C1)C(=O)OC)N2CCCC2,CCCC(C(=O)c1ccc(C(=O)OC)cc1)N1CCCC1
4842,4853,CHEMBL443922,RUEHEMMKOYGDGT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,140.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.853871964321763,CN(C)CC1=CC=CC=C1OC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1ccccc1Oc1ccc(Cl)c(Cl)c1
4843,4854,CHEMBL356531,RUFGGNDBOBTWQC-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,2800.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.552841968657781,CC(C)(C)N(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN([C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21)C(C)(C)C
4844,4855,CHEMBL356531,RUFGGNDBOBTWQC-LPHOPBHVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)N(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN([C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21)C(C)(C)C
4845,4856,CHEMBL148104,RUFGGNDBOBTWQC-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,890.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.0506099933550885,CC(C)(C)N(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN([C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21)C(C)(C)C
4846,4857,CHEMBL148104,RUFGGNDBOBTWQC-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,2700.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,5.568636235841013,CC(C)(C)N(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN([C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21)C(C)(C)C
4847,4858,CHEMBL148104,RUFGGNDBOBTWQC-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,3.0,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,3.0,CC(C)(C)N(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN([C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21)C(C)(C)C
4848,4859,CHEMBL2207489,RUIFDUVNEYPMGO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23043306.0,INHIBITION,=,15.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DAT at 1 uM by CEREP assay,Systematic in Vivo Screening of a Series of 1-Propyl-4-arylpiperidines against Dopaminergic and Serotonergic Properties in Rat Brain: A Scaffold-Jumping Approach.,J. Med. Chem.,PUBLICATION,,15.0,CCCN1CCC(CC1)C2=NOC3=C2C=CC(=C3)F,CCCN1CCC(c2noc3cc(F)ccc23)CC1
4849,4860,CHEMBL1357815,RUYRNYRGPSAXTK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21194936.0,ACTIVITY,=,83.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by radioligand binding assay,"Discovery and optimization of a novel, selective and brain penetrant M(1) positive allosteric modulator (PAM): The development of ML169, an MLPCN probe.",Bioorg. Med. Chem. Lett.,PUBLICATION,,83.0,CC1=CC(=NO1)NC(=O)CS(=O)(=O)C2=CN(C3=CC=CC=C32)CC4=C(C=CC(=C4)Br)F,Cc1cc(NC(=O)CS(=O)(=O)c2cn(Cc3cc(Br)ccc3F)c3ccccc23)no1
4850,4861,CHEMBL227180,RUZFACWXYQTPTF-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,41.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.387216143280264,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)Cl,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(Cl)cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
4851,4862,CHEMBL227180,RUZFACWXYQTPTF-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,28.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.552841968657781,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)Cl,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(Cl)cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
4852,4863,CHEMBL707,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,DOXAZOSIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,188.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.72584215073632,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
4853,4864,CHEMBL707,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,DOXAZOSIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,149.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.826813731587727,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
4854,4865,CHEMBL246519,RVDUVVPILREHEK-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,1190.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.924453038607469,C1CNC[C@H]1N(CC2=C(C(=C(C=C2)F)F)F)C3CCOCC3,Fc1ccc(CN(C2CCOCC2)[C@H]2CCNC2)c(F)c1F
4855,4866,CHEMBL561878,RVLRGNBXYBRGGM-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)N([C@H]2CCNC2)C(=O)C3=CC=CC=C3OC4=CC=CC=C4,O=C(c1ccccc1Oc1ccccc1)N(C1CCC1)[C@H]1CCNC1
4856,4867,CHEMBL1170793,RVOPEWUULYWWBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,79.43,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(N2CCNCC2Cc2ccccc2)cc1Cl
4857,4868,CHEMBL1173530,RVRYTWVPEPGNKI-CHWSQXEVSA-N,"RAC-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[4.1.0]HEPTAN-6-YL)METHANOL (STRUCTURAL MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.100015437450608,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CO,OC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4858,4869,CHEMBL1173530,RVRYTWVPEPGNKI-CHWSQXEVSA-N,"RAC-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[4.1.0]HEPTAN-6-YL)METHANOL (STRUCTURAL MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.0,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CO,OC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4859,4870,CHEMBL1173530,RVRYTWVPEPGNKI-CHWSQXEVSA-N,"RAC-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[4.1.0]HEPTAN-6-YL)METHANOL (STRUCTURAL MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,199.53,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.699991797446188,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CO,OC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4860,4871,CHEMBL189118,RVSLLQIPFFIMSB-KPKJPENVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16134937.0,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against dopamine transporter,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,PUBLICATION,,5.0,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)/C=C/C3=CC=C(C=C3)OC(F)(F)F)N(C)CCN(C)C,Cc1cc(N(C)CCN(C)C)nc2ccc(NC(=O)/C=C/c3ccc(OC(F)(F)F)cc3)cc12
4861,4872,CHEMBL491268,RVVDMQMBQDIWKD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,320.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,CN(C)CC1=CC=CC=C1CC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1ccccc1Cc1ccc(Cl)c(Cl)c1
4862,4873,CHEMBL1253709,RWBBMMXWHVZGGM-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6.3,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.200659450546418,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=C(C=C2)N,COC(=O)[C@H](c1ccc(N)cc1)[C@H]1CCCCN1
4863,4874,CHEMBL462402,RWLJNOQFNVGFMO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,4700.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.327902142064284,CC1=CC=CC=C1SC2C3=CC=CC=C3CC2(CNC)O,CNCC1(O)Cc2ccccc2C1Sc1ccccc1C
4864,4875,CHEMBL3673171,RWPUMYBDIXPXIA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,55.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.252588192113577,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC(=CC=C5)Cl,FC(F)(F)c1ccc(Oc2ccc3c(c2)CN2CCC3(c3cccc(Cl)c3)CC2)nn1
4865,4876,CHEMBL1256017,RWTGFMPOODRXIM-UHFFFAOYSA-N,ARCAINE SULFATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCN=C(N)N)CN=C(N)N.OS(=O)(=O)O,NC(N)=NCCCCN=C(N)N
4866,4877,CHEMBL1256017,RWTGFMPOODRXIM-UHFFFAOYSA-N,ARCAINE SULFATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCN=C(N)N)CN=C(N)N.OS(=O)(=O)O,NC(N)=NCCCCN=C(N)N
4867,4878,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
4868,4879,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
4869,4880,CHEMBL1909065,RWVUEZAROXKXRT-VQLSFVLHSA-N,LYSERGOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
4870,4881,CHEMBL1909065,RWVUEZAROXKXRT-VQLSFVLHSA-N,LYSERGOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
4871,4882,CHEMBL230000,RXBAZUHMGOEBGO-CLFYSBASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17705359.0,KI,=,13.0,NM,,,cell_based,,,,,HEK293,,,,,,,Binding affinity to human DAT expressed in HEK293 cells,Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,7.886056647693162,C1CC2C(C(CC1N2)C3=CC=C(C=C3)/C=C\I)C(=O)OCCF,O=C(OCCF)C1C2CCC(CC1c1ccc(/C=C\I)cc1)N2
4872,4883,CHEMBL395998,RXBAZUHMGOEBGO-LIOZXAKYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053782.0,KI,=,13.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]RTI-55 from human DAT transfected in human HEK293 cells,"Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,7.886056647693162,C1CC2C(C(CC1N2)C3=CC=C(C=C3)/C=C\I)C(=O)OCC[18F],O=C(OCCF)C1C2CCC(CC1c1ccc(/C=C\I)cc1)N2
4873,4884,CHEMBL1944833,RXBAZUHMGOEBGO-MTJIVWGXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,13.18,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.880084589742008,C1C[C@@H]2[C@H]([C@H](C[C@H]1N2)C3=CC=C(C=C3)/C=C\I)C(=O)OCCF,O=C(OCCF)[C@H]1[C@@H](c2ccc(/C=C\I)cc2)C[C@@H]2CC[C@H]1N2
4874,4885,CHEMBL552167,RXJIAQGHWRMBEZ-KGLIPLIRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560923.0,IC50,=,690.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.161150909262744,CN(C)C[C@H]1CCC[C@@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@H]1CCC[C@@H]1c1c[nH]c2ccc(C#N)cc12
4875,4886,CHEMBL552167,RXJIAQGHWRMBEZ-KGLIPLIRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20034793.0,IC50,=,690.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [I125]RTI-55 from human DAT transfected in human HEK293 cells,Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.161150909262744,CN(C)C[C@H]1CCC[C@@H]1C2=CNC3=C2C=C(C=C3)C#N,CN(C)C[C@H]1CCC[C@@H]1c1c[nH]c2ccc(C#N)cc12
4876,4887,CHEMBL610220,RXLIIMKHNRHPBV-IWIIMEHWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.599980364934843,C1[C@@H]2[C@@H](C2(COCC(F)(F)F)C3=CC(=C(C=C3)Cl)Cl)CN1,FC(F)(F)COCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CNC[C@H]21
4877,4888,CHEMBL365649,RXVOLFOXVDRZRI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15482938.0,KI,=,5.0,NM,,,,,,,,,,,,,,,Inhibition of [18F]PET binding to dopamine transporter of human brain,Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Br)C(=O)OCCCF,CN1C2CCC1C(C(=O)OCCCF)C(c1ccc(Br)cc1)C2
4878,4889,CHEMBL380316,RXWBASVYZOFLRF-UHFFFAOYSA-N,IM-094882,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19101155.0,INHIBITION,=,77.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,"Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.",Bioorg. Med. Chem.,PUBLICATION,,77.0,C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)C4=CC=CC5=C4C=CN=C5,Clc1ccc(Nc2nnc(-c3cccc4cnccc34)c3ccccc23)cc1
4879,4890,CHEMBL469912,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,PUROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@@H](n3cnc4c(N(C)C)ncnc43)[C@@H]2O)cc1
4880,4891,CHEMBL469912,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,PUROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@@H](n3cnc4c(N(C)C)ncnc43)[C@@H]2O)cc1
4881,4892,CHEMBL1214185,RXZBMPWDPOLZGW-XMRMVWPWSA-N,ROXITHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
4882,4893,CHEMBL1214185,RXZBMPWDPOLZGW-XMRMVWPWSA-N,ROXITHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
4883,4894,CHEMBL1173754,RYHCLMRIRKKHKV-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,3.98,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.400116927926312,CC(=O)[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl,CC(=O)[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
4884,4895,CHEMBL1643513,RYIJMRFACOYPNH-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,8.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.096910013008056,CN[C@@H]1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
4885,4896,CHEMBL1643511,RYIJMRFACOYPNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,39.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.4089353929735005,CNC1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
4886,4897,CHEMBL498566,RYMGUUFPMNAKMP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,5525.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.257667717642852,CCN(CCC1=CC=C(C=C1)OC(F)(F)F)CCN2CCCC2,CCN(CCc1ccc(OC(F)(F)F)cc1)CCN1CCCC1
4887,4898,CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
4888,4899,CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
4889,4900,CHEMBL225235,RYRHNOGQFYLMHQ-KOQKOIQBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,0.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,9.045757490560677,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC=C(C=C4)F)N3C,Cc1ccc([C@H]2CC3CCC([C@H]2c2ccc(F)cc2)N3C)cc1
4890,4901,CHEMBL453493,RYTIZBPXUHTIDS-UHFFFAOYSA-N,"(3,4-DICHLOROPHENYL)(2-((DIMETHYLAMINO)METHYL)PHENYL)METHANONE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,2100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6777807052660805,CN(C)CC1=CC=CC=C1C(=O)C2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1ccccc1C(=O)c1ccc(Cl)c(Cl)c1
4891,4902,CHEMBL466936,RYTXLXDKGBGSQO-HHHXNRCGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,20.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.698970004336019,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CC4=CC=CC=C4)N,N[C@H](Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4892,4903,CHEMBL466145,RYTXLXDKGBGSQO-MHZLTWQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,39.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.4089353929735005,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H](CC4=CC=CC=C4)N,N[C@@H](Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4893,4904,CHEMBL207886,RYUCCDFXIDUVPN-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,330.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.481486060122112,CC(C)CN(CC1=CC=CC=C1F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccccc1F)C1CCNCC1
4894,4905,CHEMBL1947088,RYXJNKOIIVLWKR-ANDHVUINSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,0.87,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,9.060480747381384,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C(=C/C(F)(F)F)/I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C/C(I)=C/C(F)(F)F
4895,4906,CHEMBL1947088,RYXJNKOIIVLWKR-ANDHVUINSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,RATIO KI,=,10.0,,,,,,,,,,,,,,,,Ratio of LBT999 Ki to compound Ki for human cloned DAT receptor,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,10.0,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C(=C/C(F)(F)F)/I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C/C(I)=C/C(F)(F)F
4896,4907,CHEMBL1947088,RYXJNKOIIVLWKR-ANDHVUINSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,RATIO KI,=,20.0,,,,,,,,,,,,,,,,Ratio of PE2I Ki to compound Ki for human cloned DAT receptor,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,20.0,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C(=C/C(F)(F)F)/I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C/C(I)=C/C(F)(F)F
4897,4908,CHEMBL113,RYYVLZVUVIJVGH-UHFFFAOYSA-N,CAFFEINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Cn1c(=O)c2c(ncn2C)n(C)c1=O
4898,4909,CHEMBL113,RYYVLZVUVIJVGH-UHFFFAOYSA-N,CAFFEINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Cn1c(=O)c2c(ncn2C)n(C)c1=O
4899,4910,CHEMBL550696,RYZMJJMMTKGIGG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,1600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344076,C1CNCCC1C(C2=CN=CC=C2)OC3=CC(=CC=C3)Cl,Clc1cccc(OC(c2cccnc2)C2CCNCC2)c1
4900,4911,CHEMBL1914696,RZDYKEZBUSRGJW-UMQBVGHOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,5.6,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.2518119729938,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)CNC4=NC(=CC=C4)Br,CN1C2CCC1[C@@H](CNc1cccc(Br)n1)[C@@H](c1ccc(Cl)cc1)C2
4901,4912,CHEMBL118,RZEKVGVHFLEQIL-UHFFFAOYSA-N,CELECOXIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2431.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.6142150411566645,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
4902,4913,CHEMBL118,RZEKVGVHFLEQIL-UHFFFAOYSA-N,CELECOXIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1931.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.714217726220605,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
4903,4914,CHEMBL45245,RZFVLEJOHSLEFR-UHFFFAOYSA-N,PHENANTHRIDIN-6(5H)-ONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O,O=c1[nH]c2ccccc2c2ccccc12
4904,4915,CHEMBL45245,RZFVLEJOHSLEFR-UHFFFAOYSA-N,PHENANTHRIDIN-6(5H)-ONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O,O=c1[nH]c2ccccc2c2ccccc12
4905,4916,CHEMBL122,RZJQGNCSTQAWON-UHFFFAOYSA-N,ROFECOXIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
4906,4917,CHEMBL122,RZJQGNCSTQAWON-UHFFFAOYSA-N,ROFECOXIB,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
4907,4918,CHEMBL467323,RZKZTKPGTZKVOQ-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,33.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,33.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N(C)C2=CC=CC=C2)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)N(C)c1ccccc1
4908,4919,CHEMBL2326694,RZPGXWQFZWSYES-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,9.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.045757490560675,COCCN1CC=CC[C@@H](C1)C2=CC(=C(C=C2)Cl)Cl,COCCN1CC=CC[C@H](c2ccc(Cl)c(Cl)c2)C1
4909,4920,CHEMBL1480,RZTAMFZIAATZDJ-UHFFFAOYSA-N,FELODIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
4910,4921,CHEMBL1480,RZTAMFZIAATZDJ-UHFFFAOYSA-N,FELODIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
4911,4922,CHEMBL112,RZVAJINKPMORJF-UHFFFAOYSA-N,ACETAMINOPHEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC=C(C=C1)O,CC(=O)Nc1ccc(O)cc1
4912,4923,CHEMBL112,RZVAJINKPMORJF-UHFFFAOYSA-N,ACETAMINOPHEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC=C(C=C1)O,CC(=O)Nc1ccc(O)cc1
4913,4924,CHEMBL595539,RZXLCNVGLULZII-FLNOXTKTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,890.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.0506099933550885,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NC4CCC(CC4)NC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)NC1CCC(NC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)CC1)[C@@H](c1ccc(Cl)cc1)C2
4914,4925,CHEMBL487873,RZZJNEKORGOFAD-XDGABKOJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,6.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.161150909262744,CC1=CC=C(C=C1)CC2=NOC(=C2)[C@H]3[C@H](CC4CCC3N4C)C5=CC=C(C=C5)C.Cl,Cc1ccc(Cc2cc([C@@H]3C4CCC(C[C@@H]3c3ccc(C)cc3)N4C)on2)cc1
4915,4926,CHEMBL1683900,SAARGPSTPXUSIL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,83.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.080921907623925,C1CCC(CC1)(CN)C2=CC3=CC=CC=C3C=C2,NCC1(c2ccc3ccccc3c2)CCCCC1
4916,4927,CHEMBL232674,SADMOVBJKBFJNN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,121000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.9172146296835497,COC(=O)C1=C(CCC1)C2=CC(=CC=C2)N,COC(=O)C1=C(c2cccc(N)c2)CCC1
4917,4928,CHEMBL232674,SADMOVBJKBFJNN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,875000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.057991946977687,COC(=O)C1=C(CCC1)C2=CC(=CC=C2)N,COC(=O)C1=C(c2cccc(N)c2)CCC1
4918,4929,CHEMBL232674,SADMOVBJKBFJNN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,1148153621496.88,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.0599999999999987,COC(=O)C1=C(CCC1)C2=CC(=CC=C2)N,COC(=O)C1=C(c2cccc(N)c2)CCC1
4919,4930,CHEMBL381079,SAEFVYOQTPRNBW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-17.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-17.0,CC(C)(CN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2)C#N.C(C(C(=O)O)O)(C(=O)O)O,CC(C)(C#N)CN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
4920,4931,CHEMBL451264,SAGAKZDNFJIHDD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18793858.0,KI,>,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]GBR-12935 from human cloned DAT expressed in HEK293 cells,"Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CNC)NC(=O)C3=CC=C(C=C3)F,CNCc1ccccc1Sc1ccc(C)cc1NC(=O)c1ccc(F)cc1
4921,4932,CHEMBL1173413,SAIAWHLAJVOTCR-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,158.49,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.799998134593397,COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)F)Cl,COC[C@@]12CNCC[C@]1(c1ccc(F)c(Cl)c1)C2
4922,4933,CHEMBL87708,SAPNXPWPAUFAJU-UHFFFAOYSA-N,LOFEPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1
4923,4934,CHEMBL1831166,SAUWBVJOXSKPQX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21899931.0,KI,=,5000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Synthesis and pharmacological evaluation of indole-based sigma receptor ligands.,Eur. J. Med. Chem.,PUBLICATION,,5.301029995663981,COC1=C(C=C2CN(CCC2=C1)CCCCN3C=C(C4=CC=CC=C43)C5=CC=C(C=C5)F)OC,COc1cc2c(cc1OC)CN(CCCCn1cc(-c3ccc(F)cc3)c3ccccc31)CC2
4924,4935,CHEMBL486041,SAYSUZYFOLMWGB-FOYRJYEQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,5.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.229147988357855,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=NO4)CC5=CC=C(C=C5)F)N3C.Cl,Cc1ccc([C@H]2CC3CCC([C@H]2c2cc(Cc4ccc(F)cc4)no2)N3C)cc1
4925,4936,CHEMBL402644,SBAQYPMYNRQKBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,490.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,CNCC1=C(C=CC(=C1)C(=O)N2CCN(CC2)C3CC3)OC4=CC(=C(C=C4)Cl)Cl,CNCc1cc(C(=O)N2CCN(C3CC3)CC2)ccc1Oc1ccc(Cl)c(Cl)c1
4926,4937,CHEMBL509,SBDNJUWAMKYJOX-UHFFFAOYSA-N,MECLOFENAMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
4927,4938,CHEMBL509,SBDNJUWAMKYJOX-UHFFFAOYSA-N,MECLOFENAMIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
4928,4939,CHEMBL1084971,SBKGLFTUHHUCII-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,2070.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.684029654543082,C1CN(CCN1)[C@H](CC2=CC=CC=C2O)C3=CC=CC=C3,Oc1ccccc1C[C@H](c1ccccc1)N1CCNCC1
4929,4940,CHEMBL3704750,SBTIZQKJKFHNPY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,9.0,CCOC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
4930,4941,CHEMBL3704750,SBTIZQKJKFHNPY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,13.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.872895201635193,CCOC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
4931,4942,CHEMBL3704750,SBTIZQKJKFHNPY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,38.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.415668775632469,CCOC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
4932,4943,CHEMBL3704750,SBTIZQKJKFHNPY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,38.4,NM,317680,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.415668775632469,CCOC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCOC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
4933,4944,CHEMBL1384,SBUJHOSQTJFQJX-NOAMYHISSA-N,KANAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
4934,4945,CHEMBL1384,SBUJHOSQTJFQJX-NOAMYHISSA-N,KANAMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
4935,4946,CHEMBL104700,SCDKHPSUXHBJDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CC2CCC1N2CC3=CN=CC=C3,c1cncc(CN2C3CCC2CC3)c1
4936,4947,CHEMBL1644609,SCEZKNSHVTVFNV-MUJYYYPQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=N3)C4=CC=CC=C4C#N,N#Cc1ccccc1-c1cccc(OC2C[C@@H]3CC[C@H](C2)N3)n1
4937,4948,CHEMBL1413,SCKYRAXSEDYPSA-UHFFFAOYSA-N,CICLOPIROX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(C(=C1)C2CCCCC2)O,Cc1cc(C2CCCCC2)n(O)c(=O)c1
4938,4949,CHEMBL1413,SCKYRAXSEDYPSA-UHFFFAOYSA-N,CICLOPIROX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(C(=C1)C2CCCCC2)O,Cc1cc(C2CCCCC2)n(O)c(=O)c1
4939,4950,CHEMBL3323094,SCNQXZMXILXZRI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,>,300.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,6.522878745280337,CN1CC(C2=CC=CC=C2C1)C3=CC=CC4=C3OC=C4,CN1Cc2ccccc2C(c2cccc3ccoc23)C1
4940,4951,CHEMBL3323094,SCNQXZMXILXZRI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,4.5,NM,314437,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.346787486224656,CN1CC(C2=CC=CC=C2C1)C3=CC=CC4=C3OC=C4,CN1Cc2ccccc2C(c2cccc3ccoc23)C1
4941,4952,CHEMBL396754,SDIRDYYWJCYZFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,20600.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.686132779630847,CCOC(=O)C1=C(CCNC1)C2=CC(=CC=C2)[N+](=O)[O-],CCOC(=O)C1=C(c2cccc([N+](=O)[O-])c2)CCNC1
4942,4953,CHEMBL213287,SDLVJPBOBLQFEW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,=,1300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693162,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3,Clc1ccccc1CC(c1ccccc1)N1CCNCC1
4943,4954,CHEMBL213287,SDLVJPBOBLQFEW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,1300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.886056647693162,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3,Clc1ccccc1CC(c1ccccc1)N1CCNCC1
4944,4955,CHEMBL2012106,SDPLHPFPOCEBDS-LSCKAKRGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CO4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cccc(-c3ccco3)c1)O2
4945,4956,CHEMBL2012106,SDPLHPFPOCEBDS-LSCKAKRGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CO4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1cccc(-c3ccco3)c1)O2
4946,4957,CHEMBL888,SDUQYLNIPVEERB-QPPQHZFASA-N,GEMCITABINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
4947,4958,CHEMBL888,SDUQYLNIPVEERB-QPPQHZFASA-N,GEMCITABINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
4948,4959,CHEMBL208444,SDXZUZKWTPTGAT-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,86.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.062983892535187,CC(C)CN(CC1=CC(=CC=C1)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1cccc(F)c1)C1CCNCC1
4949,4960,CHEMBL401070,SEBXOWVFQDITBN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,C1CC(=C(C1)C(=O)OCCF)C2=CC(=C(C=C2)Cl)Cl,O=C(OCCF)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
4950,4961,CHEMBL441358,SECNEKAFHNWBBW-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,190.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,CC(C)CN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
4951,4962,CHEMBL439,SEEPANYCNGTZFQ-UHFFFAOYSA-N,SULFADIAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
4952,4963,CHEMBL439,SEEPANYCNGTZFQ-UHFFFAOYSA-N,SULFADIAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
4953,4964,CHEMBL1477,SEERZIQQUAZTOL-ANMDKAQQSA-N,CERIVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
4954,4965,CHEMBL1477,SEERZIQQUAZTOL-ANMDKAQQSA-N,CERIVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
4955,4966,CHEMBL165790,SFBODOKJTYAUCM-UHFFFAOYSA-N,IPRIFLAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1
4956,4967,CHEMBL165790,SFBODOKJTYAUCM-UHFFFAOYSA-N,IPRIFLAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1
4957,4968,CHEMBL403759,SFBSHUOIEODSEA-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN(C)C)C2=CSC=C2,CCN(CC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN(C)C
4958,4969,CHEMBL543925,SFESMQNHNIKYIQ-CJRXIRLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,340.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.468521082957745,CC(C)(C)[C@@H]([C@@H](CN(C)C)C1=CC2=CC=CC=C2C=C1)O.Cl,CN(C)C[C@@H](c1ccc2ccccc2c1)[C@@H](O)C(C)(C)C
4959,4970,CHEMBL270659,SFJCDXPAZDITGW-SRDVYLRPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,55.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.259637310505756,CN1[C@@H]2CCC1C[C@@H]([C@@H]2COC(=O)CCC(=O)OC[C@H]3[C@H](CC4CCC3S4)C5=CC(=C(C=C5)Cl)Cl)C6=CC(=C(C=C6)Cl)Cl,CN1C2CC[C@@H]1[C@@H](COC(=O)CCC(=O)OC[C@@H]1C3CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)S3)[C@@H](c1ccc(Cl)c(Cl)c1)C2
4960,4971,CHEMBL432,SFLSHLFXELFNJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,8500.0,NM,,,,,,,,,,,,,,,,,,,,5.070581074285707,C1=CC(=C(C=C1C(CN)O)O)O,NCC(O)c1ccc(O)c(O)c1
4961,4972,CHEMBL432,SFLSHLFXELFNJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,9800.0,NM,,,,,,,,,,,,,,,,,,,,5.008773924307505,C1=CC(=C(C=C1C(CN)O)O)O,NCC(O)c1ccc(O)c(O)c1
4962,4973,CHEMBL432,SFLSHLFXELFNJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC(=C(C=C1C(CN)O)O)O,NCC(O)c1ccc(O)c(O)c1
4963,4974,CHEMBL3321788,SFPSQBFPUCFLEZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25070422.0,KI,=,778.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human dopamine transporter by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.109020403010312,C1CC2CC(CC1N2CCCCC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1ccc(F)cc1
4964,4975,CHEMBL378536,SFVKEKBNXMUWFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784855.0,KI,=,12.25,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT transfected in HEK293 cells,Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.9118639112994495,C=C1CN2C3CCC2C1C(C3)C4=CC=C(C=C4)Cl,C=C1CN2C3CCC2C1C(c1ccc(Cl)cc1)C3
4965,4976,CHEMBL1947098,SGCXLJVGGMOGGK-MBHMRJJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,9.55,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,8.019996628416253,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/CF)C[C@@H]1C3=CC=C(C=C3)F,COC(=O)[C@H]1[C@@H](c2ccc(F)cc2)C[C@@H]2CC[C@H]1N2C/C=C/CF
4966,4977,CHEMBL1214005,SGCXLJVGGMOGGK-PMWAWBRWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,=,9.5,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,8.022276394711152,COC(=O)[C@H]1[C@H](CC2CCC1N2C/C=C/CF)C3=CC=C(C=C3)F,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(F)cc1)N2C/C=C/CF
4967,4978,CHEMBL852,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,MELPHALAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
4968,4979,CHEMBL852,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,MELPHALAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
4969,4980,CHEMBL2432052,SGFPDDMJMPKKTB-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
4970,4981,CHEMBL282468,SGMZJAMFUVOLNK-UHFFFAOYSA-M,CHOLINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCO.[Cl-],C[N+](C)(C)CCO
4971,4982,CHEMBL282468,SGMZJAMFUVOLNK-UHFFFAOYSA-M,CHOLINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCO.[Cl-],C[N+](C)(C)CCO
4972,4983,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
4973,4984,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
4974,4985,CHEMBL429,SGUAFYQXFOLMHL-UHFFFAOYSA-N,LABETALOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1607.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.7939841232366565,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
4975,4986,CHEMBL429,SGUAFYQXFOLMHL-UHFFFAOYSA-N,LABETALOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1277.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.8938091027365855,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
4976,4987,CHEMBL566957,SGVYOOIAHHLONY-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CC1=CC=C(C=C1)[C@@H]([C@@H](CNC)O)N2C=CC3=CC=CC=C32,CNC[C@@H](O)[C@H](c1ccc(C)cc1)n1ccc2ccccc21
4977,4988,CHEMBL264159,SGXWOKUJCWMPJE-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,10800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.966576244513051,COC1=C(C=CC(=C1)Cl)O[C@H]([C@@H]2CNCCO2)C3=CC(=CC=C3)F,COc1cc(Cl)ccc1O[C@@H](c1cccc(F)c1)[C@@H]1CNCCO1
4978,4989,CHEMBL653,SGXXNSQHWDMGGP-IZZDOVSWSA-N,NIZATIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C,CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
4979,4990,CHEMBL653,SGXXNSQHWDMGGP-IZZDOVSWSA-N,NIZATIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C,CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
4980,4991,CHEMBL221067,SHAKAEUQTANHLB-NVQXNPDNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,756.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.121478204498794,CCCN1CC[C@H](C[C@@H]1CCCNC(=O)NC2=CC=CC(=C2)C(=O)C)CC3=CC=C(C=C3)F,CCCN1CC[C@@H](Cc2ccc(F)cc2)C[C@@H]1CCCNC(=O)Nc1cccc(C(C)=O)c1
4981,4992,CHEMBL41011,SHDFPJWENXXDLR-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,7.769551078621726,COC(=O)[C@@H]([C@H]1CCCCO1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@H](c1ccc(Cl)c(Cl)c1)[C@H]1CCCCO1
4982,4993,CHEMBL37918,SHDFPJWENXXDLR-OLZOCXBDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,736.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,6.133122185662501,COC(=O)[C@H]([C@H]1CCCCO1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@@H](c1ccc(Cl)c(Cl)c1)[C@H]1CCCCO1
4983,4994,CHEMBL37262,SHDFPJWENXXDLR-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,193.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,6.714442690992227,COC(=O)[C@@H]([C@@H]1CCCCO1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@H](c1ccc(Cl)c(Cl)c1)[C@@H]1CCCCO1
4984,4995,CHEMBL37262,SHDFPJWENXXDLR-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,286.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,6.543633966870957,COC(=O)[C@@H]([C@@H]1CCCCO1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@H](c1ccc(Cl)c(Cl)c1)[C@@H]1CCCCO1
4985,4996,CHEMBL417877,SHDFPJWENXXDLR-STQMWFEESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,29.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,7.536107011014093,COC(=O)[C@H]([C@@H]1CCCCO1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@@H](c1ccc(Cl)c(Cl)c1)[C@@H]1CCCCO1
4986,4997,CHEMBL417877,SHDFPJWENXXDLR-STQMWFEESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12672255.0,IC50,=,34.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 Binding to the Dopamine Transporter in Rhesus (Macaca mulatta) orCynomolgus Monkey (Macaca fascicularis) Caudate-Putamen,Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.,J. Med. Chem.,PUBLICATION,,7.468521082957745,COC(=O)[C@H]([C@@H]1CCCCO1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@@H](c1ccc(Cl)c(Cl)c1)[C@@H]1CCCCO1
4987,4998,CHEMBL599798,SHDFZRRKZIILLR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6320.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.199282921717615,C1CN(CCN1)C2=C(N=CC=C2)OC3=C(C=CC=C3Cl)F,Fc1cccc(Cl)c1Oc1ncccc1N1CCNCC1
4988,4999,CHEMBL547,SHGAZHPCJJPHSC-XFYACQKRSA-N,ISOTRETINOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
4989,5000,CHEMBL547,SHGAZHPCJJPHSC-XFYACQKRSA-N,ISOTRETINOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
4990,5001,CHEMBL38,SHGAZHPCJJPHSC-YCNIQYBTSA-N,TRETINOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
4991,5002,CHEMBL38,SHGAZHPCJJPHSC-YCNIQYBTSA-N,TRETINOIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
4992,5003,CHEMBL469552,SHJHTXWKDLOBQS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.221848749616356,C1CNCCC1COC2=CC3=C(C=C2)C=C(C=C3)C#N,N#Cc1ccc2cc(OCC3CCNCC3)ccc2c1
4993,5004,CHEMBL257336,SHSUQLQDTJDCTQ-IFXJQAMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C#CCN(C1CC1)C(=O)[C@]2(C[C@H]2CN)C3=CC4=C(C=C3)OCCO4,C#CCN(C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN)C1CC1
4994,5005,CHEMBL3673167,SHTPCUCEADJDFW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,0.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,9.154901959985743,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC(=C(C=C5)Cl)Cl,FC(F)(F)c1ccc(Oc2ccc3c(c2)CN2CCC3(c3ccc(Cl)c(Cl)c3)CC2)nn1
4995,5006,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12761331.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(CC1=CC2=C(C=C1)OCO2)NC,CNC(C)Cc1ccc2c(c1)OCO2
4996,5007,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19717215.0,IC50,=,1442.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.,Eur. J. Med. Chem.,PUBLICATION,,5.84103473961659,CC(CC1=CC2=C(C=C1)OCO2)NC,CNC(C)Cc1ccc2c(c1)OCO2
4997,5008,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20466553.0,IC50,=,1442.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,"Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines.",Bioorg. Med. Chem.,PUBLICATION,,5.84103473961659,CC(CC1=CC2=C(C=C1)OCO2)NC,CNC(C)Cc1ccc2c(c1)OCO2
4998,5009,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,2398.83,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.620000528471499,CC(CC1=CC2=C(C=C1)OCO2)NC,CNC(C)Cc1ccc2c(c1)OCO2
4999,5010,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,897.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.047207556955907,CC(CC1=CC2=C(C=C1)OCO2)NC,CNC(C)Cc1ccc2c(c1)OCO2
5000,5011,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26233799.0,EC50,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to human DAT expressed in HEK293 cells assessed as induction of [3H]MPP+ release by liquid scintillation counting method,"Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC(CC1=CC2=C(C=C1)OCO2)NC,CNC(C)Cc1ccc2c(c1)OCO2
5001,5012,CHEMBL3238488,SIBFIXSSMRRLCB-IWIPYMOSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1I)C(F)(F)F)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(I)cc3C(F)(F)F)c(O)c12
5002,5013,CHEMBL1200396,SIEYLFHKZGLBNX-UHFFFAOYSA-N,BUPIVACAINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
5003,5014,CHEMBL1200396,SIEYLFHKZGLBNX-UHFFFAOYSA-N,BUPIVACAINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
5004,5015,CHEMBL202348,SIFVHGKZPNIKBO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,18.3,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.73754891026957,C=CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,C=CCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
5005,5016,CHEMBL202348,SIFVHGKZPNIKBO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,39.9,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.399027104313253,C=CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)N2CCCC2,C=CCC(C(=O)c1ccc(Cl)c(Cl)c1)N1CCCC1
5006,5017,CHEMBL2096860,SIIICDNNMDMWCI-HXSCFSKGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,22.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.643974142806877,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@@H]1c1ccc(I)cc1)N2C
5007,5018,CHEMBL610766,SIIICDNNMDMWCI-JYVUQVBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,3.9,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.4089353929735,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(I)cc1)N2C
5008,5019,CHEMBL242338,SIIICDNNMDMWCI-KBXIAJHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,4.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.397940008672037,CN1[C@@H]2CC[C@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@H]2CC[C@@H]1N2C
5009,5020,CHEMBL242338,SIIICDNNMDMWCI-KBXIAJHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,9.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,8.045757490560675,CN1[C@@H]2CC[C@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@H]2CC[C@@H]1N2C
5010,5021,CHEMBL300226,SIIICDNNMDMWCI-LMRVLLHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,1.08,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,8.96657624451305,CN1[C@@H]2CCC1C([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@@H]1c1ccc(I)cc1)N2C
5011,5022,CHEMBL300226,SIIICDNNMDMWCI-LMRVLLHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8515428.0,IC50,=,1.6,NM,,,,,,,,,,,,,,,Compounds binding ability to dopamine transporter was evaluated by displacing [3H]beta-CFT in baboon brain,Enantioselectivity of cocaine recognition sites: binding of (1S)- and (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane (beta-CIT) to monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.795880017344075,CN1[C@@H]2CCC1C([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@@H]1c1ccc(I)cc1)N2C
5012,5023,CHEMBL375889,SIIICDNNMDMWCI-SHWKFHJASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,2.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,8.537602002101043,CN1C2CCC1[C@H]([C@@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(I)cc1)N2C
5013,5024,CHEMBL14391,SIIICDNNMDMWCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,1.08,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,8.96657624451305,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)C1C(c2ccc(I)cc2)CC2CCC1N2C
5014,5025,CHEMBL14391,SIIICDNNMDMWCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,1.26,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.899629454882437,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)C1C(c2ccc(I)cc2)CC2CCC1N2C
5015,5026,CHEMBL14391,SIIICDNNMDMWCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,2.85,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.54515513999149,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)C1C(c2ccc(I)cc2)CC2CCC1N2C
5016,5027,CHEMBL311347,SIIICDNNMDMWCI-VOFREWHGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12620070.0,KI,=,0.48,NM,,,cell_based,,,,,,,,,,,,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.,J. Med. Chem.,PUBLICATION,,9.318758762624412,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccc(I)cc1)N2C
5017,5028,CHEMBL311347,SIIICDNNMDMWCI-VOFREWHGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,1.3,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 as radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,8.886056647693161,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccc(I)cc1)N2C
5018,5029,CHEMBL311347,SIIICDNNMDMWCI-VOFREWHGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15080991.0,KI,=,0.48,NM,,,cell_based,,,,,,,,,,,,Binding affinity to dopamine transporter in membranes of cells selectively expressing the human genes for DAT,Synthesis and monoamine transporter affinity of 3'-analogs of 2-beta-carbomethoxy-3-beta-(4'-iodophenyl)tropane (beta-CIT).,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.318758762624412,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccc(I)cc1)N2C
5019,5030,CHEMBL311347,SIIICDNNMDMWCI-VOFREWHGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,1.3,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,8.886056647693161,CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccc(I)cc1)N2C
5020,5031,CHEMBL215376,SIIICDNNMDMWCI-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,35.48,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.450016388840312,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2C
5021,5032,CHEMBL215376,SIIICDNNMDMWCI-YJNKXOJESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24262882.0,KI,=,6.34,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin),"Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [(11)C]IPCIT and [(18)F]FE@IPCIT.",Bioorg. Med. Chem.,PUBLICATION,,8.197910742118268,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2C
5022,5033,CHEMBL611959,SIPPOOBBYQOQKQ-UYLXQDHASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,21.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.67778070526608,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NCC4=CC=C(C=C4)NC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)Nc1ccc(CNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)cc1)[C@@H](c1ccc(Cl)cc1)C2
5023,5034,CHEMBL187211,SIVVTQXNEALXFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,68.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(C=C3)I,COC(=O)C1=C(c2ccc(I)cc2)CC2CCC1O2
5024,5035,CHEMBL469664,SJJKUNDBFWUAQB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17925440.0,IC50,=,1700.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.,Proc. Natl. Acad. Sci. U.S.A.,PUBLICATION,,5.769551078621726,C1=CC(=CC(=C1)S(=O)(=O)NC2=CC=C(C=C2)Br)C(=O)NC3=CC=C(C=C3)Br,O=C(Nc1ccc(Br)cc1)c1cccc(S(=O)(=O)Nc2ccc(Br)cc2)c1
5025,5036,CHEMBL208993,SJKATDZDYZMMAP-VQTJNVASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,3.8,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.8,CCOC1=CC=CC=C1C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O,CCOc1ccccc1C[C@@](O)(c1ccccc1)[C@@H]1CNCCO1
5026,5037,CHEMBL291338,SJQBHPJLLIJASD-UHFFFAOYSA-N,"3,3',4',5-TETRACHLOROSALICYLANILIDE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl,O=C(Nc1ccc(Cl)c(Cl)c1)c1cc(Cl)cc(Cl)c1O
5027,5038,CHEMBL291338,SJQBHPJLLIJASD-UHFFFAOYSA-N,"3,3',4',5-TETRACHLOROSALICYLANILIDE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl,O=C(Nc1ccc(Cl)c(Cl)c1)c1cc(Cl)cc(Cl)c1O
5028,5039,CHEMBL2432050,SJWCMFMHVZULSJ-DKSPCFMDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCCC6=CC(=CC=C6)F,Fc1cccc(CCCN[C@H]2C3C4CC5C6C4CC3C6C52)c1
5029,5040,CHEMBL432571,SJWSSPYRKIZOGG-RUXDESIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,55.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.258848401148215,CN1C2C[C@@H](C1CC(=C2C(=O)OC)C3=CC(=C(C=C3)Cl)Cl)O,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2[C@@H](O)CC1N2C
5030,5041,CHEMBL554336,SKAPWNQXRANDFK-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,3160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,CN([C@H]1CCNC1)C(=O)C2=CC=CC=C2OC3=CC=CC=C3,CN(C(=O)c1ccccc1Oc1ccccc1)[C@H]1CCNC1
5031,5042,CHEMBL3329242,SKDSYDCWEKPDQT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,17.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,17.0,C1C(CN1)CN(CC2=CC=C(C=C2)Cl)C3=CC4=CC=CC=C4C=C3.C(=O)(C(F)(F)F)O,Clc1ccc(CN(CC2CNC2)c2ccc3ccccc3c2)cc1
5032,5043,CHEMBL1829960,SKDZMQCQPCAWQB-UHFFFAOYSA-N,MERIDOQUIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21907583.0,KI,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT after 1.5 hrs by scintillation counting,CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.,Bioorg. Med. Chem.,PUBLICATION,,,CCN(CC)C1=NC=CC(=N1)C2=CNC3=C2C=CC(=C3)Cl,CCN(CC)c1nccc(-c2c[nH]c3cc(Cl)ccc23)n1
5033,5044,CHEMBL270240,SKEKTDQXWYTVGO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC2=CN=CC=C2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCc1cccnc1
5034,5045,CHEMBL1914695,SKIKZARVXIZUJL-DXCLHELWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,127.0,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.896196279044043,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NC4=NC(=CC=C4)F,CN1C2CCC1[C@@H](C(=O)Nc1cccc(F)n1)[C@@H](c1ccc(Cl)cc1)C2
5035,5046,CHEMBL575133,SKJWCGCNEAHUQZ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,24.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,24.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=CC=C3Br)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2c(Br)cccc21
5036,5047,CHEMBL1171424,SKNMQBHFOCWPIZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,316.23,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,C1CCC(CC1)CC2CNCCN2C3=CC4=C(C=C3)NN=C4,c1cc2[nH]ncc2cc1N1CCNCC1CC1CCCCC1
5037,5048,CHEMBL1172524,SKRQWFVNZMYZQL-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,794.33,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CCC[C@@H]1CNCCN1C2=CC3=C(C=C2)NN=C3,CCC[C@@H]1CNCCN1c1ccc2[nH]ncc2c1
5038,5049,CHEMBL1170374,SKRQWFVNZMYZQL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,63.1,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,CCCC1CNCCN1C2=CC3=C(C=C2)NN=C3,CCCC1CNCCN1c1ccc2[nH]ncc2c1
5039,5050,CHEMBL1169912,SKRQWFVNZMYZQL-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,25.12,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CCC[C@H]1CNCCN1C2=CC3=C(C=C2)NN=C3,CCC[C@H]1CNCCN1c1ccc2[nH]ncc2c1
5040,5051,CHEMBL38942,SKSRFQROQDXMAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.82,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.82,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(CN(CCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
5041,5052,CHEMBL38942,SKSRFQROQDXMAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.86,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.86,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(CN(CCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
5042,5053,CHEMBL103936,SKSUKRWKVAZHJI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,145.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.838631997765025,COC(=O)C1=CC=CC=C1C2=CC3=CC=CC=C3C=C2,COC(=O)c1ccccc1-c1ccc2ccccc2c1
5043,5054,CHEMBL103936,SKSUKRWKVAZHJI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,4060.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.391473966422807,COC(=O)C1=CC=CC=C1C2=CC3=CC=CC=C3C=C2,COC(=O)c1ccccc1-c1ccc2ccccc2c1
5044,5055,CHEMBL103936,SKSUKRWKVAZHJI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=CC=CC=C1C2=CC3=CC=CC=C3C=C2,COC(=O)c1ccccc1-c1ccc2ccccc2c1
5045,5056,CHEMBL115280,SKVXOYIMICHFPV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,2250.0,NM,,,,,,,,,,,,,,,Binding affinity against dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.647817481888637,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CC4=CC(=CC=C4)OC5=CC=CC=C5,O=C1NCN(c2ccccc2)C12CCN(Cc1cccc(Oc3ccccc3)c1)CC2
5046,5057,CHEMBL27577,SKZKKFZAGNVIMN-UHFFFAOYSA-N,SALICYLAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)N)O,NC(=O)c1ccccc1O
5047,5058,CHEMBL27577,SKZKKFZAGNVIMN-UHFFFAOYSA-N,SALICYLAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)N)O,NC(=O)c1ccccc1O
5048,5059,CHEMBL412873,SLRCCWJSBJZJBV-TUVASFSCSA-N,SPARTEINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1
5049,5060,CHEMBL412873,SLRCCWJSBJZJBV-TUVASFSCSA-N,SPARTEINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1
5050,5061,CHEMBL1224384,SLSGGVPSCGVWNP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,36.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,36.0,CN(C)CCC(C1=CC2=C(C=C1)C=C(C=C2)OC)N3N=CN=N3,COc1ccc2cc(C(CCN(C)C)n3ncnn3)ccc2c1
5051,5062,CHEMBL218174,SLSRYMJCMOWUIE-RDPSFJRHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,96.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.017728766960433,CC(=O)C1=CC(=CC=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2C)CC3=CC=C(C=C3)F,CC(=O)c1cccc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2C)c1
5052,5063,CHEMBL1046,SLXKOJJOQWFEFD-UHFFFAOYSA-N,AMINOCAPROIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCC(=O)O)CCN,NCCCCCC(=O)O
5053,5064,CHEMBL1046,SLXKOJJOQWFEFD-UHFFFAOYSA-N,AMINOCAPROIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCC(=O)O)CCN,NCCCCCC(=O)O
5054,5065,CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,584.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.2335871528875995,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
5055,5066,CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,464.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.3334820194451185,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
5056,5067,CHEMBL186447,SMRDMANDQOCEMF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693162,COC(=O)C1=C(CC2CCC1S2)C3=CC=C(C=C3)Cl,COC(=O)C1=C(c2ccc(Cl)cc2)CC2CCC1S2
5057,5068,CHEMBL1201195,SNBUBQHDYVFSQF-HIFRSBDPSA-N,CEFMETAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
5058,5069,CHEMBL1201195,SNBUBQHDYVFSQF-HIFRSBDPSA-N,CEFMETAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
5059,5070,CHEMBL1642913,SNDGNPRZZZPUAX-BLLLJJGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,50.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.301029995663981,C1[C@H](CC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl)CCN,NCC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1
5060,5071,CHEMBL1642912,SNDGNPRZZZPUAX-WBMJQRKESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,32.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.494850021680094,C1[C@@H](CC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)CCN,NCC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
5061,5072,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2,CN1CCC[C@H]1c1cccnc1
5062,5073,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2,CN1CCC[C@H]1c1cccnc1
5063,5074,CHEMBL2386164,SNNRWIBSGBMYRF-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,>,890.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.0506099933550885,CC1=C(C=CC(=N1)OC)O[C@H](CC(C)C)[C@H]2CCNC2,COc1ccc(O[C@H](CC(C)C)[C@H]2CCNC2)c(C)n1
5064,5075,CHEMBL2386165,SNNRWIBSGBMYRF-HIFRSBDPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,>,890.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.0506099933550885,CC1=C(C=CC(=N1)OC)O[C@@H](CC(C)C)[C@@H]2CCNC2,COc1ccc(O[C@@H](CC(C)C)[C@@H]2CCNC2)c(C)n1
5065,5076,CHEMBL2386166,SNNRWIBSGBMYRF-UKRRQHHQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,>,890.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.0506099933550885,CC1=C(C=CC(=N1)OC)O[C@H](CC(C)C)[C@@H]2CCNC2,COc1ccc(O[C@H](CC(C)C)[C@@H]2CCNC2)c(C)n1
5066,5077,CHEMBL577504,SNORKSVJXFFHHB-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CN(C2=CC=CC=C12)[C@@H](C3=CC=CC=C3)[C@H](CN)O,Cc1cn([C@@H](c2ccccc2)[C@@H](O)CN)c2ccccc12
5067,5078,CHEMBL1371937,SNPLKNRPJHDVJA-UHFFFAOYSA-N,PANTHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CO)C(C(=O)NCCCO)O,CC(C)(CO)C(O)C(=O)NCCCO
5068,5079,CHEMBL1371937,SNPLKNRPJHDVJA-UHFFFAOYSA-N,PANTHENOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CO)C(C(=O)NCCCO)O,CC(C)(CO)C(O)C(=O)NCCCO
5069,5080,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,560.0,NM,,,,,,,,,,,,,,,,,,,,6.251811972993798,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5070,5081,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,784.0,NM,,,,,,,,,,,,,,,,,,,,6.105683937315562,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5071,5082,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,950.0,NM,,,,,,,,,,,,,,,,,,,,6.022276394711152,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5072,5083,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,1800.0,NM,,,,,,,,,,,,,,,,,,,,5.7447274948966935,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5073,5084,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,520.0,NM,,,,,,,,,,,,,,,,,,,,6.2839966563652006,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5074,5085,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,562.0,NM,,,,,,,,,,,,,,,,,,,,6.250263684430939,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5075,5086,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12723940.0,IC50,=,2900.0,NM,,,,,,,,,,,,,,,Inhibition of dopamine (DA) reuptake using cloned human dopamine transporter was determined,2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.,J. Med. Chem.,PUBLICATION,,5.537602002101044,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5076,5087,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,IC50,=,1567.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,5.804931003531411,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5077,5088,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,KI,=,441.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,6.355561410532162,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5078,5089,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,RATIO,=,3.0,,,,cell_based,,,,,,,,,,,,Ratio of IC50 for [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells to Ki for displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,3.0,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5079,5090,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,945.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.024568191490737,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5080,5091,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,871.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.059981844992339,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5081,5092,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,658.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.181774106386046,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5082,5093,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,660.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,6.180456064458133,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5083,5094,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,658.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,6.181774106386046,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5084,5095,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24901260.0,IC50,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) assessed as transporter-mediated dopamine reuptake,Recent developments in novel antidepressants targeting a42-nicotinic acetylcholine receptors.,J. Med. Chem.,PUBLICATION,,6.259637310505756,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5085,5096,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1033.8,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.985563472168328,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5086,5097,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,821.4,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.085445301482366,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5087,5098,CHEMBL1667967,SNQKPKFVSANKFP-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21251828.0,ACTIVITY,=,43.0,%,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,43.0,C1C[C@@H](CNC1)OC2=CC3=C(C=C2)C(=O)NC=C3,O=c1[nH]ccc2cc(O[C@H]3CCCNC3)ccc12
5088,5099,CHEMBL384649,SOCOFADTVIPCCY-CUNXSJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,2082.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.681519274825482,CCC(=O)N1CC[C@H](C[C@@H]1CCCNC(=O)NC2=CC(=CC(=C2)C(=O)C)C(=O)C)CC3=CC=C(C=C3)F,CCC(=O)N1CC[C@@H](Cc2ccc(F)cc2)C[C@@H]1CCCNC(=O)Nc1cc(C(C)=O)cc(C(C)=O)c1
5089,5100,CHEMBL373773,SOCRIYWOGGANHT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,370.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.431798275933005,C1CCNC(C1)C(CC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(Cc2ccccc2)C2CCCCN2)cc1
5090,5101,CHEMBL373773,SOCRIYWOGGANHT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,390.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.4089353929735005,C1CCNC(C1)C(CC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(Cc2ccccc2)C2CCCCN2)cc1
5091,5102,CHEMBL373773,SOCRIYWOGGANHT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,440.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.356547323513813,C1CCNC(C1)C(CC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(Cc2ccccc2)C2CCCCN2)cc1
5092,5103,CHEMBL373773,SOCRIYWOGGANHT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,550.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.259637310505756,C1CCNC(C1)C(CC2=CC=CC=C2)C3=CC=C(C=C3)Cl,Clc1ccc(C(Cc2ccccc2)C2CCCCN2)cc1
5093,5104,CHEMBL2012090,SOIKHMSXRURTFX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,7.886056647693162,COC(=O)C1=C(CC2CCC1O2)C3=CC4=CC=CC=C4S3,COC(=O)C1=C(c2cc3ccccc3s2)CC2CCC1O2
5094,5105,CHEMBL2012090,SOIKHMSXRURTFX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC4=CC=CC=C4S3,COC(=O)C1=C(c2cc3ccccc3s2)CC2CCC1O2
5095,5106,CHEMBL1818466,SOSAAAUSVCKKRE-QRWMCTBCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,31.62,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.500038134403809,CC1=CN(C=C1)CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)c1
5096,5107,CHEMBL1201353,SOYKEARSMXGVTM-HNNXBMFYSA-N,DEXCHLORPHENIRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,931.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.031050319018657,CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1
5097,5108,CHEMBL1201353,SOYKEARSMXGVTM-HNNXBMFYSA-N,DEXCHLORPHENIRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,739.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.131355561605173,CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1
5098,5109,CHEMBL326706,SPARNWYFZQKTHR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,48.98,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.309981219211304,C1CC2CC(CC1N2CCOCCO)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,OCCOCCN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2
5099,5110,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,4455.2,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.351132795118296,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
5100,5111,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,3539.7,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.4510335441509286,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
5101,5112,CHEMBL576145,SPBUAQRRWQFNRI-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,8.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=CN(C2=CC=CC=C12)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1cc(C)c2ccccc21
5102,5113,CHEMBL15511,SPFYMRJSYKOXGV-UHFFFAOYSA-N,ENROFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1
5103,5114,CHEMBL15511,SPFYMRJSYKOXGV-UHFFFAOYSA-N,ENROFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1
5104,5115,CHEMBL1085197,SPHAUOPMTCENAZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,21.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,21.0,CNCCCC1CC2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCCCC1Cc2ccccc2N(c2ccccc2F)S1(=O)=O
5105,5116,CHEMBL1493,SPIUTQOUKAMGCX-UHFFFAOYSA-N,FLAVOXATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
5106,5117,CHEMBL1493,SPIUTQOUKAMGCX-UHFFFAOYSA-N,FLAVOXATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
5107,5118,CHEMBL2031885,SPKOQCHHYOCMGR-HXUWFJFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313242.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCN2CCC3=C(C2=O)C=CC(=C3)C4=CC=C(C=C4)C(=O)N5CCCC5,C[C@@H]1CCCN1CCN1CCc2cc(-c3ccc(C(=O)N4CCCC4)cc3)ccc2C1=O
5108,5119,CHEMBL340521,SPMFHRZZZBQTCP-ISRILLDMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,24.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.619788758288393,CN1C2CCC1C([C@H](C2)OC(C3=CC=CC=C3)C4=CC=C(C=C4)Br)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccccc1)c1ccc(Br)cc1)N2C
5109,5120,CHEMBL525952,SPQWIGAZLYFACO-SREVYHEPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053782.0,KI,=,35.5,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]RTI-55 from human DAT transfected in human HEK293 cells,"Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,7.449771646944907,C1CC2C(C(CC1N2)C3=CC=CC(=C3)/C=C\Br)C(=O)OCCF,O=C(OCCF)C1C2CCC(CC1c1cccc(/C=C\Br)c1)N2
5110,5121,CHEMBL1945249,SPTMOFIPJMIUBM-BQJUDKOJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,41.69,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.3799681048737025,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CC3=CC=CC=C3)C[C@@H]1C4=CC=C(C=C4)I,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2Cc1ccccc1
5111,5122,CHEMBL2206524,SPUPMMOBNUTZEB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,98.8,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.005243055412373,CN1CC(C2=CC=CC=C2C1)C3=CC(=C(C=C3)F)F,CN1Cc2ccccc2C(c2ccc(F)c(F)c2)C1
5112,5123,CHEMBL468573,SPVLIWURVCWIKT-MUUNZHRXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,27.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.568636235841013,CO[C@H](CC1=CC=CC=C1)CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CO[C@H](Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
5113,5124,CHEMBL513858,SPVLIWURVCWIKT-NDEPHWFRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,29.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.5376020021010435,CO[C@@H](CC1=CC=CC=C1)CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CO[C@@H](Cc1ccccc1)CN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
5114,5125,CHEMBL209821,SPWZXWDPAWDKQE-UHFFFAOYSA-N,NALUZOTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16722631.0,KI,>,2000.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter by radioligand binding assay,"An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.",J. Med. Chem.,PUBLICATION,,5.698970004336019,CC(=O)NC1=CC(=CC=C1)N2CCN(CC2)CCCCNS(=O)(=O)CC3CCCCC3,CC(=O)Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2)c1
5115,5126,CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O
5116,5127,CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O
5117,5128,CHEMBL509007,SQCPLVXIAQOQFF-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CC1(C2=CC=CC=C2N(C1=O)[C@@H](CCNC)C3=CC=CC=C3)C,CNCC[C@@H](c1ccccc1)N1C(=O)C(C)(C)c2ccccc21
5118,5129,CHEMBL513912,SQCPLVXIAQOQFF-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CC1(C2=CC=CC=C2N(C1=O)[C@H](CCNC)C3=CC=CC=C3)C,CNCC[C@H](c1ccccc1)N1C(=O)C(C)(C)c2ccccc21
5119,5130,CHEMBL444742,SQKSQRKXCFBFLF-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC=C1F)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1cccc(F)c1C
5120,5131,CHEMBL444742,SQKSQRKXCFBFLF-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC=C1F)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1cccc(F)c1C
5121,5132,CHEMBL2047584,SQNUVGLAMLMYCU-HRAATJIYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,70.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,70.0,C[C@@H]([C@H](C1=CC(=CC=C1)F)O)N2CCC(=CC2)CC3=CC=CC=C3,C[C@@H]([C@@H](O)c1cccc(F)c1)N1CC=C(Cc2ccccc2)CC1
5122,5133,CHEMBL2047583,SQNUVGLAMLMYCU-IIBYNOLFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,35.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,35.0,C[C@H]([C@H](C1=CC(=CC=C1)F)O)N2CCC(=CC2)CC3=CC=CC=C3,C[C@H]([C@@H](O)c1cccc(F)c1)N1CC=C(Cc2ccccc2)CC1
5123,5134,CHEMBL584152,SQRPNDYXHFVWJL-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,12.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=CC=C3Cl)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2c(Cl)cccc21
5124,5135,CHEMBL1084033,SQSFWPVYWBTHEX-UHFFFAOYSA-N,1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,2490.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.603800652904264,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=C(C=C3)F,Fc1ccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)cc1
5125,5136,CHEMBL1084033,SQSFWPVYWBTHEX-UHFFFAOYSA-N,1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,2620.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.581698708680254,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=C(C=C3)F,Fc1ccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)cc1
5126,5137,CHEMBL1084033,SQSFWPVYWBTHEX-UHFFFAOYSA-N,1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,5090.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.293282217663241,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=C(C=C3)F,Fc1ccc(C(Cc2ccccc2OC(F)(F)F)N2CCNCC2)cc1
5127,5138,CHEMBL1902981,SQUNAWUMZGQQJD-UHFFFAOYSA-N,EPERISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1
5128,5139,CHEMBL1902981,SQUNAWUMZGQQJD-UHFFFAOYSA-N,EPERISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1
5129,5140,CHEMBL2165538,SRCUGVUYMUSXIR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,0.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CN(C)C1CCC2=C(C1)C3=CC=CC=C3N2S(=O)(=O)C4=CC(=CC=C4)Cl,CN(C)C1CCc2c(c3ccccc3n2S(=O)(=O)c2cccc(Cl)c2)C1
5130,5141,CHEMBL2165538,SRCUGVUYMUSXIR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,7.21,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.21,CN(C)C1CCC2=C(C1)C3=CC=CC=C3N2S(=O)(=O)C4=CC(=CC=C4)Cl,CN(C)C1CCc2c(c3ccccc3n2S(=O)(=O)c2cccc(Cl)c2)C1
5131,5142,CHEMBL1095525,SRKHUCZOFIQCSE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,INHIBITION,=,43.0,%,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human DAT expressed in CHO membranes at 1000 nM,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,43.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CSC(=C3)Cl)O,OC1(C(CN2CCNCC2)c2csc(Cl)c2)CCCCC1
5132,5143,CHEMBL40733,SRPXSILJHWNFMK-ZBEGNZNMSA-N,DESMETHYLSERTRALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,129.0,NM,,,,,,,,,,,,,,,,,,,,6.889410289700751,C1C[C@@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N,N[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5133,5144,CHEMBL512450,SRRVLPVASMWVKI-RBBKRZOGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18386916.0,ACTIVITY,=,23.0,NM,,,,,,,,,,,,,,,Inhibition of SLC6A3,Chemical fragments as foundations for understanding target space and activity prediction.,J. Med. Chem.,PUBLICATION,,7.638272163982407,CN1CC[C@@H]([C@@H](C1)CSCC(=O)NCCC2=CC=CC=C2)C3=CC=C(C=C3)Cl,CN1CC[C@H](c2ccc(Cl)cc2)[C@H](CSCC(=O)NCCc2ccccc2)C1
5134,5145,CHEMBL2030629,SRRZEMVAQOSBLB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CC2CCC1N2CCC3=CC=CC=N3,c1ccc(CCN2C3CCC2CC3)nc1
5135,5146,CHEMBL2047562,SSEWYSOPUMSOTB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,64.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,64.0,C1CN(CCC1(CC2=CC=CC=C2)O)CCC(C3=CSC4=CC=CC=C43)O,OC(CCN1CCC(O)(Cc2ccccc2)CC1)c1csc2ccccc12
5136,5147,CHEMBL338790,SSMIFVHARFVINF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N,Nc1ccc2c3c(cccc13)C(=O)NC2=O
5137,5148,CHEMBL338790,SSMIFVHARFVINF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N,Nc1ccc2c3c(cccc13)C(=O)NC2=O
5138,5149,CHEMBL1902627,SSMSBSWKLKKXGG-UHFFFAOYSA-N,CLORPRENALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=CC=C1Cl)O,CC(C)NCC(O)c1ccccc1Cl
5139,5150,CHEMBL1902627,SSMSBSWKLKKXGG-UHFFFAOYSA-N,CLORPRENALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=CC=C1Cl)O,CC(C)NCC(O)c1ccccc1Cl
5140,5151,CHEMBL2432062,SSQDVMAIIMMISV-SEDVZXITSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CC1=CC2=C(C=C1)OCO2)[C@H]3C4C5CC6C3C7C4CC5C67,CN(Cc1ccc2c(c1)OCO2)[C@H]1C2C3CC4C5C3CC2C5C41
5141,5152,CHEMBL218848,SSUIQPFKMQJHGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,32.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.494850021680094,CC(C)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)C(c1ccc(Cl)cc1)C1CCCCN1
5142,5153,CHEMBL218848,SSUIQPFKMQJHGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,990.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.00436480540245,CC(C)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)C(c1ccc(Cl)cc1)C1CCCCN1
5143,5154,CHEMBL218848,SSUIQPFKMQJHGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,46.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.337242168318426,CC(C)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)C(c1ccc(Cl)cc1)C1CCCCN1
5144,5155,CHEMBL218848,SSUIQPFKMQJHGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.045757490560675,CC(C)C(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)C(c1ccc(Cl)cc1)C1CCCCN1
5145,5156,CHEMBL403782,SSUXPRPQUAYFJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18242991.0,INHIBITION,=,15.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.,Bioorg. Med. Chem. Lett.,PUBLICATION,,15.0,CC1=C(C(=CC=C1)NC(=O)NCCCCCC(=O)O)C2=CC(=CC=C2)S(=O)(=O)C3=C(SC(=C3)C(=N)N)SC,CSc1sc(C(=N)N)cc1S(=O)(=O)c1cccc(-c2c(C)cccc2NC(=O)NCCCCCC(=O)O)c1
5146,5157,CHEMBL575206,SSYVIQKCLJMLJB-IOXAMRCBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,1100.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.9586073148417755,CCSC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3CC=C,C=CCN1C2CCC1[C@@H](C(=O)OC)[C@@H](c1ccc(SCC)cc1)C2
5147,5158,CHEMBL610514,STELSYDZPWCAMN-URBRKQAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,14.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,14.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2CCC3=CC=CC=C32)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CCc2ccccc21
5148,5159,CHEMBL49080,STJMRWALKKWQGH-UHFFFAOYSA-N,CLENBUTEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1
5149,5160,CHEMBL49080,STJMRWALKKWQGH-UHFFFAOYSA-N,CLENBUTEROL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1
5150,5161,CHEMBL178,STQGQHZAVUOBTE-VGBVRHCVSA-N,DAUNORUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
5151,5162,CHEMBL178,STQGQHZAVUOBTE-VGBVRHCVSA-N,DAUNORUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
5152,5163,CHEMBL451652,SUAFTJAVJHXARK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,668.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.175223537524454,COC1=CC=C(C=C1)C2CCC(O2)CN,COc1ccc(C2CCC(CN)O2)cc1
5153,5164,CHEMBL451652,SUAFTJAVJHXARK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=CC=C(C=C1)C2CCC(O2)CN,COc1ccc(C2CCC(CN)O2)cc1
5154,5165,CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1
5155,5166,CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1
5156,5167,CHEMBL417049,SUFVPROIOBRYEK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,330.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.481486060122112,CN(CCOC(C1=CC=CC=C1)C2=CC=CC=C2)C3CCN(CC3)CCCC4=CC=CC=C4,CN(CCOC(c1ccccc1)c1ccccc1)C1CCN(CCCc2ccccc2)CC1
5157,5168,CHEMBL417049,SUFVPROIOBRYEK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,30.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.522878745280337,CN(CCOC(C1=CC=CC=C1)C2=CC=CC=C2)C3CCN(CC3)CCCC4=CC=CC=C4,CN(CCOC(c1ccccc1)c1ccccc1)C1CCN(CCCc2ccccc2)CC1
5158,5169,CHEMBL605119,SUHBXDPETHQPJC-RLFYNMQTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,19.95,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.700057099977232,C1CCC(CC1)OC[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2[C@@H]3COC2CCCCC2)cc1Cl
5159,5170,CHEMBL1567463,SUHOQUVVVLNYQR-MRVPVSSYSA-N,CHOLINE ALFOSCERATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O,C[N+](C)(C)CCOP(=O)([O-])OC[C@H](O)CO
5160,5171,CHEMBL1567463,SUHOQUVVVLNYQR-MRVPVSSYSA-N,CHOLINE ALFOSCERATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O,C[N+](C)(C)CCOP(=O)([O-])OC[C@H](O)CO
5161,5172,CHEMBL43124,SUPURMVBOPJGOE-NSCUHMNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.47,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.47,COC1=CC=C(C=C1)/C=C/CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COc1ccc(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
5162,5173,CHEMBL43124,SUPURMVBOPJGOE-NSCUHMNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.19,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.19,COC1=CC=C(C=C1)/C=C/CN2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COc1ccc(/C=C/CN2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
5163,5174,CHEMBL205866,SUXMSNIBAHOLFO-RBUKOAKNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,6.2,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2,COC1=CC=C(C=C1)C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O,COc1ccc(C[C@@](O)(c2ccccc2)[C@@H]2CNCCO2)cc1
5164,5175,CHEMBL2206512,SUYOCKAQLJWIGF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,276.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.559090917934783,CC1=C2CN(CC(C2=CC=C1)C3=CC=CC=C3)C,Cc1cccc2c1CN(C)CC2c1ccccc1
5165,5176,CHEMBL1224316,SVDKSLGSXDLGEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC(C)(C)CCC1(CCNC1)C(=O)C2=NC(=C(C=C2)Cl)Cl,CC(C)(C)CCC1(C(=O)c2ccc(Cl)c(Cl)n2)CCNC1
5166,5177,CHEMBL146332,SVFXPTLYMIXFRX-BBRMVZONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,290.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.5376020021010435,CN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5167,5178,CHEMBL146332,SVFXPTLYMIXFRX-BBRMVZONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,500.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.301029995663981,CN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5168,5179,CHEMBL146332,SVFXPTLYMIXFRX-BBRMVZONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,1.7,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,1.7,CN[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5169,5185,CHEMBL296602,SVFXPTLYMIXFRX-UHFFFAOYSA-N,INDATRALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,0.794,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,9.100179497572904,CNC1CC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNC1CC(c2ccc(Cl)c(Cl)c2)c2ccccc21
5170,5186,CHEMBL341898,SVFXPTLYMIXFRX-XJKSGUPXSA-N,"(R,S)-INDATRALINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,23.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5171,5187,CHEMBL341898,SVFXPTLYMIXFRX-XJKSGUPXSA-N,"(R,S)-INDATRALINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,27.0,NM,,,,,,,,,,,,,,,Binding affinity against Dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.568636235841013,CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5172,5188,CHEMBL341898,SVFXPTLYMIXFRX-XJKSGUPXSA-N,"(R,S)-INDATRALINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,0.85,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,0.85,CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5173,5189,CHEMBL3309706,SVQJWGJWTNGCQH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,12.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,12.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1Cl
5174,5190,CHEMBL3309706,SVQJWGJWTNGCQH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,55.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,55.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1Cl
5175,5191,CHEMBL3309706,SVQJWGJWTNGCQH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=C(C=C3)Cl)Cl,Clc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1Cl
5176,5192,CHEMBL194574,SVXFDINGBNILGI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,64.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,64.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC(=CC=C3)Cl,CNCCCC1Cc2ccccc2N(c2cccc(Cl)c2)C1=O
5177,5193,CHEMBL194574,SVXFDINGBNILGI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC(=CC=C3)Cl,CNCCCC1Cc2ccccc2N(c2cccc(Cl)c2)C1=O
5178,5194,CHEMBL563384,SWADTMSKMJUFBO-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3960.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.402304814074488,C1CC(C1)CN([C@@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@@H]1CCNC1
5179,5195,CHEMBL552338,SWADTMSKMJUFBO-ZDUSSCGKSA-N,PF-3409409,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,2290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6401645176601125,C1CC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1
5180,5196,CHEMBL1683902,SWBCLQGKCJMOJJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,3.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.522878745280337,CN(C)CC1(CCCCC1)C2=CC3=CC=CC=C3C=C2,CN(C)CC1(c2ccc3ccccc3c2)CCCCC1
5181,5197,CHEMBL3334795,SWBSCJHQPHFHOQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,56.8,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,56.8,CN(C)CCC(C1=CSC2=CC=CC=C21)N3CCOCC3,CN(C)CCC(c1csc2ccccc12)N1CCOCC1
5182,5198,CHEMBL3334799,SWFPZMNSOVHJBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,80.1,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,80.1,CN(C)CCC(C1=CC(=C(C=C1)Cl)Cl)N2CCNCC2,CN(C)CCC(c1ccc(Cl)c(Cl)c1)N1CCNCC1
5183,5199,CHEMBL319244,SWUARLUWKZWEBQ-VQHVLOKHSA-N,CAFFEIC ACID PHENETHYL ESTER,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O,O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1
5184,5200,CHEMBL319244,SWUARLUWKZWEBQ-VQHVLOKHSA-N,CAFFEIC ACID PHENETHYL ESTER,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O,O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1
5185,5201,CHEMBL372312,SWUVZKWCOBGPTH-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,16.3,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.787812395596043,CCC[C@@H](C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCC[C@@H](C(=O)c1ccc(C)cc1)N1CCCC1
5186,5202,CHEMBL372312,SWUVZKWCOBGPTH-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,18.1,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.742321425130815,CCC[C@@H](C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCC[C@@H](C(=O)c1ccc(C)cc1)N1CCCC1
5187,5203,CHEMBL380699,SWUVZKWCOBGPTH-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,1790.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.747146969020108,CCC[C@H](C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCC[C@H](C(=O)c1ccc(C)cc1)N1CCCC1
5188,5204,CHEMBL380699,SWUVZKWCOBGPTH-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,1330.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.876148359032914,CCC[C@H](C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCC[C@H](C(=O)c1ccc(C)cc1)N1CCCC1
5189,5205,CHEMBL201960,SWUVZKWCOBGPTH-UHFFFAOYSA-N,PYROVALERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,52.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.2839966563652,CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1
5190,5206,CHEMBL201960,SWUVZKWCOBGPTH-UHFFFAOYSA-N,PYROVALERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,21.4,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.669586226650809,CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1
5191,5207,CHEMBL201960,SWUVZKWCOBGPTH-UHFFFAOYSA-N,PYROVALERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,IC50,=,32.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,7.494850021680094,CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1
5192,5208,CHEMBL201960,SWUVZKWCOBGPTH-UHFFFAOYSA-N,PYROVALERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,KI,=,8.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,8.096910013008056,CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1
5193,5209,CHEMBL201960,SWUVZKWCOBGPTH-UHFFFAOYSA-N,PYROVALERONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,RATIO,=,3.0,,,,cell_based,,,,,,,,,,,,Ratio of IC50 for [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells to Ki for displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,3.0,CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1
5194,5210,CHEMBL403071,SXCVOEWVYRDQSX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,421.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.375717904164333,CC1=C(C=CC(=C1)Cl)OC2=CC=CC=C2CNC,CNCc1ccccc1Oc1ccc(Cl)cc1C
5195,5211,CHEMBL1173353,SXEGCINDYXTNFI-TVQRCGJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,4200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.376750709602098,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=C(C=C2)F)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1ccc(F)cc1
5196,5212,CHEMBL599240,SXVNDMHECZDJQS-RLFYNMQTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.100015437450608,C1[C@H]2[C@@H]([C@]2(CN1)C3=CC(=C(C=C3)Cl)Cl)COC4=CC=C(C=C4)F,Fc1ccc(OC[C@H]2[C@@H]3CNC[C@@]32c2ccc(Cl)c(Cl)c2)cc1
5197,5213,CHEMBL566534,SXYIRMFQILZOAM-HVNFFKDJSA-N,ARTEMETHER,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3
5198,5214,CHEMBL566534,SXYIRMFQILZOAM-HVNFFKDJSA-N,ARTEMETHER,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3
5199,5215,CHEMBL467736,SYDKDXKLTMXNAA-JXLXBRSFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19284718.0,KI,=,2115.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,J. Med. Chem.,PUBLICATION,,5.674689628288939,C1[C@@H]([C@H]1C2=CC=CC=C2Br)CN.Cl,NC[C@H]1C[C@@H]1c1ccccc1Br
5200,5216,CHEMBL492916,SYDKDXKLTMXNAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19284718.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,J. Med. Chem.,PUBLICATION,,5.0,C1C(C1C2=CC=CC=C2Br)CN.Cl,NCC1CC1c1ccccc1Br
5201,5217,CHEMBL1683896,SYDXJSKTVHXBGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,625.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.204119982655924,CN(C)CC1(CCCCC1)C2=CC(=CC=C2)C(F)(F)F,CN(C)CC1(c2cccc(C(F)(F)F)c2)CCCCC1
5202,5218,CHEMBL470079,SYEDLPTWFRUJMC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,22.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,22.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CC(=CC=C3)F)O.Cl.Cl,OC1(C(CN2CCNCC2)c2cccc(F)c2)CCCCC1
5203,5219,CHEMBL574348,SYLMRMITUMFBTA-UHFFFAOYSA-N,4-(2-(PHENOXYMETHYL)PHENYL)PIPERIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,396.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.402304814074488,C1CNCCC1C2=CC=CC=C2COC3=CC=CC=C3,c1ccc(OCc2ccccc2C2CCNCC2)cc1
5204,5220,CHEMBL567481,SYMAJWVHHBJSJV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC(CNC(C)(C)C)C(=O)C1=CC(=CC=C1)Cl,CC(CNC(C)(C)C)C(=O)c1cccc(Cl)c1
5205,5221,CHEMBL567481,SYMAJWVHHBJSJV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC(CNC(C)(C)C)C(=O)C1=CC(=CC=C1)Cl,CC(CNC(C)(C)C)C(=O)c1cccc(Cl)c1
5206,5222,CHEMBL567481,SYMAJWVHHBJSJV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,>,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.0,CC(CNC(C)(C)C)C(=O)C1=CC(=CC=C1)Cl,CC(CNC(C)(C)C)C(=O)c1cccc(Cl)c1
5207,5223,CHEMBL1644472,SYNKGZURWSKSDC-DABQJJPHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,437.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.359518563029578,CN1[C@@H]2CC[C@H]1CC(C2)OC3=CC=CC=C3,CN1[C@H]2CC[C@@H]1CC(Oc1ccccc1)C2
5208,5224,CHEMBL563,SYTBZMRGLBWNTM-UHFFFAOYSA-N,FLURBIPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
5209,5225,CHEMBL563,SYTBZMRGLBWNTM-UHFFFAOYSA-N,FLURBIPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
5210,5226,CHEMBL1201010,SYWHXTATXSMDSB-GSLJADNHSA-N,FLUDROCORTISONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
5211,5227,CHEMBL1201010,SYWHXTATXSMDSB-GSLJADNHSA-N,FLUDROCORTISONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
5212,5228,CHEMBL250008,SZBJSPPPDLPVBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,94000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.026872146400302,CCN(CC)C(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCN(CC)C(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
5213,5229,CHEMBL241648,SZDGGXPDQJKRHQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,=,576.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.239577516576787,CN(C)CC1=C(C=CC(=C1)OC)SC2=CC=CC=C2N,COc1ccc(Sc2ccccc2N)c(CN(C)C)c1
5214,5230,CHEMBL3703742,SZGCLROZELTVOC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,33.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.481486060122112,C1C(C2=CC(=C(C=C2CN1)C3=NN=C(C=C3)OC(F)F)F)C4=CC(=C(C=C4)Cl)Cl,Fc1cc2c(cc1-c1ccc(OC(F)F)nn1)CNCC2c1ccc(Cl)c(Cl)c1
5215,5231,CHEMBL253184,SZIXMPCDFZGATL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18085744.0,KI,=,221.0,NM,,,cell_based,,,,,MDCK,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in MDCK cells,"Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands.",J. Med. Chem.,PUBLICATION,,6.655607726314889,CN(C)CC1=C(C=CC(=C1)Br)SC2=C(C=C(C=C2)CO)N,CN(C)Cc1cc(Br)ccc1Sc1ccc(CO)cc1N
5216,5232,CHEMBL50498,SZOKTSDFOPVLFD-UHFFFAOYSA-N,MERIDIANIN A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21907583.0,KI,=,2350.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT after 1.5 hrs by scintillation counting,CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.,Bioorg. Med. Chem.,PUBLICATION,,5.628932137728263,C1=CC2=C(C(=C1)O)C(=CN2)C3=NC(=NC=C3)N,Nc1nccc(-c2c[nH]c3cccc(O)c23)n1
5217,5233,CHEMBL295416,SZRPDCCEHVWOJX-UHFFFAOYSA-N,PIRINIXIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C
5218,5234,CHEMBL295416,SZRPDCCEHVWOJX-UHFFFAOYSA-N,PIRINIXIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C
5219,5235,CHEMBL270569,SZXFAVGUAGOGII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)C1(CC1CNCC2=CC=CN2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCc1ccc[nH]1
5220,5236,CHEMBL86,TTWJBBZEZQICBI-UHFFFAOYSA-N,METOCLOPRAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC
5221,5237,CHEMBL86,TTWJBBZEZQICBI-UHFFFAOYSA-N,METOCLOPRAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC
5222,5238,CHEMBL206404,TUDVVMCZTNBXMS-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,420.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.376750709602098,CN[C@H]1CC[C@H](C2=C1C(=CC=C2)C(=O)NC)C3=CC(=C(C=C3)Cl)Cl,CNC(=O)c1cccc2c1[C@@H](NC)CC[C@H]2c1ccc(Cl)c(Cl)c1
5223,5239,CHEMBL572951,TUHQZGVWJDBKNN-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C(=CC=C3)Br)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cccc(Br)c21
5224,5240,CHEMBL497845,TUPKUZCHBMCYHC-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=C(C=C1)F)O[C@@H]2[C@@H](OCC3=CC=CC=C23)CNC,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1cc(F)ccc1C
5225,5241,CHEMBL2012082,TUQGADGEWNEWII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.0,COC(=O)C1=C(CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CO4,COC(=O)C1=C(c2cccc(-c3ccco3)c2)CC2CCC1O2
5226,5242,CHEMBL2012082,TUQGADGEWNEWII-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=CC(=C3)C4=CC=CO4,COC(=O)C1=C(c2cccc(-c3ccco3)c2)CC2CCC1O2
5227,5243,CHEMBL28394,TUWFHUVJRFWFJU-FCLJUXRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,0.36,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.443697499232712,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)/C=C/Cl,CN1C2CCC1[C@@H](/C=C/Cl)[C@@H](c1ccc(Cl)cc1)C2
5228,5244,CHEMBL28394,TUWFHUVJRFWFJU-FCLJUXRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,0.73,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.136677139879543,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)/C=C/Cl,CN1C2CCC1[C@@H](/C=C/Cl)[C@@H](c1ccc(Cl)cc1)C2
5229,5245,CHEMBL28394,TUWFHUVJRFWFJU-FCLJUXRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,0.99,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.00436480540245,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)/C=C/Cl,CN1C2CCC1[C@@H](/C=C/Cl)[C@@H](c1ccc(Cl)cc1)C2
5230,5246,CHEMBL28394,TUWFHUVJRFWFJU-FCLJUXRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1.3,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)/C=C/Cl,CN1C2CCC1[C@@H](/C=C/Cl)[C@@H](c1ccc(Cl)cc1)C2
5231,5247,CHEMBL28394,TUWFHUVJRFWFJU-FCLJUXRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,0.22,NM,,,,,,,,,,,,,,,Binding constant for the ability to displace [3H]mazindol to dopamine receptor was calculated from the Cheng-Prusoff relationship,,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.657577319177793,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)/C=C/Cl,CN1C2CCC1[C@@H](/C=C/Cl)[C@@H](c1ccc(Cl)cc1)C2
5232,5248,CHEMBL28394,TUWFHUVJRFWFJU-FCLJUXRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,0.88,NM,,,,,,,,,,,,,,,Binding constant for [3H]dopamine uptake was calculated from the Cheng-Prusoff relationship,,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.05551732784983,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)/C=C/Cl,CN1C2CCC1[C@@H](/C=C/Cl)[C@@H](c1ccc(Cl)cc1)C2
5233,5249,CHEMBL2115570,TUWFHUVJRFWFJU-LVDPKSTMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.795880017344076,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=CCl,CN1C2CCC1[C@H](C=CCl)[C@@H](c1ccc(Cl)cc1)C2
5234,5250,CHEMBL2115570,TUWFHUVJRFWFJU-LVDPKSTMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,18.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.744727494896693,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=CCl,CN1C2CCC1[C@H](C=CCl)[C@@H](c1ccc(Cl)cc1)C2
5235,5251,CHEMBL2115570,TUWFHUVJRFWFJU-LVDPKSTMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,19.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.721246399047171,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=CCl,CN1C2CCC1[C@H](C=CCl)[C@@H](c1ccc(Cl)cc1)C2
5236,5252,CHEMBL2115570,TUWFHUVJRFWFJU-LVDPKSTMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,24.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.619788758288393,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C=CCl,CN1C2CCC1[C@H](C=CCl)[C@@H](c1ccc(Cl)cc1)C2
5237,5253,CHEMBL457968,TUZLHPUVXHTPCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,509.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.293282217663242,CC1=C(C=CC(=C1)CCC2CCC(O2)CCN)F,Cc1cc(CCC2CCC(CCN)O2)ccc1F
5238,5254,CHEMBL457968,TUZLHPUVXHTPCQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,6376.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.195451691611943,CC1=C(C=CC(=C1)CCC2CCC(O2)CCN)F,Cc1cc(CCC2CCC(CCN)O2)ccc1F
5239,5255,CHEMBL1144,TUZYXOIXSAXUGO-PZAWKZKUSA-N,PRAVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
5240,5256,CHEMBL1144,TUZYXOIXSAXUGO-PZAWKZKUSA-N,PRAVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
5241,5257,CHEMBL457416,TVDANBVAWXCYSJ-MKRRPMGHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,1300.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,5.886056647693162,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C(=C3)I)OC)I)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](c2cc(I)c(OC)c(I)c2)C[C@H]2CC[C@H]1N2C
5242,5258,CHEMBL2205826,TVDFWGUKMIRJAD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=C(C=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c(OC)c1
5243,5259,CHEMBL1683901,TVDNUGUVGACHFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,CNCC1(CCCCC1)C2=CC3=CC=CC=C3C=C2,CNCC1(c2ccc3ccccc3c2)CCCCC1
5244,5260,CHEMBL1683901,TVDNUGUVGACHFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,90.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.045757490560675,CNCC1(CCCCC1)C2=CC3=CC=CC=C3C=C2,CNCC1(c2ccc3ccccc3c2)CCCCC1
5245,5261,CHEMBL1095524,TVEJRNDJZBJGNP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)(C(CN2CCNCC2)C3=C(SC=C3)Cl)O,OC1(C(CN2CCNCC2)c2ccsc2Cl)CCCCC1
5246,5262,CHEMBL1237044,TVYLLZQTGLZFBW-UHFFFAOYSA-N,TRAMADOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,COc1cccc(C2(O)CCCCC2CN(C)C)c1
5247,5263,CHEMBL1237044,TVYLLZQTGLZFBW-UHFFFAOYSA-N,TRAMADOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,COc1cccc(C2(O)CCCCC2CN(C)C)c1
5248,5264,CHEMBL493057,TVYXGLWTICSLOM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,9900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.00436480540245,CN(C)CC1=CC=CC=C1SC2=CC=CC(=C2)C(F)(F)F,CN(C)Cc1ccccc1Sc1cccc(C(F)(F)F)c1
5249,5265,CHEMBL376180,TVZGACDUOSZQKY-LBPRGKRZSA-N,AMINOPTERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1
5250,5266,CHEMBL376180,TVZGACDUOSZQKY-LBPRGKRZSA-N,AMINOPTERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1
5251,5267,CHEMBL2206441,TWDISXDNMABOAR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22992024.0,ACTIVITY,=,83.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by CEREP assay,"Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,83.0,COC1=C(C=C(C=C1)F)C2CCN(CC2)C3=C(C4=NN=C(N4C=C3)CC5CC5)Cl,COc1ccc(F)cc1C1CCN(c2ccn3c(CC4CC4)nnc3c2Cl)CC1
5252,5268,CHEMBL2206441,TWDISXDNMABOAR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22992024.0,KI,=,5005.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,5.300595918184663,COC1=C(C=C(C=C1)F)C2CCN(CC2)C3=C(C4=NN=C(N4C=C3)CC5CC5)Cl,COc1ccc(F)cc1C1CCN(c2ccn3c(CC4CC4)nnc3c2Cl)CC1
5253,5269,CHEMBL2206508,TWJQHLGFNXDIDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,78.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.107905397309519,CC1=CC2=C(C=C1)C(CN(C2)C)C3=CC(=CC(=C3)F)F,Cc1ccc2c(c1)CN(C)CC2c1cc(F)cc(F)c1
5254,5270,CHEMBL3663916,TWKWOGUGCQDBEG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,>,1000.0,NM,314449,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.0,CC1=NN=C(C=C1)C2=CC3=C(C=C2)C(CN(C3)C)C4=C(C5=C(C=C4)SC=C5)OC,COc1c(C2CN(C)Cc3cc(-c4ccc(C)nn4)ccc32)ccc2sccc12
5255,5271,CHEMBL2062931,TWLFJVAENFTGAE-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.397940008672037,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)N=[N+]=[N-])I,COC(=O)[C@H](c1ccc(N=[N+]=[N-])c(I)c1)[C@H]1CCCCN1
5256,5272,CHEMBL2062931,TWLFJVAENFTGAE-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,RATIO KI,=,4.0,,,,cell_based,,,,,,,,,,,,Ratio of (+/-)-threomethylphenidate Ki to compound Ki for human DAT expressed in mouse N2A cells,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)N=[N+]=[N-])I,COC(=O)[C@H](c1ccc(N=[N+]=[N-])c(I)c1)[C@H]1CCCCN1
5257,5273,CHEMBL2062931,TWLFJVAENFTGAE-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,RATIO KI,=,91.0,,,,cell_based,,,,,,,,,,,,Ratio of (+/-)-threo-N-(p-azido-benzyl)-4-iodomethylphenidate Ki to compound Ki for human DAT expressed in mouse N2A cells,,ACS Med. Chem. Lett.,PUBLICATION,,91.0,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)N=[N+]=[N-])I,COC(=O)[C@H](c1ccc(N=[N+]=[N-])c(I)c1)[C@H]1CCCCN1
5258,5274,CHEMBL2062934,TWLFJVAENFTGAE-NOKOBQPBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,ACTIVITY,,,,Active,,cell_based,,,,,LLC-PK1,,,,,,,Binding affinity to His6-tagged human DAT expressed in pig LLC-PK1 cells at 10 nM incubated for 1.5 hrs prior to irradiation measured after 5 mins by photoaffinity labeling-based autoradiographic analysis,,ACS Med. Chem. Lett.,PUBLICATION,,,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)N=[N+]=[N-])[125I],COC(=O)[C@H](c1ccc(N=[N+]=[N-])c(I)c1)[C@H]1CCCCN1
5259,5275,CHEMBL2062934,TWLFJVAENFTGAE-NOKOBQPBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,ACTIVITY,,,,Not Active,,cell_based,,,,,LLC-PK1,,,,,,,Binding affinity to His6-tagged human DAT expressed in pig LLC-PK1 cells at 10 nM incubated for 1.5 hrs prior to irradiation measured after 5 mins by photoaffinity labeling-based autoradiographic analysis in presence of (-)-cocaine,,ACS Med. Chem. Lett.,PUBLICATION,,,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)N=[N+]=[N-])[125I],COC(=O)[C@H](c1ccc(N=[N+]=[N-])c(I)c1)[C@H]1CCCCN1
5260,5276,CHEMBL2062934,TWLFJVAENFTGAE-NOKOBQPBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,ACTIVITY,,,,Not Active,,cell_based,,,,,LLC-PK1,,,,,,,Binding affinity to His6-tagged human DAT expressed in pig LLC-PK1 cells at 10 nM incubated for 1.5 hrs prior to irradiation measured after 5 mins by photoaffinity labeling-based autoradiographic analysis in presence of D-methylphenidate,,ACS Med. Chem. Lett.,PUBLICATION,,,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)N=[N+]=[N-])[125I],COC(=O)[C@H](c1ccc(N=[N+]=[N-])c(I)c1)[C@H]1CCCCN1
5261,5277,CHEMBL2205812,TWMXGXSGGIIQDM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1
5262,5278,CHEMBL1204410,TWOLHZITFDHKDN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,IC50,=,6600.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,CNCCCC1CC2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3.Cl,CNCCCC1Cc2ccccc2N(c2ccccc2)S1(=O)=O
5263,5279,CHEMBL3334771,TWOMIKAXPRBJNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,852.3,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.069407511557403,C1CN(CC=C1CC2=CC=CC=C2)CCC(C3=CSC4=CC=CC=C43)N5CCOCC5,C1=C(Cc2ccccc2)CCN(CCC(c2csc3ccccc23)N2CCOCC2)C1
5264,5280,CHEMBL256293,TWSKMFBDRRENNV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCC1=C(C=CC(=C1)Cl)OC2=C(C=NC(=C2)C)CN(C)C,CCc1cc(Cl)ccc1Oc1cc(C)ncc1CN(C)C
5265,5281,CHEMBL256293,TWSKMFBDRRENNV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,>,34000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4685210829577455,CCC1=C(C=CC(=C1)Cl)OC2=C(C=NC(=C2)C)CN(C)C,CCc1cc(Cl)ccc1Oc1cc(C)ncc1CN(C)C
5266,5282,CHEMBL2030626,TWUZJTIHFYRNSV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC2CCC1N2CC34C5C6C3C7C6C5C47,C1CC2CCC1N2CC12C3C4C5C3C1C5C42
5267,5283,CHEMBL683,TXCGAZHTZHNUAI-UHFFFAOYSA-N,CLOFIBRIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl,CC(C)(Oc1ccc(Cl)cc1)C(=O)O
5268,5284,CHEMBL683,TXCGAZHTZHNUAI-UHFFFAOYSA-N,CLOFIBRIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl,CC(C)(Oc1ccc(Cl)cc1)C(=O)O
5269,5285,CHEMBL419385,TXMJJPVQXBIOQV-YHZLUUAOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,,,,Not Determined,,,,,,,,,,,,,,In vitro ability of compound to inhibit DA re-uptake of radiolabeled [3H]-tritium transmitter into synaptosome; ND=not determined,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)O,CN(C)C[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(O)ccc2c1
5270,5286,CHEMBL419385,TXMJJPVQXBIOQV-YHZLUUAOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,6.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,CN(C)C[C@@H]1[C@H](C2CCC1C2)C3=CC4=C(C=C3)C=C(C=C4)O,CN(C)C[C@H]1C2CCC(C2)[C@@H]1c1ccc2cc(O)ccc2c1
5271,5287,CHEMBL1196025,TXPPKWZEHFNZOE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24187998.0,KI,>,10000000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in African green monkey COS7 cells after 10 mins,"Design, synthesis, and biological evaluation of Erythrina alkaloid analogues as neuronal nicotinic acetylcholine receptor antagonists.",J. Med. Chem.,PUBLICATION,,2.0,CN1CCC2=CC(=C(C=C2C1)OC)OC,COc1cc2c(cc1OC)CN(C)CC2
5272,5288,CHEMBL1371125,TXVHTIQJNYSSKO-UHFFFAOYSA-N,BENZO[E]PYRENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4,c1ccc2c(c1)c1cccc3ccc4cccc2c4c31
5273,5289,CHEMBL1371125,TXVHTIQJNYSSKO-UHFFFAOYSA-N,BENZO[E]PYRENE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4,c1ccc2c(c1)c1cccc3ccc4cccc2c4c31
5274,5290,CHEMBL208191,TYAWVYXKOKCMIW-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-45.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-45.0,C1CCC(C1)N(CC2=CC=CC=C2C(F)(F)F)C3CCNCC3.C(=C/C(=O)O)\C(=O)O,FC(F)(F)c1ccccc1CN(C1CCCC1)C1CCNCC1
5275,5291,CHEMBL394158,TYFSSZYOVLRLQK-QXSJWSMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446069.0,KI,=,2.26,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,"Synthesis and biological evaluation of 2beta,3alpha-(substituted phenyl)nortropanes as potential norepinephrine transporter imaging agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.645891560852599,COC(=O)[C@@H]1[C@H]2CC[C@@H](N2)C[C@H]1C3=CC=C(C=C3)C#C,C#Cc1ccc([C@@H]2C[C@H]3CC[C@@H](N3)[C@H]2C(=O)OC)cc1
5276,5292,CHEMBL401976,TYJYIHODVVLAMM-FZMZJTMJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=N2,CCN(CC)C(=O)[C@@]1(c2ccccn2)C[C@H]1CN
5277,5293,CHEMBL2220427,TYQXKHPOXXXCTP-CSLYCKPJSA-N,ERYTHROMYCIN ESTOLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
5278,5294,CHEMBL2220427,TYQXKHPOXXXCTP-CSLYCKPJSA-N,ERYTHROMYCIN ESTOLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
5279,5295,CHEMBL1173594,TYRLWIIURFREJC-ZIAGYGMSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.400007822415903,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)COCC(F)(F)F,FC(F)(F)COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
5280,5296,CHEMBL493040,TYVFKNAUSZXXJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,2000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,CNCC1=CC=CC=C1CC2=CC(=C(C=C2)Cl)Cl,CNCc1ccccc1Cc1ccc(Cl)c(Cl)c1
5281,5297,CHEMBL44,TZBJGXHYKVUXJN-UHFFFAOYSA-N,GENISTEIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,16918.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.771650979376362,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
5282,5298,CHEMBL44,TZBJGXHYKVUXJN-UHFFFAOYSA-N,GENISTEIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,13442.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.8715361089352385,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
5283,5299,CHEMBL1371,TZFWDZFKRBELIQ-UHFFFAOYSA-N,CHLORZOXAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1Cl)NC(=O)O2,O=c1[nH]c2cc(Cl)ccc2o1
5284,5300,CHEMBL1371,TZFWDZFKRBELIQ-UHFFFAOYSA-N,CHLORZOXAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1Cl)NC(=O)O2,O=c1[nH]c2cc(Cl)ccc2o1
5285,5301,CHEMBL195585,TZHJRGABGIEARJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CNCCCF)N,Cc1ccc(Sc2ccccc2CNCCCF)c(N)c1
5286,5302,CHEMBL3310622,TZJCUYLPPDCFHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,19.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,19.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)Cl,Clc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
5287,5303,CHEMBL3310622,TZJCUYLPPDCFHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,71.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,71.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)Cl,Clc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
5288,5304,CHEMBL3310622,TZJCUYLPPDCFHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC=C(C=C3)Cl,Clc1ccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)cc1
5289,5305,CHEMBL380523,TZMGQAAZTGUQJN-LIRRHRJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,270.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)C(=O)N(C)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(C(=O)N(C)C)cc21
5290,5306,CHEMBL381315,TZMILLWOFHAFNQ-GTNSWQLSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,12900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.88941028970075,CN[C@H]1CC[C@H](C2=CC(=C(C=C12)NS(=O)(=O)C)C(=O)O)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2cc(C(=O)O)c(NS(C)(=O)=O)cc21
5291,5307,CHEMBL578815,TZRAZPTWNAPWGU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,1744.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.758453519403452,CCN(CC)C(C)C(=O)C1=CC(=CC=C1)Cl,CCN(CC)C(C)C(=O)c1cccc(Cl)c1
5292,5308,CHEMBL578815,TZRAZPTWNAPWGU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,2214.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.6548223834572955,CCN(CC)C(C)C(=O)C1=CC(=CC=C1)Cl,CCN(CC)C(C)C(=O)c1cccc(Cl)c1
5293,5309,CHEMBL70927,TZXKOCQBRNJULO-UHFFFAOYSA-N,DEFERIPRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C=CN1C)O,Cc1c(O)c(=O)ccn1C
5294,5310,CHEMBL70927,TZXKOCQBRNJULO-UHFFFAOYSA-N,DEFERIPRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C=CN1C)O,Cc1c(O)c(=O)ccn1C
5295,5311,CHEMBL566193,UAAZALAKZAQQRJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC(C)(C)NC1CCC2=C(C1=O)C=C(C=C2)Cl,CC(C)(C)NC1CCc2ccc(Cl)cc2C1=O
5296,5312,CHEMBL566193,UAAZALAKZAQQRJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)NC1CCC2=C(C1=O)C=C(C=C2)Cl,CC(C)(C)NC1CCc2ccc(Cl)cc2C1=O
5297,5313,CHEMBL22183,UABIXNSHHIMZEP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)N,Cc1ccc(Sc2ccccc2CN(C)C)c(N)c1
5298,5314,CHEMBL22183,UABIXNSHHIMZEP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,=,532.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.274088367704952,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)N,Cc1ccc(Sc2ccccc2CN(C)C)c(N)c1
5299,5315,CHEMBL22183,UABIXNSHHIMZEP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)N,Cc1ccc(Sc2ccccc2CN(C)C)c(N)c1
5300,5316,CHEMBL22183,UABIXNSHHIMZEP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18793858.0,KI,>,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]GBR-12935 from human cloned DAT expressed in HEK293 cells,"Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)N,Cc1ccc(Sc2ccccc2CN(C)C)c(N)c1
5301,5317,CHEMBL2338033,UAGADFQXODVTNQ-CXAGYDPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,100.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC(=CC(=C3)F)F,Fc1cc(F)cc(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1
5302,5318,CHEMBL3673146,UAJXVGMIEPUGSN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,353.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.451733454829255,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=NC5=CC=CC=C5N=C4)C6=CC=C(C=C6)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(-c4cnc5ccccc5n4)ccc23)cc1
5303,5319,CHEMBL1947090,UAMCGXVVAUEEEU-HZMVEIRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CCC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C,CCc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)cc1
5304,5320,CHEMBL1077647,UAOCSOBBQYATOV-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,2430.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.614393726401689,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C=CC(=C2)Cl)Cl,CC(C)CN(C(=O)c1cc(Cl)ccc1Cl)[C@H]1CCNC1
5305,5321,CHEMBL471029,UAUSBXOENIHVFX-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,88.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.055517327849832,CCCCN(CC1=CC2=CC=CC=C2C=C1)[C@H]3CCNC3,CCCCN(Cc1ccc2ccccc2c1)[C@H]1CCNC1
5306,5322,CHEMBL1086398,UBBWGPMMVOSPDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20153188.0,INHIBITION,=,17.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,Bioorg. Med. Chem. Lett.,PUBLICATION,,17.0,CNCCCN1CC2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3,CNCCCN1Cc2ccccc2N(c2ccccc2)S1(=O)=O
5307,5323,CHEMBL959,UBCHPRBFMUDMNC-UHFFFAOYSA-N,RIMANTADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C12CC3CC(C1)CC(C3)C2)N,CC(N)C12CC3CC(CC(C3)C1)C2
5308,5324,CHEMBL959,UBCHPRBFMUDMNC-UHFFFAOYSA-N,RIMANTADINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C12CC3CC(C1)CC(C3)C2)N,CC(N)C12CC3CC(CC(C3)C1)C2
5309,5325,CHEMBL3673132,UBFYHGZTRDBAOO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,87.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.059483515067433,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=NN=C(C=C5)OC(F)F,FC(F)Oc1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)C2)nn1
5310,5326,CHEMBL3673132,UBFYHGZTRDBAOO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1057.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,5.975925012692572,C1CN2CC3=C(C1(C2)C4=CC=C(C=C4)Cl)C=CC(=C3)C5=NN=C(C=C5)OC(F)F,FC(F)Oc1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)C2)nn1
5311,5328,CHEMBL43882,UBOXGVDOUJQMTN-UHFFFAOYSA-N,TRICHLOROETHANE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(Cl)Cl)Cl,ClCC(Cl)Cl
5312,5329,CHEMBL43882,UBOXGVDOUJQMTN-UHFFFAOYSA-N,TRICHLOROETHANE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(Cl)Cl)Cl,ClCC(Cl)Cl
5313,5330,CHEMBL3663918,UBPCUEVRWJIHLS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,41.3,NM,314453,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.384049948343598,CN1CC(C2=C(C1)C=C(C=C2)C3=NN=CC=C3)C4=CC5=CC=CC=C5O4,CN1Cc2cc(-c3cccnn3)ccc2C(c2cc3ccccc3o2)C1
5314,5331,CHEMBL234927,UBQCLKWUZCABQJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17391962.0,INHIBITION,=,23.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,CN(C)C1CCC(=CC1)C2=CNC3=C2C=C(C=C3)F,CN(C)C1CC=C(c2c[nH]c3ccc(F)cc23)CC1
5315,5332,CHEMBL3310480,UBQLLVMEOGBWCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,37.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,37.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)OC(F)(F)F,FC(F)(F)Oc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
5316,5333,CHEMBL3310480,UBQLLVMEOGBWCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)OC(F)(F)F,FC(F)(F)Oc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
5317,5334,CHEMBL3310480,UBQLLVMEOGBWCI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)OC(F)(F)F,FC(F)(F)Oc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
5318,5335,CHEMBL1835609,UBQRACCCHXXOJB-ZOWNYOTGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21905669.0,INHIBITION,=,-10.1,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by radioligand displacement assay,Discovery of Isoxazole Analogues of Sazetidine-A as Selective a42-Nicotinic Acetylcholine Receptor Partial Agonists for the Treatment of Depression.,J. Med. Chem.,PUBLICATION,,-10.1,C1CN[C@@H]1COC2=CN=CC(=C2)C3=CC(=NO3)CCCO.Cl,OCCCc1cc(-c2cncc(OC[C@@H]3CCN3)c2)on1
5319,5336,CHEMBL3334782,UBTISEJLHYNQTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,2.5,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,2.5,CN(CCC(C1=CC2=C(C=C1)C(=C(C=C2)OC)Cl)N3CCOCC3)CC4=CC=CC=C4,COc1ccc2cc(C(CCN(C)Cc3ccccc3)N3CCOCC3)ccc2c1Cl
5320,5337,CHEMBL388605,UBUINJQFQXKDNL-JHDZUBBNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,23.3,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,7.632644078973981,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC(=C(C=C4)OC)OC)N3C,COc1ccc([C@@H]2C3CCC(C[C@@H]2c2ccc(C)cc2)N3C)cc1OC
5321,5338,CHEMBL388825,UBUINJQFQXKDNL-XKXWHVAQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,980.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,6.008773924307505,CC1=CC=C(C=C1)[C@@H]2CC3CCC([C@H]2C4=CC(=C(C=C4)OC)OC)N3C,COc1ccc([C@@H]2C3CCC(C[C@H]2c2ccc(C)cc2)N3C)cc1OC
5322,5339,CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
5323,5340,CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
5324,5341,CHEMBL2430696,UCFURURGGMKGCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,32.7,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.485452247339714,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccccc1
5325,5342,CHEMBL2430696,UCFURURGGMKGCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,97.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,97.0,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccccc1
5326,5343,CHEMBL2430696,UCFURURGGMKGCC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,99.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,99.0,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C1NCC(c2ccc(Cl)cc2)C1c1ccccc1
5327,5344,CHEMBL787,UCHDWCPVSPXUMX-TZIWLTJVSA-N,MONTELUKAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2601.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.584859647804128,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
5328,5345,CHEMBL787,UCHDWCPVSPXUMX-TZIWLTJVSA-N,MONTELUKAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2067.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.684659523372713,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
5329,5346,CHEMBL89756,UCMSEZDYTMJIBW-RUXDESIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,>,150000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,3.823908740944319,CN1C2C[C@@H](C1CC(=C2C(=O)OC)C3=CC=CC=C3)O,COC(=O)C1=C(c2ccccc2)CC2[C@@H](O)CC1N2C
5330,5347,CHEMBL372795,UCSJYZPVAKXKNQ-HZYVHMACSA-N,STREPTOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
5331,5348,CHEMBL372795,UCSJYZPVAKXKNQ-HZYVHMACSA-N,STREPTOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
5332,5349,CHEMBL679,UCTWMZQNUQWSLP-VIFPVBQESA-N,EPINEPHRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNC[C@@H](C1=CC(=C(C=C1)O)O)O,CNC[C@H](O)c1ccc(O)c(O)c1
5333,5350,CHEMBL679,UCTWMZQNUQWSLP-VIFPVBQESA-N,EPINEPHRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNC[C@@H](C1=CC(=C(C=C1)O)O)O,CNC[C@H](O)c1ccc(O)c(O)c1
5334,5351,CHEMBL220819,UCYBGEFJKJSJQI-HOFKKMOUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,251.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6003262785189625,CC(=O)C1=CC(=CC=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CC3CC3)CC4=CC=C(C=C4)F,CC(=O)c1cccc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CC2CC2)c1
5335,5352,CHEMBL1643646,UCZOFGRNAPWDMW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,69.2,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1598939055432425,CC1=NOC(=C1)C2=C(CC3CCC2S3)C4=CC(=C(C=C4)Cl)Cl,Cc1cc(C2=C(c3ccc(Cl)c(Cl)c3)CC3CCC2S3)on1
5336,5353,CHEMBL343211,UDCVQVNMMCKETF-NZQKXSOJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,120.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.920818753952375,CN(CC1=CC=CC=C1)[C@@H]2C[C@H](C3=CC=CC=C23)C4=CC(=C(C=C4)Cl)Cl,CN(Cc1ccccc1)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5337,5354,CHEMBL343211,UDCVQVNMMCKETF-NZQKXSOJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.259637310505756,CN(CC1=CC=CC=C1)[C@@H]2C[C@H](C3=CC=CC=C23)C4=CC(=C(C=C4)Cl)Cl,CN(Cc1ccccc1)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5338,5355,CHEMBL343211,UDCVQVNMMCKETF-NZQKXSOJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,4.6,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,4.6,CN(CC1=CC=CC=C1)[C@@H]2C[C@H](C3=CC=CC=C23)C4=CC(=C(C=C4)Cl)Cl,CN(Cc1ccccc1)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5339,5356,CHEMBL497664,UDDSGRJSILNSQD-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)C[C@@H]1CC2=CC=CC=C2[C@@H]1OC3=CC=C(C=C3)C(F)(F)F,CN(C)C[C@@H]1Cc2ccccc2[C@@H]1Oc1ccc(C(F)(F)F)cc1
5340,5357,CHEMBL599028,UDGISDAHRCDXMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,156.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.806875401645539,CC(C(=O)C1=CC(=CC=C1)F)N2CCCCC2,CC(C(=O)c1cccc(F)c1)N1CCCCC1
5341,5358,CHEMBL584042,UEDLLBHXEVXPDP-ZEQRLZLVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1=CC=C(C=C1)CNC[C@@H]([C@H](C2=CC=CC=C2)N3C=CC4=CC=CC=C43)O,O[C@@H](CNCc1ccccc1)[C@H](c1ccccc1)n1ccc2ccccc21
5342,5359,CHEMBL482292,UEHLVCUNIAJBCM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CN(C)CC1=C(C=CC(=C1)S(=O)(=O)N)CC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1cc(S(N)(=O)=O)ccc1Cc1ccc(Cl)c(Cl)c1
5343,5360,CHEMBL558551,UEJJHQNACJXSKW-SECBINFHSA-N,(R)-THALIDOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
5344,5361,CHEMBL558551,UEJJHQNACJXSKW-SECBINFHSA-N,(R)-THALIDOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
5345,5362,CHEMBL468,UEJJHQNACJXSKW-UHFFFAOYSA-N,THALIDOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
5346,5363,CHEMBL468,UEJJHQNACJXSKW-UHFFFAOYSA-N,THALIDOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
5347,5364,CHEMBL426123,UEJJHQNACJXSKW-VIFPVBQESA-N,(-)-THALIDOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
5348,5365,CHEMBL426123,UEJJHQNACJXSKW-VIFPVBQESA-N,(-)-THALIDOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
5349,5366,CHEMBL542501,UEKLEFLNJKLESJ-LMRHVHIWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,21400.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.669586226650808,CC(C)(C)[C@@H]([C@@H](CN(C)C)C1=CC=CC=C1)O.Cl,CN(C)C[C@@H](c1ccccc1)[C@@H](O)C(C)(C)C
5350,5367,CHEMBL542436,UEOPEKUWGLOWLD-MOGJOVFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,1833546.0,KI,=,1870.0,NM,,,,,,,,,,,,,,,In vitro binding affinity for dopamine uptake site,"Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.",J. Med. Chem.,PUBLICATION,,5.7281583934635005,CC1=C(C2=C(C=C1)[C@@H](O[C@@H](C2)C3CCCCC3)CN)O.Br,Cc1ccc2c(c1O)C[C@@H](C1CCCCC1)O[C@H]2CN
5351,5368,CHEMBL1643514,UEPBVWIBDNMJPA-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.795880017344076,CN(C)[C@@H]1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
5352,5369,CHEMBL1643510,UEPBVWIBDNMJPA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,5033.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2981730696028615,CN(C)C1CCN(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)C1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21
5353,5370,CHEMBL252719,UEQUQVLFIPOEMF-GOSISDBHSA-N,(S)-MIANSERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,9400.0,NM,,,,,,,,,,,,,,,,,,,,5.026872146400302,CN1CCN2[C@H](C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1
5354,5371,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
5355,5372,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
5356,5373,CHEMBL130877,UEQXHKUXJZQGHV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,36.1,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.442492798094343,C1CN2C(=N1)C3=CC4=CC=CC=C4C=C3C2(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2cc3ccccc3cc2C2=NCCN21
5357,5374,CHEMBL130877,UEQXHKUXJZQGHV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,1.3,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,1.3,C1CN2C(=N1)C3=CC4=CC=CC=C4C=C3C2(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2cc3ccccc3cc2C2=NCCN21
5358,5375,CHEMBL257905,UETBCRHGQLBFHE-JWQCQUIFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,8.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=CC2=C(C=C1)N(C(=N2)C)[C@@H]3CCN(C[C@H]3OC)CC4CC5=CC=CC=C5C4,CO[C@@H]1CN(CC2Cc3ccccc3C2)CC[C@H]1n1c(C)nc2cc(C)ccc21
5359,5376,CHEMBL403730,UEXMLAHFKICZJK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,23.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,CC1=CC2=C(C=C1)N(C(=N2)C)C3CCN(CC3)CCCC4=CC(=CC=C4)NC(=O)C(C)C,Cc1ccc2c(c1)nc(C)n2C1CCN(CCCc2cccc(NC(=O)C(C)C)c2)CC1
5360,5377,CHEMBL438059,UEYARIMIGYJNDI-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-17.5,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-17.5,CC(C)CN(CC1=CC=CC=C1SC)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CSc1ccccc1CN(CC(C)C)C1CCNCC1
5361,5378,CHEMBL1643643,UFADDGMNQWXMSK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NOC(=C1)C2=C(CC3CCC2S3)C4=CC=C(C=C4)F,Cc1cc(C2=C(c3ccc(F)cc3)CC3CCC2S3)on1
5362,5379,CHEMBL361949,UFBLPBWRPPLNJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)CCCC1=CNC2=C1C=C(C=C2)F,CN(C)CCCc1c[nH]c2ccc(F)cc12
5363,5380,CHEMBL1683884,UFFRBOMGNQGCAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029183,CN(C)CC1(CCCCC1)C2=CC=C(C=C2)Cl,CN(C)CC1(c2ccc(Cl)cc2)CCCCC1
5364,5381,CHEMBL940,UGJMXCAKCUNAIE-UHFFFAOYSA-N,GABAPENTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)(CC(=O)O)CN,NCC1(CC(=O)O)CCCCC1
5365,5382,CHEMBL940,UGJMXCAKCUNAIE-UHFFFAOYSA-N,GABAPENTIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)(CC(=O)O)CN,NCC1(CC(=O)O)CCCCC1
5366,5383,CHEMBL3317700,UGMVHZUXVSBGFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,470.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.327902142064282,CC1C(=O)N(CCCN1)C2=CC(=C(C=C2)Cl)Cl.Cl,CC1NCCCN(c2ccc(Cl)c(Cl)c2)C1=O
5367,5384,CHEMBL1171392,UGNWXJYZJYLNRT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC=CC=C3,c1ccc(CC2CNCCN2c2ccccc2)cc1
5368,5385,CHEMBL803,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,CYTARABINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
5369,5386,CHEMBL803,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,CYTARABINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
5370,5387,CHEMBL289860,UHSCSAWACVGXHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.76,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.76,C1CN(CCN1CCCCN(CC2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,c1ccc(CCCN2CCN(CCCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
5371,5388,CHEMBL289860,UHSCSAWACVGXHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.86,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.86,C1CN(CCN1CCCCN(CC2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,c1ccc(CCCN2CCN(CCCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
5372,5389,CHEMBL218262,UHVITKONHRHSFJ-FIPFOOKPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,297.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.527243550682787,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CC=C)CC3=CC=C(C=C3)F)C(=O)C,C=CCN1CC[C@@H](Cc2ccc(F)cc2)C[C@@H]1CCCNC(=O)Nc1cc(C(C)=O)cc(C(C)=O)c1
5373,5390,CHEMBL203266,UHWVSEOVJBQKBE-UHFFFAOYSA-N,TRIMETAZIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,COc1ccc(CN2CCNCC2)c(OC)c1OC
5374,5391,CHEMBL203266,UHWVSEOVJBQKBE-UHFFFAOYSA-N,TRIMETAZIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,COc1ccc(CN2CCNCC2)c(OC)c1OC
5375,5392,CHEMBL449145,UHXIHVPCQYVYLG-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)(C)C(=O)N(CC1=C(C=C(C=C1)Cl)Cl)[C@H]2CCNC2,CC(C)(C)C(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
5376,5393,CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
5377,5394,CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
5378,5395,CHEMBL34431,UIAYVIIHMORPSJ-UHFFFAOYSA-N,CILOSTAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3,CN(C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1)C1CCCCC1
5379,5396,CHEMBL34431,UIAYVIIHMORPSJ-UHFFFAOYSA-N,CILOSTAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3,CN(C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1)C1CCCCC1
5380,5397,CHEMBL1813473,UIBIRCANCAKLIN-BXUZGUMPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,457.09,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.3399982798971175,C1CC[C@@]2(CNC[C@H]2C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CCCC[C@@H]2CNC3)cc1Cl
5381,5398,CHEMBL1813473,UIBIRCANCAKLIN-BXUZGUMPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,1023.29,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.9900012699519385,C1CC[C@@]2(CNC[C@H]2C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CCCC[C@@H]2CNC3)cc1Cl
5382,5399,CHEMBL1813472,UIBIRCANCAKLIN-RISCZKNCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,83.18,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.079981083971085,C1CC[C@]2(CNC[C@H]2C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@@]23CCCC[C@@H]2CNC3)cc1Cl
5383,5400,CHEMBL1813471,UIBIRCANCAKLIN-SMDDNHRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,204.17,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.690008071218821,C1CC[C@@]2(CNC[C@@H]2C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl
5384,5401,CHEMBL1813471,UIBIRCANCAKLIN-SMDDNHRTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,457.09,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.3399982798971175,C1CC[C@@]2(CNC[C@@H]2C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl
5385,5402,CHEMBL3331500,UIEJRRVRKHMDOB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,187.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.7281583934635005,C1C(CN1)CN(CC2=CC=C(C=C2)F)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Fc1ccc(CN(CC2CNC2)c2ccccc2)cc1
5386,5403,CHEMBL3331500,UIEJRRVRKHMDOB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,22.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,22.0,C1C(CN1)CN(CC2=CC=C(C=C2)F)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Fc1ccc(CN(CC2CNC2)c2ccccc2)cc1
5387,5404,CHEMBL380890,UIEMDECNRHYLAZ-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,210.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6777807052660805,CC(C)CN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccccc1C(F)(F)F)C1CCNCC1
5388,5405,CHEMBL211501,UIFFUZWRFRDZJC-SBOOETFBSA-N,ANTIMYCIN A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,CCCCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C
5389,5406,CHEMBL211501,UIFFUZWRFRDZJC-SBOOETFBSA-N,ANTIMYCIN A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,CCCCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C
5390,5407,CHEMBL575535,UIJBKUNWEPERDV-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,20.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,20.0,CNC[C@H]([C@H](C1=CC(=CC=C1)Cl)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1cccc(Cl)c1)n1ccc2ccccc21
5391,5408,CHEMBL1830885,UIKJCHWTULEUKX-CQSZACIVSA-N,WYE-114152,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,=,2190.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,5.6595558851598815,C1CO[C@@H](CN1)CCN2C3=CC=CC=C3N(S2(=O)=O)C4=CC=CC=C4F,O=S1(=O)N(CC[C@@H]2CNCCO2)c2ccccc2N1c1ccccc1F
5392,5409,CHEMBL3334788,UIOBXKSDWRXQBR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,37.1,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,37.1,CN(C)CCC(C1=CC=C(C=C1)C(F)(F)F)N2CCCC2,CN(C)CCC(c1ccc(C(F)(F)F)cc1)N1CCCC1
5393,5410,CHEMBL1099134,UIOCALWWKYWNPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1C=C(C2=CC=CC=C21)C(CN3CCNCC3)C4(CCCCC4)O,Cn1cc(C(CN2CCNCC2)C2(O)CCCCC2)c2ccccc21
5394,5411,CHEMBL2206523,UIVAIANIXTWVHO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,38.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.420216403383191,CN1CC(C2=CC=CC=C2C1)C3=CC=C(C=C3)Cl,CN1Cc2ccccc2C(c2ccc(Cl)cc2)C1
5395,5412,CHEMBL2206523,UIVAIANIXTWVHO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,356.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.448550002027125,CN1CC(C2=CC=CC=C2C1)C3=CC=C(C=C3)Cl,CN1Cc2ccccc2C(c2ccc(Cl)cc2)C1
5396,5413,CHEMBL1084313,UJEHPOIYQOLYRD-CYBMUJFWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,509.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,6.293282217663242,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=C(C=CC(=C3)F)F)O,CNC[C@H](O)CCN1c2ccccc2N(c2cc(F)ccc2F)S1(=O)=O
5397,5414,CHEMBL1083118,UJEHPOIYQOLYRD-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,2086.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,5.680685695909487,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=C(C=CC(=C3)F)F)O,CNC[C@@H](O)CCN1c2ccccc2N(c2cc(F)ccc2F)S1(=O)=O
5398,5415,CHEMBL3331487,UJPJRVGAMRAGHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,18.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,18.0,C1C(CN1)CN(CC2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(N(Cc2ccccc2)CC2CNC2)cc1Cl
5399,5416,CHEMBL599242,UJQCJTWDIZLQBH-BREBYQMCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.199970640755867,CSC[C@@H]1[C@@H]2[C@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CSC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1
5400,5417,CHEMBL599241,UJQCJTWDIZLQBH-OUJBWJOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.400007822415903,CSC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CSC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
5401,5418,CHEMBL599241,UJQCJTWDIZLQBH-OUJBWJOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.100015437450608,CSC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CSC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
5402,5419,CHEMBL3310640,UJWNMDBIDDUPKQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,3.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CC1=CC=CC=C1OC(CC2CNC2)C3=CC=CC=C3,Cc1ccccc1OC(CC1CNC1)c1ccccc1
5403,5420,CHEMBL404364,UJXZJZLGZRRPNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,CCCN(CC)C(=O)C1(c2ccccc2)CC1CN
5404,5421,CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
5405,5422,CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
5406,5423,CHEMBL467585,UKFMBLJGGNWPFD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,18.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.744727494896693,C=C(CCN1CCN(CC1)CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C4=CC=CC=C4,C=C(CCN1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
5407,5424,CHEMBL122859,UKJAARKQBNAPHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,>,10.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,8.0,C1CN(C(=O)CN1CCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,O=C1CN(CCc2ccccc2)CCN1CCOC(c1ccc(F)cc1)c1ccc(F)cc1
5408,5425,CHEMBL122859,UKJAARKQBNAPHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,1430.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,5.8446639625349395,C1CN(C(=O)CN1CCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,O=C1CN(CCc2ccccc2)CCN1CCOC(c1ccc(F)cc1)c1ccc(F)cc1
5409,5426,CHEMBL122859,UKJAARKQBNAPHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,>,1.7,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,1.7,C1CN(C(=O)CN1CCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,O=C1CN(CCc2ccccc2)CCN1CCOC(c1ccc(F)cc1)c1ccc(F)cc1
5410,5427,CHEMBL1684049,UKMRWNNKRBSVIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,4000.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CC(C1(CCCCC1)C2=CC=CC3=CC=CC=C32)N,CC(N)C1(c2cccc3ccccc23)CCCCC1
5411,5428,CHEMBL416800,UKQOAOAUEQYBDV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.49,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.49,CC1=CC=C(C=C1)CN(CCN2CCN(CC2)CCCC3=CC=CC=C3)C4=CC=CC=C4,Cc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccccc2)cc1
5412,5429,CHEMBL416800,UKQOAOAUEQYBDV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.37,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.37,CC1=CC=C(C=C1)CN(CCN2CCN(CC2)CCCC3=CC=CC=C3)C4=CC=CC=C4,Cc1ccc(CN(CCN2CCN(CCCc3ccccc3)CC2)c2ccccc2)cc1
5413,5430,CHEMBL1170794,UKQYNWZANZHZLT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,125.89,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,CN1C=CC2=C1C=CC(=C2)N3CCNCC3CC4=CC=CC=C4,Cn1ccc2cc(N3CCNCC3Cc3ccccc3)ccc21
5414,5431,CHEMBL2012100,UKUHBVAGJJSXOV-LSCKAKRGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,139.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.856985199745905,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CO4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3ccco3)cc1)O2
5415,5432,CHEMBL2012100,UKUHBVAGJJSXOV-LSCKAKRGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@@H](CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CO4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3ccco3)cc1)O2
5416,5433,CHEMBL2012104,UKUHBVAGJJSXOV-NRLXWARBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,64.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,7.1938200260161125,COC(=O)[C@H]1[C@H](CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CO4,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(-c3ccco3)cc1)O2
5417,5434,CHEMBL2012104,UKUHBVAGJJSXOV-NRLXWARBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)[C@H]1[C@H](CC2CCC1O2)C3=CC=C(C=C3)C4=CC=CO4,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(-c3ccco3)cc1)O2
5418,5435,CHEMBL497512,ULFUJAQEYUFVSH-HOTGVXAUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=C(C=CC=C3F)C(F)(F)F,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1c(F)cccc1C(F)(F)F
5419,5436,CHEMBL497512,ULFUJAQEYUFVSH-HOTGVXAUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=C(C=CC=C3F)C(F)(F)F,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1c(F)cccc1C(F)(F)F
5420,5437,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
5421,5438,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
5422,5439,CHEMBL2171214,ULHAPYHRFNPZCO-UHFFFAOYSA-N,"3-((3,4-DICHLOROPHENYL)(METHOXY)METHYL)AZETIDINE HCL",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,22.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,22.0,COC(C1CNC1)C2=CC(=C(C=C2)Cl)Cl.Cl,COC(c1ccc(Cl)c(Cl)c1)C1CNC1
5423,5440,CHEMBL3323185,ULLMROULDBOCOZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,570.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,6.2441251443275085,CN1CC(C2=C(C1)C=C(C=C2)N3CCCCC3)C4=CC5=CC=CC=C5S4,CN1Cc2cc(N3CCCCC3)ccc2C(c2cc3ccccc3s2)C1
5424,5441,CHEMBL201976,ULUHBYVKNOUSDX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,122.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.9136401693252525,CCCC(C(=O)C1=CC=C(C=C1)C2=CC=CO2)N3CCCC3,CCCC(C(=O)c1ccc(-c2ccco2)cc1)N1CCCC1
5425,5442,CHEMBL201976,ULUHBYVKNOUSDX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,105.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.978810700930063,CCCC(C(=O)C1=CC=C(C=C1)C2=CC=CO2)N3CCCC3,CCCC(C(=O)c1ccc(-c2ccco2)cc1)N1CCCC1
5426,5443,CHEMBL213785,ULVITMXAXCXEQQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,1600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344076,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=C(C=C3)F,Fc1ccc(C(Cc2ccccc2Cl)N2CCNCC2)cc1
5427,5444,CHEMBL2407335,UMJOPAHCVSNVNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,2400.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,5.619788758288393,C1CNCCC1C(CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OCC(c1ccc(Cl)c(Cl)c1)C1CCNCC1
5428,5445,CHEMBL207713,UMMWKVQAQBVCAO-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,20.8,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,20.8,C1CO[C@@H](CN1)[C@@](CC2=CC=CC=C2Cl)(C3=CC=CC=C3)O,O[C@](Cc1ccccc1Cl)(c1ccccc1)[C@@H]1CNCCO1
5429,5446,CHEMBL183470,UMYMNRFUWNCPOG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=CC=CC=C1OC2=C(C=C(C=C2)I)CO,CN(C)Cc1ccccc1Oc1ccc(I)cc1CO
5430,5447,CHEMBL3317701,UMZZJUZWLRKJTC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,190.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,CCC1C(=O)N(CCCN1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCC1NCCCN(c2ccc(Cl)c(Cl)c2)C1=O
5431,5448,CHEMBL1419,UNAANXDKBXWMLN-UHFFFAOYSA-N,SIBUTRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,632.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.199282921717615,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
5432,5449,CHEMBL1419,UNAANXDKBXWMLN-UHFFFAOYSA-N,SIBUTRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,502.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.29929628285498,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
5433,5450,CHEMBL1201356,UNBRKDKAWYKMIV-QWQRMKEZSA-N,METHYLERGONOVINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
5434,5451,CHEMBL1201356,UNBRKDKAWYKMIV-QWQRMKEZSA-N,METHYLERGONOVINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
5435,5452,CHEMBL356750,UNCBFTIAWJTNTF-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,8.7,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,8.060480747381384,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5436,5453,CHEMBL356750,UNCBFTIAWJTNTF-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,38.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.420216403383191,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5437,5454,CHEMBL356750,UNCBFTIAWJTNTF-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,120.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.920818753952375,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5438,5455,CHEMBL356750,UNCBFTIAWJTNTF-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,650.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.187086643357143,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5439,5456,CHEMBL356750,UNCBFTIAWJTNTF-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,14.0,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,14.0,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5440,5457,CHEMBL356750,UNCBFTIAWJTNTF-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,17.0,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,17.0,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5441,5458,CHEMBL147950,UNCBFTIAWJTNTF-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,63.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.200659450546419,CN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5442,5459,CHEMBL147950,UNCBFTIAWJTNTF-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.259637310505756,CN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5443,5460,CHEMBL147950,UNCBFTIAWJTNTF-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,8.7,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,8.7,CN(C)[C@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN(C)[C@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5444,5461,CHEMBL1224469,UNCNBGAOAXFUFU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CC1=CC2=C(C=C1)C=C(C=C2)C(CCNC)N3N=CN=N3,CNCCC(c1ccc2cc(C)ccc2c1)n1ncnn1
5445,5462,CHEMBL1167,UNFWWIHTNXNPBV-WXKVUWSESA-N,SPECTINOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O,CN[C@H]1[C@@H](O)[C@@H](NC)[C@H](O)[C@H]2O[C@@H]3O[C@H](C)CC(=O)[C@]3(O)O[C@H]12
5446,5463,CHEMBL1167,UNFWWIHTNXNPBV-WXKVUWSESA-N,SPECTINOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O,CN[C@H]1[C@@H](O)[C@@H](NC)[C@H](O)[C@H]2O[C@@H]3O[C@H](C)CC(=O)[C@]3(O)O[C@H]12
5447,5464,CHEMBL1643644,UNLVZBINAUAFIH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,155.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.809668301829707,CC1=NOC(=C1)C2=C(CC3CCC2S3)C4=CC=C(C=C4)Cl,Cc1cc(C2=C(c3ccc(Cl)cc3)CC3CCC2S3)on1
5448,5465,CHEMBL329454,UNNABHWRKRTYKT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,546.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.262807357295263,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)F,COC(=O)C1C2CCC(CC1c1ccc(F)cc1)O2
5449,5466,CHEMBL329454,UNNABHWRKRTYKT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.0,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)F,COC(=O)C1C2CCC(CC1c1ccc(F)cc1)O2
5450,5467,CHEMBL450987,UNRUJFXXAULDMY-NWDGAFQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,18680.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.728623128105926,COC1=C(C=C(C=C1)F)C[C@@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1C[C@@H]1CC[C@H](CN)O1
5451,5468,CHEMBL450987,UNRUJFXXAULDMY-NWDGAFQWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,97180.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.0124231052730135,COC1=C(C=C(C=C1)F)C[C@@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1C[C@@H]1CC[C@H](CN)O1
5452,5469,CHEMBL456221,UNRUJFXXAULDMY-VXGBXAGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,28940.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.538501473216981,COC1=C(C=C(C=C1)F)C[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1C[C@H]1CC[C@H](CN)O1
5453,5470,CHEMBL456221,UNRUJFXXAULDMY-VXGBXAGGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,27240.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.564792896759252,COC1=C(C=C(C=C1)F)C[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1C[C@H]1CC[C@H](CN)O1
5454,5471,CHEMBL481527,UNSWDCIYZPOJLJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=C(C=CC(=C1)Br)OC2=CC=C(C=C2)C(F)(F)F,CN(C)Cc1cc(Br)ccc1Oc1ccc(C(F)(F)F)cc1
5455,5472,CHEMBL3673176,UNUKMFOSTQWWQA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,35.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.452225294612178,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)F)Cl)C=CC(=C3)C5=CN6C(=NC=N6)C=C5,Fc1ccc(C23CCN(Cc4cc(-c5ccc6ncnn6c5)ccc42)C3)cc1Cl
5456,5473,CHEMBL3673176,UNUKMFOSTQWWQA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,120.8,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.917933065714887,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)F)Cl)C=CC(=C3)C5=CN6C(=NC=N6)C=C5,Fc1ccc(C23CCN(Cc4cc(-c5ccc6ncnn6c5)ccc42)C3)cc1Cl
5457,5474,CHEMBL1645613,UNWRSVCWVWOSPV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,2030.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.692503962086787,C1CNCC1OC2=C(C=CC=C2F)OC3=CC=CC=C3Cl,Fc1cccc(Oc2ccccc2Cl)c1OC1CCNC1
5458,5475,CHEMBL1224383,UOGHZTJKVOOTDF-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,91.7,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.037630664329979,CNCC[C@@H](C1=CC(=C(C=C1)Cl)Cl)N2N=C(N=N2)N3N=CC=N3,CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(-n2nccn2)n1
5459,5476,CHEMBL1224383,UOGHZTJKVOOTDF-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,44.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,44.0,CNCC[C@@H](C1=CC(=C(C=C1)Cl)Cl)N2N=C(N=N2)N3N=CC=N3,CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(-n2nccn2)n1
5460,5477,CHEMBL558525,UOLFASMVWNZYMB-AEFICSSHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19791802.0,KI,=,1910.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.",J. Med. Chem.,PUBLICATION,,5.718966632752272,CNC[C@H]1C[C@@]1(C2=CC=CS2)OC3=CC=CC4=CC=CC=C43.Cl,CNC[C@H]1C[C@]1(Oc1cccc2ccccc12)c1cccs1
5461,5478,CHEMBL553224,UOLFASMVWNZYMB-GIDGLZBFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19791802.0,KI,=,223.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.",J. Med. Chem.,PUBLICATION,,6.6516951369518384,CNC[C@@H]1C[C@]1(C2=CC=CS2)OC3=CC=CC4=CC=CC=C43.Cl,CNC[C@@H]1C[C@@]1(Oc1cccc2ccccc12)c1cccs1
5462,5479,CHEMBL553224,UOLFASMVWNZYMB-GIDGLZBFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19791802.0,KI,=,283.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.",J. Med. Chem.,PUBLICATION,,6.548213564475709,CNC[C@@H]1C[C@]1(C2=CC=CS2)OC3=CC=CC4=CC=CC=C43.Cl,CNC[C@@H]1C[C@@]1(Oc1cccc2ccccc12)c1cccs1
5463,5480,CHEMBL558065,UOLFASMVWNZYMB-WRRDZZDISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19791802.0,KI,=,913.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.",J. Med. Chem.,PUBLICATION,,6.039529222465701,CNC[C@@H]1C[C@@]1(C2=CC=CS2)OC3=CC=CC4=CC=CC=C43.Cl,CNC[C@@H]1C[C@]1(Oc1cccc2ccccc12)c1cccs1
5464,5481,CHEMBL558329,UOLFASMVWNZYMB-WSCVZUBPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19791802.0,KI,=,586.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.",J. Med. Chem.,PUBLICATION,,6.23210238398191,CNC[C@H]1C[C@]1(C2=CC=CS2)OC3=CC=CC4=CC=CC=C43.Cl,CNC[C@H]1C[C@@]1(Oc1cccc2ccccc12)c1cccs1
5465,5482,CHEMBL558329,UOLFASMVWNZYMB-WSCVZUBPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19791802.0,KI,=,790.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.",J. Med. Chem.,PUBLICATION,,6.102372908709557,CNC[C@H]1C[C@]1(C2=CC=CS2)OC3=CC=CC4=CC=CC=C43.Cl,CNC[C@H]1C[C@@]1(Oc1cccc2ccccc12)c1cccs1
5466,5483,CHEMBL402057,UOPYFDKQWMFBDI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,195.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.709965388637482,CN(C)CC1=CC=CC=C1OC2=C(C=C(C=C2)Cl)Cl,CN(C)Cc1ccccc1Oc1ccc(Cl)cc1Cl
5467,5484,CHEMBL1169916,UOSHXPJHXMVWLW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,158.49,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,COCCC1CNCCN1C2=CC3=C(C=C2)NN=C3,COCCC1CNCCN1c1ccc2[nH]ncc2c1
5468,5485,CHEMBL401347,UOTMBQUAJZORIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,IC50,=,8700.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.060480747381382,CN(C)CC1CC1C2=CC=CC3=C2C=CC(=C3)C#N,CN(C)CC1CC1c1cccc2cc(C#N)ccc12
5469,5486,CHEMBL401347,UOTMBQUAJZORIE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17766113.0,INHIBITION,=,16.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,16.0,CN(C)CC1CC1C2=CC=CC3=C2C=CC(=C3)C#N,CN(C)CC1CC1c1cccc2cc(C#N)ccc12
5470,5487,CHEMBL1172760,UOWSMEUBNCLAHO-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,1258.93,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,5.899998417198647,CC(C)N1CC[C@@]2(C[C@@]2(C1)COC)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CN(C(C)C)CC[C@]1(c1ccc(Cl)c(Cl)c1)C2
5471,5488,CHEMBL564631,UPHOWEAWENOKEG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,>,30000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5228787452803365,CSC1=CC=C(C=C1)OC(C2CCNCC2)C3=CN=CC=C3,CSc1ccc(OC(c2cccnc2)C2CCNCC2)cc1
5472,5489,CHEMBL1080155,UPQNBHKMICCAIA-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC(=CC=C5)OC(F)(F)F,C[C@H]1CN(C(=O)c2ccc(-c3cccc(OC(F)(F)F)c3)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
5473,5490,CHEMBL1020,UPSPUYADGBWSHF-UHFFFAOYSA-N,TOLMETIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
5474,5491,CHEMBL1020,UPSPUYADGBWSHF-UHFFFAOYSA-N,TOLMETIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
5475,5492,CHEMBL378804,UPTXQSAYNARODX-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,5100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.292429823902063,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)CC(=O)O)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(CC(=O)O)cc21
5476,5493,CHEMBL488222,UPUKKBZBVUXCSQ-CVEARBPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CN[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=C(C=C3)Cl,CN[C@@H]1C[C@H](Oc2ccc(Cl)cc2)c2ccccc21
5477,5494,CHEMBL3334776,UPVLRNUPSLZGHM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,238.1,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.62324060459512,C1CCN(C1)C(CCN2CCOCC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C(CCN2CCOCC2)N2CCCC2)cc1Cl
5478,5495,CHEMBL236902,UQKHQHYWAJFGDY-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17761416.0,IC50,=,3120.0,NM,,,,,,,,,,,,,,,Activity against human dopamine transporter,The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5058454059815585,C[C@H]1CN(CCN1C(=O)OCC2=CC=CC=C2)C3=NC=C(C=C3)C(=O)NC4=CC=CC=C4N,C[C@H]1CN(c2ccc(C(=O)Nc3ccccc3N)cn2)CCN1C(=O)OCc1ccccc1
5479,5496,CHEMBL3331495,UQVFXBJXAQSHFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1C(CN1)CN(CC2=CC3=CC=CC=C3C=C2)C4=CC=C(C=C4)OC5=CC=CC=C5.C(=O)(C(F)(F)F)O,c1ccc(Oc2ccc(N(Cc3ccc4ccccc4c3)CC3CNC3)cc2)cc1
5480,5497,CHEMBL1489254,URAYPUMNDPQOKB-UHFFFAOYSA-N,TRIACETIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(COC(=O)C)OC(=O)C,CC(=O)OCC(COC(C)=O)OC(C)=O
5481,5498,CHEMBL1489254,URAYPUMNDPQOKB-UHFFFAOYSA-N,TRIACETIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(COC(=O)C)OC(=O)C,CC(=O)OCC(COC(C)=O)OC(C)=O
5482,5499,CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
5483,5500,CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
5484,5501,CHEMBL632,UREBDLICKHMUKA-DVTGEIKXSA-N,BETAMETHASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
5485,5502,CHEMBL632,UREBDLICKHMUKA-DVTGEIKXSA-N,BETAMETHASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
5486,5503,CHEMBL221753,UREZNYTWGJKWBI-UHFFFAOYSA-M,BENZETHONIUM CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1365.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.864867348623225,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1
5487,5504,CHEMBL221753,UREZNYTWGJKWBI-UHFFFAOYSA-M,BENZETHONIUM CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1085.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.964570261815451,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1
5488,5505,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
5489,5506,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
5490,5507,CHEMBL2030628,URNOPSHFIGOPOJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CC2CCC1N2CCC3=CC(=CC=C3)F,Fc1cccc(CCN2C3CCC2CC3)c1
5491,5508,CHEMBL2337605,URVPSAOJVKMKND-BBRMVZONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=C(C=CC=C3Cl)Cl,Clc1cccc(Cl)c1O[C@@H](c1ccccc1)[C@H]1CCNC1
5492,5509,CHEMBL2337606,URVPSAOJVKMKND-CZUORRHYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,316.23,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=C(C=CC=C3Cl)Cl,Clc1cccc(Cl)c1O[C@H](c1ccccc1)[C@@H]1CCNC1
5493,5510,CHEMBL221886,URWAJWIAIPFPJE-YFMIWBNJSA-N,SISOMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O
5494,5511,CHEMBL221886,URWAJWIAIPFPJE-YFMIWBNJSA-N,SISOMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O
5495,5512,CHEMBL1172902,URWDPKNAGFZFDK-ZIAGYGMSSA-N,"3-(3,4-DICHLORO-PHENYL)-6-AZA-TRICYCLO[4.2.1.0*1,3*]NONANE (STRUCTURAL MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.100015437450608,C1CN2CC[C@]3([C@]1(C3)C2)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CCN4CC[C@]2(C4)C3)cc1Cl
5496,5513,CHEMBL1172902,URWDPKNAGFZFDK-ZIAGYGMSSA-N,"3-(3,4-DICHLORO-PHENYL)-6-AZA-TRICYCLO[4.2.1.0*1,3*]NONANE (STRUCTURAL MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,251.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.599997654072044,C1CN2CC[C@]3([C@]1(C3)C2)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CCN4CC[C@]2(C4)C3)cc1Cl
5497,5514,CHEMBL388850,URXGPOFPBIBVGT-NBDWZHNGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,12.6,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,7.899629454882437,CN1C2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C4=CC=CC=C4,CN1C2CCC1[C@@H](c1ccccc1)[C@@H](c1ccccc1)C2
5498,5515,CHEMBL2096874,URXGPOFPBIBVGT-ZUPWUQBJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,690.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,6.161150909262744,CN1C2CCC1[C@@H]([C@@H](C2)C3=CC=CC=C3)C4=CC=CC=C4,CN1C2CCC1[C@H](c1ccccc1)[C@H](c1ccccc1)C2
5499,5516,CHEMBL1643660,USDVATJLQVYHIW-PBWJLWFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,238.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.623423042943487,C1CC2C([C@@H](CC1S2)C3=CC=C(C=C3)Br)C4=CC(=NO4)C5=CC=CC=C5,Brc1ccc([C@@H]2CC3CCC(S3)C2c2cc(-c3ccccc3)no2)cc1
5500,5517,CHEMBL481697,USDWPOAZUSPDGS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,5800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.236572006437063,CN(C)CC1=C(C=CC(=C1)CNS(=O)(=O)C)OC2=CC=C(C=C2)OC(F)(F)F,CN(C)Cc1cc(CNS(C)(=O)=O)ccc1Oc1ccc(OC(F)(F)F)cc1
5501,5518,CHEMBL2037528,USGLWFZAXHASGB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22520153.0,KI,=,4742.0,NM,,,,,,,,,,,,,,,Displacement of [3H]GBR12935 from human DAT by liquid scintillation assay,Benzothiazoles as probes for the 5HT(1A) receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants.,Eur. J. Med. Chem.,PUBLICATION,,5.324038450357831,C1CN(CCN1CCCCC(=O)C2=NC3=CC=CC=C3S2)C4=CC=C(C=C4)Cl,O=C(CCCCN1CCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1
5502,5519,CHEMBL38696,USGPDESLGQZHAK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.3,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.3,C1CN(CCN1CCCC2=CC=C(C=C2)Cl)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccc(Cl)cc3)CC2)c2ccc(F)cc2)cc1
5503,5520,CHEMBL38696,USGPDESLGQZHAK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.09,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.09,C1CN(CCN1CCCC2=CC=C(C=C2)Cl)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(OCCN2CCN(CCCc3ccc(Cl)cc3)CC2)c2ccc(F)cc2)cc1
5504,5521,CHEMBL219649,USGRALLMTYXJMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,4.5,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.346787486224656,CCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
5505,5522,CHEMBL219649,USGRALLMTYXJMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,88.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.055517327849832,CCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
5506,5523,CHEMBL219649,USGRALLMTYXJMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,0.97,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,9.013228265733757,CCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
5507,5524,CHEMBL219649,USGRALLMTYXJMV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,43.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.366531544420414,CCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl,CCCC(c1ccc(Cl)c(Cl)c1)C1CCCCN1
5508,5525,CHEMBL157455,USKJECUROJSHQU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC(C(C1=CC=CC=C1)O)NC(C)(C)C,CC(NC(C)(C)C)C(O)c1ccccc1
5509,5526,CHEMBL157455,USKJECUROJSHQU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC(C(C1=CC=CC=C1)O)NC(C)(C)C,CC(NC(C)(C)C)C(O)c1ccccc1
5510,5527,CHEMBL190700,USOGSVQPPWDNQD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,=,279.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.554395796726402,CN(C)CC1=CC=CC=C1SC2=CC=CC=C2N,CN(C)Cc1ccccc1Sc1ccccc1N
5511,5528,CHEMBL210126,USQDYFAONFKQLW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,CCc1ccccc1CC(c1ccccc1)N1CCNCC1
5512,5529,CHEMBL1784694,USRJTKDRTOTPRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21570838.0,INHIBITION,<,50.0,%,Active,,,,,,,,,,,,,,Inhibition of human recombinant DAT at 10 uM by radioligand binding assay,Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC1=C(C=CC(=C1)C(=O)N)C2=C(C=CN2C3=CC(=C(C=C3)O)[N+](=O)[O-])C4=CC=C(C=C4)OC,COc1ccc(-c2ccn(-c3ccc(O)c([N+](=O)[O-])c3)c2-c2ccc(C(N)=O)cc2C)cc1
5513,5530,CHEMBL502896,USROQQUKEBHOFF-SKKCDYJJSA-N,CETRAXATE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O.Cl,NCC1CCC(C(=O)Oc2ccc(CCC(=O)O)cc2)CC1
5514,5531,CHEMBL502896,USROQQUKEBHOFF-SKKCDYJJSA-N,CETRAXATE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O.Cl,NCC1CCC(C(=O)Oc2ccc(CCC(=O)O)cc2)CC1
5515,5532,CHEMBL476116,USUPIRYFHGUVOR-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,3740.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.427128397799519,CC(C)C(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
5516,5533,CHEMBL476116,USUPIRYFHGUVOR-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)C(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
5517,5534,CHEMBL476116,USUPIRYFHGUVOR-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3740.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.427128397799519,CC(C)C(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
5518,5535,CHEMBL3673159,USYVVKCTZJJTBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,18.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.732828271596986,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=CN5C(=NC=N5)C=C4)C6=CC(=C(C=C6)Cl)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(-c4ccc5ncnn5c4)ccc23)cc1Cl
5519,5536,CHEMBL502620,USZYSDMBJDPRIF-SVEJIMAYSA-N,ACLARUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O,CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC
5520,5537,CHEMBL502620,USZYSDMBJDPRIF-SVEJIMAYSA-N,ACLARUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O,CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC
5521,5538,CHEMBL1333512,UTGQNNCQYDRXCH-UHFFFAOYSA-N,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3,c1ccc(Nc2ccc(Nc3ccccc3)cc2)cc1
5522,5539,CHEMBL1333512,UTGQNNCQYDRXCH-UHFFFAOYSA-N,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3,c1ccc(Nc2ccc(Nc3ccccc3)cc2)cc1
5523,5540,CHEMBL377574,UTKRCKRKACMWMX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-3.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-3.0,CCOCCN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2.C(C(C(=O)O)O)(C(=O)O)O,CCOCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
5524,5541,CHEMBL562115,UTLIGDFWNZZYCH-MANSERQUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19525112.0,IC50,=,3.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,"[(11)C]PR04.MZ, a promising DAT ligand for low concentration imaging: Synthesis, efficient (11)C-O-methylation and initial small animal PET studies.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.522878745280337,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3CC#CCF,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2CC#CCF
5525,5542,CHEMBL562115,UTLIGDFWNZZYCH-MANSERQUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22082561.0,IC50,=,1.93,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of [3H]WIN35,428 from human DAT expressed in HEK293 cells",Characterisation of [C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.714442690992227,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3CC#CCF,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2CC#CCF
5526,5543,CHEMBL562115,UTLIGDFWNZZYCH-MANSERQUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22082561.0,IC50,=,3.26,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]DA from human DAT expressed in HEK293 cells,Characterisation of [C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.486782399932059,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3CC#CCF,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2CC#CCF
5527,5544,CHEMBL569270,UTPGRZGMQVAYAA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24147864.0,KI,>,2536.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT by PDSP assay,Synthesis and evaluation in monkey of [(18)F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([(18)F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1).,J. Med. Chem.,PUBLICATION,,5.595850750790305,CNC1=NC=NC(=C1)C2=CSC(=N2)N(C)C(=O)C3=CC=C(C=C3)F,CNc1cc(-c2csc(N(C)C(=O)c3ccc(F)cc3)n2)ncn1
5528,5545,CHEMBL1683899,UTQLEVQLADDVHS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CN(C)CC1(CCCCC1)C2=CC=CC3=CC=CC=C32,CN(C)CC1(c2cccc3ccccc23)CCCCC1
5529,5546,CHEMBL13378,UUDAMDVQRQNNHZ-UHFFFAOYSA-N,"(R,S)-AMPA",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)NO1)CC(C(=O)O)N,Cc1o[nH]c(=O)c1CC(N)C(=O)O
5530,5547,CHEMBL13378,UUDAMDVQRQNNHZ-UHFFFAOYSA-N,"(R,S)-AMPA",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)NO1)CC(C(=O)O)N,Cc1o[nH]c(=O)c1CC(N)C(=O)O
5531,5548,CHEMBL3673143,UUEYKVGDKFNPHW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,83.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.078313524516398,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=NC=CN=C4)C5=CC=C(C=C5)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(-c4cnccn4)ccc23)cc1
5532,5549,CHEMBL2430687,UUNYJDCLTZOEDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,1731.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.761702932124607,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccc(Cl)c(Cl)c1
5533,5550,CHEMBL2430687,UUNYJDCLTZOEDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,55.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,55.0,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccc(Cl)c(Cl)c1
5534,5551,CHEMBL2430687,UUNYJDCLTZOEDK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,87.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,87.0,C1C(C(C(=O)N1)C2=CC(=C(C=C2)Cl)Cl)C3=CC=CC=C3Cl,O=C1NCC(c2ccccc2Cl)C1c1ccc(Cl)c(Cl)c1
5535,5552,CHEMBL357995,UUOJIACWOAYWEZ-UHFFFAOYSA-N,BOPINDOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1
5536,5553,CHEMBL357995,UUOJIACWOAYWEZ-UHFFFAOYSA-N,BOPINDOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1
5537,5554,CHEMBL24441,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,BETAHISTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC1=CC=CC=N1,CNCCc1ccccn1
5538,5555,CHEMBL24441,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,BETAHISTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC1=CC=CC=N1,CNCCc1ccccn1
5539,5556,CHEMBL2337595,UUSPTDRDECONSP-RHSMWYFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,31.62,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC(=CC=C3)Cl,Clc1cccc(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1
5540,5557,CHEMBL2337594,UUSPTDRDECONSP-YOEHRIQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CNC[C@H]1[C@H](C2=CC=CC=C2)OC3=CC(=CC=C3)Cl,Clc1cccc(O[C@@H](c2ccccc2)[C@H]2CCNC2)c1
5541,5558,CHEMBL2431797,UUUXPUGZNDRYSV-ZQIYAJFXSA-N,(-)-O-METHYLCUBEBIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24112084.0,IC50,=,78600.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in MDCK cells using [3H]-dopamine as substrate after 10 mins by scintillation counting,The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.,J. Nat. Prod.,PUBLICATION,,4.104577453960592,COC1[C@H]([C@@H](CO1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,COC1OC[C@@H](Cc2ccc3c(c2)OCO3)[C@@H]1Cc1ccc2c(c1)OCO2
5542,5559,CHEMBL1455,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,ALTRETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,CN(C)c1nc(N(C)C)nc(N(C)C)n1
5543,5560,CHEMBL1455,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,ALTRETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,CN(C)c1nc(N(C)C)nc(N(C)C)n1
5544,5561,CHEMBL577825,UUZFTXGGHPBIFW-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,8.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=CC(=CC=C1)[C@@H]([C@@H](CNC)O)N2C=CC3=CC=CC=C32,CNC[C@@H](O)[C@H](c1cccc(C)c1)n1ccc2ccccc21
5545,5562,CHEMBL479044,UVCDBPBNDXOVKD-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
5546,5563,CHEMBL605502,UVFXBMLDXDSRJM-SLEUVZQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.400007822415903,CCOC[C@H]1[C@H]2[C@@]1(CN(C2)C)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@H]1[C@@H]2CN(C)C[C@]12c1ccc(Cl)c(Cl)c1
5547,5564,CHEMBL255839,UVKUMJGXPDEXSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCNC(=O)C1(CC1CN)C2=CC=CC=C2,CCNC(=O)C1(c2ccccc2)CC1CN
5548,5565,CHEMBL648,UVKZSORBKUEBAZ-UHFFFAOYSA-N,CYCLIZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,763.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.117475462045118,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,CN1CCN(C(c2ccccc2)c2ccccc2)CC1
5549,5566,CHEMBL648,UVKZSORBKUEBAZ-UHFFFAOYSA-N,CYCLIZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,606.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.217527375833714,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,CN1CCN(C(c2ccccc2)c2ccccc2)CC1
5550,5567,CHEMBL573844,UVNCBAMPWZRVGM-CPWXKJDLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.698970004336019,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)SC(F)(F)F)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(SC(F)(F)F)cc1)N2C
5551,5568,CHEMBL408867,UVSWWUWQVAQPJR-UHFFFAOYSA-N,[11C]SA4503,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,INHIBITION,=,50.0,%,,,,,,,,,,,,,,,Binding affinity to DA transporter (unknown origin) at 10 uM by displacement assay relative to control,,MedChemComm,PUBLICATION,,50.0,COC1=C(C=C(C=C1)CCN2CCN(CC2)CCCC3=CC=CC=C3)OC,COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC
5552,5569,CHEMBL1173416,UVVKDTGZBLYAEF-COLVAYQJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.400007822415903,C[C@H]1C[C@@]2(C[C@@]2(CN1)COC)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CN[C@@H](C)C[C@]1(c1ccc(Cl)c(Cl)c1)C2
5553,5570,CHEMBL106939,UVWLEPXXYOYDGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956218.0,KI,=,1423.0,NM,,,,,,,,,,,,,,,In vitro binding affinity on cloned Dopamine transporter,"Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.",J. Med. Chem.,PUBLICATION,,5.846795099915716,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)C#N)N,CN(C)Cc1ccccc1Sc1ccc(C#N)cc1N
5554,5571,CHEMBL106939,UVWLEPXXYOYDGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)C#N)N,CN(C)Cc1ccccc1Sc1ccc(C#N)cc1N
5555,5572,CHEMBL106939,UVWLEPXXYOYDGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)C#N)N,CN(C)Cc1ccccc1Sc1ccc(C#N)cc1N
5556,5573,CHEMBL404811,UVYVLBIGDKGWPX-YCCXZQINSA-N,DIGITONIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1,C[C@H]1[C@H]2[C@@H](O[C@]13CC[C@@H](C)CO3)[C@@H](O)[C@H]1[C@@H]3CC[C@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@H](O[C@@H]6O[C@H](CO)C(O)[C@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)C[C@]4(C)[C@H]3CC[C@@]12C
5557,5574,CHEMBL404811,UVYVLBIGDKGWPX-YCCXZQINSA-N,DIGITONIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1,C[C@H]1[C@H]2[C@@H](O[C@]13CC[C@@H](C)CO3)[C@@H](O)[C@H]1[C@@H]3CC[C@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@H](O[C@@H]6O[C@H](CO)C(O)[C@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)C[C@]4(C)[C@H]3CC[C@@]12C
5558,5575,CHEMBL139835,UWFYSQMTEOIJJG-FDTZYFLXSA-N,CYPROTERONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
5559,5576,CHEMBL139835,UWFYSQMTEOIJJG-FDTZYFLXSA-N,CYPROTERONE ACETATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
5560,5577,CHEMBL2048519,UWGODAMEDSNNHJ-AXTKMDLGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,3.79,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.421360790031928,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)CN(C)CC[18F],CN(CCF)C[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2C
5561,5578,CHEMBL220247,UWHKVOABKKOHHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,8.6,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.065501548756432,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CC(c1ccc(Cl)cc1)C1CCCCN1
5562,5579,CHEMBL220247,UWHKVOABKKOHHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,380.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.420216403383191,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CC(c1ccc(Cl)cc1)C1CCCCN1
5563,5580,CHEMBL220247,UWHKVOABKKOHHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,16.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.795880017344076,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CC(c1ccc(Cl)cc1)C1CCCCN1
5564,5581,CHEMBL220247,UWHKVOABKKOHHU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,170.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.769551078621726,CC(C)CC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CC(c1ccc(Cl)cc1)C1CCCCN1
5565,5582,CHEMBL525371,UWKDYASULVDCRI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18793858.0,KI,>,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]GBR-12935 from human cloned DAT expressed in HEK293 cells,"Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC(=C(C=C1)SC2=CC=CC=C2CN(C)C)NC(=O)C3=CC=C(C=C3)F,Cc1ccc(Sc2ccccc2CN(C)C)c(NC(=O)c2ccc(F)cc2)c1
5566,5583,CHEMBL481,UWKQSNNFCGGAFS-XIFFEERXSA-N,IRINOTECAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
5567,5584,CHEMBL481,UWKQSNNFCGGAFS-XIFFEERXSA-N,IRINOTECAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
5568,5585,CHEMBL204702,UWLGSNCXKLOAAD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CCN(C1=C(C=C(C=C1)C)N)C2=CC=CC=C2CN(C)C,CCN(c1ccc(C)cc1N)c1ccccc1CN(C)C
5569,5586,CHEMBL1078073,UWLXWGKTAMTBSF-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,2560.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.591760034688151,CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)F,CC(C)CN(C(=O)c1cccc(Cl)c1F)[C@H]1CCNC1
5570,5587,CHEMBL458072,UWVXBFZXNOPEDU-CHKHYCHESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,16.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.795880017344076,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC(=C(C=C3)OC)F)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](c2ccc(OC)c(F)c2)C[C@H]2CC[C@H]1N2C
5571,5588,CHEMBL594388,UWXLPDJHYFZQEG-ZEUZZLKZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,1300.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,5.886056647693162,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NC5CCC(CC5)NC(=O)[C@H]6[C@H](CC7CCC6N7C)C8=CC=C(C=C8)C9=CSC=C9,CN1C2CCC1[C@@H](C(=O)NC1CCC(NC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(-c5ccsc5)cc3)N4C)CC1)[C@@H](c1ccc(-c3ccsc3)cc1)C2
5572,5589,CHEMBL2430697,UXGIXJLEBICYQD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,22.7,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.643974142806877,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccccc1
5573,5590,CHEMBL2430697,UXGIXJLEBICYQD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,94.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,94.0,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccccc1
5574,5591,CHEMBL2430697,UXGIXJLEBICYQD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,98.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,98.0,C1C(C(C(=O)N1)C2=CC=CC=C2)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccccc1
5575,5592,CHEMBL523916,UXQWVKZZHZNXRM-SLWGAWGTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,47.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,7.327902142064282,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CN(N=N4)CC5=CC=CC=C5.Cl,CN1[C@H]2CC[C@@H]1[C@@H](c1cn(Cc3ccccc3)nn1)[C@@H](c1ccc(Cl)cc1)C2
5576,5593,CHEMBL86754,UXZFQZANDVDGMM-UHFFFAOYSA-N,IODOQUINOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C(C=C2I)I)O)N=C1,Oc1c(I)cc(I)c2cccnc12
5577,5594,CHEMBL86754,UXZFQZANDVDGMM-UHFFFAOYSA-N,IODOQUINOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C(C=C2I)I)O)N=C1,Oc1c(I)cc(I)c2cccnc12
5578,5595,CHEMBL226984,UYCWPYLNAMMOLO-NQAVQENRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,23.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.638272163982407,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=CC=C5)[N+](=O)[O-])N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4cccc([N+](=O)[O-])c4)s2)N3C)cc1
5579,5596,CHEMBL226984,UYCWPYLNAMMOLO-NQAVQENRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,14.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.853871964321763,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=NC=C(S4)C5=CC(=CC=C5)[N+](=O)[O-])N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2c2ncc(-c4cccc([N+](=O)[O-])c4)s2)N3C)cc1
5580,5597,CHEMBL555121,UYHGUPUXXZHREH-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)N([C@H]1CCNC1)C(=O)C2=CC=CC=C2C(F)(F)F,CC(C)N(C(=O)c1ccccc1C(F)(F)F)[C@H]1CCNC1
5581,5598,CHEMBL282575,UYIFTLBWAOGQBI-BZDYCCQFSA-N,ESTRADIOL BENZOATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
5582,5599,CHEMBL282575,UYIFTLBWAOGQBI-BZDYCCQFSA-N,ESTRADIOL BENZOATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
5583,5600,CHEMBL208252,UYKZMZQXFWTAIG-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-19.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-19.0,CC(C)CN(CC1=C(C=CC(=C1)F)C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1cc(F)ccc1C(F)(F)F)C1CCNCC1
5584,5601,CHEMBL203236,UYRXAUJWAVZHMT-LIRRHRJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,1500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)S(=O)(=O)N(C)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(S(=O)(=O)N(C)C)cc21
5585,5602,CHEMBL476320,UYSHSCPIMATHOZ-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,1900.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,CCOC(=O)N(CC1=CC=CC=C1OC2=CC=CC=C2)[C@H]3CCNC3,CCOC(=O)N(Cc1ccccc1Oc1ccccc1)[C@H]1CCNC1
5586,5603,CHEMBL566830,UYZAXUWVJGHEFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,1534.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.814174640387037,CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C,CC(C(=O)c1cccc(Cl)c1)N(C)C
5587,5604,CHEMBL566830,UYZAXUWVJGHEFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,4133.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.383734594718292,CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C,CC(C(=O)c1cccc(Cl)c1)N(C)C
5588,5605,CHEMBL566830,UYZAXUWVJGHEFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,1750.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.7569619513137065,CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C,CC(C(=O)c1cccc(Cl)c1)N(C)C
5589,5606,CHEMBL3126730,UZCXWMDBXCJWSY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24494745.0,KI,=,1210.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to wild type human DAT expressed in African green monkey COS7 cells assessed as inhibition of [3H]-dopamine uptake after 5 mins by beta-scintillation counting analysis,Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues.,J. Med. Chem.,PUBLICATION,,5.917214629683549,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)SCCN)Cl,NCCSC(c1ccc(Cl)cc1)c1ccc(Cl)cc1
5590,5607,CHEMBL207374,UZGZHONLKDCUMO-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-16.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-16.0,CC1=CC(=C(C=C1)CN(CC(C)C)C2CCNCC2)C.C(=C/C(=O)O)\C(=O)O,Cc1ccc(CN(CC(C)C)C2CCNCC2)c(C)c1
5591,5608,CHEMBL80,UZHSEJADLWPNLE-GRGSLBFTSA-N,NALOXONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
5592,5609,CHEMBL80,UZHSEJADLWPNLE-GRGSLBFTSA-N,NALOXONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
5593,5610,CHEMBL487355,UZKWACFLBGIUSH-UHFFFAOYSA-N,5-(3-BENZYLPYRROLIDIN-3-YL)-1H-INDOLE (STRUCTURAL MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,11.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.9586073148417755,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
5594,5611,CHEMBL487355,UZKWACFLBGIUSH-UHFFFAOYSA-N,5-(3-BENZYLPYRROLIDIN-3-YL)-1H-INDOLE (STRUCTURAL MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,81.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.091514981121351,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
5595,5612,CHEMBL487355,UZKWACFLBGIUSH-UHFFFAOYSA-N,5-(3-BENZYLPYRROLIDIN-3-YL)-1H-INDOLE (STRUCTURAL MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CC2(c3ccc4[nH]ccc4c3)CCNC2)cc1
5596,5613,CHEMBL3094320,UZVSKGBBGCJIRV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,84.1,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,84.1,C1=CC(=CC(=C1)Cl)COC2=CC=C(C=C2)CN.Cl,NCc1ccc(OCc2cccc(Cl)c2)cc1
5597,5614,CHEMBL260335,UZYRBFYXTKDZOC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC=C)C(=O)C1(C(C1(C)C)CN)C2=CC=CC=C2,C=CCN(CC)C(=O)C1(c2ccccc2)C(CN)C1(C)C
5598,5615,CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
5599,5616,CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
5600,5617,CHEMBL542933,VAHMWGICKYTGSY-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23403082.0,IC50,=,1.7,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [125I]RTI55 from human recombinant dopamine transporter expressed in CHOK1 cells after 3 hrs,Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
5601,5618,CHEMBL542933,VAHMWGICKYTGSY-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23403082.0,INHIBITION,=,5.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [125I]RTI55 from human recombinant dopamine transporter expressed in CHOK1 cells at 10 uM after 3 hrs relative to control,Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
5602,5619,CHEMBL542933,VAHMWGICKYTGSY-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23403082.0,KI,=,1.3,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [125I]RTI55 from human recombinant dopamine transporter expressed in CHOK1 cells after 3 hrs,Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
5603,5620,CHEMBL542933,VAHMWGICKYTGSY-UHFFFAOYSA-N,GBR-12909,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24315194.0,KI,=,16.2,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),"Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.",Bioorg. Med. Chem.,PUBLICATION,,7.790484985457369,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
5604,5621,CHEMBL257704,VAIOZOCLKVMIMN-PRJWTAEASA-N,EPLIVANSERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15999145.0,KI,=,5619.0,NM,,,,,,,,,,,,,,,,,,,,5.2503409679051005,CN(C)CCO/N=C(/C=C/C1=CC=C(C=C1)O)\C2=CC=CC=C2F,CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F
5605,5622,CHEMBL272002,VANVVYOTKNTIED-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17983754.0,KI,>,3000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125]RTI35 from human DAT expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter.",Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COC(=O)c1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
5606,5623,CHEMBL137,VAOCPAMSLUNLGC-UHFFFAOYSA-N,METRONIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CCO)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CCO
5607,5624,CHEMBL137,VAOCPAMSLUNLGC-UHFFFAOYSA-N,METRONIDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CCO)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CCO
5608,5625,CHEMBL2048525,VASQEHCFVIZSPK-QUIJITIRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22658558.0,KI,=,26.9,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]IPT from DAT overexpressed in LLC-PK1 cell membrane by competitive binding assay,Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.570247719997593,CN(C)C[C@@H]1[C@H]2CC[C@H](N2CCC[18F])C[C@@H]1C3=CC=C(C=C3)Cl,CN(C)C[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2CCCF
5609,5626,CHEMBL461241,VAVYBCGVZAGHSF-ZNAMSDCWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,18.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,7.744727494896693,CC1=CC=C(C=C1)C2=NOC(=C2)[C@@H]3[C@H]4CC[C@@H](N4C)C[C@@H]3C5=CC=C(C=C5)OC.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2c2cc(-c4ccc(C)cc4)no2)N3C)cc1
5610,5627,CHEMBL1683873,VAXCWNURWRJNKL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.698970004336019,C1CCC(CC1)(CNC2CC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C2(CNC3CC3)CCCCC2)cc1Cl
5611,5628,CHEMBL573532,VAXHGPCUAFNAQS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,4730.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.325138859262188,C1CN(CCN1)C2=CC=CC=C2OC3=CC=CC=C3,c1ccc(Oc2ccccc2N2CCNCC2)cc1
5612,5629,CHEMBL569142,VBBBMMYVACZXLQ-RFLHHMENSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,ACTIVITY,,,,Active,,cell_based,,,,,HEK293,,,,,,,Binding affinity to 6xHis-tagged human dopamine transporter expressed in HEK293 cells assessed as drug incorporation at 30 nM after 1 hr by SDS-PAGE analysis,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,,CCCC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])[125I])N2CCCC2,CCCC(C(=O)c1ccc(N=[N+]=[N-])c(I)c1)N1CCCC1
5613,5630,CHEMBL569142,VBBBMMYVACZXLQ-RFLHHMENSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,ACTIVITY,,,,Not Active,,cell_based,,,,,HEK293,,,,,,,Binding affinity to 6xHis-tagged human dopamine transporter expressed in HEK293 cells assessed as drug incorporation at 30 nM after 1 hr by SDS-PAGE analysis in presence of cocaine,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,,CCCC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])[125I])N2CCCC2,CCCC(C(=O)c1ccc(N=[N+]=[N-])c(I)c1)N1CCCC1
5614,5631,CHEMBL558086,VBBBMMYVACZXLQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,IC50,=,264.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,6.578396073130169,CCCC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])I)N2CCCC2,CCCC(C(=O)c1ccc(N=[N+]=[N-])c(I)c1)N1CCCC1
5615,5632,CHEMBL558086,VBBBMMYVACZXLQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,KI,=,78.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells by scintillation counting,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,7.107905397309519,CCCC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])I)N2CCCC2,CCCC(C(=O)c1ccc(N=[N+]=[N-])c(I)c1)N1CCCC1
5616,5633,CHEMBL558086,VBBBMMYVACZXLQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19442525.0,RATIO,=,3.0,,,,cell_based,,,,,,,,,,,,Ratio of IC50 for [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells to Ki for displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells,A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.,Bioorg. Med. Chem.,PUBLICATION,,3.0,CCCC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])I)N2CCCC2,CCCC(C(=O)c1ccc(N=[N+]=[N-])c(I)c1)N1CCCC1
5617,5634,CHEMBL524624,VBCNPTPFVJBMLY-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3OC,CNC[C@H]1OCc2ccccc2[C@@H]1Oc1ccccc1OC
5618,5635,CHEMBL1170209,VBDVAWKLCDBKGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,1584.89,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,COC1=C2C(=CC(=C1)N3CCNCC3CC4=CC=CC=C4)C=CN2,COc1cc(N2CCNCC2Cc2ccccc2)cc2cc[nH]c12
5619,5636,CHEMBL3323177,VBHKUWHGDVHSSQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,110.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.9586073148417755,CN1CC(C2=C(C1)C=C(C=C2)C#N)C3=CC4=C(C=C3)SC=C4,CN1Cc2cc(C#N)ccc2C(c2ccc3sccc3c2)C1
5620,5637,CHEMBL2030637,VBKWQJLSFFFYLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,KI,=,3309.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.480303232840147,C1CCN(C1)CCCC2=CC(=CC=C2)F,Fc1cccc(CCCN2CCCC2)c1
5621,5638,CHEMBL3126750,VBLOYTBDVHDEGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24494745.0,KI,=,5500.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to wild type human DAT expressed in African green monkey COS7 cells assessed as inhibition of [3H]-dopamine uptake after 5 mins by beta-scintillation counting analysis,Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues.,J. Med. Chem.,PUBLICATION,,5.259637310505756,CNC(=O)CSC(C1=CC=CC=C1)C2=CC=CC=C2,CNC(=O)CSC(c1ccccc1)c1ccccc1
5622,5639,CHEMBL1645598,VBNJXEPLSRKHGO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,4860.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.313363730737707,C1C(CN1)OC2=C(C=CC=C2F)OC3=CC=CC=C3F,Fc1ccccc1Oc1cccc(F)c1OC1CNC1
5623,5642,CHEMBL230951,VBOQYPQEPHKASR-VKHMYHEASA-N,L-HOMOCYSTEATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCS(=O)(=O)O)C(=O)O
5624,5643,CHEMBL514193,VBPKFUYKYAIDNV-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,5.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCN1C2=CC=CC=C2N(C1=O)[C@@H](CCNC)C3=CC=CC=C3,CCCn1c(=O)n([C@@H](CCNC)c2ccccc2)c2ccccc21
5625,5644,CHEMBL461323,VBPKFUYKYAIDNV-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CCCN1C2=CC=CC=C2N(C1=O)[C@H](CCNC)C3=CC=CC=C3,CCCn1c(=O)n([C@H](CCNC)c2ccccc2)c2ccccc21
5626,5645,CHEMBL566050,VBQDZZHUUPHQGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,84.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,7.075720713938117,CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CCCC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
5627,5646,CHEMBL566050,VBQDZZHUUPHQGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,43.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,7.359518563029578,CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CCCC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
5628,5647,CHEMBL566050,VBQDZZHUUPHQGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,31.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.508638306165728,CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C,CCCC(NC(C)(C)C)C(=O)c1ccc(Cl)c(Cl)c1
5629,5648,CHEMBL364050,VCCPIFXWHLLCQB-KOLCDFICSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=CC=C3F,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2c(F)cccc12
5630,5649,CHEMBL2171413,VCDSAMDGVWEPBI-UHFFFAOYSA-N,3-((BENZYLOXY)(4-CHLOROPHENYL)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,5.7,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,5.7,C1C(CN1)C(C2=CC=C(C=C2)Cl)OCC3=CC=CC=C3.Cl,Clc1ccc(C(OCc2ccccc2)C2CNC2)cc1
5631,5650,CHEMBL3094317,VCEAPZBMHGKMHI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,61.7,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,61.7,C1=CC=C(C(=C1)COC2=CC=C(C=C2)CN)F.Cl,NCc1ccc(OCc2ccccc2F)cc1
5632,5651,CHEMBL90903,VCIKPQPFJYKGHA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.0,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)cc1)O2
5633,5652,CHEMBL90903,VCIKPQPFJYKGHA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,28.5,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.54515513999149,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)Cl,COC(=O)C1C2CCC(CC1c1ccc(Cl)cc1)O2
5634,5653,CHEMBL1765684,VCKIDQVWSDVZCZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21428406.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by radioligand binding assay,"N-(4-Cyanotetrahydro-2H-pyran-4-yl) and N-(1-Cyanocyclohexyl) Derivatives of 1,5-Diarylpyrazole-3-carboxamides Showing High Affinity for 18 kDa Translocator Protein and/or Cannabinoid Receptors.",J. Med. Chem.,PUBLICATION,,50.0,CC1=C(N(N=C1C(=O)NC2(CCCCC2)C#N)C3=CC=CC=C3Br)C4=CC=C(C=C4)OC,COc1ccc(-c2c(C)c(C(=O)NC3(C#N)CCCCC3)nn2-c2ccccc2Br)cc1
5635,5654,CHEMBL611,VCKUSRYTPJJLNI-UHFFFAOYSA-N,TERAZOSIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
5636,5655,CHEMBL611,VCKUSRYTPJJLNI-UHFFFAOYSA-N,TERAZOSIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
5637,5656,CHEMBL1083708,VCVDPONUNCPTCQ-UHFFFAOYSA-N,1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,3160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC=CC=C3,FC(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1
5638,5657,CHEMBL1083708,VCVDPONUNCPTCQ-UHFFFAOYSA-N,1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,3290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.482804102050027,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC=CC=C3,FC(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1
5639,5658,CHEMBL1083708,VCVDPONUNCPTCQ-UHFFFAOYSA-N,1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,6560.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.18309616062434,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC=CC=C3,FC(F)Oc1ccccc1CC(c1ccccc1)N1CCNCC1
5640,5659,CHEMBL220713,VCYYAUWOLSKMPO-CUNXSJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,651.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.186419011431807,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CCF)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CCF)cc(C(C)=O)c1
5641,5660,CHEMBL3331486,VDBBSSQCQRSAQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,540.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.267606240177032,C1C(CN1)CN(CC2=CC=C(C=C2)Cl)C3=CC=CC=C3,Clc1ccc(CN(CC2CNC2)c2ccccc2)cc1
5642,5661,CHEMBL3331486,VDBBSSQCQRSAQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,10.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,10.0,C1C(CN1)CN(CC2=CC=C(C=C2)Cl)C3=CC=CC=C3,Clc1ccc(CN(CC2CNC2)c2ccccc2)cc1
5643,5662,CHEMBL573667,VDFAJYFMKVKZLC-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,44.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,44.0,CNCC[C@H](C1=CC=CC=C1)N2C=CC3=CC=CC=C32,CNCC[C@H](c1ccccc1)n1ccc2ccccc21
5644,5663,CHEMBL453838,VDFAJYFMKVKZLC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,44.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,44.0,CNCCC(C1=CC=CC=C1)N2C=CC3=CC=CC=C32,CNCCC(c1ccccc1)n1ccc2ccccc21
5645,5664,CHEMBL3099899,VDWKDBPHAPPUBO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24215892.0,INHIBITION,=,-7.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 10 uM relative to control,"Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,-7.0,COC1=C(C=C(C=C1)CNC(=O)C2=C(N=CC(=C2)C3=CC(=CC(=C3)Cl)Cl)C4=CN=CC=C4)OC,COc1ccc(CNC(=O)c2cc(-c3cc(Cl)cc(Cl)c3)cnc2-c2cccnc2)cc1OC
5646,5665,CHEMBL2031874,VEGKMRUZYWQMBZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313242.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)C(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=O)N(CC3)CCN4CCCC4,CN(C)C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
5647,5666,CHEMBL133276,VEOHXIUSARYQDP-UHFFFAOYSA-N,GNF-PF-2664,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,INHIBITION,=,20.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane at a concentration of 10e-6 M,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,20.0,C1CN2C(=N1)C3=C(C2(C4=CC5=CC=CC=C5C=C4)O)C6=CC=CC=C6C7=CC=CC=C73,OC1(c2ccc3ccccc3c2)c2c(c3ccccc3c3ccccc23)C2=NCCN21
5648,5667,CHEMBL567479,VEOJUGKGLUEXTM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)NC(CCC1CCCCC1)C(=O)C2=CC(=CC=C2)Cl,CC(C)(C)NC(CCC1CCCCC1)C(=O)c1cccc(Cl)c1
5649,5668,CHEMBL567479,VEOJUGKGLUEXTM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,1700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.769551078621726,CC(C)(C)NC(CCC1CCCCC1)C(=O)C2=CC(=CC=C2)Cl,CC(C)(C)NC(CCC1CCCCC1)C(=O)c1cccc(Cl)c1
5650,5669,CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,8098.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.091622227567607,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
5651,5670,CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6434.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.1915189434340485,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
5652,5671,CHEMBL1200629,VEPSYABRBFXYIB-PWXDFCLTSA-M,VECURONIUM BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-],CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
5653,5672,CHEMBL1200629,VEPSYABRBFXYIB-PWXDFCLTSA-M,VECURONIUM BROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-],CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
5654,5673,CHEMBL277474,VEQOALNAAJBPNY-UHFFFAOYSA-N,ANTIPYRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(N1C)C2=CC=CC=C2,Cc1cc(=O)n(-c2ccccc2)n1C
5655,5674,CHEMBL277474,VEQOALNAAJBPNY-UHFFFAOYSA-N,ANTIPYRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(N1C)C2=CC=CC=C2,Cc1cc(=O)n(-c2ccccc2)n1C
5656,5675,CHEMBL131792,VETUKMSKEWYIOQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,INHIBITION,=,45.0,%,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane at a concentration of 10e-6 M,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,45.0,C1C2=CC=CC=C2N=C3N1C(C4=CC=CC=C43)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=Nc3ccccc3CN21
5657,5676,CHEMBL131792,VETUKMSKEWYIOQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,<,0.02,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,0.02,C1C2=CC=CC=C2N=C3N1C(C4=CC=CC=C43)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=Nc3ccccc3CN21
5658,5677,CHEMBL314402,VEWNLDNSIXATRX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,1900.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.721246399047171,COC(=O)C1C2CCC(O2)CC1C3=CC=CC=C3,COC(=O)C1C2CCC(CC1c1ccccc1)O2
5659,5678,CHEMBL314402,VEWNLDNSIXATRX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.0,COC(=O)C1C2CCC(O2)CC1C3=CC=CC=C3,COC(=O)C1C2CCC(CC1c1ccccc1)O2
5660,5679,CHEMBL283196,VFMMPHCGEFXGIP-UHFFFAOYSA-N,ALPHA-NAPHTHOFLAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12
5661,5680,CHEMBL283196,VFMMPHCGEFXGIP-UHFFFAOYSA-N,ALPHA-NAPHTHOFLAVONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12
5662,5681,CHEMBL317714,VFRPYBIGSSNAJS-UHFFFAOYSA-N,2-BENZOYLOXY-BENZOIC ACID METHYL ESTER,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,548.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.261219441515631,COC(=O)C1=CC=CC=C1OC(=O)C2=CC=CC=C2,COC(=O)c1ccccc1OC(=O)c1ccccc1
5663,5682,CHEMBL1643645,VFWWGMNGYMVIBX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,139.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.856985199745905,CC1=NOC(=C1)C2=C(CC3CCC2S3)C4=CC=C(C=C4)Br,Cc1cc(C2=C(c3ccc(Br)cc3)CC3CCC2S3)on1
5664,5683,CHEMBL3323180,VGAJKWKQOHMKHS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,INHIBITION,=,68.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells at 100 nM after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,68.0,CN1CC(C2=C(C1)C=C(C=C2)CN3CCOCC3)C4=CC5=C(C=C4)SC=C5,CN1Cc2cc(CN3CCOCC3)ccc2C(c2ccc3sccc3c2)C1
5665,5684,CHEMBL117537,VGBOISIRCIDEGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,954.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.020451625295905,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCCC4=CC=CC=C4,O=C(CCCc1ccccc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
5666,5685,CHEMBL29292,VGGGPCQERPFHOB-RDBSUJKOSA-N,UBENIMEX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O
5667,5686,CHEMBL29292,VGGGPCQERPFHOB-RDBSUJKOSA-N,UBENIMEX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O
5668,5687,CHEMBL207712,VGJFVJKZCAUGKE-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,5.5,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5,C1CO[C@@H](CN1)[C@@](CC2=CC=CC=C2)(C3=CC=CC=C3)O,O[C@](Cc1ccccc1)(c1ccccc1)[C@@H]1CNCCO1
5669,5688,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,25.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.602059991327962,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5670,5689,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,310.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.508638306165728,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5671,5690,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,310.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.508638306165728,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5672,5691,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,32.4,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.489454989793388,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5673,5692,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,25.8,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.58838029403677,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5674,5693,CHEMBL190573,VGKDLMBJGBXTGI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14573386.0,KI,=,26.0,NM,,,,,,,,,,,,,,,,,,,,7.585026652029183,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21
5675,5694,CHEMBL284994,VGKDLMBJGBXTGI-YVEFUNNKSA-N,"(1R,4S)-TRANS-SERTRALINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,25.0,NM,,,,,,,,,,,,,,,,,,,,7.602059991327962,CN[C@@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5676,5695,CHEMBL284994,VGKDLMBJGBXTGI-YVEFUNNKSA-N,"(1R,4S)-TRANS-SERTRALINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,22.0,NM,,,,,,,,,,,,,,,,,,,,7.657577319177793,CN[C@@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5677,5696,CHEMBL284994,VGKDLMBJGBXTGI-YVEFUNNKSA-N,"(1R,4S)-TRANS-SERTRALINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,315.0,NM,,,,,,,,,,,,,,,,,,,,6.501689446210398,CN[C@@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
5678,5697,CHEMBL444592,VGRLTUHUYGCCLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,33.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]WIN-35428 (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.481486060122112,C1CN(CCC1CCNC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC=CC=C4,Fc1ccc(C(NCCC2CCN(Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
5679,5698,CHEMBL444592,VGRLTUHUYGCCLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,58.0,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]DA (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.236572006437062,C1CN(CCC1CCNC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC=CC=C4,Fc1ccc(C(NCCC2CCN(Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
5680,5699,CHEMBL477580,VGSCEHIVOAIVKK-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,=,21600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.665546248849068,CC(C)C(=O)N(CC1=C(C(=CC(=C1)Cl)Cl)Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1cc(Cl)cc(Cl)c1Cl)[C@H]1CCNC1
5681,5700,CHEMBL555146,VGSYEFOBFMUWGO-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313227.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant DAT,Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.,J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C(=O)C4=CC=C(C=C4)F,C[C@@H]1CCCN1CCc1cc2cc(C(=O)c3ccc(F)cc3)ccc2o1
5682,5701,CHEMBL401819,VGUGGBCMZNBMLT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,2820.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.549750891680639,CC1=C(C=CC(=C1)Cl)OC2=C(C=C(C=C2)C(=O)N)CNC,CNCc1cc(C(N)=O)ccc1Oc1ccc(Cl)cc1C
5683,5702,CHEMBL2335706,VGUIDVOAJKITDB-UHFFFAOYSA-N,MARISTACHONE A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23268694.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from DAT (unknown origin) at 10 uM,Unprecedented Polyketides from a Marine Sponge-Associated Stachylidium sp.,J. Nat. Prod.,PUBLICATION,,,CC1=C(C=C(C(=C1OC)COC)C(C)O)O,COCc1c(C(C)O)cc(O)c(C)c1OC
5684,5703,CHEMBL239079,VGVAYDIHTPWEKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,=,847.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.072116589669293,CN(C)CC1=C(C=CC(=C1)OCCF)SC2=C(C=C(C=C2)Cl)N,CN(C)Cc1cc(OCCF)ccc1Sc1ccc(Cl)cc1N
5685,5704,CHEMBL2429890,VGYQUDBPYFLBLJ-PTCVETCVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC7=C(C=C6)OCO7,c1cc2c(cc1CN[C@H]1C3C4CC5C6C4CC3C6C51)OCO2
5686,5705,CHEMBL1258843,VHENJOBTWCOIPN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20727749.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,"Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OCC#C)C)C,C#CCOc1ccc(-c2nn3c(C)cc(C)nc3c2CC(=O)N(CC)CC)cc1
5687,5706,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,1080.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.966576244513051,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5688,5707,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165726,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5689,5708,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,3100.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.508638306165726,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5690,5709,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,3000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5691,5710,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,3000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5692,5711,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,3000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5693,5712,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,=,3100.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.508638306165726,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5694,5713,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,3000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.522878745280337,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5695,5714,CHEMBL641,VHGCDTVCOLNTBX-QGZVFWFLSA-N,ATOMOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,IC5,=,48.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,7.3187587626244115,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
5696,5715,CHEMBL299052,VHGCDTVCOLNTBX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,1080.0,NM,,,,,,,,,,,,,,,,,,,,5.966576244513051,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CNCCC(Oc1ccccc1C)c1ccccc1
5697,5716,CHEMBL299052,VHGCDTVCOLNTBX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,1451.0,NM,,,,,,,,,,,,,,,,,,,,5.838332587562264,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CNCCC(Oc1ccccc1C)c1ccccc1
5698,5717,CHEMBL1645604,VHKIHYNCEPOAKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6410.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.193141970481181,CC1=C(C(=CC=C1)Cl)OC2=C(C(=CC=C2)F)OC3CNC3,Cc1cccc(Cl)c1Oc1cccc(F)c1OC1CNC1
5699,5718,CHEMBL270299,VHKZGNPOHPFPER-ONNFQVAWSA-N,BAY-11-7085,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N,CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1
5700,5719,CHEMBL270299,VHKZGNPOHPFPER-ONNFQVAWSA-N,BAY-11-7085,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N,CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1
5701,5720,CHEMBL960,VHOGYURTWQBHIL-UHFFFAOYSA-N,LEFLUNOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2884.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.540004743952608,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
5702,5721,CHEMBL960,VHOGYURTWQBHIL-UHFFFAOYSA-N,LEFLUNOMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2291.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.6399749108106025,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
5703,5722,CHEMBL459165,VHOZFHYPZOTVKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,21.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.67778070526608,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)C=CN4,c1ccc(CC2(c3ccc4cc[nH]c4c3)CCNC2)cc1
5704,5723,CHEMBL459165,VHOZFHYPZOTVKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,43.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.366531544420414,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)C=CN4,c1ccc(CC2(c3ccc4cc[nH]c4c3)CCNC2)cc1
5705,5724,CHEMBL459165,VHOZFHYPZOTVKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,447.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.349692476868062,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)C=CN4,c1ccc(CC2(c3ccc4cc[nH]c4c3)CCNC2)cc1
5706,5725,CHEMBL650,VHRSUDSXCMQTMA-PJHHCJLFSA-N,METHYLPREDNISOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
5707,5726,CHEMBL650,VHRSUDSXCMQTMA-PJHHCJLFSA-N,METHYLPREDNISOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
5708,5727,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
5709,5728,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
5710,5729,CHEMBL3238497,VHZBGZHOIBUJJU-QLYXXIJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)N)O)N,Nc1ccc(-c2ccc(N=Nc3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)cc2)cc1
5711,5730,CHEMBL469150,VIHUCKRDYCSWQL-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=CC=C1N(C)[C@@H](C2=CC=CC=C2)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccccc1C
5712,5731,CHEMBL1162,VIKNJXKGJWUCNN-XGXHKTLJSA-N,NORETHINDRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
5713,5732,CHEMBL1162,VIKNJXKGJWUCNN-XGXHKTLJSA-N,NORETHINDRONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
5714,5733,CHEMBL377882,VILBBVHEBGZUJO-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-27.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-27.0,C1CC1CN(CC2=CC=CC=C2C(F)(F)F)C3CCNCC3.C(=C/C(=O)O)\C(=O)O,FC(F)(F)c1ccccc1CN(CC1CC1)C1CCNCC1
5715,5734,CHEMBL267894,VIROVYVQCGLCII-UHFFFAOYSA-N,AMOBARBITAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
5716,5735,CHEMBL267894,VIROVYVQCGLCII-UHFFFAOYSA-N,AMOBARBITAL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
5717,5736,CHEMBL550469,VITWCGUBRNYQIV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,501.19,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CNCCC1N(CC2=CC=CC=C2C#N)C3=CC4=C(C=C3)NC=C4,N#Cc1ccccc1CN(c1ccc2[nH]ccc2c1)C1CCNCC1
5718,5737,CHEMBL580143,VIWKHXNVEIOPSC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,452.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.3448615651886175,CC(C(=O)C1=CC(=CC=C1)OC)N2CCCCC2,COc1cccc(C(=O)C(C)N2CCCCC2)c1
5719,5738,CHEMBL1078162,VJADHLVJCCCGKY-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,516.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.28735029837279,CC1=C(C=CC=C1Cl)C(=O)N(CC(C)C)[C@H]2CCNC2,Cc1c(Cl)cccc1C(=O)N(CC(C)C)[C@H]1CCNC1
5720,5739,CHEMBL559137,VJAXFVGMNNFSQS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,>,1584.89,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,C1CNCCC1N(C2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(N(c2ccc3[nH]ccc3c2)C2CCNCC2)cc1
5721,5740,CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
5722,5741,CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
5723,5742,CHEMBL540978,VKEVCZGXCJOVET-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,480.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3187587626244115,C1CNCCC1C(C2=CN=CC=C2)OC3=C(C=C(C=C3)Cl)Cl,Clc1ccc(OC(c2cccnc2)C2CCNCC2)c(Cl)c1
5724,5743,CHEMBL605990,VKFRVICFXISTJZ-BHDTVMLSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,2.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2CC3(CCCC3)C4=CC=CC=C42)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC2(CCCC2)c2ccccc21
5725,5744,CHEMBL1276308,VKHAHZOOUSRJNA-GCNJZUOMSA-N,MIFEPRISTONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
5726,5745,CHEMBL1276308,VKHAHZOOUSRJNA-GCNJZUOMSA-N,MIFEPRISTONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
5727,5746,CHEMBL1643649,VKIMHTMOOFWQDW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,66.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.177178354696896,C1CC2C(=C(CC1S2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)C5=CC=CC=C5,Clc1ccc(C2=C(c3cc(-c4ccccc4)no3)C3CCC(C2)S3)cc1
5728,5747,CHEMBL12089,VKJGBAJNNALVAV-UHFFFAOYSA-M,BERBERINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-],COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
5729,5748,CHEMBL12089,VKJGBAJNNALVAV-UHFFFAOYSA-M,BERBERINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-],COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
5730,5749,CHEMBL3310638,VKOHWMDCIHAUTC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,42.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,42.0,C1C(CN1)CC(C2=CC=CC=C2)OC3=CC=CC=C3,c1ccc(OC(CC2CNC2)c2ccccc2)cc1
5731,5750,CHEMBL1726,VKQFCGNPDRICFG-UHFFFAOYSA-N,NISOLDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]
5732,5751,CHEMBL1726,VKQFCGNPDRICFG-UHFFFAOYSA-N,NISOLDIPINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]
5733,5752,CHEMBL462585,VKZWZSZGPDLBNV-FPLPWBNLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053782.0,KI,=,118.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]RTI-55 from human DAT transfected in human HEK293 cells,"Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,6.9255492810454085,C1CC2C(C(CC1N2)C3=CC=CC(=C3)/C=C\Br)C(=O)OCCCF,O=C(OCCCF)C1C2CCC(CC1c1cccc(/C=C\Br)c1)N2
5734,5753,CHEMBL564288,VLCJRBGIGILJAS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,158.49,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,C1CNCCC1N(CCC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4,c1ccc(CCN(c2ccc3[nH]ccc3c2)C2CCNCC2)cc1
5735,5754,CHEMBL541196,VLCYASXBDSCXJI-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CSC1=CC=CC=C1C(=O)N([C@H]2CCNC2)C3CCC3,CSc1ccccc1C(=O)N(C1CCC1)[C@H]1CCNC1
5736,5755,CHEMBL186119,VLIANQRCIMWNHF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15482938.0,KI,=,5.0,NM,,,,,,,,,,,,,,,Inhibition of [18F]PET binding to dopamine transporter of human brain,Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,C1CC2C(C(CC1N2)C3=CC=C(C=C3)Br)C(=O)OCCF,O=C(OCCF)C1C2CCC(CC1c1ccc(Br)cc1)N2
5737,5756,CHEMBL514354,VLIFAHMVTGLJCP-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18771916.0,ACTIVITY,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CC1(C2=C(C(=CC=C2)F)N(C1=O)[C@H](CCNC)C3=CC(=CC(=C3)Cl)F)C,CNCC[C@H](c1cc(F)cc(Cl)c1)N1C(=O)C(C)(C)c2cccc(F)c21
5738,5757,CHEMBL574921,VLLHQEDHCOUXKK-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CC1=C2C=CN(C2=CC=C1)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2c(C)cccc21
5739,5758,CHEMBL592854,VLLKJTHFWNJPCE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,842.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.074687908500351,CC1=CC(=CC=C1)C(=O)C(C)NC2CCCC2,Cc1cccc(C(=O)C(C)NC2CCCC2)c1
5740,5759,CHEMBL558,VLPIATFUUWWMKC-UHFFFAOYSA-N,MEXILETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)OCC(C)N,Cc1cccc(C)c1OCC(C)N
5741,5760,CHEMBL558,VLPIATFUUWWMKC-UHFFFAOYSA-N,MEXILETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)OCC(C)N,Cc1cccc(C)c1OCC(C)N
5742,5761,CHEMBL235409,VMBQININAKGPQP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,575439937337157.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-5.76,COC(=O)C1=C(C2CCC1N2)C3=CC4=CC=CC=C4C=C3,COC(=O)C1=C(c2ccc3ccccc3c2)C2CCC1N2
5743,5762,CHEMBL321067,VMBSZAVHWRUISI-KRCSLNALSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,89.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0506099933550885,CC1=CC=C(C=C1)[C@H]2C[C@H]3CCC4C2[C@](CN34)(C5=CC=CC=C5)O,Cc1ccc([C@H]2C[C@H]3CCC4C2[C@@](O)(c2ccccc2)CN43)cc1
5744,5763,CHEMBL589494,VMEDIUSDIYRUSA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,414.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.382999658879101,CC1=CC(=CC=C1)C(=O)C(C)N2CCCCC2,Cc1cccc(C(=O)C(C)N2CCCCC2)c1
5745,5764,CHEMBL512435,VMHPHANZAYAVEB-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNC[C@H]([C@H](C1=CC(=CC=C1)Cl)N(C)C2=CC=CC=C2)O,CNC[C@@H](O)[C@H](c1cccc(Cl)c1)N(C)c1ccccc1
5746,5765,CHEMBL50858,VMITZEMDDZVHBZ-KCNJBTMXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12723940.0,IC50,=,0.6,NM,,,,,,,,,,,,,,,Inhibition of dopamine (DA) reuptake using cloned human dopamine transporter was determined,2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.,J. Med. Chem.,PUBLICATION,,9.221848749616356,CC1=C(C=CC(=C1)[C@H]2C[C@H]3CCC(C2C(=O)OC)N3C)Cl,COC(=O)C1C2CC[C@H](C[C@@H]1c1ccc(Cl)c(C)c1)N2C
5747,5766,CHEMBL1812749,VMITZEMDDZVHBZ-UGQVUOCMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,3.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.522878745280337,CC1=C(C=CC(=C1)[C@@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)Cl,COC(=O)[C@H]1[C@H](c2ccc(Cl)c(C)c2)C[C@@H]2CC[C@H]1N2C
5748,5767,CHEMBL1812745,VMITZEMDDZVHBZ-XNISGKROSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,2.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.698970004336019,CC1=C(C=CC(=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)Cl,COC(=O)[C@H]1[C@@H](c2ccc(Cl)c(C)c2)C[C@@H]2CC[C@H]1N2C
5749,5768,CHEMBL1612004,VMPITZXILSNTON-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1N,COc1ccccc1N
5750,5769,CHEMBL1612004,VMPITZXILSNTON-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1N,COc1ccccc1N
5751,5770,CHEMBL386493,VMQXOMTZSIHVEX-LVXARBLLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,931.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.031050319018657,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CC(F)F)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CC(F)F)cc(C(C)=O)c1
5752,5771,CHEMBL207807,VMRYJLGXIPJJKQ-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,580.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.236572006437062,CC(C)CN(CC1=C(C=C(C=C1)F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccc(F)cc1F)C1CCNCC1
5753,5772,CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
5754,5773,CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
5755,5774,CHEMBL290536,VMZAHLMVORANEZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.83,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.83,C1CN(CCN1CCCCCN(CC2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,c1ccc(CCCN2CCN(CCCCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
5756,5775,CHEMBL290536,VMZAHLMVORANEZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.5,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.5,C1CN(CCN1CCCCCN(CC2=CC=CC=C2)C3=CC=CC=C3)CCCC4=CC=CC=C4,c1ccc(CCCN2CCN(CCCCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
5757,5776,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,5581.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.25328797748334,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
5758,5777,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4434.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.35320431122153,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
5759,5778,CHEMBL2432055,VNGQWOKKSKAESQ-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CC1=CC=CC=C1)[C@H]2C3C4CC5C2C6C3CC4C56,CN(Cc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41
5760,5779,CHEMBL611379,VNJFIBFHISUZRV-YESZJQIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,50.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.299988937677887,COC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC4=CC=CC=C4C=C3,COC[C@H]1[C@@H]2CNC[C@@]21c1ccc2ccccc2c1
5761,5780,CHEMBL611379,VNJFIBFHISUZRV-YESZJQIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,398.11,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.399996913372259,COC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC4=CC=CC=C4C=C3,COC[C@H]1[C@@H]2CNC[C@@]21c1ccc2ccccc2c1
5762,5781,CHEMBL598215,VNJFIBFHISUZRV-ZACQAIPSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.599980364934843,COC[C@@H]1[C@@H]2[C@]1(CNC2)C3=CC4=CC=CC=C4C=C3,COC[C@@H]1[C@H]2CNC[C@]21c1ccc2ccccc2c1
5763,5782,CHEMBL1765599,VNRFZHXTMQEXQW-XHDPSFHLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,44.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,7.356547323513813,CCN1[C@H]([C@@](OCC1(C)C)(C2=CC(=CC=C2)Cl)O)C,CCN1[C@@H](C)[C@](O)(c2cccc(Cl)c2)OCC1(C)C
5764,5783,CHEMBL1643518,VNSMQTHLCZBNAH-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN[C@H]1CC2=CC=CC=C2N(C1)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1Cc2ccccc2N(c2ccc(Cl)c(Cl)c2)C1
5765,5784,CHEMBL1643517,VNSMQTHLCZBNAH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21095126.0,IC50,=,177.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.752026733638194,CNC1CC2=CC=CC=C2N(C1)C3=CC(=C(C=C3)Cl)Cl,CNC1Cc2ccccc2N(c2ccc(Cl)c(Cl)c2)C1
5766,5785,CHEMBL1830890,VOAKSCZKUWRXKS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,INHIBITION,=,43.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells at 1 uM,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,43.0,C1COC(CN1)CCN2C3=C(C=CC(=C3)F)N(S2(=O)=O)C4=CC=CC=C4F,O=S1(=O)N(CCC2CNCCO2)c2cc(F)ccc2N1c1ccccc1F
5767,5786,CHEMBL3238487,VOAUOZIQGUSZLC-QNGOZBTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1I)F)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(I)cc3F)c(O)c12
5768,5787,CHEMBL2062932,VOLHNEGPSRUZLZ-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,9.1,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT expressed in mouse N2A cells after 15 mins by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.040958607678906,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)N)I,COC(=O)[C@H](c1ccc(N)c(I)c1)[C@H]1CCCCN1
5769,5788,CHEMBL401651,VOSGCNSEIZQWJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2130.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.671620396561263,CC1=CC(=C(C=N1)CNC)OC2=CC=CC=C2C(C)C,CNCc1cnc(C)cc1Oc1ccccc1C(C)C
5770,5789,CHEMBL1370,VOVIALXJUBGFJZ-KWVAZRHASA-N,BUDESONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
5771,5790,CHEMBL1370,VOVIALXJUBGFJZ-KWVAZRHASA-N,BUDESONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
5772,5791,CHEMBL135,VOXZDWNPVJITMN-ZBRFXRBCSA-N,ESTRADIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,14911.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.826493229791897,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
5773,5792,CHEMBL135,VOXZDWNPVJITMN-ZBRFXRBCSA-N,ESTRADIOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,11847.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.926391611543793,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
5774,5793,CHEMBL2407319,VPFSCTXNTBOTFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,79.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,7.102372908709557,CSCC(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CSCC(c1ccc(Cl)c(Cl)c1)C1CCNCC1
5775,5794,CHEMBL272531,VPKOLELPULBVMY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCCNCC1CC1(C2=CC=CC=C2)C(=O)N(CC)CC,CCCCNCC1CC1(C(=O)N(CC)CC)c1ccccc1
5776,5795,CHEMBL210026,VPNYIGJUQBPBMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,=,1400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321763,C1CN(CCN1)C(CC2=CC(=CC=C2)O)C3=CC=CC=C3,Oc1cccc(CC(c2ccccc2)N2CCNCC2)c1
5777,5796,CHEMBL526306,VPTOWUWJWIVXIJ-DYESRHJHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,4000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CNC[C@H]1CC2=CC=CC=C2[C@@H]1OC3=CC=CC4=CC=CC=C43,CNC[C@H]1Cc2ccccc2[C@@H]1Oc1cccc2ccccc12
5778,5797,CHEMBL524271,VPTOWUWJWIVXIJ-LAUBAEHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,=,5700.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2441251443275085,CNC[C@@H]1CC2=CC=CC=C2[C@@H]1OC3=CC=CC4=CC=CC=C43,CNC[C@@H]1Cc2ccccc2[C@@H]1Oc1cccc2ccccc12
5779,5798,CHEMBL1909073,VPUGSHLBERYQGC-UHFFFAOYSA-M,PIPERILATE ETHOBROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+]1(CCCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-],CC[N+]1(CCOC(=O)C(O)(c2ccccc2)c2ccccc2)CCCCC1
5780,5799,CHEMBL1909073,VPUGSHLBERYQGC-UHFFFAOYSA-M,PIPERILATE ETHOBROMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+]1(CCCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-],CC[N+]1(CCOC(=O)C(O)(c2ccccc2)c2ccccc2)CCCCC1
5781,5800,CHEMBL213496,VPVFIULLMFQQSH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCOC1=CC=CC=C1CC(C2=CN=CS2)N3CCNCC3,CCOc1ccccc1CC(c1cncs1)N1CCNCC1
5782,5801,CHEMBL325945,VPZVRDLFBIYDOY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11585444.0,IC50,=,1520.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.818156412055227,C1CN(CCC1N2C3=CC=CC=C3NC(=O)C2=O)CC4=CC5=C(C=C4Cl)OCO5,O=c1[nH]c2ccccc2n(C2CCN(Cc3cc4c(cc3Cl)OCO4)CC2)c1=O
5783,5802,CHEMBL3334790,VQCUPTYEZOLTOL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,25.8,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,25.8,CC1=CC=C(C=C1)C(CCN(C)C)N2CCOCC2,Cc1ccc(C(CCN(C)C)N2CCOCC2)cc1
5784,5803,CHEMBL1818458,VQEHAMZDBNCIFO-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,19.95,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.700057099977232,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C(=CC=N4)C#N,N#Cc1ccnn1C[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2
5785,5804,CHEMBL3673154,VQELKPWZCFCRFB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,36.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.437707135543525,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC=C(C=C5)Cl,FC(F)(F)c1ccc(Oc2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)nn1
5786,5805,CHEMBL498904,VQGISMYTICCORC-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C(=CC=C1)F)O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1c(C)cccc1F
5787,5806,CHEMBL1945127,VQGZQBKAHKWBNQ-LDVJMBRRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,30.9,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.5100415205751645,CC(C)OC(=O)[C@H]1[C@@H]2CC[C@@H](N2C)C[C@@H]1OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CC(C)OC(=O)[C@@H]1[C@@H](OC(c2ccc(F)cc2)c2ccc(F)cc2)C[C@H]2CC[C@@H]1N2C
5788,5807,CHEMBL257335,VQHFZGHDNLRMRZ-SUMWQHHRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CC(=C)F)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C=C(F)CN(C)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
5789,5808,CHEMBL563897,VQHNOBXUTWSPMZ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,-19.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,-19.0,CCN1C2=CC=CC=C2N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CCn1c(=O)n([C@@H](c2ccccc2)[C@H](O)CNC)c2ccccc21
5790,5809,CHEMBL2171212,VQJDDPXSICHYDO-UHFFFAOYSA-N,3-((4-CHLOROPHENYL)(METHOXY)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,2.6,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.6,COC(C1CNC1)C2=CC=C(C=C2)Cl.Cl,COC(c1ccc(Cl)cc1)C1CNC1
5791,5810,CHEMBL486043,VQMGCAXPAOTPQE-HOCLYGCPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.221848749616356,CC1=CC=CC=C1O[C@H]2C[C@@H](C3=CC=CC=C23)N,Cc1ccccc1O[C@H]1C[C@H](N)c2ccccc21
5792,5811,CHEMBL1201207,VQODGRNSFPNSQE-DVTGEIKXSA-N,BETAMETHASONE PHOSPHORIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
5793,5812,CHEMBL1201207,VQODGRNSFPNSQE-DVTGEIKXSA-N,BETAMETHASONE PHOSPHORIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
5794,5815,CHEMBL486236,VQTWAJKQIHYINF-QUCCMNQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,2500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,CCN(CC)[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=CC=C3C,CCN(CC)[C@@H]1C[C@H](Oc2ccccc2C)c2ccccc21
5795,5816,CHEMBL454674,VQXFWDGKPFYMCF-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,4000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CNC[C@@]1(CC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3F)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccccc1F
5796,5817,CHEMBL564021,VQXNEYZVHJNUFJ-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,1360.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.866461091629782,C1CC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3Cl,O=C(c1ccccc1Cl)N(CC1CCC1)[C@H]1CCNC1
5797,5818,CHEMBL1818457,VQZCUVHOYIJXAO-HZPDHXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,25.12,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.599980364934843,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=CC(=N4)C(F)(F)F,FC(F)(F)c1ccn(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
5798,5819,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,360.0,NM,,,,,,,,,,,,,,,,,,,,6.443697499232713,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
5799,5820,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,360.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.443697499232713,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
5800,5821,CHEMBL661,VREFGVBLTWBCJP-UHFFFAOYSA-N,ALPRAZOLAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
5801,5822,CHEMBL661,VREFGVBLTWBCJP-UHFFFAOYSA-N,ALPRAZOLAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
5802,5823,CHEMBL393386,VRKMKSUFWAHMQP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,9549925860214.37,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.98,COC(=O)C1=C(C2CCC1C2)C3=CC(=CC=C3)Cl,COC(=O)C1=C(c2cccc(Cl)c2)C2CCC1C2
5803,5824,CHEMBL194310,VROMWSWPRNOJJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,9.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CNCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCC1Cc2ccccc2N(c2ccccc2)C1=O
5804,5825,CHEMBL194310,VROMWSWPRNOJJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,13.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,13.0,CNCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCC1Cc2ccccc2N(c2ccccc2)C1=O
5805,5826,CHEMBL194310,VROMWSWPRNOJJN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCC1CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3,CNCCC1Cc2ccccc2N(c2ccccc2)C1=O
5806,5827,CHEMBL1684051,VRVDHYBVMARMIQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,2300.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,CC(C1(CCCCC1)C2=CC=C(C=C2)OC(F)(F)F)N,CC(N)C1(c2ccc(OC(F)(F)F)cc2)CCCCC1
5807,5828,CHEMBL382955,VRVNOJASIHQHAC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,543.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.265200170411153,CN1C2CCC1CC(C2)(C3C4=CC=CC=C4C5=CC=CC=C35)O,CN1C2CCC1CC(O)(C1c3ccccc3-c3ccccc31)C2
5808,5829,CHEMBL1400945,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,PREGNENOLONE CARBONITRILE ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N,CC(=O)[C@H]1[C@H](C#N)C[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C
5809,5830,CHEMBL1400945,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,PREGNENOLONE CARBONITRILE ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N,CC(=O)[C@H]1[C@H](C#N)C[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C
5810,5831,CHEMBL65,VSJKWCGYPAHWDS-FQEVSTJZSA-N,CAMPTOTHECIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
5811,5832,CHEMBL65,VSJKWCGYPAHWDS-FQEVSTJZSA-N,CAMPTOTHECIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
5812,5833,CHEMBL467,VSNHCAURESNICA-UHFFFAOYSA-N,HYDROXYUREA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(N)NO,NC(=O)NO
5813,5834,CHEMBL467,VSNHCAURESNICA-UHFFFAOYSA-N,HYDROXYUREA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(N)NO,NC(=O)NO
5814,5835,CHEMBL1224471,VSRNUBMEUKSAAJ-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=NN(N=N1)[C@@H](CCNC)C2=CC3=CC=CC=C3C=C2,CNCC[C@@H](c1ccc2ccccc2c1)n1nnc(C)n1
5815,5836,CHEMBL1224298,VSRNUBMEUKSAAJ-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CC1=NN(N=N1)[C@H](CCNC)C2=CC3=CC=CC=C3C=C2,CNCC[C@H](c1ccc2ccccc2c1)n1nnc(C)n1
5816,5837,CHEMBL386978,VSVUJKJXMNJRFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,410.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.3872161432802645,CN1C2CCC1C3COC(=O)CCCCCCCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCCCCCCC(=O)Nc3ccc(cc3)C1C2
5817,5838,CHEMBL3323110,VSXRMFADTFRTBM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,INHIBITION,=,6.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells at 100 nM after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,6.0,CN1CC(C2=CC=CC=C2C1)C3=C4C=CC=NC4=CC=C3,CN1Cc2ccccc2C(c2cccc3ncccc23)C1
5818,5839,CHEMBL488423,VSZILPWZKJQRHV-LIAHKDQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,8.6,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.065501548756432,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=CC(=NO4)CC5=CC=C(C=C5)F.Cl,CN1C2CCC1[C@@H](c1cc(Cc3ccc(F)cc3)no1)[C@@H](c1ccc(Cl)cc1)C2
5819,5840,CHEMBL483316,VTAMJLRZTZEHBO-BJUDXGSMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18487050.0,KI,=,3490.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells,Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.,Bioorg. Med. Chem.,PUBLICATION,,5.45717457304082,[11CH3]OC1=CC=CC2=C1CCN(C2)CCCC3=CNC4=C3C=C(C=C4)Br,COc1cccc2c1CCN(CCCc1c[nH]c3ccc(Br)cc13)C2
5820,5841,CHEMBL597190,VTIJRYTVJGTTAJ-BREBYQMCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.599980364934843,C1[C@@H]2[C@H]([C@@]2(CN1)C3=CC(=C(C=C3)Cl)Cl)COCC(F)(F)F,FC(F)(F)COC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1
5821,5842,CHEMBL598202,VTIJRYTVJGTTAJ-OUJBWJOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,50.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1[C@H]2[C@@H]([C@]2(CN1)C3=CC(=C(C=C3)Cl)Cl)COCC(F)(F)F,FC(F)(F)COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
5822,5843,CHEMBL598202,VTIJRYTVJGTTAJ-OUJBWJOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,630.96,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.19999817218203,C1[C@H]2[C@@H]([C@]2(CN1)C3=CC(=C(C=C3)Cl)Cl)COCC(F)(F)F,FC(F)(F)COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
5823,5844,CHEMBL76904,VTJXFTPMFYAJJU-UHFFFAOYSA-N,TYRPHOSTIN 23,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C=C(C#N)C#N)O)O,N#CC(C#N)=Cc1ccc(O)c(O)c1
5824,5845,CHEMBL76904,VTJXFTPMFYAJJU-UHFFFAOYSA-N,TYRPHOSTIN 23,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C=C(C#N)C#N)O)O,N#CC(C#N)=Cc1ccc(O)c(O)c1
5825,5846,CHEMBL124670,VTLTXYQXSCPKFW-YPBBTIAZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,80.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.0958256317158375,COC(=O)C1[C@H](CC2CCC1N2CCCC3=CC=C(C=C3)Br)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2CCCc1ccc(Br)cc1
5826,5847,CHEMBL2205818,VTLZIWJSKWWYHL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=NC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccncc1
5827,5848,CHEMBL1084829,VUEFLJKLCMGDEG-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,386.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,6.413412695328245,CNC[C@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=C(C=C3)F)O,CNC[C@@H](O)CCN1c2ccccc2N(c2ccc(F)cc2)S1(=O)=O
5828,5849,CHEMBL1084828,VUEFLJKLCMGDEG-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,IC50,=,262.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,6.581698708680254,CNC[C@@H](CCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=C(C=C3)F)O,CNC[C@H](O)CCN1c2ccccc2N(c2ccc(F)cc2)S1(=O)=O
5829,5850,CHEMBL1818451,VUEZBOYAXGKAME-ZYMOGRSISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,15.85,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.799970733446231,CC1=NN(C=C1)CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
5830,5851,CHEMBL1818451,VUEZBOYAXGKAME-ZYMOGRSISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,316.23,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.499996931948306,CC1=NN(C=C1)CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
5831,5852,CHEMBL1098855,VUNYCPOWVGTRIS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)(C(CN2CCNCC2)C3=CNC4=CC=CC=C43)O,OC1(C(CN2CCNCC2)c2c[nH]c3ccccc23)CCCCC1
5832,5853,CHEMBL479411,VUQUGOYPDVYZTL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,3800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.420216403383191,CNCC1=C(C=CC(=C1)NS(=O)(=O)C)SC2=CC=C(C=C2)SC,CNCc1cc(NS(C)(=O)=O)ccc1Sc1ccc(SC)cc1
5833,5854,CHEMBL3331488,VVBWHGPWDKYRIZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1C(CN1)CN(CC2=CC3=CC=CC=C3C=C2)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(N(Cc2ccc3ccccc3c2)CC2CNC2)cc1Cl
5834,5855,CHEMBL1679,VVIAGPKUTFNRDU-ABLWVSNPSA-N,LEUCOVORIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2
5835,5856,CHEMBL1679,VVIAGPKUTFNRDU-ABLWVSNPSA-N,LEUCOVORIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2
5836,5857,CHEMBL203403,VVIVTDYOMWHKAE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,63.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.200659450546419,CCCC(C(=O)C1=CC=CC=C1C)N2CCCC2,CCCC(C(=O)c1ccccc1C)N1CCCC1
5837,5858,CHEMBL203403,VVIVTDYOMWHKAE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,59.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.22402566887063,CCCC(C(=O)C1=CC=CC=C1C)N2CCCC2,CCCC(C(=O)c1ccccc1C)N1CCCC1
5838,5859,CHEMBL1430,VVNCNSJFMMFHPL-VKHMYHEASA-N,PENICILLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)([C@H](C(=O)O)N)S,CC(C)(S)[C@@H](N)C(=O)O
5839,5860,CHEMBL1430,VVNCNSJFMMFHPL-VKHMYHEASA-N,PENICILLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)([C@H](C(=O)O)N)S,CC(C)(S)[C@@H](N)C(=O)O
5840,5861,CHEMBL525238,VVQIWKYSMSGPNS-DNVCBOLYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CNC,CCc1ccccc1O[C@H]1c2ccccc2OC[C@H]1CNC
5841,5862,CHEMBL498481,VVQIWKYSMSGPNS-KXBFYZLASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=CC=CC=C1O[C@H]2[C@H](COC3=CC=CC=C23)CNC,CCc1ccccc1O[C@@H]1c2ccccc2OC[C@@H]1CNC
5842,5863,CHEMBL486537,VVROCSNBKQTQEO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,16.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.795880017344076,C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)SC=C4,c1ccc(CC2(c3ccc4sccc4c3)CCNC2)cc1
5843,5864,CHEMBL235833,VVUGHDDSABIECT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,67608297539198.2,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.83,COC(=O)C1=C(C2CCC1C2)C3=C(C(=CC=C3)Cl)Cl,COC(=O)C1=C(c2cccc(Cl)c2Cl)C2CCC1C2
5844,5865,CHEMBL245492,VWGQRLFYWPDXNG-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CNC[C@H]1N(CC2=C(C(=CC=C2)F)C(F)(F)F)C3CCOCC3,Fc1cccc(CN(C2CCOCC2)[C@H]2CCNC2)c1C(F)(F)F
5845,5866,CHEMBL181188,VWKLNUPRXXIKKE-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15664840.0,DISPLACEMENT,>,200.0,%,,,,,,,,,,,,,,,Displacement of dopamine by the compound against dopamine transporter was determined at 1000 nM,Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,200.0,COC1=CC=CC=C1S[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1ccccc1S[C@@H](c1ccccc1)[C@@H]1CNCCO1
5846,5867,CHEMBL181188,VWKLNUPRXXIKKE-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17983754.0,KI,>,4000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125]RTI35 from human DAT expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter.",Bioorg. Med. Chem.,PUBLICATION,,5.3979400086720375,COC1=CC=CC=C1S[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1ccccc1S[C@@H](c1ccccc1)[C@@H]1CNCCO1
5847,5868,CHEMBL1645603,VWOHPBLHZAONKH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,5940.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.226213555018807,C1C(CN1)OC2=C(C=CC=C2F)OC3=C(C=CC=C3Cl)Cl,Fc1cccc(Oc2c(Cl)cccc2Cl)c1OC1CNC1
5848,5869,CHEMBL1645611,VWOHRXMXNABMIC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6220.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.206209615309182,C1CNCC1OC2=CC=CC=C2OC3=CC=CC=C3F,Fc1ccccc1Oc1ccccc1OC1CCNC1
5849,5870,CHEMBL212878,VWOWSEBOGHLBFX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC3=CC=CC=C32)C4=CC=CC=C4,c1ccc(C(Cc2cccc3ccccc23)N2CCNCC2)cc1
5850,5871,CHEMBL649,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,NADOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
5851,5872,CHEMBL649,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,NADOLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
5852,5873,CHEMBL497550,VWPPLGQILGHEGL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.0,CCN(CCC1=CC(=CC=C1)OC(F)(F)F)CCN2CCCCC2,CCN(CCc1cccc(OC(F)(F)F)c1)CCN1CCCCC1
5853,5874,CHEMBL125871,VWUYWLASXQATSZ-YPBBTIAZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,119.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,6.924453038607469,COC(=O)C1[C@H](CC2CCC1N2CCCC3=CC=C(C=C3)I)OC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2CCCc1ccc(I)cc1
5854,5875,CHEMBL1766,VWVSBHGCDBMOOT-IIEHVVJPSA-N,DESOXIMETASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
5855,5876,CHEMBL1766,VWVSBHGCDBMOOT-IIEHVVJPSA-N,DESOXIMETASONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
5856,5877,CHEMBL573972,VWVYZCFGGWGOMP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,4420.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.354577730650909,C1CN(CCN1)C2=CC=CC=C2OC3=CC=C(C=C3)F,Fc1ccc(Oc2ccccc2N2CCNCC2)cc1
5857,5878,CHEMBL572917,VWWGPYFAWGEBAY-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,10.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C=CC(=C3)Br)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cc(Br)ccc21
5858,5879,CHEMBL477571,VXAFVYYBYDYSHN-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2080.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.681936665037237,C1CNC[C@H]1N(CC2=CC=CC=C2C3=CC=CC=C3)S(=O)(=O)C(F)(F)F,O=S(=O)(N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1)C(F)(F)F
5859,5880,CHEMBL600645,VXAKZDFZAIJNGP-MJVIPROJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,25.12,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.599980364934843,CCC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCC[C@H]1[C@@H]2CNC[C@]12c1ccc(Cl)c(Cl)c1
5860,5881,CHEMBL471002,VXBRIAOTINONRK-FZMZJTMJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.0,CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC=CS2,C=CCN(CC)C(=O)[C@@]1(c2cccs2)C[C@H]1CN
5861,5882,CHEMBL468212,VXDRWSRRRHADME-HHHXNRCGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,22.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.657577319177793,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CC4=CC=CC=C4)F,Fc1ccc(C(OCCN2CCN(C[C@H](F)Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
5862,5883,CHEMBL468211,VXDRWSRRRHADME-MHZLTWQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,2.7,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.568636235841014,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H](CC4=CC=CC=C4)F,Fc1ccc(C(OCCN2CCN(C[C@@H](F)Cc3ccccc3)CC2)c2ccc(F)cc2)cc1
5863,5884,CHEMBL611961,VXFJRJWYWCHNJF-SESHTJHWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,20.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.698970004336019,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)NCCC4=CC=C(C=C4)CNC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)Cl,CN1C2CCC1[C@@H](C(=O)NCc1ccc(CCNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(Cl)cc3)N4C)cc1)[C@@H](c1ccc(Cl)cc1)C2
5864,5885,CHEMBL1944973,VXHRYYJRPBBRRE-ABFRBSLYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,338.84,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.470005326930858,CCC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)I,CCc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)cc1I
5865,5886,CHEMBL424005,VXIRNZHRQNADGN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,0.48,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,0.48,C1CN(CCC1CNOC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CNOC(c3ccccc3)c3ccccc3)CC2)cc1
5866,5887,CHEMBL3703746,VXVOMCCQHIVMJK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,30.8,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.511449283499557,C1C(C2=C(CN1)C=C(C=C2)C3=CN4C(=NC=N4)C=C3)C5=CC(=C(C=C5)Cl)Cl,Clc1ccc(C2CNCc3cc(-c4ccc5ncnn5c4)ccc32)cc1Cl
5867,5888,CHEMBL401877,VXYNDBOWMKXSIO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,21000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6777807052660805,CNCC1=C(C=CC(=C1)C(=O)N)OC2=C(C=C(C=C2)Cl)OC,CNCc1cc(C(N)=O)ccc1Oc1ccc(Cl)cc1OC
5868,5889,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,67.0,NM,,,,,,,,,,,,,,,,,,,,7.173925197299173,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5869,5890,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,1770.0,NM,,,,,,,,,,,,,,,,,,,,5.752026733638194,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5870,5891,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,3100.0,NM,,,,,,,,,,,,,,,,,,,,5.508638306165726,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5871,5892,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,5300.0,NM,,,,,,,,,,,,,,,,,,,,5.275724130399211,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5872,5893,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,5900.0,NM,,,,,,,,,,,,,,,,,,,,5.229147988357856,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5873,5894,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,IC50,=,460.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.337242168318426,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5874,5895,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,=,6400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5875,5896,CHEMBL59,VYFYYTLLBUKUHU-UHFFFAOYSA-N,DOPAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19962901.0,ACTIVITY,>,10000.0,%,,,,,,,,,,,,,,,Inhibition of DAT PDSP analysis,"Synthesis, pharmacological studies and molecular modeling of some tetracyclic 1,3-diazepinium chlorides.",Bioorg. Med. Chem.,PUBLICATION,,10000.0,C1=CC(=C(C=C1CCN)O)O,NCCc1ccc(O)c(O)c1
5876,5897,CHEMBL101,VYMDGNCVAMGZFE-UHFFFAOYSA-N,PHENYLBUTAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
5877,5898,CHEMBL101,VYMDGNCVAMGZFE-UHFFFAOYSA-N,PHENYLBUTAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
5878,5899,CHEMBL1388,VYQNWZOUAUKGHI-UHFFFAOYSA-N,MONOBENZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)COC2=CC=C(C=C2)O,Oc1ccc(OCc2ccccc2)cc1
5879,5900,CHEMBL1388,VYQNWZOUAUKGHI-UHFFFAOYSA-N,MONOBENZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)COC2=CC=C(C=C2)O,Oc1ccc(OCc2ccccc2)cc1
5880,5901,CHEMBL1230333,VYTXLSQVYGNWLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)CCCC(=O)O,O=C(O)CCCc1cccs1
5881,5902,CHEMBL1230333,VYTXLSQVYGNWLV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)CCCC(=O)O,O=C(O)CCCc1cccs1
5882,5903,CHEMBL595751,VZAQFIJMTJXBKF-VGYQQOEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,350.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.455931955649724,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCCCCCCCCCCNC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC=C(C=C7)C8=CSC=C8,CN1C2CCC1[C@@H](C(=O)NCCCCCCCCCCNC(=O)[C@H]1C3CCC(C[C@@H]1c1ccc(-c4ccsc4)cc1)N3C)[C@@H](c1ccc(-c3ccsc3)cc1)C2
5883,5904,CHEMBL3593401,VZFSSAZWIAREQM-YLCXCWDSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC(=O)NCC[C@@H]1CNCCO[C@H]1C2=CC(=C(C=C2)Cl)Cl.Cl,CC(=O)NCC[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1
5884,5905,CHEMBL44814,VZGDMQKNWNREIO-UHFFFAOYSA-N,CARBON TETRACHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)(Cl)Cl,ClC(Cl)(Cl)Cl
5885,5906,CHEMBL44814,VZGDMQKNWNREIO-UHFFFAOYSA-N,CARBON TETRACHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)(Cl)Cl,ClC(Cl)(Cl)Cl
5886,5907,CHEMBL494814,WAIMVSIHYKGAQF-GAPKJMMISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,0.8,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,9.096910013008056,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C#CC4=CC=CC=C4.Cl,CN1[C@H]2CC[C@@H]1[C@@H](C#Cc1ccccc1)[C@@H](c1ccc(Cl)cc1)C2
5887,5908,CHEMBL3310493,WALNRLHGEDDGRH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,77.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,77.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC(=CC=C3)Cl,Fc1ccc(C(CC2CNC2)Oc2cccc(Cl)c2)cc1F
5888,5909,CHEMBL1083426,WARUECLCXNMKJR-UHFFFAOYSA-N,1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,3160.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=CC=C3F,Fc1ccccc1C(Cc1ccccc1OC(F)(F)F)N1CCNCC1
5889,5910,CHEMBL1083426,WARUECLCXNMKJR-UHFFFAOYSA-N,1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX),,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=CC=C3F,Fc1ccccc1C(Cc1ccccc1OC(F)(F)F)N1CCNCC1
5890,5911,CHEMBL1170017,WBGRUPCVVLWKNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,3.16,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381597,C1CN(C(CN1)CC2=CC=CC=C2)C3=CC4=C(C=C3)NC(=C4)C(=O)N,NC(=O)c1cc2cc(N3CCNCC3Cc3ccccc3)ccc2[nH]1
5891,5912,CHEMBL3304438,WBLVOWHFRUAMCP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25801932.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)C1=NOC(=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC3CCN(CC3)C,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1
5892,5913,CHEMBL2206534,WBMAKFNAAWXWBA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,64.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1938200260161125,CN1CC(C2=C(C1)C=C(C=C2)O)C3=CC(=C(C=C3)F)F,CN1Cc2cc(O)ccc2C(c2ccc(F)c(F)c2)C1
5893,5914,CHEMBL164290,WBNQDOYYEUMPFS-UHFFFAOYSA-N,N-NITROSODIETHYLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)N=O,CCN(CC)N=O
5894,5915,CHEMBL164290,WBNQDOYYEUMPFS-UHFFFAOYSA-N,N-NITROSODIETHYLAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)N=O,CCN(CC)N=O
5895,5916,CHEMBL381792,WBQILMOPSULAPL-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,55.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.259637310505756,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)NS(=O)(=O)C)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(NS(C)(=O)=O)cc21
5896,5917,CHEMBL600220,WBTKYJAWLLWAMV-VOMIJIAVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,18.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,18.0,CC1(CN(C2=CC=CC=C21)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1ccccc1)N1CC(C)(C)c2ccccc21
5897,5918,CHEMBL434959,WBUKLOIGDUMVEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,392000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.4067139329795433,COC(=O)C1=C(CCCCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCCCC1
5898,5919,CHEMBL434959,WBUKLOIGDUMVEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCCC1)C2=CC3=CC=CC=C3C=C2,COC(=O)C1=C(c2ccc3ccccc3c2)CCCCC1
5899,5920,CHEMBL466733,WBZDGCPWORXWIT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,410.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.3872161432802645,C=C(CC1=CC=CC=C1)CN2CCN(CC2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,C=C(Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
5900,5921,CHEMBL381045,WCMJUQVXFGLIRF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,757.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.120904120499928,CN1C2CCC1C=C(C2)C3=CC4=C(C=C3)C5=CC=CC=C5C4,CN1C2C=C(c3ccc4c(c3)Cc3ccccc3-4)CC1CC2
5901,5922,CHEMBL512202,WCTHXORWWZOJGX-HHZCPPTISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,6.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,8.187086643357143,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OC.Cl,COC(=O)[C@H]1[C@@H](c2ccc(OC)cc2)C[C@H]2CC[C@H]1N2C
5902,5923,CHEMBL184867,WCWYQSBRFMSVQV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC(=O)C1=C(CC2CCC1O2)C3=CC=CC=C3,COC(=O)C1=C(c2ccccc2)CC2CCC1O2
5903,5924,CHEMBL512130,WDAYPJKNBZKLPA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,210.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6777807052660805,C1CC(C1)N(CC2=CC3=CC=CC=C3C=C2)C4CCNCC4,c1ccc2cc(CN(C3CCC3)C3CCNCC3)ccc2c1
5904,5925,CHEMBL2337587,WDFMVSDPRALOJK-CRAIPNDOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,501.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,COC1=CC=CC=C1O[C@@H]([C@@H]2CCNC2)C3=CC=CC=C3,COc1ccccc1O[C@H](c1ccccc1)[C@@H]1CCNC1
5905,5926,CHEMBL2337588,WDFMVSDPRALOJK-MAUKXSAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,COC1=CC=CC=C1O[C@@H]([C@H]2CCNC2)C3=CC=CC=C3,COc1ccccc1O[C@H](c1ccccc1)[C@H]1CCNC1
5906,5927,CHEMBL2337589,WDFMVSDPRALOJK-QAPCUYQASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,251.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,COC1=CC=CC=C1O[C@H]([C@@H]2CCNC2)C3=CC=CC=C3,COc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CCNC1
5907,5928,CHEMBL2337586,WDFMVSDPRALOJK-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,COC1=CC=CC=C1O[C@H]([C@H]2CCNC2)C3=CC=CC=C3,COc1ccccc1O[C@@H](c1ccccc1)[C@H]1CCNC1
5908,5929,CHEMBL257389,WDJLGAAWPRVZRR-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COCCN(CC(=C)F)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C=C(F)CN(CCOC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
5909,5930,CHEMBL254219,WDJUZGPOPHTGOT-XUDUSOBPSA-N,DIGITOXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
5910,5931,CHEMBL254219,WDJUZGPOPHTGOT-XUDUSOBPSA-N,DIGITOXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
5911,5932,CHEMBL3310629,WDKXWEBKYOHYSC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,55.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,55.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC=C(C=C3)F,Fc1ccc(OC(CC2CNC2)c2ccc(F)c(F)c2)cc1
5912,5933,CHEMBL256447,WDLBUKLHPSKQTF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CCN(C1)C(=O)C2(CC2CN)C3=CC=CC=C3,NCC1CC1(C(=O)N1CCCC1)c1ccccc1
5913,5934,CHEMBL1818542,WDNOUFVJCUYSDQ-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,25.12,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.599980364934843,CC1=NN(C(=N1)C)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1nc(C)n(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
5914,5935,CHEMBL1818543,WDNOUFVJCUYSDQ-ZYMOGRSISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,15.85,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.799970733446231,CC1=NN(C(=N1)C)CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1nc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
5915,5936,CHEMBL1818543,WDNOUFVJCUYSDQ-ZYMOGRSISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,199.53,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.699991797446188,CC1=NN(C(=N1)C)CC23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1nc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
5916,5937,CHEMBL3593395,WDNXRQXGZIPADY-CSDGMEMJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,=,3100.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.508638306165726,C1CO[C@H]([C@@H](CN1)CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OC[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1
5917,5938,CHEMBL3593394,WDNXRQXGZIPADY-KATIXKQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@H](CN1)CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OC[C@H]1CNCCO[C@H]1c1ccc(Cl)c(Cl)c1
5918,5939,CHEMBL3593393,WDNXRQXGZIPADY-PKKHVXKMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@@H]([C@@H](CN1)CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OC[C@@H]1CNCCO[C@@H]1c1ccc(Cl)c(Cl)c1
5919,5940,CHEMBL3593396,WDNXRQXGZIPADY-WYUVZMMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,=,1400.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,5.853871964321763,C1CO[C@@H]([C@H](CN1)CO)C2=CC(=C(C=C2)Cl)Cl.Cl,OC[C@H]1CNCCO[C@@H]1c1ccc(Cl)c(Cl)c1
5920,5941,CHEMBL567725,WDVSSBLBRVMZEM-LLVKDONJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CC1=C(C=CC(=C1Cl)Cl)C(=O)N([C@@H]2CCNC2)C(C)C,Cc1c(C(=O)N(C(C)C)[C@@H]2CCNC2)ccc(Cl)c1Cl
5921,5942,CHEMBL370158,WDYVPLUNLVBVMN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,67000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.173925197299173,C[N+]1(C2CCC1C=C(C2)C3=CC=CC=C3C4=CC=CC=C4)CCl,C[N+]1(CCl)C2C=C(c3ccccc3-c3ccccc3)CC1CC2
5922,5943,CHEMBL1660,WDZCUPBHRAEYDL-GZAUEHORSA-N,RIFAPENTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
5923,5944,CHEMBL1660,WDZCUPBHRAEYDL-GZAUEHORSA-N,RIFAPENTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
5924,5945,CHEMBL114275,WDZSPNFWRVITEJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9986702.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,In vitro binding affinity against Dopamine transporter in LLC-PK1 cell membranes.,"A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I]IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)I)CO,CN(C)Cc1ccccc1Sc1ccc(I)cc1CO
5925,5946,CHEMBL114275,WDZSPNFWRVITEJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)I)CO,CN(C)Cc1ccccc1Sc1ccc(I)cc1CO
5926,5947,CHEMBL420,WDZVGELJXXEGPV-YIXHJXPBSA-N,GUANABENZ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl,NC(N)=N/N=C/c1c(Cl)cccc1Cl
5927,5948,CHEMBL420,WDZVGELJXXEGPV-YIXHJXPBSA-N,GUANABENZ,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl,NC(N)=N/N=C/c1c(Cl)cccc1Cl
5928,5949,CHEMBL575930,WEBWNOZIRPUGTR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1030.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.987162775294827,C1CNCCC1C2=C(C=CC=C2F)OCC3=CC=CC=C3,Fc1cccc(OCc2ccccc2)c1C1CCNCC1
5929,5950,CHEMBL485259,WEEGYLXZBRQIMU-UHFFFAOYSA-N,EUCALYPTOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C2CCC(O1)(CC2)C)C,CC12CCC(CC1)C(C)(C)O2
5930,5951,CHEMBL485259,WEEGYLXZBRQIMU-UHFFFAOYSA-N,EUCALYPTOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C2CCC(O1)(CC2)C)C,CC12CCC(CC1)C(C)(C)O2
5931,5952,CHEMBL578158,WEJSAYIWQUSTPZ-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1=CC=C(C=C1)[C@@H]([C@H](CN)O)N2C=CC3=CC=CC=C32,NC[C@H](O)[C@H](c1ccccc1)n1ccc2ccccc21
5932,5953,CHEMBL565594,WEKVVEUCXILQOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,440.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.356547323513813,CC(C)CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(C)CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5933,5954,CHEMBL565594,WEKVVEUCXILQOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,140.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.853871964321763,CC(C)CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(C)CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
5934,5955,CHEMBL227179,WEUZYHQNGQDGAB-HIUFNZKISA-N,RTI-219,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,158.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,6.801342913045577,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=CC=C5,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccccc3)s1)[C@@H](c1ccc(Cl)cc1)C2
5935,5956,CHEMBL227179,WEUZYHQNGQDGAB-HIUFNZKISA-N,RTI-219,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,18.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.744727494896693,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=CC=C5,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccccc3)s1)[C@@H](c1ccc(Cl)cc1)C2
5936,5957,CHEMBL561140,WFCCOUNTGTUDOI-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,14.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,14.0,CNC[C@H]([C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C)O,CNC[C@@H](O)[C@H](c1ccccc1)n1c(=O)n(C)c2ccccc21
5937,5958,CHEMBL456017,WFCMRRKVDOAHNR-MFKMUULPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=C(C=C1)F)[C@@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1[C@@H]1CC[C@H](CCN)O1
5938,5959,CHEMBL456017,WFCMRRKVDOAHNR-MFKMUULPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=C(C=C1)F)[C@@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1[C@@H]1CC[C@H](CCN)O1
5939,5960,CHEMBL512736,WFCMRRKVDOAHNR-ZWNOBZJWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=C(C=C(C=C1)F)[C@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1[C@H]1CC[C@H](CCN)O1
5940,5961,CHEMBL512736,WFCMRRKVDOAHNR-ZWNOBZJWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,32940.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.482276405166265,COC1=C(C=C(C=C1)F)[C@H]2CC[C@@H](O2)CCN,COc1ccc(F)cc1[C@H]1CC[C@H](CCN)O1
5941,5962,CHEMBL435954,WFFZVYUUVLQMLS-VGOFMYFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.25,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.25,COC1=CC(=C(C=C1)OC)/C=C/C(=O)N2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COc1ccc(OC)c(/C=C/C(=O)N2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c1
5942,5963,CHEMBL207854,WFIWNBXHHPXBTA-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-21.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-21.0,CCCN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
5943,5964,CHEMBL39890,WFJRJRXEODOZJG-SNAWJCMRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.22,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.22,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)F)C/C=C/C4=CC=C(C=C4)F,Fc1ccc(/C=C/CN2CCN(CCOC(c3ccccc3)c3ccc(F)cc3)CC2)cc1
5944,5965,CHEMBL39890,WFJRJRXEODOZJG-SNAWJCMRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.64,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.64,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)F)C/C=C/C4=CC=C(C=C4)F,Fc1ccc(/C=C/CN2CCN(CCOC(c3ccccc3)c3ccc(F)cc3)CC2)cc1
5945,5966,CHEMBL405017,WFOBTVZPUZNUSA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,1930.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.714442690992227,CC1=CC(=C(C=N1)CN(C)C)OC2=CC=CC=C2SC,CSc1ccccc1Oc1cc(C)ncc1CN(C)C
5946,5967,CHEMBL226646,WFOFPVXMPTVOTJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17530838.0,INHIBITION,=,92.0,%,,,,,,,,,,,,,,,Inhibition of human DOT at 10 uM relative to control,"Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.",J. Med. Chem.,PUBLICATION,,92.0,CC1=NN=C(O1)C2=NN=C(C=C2)N3CCC(CC3)OC4=C(C=CC(=C4)F)Cl,Cc1nnc(-c2ccc(N3CCC(Oc4cc(F)ccc4Cl)CC3)nn2)o1
5947,5968,CHEMBL1278088,WFQOETMVYMINSA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20931963.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human recombinant DAT,"Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.",J. Med. Chem.,PUBLICATION,,6.0,C1CCC2=C(C1)C(=O)N(C(=N2)CCCCN3CCN(CC3)C4=NC5=CC=CC=C5C=C4)N,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCCC2
5948,5969,CHEMBL197966,WFSQIXHBUDPSMK-YPMHNXCESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C2C=CC(=C3)C#N,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2cc(C#N)ccc12
5949,5970,CHEMBL20883,WFWLQNSHRPWKFK-UHFFFAOYSA-N,TEGAFUR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(OC1)N2C=C(C(=O)NC2=O)F,O=c1[nH]c(=O)n(C2CCCO2)cc1F
5950,5971,CHEMBL20883,WFWLQNSHRPWKFK-UHFFFAOYSA-N,TEGAFUR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(OC1)N2C=C(C(=O)NC2=O)F,O=c1[nH]c(=O)n(C2CCCO2)cc1F
5951,5972,CHEMBL204574,WGCRPMFFZVDRHS-BJKOFHAPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,2.9,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.9,C1CO[C@@H](CN1)[C@@](CC2=CC=CC=C2C3=CC=CC=C3)(C4=CC=CC=C4)O,O[C@](Cc1ccccc1-c1ccccc1)(c1ccccc1)[C@@H]1CNCCO1
5952,5973,CHEMBL123252,WGJCAKQLYZFCSH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,237.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.6252516539898965,CN(CCCC1=CC=CC=C1)CCCN(C)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,CN(CCCc1ccccc1)CCCN(C)CCOC(c1ccccc1)c1ccccc1
5953,5974,CHEMBL123252,WGJCAKQLYZFCSH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,122.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.9136401693252525,CN(CCCC1=CC=CC=C1)CCCN(C)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,CN(CCCc1ccccc1)CCCN(C)CCOC(c1ccccc1)c1ccccc1
5954,5975,CHEMBL123252,WGJCAKQLYZFCSH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,1.9,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,1.9,CN(CCCC1=CC=CC=C1)CCCN(C)CCOC(C2=CC=CC=C2)C3=CC=CC=C3,CN(CCCc1ccccc1)CCCN(C)CCOC(c1ccccc1)c1ccccc1
5955,5976,CHEMBL460295,WGJPAKIMPPHUPQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1OC2C3=CC=CC=C3CC2(CNCCO)O,Cc1ccccc1OC1c2ccccc2CC1(O)CNCCO
5956,5977,CHEMBL467513,WGKLCHBGQMKIIW-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC=C(C=C2)OC)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccc(OC)cc1
5957,5978,CHEMBL1172850,WGLPIGWBBSYDNT-KBPBESRZSA-N,"RAC-1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-2-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERS)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.199970640755867,COC[C@@]12CCNC[C@@]1(C2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CCNC[C@]1(c1ccc(Cl)c(Cl)c1)C2
5958,5979,CHEMBL1172850,WGLPIGWBBSYDNT-KBPBESRZSA-N,"RAC-1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-2-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERS)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.900008766455317,COC[C@@]12CCNC[C@@]1(C2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CCNC[C@]1(c1ccc(Cl)c(Cl)c1)C2
5959,5980,CHEMBL1172850,WGLPIGWBBSYDNT-KBPBESRZSA-N,"RAC-1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-2-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERS)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,630.96,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.19999817218203,COC[C@@]12CCNC[C@@]1(C2)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CCNC[C@]1(c1ccc(Cl)c(Cl)c1)C2
5960,5981,CHEMBL1683887,WGNABQIMYMHUQC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,884.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.053547734986927,CNCC1(CCCCC1)C2=CC(=CC=C2)Cl,CNCC1(c2cccc(Cl)c2)CCCCC1
5961,5982,CHEMBL1081212,WGTCBXOFOSMWEQ-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5OC,COc1ccccc1-c1ccc(C(=O)N2CCN(C(=O)c3ccc4cc[nH]c4c3)[C@@H](C)C2)cc1
5962,5983,CHEMBL3323096,WHFIZFJGGYNLFH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,4.5,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.346787486224656,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=CS4,CN1Cc2ccccc2C(c2ccc3ccsc3c2)C1
5963,5984,CHEMBL415690,WHGYBXFWUBPSRW-FOUAGVGXSA-N,BETADEX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
5964,5985,CHEMBL415690,WHGYBXFWUBPSRW-FOUAGVGXSA-N,BETADEX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
5965,5986,CHEMBL35337,WHHHJDGNBVQNAU-UHFFFAOYSA-N,AMFONELIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,3.7,NM,,,,,,,,,,,,,,,,,,,,8.431798275933005,CCN1C=C(C(=O)C2=C1N=C(C=C2)CC3=CC=CC=C3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21
5966,5987,CHEMBL35337,WHHHJDGNBVQNAU-UHFFFAOYSA-N,AMFONELIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,9.1,NM,,,,,,,,,,,,,,,,,,,,8.040958607678906,CCN1C=C(C(=O)C2=C1N=C(C=C2)CC3=CC=CC=C3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21
5967,5988,CHEMBL35337,WHHHJDGNBVQNAU-UHFFFAOYSA-N,AMFONELIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,74.3,NM,,,,,,,,,,,,,,,,,,,,7.129011186239425,CCN1C=C(C(=O)C2=C1N=C(C=C2)CC3=CC=CC=C3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21
5968,5989,CHEMBL35337,WHHHJDGNBVQNAU-UHFFFAOYSA-N,AMFONELIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,210.0,NM,,,,,,,,,,,,,,,,,,,,6.6777807052660805,CCN1C=C(C(=O)C2=C1N=C(C=C2)CC3=CC=CC=C3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21
5969,5990,CHEMBL1085321,WHMNJJQFCNBWSW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,4060.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.391473966422807,COC1=CC=CC=C1CC(C2=CC(=CC=C2)F)N3CCNCC3,COc1ccccc1CC(c1cccc(F)c1)N1CCNCC1
5970,5991,CHEMBL1224224,WHNHYVQHXLVZHR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,616.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.210419287835576,CN(C)CCC(C1=CC2=CC=CC=C2C=C1)N3N=CN=N3,CN(C)CCC(c1ccc2ccccc2c1)n1ncnn1
5971,5992,CHEMBL1224224,WHNHYVQHXLVZHR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,20.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,20.0,CN(C)CCC(C1=CC2=CC=CC=C2C=C1)N3N=CN=N3,CN(C)CCC(c1ccc2ccccc2c1)n1ncnn1
5972,5993,CHEMBL565397,WHPARCHZPIKXEX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,2000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.698970004336019,CC(C)NC(C)C(=O)C1=CC(=CC=C1)Cl,CC(C)NC(C)C(=O)c1cccc(Cl)c1
5973,5994,CHEMBL565397,WHPARCHZPIKXEX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,3980.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.4001169279263115,CC(C)NC(C)C(=O)C1=CC(=CC=C1)Cl,CC(C)NC(C)C(=O)c1cccc(Cl)c1
5974,5995,CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
5975,5996,CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
5976,5997,CHEMBL1481,WIGIZIANZCJQQY-RUCARUNLSA-N,GLIMEPIRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCC(C)CC3)cc2)C1=O
5977,5998,CHEMBL1481,WIGIZIANZCJQQY-RUCARUNLSA-N,GLIMEPIRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCC(C)CC3)cc2)C1=O
5978,5999,CHEMBL130,WIIZWVCIJKGZOK-RKDXNWHRSA-N,CHLORAMPHENICOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl
5979,6000,CHEMBL130,WIIZWVCIJKGZOK-RKDXNWHRSA-N,CHLORAMPHENICOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl
5980,6001,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1735.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.760700520873108,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
5981,6002,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1379.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.8604357338241515,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
5982,6003,CHEMBL399740,WILWGBIICPMADK-ZCQJKULCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18053732.0,IC50,=,11.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in transfected cell membrane,"The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.9586073148417755,CN1C2CCC1[C@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC(=O)CCCCCCC(=O)OC[C@H]4[C@H](CC5CCC4N5C)C6=CC(=C(C=C6)Cl)Cl,CN1C2CCC1[C@@H](COC(=O)CCCCCCC(=O)OC[C@@H]1C3CCC(C[C@@H]1c1ccc(Cl)c(Cl)c1)N3C)[C@@H](c1ccc(Cl)c(Cl)c1)C2
5983,6004,CHEMBL525717,WINONEAFBRSOAL-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,=,7000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,CNC[C@@H]1[C@@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3Cl,CNC[C@H]1OCc2ccccc2[C@H]1Oc1ccccc1Cl
5984,6005,CHEMBL448375,WINONEAFBRSOAL-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3Cl,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1Cl
5985,6006,CHEMBL448375,WINONEAFBRSOAL-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18672364.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3Cl,CNC[C@@H]1OCc2ccccc2[C@@H]1Oc1ccccc1Cl
5986,6007,CHEMBL496284,WINONEAFBRSOAL-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@H]1[C@H](C2=CC=CC=C2CO1)OC3=CC=CC=C3Cl,CNC[C@H]1OCc2ccccc2[C@@H]1Oc1ccccc1Cl
5987,6008,CHEMBL1945246,WIPQYHNDILMGTM-KGAMEKGQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,15.14,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.8198741248359465,C/C=C/CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)OC,C/C=C/CN1[C@H]2CC[C@@H]1[C@@H](C(=O)OC)[C@@H](c1ccc(I)cc1)C2
5988,6009,CHEMBL335165,WIQKRMGNDCWEGO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(=O)C1=C(C=C(C=C1)C2=C(C3CCC(C2)N3C)C(=O)OC)C(=O)C,COC(=O)C1=C(c2ccc(C(C)=O)c(C(C)=O)c2)CC2CCC1N2C
5989,6010,CHEMBL465123,WIQRCHMSJFFONW-HNNXBMFYSA-N,SEPROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,420.0,NM,,,,,,,,,,,,,,,,,,,,6.376750709602098,C1=CC=C(C=C1)[C@H](CCN)OC2=CC=C(C=C2)C(F)(F)F,NCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
5990,6011,CHEMBL465123,WIQRCHMSJFFONW-HNNXBMFYSA-N,SEPROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,=,6488.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.1878891587969,C1=CC=C(C=C1)[C@H](CCN)OC2=CC=C(C=C2)C(F)(F)F,NCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
5991,6012,CHEMBL465123,WIQRCHMSJFFONW-HNNXBMFYSA-N,SEPROXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,=,4544.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.342561677297038,C1=CC=C(C=C1)[C@H](CCN)OC2=CC=C(C=C2)C(F)(F)F,NCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
5992,6013,CHEMBL446084,WIQRCHMSJFFONW-OAHLLOKOSA-N,(R)-NORFLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,=,7133.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.146727775979317,C1=CC=C(C=C1)[C@@H](CCN)OC2=CC=C(C=C2)C(F)(F)F,NCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
5993,6014,CHEMBL446084,WIQRCHMSJFFONW-OAHLLOKOSA-N,(R)-NORFLUOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,=,3661.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.436400271118469,C1=CC=C(C=C1)[C@@H](CCN)OC2=CC=C(C=C2)C(F)(F)F,NCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
5994,6015,CHEMBL1684056,WISXSHNMYCUZHH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,63.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.200659450546419,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)NC,CNC(C)C1(c2ccc3ccccc3c2)CCCCC1
5995,6016,CHEMBL1684056,WISXSHNMYCUZHH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,100.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC(C1(CCCCC1)C2=CC3=CC=CC=C3C=C2)NC,CNC(C)C1(c2ccc3ccccc3c2)CCCCC1
5996,6017,CHEMBL625,WJCNZQLZVWNLKY-UHFFFAOYSA-N,THIABENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,c1ccc2[nH]c(-c3cscn3)nc2c1
5997,6018,CHEMBL625,WJCNZQLZVWNLKY-UHFFFAOYSA-N,THIABENDAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,c1ccc2[nH]c(-c3cscn3)nc2c1
5998,6019,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,18636.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.729647298223816,C1=CC=C2C(=C1)NC3=CC=CC=C3S2,c1ccc2c(c1)Nc1ccccc1S2
5999,6020,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,14807.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.829532923614063,C1=CC=C2C(=C1)NC3=CC=CC=C3S2,c1ccc2c(c1)Nc1ccccc1S2
6000,6021,CHEMBL2165527,WJGHDFLJHZUCKM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,1.48,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,1.48,CN(C)C1CCC2=C(C1)C3=C(N2S(=O)(=O)C4=CC=CC=C4)C=CC(=C3)OC,COc1ccc2c(c1)c1c(n2S(=O)(=O)c2ccccc2)CCC(N(C)C)C1
6001,6022,CHEMBL2165527,WJGHDFLJHZUCKM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,6.23,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.23,CN(C)C1CCC2=C(C1)C3=C(N2S(=O)(=O)C4=CC=CC=C4)C=CC(=C3)OC,COc1ccc2c(c1)c1c(n2S(=O)(=O)c2ccccc2)CCC(N(C)C)C1
6002,6023,CHEMBL382741,WJNQZXPCJCLCNG-JOCHJYFZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821575.0,IC50,=,0.002,NM,,,,,,,,,,,,,,,Inhibition of DAT,Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,11.698970004336019,CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=CC=CC=C3C#N)O,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1ccccc1C#N
6003,6024,CHEMBL1501,WJOHZNCJWYWUJD-IUGZLZTKSA-N,FLUOCINONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
6004,6025,CHEMBL1501,WJOHZNCJWYWUJD-IUGZLZTKSA-N,FLUOCINONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
6005,6026,CHEMBL1258223,WKWADEWWLCVVLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20812727.0,KI,=,2020.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,"Synthesis, structure--affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.",J. Med. Chem.,PUBLICATION,,5.6946486305533774,CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)NC)Cl,CCCCN1CCC(COC(=O)c2cc(Cl)c(NC)c3c2OCCO3)CC1
6006,6027,CHEMBL43125,WLBSIWPEWGDCNF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.91,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.91,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=CC=C3)C4=CC=CC=N4,c1ccc(CCCN2CCN(CCN(Cc3ccccc3)c3ccccn3)CC2)cc1
6007,6028,CHEMBL43125,WLBSIWPEWGDCNF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.04,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.04,C1CN(CCN1CCCC2=CC=CC=C2)CCN(CC3=CC=CC=C3)C4=CC=CC=N4,c1ccc(CCCN2CCN(CCN(Cc3ccccc3)c3ccccn3)CC2)cc1
6008,6029,CHEMBL1258671,WLHFUBIRAHRPHA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20812727.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,"Synthesis, structure--affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.",J. Med. Chem.,PUBLICATION,,5.0,CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)F,CCCCN1CCC(COC(=O)c2cc(F)c(N)c3c2OCCO3)CC1
6009,6030,CHEMBL269798,WLIAMZZYIMPMEA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C(C1(C2=CC=CC=C2)C(=O)NCC3=CC=CC=C3)CN,NCC1CC1(C(=O)NCc1ccccc1)c1ccccc1
6010,6031,CHEMBL574127,WLIGTTARDYGFBV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,701.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.154281982033341,C1CN(CCN1)C2=CC=CC=C2COC3=CC=CC=C3,c1ccc(OCc2ccccc2N2CCNCC2)cc1
6011,6032,CHEMBL576170,WLILWEIYLCPPKG-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,23.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,23.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=CC=CC=C32)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2ccccc21
6012,6033,CHEMBL583752,WLJMFBUPVRQPDQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,EC50,=,657.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.182434630440218,C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)F,Fc1cccc(Oc2ccccc2C2CCNCC2)c1
6013,6034,CHEMBL583752,WLJMFBUPVRQPDQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,166.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.779891911959945,C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)F,Fc1cccc(Oc2ccccc2C2CCNCC2)c1
6014,6035,CHEMBL595252,WLLDZAMGIXUOIX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19836247.0,INHIBITION,=,3.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human DAT expressed in CHO cells at 1 uM after 20 mins by scintillation counting,"Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.",Bioorg. Med. Chem.,PUBLICATION,,3.0,C1CCN(CC1)CCC2=C3C(=CC=C2)NC=C3S(=O)(=O)C4=CC=CC=C4,O=S(=O)(c1ccccc1)c1c[nH]c2cccc(CCN3CCCCC3)c12
6015,6036,CHEMBL599760,WLMBSKSEPQCRJV-OAHLLOKOSA-N,RO-85,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20045645.0,ACTIVITY,>,50.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]BTCP from human recombinant DAT expressed in CHO cells at 10 uM after 120 mins by scintillation counting,"Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C[C@H](CN1CCN(CC1)C(=O)C)NC(=O)C2=CC3=C(S2)N(N=C3C4=CC=CC=C4)C,CC(=O)N1CCN(C[C@@H](C)NC(=O)c2cc3c(-c4ccccc4)nn(C)c3s2)CC1
6016,6037,CHEMBL232671,WLWFROPHDLATTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,3300.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.481486060122113,COC(=O)C1=C(CCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCC1
6017,6038,CHEMBL232671,WLWFROPHDLATTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,34000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.4685210829577455,COC(=O)C1=C(CCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCC1
6018,6039,CHEMBL232671,WLWFROPHDLATTA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,28840315031266.1,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-4.460000000000001,COC(=O)C1=C(CCC1)C2=CC(=CC=C2)Cl,COC(=O)C1=C(c2cccc(Cl)c2)CCC1
6019,6040,CHEMBL1224094,WMONHIUXMOXBDS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.16,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381597,CC(C)(C)CCC1(CCCN1)C(=O)C2=CC3=C(C=C2)NN=C3,CC(C)(C)CCC1(C(=O)c2ccc3[nH]ncc3c2)CCCN1
6020,6041,CHEMBL243204,WMVXAQQBRYETCJ-CHWSQXEVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,8510.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.070070439915412,CN1CC[C@@H]([C@@H](C1)C(=O)OC)C2=CC=CC=C2,COC(=O)[C@@H]1CN(C)CC[C@@H]1c1ccccc1
6021,6042,CHEMBL388255,WMVXAQQBRYETCJ-QWHCGFSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,17400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.7594507517174005,CN1CC[C@H]([C@@H](C1)C(=O)OC)C2=CC=CC=C2,COC(=O)[C@@H]1CN(C)CC[C@H]1c1ccccc1
6022,6043,CHEMBL397392,WMWARSGGACJLII-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,1200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920818753952375,CC1=CC=CC=C1CN([C@H]2CCNC2)C3CCOCC3,Cc1ccccc1CN(C1CCOCC1)[C@H]1CCNC1
6023,6044,CHEMBL3703747,WNADNMZKSSOJHJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,83.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.079876673709277,C1C(C2=CC(=C(C=C2CN1)C3=CN4C(=NC=N4)C=C3)F)C5=CC(=C(C=C5)Cl)Cl,Fc1cc2c(cc1-c1ccc3ncnn3c1)CNCC2c1ccc(Cl)c(Cl)c1
6024,6045,CHEMBL103831,WNAFVJVEADYQAI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,>,100000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.0,COC(=O)C1=CC=CC=C1C2=CC=CC=C2,COC(=O)c1ccccc1-c1ccccc1
6025,6046,CHEMBL3331475,WNGQDNLTBDXLGF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,2.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,2.0,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC5=CC=CC=C5C=C4,c1ccc2cc(CN(c3ccc4ccccc4c3)C3CNC3)ccc2c1
6026,6047,CHEMBL567656,WNNACCODSWYYDZ-VXKWHMMOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCN(CC1)C[C@@H]([C@H](C2=CC=CC=C2)N3C=CC4=CC=CC=C43)O,CN1CCN(C[C@H](O)[C@H](c2ccccc2)n2ccc3ccccc32)CC1
6027,6048,CHEMBL402088,WNRLDTKTSLUNNC-GXTWGEPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CN=CC=C2,CCN(CC)C(=O)[C@@]1(c2cccnc2)C[C@H]1CN
6028,6049,CHEMBL445185,WNSBUBHOLORHPN-CVEARBPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,5000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CN[C@@H]1C[C@@H](C2=CC=CC=C12)OC3=CC=CC=C3,CN[C@@H]1C[C@H](Oc2ccccc2)c2ccccc21
6029,6050,CHEMBL449015,WNTGIUMXZUDPIG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,1500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,CN(C)CC1=C(C=CC(=C1)NS(=O)(=O)C)SC2=CC=C(C=C2)SC,CSc1ccc(Sc2ccc(NS(C)(=O)=O)cc2CN(C)C)cc1
6030,6051,CHEMBL3673165,WOGNFHHHGZELSI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,43.8,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.358525889495901,CC1=CC2=NC=NN2C=C1C3=CC4=C(C=C3)C5(CCN(C4)CC5)C6=CC(=C(C=C6)Cl)Cl,Cc1cc2ncnn2cc1-c1ccc2c(c1)CN1CCC2(c2ccc(Cl)c(Cl)c2)CC1
6031,6052,CHEMBL557119,WOINXFXWLFAPBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,125.89,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CNCCC1N(CC2=CC=CC=C2F)C3=CC4=C(C=C3)NC=C4,Fc1ccccc1CN(c1ccc2[nH]ccc2c1)C1CCNCC1
6032,6053,CHEMBL3673172,WOOPIGBZZPHOGG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,63.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.199282921717615,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NN=C(C=C4)C(F)(F)F)C5=CC(=C(C=C5)F)F,Fc1ccc(C23CCN(CC2)Cc2cc(Oc4ccc(C(F)(F)F)nn4)ccc23)cc1F
6033,6054,CHEMBL383071,WOORERZMTSEMTL-BQAIUKQQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.3,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.886056647693161,C[C@@H](CCN1CCC(CC1)CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C4=CC=CC=C4.C(=O)(C(=O)O)O,C[C@@H](CCN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
6034,6055,CHEMBL383071,WOORERZMTSEMTL-BQAIUKQQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,2.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.67778070526608,C[C@@H](CCN1CCC(CC1)CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C4=CC=CC=C4.C(=O)(C(=O)O)O,C[C@@H](CCN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
6035,6056,CHEMBL424682,WOORERZMTSEMTL-GNAFDRTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,2.2,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.657577319177793,C[C@H](CCN1CCC(CC1)CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C4=CC=CC=C4.C(=O)(C(=O)O)O,C[C@H](CCN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccccc1
6036,6057,CHEMBL322923,WOUIJACXIRZSFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,7.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.148741651280925,COC(=O)C1=C(CC2CCC1C2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2CCC1C2
6037,6058,CHEMBL3703737,WOWZZXDFWZHBKO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,101.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,6.995678626217357,CS(=O)(=O)C1=CC=CC(=C1)C2=C(C=C3C(CNCC3=C2)C4=CC(=C(C=C4)Cl)Cl)F,CS(=O)(=O)c1cccc(-c2cc3c(cc2F)C(c2ccc(Cl)c(Cl)c2)CNC3)c1
6038,6059,CHEMBL88792,WOXYISRTCDNTFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,9.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.045757490560675,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)Br,COC(=O)C1C2CCC(CC1c1ccc(Br)cc1)O2
6039,6060,CHEMBL88792,WOXYISRTCDNTFN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,22.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.657577319177793,COC(=O)C1C2CCC(O2)CC1C3=CC=C(C=C3)Br,COC(=O)C1C2CCC(CC1c1ccc(Br)cc1)O2
6040,6061,CHEMBL66112,WPCCYICQOQQNOQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.301029995663981,C1CC(CN(C1)CCC2=CC=C(C=C2)F)CNCCOC(C3=CC=CC=C3)C4=CC=CC=C4,Fc1ccc(CCN2CCCC(CNCCOC(c3ccccc3)c3ccccc3)C2)cc1
6041,6062,CHEMBL66112,WPCCYICQOQQNOQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,100.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.0,C1CC(CN(C1)CCC2=CC=C(C=C2)F)CNCCOC(C3=CC=CC=C3)C4=CC=CC=C4,Fc1ccc(CCN2CCCC(CNCCOC(c3ccccc3)c3ccccc3)C2)cc1
6042,6063,CHEMBL206697,WPEZYNICVOURFR-UGSOOPFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,20.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.698970004336019,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)CO)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(CO)cc21
6043,6064,CHEMBL451120,WPGUQXCZGQYNLZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,1800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7447274948966935,CN(C)CC1=C(C=CC(=C1)Br)OC2=CC=C(C=C2)SC,CSc1ccc(Oc2ccc(Br)cc2CN(C)C)cc1
6044,6065,CHEMBL486044,WPKZZLMFEYGCJR-RDJZCZTQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,180.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,CC1=CC=CC=C1O[C@H]2C[C@@H](C3=CC=CC=C23)NC,CN[C@H]1C[C@H](Oc2ccccc2C)c2ccccc21
6045,6066,CHEMBL446570,WPKZZLMFEYGCJR-WBVHZDCISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,4600.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.337242168318426,CC1=CC=CC=C1O[C@H]2C[C@H](C3=CC=CC=C23)NC,CN[C@@H]1C[C@H](Oc2ccccc2C)c2ccccc21
6046,6067,CHEMBL1224034,WPNGDOZEXVRNMZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20692833.0,INHIBITION,=,66.3,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-3542 from human DAT at 10 uM,N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.,Bioorg. Med. Chem. Lett.,PUBLICATION,,66.3,C1CCC(CC1)NC(=O)N2C3C(CO2)CSC4=C3C=C(C=C4)F,O=C(NC1CCCCC1)N1OCC2CSc3ccc(F)cc3C21
6047,6068,CHEMBL1224034,WPNGDOZEXVRNMZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20692833.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-3542 from human DAT,N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CCC(CC1)NC(=O)N2C3C(CO2)CSC4=C3C=C(C=C4)F,O=C(NC1CCCCC1)N1OCC2CSc3ccc(F)cc3C21
6048,6069,CHEMBL19236,WPNJAUFVNXKLIM-UHFFFAOYSA-N,MOXONIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,COc1nc(C)nc(Cl)c1NC1=NCCN1
6049,6070,CHEMBL19236,WPNJAUFVNXKLIM-UHFFFAOYSA-N,MOXONIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,COc1nc(C)nc(Cl)c1NC1=NCCN1
6050,6071,CHEMBL86590,WPSZKOIIDITBPV-NHMWQASMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,0.81,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,9.09151498112135,CCOC(=O)C1C(CC2C[C@H](C1N2C)O)C3=CC(=C(C=C3)Cl)Cl,CCOC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)C1N2C
6051,6072,CHEMBL86590,WPSZKOIIDITBPV-NHMWQASMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,1.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,8.958607314841776,CCOC(=O)C1C(CC2C[C@H](C1N2C)O)C3=CC(=C(C=C3)Cl)Cl,CCOC(=O)C1C(c2ccc(Cl)c(Cl)c2)CC2C[C@@H](O)C1N2C
6052,6073,CHEMBL541,WPYMKLBDIGXBTP-UHFFFAOYSA-N,BENZOIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)O,O=C(O)c1ccccc1
6053,6074,CHEMBL541,WPYMKLBDIGXBTP-UHFFFAOYSA-N,BENZOIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)O,O=C(O)c1ccccc1
6054,6075,CHEMBL574231,WPYMMOOTBZOFOZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,6.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,C1CNCCC1C2=C(C=CC=C2F)OC3=CC=C(C=C3)F,Fc1ccc(Oc2cccc(F)c2C2CCNCC2)cc1
6055,6076,CHEMBL558853,WQAXZHUMPQMMEW-GOSISDBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,4100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3872161432802645,C1CC(C1)CN([C@@H]2CCNC2)C(=O)C3=CC=CC=C3OC4=CC=CC=C4,O=C(c1ccccc1Oc1ccccc1)N(CC1CCC1)[C@@H]1CCNC1
6056,6077,CHEMBL549584,WQAXZHUMPQMMEW-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3OC4=CC=CC=C4,O=C(c1ccccc1Oc1ccccc1)N(CC1CCC1)[C@H]1CCNC1
6057,6078,CHEMBL1683898,WQBHQWJJWWMKPS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,1777.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.750312572194699,CNCC1(CCCCC1)C2=CC=CC3=CC=CC=C32,CNCC1(c2cccc3ccccc23)CCCCC1
6058,6079,CHEMBL2105807,WQGJEAMPBSZCIF-HKSLRPGUSA-N,MADURAMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C.N,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
6059,6080,CHEMBL2105807,WQGJEAMPBSZCIF-HKSLRPGUSA-N,MADURAMICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C.N,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
6060,6081,CHEMBL307145,WQGWDDDVZFFDIG-UHFFFAOYSA-N,PYROGALLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)O)O)O,Oc1cccc(O)c1O
6061,6082,CHEMBL307145,WQGWDDDVZFFDIG-UHFFFAOYSA-N,PYROGALLOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)O)O)O,Oc1cccc(O)c1O
6062,6083,CHEMBL510915,WQHNJPRNTDZGGW-RRPNLBNLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNC[C@@]1(CC2=CC=CC=C2[C@@H]1OC3=CC=CC=C3C4=CC=CC5=CC=CC=C54)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccccc1-c1cccc2ccccc12
6063,6084,CHEMBL1946575,WQMIQGVRKVRFTF-XSBOKVBDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22119468.0,ACTIVITY,,,,Active,,cell_based,,,,,,,,,,,,Binding affinity to human His6-DAT expressed in LLCPK1 cells at 10 nM after 1.5 hrs measured 2 mins post-irradiation by SDS-PAGE/autoradiography,"()-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])[125I])NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(N=[N+]=[N-])c(I)c1
6064,6085,CHEMBL1946575,WQMIQGVRKVRFTF-XSBOKVBDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22119468.0,ACTIVITY,,,,Not Active,,cell_based,,,,,,,,,,,,Binding affinity to human His6-DAT expressed in LLCPK1 cells at 10 nM after 1.5 hrs measured 2 mins post-irradiation by autoradiography in the presence of (+/-)-bupropion,"()-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])[125I])NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(N=[N+]=[N-])c(I)c1
6065,6086,CHEMBL1946575,WQMIQGVRKVRFTF-XSBOKVBDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22119468.0,ACTIVITY,,,,Not Active,,cell_based,,,,,,,,,,,,Binding affinity to human His6-DAT expressed in LLCPK1 cells at 10 nM after 1.5 hrs measured 2 mins post-irradiation by autoradiography in the presence of (+/-)-cocaine,"()-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C(=O)C1=CC(=C(C=C1)N=[N+]=[N-])[125I])NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1ccc(N=[N+]=[N-])c(I)c1
6066,6087,CHEMBL1644480,WQUWMFJMVPTZHQ-DDFAGTSDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,2010.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.696803942579511,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC=CC(=C3)[N+](=O)[O-],O=[N+]([O-])c1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
6067,6088,CHEMBL442924,WQZFFUKLKSSLDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,331.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.480172006224282,CNC(=O)C1=CC2=C(N1)C=CC(=C2)C3(CCNC3)CC4=CC=CC=C4,CNC(=O)c1cc2cc(C3(Cc4ccccc4)CCNC3)ccc2[nH]1
6068,6089,CHEMBL1173600,WROCJHDKYNTMKL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,>,100000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,4.0,CC1C(OCC(N1)(C)C)(C2=CC=CC=N2)O,CC1NC(C)(C)COC1(O)c1ccccn1
6069,6090,CHEMBL410622,WRXKFTMLELOBNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(C2=CC=CC=C21)C(=O)C3(CC3CNC(=O)CN)C4=CC=CC=C4,NCC(=O)NCC1CC1(C(=O)N1CCc2ccccc21)c1ccccc1
6070,6091,CHEMBL556025,WSDLKTZBSNTKJA-QJHJCNPRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,12000.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter -hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920818753952375,CN(C)C[C@@H](C1=CC=CC=C1)[C@H](C2=CC=CC=C2)O.Cl,CN(C)C[C@@H](c1ccccc1)[C@@H](O)c1ccccc1
6071,6092,CHEMBL1508,WSEQXVZVJXJVFP-FQEVSTJZSA-N,ESCITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24944746.0,INHIBITION,,,,Not Active,,cell_based,,,,,,,,,,,,"Inhibition of 2,5,6-[3H]-dopamine uptake at human DAT expressed in African green monkey COS7 cells at 10 uM incubated for 10 mins prior to radioligand addition measured after 5 mins by scintillation counting analysis",Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram.,ACS Med. Chem. Lett.,PUBLICATION,,,CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6072,6093,CHEMBL399730,WSEQXVZVJXJVFP-HXUWFJFHSA-N,(R)-CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CCC[C@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCC[C@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6073,6094,CHEMBL1628605,WSEQXVZVJXJVFP-OAWTUDSLSA-N,[3H]CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,ACTIVITY,=,17700.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,4.752026733638194,[3H]C(CCN(C)C)C1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,[H]C(CCN(C)C)C1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6074,6095,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6075,6096,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11454918.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6076,6097,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12232544.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6077,6098,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6078,6099,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14971892.0,KI,=,16540.0,NM,,,,,,,,,,,,,,,In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 radioligand,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.",J. Med. Chem.,PUBLICATION,,4.781464494783472,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6079,6100,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23168018.0,KI,>,1000000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in COS7 cells after 3 mins by beta-counting,A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6080,6101,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6081,6102,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
6082,6103,CHEMBL422290,WSLCFIYYDJNWLK-KAXARAQCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9804682.0,IC50,=,0.227,NM,,,,,,,,,,,,,,,The compound was tested in vitro for high binding affinity for the Dopamine transporter (DAT) using competitive binding assay.,TROTEC-1: a new high-affinity ligand for labeling of the dopamine transporter.,J. Med. Chem.,PUBLICATION,,9.643974142806877,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)F)COC(=O)CCSCCSC,CSCCSCCC(=O)OC[C@@H]1C2CCC(C[C@@H]1c1ccc(F)cc1)N2C
6083,6104,CHEMBL422290,WSLCFIYYDJNWLK-KAXARAQCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9804682.0,IC50,=,5.69,NM,,,,,,,,,,,,,,,The compound was tested in vitro for low binding affinity for the Dopamine transporter (DAT) using competitive binding assay.,TROTEC-1: a new high-affinity ligand for labeling of the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.244887733604928,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)F)COC(=O)CCSCCSC,CSCCSCCC(=O)OC[C@@H]1C2CCC(C[C@@H]1c1ccc(F)cc1)N2C
6084,6105,CHEMBL576622,WSLDIWPVDFGUNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,69.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,7.161150909262744,CCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
6085,6106,CHEMBL576622,WSLDIWPVDFGUNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,350.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.455931955649724,CCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CCCCC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
6086,6107,CHEMBL514232,WSUKOKAEFHVCAH-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2690.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.570247719997592,CN(C)S(=O)(=O)N(CC1=CC=CC=C1C2=CC=CC=C2)[C@H]3CCNC3,CN(C)S(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1
6087,6108,CHEMBL467094,WSVWKHTVFGTTKJ-UHFFFAOYSA-N,NANTENINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19963380.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OC)OC,COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4
6088,6109,CHEMBL443979,WSZDFPKNUKEBNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CS1)C#CC2=CC(=C(C=C2)C3=CN=CC=C3)F,Cc1nc(C#Cc2ccc(-c3cccnc3)c(F)c2)cs1
6089,6110,CHEMBL443979,WSZDFPKNUKEBNH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CS1)C#CC2=CC(=C(C=C2)C3=CN=CC=C3)F,Cc1nc(C#Cc2ccc(-c3cccnc3)c(F)c2)cs1
6090,6111,CHEMBL1224165,WTCFDFPSNBMAOR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,3.98,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,CCCC1(CCCN1)C(=O)C2=CC(=C3C(=C2)C=CN3)F,CCCC1(C(=O)c2cc(F)c3[nH]ccc3c2)CCCN1
6091,6112,CHEMBL1009,WTDRDQBEARUVNC-LURJTMIESA-N,LEVODOPA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
6092,6113,CHEMBL1009,WTDRDQBEARUVNC-LURJTMIESA-N,LEVODOPA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
6093,6114,CHEMBL3310495,WTHYQJZGHQZHTL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,39.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,39.0,C1C(CN1)CC(C2=CC3=CC=CC=C3C=C2)OC4=CC=CC=C4,c1ccc(OC(CC2CNC2)c2ccc3ccccc3c2)cc1
6094,6115,CHEMBL363396,WTJNBQYUXJFISF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CCCF)N,CN(C)Cc1ccccc1Sc1ccc(CCCF)cc1N
6095,6116,CHEMBL363396,WTJNBQYUXJFISF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,5000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,5.301029995663981,CN(C)CC1=CC=CC=C1SC2=C(C=C(C=C2)CCCF)N,CN(C)Cc1ccccc1Sc1ccc(CCCF)cc1N
6096,6117,CHEMBL229429,WTLBLIGPXACYET-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17571866.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.,J. Med. Chem.,PUBLICATION,,5.0,C1=C(C=C(C=C1C#N)F)C#CC2=CSC(=N2)CF,N#Cc1cc(F)cc(C#Cc2csc(CF)n2)c1
6097,6118,CHEMBL2171412,WTTOEXNCJGXGDZ-UHFFFAOYSA-N,3-((BENZYLOXY)(PHENYL)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,2.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.0,C1C(CN1)C(C2=CC=CC=C2)OCC3=CC=CC=C3.Cl,c1ccc(COC(c2ccccc2)C2CNC2)cc1
6098,6119,CHEMBL241228,WTZRMYOBIYKNQJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,=,659.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.1811145854059895,CN(C)CC1=C(C=CC(=C1)O)SC2=CC=CC=C2N,CN(C)Cc1cc(O)ccc1Sc1ccccc1N
6099,6120,CHEMBL1169,WUBBRNOQWQTFEX-UHFFFAOYSA-N,AMINOSALICYLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1N)O)C(=O)O,Nc1ccc(C(=O)O)c(O)c1
6100,6121,CHEMBL1169,WUBBRNOQWQTFEX-UHFFFAOYSA-N,AMINOSALICYLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1N)O)C(=O)O,Nc1ccc(C(=O)O)c(O)c1
6101,6122,CHEMBL388760,WUFOGTRCLDMXRM-RYTRXMBJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,45.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.346787486224656,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=CC=C5)[N+](=O)[O-],CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3cccc([N+](=O)[O-])c3)s1)[C@@H](c1ccc(Cl)cc1)C2
6102,6123,CHEMBL388760,WUFOGTRCLDMXRM-RYTRXMBJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,7.7,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,8.113509274827518,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC(=CC=C5)[N+](=O)[O-],CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3cccc([N+](=O)[O-])c3)s1)[C@@H](c1ccc(Cl)cc1)C2
6103,6124,CHEMBL1598608,WUKZPHOXUVCQOR-UHFFFAOYSA-N,AZASETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,CN1C(=O)COc2c(C(=O)NC3CN4CCC3CC4)cc(Cl)cc21
6104,6125,CHEMBL1598608,WUKZPHOXUVCQOR-UHFFFAOYSA-N,AZASETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,CN1C(=O)COc2c(C(=O)NC3CN4CCC3CC4)cc(Cl)cc21
6105,6126,CHEMBL2206536,WUPUWAHXLJUMFK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,106.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9746941347352305,CC1=CC2=C(C=C1)C(CN(C2)C)C3=CC(=C(C=C3)F)F,Cc1ccc2c(c1)CN(C)CC2c1ccc(F)c(F)c1
6106,6127,CHEMBL1642910,WUSGTAILSJGBRD-DYVFJYSZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,332.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.478861916295964,CN(C)C[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)C[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
6107,6128,CHEMBL1642911,WUSGTAILSJGBRD-GUYCJALGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,339.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.4698003017969175,CN(C)C[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC(=C(C=C3)Cl)Cl,CN(C)C[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1
6108,6129,CHEMBL1078169,WUTRVCAUFFQVGX-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,3590.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.444905551421682,CC(C)CN([C@H]1CCNC1)C(=O)C2=CC=CC=C2C(C)C,CC(C)CN(C(=O)c1ccccc1C(C)C)[C@H]1CCNC1
6109,6130,CHEMBL273348,WUWFMDMBOJLQIV-UHFFFAOYSA-N,TOSUFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F,NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1
6110,6131,CHEMBL273348,WUWFMDMBOJLQIV-UHFFFAOYSA-N,TOSUFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F,NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1
6111,6132,CHEMBL720,WVDDGKGOMKODPV-UHFFFAOYSA-N,BENZYL ALCOHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CO,OCc1ccccc1
6112,6133,CHEMBL720,WVDDGKGOMKODPV-UHFFFAOYSA-N,BENZYL ALCOHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CO,OCc1ccccc1
6113,6134,CHEMBL469889,WVFLQQCCAZKCGK-LIAHKDQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,65.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.182434630440218,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=C(C(=NO4)C)C5=CC=C(C=C5)Cl)N3C.Cl,Cc1ccc([C@H]2CC3CCC([C@H]2c2onc(C)c2-c2ccc(Cl)cc2)N3C)cc1
6114,6135,CHEMBL428,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,TROVAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,62191.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.2062724598935,C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F,NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12
6115,6136,CHEMBL428,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,TROVAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,49412.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.306167567252356,C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F,NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12
6116,6137,CHEMBL119443,WVVSZNPYNCNODU-XTQGRXLLSA-N,ERGONOVINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
6117,6138,CHEMBL119443,WVVSZNPYNCNODU-XTQGRXLLSA-N,ERGONOVINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
6118,6139,CHEMBL154111,WVYADZUPLLSGPU-UHFFFAOYSA-N,SALSALATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,O=C(Oc1ccccc1C(=O)O)c1ccccc1O
6119,6140,CHEMBL154111,WVYADZUPLLSGPU-UHFFFAOYSA-N,SALSALATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,O=C(Oc1ccccc1C(=O)O)c1ccccc1O
6120,6141,CHEMBL1224089,WVZMHYCNWMCWBJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,6.31,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,CCCC1(CCCN1)C(=O)C2=CC(=C(C=C2)N)Cl,CCCC1(C(=O)c2ccc(N)c(Cl)c2)CCCN1
6121,6142,CHEMBL3334769,WWEXFJSAHWQFBA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,IC50,=,325.4,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,6.4875824513991605,C1CCN(C1)C(CCN2CCC(=CC2)CC3=CC=CC=C3)C4=CSC5=CC=CC=C54,C1=C(Cc2ccccc2)CCN(CCC(c2csc3ccccc23)N2CCCC2)C1
6122,6143,CHEMBL583751,WWIFVPBPYYVHTD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,EC50,=,982.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.00788851221305,C1CNCCC1C2=C(C(=CC=C2)F)OC3=CC=CC=C3,Fc1cccc(C2CCNCC2)c1Oc1ccccc1
6123,6144,CHEMBL583751,WWIFVPBPYYVHTD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,239.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.621602099051862,C1CNCCC1C2=C(C(=CC=C2)F)OC3=CC=CC=C3,Fc1cccc(C2CCNCC2)c1Oc1ccccc1
6124,6145,CHEMBL601879,WWIVDDWMWBWRJK-KGQXAQPSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,45.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,45.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2CCC3=C2C=CC(=C3)OCC4=CC=CC=C4)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CCc2cc(OCc3ccccc3)ccc21
6125,6146,CHEMBL358967,WWPITPSIWMXDPE-UHFFFAOYSA-N,PARA-CHLOROAMPHETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19717215.0,IC50,=,424.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.,Eur. J. Med. Chem.,PUBLICATION,,6.372634143407267,CC(CC1=CC=C(C=C1)Cl)N,CC(N)Cc1ccc(Cl)cc1
6126,6147,CHEMBL1645597,WWTGDTLFSFRIFW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,2040.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.690369832574102,C1C(CN1)OC2=CC=CC=C2OC3=CC=CC=C3F,Fc1ccccc1Oc1ccccc1OC1CNC1
6127,6148,CHEMBL1683886,WWUXHADAODEZLF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.376750709602098,CN(C)CC1(CCCCC1)C2=CC(=CC=C2)Cl,CN(C)CC1(c2cccc(Cl)c2)CCCCC1
6128,6149,CHEMBL2205823,WWXCWTRLUXMAHX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,COC1=CC=CC=C1CN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccccc1CN1C2C3C4CC5C6C4C2C6C1(O)C53
6129,6150,CHEMBL2107797,WWYNJERNGUHSAO-CULCCENASA-N,NORGESTREL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC
6130,6151,CHEMBL2107797,WWYNJERNGUHSAO-CULCCENASA-N,NORGESTREL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC
6131,6152,CHEMBL564934,WXFURHRZZPXAMP-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,2750.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.560667306169737,C1CCC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N(CC1CCCC1)[C@H]1CCNC1
6132,6153,CHEMBL3323109,WXJVSDNWZOTTOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,890.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.0506099933550885,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)N=CC=C4,CN1Cc2ccccc2C(c2ccc3ncccc3c2)C1
6133,6154,CHEMBL197960,WXJZYVUSQHOXID-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,6.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CCC1(CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC,CCC1(CCCNC)Cc2ccccc2N(c2ccccc2)C1=O
6134,6155,CHEMBL197960,WXJZYVUSQHOXID-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CCC1(CC2=CC=CC=C2N(C1=O)C3=CC=CC=C3)CCCNC,CCC1(CCCNC)Cc2ccccc2N(c2ccccc2)C1=O
6135,6156,CHEMBL493369,WXNMBSMVRGWTNC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,6331.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.198527686478529,CN(CCC1=CC=C(C=C1)OC(F)(F)F)CCN2CCCC2,CN(CCc1ccc(OC(F)(F)F)cc1)CCN1CCCC1
6136,6157,CHEMBL556539,WXQUVTDLXMNHNT-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3670.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.435333935747911,CCSC1=CC=CC=C1C(=O)N(CC2CCC2)[C@H]3CCNC3,CCSc1ccccc1C(=O)N(CC1CCC1)[C@H]1CCNC1
6137,6158,CHEMBL502129,WXULFWHQRUUESN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=C(C=CC(=C1)C(=O)N(C)C)OC2=CC=C(C=C2)OC(F)(F)F,CN(C)Cc1cc(C(=O)N(C)C)ccc1Oc1ccc(OC(F)(F)F)cc1
6138,6159,CHEMBL3331474,WXWLFJMECDDEAB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,13.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,13.0,C1C(CN1)N(CCCC2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(N(CCCc2ccccc2)C2CNC2)cc1Cl
6139,6160,CHEMBL208067,WXXAHIZLARZXBW-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,KI,=,240.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.619788758288393,CC1=CC=CC=C1CN(CC(C)C)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,Cc1ccccc1CN(CC(C)C)C1CCNCC1
6140,6161,CHEMBL405613,WYBWTBVGJJOVDM-KBXCAEBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC(=C)F)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCCO3,C=C(F)CN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
6141,6162,CHEMBL257423,WYCWVUGQDBCHEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,124.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.906578314837764,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)Cl,CN(C)Cc1ccccc1Oc1ccc(Cl)cc1
6142,6163,CHEMBL257423,WYCWVUGQDBCHEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)Cl,CN(C)Cc1ccccc1Oc1ccc(Cl)cc1
6143,6164,CHEMBL219048,WYKUNXLKNJTHND-UGKGYDQZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,219.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6595558851598815,CC(=O)C1=CC(=CC=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2)CC3=CC=C(C=C3)F,CC(=O)c1cccc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2)c1
6144,6165,CHEMBL2336611,WYURUVQXJTWRLS-NUSMLGSUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23168018.0,KI,=,62.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in COS7 cells after 3 mins by beta-counting,A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.207608310501746,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCN5[C@@H]6CC[C@@H]5[C@H]([C@H](C6)C7=CC(=C(C=C7)Cl)Cl)C(=O)OC)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCN4[C@@H]5CC[C@@H]4[C@@H](C(=O)OC)[C@@H](c4ccc(Cl)c(Cl)c4)C5)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
6145,6166,CHEMBL196760,WYURUVQXJTWRLS-QEJKBDCMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,18.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]CFT from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.744727494896693,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCN5C6CCC5[C@H]([C@H](C6)C7=CC(=C(C=C7)Cl)Cl)C(=O)OC)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCN4C5CCC4[C@@H](C(=O)OC)[C@@H](c4ccc(Cl)c(Cl)c4)C5)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
6146,6167,CHEMBL196760,WYURUVQXJTWRLS-QEJKBDCMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,62.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]dopamine from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.207608310501746,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCN5C6CCC5[C@H]([C@H](C6)C7=CC(=C(C=C7)Cl)Cl)C(=O)OC)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCN4C5CCC4[C@@H](C(=O)OC)[C@@H](c4ccc(Cl)c(Cl)c4)C5)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
6147,6168,CHEMBL196760,WYURUVQXJTWRLS-QEJKBDCMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24944746.0,KI,=,20.0,NM,,,cell_based,,,,,,,,,,,,"Inhibition of 2,5,6-[3H]-dopamine uptake at human DAT expressed in African green monkey COS7 cells incubated for 10 mins prior to radioligand addition measured after 5 mins by scintillation counting analysis",Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram.,ACS Med. Chem. Lett.,PUBLICATION,,7.698970004336019,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCN5C6CCC5[C@H]([C@H](C6)C7=CC(=C(C=C7)Cl)Cl)C(=O)OC)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCN4C5CCC4[C@@H](C(=O)OC)[C@@H](c4ccc(Cl)c(Cl)c4)C5)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
6148,6169,CHEMBL727,WYWHKKSPHMUBEB-UHFFFAOYSA-N,THIOGUANINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=C(N2)N,Nc1nc(=S)c2[nH]cnc2[nH]1
6149,6170,CHEMBL727,WYWHKKSPHMUBEB-UHFFFAOYSA-N,THIOGUANINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=C(N2)N,Nc1nc(=S)c2[nH]cnc2[nH]1
6150,6171,CHEMBL762,WYWIFABBXFUGLM-UHFFFAOYSA-N,OXYMETAZOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
6151,6172,CHEMBL762,WYWIFABBXFUGLM-UHFFFAOYSA-N,OXYMETAZOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
6152,6173,CHEMBL564201,WYXSYVWAUAUWLD-SHUUEZRQSA-N,6-AZAURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,O=c1cnn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1
6153,6174,CHEMBL564201,WYXSYVWAUAUWLD-SHUUEZRQSA-N,6-AZAURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,O=c1cnn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1
6154,6175,CHEMBL1645605,WYYIFGYFQYWQOA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,312.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.505845405981558,C1C(CN1)OC2=C(C=CC=C2F)OC3=C(C(=CC=C3)Cl)Cl,Fc1cccc(Oc2cccc(Cl)c2Cl)c1OC1CNC1
6155,6176,CHEMBL1944971,WYYNFHYJIMPILR-MANSERQUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,CCCCC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C,CCCCc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)cc1
6156,6177,CHEMBL2103774,WZDGZWOAQTVYBX-XOINTXKNSA-N,TIBOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C
6157,6178,CHEMBL2103774,WZDGZWOAQTVYBX-XOINTXKNSA-N,TIBOLONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C
6158,6179,CHEMBL2031873,WZHAQWFZACLGKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22313242.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,C1CCC(C1)NC(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5,O=C(NC1CCCC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
6159,6180,CHEMBL1480987,WZHCOOQXZCIUNC-UHFFFAOYSA-N,CYCLANDELATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O,CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)C1
6160,6181,CHEMBL1480987,WZHCOOQXZCIUNC-UHFFFAOYSA-N,CYCLANDELATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O,CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)C1
6161,6182,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,63.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.200659450546419,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
6162,6183,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,50.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.301029995663981,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
6163,6184,CHEMBL257940,WZHXVKWOVBWNIB-RHDGDCLCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18160282.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,Discovery of novel orally active ureido NPY Y5 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC(=O)N1CCC(CC1)N(C)C(=O)NC2CCC(CC2)C3=CC(=CC(=C3)F)F,CC(=O)N1CCC(N(C)C(=O)NC2CCC(c3cc(F)cc(F)c3)CC2)CC1
6164,6185,CHEMBL245416,WZNJWVWKTVETCG-YFKPBYRVSA-N,L-MIMOSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N,N[C@@H](Cn1ccc(=O)c(O)c1)C(=O)O
6165,6186,CHEMBL245416,WZNJWVWKTVETCG-YFKPBYRVSA-N,L-MIMOSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N,N[C@@H](Cn1ccc(=O)c(O)c1)C(=O)O
6166,6187,CHEMBL158,WZPBZJONDBGPKJ-VEHQQRBSSA-N,AZTREONAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
6167,6188,CHEMBL158,WZPBZJONDBGPKJ-VEHQQRBSSA-N,AZTREONAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
6168,6189,CHEMBL513204,WZTBYHQYXSTVTK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,29.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,29.0,CN1CCN(CC1)CC(C2=CC(=CC=C2)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(CC(c2cccc(F)c2)C2(O)CCCCC2)CC1
6169,6190,CHEMBL453321,WZVJYHZPOKMITP-NVXWUHKLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=CC=C1O[C@@H]2CC[C@H](C3=CC=CC=C23)N,Cc1ccccc1O[C@@H]1CC[C@@H](N)c2ccccc21
6170,6191,CHEMBL453061,WZVJYHZPOKMITP-WBVHZDCISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=CC=C1O[C@H]2CC[C@H](C3=CC=CC=C23)N,Cc1ccccc1O[C@H]1CC[C@@H](N)c2ccccc21
6171,6192,CHEMBL602323,WZYMYZUFIBBREW-OKCYCAHKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,10.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,8.0,COCCC1([C@H]2[C@@H]1CNC2)C3=CC(=C(C=C3)Cl)Cl.Cl,COCCC1(c2ccc(Cl)c(Cl)c2)[C@H]2CNC[C@H]21
6172,6193,CHEMBL1696,XAEWZDYWZHIUCT-UHFFFAOYSA-N,DESIPRAMINE HYDROCHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,,,,Not Determined,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,CNCCCN1c2ccccc2CCc2ccccc21
6173,6194,CHEMBL256039,XAFDYZFDMXIOPG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,CCCCN(CC)C(=O)C1(c2ccccc2)CC1CN
6174,6195,CHEMBL543390,XAJYZZVCTFHTRT-YYLIZZNMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,1833546.0,KI,>,30000.0,NM,,,,,,,,,,,,,,,In vitro binding affinity for dopamine uptake site,"Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.",J. Med. Chem.,PUBLICATION,,4.5228787452803365,C1[C@H](O[C@H](C2=C1C(=C(C=C2)Br)O)CN)C3=CC=CC=C3.Cl,NC[C@@H]1O[C@H](c2ccccc2)Cc2c1ccc(Br)c2O
6175,6196,CHEMBL1818449,XAKHVFLBNVAXLY-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,63.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.199970640755867,CC1=COC(=N1)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1coc(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
6176,6197,CHEMBL373710,XANSRGJYZPYJFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,14.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.853871964321763,CC(C)CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CCC(c1ccc(Cl)cc1)C1CCCCN1
6177,6198,CHEMBL373710,XANSRGJYZPYJFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,680.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.167491087293763,CC(C)CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CCC(c1ccc(Cl)cc1)C1CCCCN1
6178,6199,CHEMBL373710,XANSRGJYZPYJFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,3.6,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.443697499232712,CC(C)CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CCC(c1ccc(Cl)cc1)C1CCCCN1
6179,6200,CHEMBL373710,XANSRGJYZPYJFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,510.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.292429823902062,CC(C)CCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CC(C)CCC(c1ccc(Cl)cc1)C1CCCCN1
6180,6201,CHEMBL1684042,XAXLSVQFDZVYNG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,69.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.161150909262744,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N,CC(N)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
6181,6202,CHEMBL1684042,XAXLSVQFDZVYNG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,180.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N,CC(N)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
6182,6203,CHEMBL1684042,XAXLSVQFDZVYNG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,770.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.113509274827518,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)N,CC(N)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
6183,6204,CHEMBL113136,XAYGSYISSLIYTN-CXMPNGEBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,IC50,=,165.0,NM,,,,,,,,,,,,,,,In vitro inhibition of DA re-uptake into synaptosome,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.782516055786092,CN(C)C[C@@H]1[C@H](C2CCC1CC2)C3=CC(=CC=C3)Cl,CN(C)C[C@H]1C2CCC(CC2)[C@@H]1c1cccc(Cl)c1
6184,6205,CHEMBL113136,XAYGSYISSLIYTN-CXMPNGEBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12951108.0,KI,=,64.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine transporter,Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1938200260161125,CN(C)C[C@@H]1[C@H](C2CCC1CC2)C3=CC(=CC=C3)Cl,CN(C)C[C@H]1C2CCC(CC2)[C@@H]1c1cccc(Cl)c1
6185,6206,CHEMBL365183,XAYGSYISSLIYTN-YAAHMLIESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16220969.0,IC50,=,28.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against dopamine transporter,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.552841968657781,CN(C)CC1[C@H](C2CCC1CC2)C3=CC(=CC=C3)Cl,CN(C)CC1C2CCC(CC2)[C@@H]1c1cccc(Cl)c1
6186,6207,CHEMBL3673177,XBECXOYAIBURBV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,11.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.943095148663526,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)F)Cl)C=CC(=C3)C5=NN=C(C=C5)C(F)(F)F,Fc1ccc(C23CCN(Cc4cc(-c5ccc(C(F)(F)F)nn5)ccc42)C3)cc1Cl
6187,6208,CHEMBL3673177,XBECXOYAIBURBV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,243.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.614393726401688,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)F)Cl)C=CC(=C3)C5=NN=C(C=C5)C(F)(F)F,Fc1ccc(C23CCN(Cc4cc(-c5ccc(C(F)(F)F)nn5)ccc42)C3)cc1Cl
6188,6209,CHEMBL101986,XBEHQYYSOYTBFQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,675.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.170696227168975,COC(=O)C1=CC=CC=C1C2=CC=C(C=C2)Cl,COC(=O)c1ccccc1-c1ccc(Cl)cc1
6189,6210,CHEMBL37858,XBHBWNFJWIASRO-UHFFFAOYSA-N,SARAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O
6190,6211,CHEMBL37858,XBHBWNFJWIASRO-UHFFFAOYSA-N,SARAFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O
6191,6212,CHEMBL383464,XBIRPUDVQBQYMW-JMAPEOGHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.6,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.795880017344075,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H](CCC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@@H](CCc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6192,6213,CHEMBL202860,XBIRPUDVQBQYMW-XXIQNXCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.853871964321762,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CCC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@H](CCc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6193,6214,CHEMBL202860,XBIRPUDVQBQYMW-XXIQNXCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,2.1,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.67778070526608,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CCC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@H](CCc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6194,6215,CHEMBL6273,XBJBPGROQZJDOJ-UHFFFAOYSA-N,FLEROXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F,CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1
6195,6216,CHEMBL6273,XBJBPGROQZJDOJ-UHFFFAOYSA-N,FLEROXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F,CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1
6196,6217,CHEMBL261465,XBLJZKGUMJUESI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,2280.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.642065152999545,CCC1=CC=CC=C1OC2=C(C=NC(=C2)C)CNC,CCc1ccccc1Oc1cc(C)ncc1CNC
6197,6218,CHEMBL513577,XBSXEAMPHZZPKZ-LJQANCHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,22.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,22.0,CNCC[C@H](C1=CC=CC=C1)N2C3=CC=CC=C3N(C2=O)C4CCCC4,CNCC[C@H](c1ccccc1)n1c(=O)n(C2CCCC2)c2ccccc21
6198,6219,CHEMBL463387,XBZYPUYXVGRGJR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,104.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.982966660701218,CN(C)C(=O)C1=CC2=C(N1)C=CC(=C2)C3(CCNC3)CC4=CC=CC=C4,CN(C)C(=O)c1cc2cc(C3(Cc4ccccc4)CCNC3)ccc2[nH]1
6199,6220,CHEMBL3704748,XCAMEKYVLTTXGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,7.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.142667503568731,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCC(=O)OCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6200,6221,CHEMBL3704748,XCAMEKYVLTTXGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,10.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.9746941347352305,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCC(=O)OCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6201,6222,CHEMBL3704748,XCAMEKYVLTTXGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,38.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.4179366370882915,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCC(=O)OCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6202,6223,CHEMBL3704748,XCAMEKYVLTTXGP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,7.2,NM,317678,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.142667503568731,CCC(=O)OCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCC(=O)OCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6203,6224,CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C
6204,6225,CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C
6205,6226,CHEMBL137718,XCEOQSGAJFHDBK-QPJJXVBHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,0.45,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,9.346787486224656,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C/C=C/C4=CC=CC=C4,Fc1ccc(C(OCCC2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
6206,6227,CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
6207,6228,CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
6208,6229,CHEMBL203563,XCHIECWEKDGHNL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,49.7,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.303643611266668,CCCC(C(=O)C1=CC=C(C=C1)O)N2CCCC2,CCCC(C(=O)c1ccc(O)cc1)N1CCCC1
6209,6230,CHEMBL203563,XCHIECWEKDGHNL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,125.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.903089986991943,CCCC(C(=O)C1=CC=C(C=C1)O)N2CCCC2,CCCC(C(=O)c1ccc(O)cc1)N1CCCC1
6210,6231,CHEMBL512851,XCOOHOIRZJLJRQ-WFASDCNBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,5.0,C=CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC=CS2,C=CCN(CC=C)C(=O)[C@@]1(c2cccs2)C[C@H]1CN
6211,6232,CHEMBL3310634,XCSFWQOZLCRJAK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,14.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,14.0,C1C(CN1)CC(C2=CC(=C(C=C2)F)F)OC3=CC=C(C=C3)OC(F)(F)F,Fc1ccc(C(CC2CNC2)Oc2ccc(OC(F)(F)F)cc2)cc1F
6212,6233,CHEMBL257388,XCUFOYFDVQBJRW-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C#CCN(CC#C)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,C#CCN(CC#C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
6213,6234,CHEMBL606174,XCXKFSMMFREDTK-SRJVRDNSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,31.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,31.0,CC(C)C1CN(C2=CC=CC=C12)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1CC(C(C)C)c2ccccc21
6214,6235,CHEMBL470313,XCYJTWMYHQVABH-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,31.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,31.0,CC(C)N1C2=C(C(=CC=C2)F)N(C1=O)[C@@H](CCNC)C3=CC=CC=C3,CNCC[C@@H](c1ccccc1)n1c(=O)n(C(C)C)c2cccc(F)c21
6215,6236,CHEMBL516965,XCYJTWMYHQVABH-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,INHIBITION,=,5.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)N1C2=C(C(=CC=C2)F)N(C1=O)[C@H](CCNC)C3=CC=CC=C3,CNCC[C@H](c1ccccc1)n1c(=O)n(C(C)C)c2cccc(F)c21
6216,6237,CHEMBL595677,XDCKKLJZZNMBOS-CHPDAQJUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,2.5,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.602059991327963,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(-c3ccsc3)cc1)N2C
6217,6238,CHEMBL95764,XDDAORKBJWWYJS-UHFFFAOYSA-N,GLYPHOSATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)NCP(=O)(O)O,O=C(O)CNCP(=O)(O)O
6218,6239,CHEMBL95764,XDDAORKBJWWYJS-UHFFFAOYSA-N,GLYPHOSATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)NCP(=O)(O)O,O=C(O)CNCP(=O)(O)O
6219,6240,CHEMBL2171410,XDHXBWIHBPXIJQ-UHFFFAOYSA-N,3-((4-CHLOROPHENYL)(PHENOXY)METHYL)AZETIDINE HCL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,36.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,36.0,C1C(CN1)C(C2=CC=C(C=C2)Cl)OC3=CC=CC=C3.Cl,Clc1ccc(C(Oc2ccccc2)C2CNC2)cc1
6220,6241,CHEMBL507422,XDILVFHJKVYNDZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,4200.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.376750709602098,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)C3CC3,CN(C)Cc1ccccc1Oc1ccc(C2CC2)cc1
6221,6242,CHEMBL55,XDRYMKDFEDOLFX-UHFFFAOYSA-N,PENTAMIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,3159.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.500450374094851,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1
6222,6243,CHEMBL55,XDRYMKDFEDOLFX-UHFFFAOYSA-N,PENTAMIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2510.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.600326278518962,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1
6223,6244,CHEMBL186242,XDVKKPZOVYWLDP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,4.5,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.346787486224656,COC(=O)C1=C(CC2CCC1S2)C3=CC(=C(C=C3)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CC2CCC1S2
6224,6245,CHEMBL1117,XDXDZDZNSLXDNA-TZNDIEGXSA-N,IDARUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
6225,6246,CHEMBL1117,XDXDZDZNSLXDNA-TZNDIEGXSA-N,IDARUBICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
6226,6247,CHEMBL391912,XDXOHQKHKUUZHQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,234422881531993.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-5.370000000000001,COC(=O)C1=C(C2CCC1C2)C3=CC4=CC=CC=C4C=C3,COC(=O)C1=C(c2ccc3ccccc3c2)C2CCC1C2
6227,6248,CHEMBL249214,XEKOGGCKFOLDIR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,300.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,C1CC(=C(C1)C(=O)OCCO)C2=CC(=C(C=C2)Cl)Cl,O=C(OCCO)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
6228,6249,CHEMBL1224381,XENSJUHNMOKFGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,116.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.935542010773082,CNCCC(C1=CC(=C(C=C1)Cl)Cl)N2N=CN=N2,CNCCC(c1ccc(Cl)c(Cl)c1)n1ncnn1
6229,6250,CHEMBL1224381,XENSJUHNMOKFGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,48.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,48.0,CNCCC(C1=CC(=C(C=C1)Cl)Cl)N2N=CN=N2,CNCCC(c1ccc(Cl)c(Cl)c1)n1ncnn1
6230,6251,CHEMBL3319405,XEOOLDLJXYEALJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24967667.0,KI,=,290.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),"Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists.",J. Med. Chem.,PUBLICATION,,6.5376020021010435,CN1CCC(CC1)S(=O)(=O)C2=CC3=C(C=C2)N=C(S3)NC(=O)NC(=O)C4=C(C=CC(=C4)N5CCOCC5)Cl,CN1CCC(S(=O)(=O)c2ccc3nc(NC(=O)NC(=O)c4cc(N5CCOCC5)ccc4Cl)sc3c2)CC1
6231,6252,CHEMBL377189,XEWUKTSZOJWBEW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CN=CS3,Clc1ccccc1CC(c1cncs1)N1CCNCC1
6232,6253,CHEMBL3238498,XEYYBSNVSWTRJJ-HFTWOUSFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=C(C=C1C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)N)O)Cl)Cl)N,Nc1ccc(-c2ccc(N=Nc3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(Cl)c2)cc1Cl
6233,6254,CHEMBL365812,XEZCTGHRWRPHGS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15801845.0,KI,=,2908.0,NM,,,cell_based,,,,,HEK293,,,,,,,In vitro displacement of [3H]GBR-12935 from human dopamine transporter expressed in HEK293 cells,"Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.",J. Med. Chem.,PUBLICATION,,5.536405597812999,CC1=CC(=C(C=C1)SC2=CC=CC=C2CNCC=C)N,C=CCNCc1ccccc1Sc1ccc(C)cc1N
6234,6255,CHEMBL1754,XFDJYSQDBULQSI-UHFFFAOYSA-N,DOXAPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
6235,6256,CHEMBL1754,XFDJYSQDBULQSI-UHFFFAOYSA-N,DOXAPRAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
6236,6257,CHEMBL1645607,XFIFFAHPFWAWSS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,2190.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6595558851598815,C1CNCCC1OC2=C(C=CC=C2F)OC3=CC=CC=C3F,Fc1ccccc1Oc1cccc(F)c1OC1CCNCC1
6237,6258,CHEMBL238868,XFIVQANHMYEPDG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=C(C=CC(=C1)OCCF)SC2=C(C=C(C=C2)F)N,CN(C)Cc1cc(OCCF)ccc1Sc1ccc(F)cc1N
6238,6259,CHEMBL476942,XFORZXNXAQQOKS-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,3410.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.467245621007502,CC(C)C1=CC=CC=C1CN([C@H]2CCNC2)C(=O)C(C)C,CC(C)C(=O)N(Cc1ccccc1C(C)C)[C@H]1CCNC1
6239,6260,CHEMBL522699,XFRJSOUJVWXXAT-GAPKJMMISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,0.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,9.045757490560677,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C#CC4=CC=C(C=C4)[N+](=O)[O-].Cl,CN1[C@H]2CC[C@@H]1[C@@H](C#Cc1ccc([N+](=O)[O-])cc1)[C@@H](c1ccc(Cl)cc1)C2
6240,6261,CHEMBL2103747,XFSBVAOIAHNAPC-FKHWODAVSA-N,ACONITINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C[C@@]2([C@@H](C[C@H]([C@@]34[C@@H]2[C@H]([C@@H]([C@@H]31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC,CCN1C[C@@]2(COC)[C@H]3[C@@H](OC)[C@H]4[C@H]1[C@]3([C@H](OC)C[C@H]2O)[C@@H]1C[C@]2(O)[C@@H](OC)[C@H](O)[C@@]4(OC(C)=O)[C@H]1[C@H]2OC(=O)c1ccccc1
6241,6262,CHEMBL2103747,XFSBVAOIAHNAPC-FKHWODAVSA-N,ACONITINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C[C@@]2([C@@H](C[C@H]([C@@]34[C@@H]2[C@H]([C@@H]([C@@H]31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC,CCN1C[C@@]2(COC)[C@H]3[C@@H](OC)[C@H]4[C@H]1[C@]3([C@H](OC)C[C@H]2O)[C@@H]1C[C@]2(O)[C@@H](OC)[C@H](O)[C@@]4(OC(C)=O)[C@H]1[C@H]2OC(=O)c1ccccc1
6242,6263,CHEMBL3673162,XGJMFUFVUDLHTF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,5.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.229147988357855,COC1=NN=C(C=C1)C2=CC3=C(C=C2)C4(CCN(C3)CC4)C5=CC(=C(C=C5)Cl)Cl,COc1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)c(Cl)c3)CC2)nn1
6243,6264,CHEMBL607547,XHEKSGUJENDBTI-SCCDFBDJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,160.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.795880017344076,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCCC5=CC=C(C=C5)CNC(=O)[C@H]6[C@H](CC7CCC6N7C)C8=CC=C(C=C8)C9=CSC=C9,CN1C2CCC1[C@@H](C(=O)NCc1ccc(CCNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(-c5ccsc5)cc3)N4C)cc1)[C@@H](c1ccc(-c3ccsc3)cc1)C2
6244,6265,CHEMBL505902,XHOQDMBOUAKHDY-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18667309.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1O[C@@H]2[C@@H](CC3=CC=CC=C23)CN(C)C,Cc1ccccc1O[C@H]1c2ccccc2C[C@H]1CN(C)C
6245,6266,CHEMBL41222,XIAXJMRDIVBEHN-NTEUORMPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.1,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.1,C1CN(CCN1CCN(CC2=CC=CC=C2)C3=CC=CC=N3)C/C=C/C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(CCN(Cc2ccccc2)c2ccccn2)CC1
6246,6267,CHEMBL41222,XIAXJMRDIVBEHN-NTEUORMPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.0,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.0,C1CN(CCN1CCN(CC2=CC=CC=C2)C3=CC=CC=N3)C/C=C/C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(CCN(Cc2ccccc2)c2ccccn2)CC1
6247,6268,CHEMBL575648,XIHXZWUTKBABCV-IOXAMRCBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,900.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.045757490560675,CCCN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)SCC)C(=O)OC,CCCN1C2CCC1[C@@H](C(=O)OC)[C@@H](c1ccc(SCC)cc1)C2
6248,6269,CHEMBL404258,XIINYKRQARUYJK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,3780.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.422508200162776,CN(C)CC1=CC=CC=C1OC2=C(C=C(C=C2)Cl)OC,COc1cc(Cl)ccc1Oc1ccccc1CN(C)C
6249,6270,CHEMBL1231,XIQVNETUBQGFHX-UHFFFAOYSA-N,OXYBUTYNIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,85.5,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.068033885271827,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
6250,6271,CHEMBL1231,XIQVNETUBQGFHX-UHFFFAOYSA-N,OXYBUTYNIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,67.9,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,7.168130225719497,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
6251,6272,CHEMBL189375,XIVFNOGFYONSDE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15974579.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,In vitro inhibition of [3H]WIN-35428 binding to human dopamine transporter expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.",J. Med. Chem.,PUBLICATION,,6.0,CCC1=CC(=C(C=C1)SC2=CC=CC=C2CNC)N,CCc1ccc(Sc2ccccc2CNC)c(N)c1
6252,6273,CHEMBL3334778,XIYLELDHKGRFPU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,36.6,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,36.6,CCOC(=O)C1CCCN(C1)C(CCN2CCOCC2)C3=CC(=C(C=C3)Cl)Cl,CCOC(=O)C1CCCN(C(CCN2CCOCC2)c2ccc(Cl)c(Cl)c2)C1
6253,6274,CHEMBL1909070,XJGBDJOMWKAZJS-UHFFFAOYSA-N,NAFENOPIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,CC(C)(Oc1ccc(C2CCCc3ccccc32)cc1)C(=O)O
6254,6275,CHEMBL1909070,XJGBDJOMWKAZJS-UHFFFAOYSA-N,NAFENOPIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,CC(C)(Oc1ccc(C2CCCc3ccccc32)cc1)C(=O)O
6255,6276,CHEMBL573769,XJJHPGZYVOFINN-UHFFFAOYSA-N,4-(2-(BENZYLOXY)PHENYL)PIPERIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CNCCC1C2=CC=CC=C2OCC3=CC=CC=C3,c1ccc(COc2ccccc2C2CCNCC2)cc1
6256,6277,CHEMBL3317702,XJTZQDVYMGLFOP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,340.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.468521082957745,CC1C(=O)N(CCCN1)C2=CC3=CC=CC=C3C=C2.Cl,CC1NCCCN(c2ccc3ccccc3c2)C1=O
6257,6278,CHEMBL3317705,XJTZQDVYMGLFOP-UTONKHPSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@@H]1C(=O)N(CCCN1)C2=CC3=CC=CC=C3C=C2.Cl,C[C@H]1NCCCN(c2ccc3ccccc3c2)C1=O
6258,6279,CHEMBL3317704,XJTZQDVYMGLFOP-YDALLXLXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25017029.0,IC50,=,160.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHO cells after 60 mins by scintillation counting,"Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344076,C[C@H]1C(=O)N(CCCN1)C2=CC3=CC=CC=C3C=C2.Cl,C[C@@H]1NCCCN(c2ccc3ccccc3c2)C1=O
6259,6280,CHEMBL479999,XKDQGWQMRLNJCO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,260.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.585026652029183,CN(C)CC1=C(C=CC(=C1)C(=O)N)CC2=CC(=C(C=C2)Cl)Cl,CN(C)Cc1cc(C(N)=O)ccc1Cc1ccc(Cl)c(Cl)c1
6260,6281,CHEMBL59986,XKFMBGWHHBCWCD-QMMMGPOBSA-N,A-85380,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8887981.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CN[C@@H]1COC2=CN=CC=C2,c1cncc(OC[C@@H]2CCN2)c1
6261,6282,CHEMBL404730,XKGBYDWMVKBQIC-OXJNMPFZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C#CCN(CC1CC1)C(=O)[C@]2(C[C@H]2CN)C3=CC4=C(C=C3)OCCO4,C#CCN(CC1CC1)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN
6262,6283,CHEMBL3104093,XKGPHJMKJBEURD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24365159.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin) by radioligand displacement assay,"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=C4N2CCC5=CC=CC=C5C4=CC=C3,CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1
6263,6284,CHEMBL3360718,XKMLYHZJKCRLOI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25530830.0,INHIBITION,=,68.0,%,,,cell_based,,,,,,,,,,,,Displacement of [125I] RTI-55 from human recombinant DAT expressed in CHOK1 cells after 3 hrs,,ACS Med. Chem. Lett.,PUBLICATION,,68.0,C1CN(CCC1Cl)S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=CC=C(O3)[N+](=O)[O-],O=C(Nc1ccc(S(=O)(=O)N2CCC(Cl)CC2)cc1)c1ccc([N+](=O)[O-])o1
6264,6285,CHEMBL258713,XKQXMBVWEDMNAK-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=CC(=C1)Br)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1cc(Br)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
6265,6286,CHEMBL2171418,XKYAZKCRLILWNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,54.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.267606240177032,C1C(CN1)C(C2=CC3=CC=CC=C3C=C2)OC4=CC(=C(C=C4)Cl)Cl.Cl,Clc1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1Cl
6266,6287,CHEMBL2171418,XKYAZKCRLILWNB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,68.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,68.0,C1C(CN1)C(C2=CC3=CC=CC=C3C=C2)OC4=CC(=C(C=C4)Cl)Cl.Cl,Clc1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1Cl
6267,6288,CHEMBL563987,XLDPRVVEMAUFLK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,1070.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.97061622231479,C1CNCCC1C(C2=CN=CC=C2)OC3=C(C(=CC=C3)F)F,Fc1cccc(OC(c2cccnc2)C2CCNCC2)c1F
6268,6289,CHEMBL1224226,XLHBGLMPNFVKBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NN(N=N1)C(CCN(C)C)C2=CC3=C(C=C2)C=C(C=C3)F,Cc1nnn(C(CCN(C)C)c2ccc3cc(F)ccc3c2)n1
6269,6290,CHEMBL101055,XLJMMCKWKGQCNY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,9.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,9.0,CN(C)CC(C1=CC(=CC=C1)OC)C2(CCCCC2)O,COc1cccc(C(CN(C)C)C2(O)CCCCC2)c1
6270,6291,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,23517.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.628618080833348,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
6271,6292,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,18685.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,4.728506897814343,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
6272,6293,CHEMBL3323108,XMNGPUYPQMMGIP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,44.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,7.356547323513813,CN1CC(C2=CC=CC=C2C1)C3=CN4C(=CC=N4)C=C3,CN1Cc2ccccc2C(c2ccc3ccnn3c2)C1
6273,6294,CHEMBL410054,XMOVWPQOTYUSTK-FXAWDEMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC#CCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,C=CCN(CC#CC)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
6274,6295,CHEMBL575899,XMQIWPUGABPALG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3F,Fc1ccccc1COc1ccccc1N1CCNCC1
6275,6296,CHEMBL1321154,XMVJITFPVVRMHC-UHFFFAOYSA-N,ROXARSONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,O=[N+]([O-])c1cc([As](=O)(O)O)ccc1O
6276,6297,CHEMBL1321154,XMVJITFPVVRMHC-UHFFFAOYSA-N,ROXARSONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,O=[N+]([O-])c1cc([As](=O)(O)O)ccc1O
6277,6298,CHEMBL14376,XMXHEBAFVSFQEX-UHFFFAOYSA-N,ILOPERIDONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11750183.0,KI,=,2951.0,NM,,,,,,,,,,,,,,,,,,,,5.5300307905000405,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1
6278,6299,CHEMBL3663910,XNBOTHGRHLGURP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,2787.0,NM,314433,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,5.554863031286696,CN1CC(C2=CC=CC=C2C1)C3=CN=C(C=C3)OC,COc1ccc(C2CN(C)Cc3ccccc32)cn1
6279,6300,CHEMBL2057417,XNCQMFVABACABG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23177787.0,INHIBITION,=,74.0,%,,,,,,,,,,,,,,,Binding affinity to human DAT at 10 uM by radioligand binding assay,"Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,74.0,CC1=C2C(=C(SC2=NC(=C1Cl)C)C(=O)NCC3=CC=NC=C3)N,Cc1nc2sc(C(=O)NCc3ccncc3)c(N)c2c(C)c1Cl
6280,6301,CHEMBL314912,XNEPFMQTSJAQGW-VGLNDMCTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,6300.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,5.200659450546418,CN1C2C[C@H](C1C(C(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC)O,COC(=O)C1C(OC(c2ccc(F)cc2)c2ccc(F)cc2)CC2C[C@@H](O)C1N2C
6281,6302,CHEMBL2165541,XNHXAWXVLOOHSD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,18.36,%,,,,,,,,,,,,,,,Inhibition of DAT at 1 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,18.36,CN(C)C1CCC2=C(C1)C3=CC=CC=C3N2S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F,CN(C)C1CCc2c(c3ccccc3n2S(=O)(=O)c2cccc(C(F)(F)F)c2)C1
6282,6303,CHEMBL2165541,XNHXAWXVLOOHSD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23036955.0,INHIBITION,=,24.75,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,24.75,CN(C)C1CCC2=C(C1)C3=CC=CC=C3N2S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F,CN(C)C1CCc2c(c3ccccc3n2S(=O)(=O)c2cccc(C(F)(F)F)c2)C1
6283,6304,CHEMBL991,XNKLLVCARDGLGL-JGVFFNPUSA-N,STAVUDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
6284,6305,CHEMBL991,XNKLLVCARDGLGL-JGVFFNPUSA-N,STAVUDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
6285,6306,CHEMBL20648,XNPXCWOQSAQIEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,=,37.6,NM,,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]WIN-35428 (radioligand) on Cloned human Dopamine transporter expressed in HEK cells,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.424812155072338,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
6286,6307,CHEMBL20648,XNPXCWOQSAQIEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9703474.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Affinity was evaluated using [3H]DA (radioligand) on Cloned human Dopamine transporter expressed in HEK cells; not determined,Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
6287,6308,CHEMBL20648,XNPXCWOQSAQIEL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,0.14,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,0.14,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
6288,6309,CHEMBL1765600,XNZHLLAIQAZMMY-BLLLJJGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,61.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,7.214670164989233,CCCN1[C@H]([C@@](OCC1(C)C)(C2=CC(=CC=C2)Cl)O)C,CCCN1[C@@H](C)[C@](O)(c2cccc(Cl)c2)OCC1(C)C
6289,6310,CHEMBL1947087,XOBBOJHELMBHFC-JVEPLPTMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,116.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.935542010773082,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C=C(/C(F)(F)F)\I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C/C=C(\I)C(F)(F)F
6290,6311,CHEMBL635,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,PREDNISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
6291,6312,CHEMBL635,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,PREDNISONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
6292,6313,CHEMBL975,XOGTZOOQQBDUSI-UHFFFAOYSA-M,MESNA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CS(=O)(=O)[O-])S.[Na+],O=S(=O)([O-])CCS
6293,6314,CHEMBL975,XOGTZOOQQBDUSI-UHFFFAOYSA-M,MESNA,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CS(=O)(=O)[O-])S.[Na+],O=S(=O)([O-])CCS
6294,6315,CHEMBL2430692,XOMFYIZXAHTPCL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,41.7,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.379863945026242,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1cccc(Cl)c1
6295,6316,CHEMBL2430692,XOMFYIZXAHTPCL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,87.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,87.0,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1cccc(Cl)c1
6296,6317,CHEMBL2430692,XOMFYIZXAHTPCL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,95.4,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,95.4,C1C(C(C(=O)N1)C2=CC(=CC=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1cccc(Cl)c1
6297,6318,CHEMBL197354,XOQCOACREKNTCH-YPMHNXCESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16162005.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding inhibition towards human dopamine transporter at 1 uM,Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,50.0,CN(C)C[C@H]1C[C@@H]1C2=CNC3=C(C=CC=C23)C#N,CN(C)C[C@H]1C[C@@H]1c1c[nH]c2c(C#N)cccc12
6298,6319,CHEMBL208533,XOXGVFCUPFEFPL-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-37.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-37.0,CC(C)CN(CC1=C(C(=CC=C1)C(F)(F)F)Cl)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1cccc(C(F)(F)F)c1Cl)C1CCNCC1
6299,6320,CHEMBL838,XPCFTKFZXHTYIP-PMACEKPBSA-N,BENAZEPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
6300,6321,CHEMBL838,XPCFTKFZXHTYIP-PMACEKPBSA-N,BENAZEPRIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
6301,6322,CHEMBL1830886,XPDPSRJQWMZUMS-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,IC50,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,,COC1=CC=CC(=C1)N2C3=CC=CC=C3N(S2(=O)=O)CC[C@@H]4CNCCO4,COc1cccc(N2c3ccccc3N(CC[C@@H]3CNCCO3)S2(=O)=O)c1
6302,6323,CHEMBL1173086,XPEGTFDNPKUQMC-RBSFLKMASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,398.11,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.399996913372259,COC[C@]12C[C@]1([C@@H](CNC2)OC)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNC[C@@H](OC)[C@]1(c1ccc(Cl)c(Cl)c1)C2
6303,6324,CHEMBL1173085,XPEGTFDNPKUQMC-RRFJBIMHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,501.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,6.299997602857746,COC[C@]12C[C@]1([C@H](CNC2)OC)C3=CC(=C(C=C3)Cl)Cl,COC[C@@]12CNC[C@H](OC)[C@]1(c1ccc(Cl)c(Cl)c1)C2
6304,6325,CHEMBL918,XPFRXWCVYUEORT-UHFFFAOYSA-N,PHENACEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CC(=O)NC(=O)N,NC(=O)NC(=O)Cc1ccccc1
6305,6326,CHEMBL918,XPFRXWCVYUEORT-UHFFFAOYSA-N,PHENACEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CC(=O)NC(=O)N,NC(=O)NC(=O)Cc1ccccc1
6306,6327,CHEMBL455221,XPMTXFPUXPYNCB-LSDHHAIUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,16540.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,4.781464494783472,COC1=C(C=C(C=C1)F)CCCC[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CCCC[C@H]1CC[C@H](CN)O1
6307,6328,CHEMBL455221,XPMTXFPUXPYNCB-LSDHHAIUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,3868.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.412513534589037,COC1=C(C=C(C=C1)F)CCCC[C@H]2CC[C@@H](O2)CN,COc1ccc(F)cc1CCCC[C@H]1CC[C@H](CN)O1
6308,6329,CHEMBL204586,XPPDUQXXSFOWGY-JCOPYZAKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,1.4,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.853871964321762,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C[C@H](CC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@@H](Cc1ccccc1)CN1CCC(CCOC(c2ccccc2)c2ccccc2)CC1
6309,6330,CHEMBL382783,XPPDUQXXSFOWGY-LNLSOMNWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,6.9,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.161150909262744,C1CN(CCC1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C[C@@H](CC4=CC=CC=C4)O.C(=O)(C(=O)O)O,O[C@H](Cc1ccccc1)CN1CCC(CCOC(c2ccccc2)c2ccccc2)CC1
6310,6331,CHEMBL210028,XPYLNZBNFQMTKZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3,Cc1ccccc1CC(c1ccccc1)N1CCNCC1
6311,6332,CHEMBL788,XQFRJNBWHJMXHO-RRKCRQDMSA-N,IDOXURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I
6312,6333,CHEMBL788,XQFRJNBWHJMXHO-RRKCRQDMSA-N,IDOXURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I
6313,6334,CHEMBL575132,XQGCYOUBZLLPMY-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,8.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C(=CC=C3)F)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cccc(F)c21
6314,6335,CHEMBL571536,XQHYQPRYOHIDGH-SNVBAGLBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CCN([C@@H]1CCNC1)C(=O)C2=C(C(=C(C=C2)Cl)Cl)C,CCN(C(=O)c1ccc(Cl)c(Cl)c1C)[C@@H]1CCNC1
6315,6336,CHEMBL2047582,XQLBAPHRSPLANO-HTAPYJJXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,68.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,68.0,C[C@@H]([C@H](C1=CC=C(C=C1)OC)O)N2CCC(=CC2)CC3=CC=CC=C3,COc1ccc([C@H](O)[C@H](C)N2CC=C(Cc3ccccc3)CC2)cc1
6316,6337,CHEMBL2047581,XQLBAPHRSPLANO-VGOFRKELSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22608762.0,INHIBITION,=,70.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in CHO cells at 10 uM after 10 mins by scintillation counting,Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,70.0,C[C@H]([C@H](C1=CC=C(C=C1)OC)O)N2CCC(=CC2)CC3=CC=CC=C3,COc1ccc([C@H](O)[C@@H](C)N2CC=C(Cc3ccccc3)CC2)cc1
6317,6338,CHEMBL470481,XQNGYGNOPUIZQG-RMRYJAPISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,15.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,15.0,C1CCC(CC1)([C@@H](CN2CCNCC2)C3=CC(=CC=C3)OC(F)(F)F)O.Cl.Cl,OC1([C@@H](CN2CCNCC2)c2cccc(OC(F)(F)F)c2)CCCCC1
6318,6339,CHEMBL469476,XQNGYGNOPUIZQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,13.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,13.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CC(=CC=C3)OC(F)(F)F)O.Cl.Cl,OC1(C(CN2CCNCC2)c2cccc(OC(F)(F)F)c2)CCCCC1
6319,6340,CHEMBL470482,XQNGYGNOPUIZQG-ZEECNFPPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,13.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,13.0,C1CCC(CC1)([C@H](CN2CCNCC2)C3=CC(=CC=C3)OC(F)(F)F)O.Cl.Cl,OC1([C@H](CN2CCNCC2)c2cccc(OC(F)(F)F)c2)CCCCC1
6320,6341,CHEMBL204814,XQOCAAJLFFVLEP-QDSLRZTOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,12.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,7.920818753952375,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CC4=CC=CC=C4)N.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,N[C@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6321,6342,CHEMBL204814,XQOCAAJLFFVLEP-QDSLRZTOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,7.769551078621726,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@@H](CC4=CC=CC=C4)N.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,N[C@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6322,6343,CHEMBL381842,XQOCAAJLFFVLEP-ZXVJYWQYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,6.3,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI-55 from DAT,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,8.200659450546418,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H](CC4=CC=CC=C4)N.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,N[C@@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6323,6344,CHEMBL381842,XQOCAAJLFFVLEP-ZXVJYWQYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16509591.0,KI,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake,Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.,J. Med. Chem.,PUBLICATION,,7.886056647693162,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C[C@H](CC4=CC=CC=C4)N.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,N[C@@H](Cc1ccccc1)CN1CCC(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6324,6345,CHEMBL403148,XQRFKDJVDZKQDO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,7000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,CC(C)N1CCN(CC1)C(=O)C2=CC(=C(C=C2)OC3=CC=CC(=C3)OC)CNC,CNCc1cc(C(=O)N2CCN(C(C)C)CC2)ccc1Oc1cccc(OC)c1
6325,6346,CHEMBL1683895,XQUUVZDIAMCEHA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,384.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4156687756324695,CN(C)CC1(CCCCC1)C2=CC=CC=C2,CN(C)CC1(c2ccccc2)CCCCC1
6326,6347,CHEMBL19224,XQYZDYMELSJDRZ-UHFFFAOYSA-N,PAPAVERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC
6327,6348,CHEMBL19224,XQYZDYMELSJDRZ-UHFFFAOYSA-N,PAPAVERINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC
6328,6349,CHEMBL712,XRCFXMGQEVUZFC-UHFFFAOYSA-N,ANISINDIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1
6329,6350,CHEMBL712,XRCFXMGQEVUZFC-UHFFFAOYSA-N,ANISINDIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1
6330,6351,CHEMBL2179222,XRDVQWJPAZZLKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23006002.0,KI,=,3221.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,5.492009275180309,CC1=CN(C2=C1C=C(C=N2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1
6331,6352,CHEMBL1463,XRECTZIEBJDKEO-UHFFFAOYSA-N,FLUCYTOSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=O)NC(=C1F)N,Nc1[nH]c(=O)ncc1F
6332,6353,CHEMBL1463,XRECTZIEBJDKEO-UHFFFAOYSA-N,FLUCYTOSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=O)NC(=C1F)N,Nc1[nH]c(=O)ncc1F
6333,6354,CHEMBL397490,XRGOEISCAQSORF-GHMZBOCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,322.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.492144128304169,CN1CC[C@@H]([C@@H](C1)C(=O)OC)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@@H]1CN(C)CC[C@@H]1c1ccc(Cl)c(Cl)c1
6334,6355,CHEMBL397490,XRGOEISCAQSORF-GHMZBOCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,59400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,4.226213555018807,CN1CC[C@@H]([C@@H](C1)C(=O)OC)C2=CC(=C(C=C2)Cl)Cl,COC(=O)[C@@H]1CN(C)CC[C@@H]1c1ccc(Cl)c(Cl)c1
6335,6356,CHEMBL1171425,XRHNNEJZJBTDKD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,COCC1CNCCN1C2=CC3=C(C=C2)NN=C3,COCC1CNCCN1c1ccc2[nH]ncc2c1
6336,6357,CHEMBL420333,XRLXHADLAXWZDU-WVEVRRLPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,909.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,6.041436116778033,CN1C2CCC1C([C@H](C2)OC(C3=CC=C(C=C3)I)C4=CC=C(C=C4)I)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(I)cc1)c1ccc(I)cc1)N2C
6337,6358,CHEMBL503378,XROTXTXRLBZJNT-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,3340.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4762535331884346,CCOC(=O)N(CC1=CC=CC=C1C(C)C)[C@H]2CCNC2,CCOC(=O)N(Cc1ccccc1C(C)C)[C@H]1CCNC1
6338,6359,CHEMBL1683892,XRXPUZOKWCSSLL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,3639.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.439017944413765,CNCC1(CCCCC1)C2=CC(=C(C=C2)F)F,CNCC1(c2ccc(F)c(F)c2)CCCCC1
6339,6360,CHEMBL945,XSDQTOBWRPYKKA-UHFFFAOYSA-N,AMILORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,NC(N)=NC(=O)c1nc(Cl)c(N)nc1N
6340,6361,CHEMBL945,XSDQTOBWRPYKKA-UHFFFAOYSA-N,AMILORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,NC(N)=NC(=O)c1nc(Cl)c(N)nc1N
6341,6362,CHEMBL1512,XSFJVAJPIHIPKU-XWCQMRHXSA-N,FLUNISOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
6342,6363,CHEMBL1512,XSFJVAJPIHIPKU-XWCQMRHXSA-N,FLUNISOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
6343,6364,CHEMBL1643654,XSRDSAWNNVBILO-UMAGBFNSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,32.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.485452247339714,CC1=NOC(=C1)[C@H]2[C@@H](CC3CCC2S3)C4=CC=C(C=C4)Cl,Cc1cc([C@@H]2C3CCC(C[C@H]2c2ccc(Cl)cc2)S3)on1
6344,6365,CHEMBL1643664,XSRDSAWNNVBILO-VVBDHPJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,7.2,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.142667503568731,CC1=NOC(=C1)[C@H]2[C@H](CC3CCC2S3)C4=CC=C(C=C4)Cl,Cc1cc([C@@H]2C3CCC(C[C@@H]2c2ccc(Cl)cc2)S3)on1
6345,6366,CHEMBL1945126,XSYGBVSQKPLETJ-ANULTFPQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,13.49,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.869988050328097,CN1[C@@H]2CC[C@H]1[C@@H]([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@@H]1[C@@H](OC(c2ccc(F)cc2)c2ccc(F)cc2)C[C@H]2CC[C@@H]1N2C
6346,6367,CHEMBL327314,XSYGBVSQKPLETJ-JSRAGOMMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,1750.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.7569619513137065,CN1C2CCC1[C@@H]([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6347,6368,CHEMBL327314,XSYGBVSQKPLETJ-JSRAGOMMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,21900.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.6595558851598815,CN1C2CCC1[C@@H]([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6348,6369,CHEMBL607377,XSYGBVSQKPLETJ-NFYVFUGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,1750.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,5.7569619513137065,CN1[C@@H]2CCC1C([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6349,6370,CHEMBL607377,XSYGBVSQKPLETJ-NFYVFUGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,2040.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,5.690369832574102,CN1[C@@H]2CCC1C([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6350,6371,CHEMBL607377,XSYGBVSQKPLETJ-NFYVFUGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,3840.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,5.4156687756324695,CN1[C@@H]2CCC1C([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6351,6372,CHEMBL607377,XSYGBVSQKPLETJ-NFYVFUGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,5.050609993355088,CN1[C@@H]2CCC1C([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6352,6373,CHEMBL607377,XSYGBVSQKPLETJ-NFYVFUGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,2040.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.690369832574102,CN1[C@@H]2CCC1C([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6353,6374,CHEMBL607377,XSYGBVSQKPLETJ-NFYVFUGESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,3380.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.471083299722345,CN1[C@@H]2CCC1C([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6354,6375,CHEMBL310650,XSYGBVSQKPLETJ-NSKBAKJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,10.9,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,7.962573502059376,CN1C2CCC1[C@H]([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6355,6376,CHEMBL310650,XSYGBVSQKPLETJ-NSKBAKJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,10.9,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,7.962573502059376,CN1C2CCC1[C@H]([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6356,6377,CHEMBL310650,XSYGBVSQKPLETJ-NSKBAKJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,13500.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,4.869666231504994,CN1C2CCC1[C@H]([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6357,6378,CHEMBL607430,XSYGBVSQKPLETJ-OSIBBQKWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,11700.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,4.931814138253839,CN1[C@@H]2CCC1C([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6358,6379,CHEMBL607430,XSYGBVSQKPLETJ-OSIBBQKWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,21900.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,4.6595558851598815,CN1[C@@H]2CCC1C([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6359,6380,CHEMBL2373379,XSYGBVSQKPLETJ-QEMIJWRASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,10.9,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.962573502059376,CN1[C@H]2CCC1C([C@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)C1C2CC[C@@H](C[C@@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6360,6381,CHEMBL607431,XSYGBVSQKPLETJ-RQZKWSAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8027983.0,IC50,=,3380.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from monkey dopamine transporter,The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites.,J. Med. Chem.,PUBLICATION,,5.471083299722345,CN1[C@@H]2CCC1C[C@H]([C@@H]2C(=O)OC)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COC(=O)[C@H]1[C@H](OC(c2ccc(F)cc2)c2ccc(F)cc2)CC2CC[C@H]1N2C
6361,6382,CHEMBL89284,XSYGBVSQKPLETJ-VFUGHAIPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,3840.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.4156687756324695,CN1C2CCC1[C@@H]([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6362,6383,CHEMBL89284,XSYGBVSQKPLETJ-VFUGHAIPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,8900.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,5.050609993355088,CN1C2CCC1[C@@H]([C@@H](C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@H]1OC(c1ccc(F)cc1)c1ccc(F)cc1)N2C
6363,6384,CHEMBL259765,XSZZVXRYXJUWCA-QZTJIDSGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=CC(=C1)F)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,COc1cc(F)ccc1O[C@H](c1ccccc1)[C@H]1CNCCO1
6364,6385,CHEMBL260258,XSZZVXRYXJUWCA-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,3080.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.511449283499557,COC1=C(C=CC(=C1)F)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,COc1cc(F)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
6365,6386,CHEMBL333331,XTEKMJCKVNQZRJ-WVEVRRLPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,91.4,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.0390538042661674,CN1C2CCC1C([C@H](C2)OC(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccc(Cl)cc1)c1ccc(Cl)cc1)N2C
6366,6387,CHEMBL255448,XTOFIVJPRPHPAF-WCQYABFASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CCOC)C(=O)[C@]1(C[C@H]1CN)C2=CSC=C2,COCCN(C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN
6367,6388,CHEMBL360328,XTTZERNUQAFMOF-QMMMGPOBSA-N,LORCASERIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19284718.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,J. Med. Chem.,PUBLICATION,,5.0,C[C@H]1CNCCC2=C1C=C(C=C2)Cl,C[C@H]1CNCCc2ccc(Cl)cc21
6368,6389,CHEMBL294105,XTYJQBUILMRWGE-GZAGPRJLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,=,910.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for inhibition of [3H]DA uptake in HEK-hDAT cells expressing Human dopamine Transporter,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,6.040958607678906,COC(=O)[C@@H]1[C@@H]\2C[C@H]3CCC1N3C/C2=C\C4=CC=CC=C4,COC(=O)[C@H]1C2CC[C@@H]3C[C@@H]1/C(=C/c1ccccc1)CN23
6369,6390,CHEMBL294105,XTYJQBUILMRWGE-GZAGPRJLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,=,1570.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for binding affinity to dopamine transporter using [125I]RTI-55 as a radioligand in HEK cells expressing human transporters.,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,5.804100347590767,COC(=O)[C@@H]1[C@@H]\2C[C@H]3CCC1N3C/C2=C\C4=CC=CC=C4,COC(=O)[C@H]1C2CC[C@@H]3C[C@@H]1/C(=C/c1ccccc1)CN23
6370,6391,CHEMBL31,XUBOMFCQGDBHNK-UHFFFAOYSA-N,GATIFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
6371,6392,CHEMBL31,XUBOMFCQGDBHNK-UHFFFAOYSA-N,GATIFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
6372,6393,CHEMBL67387,XUBVUMLIQBPHGD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,27.8,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,7.555955204081924,CN1C2CCC1C(C(C2)C3=CC(=CC=C3)I)C(=O)OC,COC(=O)C1C(c2cccc(I)c2)CC2CCC1N2C
6373,6394,CHEMBL67387,XUBVUMLIQBPHGD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15080991.0,KI,=,182.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to dopamine transporter in membranes of cells selectively expressing the human genes for DAT,Synthesis and monoamine transporter affinity of 3'-analogs of 2-beta-carbomethoxy-3-beta-(4'-iodophenyl)tropane (beta-CIT).,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.739928612014924,CN1C2CCC1C(C(C2)C3=CC(=CC=C3)I)C(=O)OC,COC(=O)C1C(c2cccc(I)c2)CC2CCC1N2C
6374,6395,CHEMBL461727,XUCIJNAGGSZNQT-JHSLDZJXSA-N,AMYGDALIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,N#C[C@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)c1ccccc1
6375,6396,CHEMBL461727,XUCIJNAGGSZNQT-JHSLDZJXSA-N,AMYGDALIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,N#C[C@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)c1ccccc1
6376,6397,CHEMBL902,XUFQPHANEAPEMJ-UHFFFAOYSA-N,FAMOTIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1
6377,6398,CHEMBL902,XUFQPHANEAPEMJ-UHFFFAOYSA-N,FAMOTIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1
6378,6399,CHEMBL1566,XUFXOAAUWZOOIT-SXARVLRPSA-N,ACARBOSE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
6379,6400,CHEMBL1566,XUFXOAAUWZOOIT-SXARVLRPSA-N,ACARBOSE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
6380,6401,CHEMBL54943,XUJNEKJLAYXESH-UHFFFAOYSA-N,CYSTEINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S,NC(CS)C(=O)O
6381,6402,CHEMBL1829335,XUKROCVZGZNGSI-CQSZACIVSA-N,IRDABISANT,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21634396.0,IC50,=,9400.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human dopamine transporter,"Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.",J. Med. Chem.,PUBLICATION,,5.026872146400302,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1
6382,6403,CHEMBL1829335,XUKROCVZGZNGSI-CQSZACIVSA-N,IRDABISANT,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21634396.0,KI,=,11000.0,NM,,,,,,,,,,,,,,,Inhibition of dopamine transporter,"Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.",J. Med. Chem.,PUBLICATION,,4.9586073148417755,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1
6383,6404,CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
6384,6405,CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
6385,6406,CHEMBL1945243,XULNFQZLJQACOK-IDCNUPLLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,371.54,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,6.429994423238213,CCCCC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3)I,CCCCc1ccc([C@H]2C[C@@H]3CC[C@@H](N3)[C@H]2C(=O)OC)cc1I
6386,6407,CHEMBL214121,XURYNEATXQVNNR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,2300.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC(=CC=C3)F,Fc1cccc(C(Cc2ccccc2Cl)N2CCNCC2)c1
6387,6408,CHEMBL572350,XUWDFILRONYSDW-PMACEKPBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CCNC[C@@H]([C@H](C1=CC=CC=C1)N2C=C(C3=CC=CC=C32)C)O,CCNC[C@H](O)[C@H](c1ccccc1)n1cc(C)c2ccccc21
6388,6409,CHEMBL149878,XVELJKVGYZEBLI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Affinity to displace binding of [3H]WIN-35428 to dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C4=CN=CC=C4,c1cncc(-c2c3ccccc3cc3ccccc23)c1
6389,6410,CHEMBL149878,XVELJKVGYZEBLI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake evaluated at the dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C4=CN=CC=C4,c1cncc(-c2c3ccccc3cc3ccccc23)c1
6390,6411,CHEMBL488424,XVISEQWOYJEMBG-CABCVRRESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18550369.0,IC50,=,2400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT in human HEK293 cells,"Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.619788758288393,C1[C@H](C2=CC=CC=C2[C@H]1OC3=CC=C(C=C3)Cl)N,N[C@@H]1C[C@H](Oc2ccc(Cl)cc2)c2ccccc21
6391,6412,CHEMBL3094313,XVKBXJCHXRLYAQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,45.5,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,45.5,C1=CC(=CC(=C1)OC(F)(F)F)COC2=CC=C(C=C2)CN.Cl,NCc1ccc(OCc2cccc(OC(F)(F)F)c2)cc1
6392,6413,CHEMBL1171434,XVOYSCVBGLVSOL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12649361.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S(=O)(=O)O,NC(CS(=O)(=O)O)C(=O)O
6393,6414,CHEMBL69380,XVRWPBKYLFMIHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,1260.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,5.8996294548824375,CN(CCC1=CC=C(C=C1)F)CC2CCCN(C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,CN(CCc1ccc(F)cc1)CC1CCCN(CCOC(c2ccccc2)c2ccccc2)C1
6394,6415,CHEMBL69380,XVRWPBKYLFMIHN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,90.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,7.045757490560675,CN(CCC1=CC=C(C=C1)F)CC2CCCN(C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4,CN(CCc1ccc(F)cc1)CC1CCCN(CCOC(c2ccccc2)c2ccccc2)C1
6395,6416,CHEMBL1173598,XVUDIIQDUSBBTF-IINYFYTJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,2870.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,5.542118103266008,C[C@H]1[C@@](OCC(N1C)(C)C)(C2=CC=C(C=C2)Cl)O,C[C@@H]1N(C)C(C)(C)CO[C@@]1(O)c1ccc(Cl)cc1
6396,6417,CHEMBL3334503,XWALEBCOFGKXBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,79.5,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,79.5,COC1=C(C2=C(C=C1)C=C(C=C2)C(CCN3CCC(=CC3)CC4=CC=CC=C4)N5CCCC5)Cl,COc1ccc2cc(C(CCN3CC=C(Cc4ccccc4)CC3)N3CCCC3)ccc2c1Cl
6397,6418,CHEMBL1644478,XWDJHMXLIXWQGQ-PTEHBNRSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21112782.0,IC50,=,750.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at DAT expressed in HEK293 cells scintillation counting,"The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1249387366083,C1C[C@H]2CC(C[C@@H]1N2)OC3=CC(=CC=C3)F,Fc1cccc(OC2C[C@@H]3CC[C@H](C2)N3)c1
6398,6419,CHEMBL551474,XWEOTQVRTMMRCV-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,IC5,=,6318.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,5.199420378430871,CC(C)N1C2=C(C(=CC=C2)F)N(C1=O)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1c(=O)n(C(C)C)c2cccc(F)c21
6399,6420,CHEMBL551474,XWEOTQVRTMMRCV-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,27.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,27.0,CC(C)N1C2=C(C(=CC=C2)F)N(C1=O)[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1c(=O)n(C(C)C)c2cccc(F)c21
6400,6421,CHEMBL411262,XWFSWRARAVLBFN-ICSRJNTNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17983754.0,KI,>,9000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125]RTI35 from human DAT expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter.",Bioorg. Med. Chem.,PUBLICATION,,5.045757490560675,C1CO[C@@H](CN1)[C@H](C2=CC=CC=C2)SC3=CC=CC=C3OCCCF,FCCCOc1ccccc1S[C@@H](c1ccccc1)[C@@H]1CNCCO1
6401,6422,CHEMBL256135,XWGDWRZGNMYDDL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CNCC1=C(C=CN=C1)OC2=C(C=C(C=C2)Cl)Br,CNCc1cnccc1Oc1ccc(Cl)cc1Br
6402,6423,CHEMBL239616,XWGLMCFWNRNHDU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23707254.0,KI,=,92.0,NM,,,,,,,,,,,,,,,Antagonist activity at DAT (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.036212172654443,C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C4=CC(=CC=C4)Br,O=C(c1cccc(Br)c1)N1c2ccccc2Sc2ccccc21
6403,6424,CHEMBL1683897,XWHBDOLRNWCIGO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,6043.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.218747405751544,C1CCC(CC1)(CN)C2=CC=CC3=CC=CC=C32,NCC1(c2cccc3ccccc23)CCCCC1
6404,6425,CHEMBL1235242,XWHHYOYVRVGJJY-QMMMGPOBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)F,N[C@@H](Cc1ccc(F)cc1)C(=O)O
6405,6426,CHEMBL1235242,XWHHYOYVRVGJJY-QMMMGPOBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)F,N[C@@H](Cc1ccc(F)cc1)C(=O)O
6406,6427,CHEMBL2430676,XWQSXOFSOWLMBI-DJIMGWMZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,5.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC2=C(C=CC(=C2Cl)Cl)[C@H]3[C@@H]1NC[C@@H]3C4=CC=CC=C4,Clc1ccc2c(c1Cl)CC[C@H]1NC[C@H](c3ccccc3)[C@@H]21
6407,6428,CHEMBL1760,XWTYSIMOBUGWOL-UHFFFAOYSA-N,TERBUTALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,CC(C)(C)NCC(O)c1cc(O)cc(O)c1
6408,6429,CHEMBL1760,XWTYSIMOBUGWOL-UHFFFAOYSA-N,TERBUTALINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,CC(C)(C)NCC(O)c1cc(O)cc(O)c1
6409,6430,CHEMBL194907,XWULIDJGQOXILD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,5.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)F,CNCCCC1Cc2ccccc2N(c2ccc(F)cc2)C1=O
6410,6431,CHEMBL194907,XWULIDJGQOXILD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)F,CNCCCC1Cc2ccccc2N(c2ccc(F)cc2)C1=O
6411,6432,CHEMBL397520,XWZLDADSUCQSKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1660000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,2.779891911959945,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)OC(F)(F)F,COC(=O)C1=C(c2ccc(OC(F)(F)F)cc2)CCCC1
6412,6433,CHEMBL397520,XWZLDADSUCQSKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)OC(F)(F)F,COC(=O)C1=C(c2ccc(OC(F)(F)F)cc2)CCCC1
6413,6434,CHEMBL457966,XXFWDPHWYVNJQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,2532.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.596536298654684,C1CC(OC1CCC2=CC=C(C=C2)O)CCN,NCCC1CCC(CCc2ccc(O)cc2)O1
6414,6435,CHEMBL457966,XXFWDPHWYVNJQG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,5498.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.25979526449255,C1CC(OC1CCC2=CC=C(C=C2)O)CCN,NCCC1CCC(CCc2ccc(O)cc2)O1
6415,6436,CHEMBL549761,XXHZUORXKGMGAL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,>,2920.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5346171485515825,CCOC1=CC=CC=C1OC(C2CCNCC2)C3=CN=CC=C3,CCOc1ccccc1OC(c1cccnc1)C1CCNCC1
6416,6437,CHEMBL51697,XXPANQJNYNUNES-AWEZNQCLSA-N,(S)-NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,43.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.366531544420414,CN1C[C@H](C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2[C@H](c2ccccc2)C1
6417,6438,CHEMBL51697,XXPANQJNYNUNES-AWEZNQCLSA-N,(S)-NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,7.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.154901959985743,CN1C[C@H](C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2[C@H](c2ccccc2)C1
6418,6439,CHEMBL400964,XXPANQJNYNUNES-CQSZACIVSA-N,(R)-NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,13400.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.872895201635194,CN1C[C@@H](C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2[C@@H](c2ccccc2)C1
6419,6440,CHEMBL400964,XXPANQJNYNUNES-CQSZACIVSA-N,(R)-NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,450.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,6.346787486224656,CN1C[C@@H](C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2[C@@H](c2ccccc2)C1
6420,6441,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,40.2,NM,,,,,,,,,,,,,,,,,,,,7.39577394691553,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6421,6442,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,42.0,NM,,,,,,,,,,,,,,,,,,,,7.376750709602098,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6422,6443,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,53.0,NM,,,,,,,,,,,,,,,,,,,,7.275724130399211,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6423,6444,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,56.4,NM,,,,,,,,,,,,,,,,,,,,7.248720896016657,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6424,6445,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8496700.0,ACTIVITY,=,75.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-from cocaine site of dopamine transporter assessed as specific binding relative to total binding,The role of receptor binding in drug discovery.,J. Nat. Prod.,PUBLICATION,,75.0,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6425,6446,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8496700.0,KI,=,23.5,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-from cocaine site of dopamine transporter,The role of receptor binding in drug discovery.,J. Nat. Prod.,PUBLICATION,,7.628932137728263,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6426,6447,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,56.0,NM,,,,,,,,,,,,,,,,,,,,7.251811972993798,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6427,6448,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12431845.0,KI,=,53.0,NM,,,,,,,,,,,,,,,,,,,,7.275724130399211,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6428,6449,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,30.2,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.519993057042849,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6429,6450,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,31.62,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6430,6451,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,7.500038134403809,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6431,6452,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,84.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.075720713938117,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6432,6453,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,281.84,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.549997369826814,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6433,6454,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,109.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.962573502059376,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6434,6455,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,10.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.0,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
6435,6456,CHEMBL234926,XXROGKLTLUQVRX-UHFFFAOYSA-N,ALLYL ALCOHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCO,C=CCO
6436,6457,CHEMBL234926,XXROGKLTLUQVRX-UHFFFAOYSA-N,ALLYL ALCOHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCO,C=CCO
6437,6458,CHEMBL1535,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,HYDROXYCHLOROQUINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
6438,6459,CHEMBL1535,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,HYDROXYCHLOROQUINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
6439,6460,CHEMBL2321990,XXTLAOZBJDRYIU-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,91.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.040958607678906,C1CCNC[C@](C1)(CCO)C2=CC(=C(C=C2)Cl)Cl,OCC[C@@]1(c2ccc(Cl)c(Cl)c2)CCCCNC1
6440,6461,CHEMBL2326695,XXTLAOZBJDRYIU-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4.2,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,8.3767507096021,C1CCNC[C@@](C1)(CCO)C2=CC(=C(C=C2)Cl)Cl,OCC[C@]1(c2ccc(Cl)c(Cl)c2)CCCCNC1
6441,6462,CHEMBL485549,XXUXXCZCUGIGPP-WLRTZDKTSA-N,NIFURSOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O,O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O
6442,6463,CHEMBL485549,XXUXXCZCUGIGPP-WLRTZDKTSA-N,NIFURSOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O,O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O
6443,6464,CHEMBL255112,XXWKAPSDJYNICL-SVBPBHIXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18243691.0,INHIBITION,=,32.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,"Potent, selective MCH-1 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,32.0,CC1=CC2=C(C=C1)N(C(=N2)C)[C@H]3CCN(C[C@@H]3OC)CCCC4=CC(=CC=C4)NC(=O)C5CC5,CO[C@H]1CN(CCCc2cccc(NC(=O)C3CC3)c2)CC[C@@H]1n1c(C)nc2cc(C)ccc21
6444,6465,CHEMBL844,XYLJNLCSTIOKRM-UHFFFAOYSA-N,BRIMONIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,Brc1c(NC2=NCCN2)ccc2nccnc12
6445,6466,CHEMBL844,XYLJNLCSTIOKRM-UHFFFAOYSA-N,BRIMONIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,Brc1c(NC2=NCCN2)ccc2nccnc12
6446,6467,CHEMBL401621,XYNHEKMBRVZVQR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,6200.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2076083105017466,CCN(CC)C(=O)C1(CC1CNCC2=CC=CC=N2)C3=CC=CC=C3,CCN(CC)C(=O)C1(c2ccccc2)CC1CNCc1ccccn1
6447,6468,CHEMBL388257,XYPXWICAIAFXBP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,79.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.102372908709557,CCOC(=O)C1=C(CCNC1)C2=CC3=CC=CC=C3C=C2,CCOC(=O)C1=C(c2ccc3ccccc3c2)CCNC1
6448,6469,CHEMBL2180074,XYRJHICAYZEKEV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23025719.0,KI,=,1200.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors.",J. Med. Chem.,PUBLICATION,,5.920818753952375,CC(C1=NC2=C(C=NN2C3CCOCC3)C(=O)N1)N4CC(C4)OC5=CC=C(C=C5)F,CC(c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1)N1CC(Oc2ccc(F)cc2)C1
6449,6470,CHEMBL3608450,XYYAWEJOUNEPTR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26227772.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) at 10 uM,C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CN1CC(C2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OC)OC)C6=CC=CC=C6,COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4
6450,6471,CHEMBL246955,XYYGFCDTBHAUSN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17127059.0,KI,=,29.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-uptake in human DAT expressed in CHO cells,Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.5376020021010435,CN1CC(C2=C(C1)C=C(C=C2)OCCCN3CCOCC3)C4=CC=C(C=C4)SC,CSc1ccc(C2CN(C)Cc3cc(OCCCN4CCOCC4)ccc32)cc1
6451,6472,CHEMBL2171417,XZKCSWMXTDEREX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,35.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.455931955649724,C1C(CN1)C(C2=CC3=CC=CC=C3C=C2)OC4=CC=CC=C4.Cl,c1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1
6452,6473,CHEMBL2171417,XZKCSWMXTDEREX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,64.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,64.0,C1C(CN1)C(C2=CC3=CC=CC=C3C=C2)OC4=CC=CC=C4.Cl,c1ccc(OC(c2ccc3ccccc3c2)C2CNC2)cc1
6453,6474,CHEMBL1169524,XZQBKIYIWLHZIO-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CNC(=O)CN)C2=CC=CC=C2,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CNC(=O)CN
6454,6475,CHEMBL3310498,XZQIYFJCZFNASH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,55.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,55.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)Cl,Clc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6455,6476,CHEMBL3310498,XZQIYFJCZFNASH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)Cl,Clc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6456,6477,CHEMBL3310498,XZQIYFJCZFNASH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)Cl,Clc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6457,6478,CHEMBL1214060,XZWRXMFAFBSAJC-OWANBTPYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,=,2.7,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,8.568636235841014,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3C/C=C/CF,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(C)cc1)N2C/C=C/CF
6458,6479,CHEMBL1214060,XZWRXMFAFBSAJC-OWANBTPYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,IC50,=,2.4,NM,,,,,,,,,,,,,,,Inhibition of DAT,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C(=O)OC)N3C/C=C/CF,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(C)cc1)N2C/C=C/CF
6459,6480,CHEMBL1431,XZWYZXLIPXDOLR-UHFFFAOYSA-N,METFORMIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=N)N=C(N)N,CN(C)C(=N)N=C(N)N
6460,6481,CHEMBL1431,XZWYZXLIPXDOLR-UHFFFAOYSA-N,METFORMIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=N)N=C(N)N,CN(C)C(=N)N=C(N)N
6461,6482,CHEMBL1788140,YABYABUWFUDQKN-GUUGRXDUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,19.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,7.721246399047171,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.C(=C\C(=O)O)\C(=O)O,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
6462,6483,CHEMBL1788140,YABYABUWFUDQKN-GUUGRXDUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,200.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.698970004336019,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.C(=C\C(=O)O)\C(=O)O,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
6463,6484,CHEMBL1788140,YABYABUWFUDQKN-GUUGRXDUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,11.0,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,11.0,CN(C)[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.C(=C\C(=O)O)\C(=O)O,CN(C)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
6464,6485,CHEMBL2029055,YAGXEFDTWYZUEO-PHHSGPBWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,>,10000000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.0,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)OC,CNCC[C@H](Oc1cccc2c(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)c(OC)ccc12)c1cccs1
6465,6486,CHEMBL1944824,YANGDSFZAMQEBP-MBHMRJJTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,0.501,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,9.300162274132754,COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/CF)C[C@@H]1C3=CC=C(C=C3)I,COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2C/C=C/CF
6466,6487,CHEMBL1214059,YANGDSFZAMQEBP-PMWAWBRWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20597489.0,KI,=,0.5,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT,"Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.",J. Med. Chem.,PUBLICATION,,9.30102999566398,COC(=O)[C@H]1[C@H](CC2CCC1N2C/C=C/CF)C3=CC=C(C=C3)I,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(I)cc1)N2C/C=C/CF
6467,6488,CHEMBL459644,YAOMVDAPALQFPR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,35.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,35.0,C1CCC(CC1)(C(CN2CCNCC2)C3=CC=C(C=C3)Cl)O.Cl.Cl,OC1(C(CN2CCNCC2)c2ccc(Cl)cc2)CCCCC1
6468,6489,CHEMBL121,YASAKCUCGLMORW-UHFFFAOYSA-N,ROSIGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
6469,6490,CHEMBL121,YASAKCUCGLMORW-UHFFFAOYSA-N,ROSIGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
6470,6491,CHEMBL1399,YBBLVLTVTVSKRW-UHFFFAOYSA-N,ANASTROZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
6471,6492,CHEMBL1399,YBBLVLTVTVSKRW-UHFFFAOYSA-N,ANASTROZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
6472,6493,CHEMBL2114227,YBJTZWKCKAIXPV-QMENKUSVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,14.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.85078088734462,CN1C2CC(=O)C1[C@@H](C[C@H]2C3=CC(=C(C=C3)Cl)Cl)C(=O)OC,COC(=O)[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)C2CC(=O)C1N2C
6473,6494,CHEMBL411693,YBLHYQJAYABBGT-SJCJKPOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,830.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.080921907623925,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)[N+](=O)[O-])C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc([N+](=O)[O-])cc21
6474,6495,CHEMBL574317,YBLWMYFOFQPXMI-UEXOWVPHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,91.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.040958607678906,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)S(=O)C)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc([S+](C)[O-])cc1)N2C
6475,6496,CHEMBL448689,YBOXDTVMHIUYEG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,6100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989234,CN(C)CC1=C(C=CC(=C1)Cl)OC2=CC=C(C=C2)SC,CSc1ccc(Oc2ccc(Cl)cc2CN(C)C)cc1
6476,6497,CHEMBL85728,YBRVSVVVWCFQMG-UHFFFAOYSA-N,"4,4'-METHYLENEDIANILINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Nc1ccc(Cc2ccc(N)cc2)cc1
6477,6498,CHEMBL85728,YBRVSVVVWCFQMG-UHFFFAOYSA-N,"4,4'-METHYLENEDIANILINE",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Nc1ccc(Cc2ccc(N)cc2)cc1
6478,6499,CHEMBL357312,YBUFEUDZXKMCFS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Affinity to displace binding of [3H]WIN-35428 to dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C4=CC=NC=C4,c1ccc2c(-c3ccncc3)c3ccccc3cc2c1
6479,6500,CHEMBL357312,YBUFEUDZXKMCFS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake evaluated at the dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C4=CC=NC=C4,c1ccc2c(-c3ccncc3)c3ccccc3cc2c1
6480,6501,CHEMBL1812746,YBVYVIFNGYOFSX-MXYBEHONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,2.3,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.638272163982407,CC1=C(C=CC(=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3)Cl,COC(=O)[C@H]1[C@@H](c2ccc(Cl)c(C)c2)C[C@@H]2CC[C@H]1N2
6481,6502,CHEMBL1818459,YBZZUBMYXLOQMZ-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,25.12,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.599980364934843,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=CC(=N4)C#N,N#Cc1ccn(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
6482,6503,CHEMBL3673178,YCAOLYRUUFDEGF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,58.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.229884705212897,C1CN2CCC1(C3=C(C2)C=C(C=C3)N4CCOCC4)C5=CC=C(C=C5)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(N4CCOCC4)ccc23)cc1
6483,6504,CHEMBL280998,YCIMNLLNPGFGHC-UHFFFAOYSA-N,CATECHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)O)O,Oc1ccccc1O
6484,6505,CHEMBL280998,YCIMNLLNPGFGHC-UHFFFAOYSA-N,CATECHOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)O)O,Oc1ccccc1O
6485,6506,CHEMBL495778,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,PENICILLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)C1(C(=CC(=O)O1)OC)O,C=C(C)C1(O)OC(=O)C=C1OC
6486,6507,CHEMBL495778,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,PENICILLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)C1(C(=CC(=O)O1)OC)O,C=C(C)C1(O)OC(=O)C=C1OC
6487,6508,CHEMBL2336610,YCPGWXQYWPBVKD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23168018.0,KI,=,10900.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in COS7 cells after 3 mins by beta-counting,A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.962573502059376,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCC(=O)NC5=CC=CC(=C5)C6=CC7=C(C=C6)C(OC7)(CCCN(C)C)C8=CC=C(C=C8)F)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCC(=O)Nc4cccc(-c5ccc6c(c5)COC6(CCCN(C)C)c5ccc(F)cc5)c4)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
6488,6509,CHEMBL491754,YCWGZWYJTIJTHX-UHFFFAOYSA-N,KF-A5,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,5.0,CCN(CC)CCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31,CCN(CC)CCCCCn1c2ccccc2c(=O)c2ccccc21
6489,6510,CHEMBL466500,YDGFCJZXRYFURC-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,33.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,33.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC(=CC=C2)Cl)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1cccc(Cl)c1
6490,6511,CHEMBL566832,YDGOUEKZXBLUDG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC1=CC(=CC=C1)C(=O)C(C)NC(C)(C)C,Cc1cccc(C(=O)C(C)NC(C)(C)C)c1
6491,6512,CHEMBL566832,YDGOUEKZXBLUDG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC1=CC(=CC=C1)C(=O)C(C)NC(C)(C)C,Cc1cccc(C(=O)C(C)NC(C)(C)C)c1
6492,6513,CHEMBL566832,YDGOUEKZXBLUDG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,1470.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.832682665251824,CC1=CC(=CC=C1)C(=O)C(C)NC(C)(C)C,Cc1cccc(C(=O)C(C)NC(C)(C)C)c1
6493,6514,CHEMBL205082,YDIIDRWHPFMLGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,52.3,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.281498311132727,CCCC(C(=O)C1=CC=CC=C1)N2CCCC2,CCCC(C(=O)c1ccccc1)N1CCCC1
6494,6515,CHEMBL205082,YDIIDRWHPFMLGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,33.7,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.472370099128661,CCCC(C(=O)C1=CC=CC=C1)N2CCCC2,CCCC(C(=O)c1ccccc1)N1CCCC1
6495,6516,CHEMBL574544,YDNOASAJYGOBQG-CPWXKJDLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,28.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.552841968657781,COC(=O)[C@H]1[C@H](CC2CCC1N2)C3=CC=C(C=C3)SC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(SC)cc1)N2
6496,6517,CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
6497,6518,CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
6498,6519,CHEMBL432727,YDRFQAANTRDVRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,IC50,=,1401.0,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [3H]DA binding to dopamine (DAT) transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.8535618647142265,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
6499,6520,CHEMBL432727,YDRFQAANTRDVRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,KI,=,18.4,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [125I]RTI-55 binding to dopamine transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.735182176990462,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
6500,6521,CHEMBL432727,YDRFQAANTRDVRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,0.18,,,,,,,,,,,,,,,,Selectivity ratio determined of Ki human Dopamine transporter to Ki human Norepinephrine transporter,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.18,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
6501,6522,CHEMBL432727,YDRFQAANTRDVRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,76.3,,,,,,,,,,,,,,,,Ratio of uptake inhibition to binding affinity to human DAT (IC50/Ki),Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,76.3,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
6502,6523,CHEMBL3238481,YDSSSULQNVANSG-XKZIYDEJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=C2C=C(C(=C(C2=C(C=C1S(=O)(=O)O)N)O)N=NC3=C(C(=C(C(=C3F)F)C(=O)O)F)O)S(=O)(=O)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3c(O)c(F)c(C(=O)O)c(F)c3F)c(O)c12
6503,6524,CHEMBL1818461,YEAGKKNHGFQLKI-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,1.26,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,8.899629454882437,CC1=NN(C(=C1)C(F)(F)F)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1cc(C(F)(F)F)n(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1
6504,6525,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,879.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.056011124926227,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
6505,6526,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,699.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.155522824254319,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
6506,6527,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
6507,6528,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
6508,6529,CHEMBL531,YEHCICAEULNIGD-MZMPZRCHSA-N,PERGOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
6509,6530,CHEMBL531,YEHCICAEULNIGD-MZMPZRCHSA-N,PERGOLIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
6510,6531,CHEMBL257592,YEIRDCHLYKWPAP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCC1=C(C=CC(=C1)Cl)OC2=C(C=NC=C2)CNC,CCc1cc(Cl)ccc1Oc1ccncc1CNC
6511,6532,CHEMBL1683893,YEMZPAKBIRTBDG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,546.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.262807357295263,CN(C)CC1(CCCCC1)C2=CC(=CC=C2)F,CN(C)CC1(c2cccc(F)c2)CCCCC1
6512,6533,CHEMBL544370,YEPHLOVPJHBBRN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,1.09,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 radioligand binding to the Dopamine Transporter in guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.962573502059378,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC5=C(C=C4)OCO5)O.Cl,OC1(c2ccc3c(c2)OCO3)c2ccccc2C2=NCCCN21
6513,6534,CHEMBL544370,YEPHLOVPJHBBRN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,2.21,NM,,,,,,,,,,,,,,,Ability to block the uptake of 5-HT at the Dopamine transporter of HEK cells expressing cDNA for the human transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.655607726314889,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC5=C(C=C4)OCO5)O.Cl,OC1(c2ccc3c(c2)OCO3)c2ccccc2C2=NCCCN21
6514,6535,CHEMBL544370,YEPHLOVPJHBBRN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,2.55,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.593459819566045,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC5=C(C=C4)OCO5)O.Cl,OC1(c2ccc3c(c2)OCO3)c2ccccc2C2=NCCCN21
6515,6536,CHEMBL3331471,YEQRNZCSYYLDSS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,8.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,8.0,C1C(CN1)N(CCC2=CC=CC=C2)C3=CC=CC=C3,c1ccc(CCN(c2ccccc2)C2CNC2)cc1
6516,6537,CHEMBL1643655,YEUFVHULUPJOQC-UMAGBFNSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,46.6,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.331614083310001,CC1=NOC(=C1)[C@H]2[C@@H](CC3CCC2S3)C4=CC=C(C=C4)Br,Cc1cc([C@@H]2C3CCC(C[C@H]2c2ccc(Br)cc2)S3)on1
6517,6538,CHEMBL1643665,YEUFVHULUPJOQC-VVBDHPJYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,14.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321763,CC1=NOC(=C1)[C@H]2[C@H](CC3CCC2S3)C4=CC=C(C=C4)Br,Cc1cc([C@@H]2C3CCC(C[C@@H]2c2ccc(Br)cc2)S3)on1
6518,6539,CHEMBL148489,YFCWBKBNFCDPDF-UHFFFAOYSA-N,N-(3-PYRIDYLMETHYL)PYRROLIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22607684.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT at 10 uM,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCN(C1)CC2=CN=CC=C2,c1cncc(CN2CCCC2)c1
6519,6540,CHEMBL3310483,YFFZLXAPKOKACC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,82.5,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0835460514500745,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)Cl,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl
6520,6541,CHEMBL3310483,YFFZLXAPKOKACC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,87.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,87.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)Cl,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl
6521,6542,CHEMBL3310483,YFFZLXAPKOKACC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)Cl,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl
6522,6543,CHEMBL3310483,YFFZLXAPKOKACC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)F)OC3=CC(=CC=C3)Cl,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl
6523,6544,CHEMBL1373,YFGHCGITMMYXAQ-UHFFFAOYSA-N,MODAFINIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24494745.0,KI,=,13000.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity to wild type human DAT expressed in African green monkey COS7 cells assessed as inhibition of [3H]-dopamine uptake after 5 mins by beta-scintillation counting analysis,Elucidation of Structural Elements for Selectivity across Monoamine Transporters: Novel 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues.,J. Med. Chem.,PUBLICATION,,4.886056647693163,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1
6524,6545,CHEMBL1373,YFGHCGITMMYXAQ-UHFFFAOYSA-N,MODAFINIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1832.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.73707453066817,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1
6525,6546,CHEMBL1373,YFGHCGITMMYXAQ-UHFFFAOYSA-N,MODAFINIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1456.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.836838625022982,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1
6526,6547,CHEMBL2171419,YFIDHTXSPXGKFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,IC50,=,148.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.8297382846050425,C1C(CN1)C(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3.Cl,Fc1cc(C(Oc2ccccc2)C2CNC2)ccc1Cl
6527,6548,CHEMBL2171419,YFIDHTXSPXGKFL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22938049.0,INHIBITION,=,30.0,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake at 0.1 uM after 15 mins by fluorescence assay,Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,30.0,C1C(CN1)C(C2=CC(=C(C=C2)Cl)F)OC3=CC=CC=C3.Cl,Fc1cc(C(Oc2ccccc2)C2CNC2)ccc1Cl
6528,6549,CHEMBL562569,YFOORSARAMYVQM-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,=,3720.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.429457060118103,C1CCC(C1)C2=CC=CC=C2C(=O)N(CC3CCC3)[C@H]4CCNC4,O=C(c1ccccc1C1CCCC1)N(CC1CCC1)[C@H]1CCNC1
6529,6550,CHEMBL365092,YFRZQRLMBALBGA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15546718.0,IC50,=,8.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to human dopamine transporter (hDAT),Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.096910013008056,COC(=O)C1=C(CC2CCC1S2)C3=CC4=CC=CC=C4C=C3,COC(=O)C1=C(c2ccc3ccccc3c2)CC2CCC1S2
6530,6551,CHEMBL1173771,YFWBKVXUOIZZMD-QMHKHESXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,453.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,6.3439017979871695,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC(=C2)C3=CC4=CC=CC=C4C=C3)O,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(-c2ccc3ccccc3c2)c1
6531,6552,CHEMBL1085831,YFXILLLEWBTOSN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,INHIBITION,=,40.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 10 uM,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,40.0,CNCCCCN1C2=CC=CC=C2N(S1(=O)=O)C3=CC=CC=C3F,CNCCCCN1c2ccccc2N(c2ccccc2F)S1(=O)=O
6532,6553,CHEMBL424,YGSDEFSMJLZEOE-UHFFFAOYSA-N,SALICYLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)O)O,O=C(O)c1ccccc1O
6533,6554,CHEMBL424,YGSDEFSMJLZEOE-UHFFFAOYSA-N,SALICYLIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)O)O,O=C(O)c1ccccc1O
6534,6555,CHEMBL2430678,YGVBSRWLELWASD-KZNAEPCWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,5.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC2=C(C=C(C=C2)Cl)[C@H]3[C@@H]1NC[C@@H]3C4=CC=CC=C4,Clc1ccc2c(c1)[C@@H]1[C@@H](c3ccccc3)CN[C@@H]1CC2
6535,6556,CHEMBL377714,YGVNVXMPAVCLBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)N(C)C2=CC=CC=C2CN(C)C)N,Cc1ccc(N(C)c2ccccc2CN(C)C)c(N)c1
6536,6557,CHEMBL2430699,YHCGXHXZKOJYFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,120.9,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.917573699139228,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC(=C(C=C4)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc2ccccc2c1
6537,6558,CHEMBL2430699,YHCGXHXZKOJYFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,82.6,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,82.6,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC(=C(C=C4)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc2ccccc2c1
6538,6559,CHEMBL2430699,YHCGXHXZKOJYFY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,86.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,86.0,C1C(C(C(=O)N1)C2=CC3=CC=CC=C3C=C2)C4=CC(=C(C=C4)Cl)Cl,O=C1NCC(c2ccc(Cl)c(Cl)c2)C1c1ccc2ccccc2c1
6539,6560,CHEMBL2337591,YHCLEHAMAKETBI-SJLPKXTDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,125.89,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,CC1=CC=CC=C1O[C@@H]([C@@H]2CCNC2)C3=CC=CC=C3,Cc1ccccc1O[C@H](c1ccccc1)[C@@H]1CCNC1
6540,6561,CHEMBL2337590,YHCLEHAMAKETBI-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,158.49,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,CC1=CC=CC=C1O[C@H]([C@H]2CCNC2)C3=CC=CC=C3,Cc1ccccc1O[C@@H](c1ccccc1)[C@H]1CCNC1
6541,6562,CHEMBL567933,YHNAHEPHKZYDTN-SECBINFHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN([C@@H]1CCNC1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CN(C(=O)c1ccc(Cl)c(Cl)c1)[C@@H]1CCNC1
6542,6563,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
6543,6564,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
6544,6565,CHEMBL491889,YHXSELHUXJAOLR-UHFFFAOYSA-N,KF-A6,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,5.0,CCN(CC)CCCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31,CCN(CC)CCCCCCn1c2ccccc2c(=O)c2ccccc21
6545,6566,CHEMBL462401,YIEXSVBTWQZEGZ-MSOLQXFVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,2300.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,CC1=CC=CC=C1O[C@@H]2C3=CC=CC=C3C[C@@]2(CNC)O,CNC[C@@]1(O)Cc2ccccc2[C@H]1Oc1ccccc1C
6546,6567,CHEMBL455448,YIEXSVBTWQZEGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,2700.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.568636235841013,CC1=CC=CC=C1OC2C3=CC=CC=C3CC2(CNC)O,CNCC1(O)Cc2ccccc2C1Oc1ccccc1C
6547,6568,CHEMBL507359,YIEXSVBTWQZEGZ-ZWKOTPCHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954981.0,IC50,=,1600.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake at human DAT transfected in HEK cells,Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344076,CC1=CC=CC=C1O[C@H]2C3=CC=CC=C3C[C@]2(CNC)O,CNC[C@]1(O)Cc2ccccc2[C@@H]1Oc1ccccc1C
6548,6569,CHEMBL1645609,YIGLINOPTZCHQC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,6460.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.189767482004916,CC1=C(C(=CC=C1)F)OC2=C(C(=CC=C2)F)OC3CCNCC3,Cc1cccc(F)c1Oc1cccc(F)c1OC1CCNCC1
6549,6570,CHEMBL235351,YIHHXEULFIHNGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,32200.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,4.492144128304169,CC1=CC(=C(C=C1C)C2=C(C3CCC2C3)C(=O)OC)C,COC(=O)C1=C(c2cc(C)c(C)cc2C)C2CCC1C2
6550,6571,CHEMBL534723,YIQFFQJVNKNCNB-FSRHSHDFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCOC1=CC=CC=C1C[C@H](C2=CC=CC=C2)N3CCNCC3.Cl,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1
6551,6572,CHEMBL540107,YIQFFQJVNKNCNB-FYZYNONXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CCOC1=CC=CC=C1C[C@@H](C2=CC=CC=C2)N3CCNCC3.Cl,CCOc1ccccc1C[C@@H](c1ccccc1)N1CCNCC1
6552,6573,CHEMBL273157,YIRWGCANORBOOM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,4000.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CC1=C(C=CC(=C1)OC2=C(C=C(C=C2)C(=O)N3CCN(CC3)C(C)C)CNC)SC,CNCc1cc(C(=O)N2CCN(C(C)C)CC2)ccc1Oc1ccc(SC)c(C)c1
6553,6574,CHEMBL2430690,YIXJHLSDNZJSDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,IC50,=,17.3,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.761953896871206,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccccc1Cl
6554,6575,CHEMBL2430690,YIXJHLSDNZJSDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,93.8,%,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,93.8,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccccc1Cl
6555,6576,CHEMBL2430690,YIXJHLSDNZJSDC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,96.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,96.0,C1C(C(C(=O)N1)C2=CC=CC=C2Cl)C3=CC(=CC=C3)Cl,O=C1NCC(c2cccc(Cl)c2)C1c1ccccc1Cl
6556,6577,CHEMBL132962,YJFUNBFSTGZINW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,125.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.903089986991943,CC1(C2=CC=CC=C2C3=NCCCN31)C4=CC=C(C=C4)Cl,CC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
6557,6578,CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
6558,6579,CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
6559,6580,CHEMBL2012120,YJIWRAUNQQMWPS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,=,1720.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.764471553092451,C1CC2C=C(CC1O2)C3=CC=CC4=CC=CC=C43,C1=C(c2cccc3ccccc23)CC2CCC1O2
6560,6581,CHEMBL402345,YJNSSHGTSILZGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CNCC1=C(C=CC(=C1)C(=O)N(C)C)OC2=C(C=C(C=C2)Cl)OC,CNCc1cc(C(=O)N(C)C)ccc1Oc1ccc(Cl)cc1OC
6561,6582,CHEMBL402345,YJNSSHGTSILZGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,CNCC1=C(C=CC(=C1)C(=O)N(C)C)OC2=C(C=C(C=C2)Cl)OC,CNCc1cc(C(=O)N(C)C)ccc1Oc1ccc(Cl)cc1OC
6562,6583,CHEMBL3673155,YJSPAIGIXYSMEQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,116.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.934793871945687,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NC=CN=C4)C5=CC=C(C=C5)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(Oc4cnccn4)ccc23)cc1
6563,6584,CHEMBL2430679,YJTXADGPCUCDFY-KZNAEPCWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24012181.0,INHIBITION,=,5.0,%,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells at 10 uM,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC2=C(C=CC(=C2)Cl)[C@H]3[C@@H]1NC[C@@H]3C4=CC=CC=C4,Clc1ccc2c(c1)CC[C@H]1NC[C@H](c3ccccc3)[C@@H]21
6564,6585,CHEMBL224771,YJWQTICONBXOHT-KOQKOIQBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,1.96,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,8.707743928643524,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC=CC=C4)N3C,Cc1ccc([C@H]2CC3CCC([C@H]2c2ccccc2)N3C)cc1
6565,6586,CHEMBL2096875,YJWQTICONBXOHT-KWJLTHHISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,430.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,6.366531544420414,CC1=CC=C(C=C1)[C@@H]2CC3CCC([C@@H]2C4=CC=CC=C4)N3C,Cc1ccc([C@@H]2CC3CCC([C@@H]2c2ccccc2)N3C)cc1
6566,6587,CHEMBL3673141,YJYMMJSBCVZBHP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,121.4,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.915781313260761,CC1=NN=C(C=C1)C2=CC3=C(C=C2)C4(CCN(C3)CC4)C5=CC=C(C=C5)Cl,Cc1ccc(-c2ccc3c(c2)CN2CCC3(c3ccc(Cl)cc3)CC2)nn1
6567,6588,CHEMBL391074,YKCOYIKIANOWTN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17616397.0,KI,=,190.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,CNCC1=C(C=CC(=C1)C#CCCN2CCC(CC2)F)OC3=CC=C(C=C3)SC,CNCc1cc(C#CCCN2CCC(F)CC2)ccc1Oc1ccc(SC)cc1
6568,6589,CHEMBL570317,YKDPKVFUKKJFFE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,31.62,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CNCCC1N(CC2=CC(=CC=C2)C#N)C3=CC4=C(C=C3)NC=C4,N#Cc1cccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)c1
6569,6590,CHEMBL177756,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,FLUORESCEIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O,O=C(O)c1ccccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12
6570,6591,CHEMBL177756,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,FLUORESCEIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O,O=C(O)c1ccccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12
6571,6592,CHEMBL423192,YKJYKKNCCRKFSL-RDBSUJKOSA-N,ANISOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1
6572,6593,CHEMBL423192,YKJYKKNCCRKFSL-RDBSUJKOSA-N,ANISOMYCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1
6573,6594,CHEMBL3331490,YKMARLUBARXPRP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,7.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,7.0,C1CCC(CC1)N(CC2CNC2)CC3=CC4=CC=CC=C4C=C3,c1ccc2cc(CN(CC3CNC3)C3CCCCC3)ccc2c1
6574,6595,CHEMBL39262,YKONJESBVFRUPH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,2.5,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,2.5,C1CN(CCC1CNCC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=C(C=C4)F,Fc1ccc(CN2CCC(CNCC(c3ccccc3)c3ccccc3)CC2)cc1
6575,6596,CHEMBL569700,YKOZIWZLLJVPPD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,265.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.576754126063192,CC(C(=O)C1=CC(=CC=C1)Cl)NC2CC2,CC(NC1CC1)C(=O)c1cccc(Cl)c1
6576,6597,CHEMBL569700,YKOZIWZLLJVPPD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,1150.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.939302159646387,CC(C(=O)C1=CC(=CC=C1)Cl)NC2CC2,CC(NC1CC1)C(=O)c1cccc(Cl)c1
6577,6598,CHEMBL294199,YKPUWZUDDOIDPM-SOFGYWHQSA-N,CAPSAICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
6578,6599,CHEMBL294199,YKPUWZUDDOIDPM-SOFGYWHQSA-N,CAPSAICIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
6579,6600,CHEMBL407135,YKQOSKADJPQZHB-YNWHQGOSSA-N,COLISTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
6580,6601,CHEMBL407135,YKQOSKADJPQZHB-YNWHQGOSSA-N,COLISTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
6581,6602,CHEMBL382034,YKRZGFVSJMTZLF-LEWJYISDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,5.1,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1,CC(C)OC1=CC=CC=C1C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O,CC(C)Oc1ccccc1C[C@@](O)(c1ccccc1)[C@@H]1CNCCO1
6582,6603,CHEMBL555565,YKTFTKYTVUHUCP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,3981.07,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,C1CNCCC1N(C2=CC3=C(C=C2)NC=C3)C(=O)C4=CC=CC=C4,O=C(c1ccccc1)N(c1ccc2[nH]ccc2c1)C1CCNCC1
6583,6604,CHEMBL1812739,YKXMGNSTADTLNN-MLHJIOFPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,0.83,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,9.080921907623924,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC(C)C)N3C,Cc1ccc([C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC(C)C)N3C)cc1
6584,6605,CHEMBL258450,YKZNMHWYVVPEPW-WMLDXEAASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OC=C3,CCN(CC)C(=O)[C@@]1(c2ccc3occc3c2)C[C@H]1CN
6585,6606,CHEMBL2407320,YLCDOWWZEWUKRA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,72.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,7.142667503568733,CCSCC(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CCSCC(c1ccc(Cl)c(Cl)c1)C1CCNCC1
6586,6607,CHEMBL95,YLJREFDVOIBQDA-UHFFFAOYSA-N,TACRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,Nc1c2c(nc3ccccc13)CCCC2
6587,6608,CHEMBL95,YLJREFDVOIBQDA-UHFFFAOYSA-N,TACRINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,Nc1c2c(nc3ccccc13)CCCC2
6588,6609,CHEMBL256019,YLMUIVZGFNCEHD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,7400.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.130768280269023,C1COCCN1C(=O)C2(CC2CN)C3=CC=CC=C3,NCC1CC1(C(=O)N1CCOCC1)c1ccccc1
6589,6610,CHEMBL179249,YLQFFYJKBKUKLF-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19067522.0,KI,=,275.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT receptor expressed in canine kidney cells,"Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter.",J. Med. Chem.,PUBLICATION,,6.560667306169737,CC1=CC=CC=C1S[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,Cc1ccccc1S[C@@H](c1ccccc1)[C@@H]1CNCCO1
6590,6611,CHEMBL2432059,YLVXPEMITKSDOS-RAOGCBAWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,INHIBITION,<,50.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes at 10 uM relative to control","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,50.0,CN(CCC1=CC=CC=N1)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CCc1ccccn1)[C@H]1C2C3CC4C5C3CC2C5C41
6591,6612,CHEMBL579244,YLXJJHBNSKFHOT-AEFFLSMTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19713106.0,INHIBITION,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.0,CNC[C@H]([C@H](C1=CC(=CC=C1)F)N2C=CC3=C2C(=CC=C3)Cl)O,CNC[C@@H](O)[C@H](c1cccc(F)c1)n1ccc2cccc(Cl)c21
6592,6613,CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
6593,6614,CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
6594,6615,CHEMBL19299,YMBXTVYHTMGZDW-UHFFFAOYSA-N,LOXOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
6595,6616,CHEMBL19299,YMBXTVYHTMGZDW-UHFFFAOYSA-N,LOXOPROFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
6596,6617,CHEMBL260037,YMESBXUQEPAMAY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCOC1=C(C=CC(=C1)Cl)OC2=C(C=NC=C2)CNC,CCOc1cc(Cl)ccc1Oc1ccncc1CNC
6597,6618,CHEMBL3309703,YMKIEQRAGKLOPM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,40.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,40.0,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6598,6619,CHEMBL3309703,YMKIEQRAGKLOPM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6599,6620,CHEMBL3309703,YMKIEQRAGKLOPM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,CC1=CC(=CC=C1)OC(CC2CNC2)C3=CC(=C(C=C3)Cl)Cl,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6600,6621,CHEMBL608430,YMQUDJCSTPMZTF-HEHGZKQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,12.59,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.899974269892138,C1CC(C1)OC[C@H]2[C@H]3[C@@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CNC[C@H]2[C@@H]3COC2CCC2)cc1Cl
6601,6622,CHEMBL596784,YMQUDJCSTPMZTF-IOASZLSFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,251.19,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.599997654072044,C1CC(C1)OC[C@@H]2[C@@H]3[C@]2(CNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@@]23CNC[C@@H]2[C@H]3COC2CCC2)cc1Cl
6602,6623,CHEMBL3703727,YMSGTOASAZCQKN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,31.2,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,7.505845405981558,C1C(C2=C(CN1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC=C(C=C4)Cl,Nc1ccc(-c2ccc3c(c2)CNCC3c2ccc(Cl)cc2)nn1
6603,6624,CHEMBL672,YMTINGFKWWXKFG-UHFFFAOYSA-N,FENOFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,8633.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.0638382590888416,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
6604,6625,CHEMBL672,YMTINGFKWWXKFG-UHFFFAOYSA-N,FENOFIBRATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6859.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.1637391971415125,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
6605,6626,CHEMBL1504,YNDXUCZADRHECN-JNQJZLCISA-N,TRIAMCINOLONE ACETONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
6606,6627,CHEMBL1504,YNDXUCZADRHECN-JNQJZLCISA-N,TRIAMCINOLONE ACETONIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
6607,6628,CHEMBL14053,YNJBWRMUSHSURL-UHFFFAOYSA-N,TRICHLOROACETIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(C(Cl)(Cl)Cl)O,O=C(O)C(Cl)(Cl)Cl
6608,6629,CHEMBL14053,YNJBWRMUSHSURL-UHFFFAOYSA-N,TRICHLOROACETIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(C(Cl)(Cl)Cl)O,O=C(O)C(Cl)(Cl)Cl
6609,6630,CHEMBL121857,YNLQRXLPKBOEEW-ISRILLDMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,55.9,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,7.252588192113577,CN1C2CCC1C([C@H](C2)OC(C3=CC=CC=C3)C4=CC=C(C=C4)I)C(=O)OC,COC(=O)C1C2CCC(C[C@@H]1OC(c1ccccc1)c1ccc(I)cc1)N2C
6610,6631,CHEMBL1081648,YNLYAYGRKYOTBJ-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC(=CC=C5)OC,COc1cccc(-c2ccc(C(=O)N3CCN(C(=O)c4ccc5cc[nH]c5c4)[C@@H](C)C3)cc2)c1
6611,6632,CHEMBL1081649,YNLYAYGRKYOTBJ-LJQANCHMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC(=CC=C5)OC,COc1cccc(-c2ccc(C(=O)N3CCN(C(=O)c4ccc5cc[nH]c5c4)[C@H](C)C3)cc2)c1
6612,6633,CHEMBL1626,YNNUSGIPVFPVBX-NHCUHLMSSA-N,CLEMASTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,678.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.168770306132936,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
6613,6634,CHEMBL1626,YNNUSGIPVFPVBX-NHCUHLMSSA-N,CLEMASTINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,538.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,6.269217724333612,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
6614,6635,CHEMBL256397,YNXFZOVYRWOMIR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)N(C(C)C)C(=O)C1(CC1CN)C2=CC=CC=C2,CC(C)N(C(=O)C1(c2ccccc2)CC1CN)C(C)C
6615,6636,CHEMBL567248,YNZNOMFLFOSBEA-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC2=CC=CC=C2N1[C@@H](C3=CC=CC=C3)[C@H](CNC)O,CNC[C@H](O)[C@H](c1ccccc1)n1c(C)cc2ccccc21
6616,6637,CHEMBL463388,YOAPWCHKPSMTER-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954985.0,KI,=,550.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.259637310505756,CC1(CCNC1)C2=CC3=C(C=C2)NC=C3,CC1(c2ccc3[nH]ccc3c2)CCNC1
6617,6638,CHEMBL983,YOEWQQVKRJEPAE-UHFFFAOYSA-L,SUCCINYLCHOLINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
6618,6639,CHEMBL983,YOEWQQVKRJEPAE-UHFFFAOYSA-L,SUCCINYLCHOLINE CHLORIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
6619,6640,CHEMBL2012102,YOFKXSATJFBEHG-JZRYZNKLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1C=CC=C1C2=CC=C(C=C2)[C@@H]3CC4CCC([C@H]3C(=O)OC)O4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3cccn3C)cc1)O2
6620,6641,CHEMBL2012102,YOFKXSATJFBEHG-JZRYZNKLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,CN1C=CC=C1C2=CC=C(C=C2)[C@@H]3CC4CCC([C@H]3C(=O)OC)O4,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(-c3cccn3C)cc1)O2
6621,6642,CHEMBL2012105,YOFKXSATJFBEHG-KXWSQRDISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1C=CC=C1C2=CC=C(C=C2)[C@H]3CC4CCC([C@H]3C(=O)OC)O4,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(-c3cccn3C)cc1)O2
6622,6643,CHEMBL2012105,YOFKXSATJFBEHG-KXWSQRDISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,CN1C=CC=C1C2=CC=C(C=C2)[C@H]3CC4CCC([C@H]3C(=O)OC)O4,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(-c3cccn3C)cc1)O2
6623,6644,CHEMBL1513,YOSHYTLCDANDAN-UHFFFAOYSA-N,IRBESARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
6624,6645,CHEMBL1513,YOSHYTLCDANDAN-UHFFFAOYSA-N,IRBESARTAN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
6625,6646,CHEMBL1683879,YOVGBLUPSNTJCU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.698970004336019,C1CCC(CC1)(CN2CCOCC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C2(CN3CCOCC3)CCCCC2)cc1Cl
6626,6647,CHEMBL199116,YPBIYYFCLCGRRL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,9.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CCCC1(CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCCC1(CCCNC)Cc2ccccc2N(c2ccc(C)cc2)C1=O
6627,6648,CHEMBL199116,YPBIYYFCLCGRRL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CCCC1(CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCCC1(CCCNC)Cc2ccccc2N(c2ccc(C)cc2)C1=O
6628,6649,CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1
6629,6650,CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1
6630,6651,CHEMBL123292,YPHMISFOHDHNIV-FSZOTQKASA-N,CYCLOHEXIMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C,C[C@H]1C[C@H](C)C(=O)[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C1
6631,6652,CHEMBL123292,YPHMISFOHDHNIV-FSZOTQKASA-N,CYCLOHEXIMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C,C[C@H]1C[C@H](C)C(=O)[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C1
6632,6653,CHEMBL1818469,YPIFSSZDJKDNEK-HUUCEWRRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,199.53,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.699991797446188,C1CNC[C@@]2([C@]1(C2)C3=CC(=C(C=C3)Cl)Cl)CN4C=NC=N4,Clc1ccc([C@]23CCNC[C@@]2(Cn2cncn2)C3)cc1Cl
6633,6654,CHEMBL132954,YPRKQXGDPALXAP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,60.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.221848749616356,COC1=CC=CC2=C1C(N3C2=NCC3)(C4=CC=C(C=C4)Cl)O,COc1cccc2c1C(O)(c1ccc(Cl)cc1)N1CCN=C21
6634,6655,CHEMBL132954,YPRKQXGDPALXAP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,67.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.173277479831008,COC1=CC=CC2=C1C(N3C2=NCC3)(C4=CC=C(C=C4)Cl)O,COc1cccc2c1C(O)(c1ccc(Cl)cc1)N1CCN=C21
6635,6656,CHEMBL132954,YPRKQXGDPALXAP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,10.3,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.987162775294827,COC1=CC=CC2=C1C(N3C2=NCC3)(C4=CC=C(C=C4)Cl)O,COc1cccc2c1C(O)(c1ccc(Cl)cc1)N1CCN=C21
6636,6657,CHEMBL1668584,YPVOSIDECMYMTD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21333408.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Binding affinity to Dopamine transporter at 10 uM by radioligand binding assay,"2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: new series of highly potent and specific serotonin 5-HT6 receptor antagonists.",Eur. J. Med. Chem.,PUBLICATION,,,CC1=CC(=NC2=C(C(=NN12)NC)S(=O)(=O)C3=CC=CC=C3)C,CNc1nn2c(C)cc(C)nc2c1S(=O)(=O)c1ccccc1
6637,6658,CHEMBL1372,YPZRWBKMTBYPTK-BJDJZHNGSA-N,OXIGLUTATIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
6638,6659,CHEMBL1372,YPZRWBKMTBYPTK-BJDJZHNGSA-N,OXIGLUTATIONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
6639,6660,CHEMBL575699,YQANZQCQGNYBAC-MOSHPQCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,1360.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.866461091629782,C1CN(CCN1)C2=CC=CC=C2/C=C\3/C(=O)N(CCS3)C4=C(C=C(C=C4)F)F,O=C1/C(=C/c2ccccc2N2CCNCC2)SCCN1c1ccc(F)cc1F
6640,6661,CHEMBL742,YQEZLKZALYSWHR-UHFFFAOYSA-N,KETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CNC1(c2ccccc2Cl)CCCCC1=O
6641,6662,CHEMBL742,YQEZLKZALYSWHR-UHFFFAOYSA-N,KETAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CNC1(c2ccccc2Cl)CCCCC1=O
6642,6663,CHEMBL252004,YQJRHMKRLFALRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18242991.0,INHIBITION,=,74.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.,Bioorg. Med. Chem. Lett.,PUBLICATION,,74.0,CC1=NC(=CC=C1)C2=CC(=CC=C2)S(=O)(=O)C3=C(SC(=C3)C(=N)N)SC,CSc1sc(C(=N)N)cc1S(=O)(=O)c1cccc(-c2cccc(C)n2)c1
6643,6664,CHEMBL198275,YQMJGYZSSOOMCO-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693162,CNCCCC1CC2=CC=CC=C2N(C1=O)C3=CC(=C(C=C3)Cl)Cl,CNCCCC1Cc2ccccc2N(c2ccc(Cl)c(Cl)c2)C1=O
6644,6665,CHEMBL568095,YQOJGBMYXRTDBS-OALUTQOASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCNC[C@@H]([C@H](C1=CC=CC=C1)N2C=CC3=C2C=CC(=C3)F)O,CCNC[C@H](O)[C@H](c1ccccc1)n1ccc2cc(F)ccc21
6645,6666,CHEMBL403080,YQRYFSQPEXVGIK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,=,5040.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.297569463554475,CC1=CC(=C(C=N1)CN(C)C)OC2=C(C=C(C=C2)Cl)OC,COc1cc(Cl)ccc1Oc1cc(C)ncc1CN(C)C
6646,6667,CHEMBL3593403,YQVZJLGBHWQCGT-UOUQJYNVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC(=O)NC[C@@H]1CNCCO[C@H]1C2=CC(=C(C=C2)F)Cl.C(=C/C(=O)O)\C(=O)O,CC(=O)NC[C@@H]1CNCCO[C@H]1c1ccc(F)c(Cl)c1
6647,6668,CHEMBL120512,YQXNPUPTPJOJOV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9748351.0,IC50,=,6500.0,NM,,,,,,,,,,,,,,,Inhibition of dopamine uptake from dopamine uptake site,"New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.",J. Med. Chem.,PUBLICATION,,5.187086643357143,CN1CCN(CC1)C2CN3C=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(C2Cn3cccc3Sc3ccc(Cl)cc32)CC1
6648,6669,CHEMBL513139,YRBVTLBLPHIXQP-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,>,40000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CC(C)C(=O)N(CC1=C(C=C(C=C1)Cl)Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1ccc(Cl)cc1Cl)[C@H]1CCNC1
6649,6670,CHEMBL1219,YREYEVIYCVEVJK-UHFFFAOYSA-N,RABEPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C
6650,6671,CHEMBL1219,YREYEVIYCVEVJK-UHFFFAOYSA-N,RABEPRAZOLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C
6651,6672,CHEMBL518580,YRGCYAJUEHMWAR-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)C(=O)N(CC1=C(C=C(C=C1)F)Cl)[C@H]2CCNC2,CC(C)C(=O)N(Cc1ccc(F)cc1Cl)[C@H]1CCNC1
6652,6673,CHEMBL369406,YRINJANLFJZAOU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11300876.0,RATIO,=,1.5,,,,,,,,,,,,,,,,Ratio of ([3H]-DA uptake) / [3H]WIN-35428 binding was determined in rat cytosol,Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.,J. Med. Chem.,PUBLICATION,,1.5,C1CN(CCC1CCNC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC(=C(C=C4)F)F,Fc1ccc(CN2CCC(CCNC(c3ccccc3)c3ccccc3)CC2)cc1F
6653,6674,CHEMBL2407325,YROYMUJBXFJCBF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,180.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.7447274948966935,CC(=O)C(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CC(=O)C(c1ccc(Cl)c(Cl)c1)C1CCNCC1
6654,6675,CHEMBL1189234,YSEXVIPNIGQQMN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1
6655,6676,CHEMBL1189234,YSEXVIPNIGQQMN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1
6656,6677,CHEMBL2322002,YSGVIJFMBOEZJZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,49.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human recombinant DAT expressed in HEK cells,,ACS Med. Chem. Lett.,PUBLICATION,,7.309803919971486,CC1=C(C=C(C=C1)C2CC=CCNC2)Cl,Cc1ccc(C2CC=CCNC2)cc1Cl
6657,6678,CHEMBL1566956,YSIITVVESCNIPR-UHFFFAOYSA-N,TROXIPIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCCNC2,COc1cc(C(=O)NC2CCCNC2)cc(OC)c1OC
6658,6679,CHEMBL1566956,YSIITVVESCNIPR-UHFFFAOYSA-N,TROXIPIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCCNC2,COc1cc(C(=O)NC2CCCNC2)cc(OC)c1OC
6659,6680,CHEMBL289446,YSJQOZFUGFOQTD-OUKQBFOZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,5.82,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.82,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)/C=C/C4=C(C=CC=C4Cl)Cl,O=C(/C=C/c1c(Cl)cccc1Cl)N1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6660,6681,CHEMBL3673160,YSRPCSSZNWLITA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,25.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.5934598195660445,C1CN2CCC1(C3=C(C2)C=C(C=C3)C4=CC5=C(C=C4)NC(=O)O5)C6=CC(=C(C=C6)Cl)Cl,O=c1[nH]c2ccc(-c3ccc4c(c3)CN3CCC4(c4ccc(Cl)c(Cl)c4)CC3)cc2o1
6661,6682,CHEMBL3323089,YSXLAKJPPGTIOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,5.7,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.244125144327509,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)OC=C4,CN1Cc2ccccc2C(c2ccc3occc3c2)C1
6662,6683,CHEMBL3323089,YSXLAKJPPGTIOK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,4.5,NM,314440,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,8.346787486224656,CN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)OC=C4,CN1Cc2ccccc2C(c2ccc3occc3c2)C1
6663,6684,CHEMBL511603,YSZKSMMSKUUKKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CS1)C#CC2=CC(=CC(=C2)F)C3=CN=CC=C3,Cc1nc(C#Cc2cc(F)cc(-c3cccnc3)c2)cs1
6664,6685,CHEMBL511603,YSZKSMMSKUUKKE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19445453.0,KI,>,6000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.,J. Med. Chem.,PUBLICATION,,5.221848749616356,CC1=NC(=CS1)C#CC2=CC(=CC(=C2)F)C3=CN=CC=C3,Cc1nc(C#Cc2cc(F)cc(-c3cccnc3)c2)cs1
6665,6686,CHEMBL1642917,YTBOYUYWXPLZQM-DLBZAZTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,1616.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.791558643561433,CN[C@H]1CCC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CCc2ccccc2[C@H]1c1ccc(Cl)c(Cl)c1
6666,6687,CHEMBL1642916,YTBOYUYWXPLZQM-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,212.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.6736641390712474,CN[C@@H]1CCC2=CC=CC=C2[C@H]1C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CCc2ccccc2[C@H]1c1ccc(Cl)c(Cl)c1
6667,6688,CHEMBL1642914,YTBOYUYWXPLZQM-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,91.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,7.040958607678906,CN[C@H]1CCC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CCc2ccccc2[C@@H]1c1ccc(Cl)c(Cl)c1
6668,6689,CHEMBL1642915,YTBOYUYWXPLZQM-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21093273.0,IC50,=,559.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.252588192113577,CN[C@@H]1CCC2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CCc2ccccc2[C@@H]1c1ccc(Cl)c(Cl)c1
6669,6690,CHEMBL227232,YTNASRCFNXLDGR-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,30.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.522878745280337,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)[N+](=O)[O-],CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc([N+](=O)[O-])cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
6670,6691,CHEMBL227232,YTNASRCFNXLDGR-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,6.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,8.214670164989233,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)[N+](=O)[O-],CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc([N+](=O)[O-])cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
6671,6692,CHEMBL611677,YTQLIVFAWSALJC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,>,6650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.177178354696896,C1CNCCC1C2=C(N=CC=C2)OC3=C(C(=CC=C3)F)F,Fc1cccc(Oc2ncccc2C2CCNCC2)c1F
6672,6693,CHEMBL314138,YTQPASGYLGFPBP-GLWUULTISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,7730.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,5.111820506081675,CN1C2C[C@H](C1C(=C(C2)C3=CC=C(C=C3)F)C(=O)OC)O,COC(=O)C1=C(c2ccc(F)cc2)CC2C[C@@H](O)C1N2C
6673,6694,CHEMBL372378,YTXXRXPLJHCYAH-NUUPQPAYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,27.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]CFT from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.568636235841013,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCOC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC(=C(C=C7)Cl)Cl)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCOC(=O)[C@@H]4C5CCC(C[C@@H]4c4ccc(Cl)c(Cl)c4)N5C)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
6674,6695,CHEMBL372378,YTXXRXPLJHCYAH-NUUPQPAYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16302792.0,KI,=,72.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]dopamine from human DAT expressed in COS7 cells,"Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.142667503568733,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCOC(=O)[C@H]5[C@H](CC6CCC5N6C)C7=CC(=C(C=C7)Cl)Cl)S(=O)(=O)[O-],CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCCC(=O)NCCOC(=O)[C@@H]4C5CCC(C[C@@H]4c4ccc(Cl)c(Cl)c4)N5C)cc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1
6675,6696,CHEMBL3663908,YTYBDRIOUDWUGR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,2250.0,NM,314431,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,5.647817481888637,CC1=CC=C(S1)C2CN(CC3=CC=CC=C23)C,Cc1ccc(C2CN(C)Cc3ccccc32)s1
6676,6697,CHEMBL497338,YUFDTETVOKSVLR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,11920.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,4.923723744595782,CN(CCC1=CC=CC=C1OC(F)(F)F)CCN2CCCCC2,CN(CCc1ccccc1OC(F)(F)F)CCN1CCCCC1
6677,6698,CHEMBL3318585,YUHUOLOVNSFCND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25037917.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM,Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CN(CC1N2C3=NC=CC=N3)C(=O)C4=CC=C(C=C4)C5=CC(=CC=C5)Cl,O=C(c1ccc(-c2cccc(Cl)c2)cc1)N1CC2CCC(C1)N2c1ncccn1
6678,6699,CHEMBL38737,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,THIOACETAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=S)N,CC(N)=S
6679,6700,CHEMBL38737,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,THIOACETAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=S)N,CC(N)=S
6680,6701,CHEMBL235569,YUMUSCBAOZYAIX-BARDWOONSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446069.0,KI,=,11.47,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK293 cells,"Synthesis and biological evaluation of 2beta,3alpha-(substituted phenyl)nortropanes as potential norepinephrine transporter imaging agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.940436582098732,CC1=CC=C(C=C1)[C@@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OC)N3,COC(=O)[C@@H]1[C@H]2CC[C@H](C[C@H]1c1ccc(C)cc1)N2
6681,6702,CHEMBL2164354,YUOLKUGHNOWKJF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22738628.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by radioligand binding assay,Moderate chemical modifications of WAY-100635 improve the selectivity for 5-HT1A versus D4 receptors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1CCC(CC1)C(=O)N(CCN2CCC(=CC2)C3=CC=CC=C3)C4=CC=CC=N4,O=C(C1CCCCC1)N(CCN1CC=C(c2ccccc2)CC1)c1ccccn1
6682,6703,CHEMBL2021577,YUSAYELUMYRKMP-CIUDSAMLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,199.53,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.699991797446188,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C,CCOC[C@H]1[C@@H]2CNC[C@@]21C
6683,6704,CHEMBL99653,YUTGLCAFRPAGFA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,15.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,15.0,CN(C)CC(C1=CC(=CC=C1)C(F)(F)F)C2(CCCCC2)O,CN(C)CC(c1cccc(C(F)(F)F)c1)C1(O)CCCCC1
6684,6705,CHEMBL2337599,YVEIFDFSCWTJRT-SJLPKXTDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,PKI,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CNC[C@@H]1[C@@H](C2=CC=CC=C2)OC3=CC=CC(=C3)C#N,N#Cc1cccc(O[C@H](c2ccccc2)[C@@H]2CCNC2)c1
6685,6706,CHEMBL471898,YVGUKIACEDKFHT-LIAHKDQHSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,76.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.1191864077192095,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=C(C(=NO4)C)C5=CC=C(C=C5)F)N3C.Cl,Cc1ccc([C@H]2CC3CCC([C@H]2c2onc(C)c2-c2ccc(F)cc2)N3C)cc1
6686,6707,CHEMBL361259,YVKDUIAAPBKHMJ-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9986702.0,KI,=,23.5,NM,,,,,,,,,,,,,,,Concentration inhibiting Dopamine transporter,"A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I]IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol.",J. Med. Chem.,PUBLICATION,,7.628932137728263,CSC1=CC=C(C=C1)[C@H]2CN3CCC[C@H]3C4=CC=CC=C24,CSc1ccc([C@H]2CN3CCC[C@H]3c3ccccc32)cc1
6687,6708,CHEMBL361259,YVKDUIAAPBKHMJ-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9986702.0,KI,=,112.0,NM,,,cell_based,,,,,,,,,,,,In vitro binding affinity against Dopamine transporter in LLC-PK1 cell membranes.,"A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I]IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol.",J. Med. Chem.,PUBLICATION,,6.950781977329817,CSC1=CC=C(C=C1)[C@H]2CN3CCC[C@H]3C4=CC=CC=C24,CSc1ccc([C@H]2CN3CCC[C@H]3c3ccccc32)cc1
6688,6709,CHEMBL361259,YVKDUIAAPBKHMJ-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15456270.0,KI,=,112.0,NM,,,cell_based,,,,,,,,,,,,Binding affinity for dopamine transporter expressed in LCK PK1 cells,2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent.,J. Med. Chem.,PUBLICATION,,6.950781977329817,CSC1=CC=C(C=C1)[C@H]2CN3CCC[C@H]3C4=CC=CC=C24,CSc1ccc([C@H]2CN3CCC[C@H]3c3ccccc32)cc1
6689,6710,CHEMBL3334777,YVOMATWVFCSQME-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,54.3,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,54.3,CC1CCCN(C1)C(CCN2CCOCC2)C3=CC(=C(C=C3)Cl)Cl,CC1CCCN(C(CCN2CCOCC2)c2ccc(Cl)c(Cl)c2)C1
6690,6711,CHEMBL1738699,YVPGZQLRPAGKLA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21570838.0,INHIBITION,<,50.0,%,Not Active,,,,,,,,,,,,,,Inhibition of human recombinant DAT at 10 uM by radioligand binding assay,Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1
6691,6712,CHEMBL1201220,YVPYQUNUQOZFHG-UHFFFAOYSA-N,DIATRIZOIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
6692,6713,CHEMBL1201220,YVPYQUNUQOZFHG-UHFFFAOYSA-N,DIATRIZOIC ACID,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
6693,6714,CHEMBL339481,YVTLPBYWTMWEPR-LESVLKBLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8558504.0,IC50,=,1480.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in the cynomolgus (macaca fascicularis) monkey caudate-putamen.,"2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.",J. Med. Chem.,PUBLICATION,,5.8297382846050425,CCC(C1=CC=CC=C1)O[C@H]2CC3CCC(C2C(=O)OC)N3C,CCC(O[C@H]1CC2CCC(C1C(=O)OC)N2C)c1ccccc1
6694,6715,CHEMBL575077,YWIYMDPWBAXEKQ-UHFFFAOYSA-N,4-(2-PHENOXYPHENYL)PIPERIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,=,284.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.546681659952962,C1CNCCC1C2=CC=CC=C2OC3=CC=CC=C3,c1ccc(Oc2ccccc2C2CCNCC2)cc1
6695,6716,CHEMBL1683877,YWOVEHIRDVATGZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.698970004336019,C1CCC(CC1)(CN2CCCC2)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(C2(CN3CCCC3)CCCCC2)cc1Cl
6696,6717,CHEMBL306700,YWPHCCPCQOJSGZ-UHFFFAOYSA-N,VILOXAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCOC1=CC=CC=C1OCC2CNCCO2,CCOc1ccccc1OCC1CNCCO1
6697,6718,CHEMBL306700,YWPHCCPCQOJSGZ-UHFFFAOYSA-N,VILOXAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9871604.0,KD,=,155.0,NM,,,,,,,,,,,,,,,Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT,"Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.809668301829707,CCOC1=CC=CC=C1OCC2CNCCO2,CCOc1ccccc1OCC1CNCCO1
6698,6719,CHEMBL571893,YXAAWHCXAGWLQX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,501.19,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CNCCC1N(CC2CCOCC2)C3=CC4=C(C=C3)NC=C4,c1cc2cc(N(CC3CCOCC3)C3CCNCC3)ccc2[nH]1
6699,6720,CHEMBL564094,YXBAJJFUPMTDTL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,79.43,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,C1CNCCC1N(CC2=CC(=CC=C2)F)C3=CC4=C(C=C3)NC=C4,Fc1cccc(CN(c2ccc3[nH]ccc3c2)C2CCNCC2)c1
6700,6721,CHEMBL40429,YXBBKRPEQRPZSX-DHZHZOJOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.78,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.78,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN3CCN(CC3)C/C=C/C4=CC=CC=C4,Cc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc2)cc1
6701,6722,CHEMBL40429,YXBBKRPEQRPZSX-DHZHZOJOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.95,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.95,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN3CCN(CC3)C/C=C/C4=CC=CC=C4,Cc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc2)cc1
6702,6723,CHEMBL1170212,YXKXFXIRENCHSD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,501.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(C(CN1)CC2=CC=CC=C2)C3=CN=C4C(=C3)C=CN4,c1ccc(CC2CNCCN2c2cnc3[nH]ccc3c2)cc1
6703,6724,CHEMBL3238477,YXTCNRORGOLYJQ-HKWRFOASSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,C1=CC(=CC=C1C(=O)O)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccc(C(=O)O)cc3)c(O)c12
6704,6725,CHEMBL538405,YXXIVPQOYVBQQR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213078.0,KI,=,0.73,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter (DAT) by using [125I]RTI-55 radioligand,Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter.,J. Med. Chem.,PUBLICATION,,9.136677139879543,C1CN(CCC1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC4=CC5=CC=CC=C5N4,Fc1ccc(C(OCCC2CCN(Cc3cc4ccccc4[nH]3)CC2)c2ccc(F)cc2)cc1
6705,6726,CHEMBL252619,YXZFTTDBDFNQJY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18242991.0,INHIBITION,=,47.0,%,,,,,,,,,,,,,,,Inhibition of dopamine transporter at 10 uM,Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.,Bioorg. Med. Chem. Lett.,PUBLICATION,,47.0,CC1=C(C(=CC=C1)NC(=O)CS(=O)(=O)C)C2=CC(=CC=C2)S(=O)(=O)C3=C(SC(=C3)C(=N)N)SC,CSc1sc(C(=N)N)cc1S(=O)(=O)c1cccc(-c2c(C)cccc2NC(=O)CS(C)(=O)=O)c1
6706,6727,CHEMBL538876,YYCOWMQMXNLRHZ-DXWKFQSLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,16.98,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.770062314092066,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C=C/I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
6707,6728,CHEMBL538876,YYCOWMQMXNLRHZ-DXWKFQSLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,17.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.769551078621726,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C=C/I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
6708,6729,CHEMBL538876,YYCOWMQMXNLRHZ-DXWKFQSLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24262882.0,KI,=,17.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin),"Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [(11)C]IPCIT and [(18)F]FE@IPCIT.",Bioorg. Med. Chem.,PUBLICATION,,7.769551078621726,CC1=CC=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C/C=C/I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
6709,6730,CHEMBL1643897,YYCOWMQMXNLRHZ-GOOGKZTPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146989.0,KI,=,17.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.769551078621726,CC1=CC=C(C=C1)[C@H]2C[C@H]3CC[C@@H]([C@H]2C(=O)OC)N3C/C=C/I,COC(=O)[C@H]1[C@@H](c2ccc(C)cc2)C[C@H]2CC[C@@H]1N2C/C=C/I
6710,6731,CHEMBL605213,YYHJBTRUWUYGMM-MAOIFBLLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,33.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,33.0,CC1CC2=CC=CC=C2N1[C@@H](C3=CC(=CC=C3)F)[C@@H](CNC)O.Cl,CNC[C@@H](O)[C@H](c1cccc(F)c1)N1c2ccccc2CC1C
6711,6732,CHEMBL518195,YYJIBHFMUZUGND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,13.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,13.0,CN1CCN(CC1)CC(C2=CC=C(C=C2)OC(F)(F)F)C3(CCCCC3)O.Cl.Cl,CN1CCN(CC(c2ccc(OC(F)(F)F)cc2)C2(O)CCCCC2)CC1
6712,6733,CHEMBL3593402,YYOKDTWKQIVDFK-XCBLFTOQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26051602.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in CHOK1 cells incubated for 60 mins by [3H]-dopamine uptake assay,"Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC(=O)NC[C@@H]1CNCCO[C@H]1C2=CC(=C(C=C2)Cl)F.Cl,CC(=O)NC[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
6713,6734,CHEMBL3593402,YYOKDTWKQIVDFK-XCBLFTOQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC(=O)NC[C@@H]1CNCCO[C@H]1C2=CC(=C(C=C2)Cl)F.Cl,CC(=O)NC[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
6714,6735,CHEMBL3094319,YYONFKYBFNEIKC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24238903.0,INHIBITION,=,48.2,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM relative to control,Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.,Bioorg. Med. Chem.,PUBLICATION,,48.2,C1=CC(=CC=C1CN)OCC2=CC=C(C=C2)F.Cl,NCc1ccc(OCc2ccc(F)cc2)cc1
6715,6736,CHEMBL3673166,YYPCUZDBNVUASA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,33.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.469800301796917,C1CN2CCC1(C3=C(C2)C=C(C=C3)OC4=NC=CN=C4)C5=CC(=C(C=C5)Cl)Cl,Clc1ccc(C23CCN(CC2)Cc2cc(Oc4cnccn4)ccc23)cc1Cl
6716,6737,CHEMBL411941,YYQUWEHEBOMRPH-NYUBLWNDSA-N,CYCLORGDFV,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16722631.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to dopamine transporter by radioligand binding assay,"An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.",J. Med. Chem.,PUBLICATION,,,CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N,CC(C)[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC1=O
6717,6738,CHEMBL1645610,YYTDEVINWTYBOD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,>,5590.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.252588192113577,C1CC(CNC1)OC2=C(C=CC=C2F)OC3=CC=CC=C3F,Fc1ccccc1Oc1cccc(F)c1OC1CCCNC1
6718,6739,CHEMBL448900,YYVFHUIYCOUOCD-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)CC(=O)N(CC1=C(C(=CC=C1)Cl)Cl)[C@H]2CCNC2,CC(C)CC(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1
6719,6740,CHEMBL2407334,YYWIEWLZZQPVRT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23769168.0,IC50,=,160.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-dopamine from human DAT expressed in CHO cells by TopCounting analysis,"Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.",Bioorg. Med. Chem.,PUBLICATION,,6.795880017344076,CC(C1CCNCC1)C2=CC(=C(C=C2)Cl)Cl.Cl,CC(c1ccc(Cl)c(Cl)c1)C1CCNCC1
6720,6741,CHEMBL2206307,YYXOKPOCUHEGJE-JJXSEGSLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22082561.0,KI,=,8.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,Characterisation of [C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.096910013008056,COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCF)C[C@@H]1C3=CC=C(C=C3)Cl,COC(=O)[C@H]1[C@@H](c2ccc(Cl)cc2)C[C@@H]2CC[C@H]1N2CCF
6721,6742,CHEMBL265951,YYYWQSQFBVNAPA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18313294.0,KI,=,4060.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]WIN-35428 uptake in human DAT transfected HEK293 cells,[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.391473966422807,CC1=CC(=C(C=N1)CN(C)C)OC2=CC=CC=C2OC,COc1ccccc1Oc1cc(C)ncc1CN(C)C
6722,6743,CHEMBL3331469,YYZODXXLBSUZSX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,678.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.168770306132936,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4.Cl,c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
6723,6744,CHEMBL3331469,YYZODXXLBSUZSX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4.Cl,c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
6724,6745,CHEMBL1645606,YZDRSNBYBMAHDD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,4510.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.345823458122039,C1CNCCC1OC2=CC=CC=C2OC3=CC=CC=C3F,Fc1ccccc1Oc1ccccc1OC1CCNCC1
6725,6746,CHEMBL481353,YZFBWQVFTDRJGQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,5800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.236572006437063,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)OC(F)(F)F,CN(C)Cc1ccccc1Oc1ccc(OC(F)(F)F)cc1
6726,6747,CHEMBL7002,YZFWTZACSRHJQD-UHFFFAOYSA-N,CIGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1
6727,6748,CHEMBL7002,YZFWTZACSRHJQD-UHFFFAOYSA-N,CIGLITAZONE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1
6728,6749,CHEMBL426316,YZGSHBDJMLWEBX-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-32.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-32.0,CCCCN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CCCCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
6729,6750,CHEMBL438889,YZHPFFVLNPTVQU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,138.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.860120913598763,CNCC1=C(C=CC(=C1)N2CCCS2(=O)=O)OC3=C(C=C(C=C3)Cl)Cl,CNCc1cc(N2CCCS2(=O)=O)ccc1Oc1ccc(Cl)cc1Cl
6730,6751,CHEMBL591928,YZJOPQCWTRXOHP-URBRKQAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,IC50,=,20927.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,4.679293025690409,CC1(CN(C2=C1C=CC=C2F)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1ccccc1)N1CC(C)(C)c2cccc(F)c21
6731,6752,CHEMBL591928,YZJOPQCWTRXOHP-URBRKQAFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20131864.0,INHIBITION,=,7.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in CHO cells at 1 uM,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.0,CC1(CN(C2=C1C=CC=C2F)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O)C.Cl,CNC[C@@H](O)[C@H](c1ccccc1)N1CC(C)(C)c2cccc(F)c21
6732,6753,CHEMBL564071,YZKDZSSMZPGBAY-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19616432.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of radioligand from human recombinant DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)CN([C@H]1CCNC1)C(=O)C2=CC=CC=C2C3=CC=CC=C3,CC(C)CN(C(=O)c1ccccc1-c1ccccc1)[C@H]1CCNC1
6733,6754,CHEMBL403469,YZLURQAUJPJHIZ-QFBILLFUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCN(CC=C)C(=O)[C@]1(C[C@H]1CN)C2=CC3=C(C=C2)OCC3,C=CCN(CCC)C(=O)[C@@]1(c2ccc3c(c2)CCO3)C[C@H]1CN
6734,6755,CHEMBL442234,YZQHGCDBPHKCKB-CHWSQXEVSA-N,METHYL 2-(4-(TRIFLUOROMETHOXY)PHENYL)CYCLOHEXANECARBOXYLATE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1180000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,2.9281179926938745,COC(=O)[C@@H]1CCCC[C@@H]1C2=CC=C(C=C2)OC(F)(F)F,COC(=O)[C@@H]1CCCC[C@@H]1c1ccc(OC(F)(F)F)cc1
6735,6756,CHEMBL474922,YZSUSCODCJEDGG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,=,6400.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.1938200260161125,CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)OC,COc1ccc(Oc2ccccc2CN(C)C)cc1
6736,6757,CHEMBL3673136,YZTRIEWOXRNWOV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,37.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.425968732272282,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)Cl)Cl)C=CC(=C3)C5=CN6C(=NC=N6)C=C5,Clc1ccc(C23CCN(Cc4cc(-c5ccc6ncnn6c5)ccc42)C3)cc1Cl
6737,6758,CHEMBL3673136,YZTRIEWOXRNWOV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,49.5,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 pM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,7.305394801066433,C1CN2CC3=C(C1(C2)C4=CC(=C(C=C4)Cl)Cl)C=CC(=C3)C5=CN6C(=NC=N6)C=C5,Clc1ccc(C23CCN(Cc4cc(-c5ccc6ncnn6c5)ccc42)C3)cc1Cl
6738,6759,CHEMBL438321,YZXXWGROTHDVOH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,590000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,3.229147988357856,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)C(F)(F)F,COC(=O)C1=C(c2ccc(C(F)(F)F)cc2)CCCC1
6739,6760,CHEMBL438321,YZXXWGROTHDVOH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CCCC1)C2=CC=C(C=C2)C(F)(F)F,COC(=O)C1=C(c2ccc(C(F)(F)F)cc2)CCCC1
6740,6761,CHEMBL3331470,YZYKKYIJQMFWMY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,10.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,10.0,C1C(CN1)N(CC2=CC=CC=C2)C3=CC=CC=C3,c1ccc(CN(c2ccccc2)C2CNC2)cc1
6741,6762,CHEMBL1727,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,CEPHALEXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
6742,6763,CHEMBL1727,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,CEPHALEXIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
6743,6764,CHEMBL257550,ZAKNFBUXJCNYEX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18445525.0,IC50,=,4300.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.366531544420414,C1CN(C2=CC=CC=C21)C(=O)C3(C(C3C4=CC=CC=C4)CN)C5=CC=CC=C5,NCC1C(c2ccccc2)C1(C(=O)N1CCc2ccccc21)c1ccccc1
6744,6765,CHEMBL2380983,ZALXONRNDYIIGY-AAEUAGOBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(C)C[C@@H]1C[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@@H]1C[C@H]1c1ccc2[nH]cc(C#N)c2c1
6745,6766,CHEMBL2380983,ZALXONRNDYIIGY-AAEUAGOBSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23578689.0,INHIBITION,=,39.0,%,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in HEK293 cell membranes at 1 uM,Conformationally restricted homotryptamines. Part 6: Indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,39.0,CN(C)C[C@@H]1C[C@H]1C2=CC3=C(C=C2)NC=C3C#N,CN(C)C[C@@H]1C[C@H]1c1ccc2[nH]cc(C#N)c2c1
6746,6767,CHEMBL1081254,ZALZZXXESRJJEH-IBGZPJMESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=C(C=C5)OC,COc1ccc(-c2ccc(C(=O)N3CCN(C(=O)c4ccc5cc[nH]c5c4)[C@@H](C)C3)cc2)cc1
6747,6768,CHEMBL3105242,ZASUYZQUSFFDOQ-AACQVBLVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24262882.0,KI,=,36.99,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT after 2 hrs by liquid scintillation counting analysis,"Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [(11)C]IPCIT and [(18)F]FE@IPCIT.",Bioorg. Med. Chem.,PUBLICATION,,7.431915668684605,C1C[C@@H]2[C@H]([C@H](C[C@H]1N2C/C=C/I)C3=CC=C(C=C3)I)C(=O)O,O=C(O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2C/C=C/I
6748,6769,CHEMBL469460,ZASZYPPXOGNZRV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,2.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,2.0,COC1=CC=CC(=C1)C(CN2CCNCC2)C3(CCCCC3)O.Cl.Cl,COc1cccc(C(CN2CCNCC2)C2(O)CCCCC2)c1
6749,6770,CHEMBL217975,ZBCBLJHLBKPDBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,35.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.455931955649724,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)OC,COc1cccc(C(CC(C)C)C2CCCCN2)c1
6750,6771,CHEMBL217975,ZBCBLJHLBKPDBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,140.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.853871964321763,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)OC,COc1cccc(C(CC(C)C)C2CCCCN2)c1
6751,6772,CHEMBL217975,ZBCBLJHLBKPDBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,22.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.657577319177793,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)OC,COc1cccc(C(CC(C)C)C2CCCCN2)c1
6752,6773,CHEMBL217975,ZBCBLJHLBKPDBD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,950.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.022276394711152,CC(C)CC(C1CCCCN1)C2=CC(=CC=C2)OC,COc1cccc(C(CC(C)C)C2CCCCN2)c1
6753,6774,CHEMBL477586,ZBFNMJAOUOICQA-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)C(=O)N(CC1=C(C=C(C=C1)F)F)[C@H]2CCNC2,CC(C)C(=O)N(Cc1ccc(F)cc1F)[C@H]1CCNC1
6754,6775,CHEMBL609624,ZBHICRAJUNKGFK-QNGOZBTKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20020710.0,ACTIVITY,=,21.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by displacement assay,Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.,J. Med. Chem.,PUBLICATION,,21.0,CN\1C2=C(C=C(C=C2)OC(F)(F)F)S/C1=N\NC(=O)CC3CCCC3,Cn1/c(=N/NC(=O)CC2CCCC2)sc2cc(OC(F)(F)F)ccc21
6755,6776,CHEMBL2206520,ZBINDVNASLJSJF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,107.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.97061622231479,CC1=CC2=C(CN(CC2C3=CC=CC=C3)C)C=C1,Cc1ccc2c(c1)C(c1ccccc1)CN(C)C2
6756,6777,CHEMBL471,ZBMZVLHSJCTVON-UHFFFAOYSA-N,SOTALOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
6757,6778,CHEMBL471,ZBMZVLHSJCTVON-UHFFFAOYSA-N,SOTALOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
6758,6779,CHEMBL2338039,ZBOZPXXCXYETEE-YJBOKZPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,39.81,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,CC1=C(C=CC(=C1)Cl)O[C@H]([C@H]2CCNC2)C3=CC=CC=C3,Cc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@H]1CCNC1
6759,6780,CHEMBL1077,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,BROMFENAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
6760,6781,CHEMBL1077,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,BROMFENAC,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
6761,6782,CHEMBL415886,ZBPXHTCVLBTEET-LZWSPWQCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.44,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.44,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)/C=C/C4=CC=C(C=C4)Cl,O=C(/C=C/c1ccc(Cl)cc1)N1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6762,6783,CHEMBL415886,ZBPXHTCVLBTEET-LZWSPWQCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.37,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.37,C1CN(CCN1CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)/C=C/C4=CC=C(C=C4)Cl,O=C(/C=C/c1ccc(Cl)cc1)N1CCN(CCOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
6763,6784,CHEMBL498565,ZCFQGAKEQPCWDE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,=,11970.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,4.921905849593589,CN(CCC1=CC=CC=C1OC(F)(F)F)CCN2CCCC2,CN(CCc1ccccc1OC(F)(F)F)CCN1CCCC1
6764,6785,CHEMBL2096878,ZCJYSKHDYKCJTO-CFBBYLOMSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,238.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,6.623423042943487,CC1=CC=C(C=C1)[C@@H]2CC3CCC([C@@H]2C4=CC=C(C=C4)OC)N3C,COc1ccc([C@H]2C3CCC(C[C@H]2c2ccc(C)cc2)N3C)cc1
6765,6786,CHEMBL224062,ZCJYSKHDYKCJTO-MOUZIVPDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,1.23,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,8.910094888560602,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=CC=C(C=C4)OC)N3C,COc1ccc([C@@H]2C3CCC(C[C@@H]2c2ccc(C)cc2)N3C)cc1
6766,6787,CHEMBL264160,ZCLPMZOFUORDSQ-ROUUACIJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1090.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.962573502059376,COC1=CC(=C(C=C1)O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3)Cl,COc1ccc(O[C@@H](c2ccccc2)[C@@H]2CNCCO2)c(Cl)c1
6767,6788,CHEMBL207804,ZCPBUGPJVONOEH-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,3.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.0,CN(CC1=CC=CC=C1C(F)(F)F)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CN(Cc1ccccc1C(F)(F)F)C1CCNCC1
6768,6789,CHEMBL554800,ZCSHCEYGULDLOB-SCGPDRHWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16413778.0,INHIBITION,=,3.8,%,,,,,,,,,,,,,,,Displacement of [3H]5-HT from DAT at 1000 nM,Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.8,COC1=CC=CC=C1C[C@]([C@@H]2CNCCO2)(C3=CC=CC=C3)O.Cl.Cl.Cl,COc1ccccc1C[C@@](O)(c1ccccc1)[C@@H]1CNCCO1
6769,6790,CHEMBL466501,ZCUPCXFJNBQNMK-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,4.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC=C(C=C2)Cl)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccc(Cl)cc1
6770,6791,CHEMBL469606,ZCVDRKAWDMMKKP-AWEZNQCLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN([C@H]1CCNC1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2,CN([C@H]1CCNC1)S(=O)(=O)c1ccc2ccccc2c1
6771,6792,CHEMBL469605,ZCVDRKAWDMMKKP-CQSZACIVSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN([C@@H]1CCNC1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2,CN([C@@H]1CCNC1)S(=O)(=O)c1ccc2ccccc2c1
6772,6793,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
6773,6794,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
6774,6795,CHEMBL207634,ZDCUVFAPACGOSD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-23.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-23.0,CC(C)(CCN(CC1=C(C=C(C=C1)F)C(F)(F)F)C2CCNCC2)C#N.C(C(C(=O)O)O)(C(=O)O)O,CC(C)(C#N)CCN(Cc1ccc(F)cc1C(F)(F)F)C1CCNCC1
6775,6796,CHEMBL3703739,ZDIVPUUGCMEOOI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,5.8,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,8.236572006437061,C1C(C2=CC(=C(C=C2CN1)C3=CC=C(C=C3)C(=O)N)F)C4=CC(=C(C=C4)Cl)Cl,NC(=O)c1ccc(-c2cc3c(cc2F)C(c2ccc(Cl)c(Cl)c2)CNC3)cc1
6776,6797,CHEMBL377900,ZDQCOGINXTZCCG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,>,4000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C1CN(CCN1)C(CC2=C(C=CC(=C2)Cl)Cl)C3=CC=CC=C3,Clc1ccc(Cl)c(CC(c2ccccc2)N2CCNCC2)c1
6777,6798,CHEMBL466293,ZDXWQKDOOAYJBD-SJORKVTESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,INHIBITION,=,6.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 1 uM,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CNC[C@H]([C@H](C1=CC=CC=C1)N(C)C2=CC=C(C=C2)F)O,CNC[C@@H](O)[C@H](c1ccccc1)N(C)c1ccc(F)cc1
6778,6799,CHEMBL3323175,ZDZGDSLKDOSHHZ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,6.9,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,8.161150909262744,CN1CC(C2=C(C1)C=C(C=C2)O)C3=CC4=C(C=C3)SC=C4,CN1Cc2cc(O)ccc2C(c2ccc3sccc3c2)C1
6779,6800,CHEMBL2112075,ZEBNDUQLNGYBNL-VEIFNGETSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19492813.0,IC50,=,200.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.,J. Med. Chem.,PUBLICATION,,6.698970004336019,CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=C(C(=CC=C3)Cl)C#N)O.Cl,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N
6780,6801,CHEMBL89469,ZECSPXOBAAGUES-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10956207.0,IC50,=,408.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to the dopamine transporter in cynomolgus (macaca fascicularis) monkey caudate putamen.,2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,6.38933983691012,CN1C2CCC1C(=C(C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)C1=C(c2ccc(F)cc2)CC2CCC1N2C
6781,6802,CHEMBL89469,ZECSPXOBAAGUES-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,408.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,6.38933983691012,CN1C2CCC1C(=C(C2)C3=CC=C(C=C3)F)C(=O)OC,COC(=O)C1=C(c2ccc(F)cc2)CC2CCC1N2C
6782,6803,CHEMBL3704757,ZEFQZGJPKZZHJW-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2.79,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.554395796726402,CCOC1=CC=C(C=C1)C2(CCC2)C[C@@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@@H](C)CCNCCCC(N)=O)CCC2)cc1
6783,6804,CHEMBL3704757,ZEFQZGJPKZZHJW-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,130.3,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.885055584287414,CCOC1=CC=C(C=C1)C2(CCC2)C[C@@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@@H](C)CCNCCCC(N)=O)CCC2)cc1
6784,6805,CHEMBL3704757,ZEFQZGJPKZZHJW-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,6515.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.1860855799513965,CCOC1=CC=C(C=C1)C2(CCC2)C[C@@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@@H](C)CCNCCCC(N)=O)CCC2)cc1
6785,6806,CHEMBL3704757,ZEFQZGJPKZZHJW-KRWDZBQOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,130.3,NM,317688,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.885055584287414,CCOC1=CC=C(C=C1)C2(CCC2)C[C@@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@@H](C)CCNCCCC(N)=O)CCC2)cc1
6786,6807,CHEMBL3704758,ZEFQZGJPKZZHJW-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,328.9,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.4829361265173455,CCOC1=CC=C(C=C1)C2(CCC2)C[C@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@H](C)CCNCCCC(N)=O)CCC2)cc1
6787,6808,CHEMBL3704758,ZEFQZGJPKZZHJW-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,1086.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.9641701747471725,CCOC1=CC=C(C=C1)C2(CCC2)C[C@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@H](C)CCNCCCC(N)=O)CCC2)cc1
6788,6809,CHEMBL3704758,ZEFQZGJPKZZHJW-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,4026.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.3951262294473645,CCOC1=CC=C(C=C1)C2(CCC2)C[C@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@H](C)CCNCCCC(N)=O)CCC2)cc1
6789,6810,CHEMBL3704758,ZEFQZGJPKZZHJW-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,4026.0,NM,317689,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.3951262294473645,CCOC1=CC=C(C=C1)C2(CCC2)C[C@H](C)CCNCCCC(=O)N,CCOc1ccc(C2(C[C@H](C)CCNCCCC(N)=O)CCC2)cc1
6790,6811,CHEMBL3704756,ZEFQZGJPKZZHJW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,5.49,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,8.260427655549908,CCOC1=CC=C(C=C1)C2(CCC2)CC(C)CCNCCCC(=O)N,CCOc1ccc(C2(CC(C)CCNCCCC(N)=O)CCC2)cc1
6791,6812,CHEMBL3704756,ZEFQZGJPKZZHJW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,471.6,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.326426203576949,CCOC1=CC=C(C=C1)C2(CCC2)CC(C)CCNCCCC(=O)N,CCOc1ccc(C2(CC(C)CCNCCCC(N)=O)CCC2)cc1
6792,6813,CHEMBL3704756,ZEFQZGJPKZZHJW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,>,10000.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,5.0,CCOC1=CC=C(C=C1)C2(CCC2)CC(C)CCNCCCC(=O)N,CCOc1ccc(C2(CC(C)CCNCCCC(N)=O)CCC2)cc1
6793,6814,CHEMBL3704756,ZEFQZGJPKZZHJW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,471.6,NM,317687,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,6.326426203576949,CCOC1=CC=C(C=C1)C2(CCC2)CC(C)CCNCCCC(=O)N,CCOc1ccc(C2(CC(C)CCNCCCC(N)=O)CCC2)cc1
6794,6815,CHEMBL260038,ZEFZLXPQUSMAFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18417343.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human recombinant DAT expressed in HEK293 cells,Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=C1)OC2=C(C=NC(=C2)C)CNC)OC,CNCc1cnc(C)cc1Oc1ccc(C)cc1OC
6795,6816,CHEMBL3331507,ZEIUBTWYEVLKJP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,394.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.404503778174425,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC(=CC=C4)Cl,Clc1cccc(N(Cc2ccc3ccccc3c2)C2CNC2)c1
6796,6817,CHEMBL561,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,LOMEFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
6797,6818,CHEMBL561,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,LOMEFLOXACIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
6798,6819,CHEMBL3309705,ZEMHRXZHHOGKCW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6799,6820,CHEMBL3309705,ZEMHRXZHHOGKCW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6800,6821,CHEMBL3309705,ZEMHRXZHHOGKCW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,INHIBITION,=,100.0,%,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,100.0,C1C(CN1)CC(C2=CC(=C(C=C2)Cl)Cl)OC3=CC(=CC=C3)F,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(Cl)c2)c1
6801,6822,CHEMBL374712,ZEOHVQFWFVMPGM-FGDMXMHKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,11.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.931814138253839,CN1[C@@H]2CCC1C[C@H]([C@H]2C(=O)OC)C3=CC=C(C=C3)Cl,COC(=O)[C@@H]1[C@H](c2ccc(Cl)cc2)CC2CC[C@H]1N2C
6802,6823,CHEMBL2096858,ZEOHVQFWFVMPGM-HXSCFSKGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,25.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.602059991327962,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)[C@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C
6803,6824,CHEMBL608703,ZEOHVQFWFVMPGM-JYVUQVBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,2.7,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,8.568636235841014,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C
6804,6825,CHEMBL608703,ZEOHVQFWFVMPGM-JYVUQVBGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21458259.0,KI,=,5.1,NM,,,cell_based,,,,,LLC-PK1,,,,,,,Displacement of [125I]-IPT from DAT transfected in pig LLC-PK1 cells by radioligand competition binding assay,Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.292429823902062,CN1C2CCC1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@@H]1c1ccc(Cl)cc1)N2C
6805,6826,CHEMBL610897,ZEOHVQFWFVMPGM-LMRVLLHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,1.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,8.958607314841776,CN1[C@@H]2CCC1C([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@@H]1c1ccc(Cl)cc1)N2C
6806,6827,CHEMBL610897,ZEOHVQFWFVMPGM-LMRVLLHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,1.7,NM,,,,,,,,,,,,,,,Ability to displace [3H]mazindol from dopamine transporter,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,CN1[C@@H]2CCC1C([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@@H]1c1ccc(Cl)cc1)N2C
6807,6828,CHEMBL610897,ZEOHVQFWFVMPGM-LMRVLLHPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,3.2,NM,,,,,,,,,,,,,,,Inhibitory concentration against [3H]dopamine uptake,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.494850021680094,CN1[C@@H]2CCC1C([C@H](C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C2CC[C@H](C[C@@H]1c1ccc(Cl)cc1)N2C
6808,6829,CHEMBL375888,ZEOHVQFWFVMPGM-SHWKFHJASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,3.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,8.508638306165727,CN1C2CCC1[C@H]([C@@H](C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)[C@@H]1C2CCC(C[C@H]1c1ccc(Cl)cc1)N2C
6809,6830,CHEMBL306208,ZEOHVQFWFVMPGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,8.853871964321762,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
6810,6831,CHEMBL306208,ZEOHVQFWFVMPGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,1.4,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.853871964321762,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
6811,6832,CHEMBL306208,ZEOHVQFWFVMPGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9276012.0,IC50,=,2.4,NM,,,,,,,,,,,,,,,inhibition of [3H]WIN-35428 binding to the dopamine transporter (DAT) in monkey caudate-putamen.,2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters.,J. Med. Chem.,PUBLICATION,,8.619788758288394,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
6812,6833,CHEMBL306208,ZEOHVQFWFVMPGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,IC50,=,1.7,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [3H]DA binding to dopamine (DAT) transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
6813,6834,CHEMBL306208,ZEOHVQFWFVMPGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,KI,=,1.1,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [125I]RTI-55 binding to dopamine transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.958607314841776,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
6814,6835,CHEMBL306208,ZEOHVQFWFVMPGM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,1.5,,,,,,,,,,,,,,,,Ratio of uptake inhibition to binding affinity to human DAT (IC50/Ki),Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.5,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)OC,COC(=O)C1C(c2ccc(Cl)cc2)CC2CCC1N2C
6815,6836,CHEMBL611963,ZERAVOYPKCPVKA-VQTBRTBSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,800.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.096910013008057,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCC5=CC=C(C=C5)NC(=O)[C@H]6[C@H](CC7CCC6N7C)C8=CC=C(C=C8)C9=CSC=C9,CN1C2CCC1[C@@H](C(=O)Nc1ccc(CNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(-c5ccsc5)cc3)N4C)cc1)[C@@H](c1ccc(-c3ccsc3)cc1)C2
6816,6837,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11750180.0,KI,=,240.0,NM,,,,,,,,,,,,,,,,,,,,6.619788758288393,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6817,6838,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14643350.0,KI,=,240.0,NM,,,,,,,,,,,,,,,Ability to inhibit the reuptake of dopamine at human dopamine transporter,"Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.619788758288393,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6818,6839,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,=,240000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]WIN-35428 binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.6197887582883936,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6819,6840,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16220969.0,KI,=,370.0,NM,,,,,,,,,,,,,,,Inhibition constant against dopamine transporter,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,6.431798275933005,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6820,6841,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750359.0,IC50,=,870.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of DA transporter expressed in HEK293 cells,"N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0604807473813835,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6821,6842,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16750363.0,IC50,=,870.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0604807473813835,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6822,6843,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17267217.0,IC50,=,870.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human DAT expressed in HEK293 cells,N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0604807473813835,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6823,6844,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,=,660.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.180456064458133,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6824,6845,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,435.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.361510743045362,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6825,6846,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18954038.0,IC50,=,660.0,NM,,,cell_based,,,,,HEK293,,,,,,,"Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",J. Med. Chem.,PUBLICATION,,6.180456064458133,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6826,6847,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19359175.0,IC50,=,590.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressed in HEK293 cells,"4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.229147988357856,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6827,6848,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19592243.0,KI,=,251.19,NM,,,,,,,,,,,,,,,Inhibition of DAT,"Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6828,6849,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,435.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.361510743045362,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6829,6850,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6830,6851,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20471260.0,KI,=,435.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT expressed in HEK293 cells by scintillation proximity assay,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.361510743045362,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6831,6852,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23347683.0,KI,=,316.23,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane,A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6832,6853,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24974340.0,IC50,=,977.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.010105436281228,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6833,6854,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,977.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.010105436281228,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6834,6855,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,484.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,6.315154638355588,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
6835,6856,CHEMBL336920,ZEUITGRIYCTCEM-QGZVFWFLSA-N,(R)-DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,=,809.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,6.092051478387727,CNCC[C@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@@H](Oc1cccc2ccccc12)c1cccs1
6836,6857,CHEMBL336920,ZEUITGRIYCTCEM-QGZVFWFLSA-N,(R)-DULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,=,550.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,6.259637310505756,CNCC[C@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@@H](Oc1cccc2ccccc12)c1cccs1
6837,6858,CHEMBL424660,ZEUITGRIYCTCEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14573386.0,KI,=,240.0,NM,,,,,,,,,,,,,,,,,,,,6.619788758288393,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCCC(Oc1cccc2ccccc12)c1cccs1
6838,6859,CHEMBL424660,ZEUITGRIYCTCEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,230.0,NM,,,,,,,,,,,,,,,,,,,,6.638272163982407,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCCC(Oc1cccc2ccccc12)c1cccs1
6839,6860,CHEMBL424660,ZEUITGRIYCTCEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14744476.0,KI,=,439.0,NM,,,,,,,,,,,,,,,,,,,,6.357535479757877,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCCC(Oc1cccc2ccccc12)c1cccs1
6840,6861,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
6841,6862,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
6842,6863,CHEMBL3331478,ZFASHAXWGYISLR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,4.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,C1C(CN1)N(CC2=CC=C(C=C2)Cl)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc(CN(c2ccc(Cl)c(Cl)c2)C2CNC2)cc1
6843,6864,CHEMBL477584,ZFAZBQUXCIBGID-ZDUSSCGKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18625557.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells by scintillation counting,N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C)C(=O)N(CC1=C(C=C(C=C1)C(F)(F)F)F)[C@H]2CCNC2,CC(C)C(=O)N(Cc1ccc(C(F)(F)F)cc1F)[C@H]1CCNC1
6844,6865,CHEMBL595767,ZFJXYVKPCIOHJP-DDZGMJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19560930.0,KI,=,93.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]methyl 3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylate from human recombinant DAT expressed in african green monkey COS1 cells by liquid scintillation counting,An extended study of dimeric phenyl tropanes.,Bioorg. Med. Chem.,PUBLICATION,,7.031517051446066,CN1C2CCC1[C@@H]([C@H](C2)C3=CC=C(C=C3)C4=CSC=C4)C(=O)NCC5=CC=C(C=C5)CNC(=O)[C@H]6[C@H](CC7CCC6N7C)C8=CC=C(C=C8)C9=CSC=C9,CN1C2CCC1[C@@H](C(=O)NCc1ccc(CNC(=O)[C@H]3C4CCC(C[C@@H]3c3ccc(-c5ccsc5)cc3)N4C)cc1)[C@@H](c1ccc(-c3ccsc3)cc1)C2
6845,6866,CHEMBL464099,ZFLRVRLYWHNAEC-AWEZNQCLSA-N,N-METHYLLAUROTETANINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25695425.0,KI,>,950.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN35428 from human recombinant DAT expressed in HEK cell membranes by radioligand binding assay,Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors.,J. Nat. Prod.,PUBLICATION,,6.022276394711152,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)O)OC)OC,COc1cc2c(cc1O)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C
6846,6867,CHEMBL802,ZFMITUMMTDLWHR-UHFFFAOYSA-N,MINOXIDIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,N=c1nc(N2CCCCC2)cc(N)n1O
6847,6868,CHEMBL802,ZFMITUMMTDLWHR-UHFFFAOYSA-N,MINOXIDIL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,N=c1nc(N2CCCCC2)cc(N)n1O
6848,6869,CHEMBL289554,ZFNSJMUDZCPHCI-SYZQJQIISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.87,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.87,COC1=CC=C(C=C1)/C=C/C(=O)N2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COc1ccc(/C=C/C(=O)N2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
6849,6870,CHEMBL289554,ZFNSJMUDZCPHCI-SYZQJQIISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.31,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.31,COC1=CC=C(C=C1)/C=C/C(=O)N2CCN(CC2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,COc1ccc(/C=C/C(=O)N2CCN(CCOC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
6850,6871,CHEMBL466750,ZFPHIEDKJKNXOI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,10.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.0,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC(=O)CC4=CC=CC=C4,O=C(Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
6851,6872,CHEMBL249854,ZFRLEPMXXGKKBN-WPFOTENUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17418570.0,KI,=,6500.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357143,CC1=C(SC(=N1)NC(=O)N[C@@H]2CN(CC[C@H]2CN3CCC[C@H](C3)CC4=CC=C(C=C4)F)C(=O)C)C(=O)C,CC(=O)c1sc(NC(=O)N[C@@H]2CN(C(C)=O)CC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C
6852,6873,CHEMBL482496,ZFUOLNAKPBFDIJ-VQBNBCTGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468904.0,KI,>,500.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine uptake transporter,"High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.",Bioorg. Med. Chem.,PUBLICATION,,6.301029995663981,[3H]C([3H])([3H])OC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC([3H])([3H])[3H])I)OC,[H]C([H])([H])Oc1cc(I)c(OC)cc1CCNCc1ccccc1OC([H])([H])[H]
6853,6874,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Cn1c(=O)c2[nH]cnc2n(C)c1=O
6854,6875,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Cn1c(=O)c2[nH]cnc2n(C)c1=O
6855,6876,CHEMBL2432061,ZFZXJOHWFSRUAO-LLOIJXFCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CC1=CC(=C(C(=C1)OC)OC)OC)[C@H]2C3C4CC5C2C6C3CC4C56,COc1cc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC
6856,6877,CHEMBL3334791,ZGHQVNYQNYKDCM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,35.7,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,35.7,CN(C)CCC(C1=CC=C(C=C1)Cl)N2CCOCC2,CN(C)CCC(c1ccc(Cl)cc1)N1CCOCC1
6857,6878,CHEMBL130477,ZGLAJTSGABGHND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,3.7,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.431798275933005,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
6858,6879,CHEMBL130477,ZGLAJTSGABGHND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,4.2,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from Dopamine Transporter in guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.3767507096021,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
6859,6880,CHEMBL130477,ZGLAJTSGABGHND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,1.7,NM,,,,,,,,,,,,,,,Ability to displace [125I]- RTI-55 binding at the Dopamine transporter site on HEK cells expressing cDNA for the human transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.769551078621726,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
6860,6881,CHEMBL130477,ZGLAJTSGABGHND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,4.2,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.3767507096021,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
6861,6882,CHEMBL130477,ZGLAJTSGABGHND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,KI,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of [125I]- RTI -55 binding at the Dopamine transporter sites on HEK-hDAT cells,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.769551078621726,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
6862,6883,CHEMBL130477,ZGLAJTSGABGHND-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,10.1,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,10.1,C1CN=C2C3=CC=CC=C3C(N2C1)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCCN21
6863,6884,CHEMBL239297,ZGPGDMLZVXIWAH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,>,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.0,CN(C)CC1=C(C=CC(=C1)OCCF)SC2=C(C=C(C=C2)Br)N,CN(C)Cc1cc(OCCF)ccc1Sc1ccc(Br)cc1N
6864,6885,CHEMBL606120,ZGPLGLWQWPXKAN-HOTUBEGUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,457.09,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.3399982798971175,C1[C@H]2[C@@H]([C@]2(CN1)C3=CC(=C(C=C3)Cl)Cl)CO,OC[C@H]1[C@@H]2CNC[C@]12c1ccc(Cl)c(Cl)c1
6865,6886,CHEMBL592375,ZGPLGLWQWPXKAN-YGOYTEALSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,478.63,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.320000083770781,C1[C@H]2[C@H]([C@]2(CN1)C3=CC(=C(C=C3)Cl)Cl)CO,OC[C@@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
6866,6887,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
6867,6888,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
6868,6889,CHEMBL403570,ZGYZPKKUJVRLKR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,220.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,CC1=CC=CC=C1OC(=O)C2=C(CCC2)C3=CC(=C(C=C3)Cl)Cl,Cc1ccccc1OC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
6869,6890,CHEMBL1173279,ZHBAFJPTWCEURK-IINYFYTJSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,16000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,4.795880017344076,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)OC)O,COc1cccc([C@]2(O)OCC(C)(C)N[C@H]2C)c1
6870,6891,CHEMBL1824777,ZHHLHBNBIKLLJG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21788137.0,INHIBITION,,,,Not Determined,,,,,,,,,,,,,,Inhibition of DAT transporter at 10 uM by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2CC3CC1CC(C2)(N3CC4=CC=CC=C4)O.Cl,OC12CC3CC(CC(C3)N1Cc1ccccc1)C2
6871,6892,CHEMBL497549,ZHLYFJIHCTWRCA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18461921.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,Trifluoromethoxyl substituted phenylethylene diamines as high affinity sigma receptor ligands with potent anti-cocaine actions.,J. Med. Chem.,PUBLICATION,,5.0,CN(CCC1=CC(=CC=C1)OC(F)(F)F)CCN2CCCCC2,CN(CCc1cccc(OC(F)(F)F)c1)CCN1CCCCC1
6872,6893,CHEMBL375118,ZHNMSSREJSABQA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,27.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.568636235841013,C1CCC(C1)C(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(C2CCCC2)C2CCCCN2)cc1
6873,6894,CHEMBL375118,ZHNMSSREJSABQA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,240.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.619788758288393,C1CCC(C1)C(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(C2CCCC2)C2CCCCN2)cc1
6874,6895,CHEMBL375118,ZHNMSSREJSABQA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,36.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,7.443697499232713,C1CCC(C1)C(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(C2CCCC2)C2CCCCN2)cc1
6875,6896,CHEMBL375118,ZHNMSSREJSABQA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,690.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.161150909262744,C1CCC(C1)C(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(C2CCCC2)C2CCCCN2)cc1
6876,6897,CHEMBL260823,ZHYJMAJSBAQRIU-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,760.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1191864077192095,C1CO[C@H](CN1)[C@@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)F)Cl,Fc1ccc(O[C@H](c2ccccc2)[C@H]2CNCCO2)c(Cl)c1
6877,6898,CHEMBL407732,ZHYJMAJSBAQRIU-IRXDYDNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18387300.0,KI,=,1170.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.931814138253839,C1CO[C@@H](CN1)[C@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)F)Cl,Fc1ccc(O[C@@H](c2ccccc2)[C@@H]2CNCCO2)c(Cl)c1
6878,6899,CHEMBL3331485,ZIAIFHJOUYILEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,684.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.1649438982798825,C1C(CN1)CN(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4,c1ccc(N(Cc2ccc3ccccc3c2)CC2CNC2)cc1
6879,6900,CHEMBL3331485,ZIAIFHJOUYILEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,4.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,C1C(CN1)CN(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4,c1ccc(N(Cc2ccc3ccccc3c2)CC2CNC2)cc1
6880,6901,CHEMBL1824785,ZILQWXOKQUVSTI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21788137.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT transporter at 10 uM by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,50.0,C1C2CC3CC1CC(C2)N3CC4=CC(=CC=C4)F.Cl,Fc1cccc(CN2C3CC4CC(C3)CC2C4)c1
6881,6902,CHEMBL1944972,ZILVUMKQTCCDKV-XNISGKROSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22300887.0,KI,=,46.77,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN35428 from human cloned DAT receptor expressed in human HEK293 cells,QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).,Bioorg. Med. Chem.,PUBLICATION,,7.330032630091495,CC1=C(C=C(C=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)I,COC(=O)[C@H]1[C@@H](c2ccc(C)c(I)c2)C[C@@H]2CC[C@H]1N2C
6882,6903,CHEMBL444985,ZINGRQZUIVEPKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19282174.0,IC50,=,8800.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of radiolabeled dopamine reuptake at human DAT expressed in HEK293 cells,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.055517327849831,C1CNCCC1COC2=CC3=C(C=CC(=C3)C#N)C=C2,N#Cc1ccc2ccc(OCC3CCNCC3)cc2c1
6883,6904,CHEMBL481863,ZIQGASWXUSSORV-UHFFFAOYSA-N,JNJ-10392980,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18588282.0,INHIBITION,=,13.0,%,,,,,,,,,,,,,,,Inhibition of human DAT at 1 uM,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,PUBLICATION,,13.0,C1CCN(CC1)CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4O3,c1ccc2oc(Oc3ccc(OCCN4CCCCC4)cc3)nc2c1
6884,6905,CHEMBL666,ZJAOAACCNHFJAH-UHFFFAOYSA-N,FOSCARNET,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(O)P(=O)(O)O,O=C(O)P(=O)(O)O
6885,6906,CHEMBL666,ZJAOAACCNHFJAH-UHFFFAOYSA-N,FOSCARNET,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(O)P(=O)(O)O,O=C(O)P(=O)(O)O
6886,6907,CHEMBL287257,ZJDCGVDEEHWEIG-UHFFFAOYSA-N,DICLOFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,4.6,NM,,,,,,,,,,,,,,,,,,,,8.337242168318426,CN1CC(C2=C(C1)C=C(C=C2)OC)C3=CC(=C(C=C3)Cl)Cl,COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
6887,6908,CHEMBL287257,ZJDCGVDEEHWEIG-UHFFFAOYSA-N,DICLOFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,8.0,NM,,,,,,,,,,,,,,,,,,,,8.096910013008056,CN1CC(C2=C(C1)C=C(C=C2)OC)C3=CC(=C(C=C3)Cl)Cl,COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
6888,6909,CHEMBL287257,ZJDCGVDEEHWEIG-UHFFFAOYSA-N,DICLOFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,240.0,NM,,,,,,,,,,,,,,,,,,,,6.619788758288393,CN1CC(C2=C(C1)C=C(C=C2)OC)C3=CC(=C(C=C3)Cl)Cl,COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
6889,6910,CHEMBL287257,ZJDCGVDEEHWEIG-UHFFFAOYSA-N,DICLOFENSINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,606.0,NM,,,,,,,,,,,,,,,,,,,,6.217527375833714,CN1CC(C2=C(C1)C=C(C=C2)OC)C3=CC(=C(C=C3)Cl)Cl,COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
6890,6911,CHEMBL3323186,ZJEDITUWACTVKK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,INHIBITION,=,5.0,%,,,cell_based,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human DAT expressed in HEK293E cells at 100 nM after 1 hr by liquid scintillation counting",,ACS Med. Chem. Lett.,PUBLICATION,,5.0,CN1CC(C2=C(C1)C=C(C=C2)N3CCCC3)C4=CC5=CC=CC=C5S4,CN1Cc2cc(N3CCCC3)ccc2C(c2cc3ccccc3s2)C1
6891,6912,CHEMBL3704752,ZJFMMMXNSXCMOB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,27.8,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.555955204081924,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6892,6913,CHEMBL3704752,ZJFMMMXNSXCMOB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,52.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.278189384787455,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6893,6914,CHEMBL3704752,ZJFMMMXNSXCMOB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,77.7,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.1095789811990855,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6894,6915,CHEMBL3704752,ZJFMMMXNSXCMOB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,52.7,NM,317682,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros, B. et al., Trends Pharmcol. Sci. 1993, 14, 43-49; Gu, H. et al., J. Biol. Chem. 1994, 269(10), 7124-7130; Shearman, L. P. et al, Am. J. Physiol., 1998, 275(6 Pt 1), C1621-1629; Wolf, W. A. et al., J. Biol. Chem. 1992, 267(29), 20820-20825). The human recombinant transporter proteins dopamine (DAT), norepinephrine (NET) and serotonin (SERT) were selected for the in vitro assays. The radioligand binding assays were carried out at 11 different test concentrations 0.1 nm to 1 M.",Methods of using cycloalkylmethylamine derivatives,,PATENT,,7.278189384787455,CCCC(=O)NCCNC(CC(C)C)C1(CCC1)C2=CC(=C(C=C2)Cl)Cl,CCCC(=O)NCCNC(CC(C)C)C1(c2ccc(Cl)c(Cl)c2)CCC1
6895,6916,CHEMBL1170397,ZJJWZZFPUVRGQQ-INIZCTEOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,50.12,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1COCCC1C[C@H]2CNCCN2C3=CC4=C(C=C3)NN=C4,c1cc2[nH]ncc2cc1N1CCNC[C@@H]1CC1CCOCC1
6896,6917,CHEMBL1171007,ZJJWZZFPUVRGQQ-MRXNPFEDSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,1000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1COCCC1C[C@@H]2CNCCN2C3=CC4=C(C=C3)NN=C4,c1cc2[nH]ncc2cc1N1CCNC[C@H]1CC1CCOCC1
6897,6918,CHEMBL1170396,ZJJWZZFPUVRGQQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20570146.0,KI,=,39.81,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]-Vanoxerine from DAT expressed in HEK293 cells by scintillation proximity assay,2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1COCCC1CC2CNCCN2C3=CC4=C(C=C3)NN=C4,c1cc2[nH]ncc2cc1N1CCNCC1CC1CCOCC1
6898,6919,CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
6899,6920,CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
6900,6921,CHEMBL1684045,ZJNJPYFFMXVAGY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,30.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)NC,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
6901,6922,CHEMBL1684045,ZJNJPYFFMXVAGY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,86.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0655015487564325,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)NC,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
6902,6923,CHEMBL1684045,ZJNJPYFFMXVAGY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310612.0,IC50,=,300.0,NM,,,cell_based,,,,,COS-7,,,,,,,Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.522878745280337,CC(C1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl)NC,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1
6903,6924,CHEMBL401804,ZJRXMULNBNPBBB-SDBXPKJASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC(=C(S2)Cl)Cl,CCN(CC)C(=O)[C@@]1(c2cc(Cl)c(Cl)s2)C[C@H]1CN
6904,6925,CHEMBL421546,ZJVFNVXAUVNIQE-URSIVYNOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11472216.0,IC50,=,45.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]WIN-35428 binding to Dopamine transporter in rhesus (Macaca mulatta) or cynomolgus monkey (Macaca fascicularis) caudate-putamen,Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.,J. Med. Chem.,PUBLICATION,,7.346787486224656,CN1C2C[C@H](C1C(=C(C2)C3=CC4=CC=CC=C4C=C3)C(=O)OC)O,COC(=O)C1=C(c2ccc3ccccc3c2)CC2C[C@@H](O)C1N2C
6905,6926,CHEMBL245061,ZKDZVMXERDGTGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,1900.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.721246399047171,COC(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
6906,6927,CHEMBL245061,ZKDZVMXERDGTGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,5500.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,5.259637310505756,COC(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
6907,6928,CHEMBL245061,ZKDZVMXERDGTGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,512861383991366.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-5.710000000000001,COC(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
6908,6929,CHEMBL245061,ZKDZVMXERDGTGV-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,1900.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.721246399047171,COC(=O)C1=C(CCC1)C2=CC(=C(C=C2)Cl)Cl,COC(=O)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
6909,6930,CHEMBL578611,ZKFFJBXJJFDBJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,,,,Not Determined,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,,CC(C(=O)C1=CC(=CC(=C1)Cl)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cc(Cl)cc(Cl)c1
6910,6931,CHEMBL578611,ZKFFJBXJJFDBJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,5.0,CC(C(=O)C1=CC(=CC(=C1)Cl)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cc(Cl)cc(Cl)c1
6911,6932,CHEMBL578611,ZKFFJBXJJFDBJM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,>,100.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,7.0,CC(C(=O)C1=CC(=CC(=C1)Cl)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cc(Cl)cc(Cl)c1
6912,6933,CHEMBL41974,ZKMLAACIBJTRKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,5.83,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,5.83,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
6913,6934,CHEMBL41974,ZKMLAACIBJTRKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.07,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.07,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
6914,6935,CHEMBL41974,ZKMLAACIBJTRKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.72,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.72,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
6915,6936,CHEMBL41974,ZKMLAACIBJTRKI-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,8.0,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,8.0,C1CN(CCN1CCCC2=CC=CC=C2)CCCN(CC3=CC=CC=C3)C4=CC=CC=C4,c1ccc(CCCN2CCN(CCCN(Cc3ccccc3)c3ccccc3)CC2)cc1
6916,6937,CHEMBL2205811,ZKOQRCXMSDAJIR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,=,3180.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.497572880015566,COC1=CC=CC(=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1
6917,6938,CHEMBL1818453,ZKPUOIMTKQGENL-IAGOWNOFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21550808.0,KI,=,125.89,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT by scintillation proximity assay,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.900008766455317,CC1=CN(N=C1)C[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Cc1cnn(C[C@@]23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)c1
6918,6939,CHEMBL3334786,ZKYDECUCAZOZDB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25164761.0,INHIBITION,=,40.1,%,,,cell_based,,,,,,,,,,,,Inhibition of [3H]-DA uptake in human dopamine transporter expressed in HEK293 cells at 10 uM by scintillation counting,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,Eur. J. Med. Chem.,PUBLICATION,,40.1,CN(C)CCC(C1=CC=C(C=C1)F)N2CCCCC2,CN(C)CCC(c1ccc(F)cc1)N1CCCCC1
6919,6940,CHEMBL38773,ZLMSKRWURWKHQQ-BQYQJAHWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.26,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.26,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C/C=C/C4=CC=C(C=C4)F,Fc1ccc(/C=C/CN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
6920,6941,CHEMBL38773,ZLMSKRWURWKHQQ-BQYQJAHWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.8,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.8,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C/C=C/C4=CC=C(C=C4)F,Fc1ccc(/C=C/CN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1
6921,6942,CHEMBL511288,ZLNPNQNLLKIKSH-FOYRJYEQSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18556210.0,IC50,=,173.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.,Bioorg. Med. Chem.,PUBLICATION,,6.761953896871206,CC1=CC=C(C=C1)[C@H]2CC3CCC([C@H]2C4=C(C(=NO4)C)C5=CC=C(C=C5)C)N3C.Cl,Cc1ccc(-c2c(C)noc2[C@@H]2C3CCC(C[C@@H]2c2ccc(C)cc2)N3C)cc1
6922,6943,CHEMBL1224382,ZLRRLSAVNUFCQT-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,IC50,=,58.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.236572006437062,CC1=NN(N=N1)[C@@H](CCNC)C2=CC(=C(C=C2)Cl)Cl,CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(C)n1
6923,6944,CHEMBL1224382,ZLRRLSAVNUFCQT-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20724153.0,INHIBITION,=,62.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells at 100 uM,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,62.0,CC1=NN(N=N1)[C@@H](CCNC)C2=CC(=C(C=C2)Cl)Cl,CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(C)n1
6924,6945,CHEMBL1080556,ZMAZHOAGBMLOSO-SFHVURJKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20137933.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1CN(CCN1C(=O)C2=CC3=C(C=C2)C=CN3)C(=O)C4=CC=C(C=C4)C5=CC=CC=C5Cl,C[C@H]1CN(C(=O)c2ccc(-c3ccccc3Cl)cc2)CCN1C(=O)c1ccc2cc[nH]c2c1
6925,6946,CHEMBL1078742,ZMEHJZMEBDWMRH-LBPRGKRZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19647430.0,KI,=,430.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human DAT receptor expressed in HEK293 cells by scintillation counting,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.366531544420414,CC(C)CN([C@H]1CCNC1)C(=O)C2=CC(=C(C=C2)Cl)Cl,CC(C)CN(C(=O)c1ccc(Cl)c(Cl)c1)[C@H]1CCNC1
6926,6947,CHEMBL383873,ZMKPUZMPYBNAFS-WQLSENKSSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16784855.0,KI,=,2.94,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT transfected in HEK293 cells,Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.531652669587842,COC(=O)/C=C\1/CN2C3CCC2C1C(C3)C4=CC=C(C=C4)Br,COC(=O)/C=C1/CN2C3CCC2C1C(c1ccc(Br)cc1)C3
6927,6948,CHEMBL482293,ZMMDUENTAOWDLQ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18571404.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human dopamine transporter expressed in HEK293 cells,Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(C)CC1=C(C=CC(=C1)S(=O)(=O)N)SC2=CC=CC(=C2)C(F)(F)F,CN(C)Cc1cc(S(N)(=O)=O)ccc1Sc1cccc(C(F)(F)F)c1
6928,6949,CHEMBL1627,ZMOPTLXEYOVARP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18783208.0,ACTIVITY,<,50.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT at 10 uM,Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.,J. Med. Chem.,PUBLICATION,,50.0,CNC(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
6929,6950,CHEMBL242273,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,SAFROLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCC1=CC2=C(C=C1)OCO2,C=CCc1ccc2c(c1)OCO2
6930,6951,CHEMBL242273,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,SAFROLE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCC1=CC2=C(C=C1)OCO2,C=CCc1ccc2c(c1)OCO2
6931,6952,CHEMBL2349310,ZMQSLMZOWVGBSM-GXTWGEPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23516963.0,ACTIVITY,,,,Active,,,,,,,,,,,,,,Binding affinity to dopamine transporter (unknown origin),"Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1).",J. Med. Chem.,PUBLICATION,,,C[C@@H](C1=CC=CC=C1)SC2=NC3=C(C(=N2)N[C@H](CC(C)C)CO)SC(=N3)N,CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12
6932,6953,CHEMBL589250,ZMRXSORFBXMBCB-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,2270.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,5.6439741428068775,CC(C(=O)C1=CC(=CC=C1)OC)NC2CCCC2,COc1cccc(C(=O)C(C)NC2CCCC2)c1
6933,6954,CHEMBL268291,ZMXDDKWLCZADIW-UHFFFAOYSA-N,DIMETHYLFORMAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C=O,CN(C)C=O
6934,6955,CHEMBL268291,ZMXDDKWLCZADIW-UHFFFAOYSA-N,DIMETHYLFORMAMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C=O,CN(C)C=O
6935,6956,CHEMBL595063,ZMXLKLOJDLMZFC-INIZCTEOSA-N,(S)-NORDULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1=CC=C2C(=C1)C=CC=C2O[C@@H](CCN)C3=CC=CS3,NCC[C@H](Oc1cccc2ccccc12)c1cccs1
6936,6957,CHEMBL595063,ZMXLKLOJDLMZFC-INIZCTEOSA-N,(S)-NORDULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1=CC=C2C(=C1)C=CC=C2O[C@@H](CCN)C3=CC=CS3,NCC[C@H](Oc1cccc2ccccc12)c1cccs1
6937,6958,CHEMBL594585,ZMXLKLOJDLMZFC-MRXNPFEDSA-N,R-NORDULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1=CC=C2C(=C1)C=CC=C2O[C@H](CCN)C3=CC=CS3,NCC[C@@H](Oc1cccc2ccccc12)c1cccs1
6938,6959,CHEMBL594585,ZMXLKLOJDLMZFC-MRXNPFEDSA-N,R-NORDULOXETINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,=,3549.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,5.449894000652408,C1=CC=C2C(=C1)C=CC=C2O[C@H](CCN)C3=CC=CS3,NCC[C@@H](Oc1cccc2ccccc12)c1cccs1
6939,6960,CHEMBL3703744,ZNELUNAFGGGGOF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,7.1,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,8.148741651280925,C1C(C2=C(CN1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC(=C(C=C4)Cl)Cl,Nc1ccc(-c2ccc3c(c2)CNCC3c2ccc(Cl)c(Cl)c2)nn1
6940,6961,CHEMBL472,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,GLYBURIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
6941,6962,CHEMBL472,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,GLYBURIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
6942,6963,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
6943,6964,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
6944,6965,CHEMBL2093958,ZNSNAOXTBUHNKX-IODNYQNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,27.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing human dopamine transporter,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,7.568636235841013,CCOC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2.Cl,CCOC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
6945,6966,CHEMBL2093958,ZNSNAOXTBUHNKX-IODNYQNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,230.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]-RTI-55 from Dopamine transporter expressed in HEK293 cells,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,6.638272163982407,CCOC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2.Cl,CCOC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
6946,6967,CHEMBL2093958,ZNSNAOXTBUHNKX-IODNYQNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,1730.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing human dopamine transporter,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,5.761953896871206,CCOC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2.Cl,CCOC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
6947,6968,CHEMBL2093958,ZNSNAOXTBUHNKX-IODNYQNNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,2700.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]-RTI-55 from Dopamine transporter expressed in HEK293 cells,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,5.568636235841013,CCOC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2.Cl,CCOC(=O)[C@@H](c1ccccc1)[C@@H]1CCCCN1
6948,6969,CHEMBL534479,ZNSNAOXTBUHNKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,95.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing human dopamine transporter,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,7.022276394711152,CCOC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,CCOC(=O)C(c1ccccc1)C1CCCCN1
6949,6970,CHEMBL534479,ZNSNAOXTBUHNKX-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,319.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]-RTI-55 from Dopamine transporter expressed in HEK293 cells,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,6.496209316942818,CCOC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,CCOC(=O)C(c1ccccc1)C1CCCCN1
6950,6971,CHEMBL1779060,ZOAKYUHDXICZSY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=C1)OC)C(=O)NCCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccc(C)cc1C(=O)NCCN1C2C3C4CC5C6C4C2C6C1(O)C53
6951,6972,CHEMBL371726,ZOMRBJBMKLVVRD-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16202585.0,IC50,=,603.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.219682687859849,CN1C2CCC1C=C(C2)C3=CNC4=CC=CC=C43,CN1C2C=C(c3c[nH]c4ccccc34)CC1CC2
6952,6973,CHEMBL1812744,ZONWPEAFLDQJPL-KKXYHZGYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,7.3,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.136677139879543,CC1=CC2=C(C=C1C)N=C(N2)[C@@H]3[C@H]4CC[C@H](N4C)C[C@@H]3C5=CC=C(C=C5)Cl,Cc1cc2nc([C@H]3[C@@H](c4ccc(Cl)cc4)C[C@@H]4CC[C@H]3N4C)[nH]c2cc1C
6953,6974,CHEMBL1224563,ZOOYCXCRVKSAIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,7.94,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CNCC1(CC2=CC=CC=C2)C(=O)C3=CC(=C4C(=C3)C=CN4)F,O=C(c1cc(F)c2[nH]ccc2c1)C1(Cc2ccccc2)CCNC1
6954,6975,CHEMBL1224563,ZOOYCXCRVKSAIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,12.59,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,C1CNCC1(CC2=CC=CC=C2)C(=O)C3=CC(=C4C(=C3)C=CN4)F,O=C(c1cc(F)c2[nH]ccc2c1)C1(Cc2ccccc2)CCNC1
6955,6976,CHEMBL1224563,ZOOYCXCRVKSAIY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20691589.0,KI,=,199.53,NM,,,,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at dopamine transporter,"Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,C1CNCC1(CC2=CC=CC=C2)C(=O)C3=CC(=C4C(=C3)C=CN4)F,O=C(c1cc(F)c2[nH]ccc2c1)C1(Cc2ccccc2)CCNC1
6956,6977,CHEMBL557528,ZOPKRUALFVBFRZ-MOPGFXCFSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,INHIBITION,=,16.0,%,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells at 10 uM by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,16.0,CCCN1C2=C(C=C(C=C2)F)N(C1=O)[C@@H](C3=CC=CC=C3)[C@@H](CNC)O,CCCn1c(=O)n([C@@H](c2ccccc2)[C@H](O)CNC)c2cc(F)ccc21
6957,6978,CHEMBL1813474,ZOSQXAHBYHMVCA-GXFFZTMASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,141.25,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.850011543508524,C1C[C@H]2CNC[C@]2(C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@]23CCC[C@H]2CNC3)cc1Cl
6958,6979,CHEMBL1813475,ZOSQXAHBYHMVCA-MFKMUULPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,=,123.03,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,6.909988975992852,C1C[C@@H]2CNC[C@@]2(C1)C3=CC(=C(C=C3)Cl)Cl,Clc1ccc([C@@]23CCC[C@@H]2CNC3)cc1Cl
6959,6980,CHEMBL333667,ZOVQSSMFGDAFDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,80.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.096910013008057,C1=CC=C(C=C1)CC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(Cc1ccccc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
6960,6981,CHEMBL333667,ZOVQSSMFGDAFDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,54.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,7.267606240177032,C1=CC=C(C=C1)CC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(Cc1ccccc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
6961,6982,CHEMBL333667,ZOVQSSMFGDAFDJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,RATIO,=,1.5,,,,,,,,,,,,,,,,Ratio between [3H]DA reuptake and DAT binding,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,1.5,C1=CC=C(C=C1)CC(=O)NCCNCCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,O=C(Cc1ccccc1)NCCNCCOC(c1ccc(F)cc1)c1ccc(F)cc1
6962,6983,CHEMBL390743,ZPAUAFZKIQYYOJ-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,IC50,=,30.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT in HEK cells assessed as [3H]dopamine reuptake,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.522878745280337,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)F,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(F)cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
6963,6984,CHEMBL390743,ZPAUAFZKIQYYOJ-HIUFNZKISA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17602602.0,KI,=,12.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK cells after 90 mins,"Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.",J. Med. Chem.,PUBLICATION,,7.920818753952375,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=C(C=C5)F,CN1[C@H]2CC[C@@H]1[C@@H](c1ncc(-c3ccc(F)cc3)s1)[C@@H](c1ccc(Cl)cc1)C2
6964,6985,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,2643.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.577902836868288,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
6965,6986,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,2100.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.6777807052660805,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
6966,6987,CHEMBL402851,ZPMMCRKQYUFTEM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18240382.0,IC50,=,2730.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in HEK293 cells,"1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.563837352959244,CN(C)CC1=CC=CC=C1OC2=CC=CC=C2Cl,CN(C)Cc1ccccc1Oc1ccccc1Cl
6967,6988,CHEMBL1173595,ZPPOFTVMEMXBDU-IAGOWNOFSA-N,"1-((CYCLOPROPYLMETHOXY)METHYL)-6-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,3.16,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,8.500312917381597,C1CC1COC[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CCNC[C@@]2(COCC2CC2)C3)cc1Cl
6968,6989,CHEMBL1173595,ZPPOFTVMEMXBDU-IAGOWNOFSA-N,"1-((CYCLOPROPYLMETHOXY)METHYL)-6-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,12.59,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.899974269892138,C1CC1COC[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CCNC[C@@]2(COCC2CC2)C3)cc1Cl
6969,6990,CHEMBL1173595,ZPPOFTVMEMXBDU-IAGOWNOFSA-N,"1-((CYCLOPROPYLMETHOXY)METHYL)-6-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)",,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20527970.0,KI,=,63.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [N-methyl-3H]WIN-35428 from human recombinant DAT expressed in pig LLCPK cells after 2 hrs by liquid scintillation counting,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,PUBLICATION,,7.199970640755867,C1CC1COC[C@]23C[C@]2(CCNC3)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc([C@]23CCNC[C@@]2(COCC2CC2)C3)cc1Cl
6970,6991,CHEMBL2179217,ZPUAIXYROPYWKA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23006002.0,KI,=,2899.0,NM,,,,,,,,,,,,,,,Binding affinity to dopamine transporter,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,5.5377517846450015,CC1=CN(C2=C1C=C(C=C2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1
6971,6992,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,68.5,NM,,,,,,,,,,,,,,,,,,,,7.164309428507575,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6972,6993,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,240.0,NM,,,,,,,,,,,,,,,,,,,,6.619788758288393,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6973,6994,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,331.0,NM,,,,,,,,,,,,,,,,,,,,6.480172006224282,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6974,6995,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,743.0,NM,,,,,,,,,,,,,,,,,,,,6.129011186239425,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6975,6996,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8464040.0,IC50,=,95.6,NM,,,,,,,,,,,,,,,Inhibition of [3H]3-beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester binding to dopamine transporter of cynomolgus monkey striatum,"Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging.",J. Med. Chem.,PUBLICATION,,7.0195421077239,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6976,6997,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8691489.0,IC50,=,405.0,NM,,,,,,,,,,,,,,,Inhibitory activity against [3H]-Dopamine uptake from Dopamine transporter in rat caudate putamen tissue,Synthesis and ligand binding of eta(6)-(2beta-carbomethoxy-3beta-phenyltropane) transition metal complexes.,J. Med. Chem.,PUBLICATION,,6.392544976785332,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6977,6998,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8691489.0,KI,=,32.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter using [3H]WIN-35428 as radioligand from rat caudate putamen tissue (high affinity),Synthesis and ligand binding of eta(6)-(2beta-carbomethoxy-3beta-phenyltropane) transition metal complexes.,J. Med. Chem.,PUBLICATION,,7.494850021680094,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6978,6999,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8691489.0,KI,=,388.0,NM,,,,,,,,,,,,,,,Binding affinity towards dopamine transporter using [3H]WIN-35428 as radioligand from rat caudate putamen tissue (low affinity),Synthesis and ligand binding of eta(6)-(2beta-carbomethoxy-3beta-phenyltropane) transition metal complexes.,J. Med. Chem.,PUBLICATION,,6.411168274405793,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6979,7000,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,IC50,=,190.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in HEK cells expressing dopamine transporter,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.721246399047171,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6980,7001,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10479296.0,KI,=,759.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding at Dopamine transporter (DAT) expressed in HEK cells,"Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.",J. Med. Chem.,PUBLICATION,,6.11975822410452,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6981,7002,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,IC50,=,190.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake in HEK293 cells expressing human dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.721246399047171,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6982,7003,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10649976.0,KI,=,760.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]RTI-55 binding to dopamine transporter,Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: synthesis and evaluation as dopamine transporter ligands.,J. Med. Chem.,PUBLICATION,,6.1191864077192095,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6983,7004,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10669562.0,KI,=,231.0,NM,,,,,,,,,,,,,,,Binding Affinity to Dopamine transporter in caudate nuclei which was homogenized and incubated with [3H]mazindol. ,"Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies.",J. Med. Chem.,PUBLICATION,,6.636388020107857,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6984,7005,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10698458.0,IC50,=,301.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human Dopamine transporter,"Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.521433504406158,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6985,7006,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,=,258.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for binding affinity to dopamine transporter using [125I]RTI-55 as a radioligand in HEK cells expressing human transporters.,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,6.58838029403677,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6986,7007,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,10821718.0,KI,=,276.0,NM,,,cell_based,,,,,,,,,,,,Compound was evaluated for inhibition of [3H]DA uptake in HEK-hDAT cells expressing Human dopamine Transporter,Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,6.559090917934783,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6987,7008,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,300.0,NM,,,,,,,,,,,,,,,Binding affinity against cloned human dopamine transporter using 40-80 pM [125I]RTI.,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.522878745280337,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6988,7009,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,KI,=,330.0,NM,,,,,,,,,,,,,,,Inhibition of reuptake of [3H]DA (20 nM) by dopamine transporter,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,6.481486060122112,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6989,7010,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11150168.0,RATIO,=,1.1,,,,,,,,,,,,,,,,Ratio of dopamine uptake to dopamine binding,"Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.",J. Med. Chem.,PUBLICATION,,1.1,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6990,7011,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,296.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.528708288941061,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6991,7012,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,490.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,6.309803919971486,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6992,7013,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,270.0,NM,,,,,,,,,,,,,,,Affinity to inhibit [3H]DA uptake,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.568636235841013,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6993,7014,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,IC50,=,267.0,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [3H]DA binding to Dopamine transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.573488738635424,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6994,7015,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,KI,=,272.0,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [125I]RTI-55 binding to dopamine transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5654310959658,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6995,7016,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,1.0,,,,,,,,,,,,,,,,Ratio of uptake inhibition to binding affinity to human Dopamine transporter (IC50/Ki),Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,1.0,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6996,7017,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,IC50,=,330.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine uptake in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.481486060122112,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6997,7018,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,14592523.0,KI,=,419.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.377785977033705,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6998,7019,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15566309.0,IC50,=,89.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.",J. Med. Chem.,PUBLICATION,,7.050122295963125,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
6999,7020,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15808487.0,KI,=,234.42,NM,,,,,,,,,,,,,,,Ability of compound to inhibit dopamine uptake of receptor was determined,The role of QSAR in dopamine interactions.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.630005338391572,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7000,7021,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,289.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing human dopamine transporter,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,6.539102157243452,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7001,7022,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15828826.0,IC50,=,367.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]-RTI-55 from Dopamine transporter expressed in HEK293 cells,Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.,J. Med. Chem.,PUBLICATION,,6.435333935747911,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7002,7023,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16279803.0,IC50,=,89.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.",J. Med. Chem.,PUBLICATION,,7.050122295963125,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7003,7024,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,IC50,=,461.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.336299074610353,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7004,7025,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16480278.0,KI,=,432.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.364516253185087,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7005,7026,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,89.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,7.050122295963125,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7006,7027,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,240.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.619788758288393,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7007,7028,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,500.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.301029995663981,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7008,7029,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17255098.0,IC50,=,392.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]CFT from human DAT expressed in HEK293 cells,Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter.,J. Biol. Chem.,PUBLICATION,,6.406713932979543,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7009,7030,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17255098.0,IC50,=,1060.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter.,J. Biol. Chem.,PUBLICATION,,5.9746941347352305,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7010,7031,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,347.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]DA uptake in human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.459670525209127,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7011,7032,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17446076.0,KI,=,630.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in COS1 cell membrane,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,6.200659450546419,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7012,7033,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17846138.0,IC50,=,130.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,6.886056647693162,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7013,7034,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,IC50,=,478.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake in DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.32057210338788,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7014,7035,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,341.0,NM,,,,,,,,,,,,,,,Binding affinity at DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,6.467245621007503,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7015,7036,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18434164.0,IC50,=,89.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from dopamine transporter,"Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.",Bioorg. Med. Chem.,PUBLICATION,,7.050122295963125,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7016,7037,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,IC50,=,303.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,6.518557371497695,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7017,7038,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19014888.0,KI,=,371.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells,Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,6.430626090384954,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7018,7039,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,=,590.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.229147988357856,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7019,7040,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,=,371.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,6.430626090384954,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7020,7041,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,IC50,=,303.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,6.518557371497695,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7021,7042,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19256502.0,KI,=,371.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting,Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.,J. Med. Chem.,PUBLICATION,,6.430626090384954,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7022,7043,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19523837.0,IC50,=,89.1,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",Bioorg. Med. Chem.,PUBLICATION,,7.050122295963125,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7023,7044,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,IC50,=,227.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA reuptake at human DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,6.6439741428068775,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7024,7045,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740668.0,KI,=,431.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells,Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression.,Bioorg. Med. Chem.,PUBLICATION,,6.3655227298392685,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7025,7046,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,IC50,=,267.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.573488738635424,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7026,7047,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19821577.0,KI,=,272.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI55 from cloned human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.,J. Med. Chem.,PUBLICATION,,6.5654310959658,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7027,7048,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21146984.0,IC50,=,670.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human DAT transfected cell membrane,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.173925197299173,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7028,7049,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,IC50,=,645.65,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1900028446378075,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7029,7050,CHEMBL370805,ZPUCINDJVBIVPJ-LJISPDSOSA-N,COCAINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23602445.0,KI,=,249.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.603800652904264,CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
7030,7051,CHEMBL32363,ZPUCINDJVBIVPJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15121762.0,KI,=,469.0,NM,,,,,,,,,,,,,,,,,,,,6.328827157284918,CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,COC(=O)C1C(OC(=O)c2ccccc2)CC2CCC1N2C
7031,7052,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,15.4,NM,,,,,,,,,,,,,,,,,,,,7.812479279163537,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7032,7053,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,22.6,NM,,,,,,,,,,,,,,,,,,,,7.645891560852599,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7033,7054,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,24.0,NM,,,,,,,,,,,,,,,,,,,,7.619788758288393,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7034,7055,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,8302271.0,KI,=,60.0,NM,,,,,,,,,,,,,,,,,,,,7.221848749616356,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7035,7056,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,42.6,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from Dopamine Transporter in guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.370590400897282,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7036,7057,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,43.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.366531544420414,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7037,7058,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,45.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.346787486224656,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7038,7059,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,IC50,=,42.6,NM,,,,,,,,,,,,,,,Ability to displace [3H]WIN-35428 from dopamine transporter on guinea pig striatal membrane.,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.370590400897282,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7039,7060,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,KI,=,45.0,NM,,,,,,,,,,,,,,,Inhibition of [125I]- RTI -55 binding at the Dopamine transporter sites on HEK-hDAT cells,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.346787486224656,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7040,7061,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213054.0,RATIO,=,1.0,,,,,,,,,,,,,,,,Ratio of the IC50 value of Mazindol to that in guinea pig was determined,Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,1.0,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7041,7062,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16675639.0,KI,=,18.0,NM,,,,,,,,,,,,,,,,,,,,7.744727494896693,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7042,7063,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,22.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.655607726314889,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7043,7064,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18951020.0,IC50,=,22.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.655607726314889,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7044,7065,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19329313.0,IC50,=,22.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.657577319177793,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7045,7066,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19632110.0,INHIBITION,=,22.1,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells at 1 uM,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,PUBLICATION,,22.1,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7046,7067,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19722525.0,KI,=,22.1,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-35428 binding to human recombinant DAT expressed in CHO cells by scintillation counting,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",J. Med. Chem.,PUBLICATION,,7.655607726314889,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7047,7068,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20378347.0,IC50,=,22.1,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 form human DAT expressed in CHO cell membranes,Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.655607726314889,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7048,7069,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20462211.0,KI,=,22.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in CHO cells,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).",J. Med. Chem.,PUBLICATION,,7.655607726314889,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7049,7070,CHEMBL781,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,MAZINDOL,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21916421.0,KI,=,22.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]-WIN-35428 from human DAT expressed in CHO cells,"Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152).",J. Med. Chem.,PUBLICATION,,7.655607726314889,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
7050,7071,CHEMBL1651219,ZQBPXBADOJMCRU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23009245.0,INHIBITION,=,12.0,%,,,,,,,,,,,,,,,Inhibition of radioligand binding to human DAT at 10 uM,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,12.0,C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl
7051,7072,CHEMBL565639,ZQHFQDYTXXQENI-QGZVFWFLSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19740658.0,IC50,>,14000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine reuptake at human dopamine transporter expressed in HEK293 cells after 5 mins by scintillation counting,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,CC(C)N([C@@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2,CC(C)N(C(=O)c1ccc2ccccc2c1)[C@@H]1CCNC1
7052,7073,CHEMBL3238483,ZQKIPXFFTJJUOL-XLNRJJMWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24686010.0,INHIBITION,,,,Not Active,,,,,,,,,,,,,,Inhibition of dopamine transporter (unknown origin) assessed as inhibition of dopamine uptake at 200 uM,"Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.",Eur. J. Med. Chem.,PUBLICATION,,,CC1=CC(=CC(=C1N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O)C)C(=O)O,Cc1cc(C(=O)O)cc(C)c1N=Nc1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
7053,7074,CHEMBL303266,ZQNWAFLIAPMFBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,IC50,=,52.2,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [3H]DA binding to dopamine (DAT) transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.282329496997738,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
7054,7075,CHEMBL303266,ZQNWAFLIAPMFBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,KI,=,65.1,NM,,,cell_based,,,,,,,,,,,,Compound was tested for inhibition of [125I]RTI-55 binding to dopamine transporter in HEK cells,Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.186419011431807,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
7055,7076,CHEMBL303266,ZQNWAFLIAPMFBG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12798324.0,RATIO,=,0.8,,,,,,,,,,,,,,,,Ratio of uptake inhibition to binding affinity to human DAT (IC50/Ki),Bivalent biogenic amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,0.8,CN1C2CCC1C(C(C2)C3=CC=C(C=C3)Cl)C(=O)NCCCNC(=O)C4C5CCC(N5C)CC4C6=CC=C(C=C6)Cl,CN1C2CCC1C(C(=O)NCCCNC(=O)C1C(c3ccc(Cl)cc3)CC3CCC1N3C)C(c1ccc(Cl)cc1)C2
7056,7077,CHEMBL508044,ZQUSYVORYNBGLG-FQEVSTJZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,24332089.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin),Imidazole-derived agonists for the neurotensin 1 receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)C[C@@H](C(=O)O)NC(=O)C1=NN(C(=C1)C2=C(C=CC=C2OC)OC)C3=C4C=CC(=CC4=NC=C3)Cl,COc1cccc(OC)c1-c1cc(C(=O)N[C@@H](CC(C)C)C(=O)O)nn1-c1ccnc2cc(Cl)ccc12
7057,7078,CHEMBL2012097,ZQVAZFQVPHFFCY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,IC50,>,3000.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,5.522878745280337,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(S3)C4=CC=CC=C4,COC(=O)C1=C(c2ccc(-c3ccccc3)s2)CC2CCC1O2
7058,7079,CHEMBL2012097,ZQVAZFQVPHFFCY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22398259.0,INHIBITION,,,,Dose-dependent effect,,,,,,,,,,,,,,"Displacement of [3H]WIN 35,428 from human dopamine active transporter",Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.,Bioorg. Med. Chem.,PUBLICATION,,,COC(=O)C1=C(CC2CCC1O2)C3=CC=C(S3)C4=CC=CC=C4,COC(=O)C1=C(c2ccc(-c3ccccc3)s2)CC2CCC1O2
7059,7081,CHEMBL336613,ZRGPKZSODCXXDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,6.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of dopamine uptake in HEK cells expressing human dopamine transporter (hDAT),Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,8.221848749616356,C1CN2C(C3=CC=CC=C3C2=N1)C4=CC=C(C=C4)Cl,Clc1ccc(C2c3ccccc3C3=NCCN32)cc1
7060,7082,CHEMBL336613,ZRGPKZSODCXXDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,IC50,=,29.7,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from Dopamine Transporter of guinea pig striatal membrane,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.527243550682787,C1CN2C(C3=CC=CC=C3C2=N1)C4=CC=C(C=C4)Cl,Clc1ccc(C2c3ccccc3C3=NCCN32)cc1
7061,7083,CHEMBL336613,ZRGPKZSODCXXDH-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12213053.0,KI,=,23.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]- RTI-55 from Dopamine transporter expressed in HEK cells,Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter.,J. Med. Chem.,PUBLICATION,,7.638272163982407,C1CN2C(C3=CC=CC=C3C2=N1)C4=CC=C(C=C4)Cl,Clc1ccc(C2c3ccccc3C3=NCCN32)cc1
7062,7084,CHEMBL401683,ZRHGDWMRFCDZHY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18060777.0,KI,=,7300.0,NM,,,,,,,,,,,,,,,Binding affinity to human DAT,Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.136677139879544,CNCC1=C(C=CC(=C1)C(=O)N2CCCN(CC2)C3CC3)OC4=CC=CC=C4,CNCc1cc(C(=O)N2CCCN(C3CC3)CC2)ccc1Oc1ccccc1
7063,7085,CHEMBL1255901,ZRJBHWIHUMBLCN-HZRLMBICSA-N,HUPERZINE A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C/1\[C@@H]2CC3=C([C@@]1(CC(=C2)C)N)C=CC(=O)N3,C/C=C1\[C@H]2C=C(C)C[C@@]1(N)c1ccc(=O)[nH]c1C2
7064,7086,CHEMBL1255901,ZRJBHWIHUMBLCN-HZRLMBICSA-N,HUPERZINE A,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C/1\[C@@H]2CC3=C([C@@]1(CC(=C2)C)N)C=CC(=O)N3,C/C=C1\[C@H]2C=C(C)C[C@@]1(N)c1ccc(=O)[nH]c1C2
7065,7087,CHEMBL3331508,ZRNXFPVASWCYKR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,IC50,=,441.0,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,6.355561410532162,C1C(CN1)CN(CC2=CC=CC=C2Cl)C3=CC=CC=C3.C(=O)(C(F)(F)F)O,Clc1ccccc1CN(CC1CNC1)c1ccccc1
7066,7088,CHEMBL599,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,MELOXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
7067,7089,CHEMBL599,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,MELOXICAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
7068,7090,CHEMBL3331477,ZRWQJQNDWMIWEY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25221656.0,INHIBITION,=,4.0,%,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay,,ACS Med. Chem. Lett.,PUBLICATION,,4.0,C1C(CN1)N(CC2=CC3=CC=CC=C3C=C2)C4=CC(=C(C=C4)Cl)Cl,Clc1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1Cl
7069,7091,CHEMBL3323184,ZRXUBWRDOKMUIN-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,25050161.0,IC50,=,5.8,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]-RTI-55 from recombinant DAT (unknown origin) expressed in HEK cells by saturation binding analysis,,ACS Med. Chem. Lett.,PUBLICATION,,8.236572006437061,CN1CC(C2=C(C1)C=C(C=C2)N3CCOCC3)C4=CC5=CC=CC=C5S4,CN1Cc2cc(N3CCOCC3)ccc2C(c2cc3ccccc3s2)C1
7070,7092,CHEMBL644,ZSCDBOWYZJWBIY-UHFFFAOYSA-N,TRIMIPRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,9537821.0,KI,=,3780.0,NM,,,,,,,,,,,,,,,,,,,,5.422508200162776,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
7071,7093,CHEMBL1812747,ZSEXNBSYJGXEIW-MGTHKWJCSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21058665.0,IC50,=,1.5,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of [3H]DA reuptake after 10 mins by scintillation counting,Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2-substituted Tropanes.,J. Med. Chem.,PUBLICATION,,8.823908740944319,CC1=C(C=CC(=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C4=CC(=NO4)C)N3C)Cl,Cc1cc([C@H]2[C@@H](c3ccc(Cl)c(C)c3)C[C@@H]3CC[C@H]2N3C)on1
7072,7094,CHEMBL2207498,ZSFVXIXYHJMAHE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23043306.0,INHIBITION,=,67.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human DAT at 1 uM by CEREP assay,Systematic in Vivo Screening of a Series of 1-Propyl-4-arylpiperidines against Dopaminergic and Serotonergic Properties in Rat Brain: A Scaffold-Jumping Approach.,J. Med. Chem.,PUBLICATION,,67.0,CCCN1CCC(CC1)C2=CC3=CC=CC=C3S2,CCCN1CCC(c2cc3ccccc3s2)CC1
7073,7095,CHEMBL384199,ZSHFBVRJUAGORQ-FIPFOOKPSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,609.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.215382707367125,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2CCCO)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2CCCO)cc(C(C)=O)c1
7074,7096,CHEMBL598346,ZSIHFDAUAFSTIM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,EC50,=,498.0,NM,,,,,,,,,,,,,,,Agonist activity at DAT,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.302770657240282,C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3F,Fc1ccccc1Oc1cccc(F)c1C1CCNCC1
7075,7097,CHEMBL598346,ZSIHFDAUAFSTIM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,278.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.555955204081924,C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3F,Fc1ccccc1Oc1cccc(F)c1C1CCNCC1
7076,7098,CHEMBL598346,ZSIHFDAUAFSTIM-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21185183.0,KI,=,278.0,NM,,,,,,,,,,,,,,,"Displacement of [3H]WIN-35,428 from human DAT by scintillation proximity assay","Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.555955204081924,C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3F,Fc1ccccc1Oc1cccc(F)c1C1CCNCC1
7077,7099,CHEMBL1651906,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,STREPTOZOTOCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O)N=O,CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
7078,7100,CHEMBL1651906,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,STREPTOZOTOCIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O)N=O,CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
7079,7101,CHEMBL383427,ZSNSOTIXFBSXLU-LIRRHRJNSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16314097.0,IC50,=,250.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells,"Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.6020599913279625,CN[C@H]1CC[C@H](C2=C1C=C(C=C2)N3C=NC=N3)C4=CC(=C(C=C4)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccc(-n3cncn3)cc21
7080,7102,CHEMBL459333,ZSXFOCIJQHAVQI-JRTRGBLZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19053748.0,IC50,=,102.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from DAT,Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.,J. Med. Chem.,PUBLICATION,,6.991399828238082,CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)OC)C(=O)OCCC4=CC(=C(C(=C4)I)N)I.Cl,COc1ccc([C@H]2C[C@H]3CC[C@H]([C@H]2C(=O)OCCc2cc(I)c(N)c(I)c2)N3C)cc1
7081,7103,CHEMBL573973,ZTEDPRVVBLHAKJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19854053.0,KI,>,7000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells,Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.154901959985743,C1CN(CCN1)C2=CC=CC=C2OC3=CC(=CC=C3)F,Fc1cccc(Oc2ccccc2N2CCNCC2)c1
7082,7104,CHEMBL2391147,ZTGRWYMPQCQTHD-ONGXEEELSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23582449.0,INHIBITION,=,4.0,%,,,,,,,,,,,,,,,Binding affinity to human dopamine transporter at 10 uM by radioligand displacement assay relative to control,Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.,Bioorg. Med. Chem.,PUBLICATION,,4.0,C[C@H]1[C@H](CC(=O)N1CC(=O)N)C2=CC=CC=C2,C[C@H]1[C@@H](c2ccccc2)CC(=O)N1CC(N)=O
7083,7105,CHEMBL382001,ZTKREAOJYPYCOX-WLHGVMLRSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-24.2,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-24.2,CC(C)CN(CC1=CC=C(C=C1)C#N)C2CCNCC2.C(=C/C(=O)O)\C(=O)O,CC(C)CN(Cc1ccc(C#N)cc1)C1CCNCC1
7084,7106,CHEMBL382554,ZTLCDNXGGSLCCK-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16497500.0,INHIBITION,=,-22.0,%,,,,,,,,,,,,,,,Displacement of [3H]WIN-35 from DAT at 1 uM,N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.,Bioorg. Med. Chem. Lett.,PUBLICATION,,-22.0,C1CNCCC1N(CC2=CC=CC=C2C(F)(F)F)CC(F)(F)F.C(C(C(=O)O)O)(C(=O)O)O,FC(F)(F)CN(Cc1ccccc1C(F)(F)F)C1CCNCC1
7085,7107,CHEMBL196110,ZTNSUUWAQMMYEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,ACTIVITY,=,18.0,%,,,,,,,,,,,,,,,Percentage displacement of [3H]WIN-35428 radioligand from dopamine transporter at concentration of 1000 nM,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,18.0,CCCCC1(CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCCCC1(CCCNC)Cc2ccccc2N(c2ccc(C)cc2)C1=O
7086,7108,CHEMBL196110,ZTNSUUWAQMMYEF-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16137883.0,KI,>,200.0,NM,,,,,,,,,,,,,,,Inhibition of monoamine reuptake at dopamine transporter,"1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.698970004336019,CCCCC1(CC2=CC=CC=C2N(C1=O)C3=CC=C(C=C3)C)CCCNC,CCCCC1(CCCNC)Cc2ccccc2N(c2ccc(C)cc2)C1=O
7087,7109,CHEMBL219707,ZTZXXNVAKZPHBL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,230.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.638272163982407,C1CCC(CC1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCCC2)C2CCCCN2)cc1
7088,7110,CHEMBL219707,ZTZXXNVAKZPHBL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,410.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.3872161432802645,C1CCC(CC1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCCC2)C2CCCCN2)cc1
7089,7111,CHEMBL219707,ZTZXXNVAKZPHBL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,130.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.886056647693162,C1CCC(CC1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCCC2)C2CCCCN2)cc1
7090,7112,CHEMBL219707,ZTZXXNVAKZPHBL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,260.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.585026652029183,C1CCC(CC1)CC(C2CCCCN2)C3=CC=C(C=C3)Cl,Clc1ccc(C(CC2CCCCC2)C2CCCCN2)cc1
7091,7113,CHEMBL461095,ZUFCXVFSSJFSOT-HNNXBMFYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,17.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,17.0,CN(C)C[C@@H](C1=CC(=CC=C1)Cl)C2(CCCCC2)O,CN(C)C[C@@H](c1cccc(Cl)c1)C1(O)CCCCC1
7092,7114,CHEMBL448953,ZUFCXVFSSJFSOT-OAHLLOKOSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,0.0,CN(C)C[C@H](C1=CC(=CC=C1)Cl)C2(CCCCC2)O,CN(C)C[C@H](c1cccc(Cl)c1)C1(O)CCCCC1
7093,7115,CHEMBL101899,ZUFCXVFSSJFSOT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,28.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,28.0,CN(C)CC(C1=CC(=CC=C1)Cl)C2(CCCCC2)O,CN(C)CC(c1cccc(Cl)c1)C1(O)CCCCC1
7094,7116,CHEMBL2205832,ZUHLFYHHSNMSRE-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,22959245.0,KI,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to DAT,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=N7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccn1
7095,7117,CHEMBL459390,ZUIXQIJYPVGBQL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,IC50,,,,Not Determined,,cell_based,,,,,,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,,COC1=CC=C(C2=CC=CC=C21)CCC3CCC(O3)CCN,COc1ccc(CCC2CCC(CCN)O2)c2ccccc12
7096,7118,CHEMBL459390,ZUIXQIJYPVGBQL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,19201198.0,KI,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT expressed in HEK cells,"2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.",Bioorg. Med. Chem.,PUBLICATION,,5.0,COC1=CC=C(C2=CC=CC=C21)CCC3CCC(O3)CCN,COc1ccc(CCC2CCC(CCN)O2)c2ccccc12
7097,7119,CHEMBL253387,ZUJSUIUCXPKMMG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18085744.0,KI,>,2000.0,NM,,,cell_based,,,,,MDCK,,,,,,,Displacement of [125I]RTI-55 from human DAT expressed in MDCK cells,"Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands.",J. Med. Chem.,PUBLICATION,,5.698970004336019,CN(C)CC1=C(C=CC(=C1)I)SC2=C(C=C(C=C2)CO)N,CN(C)Cc1cc(I)ccc1Sc1ccc(CO)cc1N
7098,7120,CHEMBL403760,ZUTOYMZNVAREQR-GXTWGEPZSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18468895.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of dopamine uptake at human DAT expressed in HEK293 cells,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(CC)C(=O)[C@]1(C[C@H]1CNC)C2=CSC=C2,CCN(CC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CNC
7099,7121,CHEMBL1813481,ZUYOKFFWVNAACC-DZGCQCFKSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21739935.0,IC50,>,10000.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,PUBLICATION,,5.0,CN1C[C@@H]2CCC[C@@]2(C1)C3=CC(=CC=C3)OC,COc1cccc([C@]23CCC[C@H]2CN(C)C3)c1
7100,7122,CHEMBL3663919,ZUZFJRJMEROGCY-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,105.0,NM,314457,,,,,,,,,,,,,,"BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added.","Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin",,PATENT,,6.978810700930063,CCN1CC(C2=CC=CC=C2C1)C3=CC4=C(C=C3)C=NN4,CCN1Cc2ccccc2C(c2ccc3cn[nH]c3c2)C1
7101,7123,CHEMBL1765683,ZVRXOXFSMYJETP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21428406.0,INHIBITION,<,50.0,%,,,,,,,,,,,,,,,Binding affinity to DAT at 10 uM by radioligand binding assay,"N-(4-Cyanotetrahydro-2H-pyran-4-yl) and N-(1-Cyanocyclohexyl) Derivatives of 1,5-Diarylpyrazole-3-carboxamides Showing High Affinity for 18 kDa Translocator Protein and/or Cannabinoid Receptors.",J. Med. Chem.,PUBLICATION,,50.0,CC1=C(N(N=C1C(=O)NC2(CCOCC2)C#N)C3=CC=CC=C3Br)C4=CC=C(C=C4)OC,COc1ccc(-c2c(C)c(C(=O)NC3(C#N)CCOCC3)nn2-c2ccccc2Br)cc1
7102,7124,CHEMBL211372,ZVUBOJJCNXGQFS-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16854064.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human DAT,"Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.",J. Med. Chem.,PUBLICATION,,6.886056647693162,CN1C2CCC1C3COC(=O)CCCCCCCCC(=O)NC4=CC=C(C3C2)C=C4,CN1C2CCC1C1COC(=O)CCCCCCCCC(=O)Nc3ccc(cc3)C1C2
7103,7125,CHEMBL41390,ZVXTZYNQLSAYCQ-JXMROGBWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,6.05,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.05,COC1=CC=CC(=C1)C(C2=CC(=CC=C2)Br)OCCN3CCN(CC3)C/C=C/C4=CC=CC=C4,COc1cccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2cccc(Br)c2)c1
7104,7126,CHEMBL41390,ZVXTZYNQLSAYCQ-JXMROGBWSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,6.88,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,6.88,COC1=CC=CC(=C1)C(C2=CC(=CC=C2)Br)OCCN3CCN(CC3)C/C=C/C4=CC=CC=C4,COc1cccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2cccc(Br)c2)c1
7105,7127,CHEMBL598216,ZVZFXZCYKJIUGR-KWBADKCTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20170186.0,KI,=,79.43,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]WIN-35428 from human recombinant DAT expressed in BacMam virus-transduced cells by scintillation proximity assay,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,7.100015437450608,C1[C@H]2[C@@H]([C@]2(CN1)C3=CC(=C(C=C3)Cl)Cl)CCO,OCC[C@H]1[C@@H]2CNC[C@]12c1ccc(Cl)c(Cl)c1
7106,7128,CHEMBL3703733,ZWAMWGRVKGXYIC-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,213.0,NM,,,,,,,,,,,,,,,"BindingDB_Patents: Radioligand Binding Assay. Compounds were dissolved in 100% DMSO at a concentration 100 times the desired highest assay concentration, serially diluted 1:3 in 100% DMSO, and 0.4 ul/well of each solution was dispensed to a Nunc polypropylene, round bottom, 384-well plate. 100% inhibition is defined with 0.4 ul/well of 1 mM GBR-12935 dissolved in DMSO. 20 ul/well of a 2x membrane preparation (12.5 ug/ml in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) and 20 ul/well of a 2x radioligand solution (250 uM [125I]RTI-55 in 30 mM sodium phosphate buffer, pH 7.9 at 4 C.) were added to the well and the reaction incubated for 1 hour at room temperature. The contents of the assay plate were then transferred to a Millipore MultiscreenHTS GF/B filter plate which was pretreated with 0.5% PEI for at least one hour. The plate was vacuum-filtered and washed with 7 washes of 100 ul/well 50 mM Tris-Cl, pH 7.5, 120 mM NaCl, 5 mM KCl chilled to 4 C.","Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof",,PATENT,,6.671620396561263,C1C(C2=C(CN1)C=C(C=C2)C3=CC=CC(=C3)C#N)C4=CC(=C(C=C4)Cl)Cl,N#Cc1cccc(-c2ccc3c(c2)CNCC3c2ccc(Cl)c(Cl)c2)c1
7107,7129,CHEMBL1130,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,DOXIFLURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O,C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
7108,7130,CHEMBL1130,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,DOXIFLURIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O,C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
7109,7131,CHEMBL2432045,ZWCQZHOWEDKJBN-CAUKCHDASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23981939.0,KI,=,3480.0,NM,,,cell_based,,,,,,,,,,,,"Displacement of [3H]-WIN-35,428 from human DAT expressed in HEK cell membranes","N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.458420756053419,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC=CC=C6,c1ccc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc1
7110,7132,CHEMBL596715,ZWJLIFWNALUYLT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20031410.0,KI,=,6650.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]WIN-35428 from human DAT expressed in HEK293 cells by scintillation proximity assay,"Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.177178354696896,C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3C(F)(F)F,FC(F)(F)c1ccccc1Oc1ncccc1C1CCNCC1
7111,7133,CHEMBL150045,ZWLWOTHDIGRTNE-UHFFFAOYSA-N,4-BENZHYDRYL-PYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,79.0,NM,,,,,,,,,,,,,,,Affinity to displace binding of [3H]WIN-35428 to dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.102372908709557,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=NC=C3,c1ccc(C(c2ccccc2)c2ccncc2)cc1
7112,7134,CHEMBL150045,ZWLWOTHDIGRTNE-UHFFFAOYSA-N,4-BENZHYDRYL-PYRIDINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,12565962.0,KI,=,255.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]DA uptake evaluated at the dopamine transporter,Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5934598195660445,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=NC=C3,c1ccc(C(c2ccccc2)c2ccncc2)cc1
7113,7135,CHEMBL1173597,ZWMHSADWUIOURG-ZFWWWQNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20509659.0,IC50,=,30.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells after 90 mins by scintillation counting,Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.,J. Med. Chem.,PUBLICATION,,7.522878745280337,CCC[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,CCC[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
7114,7136,CHEMBL1173597,ZWMHSADWUIOURG-ZFWWWQNUSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21319801.0,IC50,=,6.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of human DAT in HEK293 cells assessed as inhibition of [3H]dopamine uptake,"Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.",J. Med. Chem.,PUBLICATION,,8.221848749616356,CCC[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,CCC[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1
7115,7137,CHEMBL272003,ZWMWTNKSRCRPSI-WMZOPIPTSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17983754.0,KI,>,6000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125]RTI35 from human DAT expressed in canine kidney cells,"Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter.",Bioorg. Med. Chem.,PUBLICATION,,5.221848749616356,CSC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CSc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
7116,7138,CHEMBL469666,ZWZSMMPAZKEDJW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18557608.0,ACTIVITY,=,0.0,%,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]WIN-35428 from human recombinant dopamine transporter expressed in CHO cells at 1000 nM,Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,0.0,CN1CCN(CC1)CC(C2=CC=C(C=C2)OC)C3(CCCCC3)O.Cl.Cl,COc1ccc(C(CN2CCN(C)CC2)C2(O)CCCCC2)cc1
7117,7139,CHEMBL1683876,ZXAIYPYVRUXIRT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,<,1.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CCN(CC)CC1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,CCN(CC)CC1(c2ccc(Cl)c(Cl)c2)CCCCC1
7118,7140,CHEMBL501919,ZXJNEUYTPXBETE-NSHDSACASA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18621528.0,KI,=,2890.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine reuptake at human DAT expressed in HEK293 cells by SPA,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.539102157243452,CS(=O)(=O)N(CC1=CC=CC=C1C(F)(F)F)[C@H]2CCNC2,CS(=O)(=O)N(Cc1ccccc1C(F)(F)F)[C@H]1CCNC1
7119,7141,CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,=,4069.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.390512310146715,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
7120,7142,CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,=,3233.0,NM,,,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,5.490394295388444,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
7121,7143,CHEMBL36994,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,ANIRACETAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,COc1ccc(C(=O)N2CCCC2=O)cc1
7122,7144,CHEMBL36994,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,ANIRACETAM,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,COc1ccc(C(=O)N2CCCC2=O)cc1
7123,7145,CHEMBL2206507,ZXQHLFVRUPRIEJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,23084899.0,KI,=,36.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.443697499232713,CC1=CC2=C(C=C1)C(CN(C2)C)C3=CC(=CC=C3)Cl,Cc1ccc2c(c1)CN(C)CC2c1cccc(Cl)c1
7124,7146,CHEMBL204591,ZXSCHWNAHIGTOP-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16337793.0,IC50,>,100.0,NM,,,,,,,,,,,,,,,Inhibitory activity against DAT,Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=CC(=C(C=C1)C(C2=CC=CC=C2CN(C)C)O)N,Cc1ccc(C(O)c2ccccc2CN(C)C)c(N)c1
7125,7147,CHEMBL394470,ZXTICJSOBQXOSW-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17517511.0,KI,=,2238721138568.34,NM,,,cell_based,,,,,,,,,,,,Inhibition of human DAT expressed in COS1 cells,QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter.,Bioorg. Med. Chem.,PUBLICATION,,-3.35,COC(=O)C1=C(C2CCC1N2)C3=CC=CC=C3,COC(=O)C1=C(c2ccccc2)C2CCC1N2
7126,7148,CHEMBL241647,ZXTNAQHXTXATFR-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18052090.0,KI,=,443.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells,2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.,J. Med. Chem.,PUBLICATION,,6.3535962737769305,CN(C)CC1=C(C=CC(=C1)OCCCO)SC2=CC=CC=C2N,CN(C)Cc1cc(OCCCO)ccc1Sc1ccccc1N
7127,7149,CHEMBL395368,ZYALYWXELCWDBL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17127059.0,KI,=,46.0,NM,,,cell_based,,,,,CHO,,,,,,,Inhibition of [3H]WIN-uptake in human DAT expressed in CHO cells,Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.337242168318426,CN1CC(C2=C(C1)C=C(C=C2)OCCCN3CCC(CC3)F)C4=CC=C(C=C4)SC,CSc1ccc(C2CN(C)Cc3cc(OCCCN4CCC(F)CC4)ccc32)cc1
7128,7150,CHEMBL6466,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,COUMARIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC(=O)O2,O=c1ccc2ccccc2o1
7129,7151,CHEMBL6466,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,COUMARIN,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC(=O)O2,O=c1ccc2ccccc2o1
7130,7152,CHEMBL218849,ZYPXTTXHMBCKFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,8.2,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.086186147616283,CCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCC(c1ccc(Cl)cc1)C1CCCCN1
7131,7153,CHEMBL218849,ZYPXTTXHMBCKFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,IC50,=,170.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]DA uptake at human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.769551078621726,CCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCC(c1ccc(Cl)cc1)C1CCCCN1
7132,7154,CHEMBL218849,ZYPXTTXHMBCKFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,7.8,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,8.10790539730952,CCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCC(c1ccc(Cl)cc1)C1CCCCN1
7133,7155,CHEMBL218849,ZYPXTTXHMBCKFT-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17228864.0,KI,=,290.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [125I]RTI-55 from human DAT expressing HEK293 cells,"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.",J. Med. Chem.,PUBLICATION,,6.5376020021010435,CCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl,CCCCC(c1ccc(Cl)cc1)C1CCCCN1
7134,7156,CHEMBL450623,ZYQIUGBSDWKKMU-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18207394.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT,Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC1NC(=O)C2(CC2CN)C3=CC=CC=C3,NCC1CC1(C(=O)NC1CC1)c1ccccc1
7135,7157,CHEMBL420142,ZYSPQRLLQVFKDB-NTISSMGPSA-M,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,15177457.0,KI,>,10000000.0,NM,,,,,,,,,,,,,,,Ability to inhibit [3H]mazindol binding to cloned human dopamine (DA) transporter,Synthesis and biological activity of some known and putative duloxetine metabolites.,Bioorg. Med. Chem. Lett.,PUBLICATION,,2.0,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=C2C=CC(=C3OS(=O)(=O)[O-])OC.[Na+],CNCC[C@H](Oc1cccc2c(OS(=O)(=O)[O-])c(OC)ccc12)c1cccs1
7136,7158,CHEMBL398559,ZYTLNNQUXXHCCG-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,17869101.0,KI,=,70.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [125I]RTI55 from human DAT transfected in COS1 cells,High dopamine transporter selectivity can be displayed by remarkably simple non-nitrogen containing inhibitors.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985742,C1CC(=C(C1)C(=O)NCCF)C2=CC(=C(C=C2)Cl)Cl,O=C(NCCF)C1=C(c2ccc(Cl)c(Cl)c2)CCC1
7137,7159,CHEMBL288823,ZYWYGPJJVKXGOA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,LOG 1/C,=,7.49,,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake in HEK293 cells expressing recombinant Dopamine transporter,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.49,C1CN(CCN1CCCC2=CC=C(C=C2)F)CCOC(C3=CC=CC=C3)C4=CC=C(C=C4)F,Fc1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccc(F)cc3)CC2)cc1
7138,7160,CHEMBL288823,ZYWYGPJJVKXGOA-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,11931612.0,PKD,=,7.51,,,,cell_based,,,,,,,,,,,,Inhibition of radioligand [125I]RTI-55 binding to human Dopamine transporter in clonal cells,GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).,J. Med. Chem.,PUBLICATION,,7.51,C1CN(CCN1CCCC2=CC=C(C=C2)F)CCOC(C3=CC=CC=C3)C4=CC=C(C=C4)F,Fc1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccc(F)cc3)CC2)cc1
7139,7161,CHEMBL282380,ZZHKHRXDQLQSFW-HHHXNRCGSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,25.0,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,7.602059991327962,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C[C@@H](CC4=CC=CC=C4)O,O[C@H](Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
7140,7162,CHEMBL28149,ZZHKHRXDQLQSFW-MHZLTWQESA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,18393401.0,KI,=,2.3,NM,,,,,,,,,,,,,,,Displacement of [125I]RTI55 from DAT,"Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters.",J. Med. Chem.,PUBLICATION,,8.638272163982407,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C[C@H](CC4=CC=CC=C4)O,O[C@@H](Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
7141,7163,CHEMBL383879,ZZJGNQRWIXQQDJ-CUNXSJBXSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,16931001.0,KI,=,1224.0,NM,,,,,,,,,,,,,,,Inhibition of DAT,"2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.912218582190458,CC(=O)C1=CC(=CC(=C1)NC(=O)NCCC[C@H]2C[C@@H](CCN2C(=O)C)CC3=CC=C(C=C3)F)C(=O)C,CC(=O)c1cc(NC(=O)NCCC[C@H]2C[C@H](Cc3ccc(F)cc3)CCN2C(C)=O)cc(C(C)=O)c1
7142,7164,CHEMBL62193,ZZORFUFYDOWNEF-UHFFFAOYSA-N,SULFADIMETHOXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1
7143,7165,CHEMBL62193,ZZORFUFYDOWNEF-UHFFFAOYSA-N,SULFADIMETHOXINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1
7144,7166,CHEMBL1683875,ZZRHLICOWQQNJL-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,21310609.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant dopamine transporter,"Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CCN(C)CC1(CCCCC1)C2=CC(=C(C=C2)Cl)Cl,CCN(C)CC1(c2ccc(Cl)c(Cl)c2)CCCCC1
7145,7167,CHEMBL35,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,FUROSEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
7146,7168,CHEMBL35,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,FUROSEMIDE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
7147,7169,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
7148,7170,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
7149,7171,CHEMBL599846,ZZWUEOYQVWAKCJ-UHFFFAOYSA-N,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,20158204.0,IC50,=,845.0,NM,,,cell_based,,,,,HEK293,,,,,,,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.,J. Med. Chem.,PUBLICATION,,6.073143291050307,CC(C(=O)C1=CC(=CC=C1)Br)NC2CCCC2,CC(NC1CCCC1)C(=O)c1cccc(Br)c1
7150,7259,CHEMBL3735756,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Ki,=,498.0,NM,,,,,,,,,,,,,,,Displacement of [3H]WIN35428 from human dopamine transporter stably expressed in HEK293 cells after 30 mins by neurotransmitter transporter uptake assay,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,MedChemComm,PUBLICATION,,6.302770657240282,COC1=C(C=C(C=C1)CCN(CCCC2=CC=CC=C2)CCC3=CC4=C(C=C3)OCO4)OC,COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC
7151,7260,CHEMBL3740472,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26363507.0,Inhibition,<,50.0,%,,,,,,,,,,,,,,,Agonist activity at human recombinant DAT expressed in CHO cells assessed as cAMP level at 10 uM after 4 hrs by luciferase reporter gene assay,"Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.",Eur. J. Med. Chem.,PUBLICATION,,50.0,CC(C)C1=NC(=C2N1C=CC=C2)C(=O)NCC3[C@H]4[C@@H]3CN(C4)CCCOC,COCCCN1C[C@H]2C(CNC(=O)c3nc(C(C)C)n4ccccc34)[C@H]2C1
7152,7261,CHEMBL3740472,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26363507.0,Inhibition,<,50.0,%,,,,,,,,,,,,,,,Antagonist activity at human recombinant DAT expressed in CHO cells assessed as cAMP level at 10 uM after 4 hrs by luciferase reporter gene assay,"Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.",Eur. J. Med. Chem.,PUBLICATION,,50.0,CC(C)C1=NC(=C2N1C=CC=C2)C(=O)NCC3[C@H]4[C@@H]3CN(C4)CCCOC,COCCCN1C[C@H]2C(CNC(=O)c3nc(C(C)C)n4ccccc34)[C@H]2C1
7153,7262,CHEMBL3741589,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26509640.0,Activity,=,63.0,%,,,,,,,,,,,,,,,Binding affinity to human recombinant dopamine transporter expressed in CHO cells,"Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.",J. Med. Chem.,PUBLICATION,,63.0,C1C(CN1CC2=CC=C(C=C2)OCC3=CC(=C(C=C3)Cl)Cl)C(=O)O,O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1
7154,7263,CHEMBL3741992,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26460788.0,Inhibition,<,30.0,%,,,,,,,,,,,,,,,Inhibition of human dopamine transporter at 10 uM,Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.,J. Med. Chem.,PUBLICATION,,30.0,CC1=CC(=C(C=C1NC(=O)C2=CNC(=O)C[C@H]2C3=CC=C(C=C3)F)OCCO)Cl,Cc1cc(Cl)c(OCCO)cc1NC(=O)C1=CNC(=O)C[C@H]1c1ccc(F)cc1
7155,7264,CHEMBL3752576,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26739781.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,C=CCN(CCC1=CNC2=CC=CC=C21)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccccc12
7156,7265,CHEMBL3752900,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26739781.0,Ki,=,794.33,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,C=CCN(CCC1=CNC2=C1C=C(C=C2)Cl)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12
7157,7266,CHEMBL3753318,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26739781.0,Ki,=,3162.28,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12
7158,7267,CHEMBL3754166,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26739781.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,C=CCN(CCC1=CNC2=C1C=C(C=C2)Br)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12
7159,7268,CHEMBL3754496,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26739781.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Binding affinity to DAT (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C=CCN(CCC1=CNC2=C1C=C(C=C2)F)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12
7160,7269,CHEMBL3763166,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26653033.0,Inhibition,<,50.0,%,,,,,,,,,,,,,,,Inhibition of DAT (unknown origin) at 10 uM,"Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy.",J. Med. Chem.,PUBLICATION,,50.0,C1C2=C(C=CC(=C2)S(=O)(=O)NNC3=CC=C(C=C3)Br)NC1=O,O=C1Cc2cc(S(=O)(=O)NNc3ccc(Br)cc3)ccc2N1
7161,7270,CHEMBL3763934,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26709102.0,IC50,=,4800.0,NM,,,,,,,,,,,,,,,Inhibition of human dopamine transporter,Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,PUBLICATION,,5.318758762624412,C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=CC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2cccc(=O)n21
7162,7271,CHEMBL3769872,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26935940.0,IC50,=,21.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human DA transporter assessed as reduction in [3H]-DA reuptake,Emerging targets and new small molecule therapies in Parkinson's disease treatment.,Bioorg. Med. Chem.,PUBLICATION,,7.67778070526608,CC(C)C(C)C1(CCC(CC1)(C)O)C2=CC3=CC=CC=C3C=C2,CC(C)C(C)C1(c2ccc3ccccc3c2)CCC(C)(O)CC1
7163,7272,CHEMBL3770651,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26935940.0,IC50,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human DA transporter assessed as reduction in [3H]-DA reuptake,Emerging targets and new small molecule therapies in Parkinson's disease treatment.,Bioorg. Med. Chem.,PUBLICATION,,7.886056647693162,CN(C)CC1(CCCC(C1)O)C2=CC(=C(C=C2)Cl)Cl,CN(C)CC1(c2ccc(Cl)c(Cl)c2)CCCC(O)C1
7164,7273,CHEMBL3770663,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26935940.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human DA transporter assessed as reduction in [3H]-DA reuptake,Emerging targets and new small molecule therapies in Parkinson's disease treatment.,Bioorg. Med. Chem.,PUBLICATION,,7.397940008672037,CC1(CCC(CC1)(CNC)C2=CC3=CC=CC=C3C=C2)O,CNCC1(c2ccc3ccccc3c2)CCC(C)(O)CC1
7165,7274,CHEMBL3774784,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26774927.0,Activity,=,13.5,%,,,,,,,,,,,,,,,Binding affinity to human dopamine transporter at 10 uM by radioligand binding assay,Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.,Eur. J. Med. Chem.,PUBLICATION,,13.5,CCCCCCNC(=O)OC1=CC=CC(=C1)C2=C(C=C(C=C2)[C@H](C)C(=O)O)F,CCCCCCNC(=O)Oc1cccc(-c2ccc([C@H](C)C(=O)O)cc2F)c1
7166,7275,CHEMBL3775436,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26988801.0,Inhibition,=,24.5,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human recombinant dopamine transporter expressed in CHO cells at 10'-5 M,"Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.",Bioorg. Med. Chem.,PUBLICATION,,24.5,CC1=C(C(=CC=C1)C)OCCOCCN[C@H](C)CO.Cl,Cc1cccc(C)c1OCCOCCN[C@H](C)CO
7167,7276,CHEMBL3775769,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26988801.0,Inhibition,=,16.2,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human recombinant dopamine transporter expressed in CHO cells at 10'-5 M,"Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.",Bioorg. Med. Chem.,PUBLICATION,,16.2,CC1=C(C(=CC=C1)C)OCCOCCN[C@@H](C)CO.Cl,Cc1cccc(C)c1OCCOCCN[C@@H](C)CO
7168,7277,CHEMBL3785736,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26942860.0,Activity,>,77.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human recombinant dopamine transporter expressed in CHO cells assessed as remaining radioligand binding at 10 uM after 120 mins by scintillation counting method relative to control,Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.,J. Med. Chem.,PUBLICATION,,77.0,CN1C=NC2=C1C(=O)N(C=N2)CC3=NC(=NO3)CCC4=CC=C(C=C4)Cl,Cn1cnc2ncn(Cc3nc(CCc4ccc(Cl)cc4)no3)c(=O)c21
7169,7278,CHEMBL3800048,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,26890707.0,Activity,=,200.0,%,,,,,,,,,,,,,,,"Increase in [3H]methyl (1R,2S,3S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate binding to recombinant human DAT expressed in HEK293 cells at 10 uM by PDSP assay",Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists.,J. Med. Chem.,PUBLICATION,,200.0,CC1=C2C(=NC(=N1)C#CC3=CC=CC=C3)N(C=N2)[C@@H]4[C@H]5C[C@]5([C@H]([C@H]4O)O)C(=O)NC,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(C)nc(C#Cc4ccccc4)nc31)[C@H](O)[C@@H]2O
7170,7279,CHEMBL3817915,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,=,130.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.886056647693162,C1CCN(C(=O)C1)C[C@@H]2CNCCO[C@H]2C3=CC(=C(C=C3)Cl)F.Cl,O=C1CCCCN1C[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
7171,7280,CHEMBL3818117,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,=,66.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,7.180456064458133,C1CNC(=O)N(C1)C[C@@H]2CNCCO[C@H]2C3=CC(=C(C=C3)Cl)F.Cl,O=C1NCCCN1C[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
7172,7281,CHEMBL3818345,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@@H](CN1)CN2C=CC=C(C2=O)C3=NOC(=O)N3)C4=CC(=C(C=C4)Cl)F.Cl,O=c1[nH]c(-c2cccn(C[C@@H]3CNCCO[C@H]3c3ccc(Cl)c(F)c3)c2=O)no1
7173,7282,CHEMBL3818471,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=NC(=NN1)C2=CC=CN(C2=O)C[C@@H]3CNCCO[C@H]3C4=CC(=C(C=C4)Cl)F.Cl,Cc1nc(-c2cccn(C[C@@H]3CNCCO[C@H]3c3ccc(Cl)c(F)c3)c2=O)n[nH]1
7174,7283,CHEMBL3818596,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@@H](CN1)CN2C=C(C=CC2=O)C3=NOC(=O)N3)C4=CC(=C(C=C4)Cl)F.Cl,O=c1[nH]c(-c2ccc(=O)n(C[C@@H]3CNCCO[C@H]3c3ccc(Cl)c(F)c3)c2)no1
7175,7284,CHEMBL3818901,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,COC(=O)C1=CC=CN(C1=O)C[C@@H]2CNCCO[C@H]2C3=CC(=C(C=C3)Cl)F.Cl,COC(=O)c1cccn(C[C@@H]2CNCCO[C@H]2c2ccc(Cl)c(F)c2)c1=O
7176,7285,CHEMBL3818946,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@@H](CN1)CN2C=CC=C(C2=O)C3=NNN=N3)C4=CC(=C(C=C4)Cl)F.Cl,O=c1c(-c2nn[nH]n2)cccn1C[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
7177,7286,CHEMBL3818953,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,=,400.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.3979400086720375,C1CC(=O)N(C1)C[C@@H]2CNCCO[C@H]2C3=CC(=C(C=C3)Cl)F.Cl,O=C1CCCN1C[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
7178,7287,CHEMBL3819009,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@@H](CN1)CN2C=CC(=CC2=O)C3=NOC(=O)N3)C4=CC(=C(C=C4)Cl)F.Cl,O=c1[nH]c(-c2ccn(C[C@@H]3CNCCO[C@H]3c3ccc(Cl)c(F)c3)c(=O)c2)no1
7179,7288,CHEMBL3819201,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@@H](CN1)CN2C=CC=CC2=O)C3=CC(=C(C=C3)Cl)F.Cl,O=c1ccccn1C[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
7180,7289,CHEMBL3819217,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@@H](CN1)CN2C(=O)C=CC=C2C3=NOC(=O)N3)C4=CC(=C(C=C4)Cl)F.Cl,O=c1[nH]c(-c2cccc(=O)n2C[C@@H]2CNCCO[C@H]2c2ccc(Cl)c(F)c2)no1
7181,7290,CHEMBL3819243,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,=,240.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.619788758288393,C1CO[C@H]([C@@H](CN1)CN2C(=O)C=CC=N2)C3=CC(=C(C=C3)Cl)F.Cl,O=c1cccnn1C[C@@H]1CNCCO[C@H]1c1ccc(Cl)c(F)c1
7182,7291,CHEMBL3819441,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,27325446.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of human DAT expressed in CHO cells assessed as [3H]-dopamine reuptake incubated for 60 mins measured after 30 mins by topcount method,"Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.",Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CO[C@H]([C@@H](CN1)CN2C=CC=C(C2=O)C(=O)O)C3=CC(=C(C=C3)Cl)F.Cl,O=C(O)c1cccn(C[C@@H]2CNCCO[C@H]2c2ccc(Cl)c(F)c2)c1=O
7183,7292,CHEMBL3823832,,,,Q01959,DOPAMINE TRANSPORTER,SLC6A3,,,,Inhibition,=,78.0,%,,,,,,,,,,,,,,,Displacement of [3H]BTCP from human recombinant dopamine transporter expressed in CHO cells at 10 uM after 120 mins by scintillation counting analysis,In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents,MedChemComm,PUBLICATION,,78.0,CC1=C(C2=CC=CC=C2S1)[C@@H]3C=CNC=N3,Cc1sc2ccccc2c1[C@@H]1C=CNC=N1
